

AD A100636

The state of the s

DISCLAIMER NOTICE

THIS DOCUMENT IS BEST QUALITY PRACTICABLE. THE COPY FURNISHED TO DTIC CONTAINED A SIGNIFICANT NUMBER OF PAGES WHICH DO NOT REPRODUCE LEGIBLY.

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered) READ INSTRUCTIONS REPORT DOCUMENTATION PAGE BEFORE COMPLETING FORM 2. SOVT ACCESSION NO. 3. RECIPIENT'S CATALOG NUMBER I. REPORT NUMBER 700636 MED-300 TYPE OF REPORT & PERIOD COVERED 4. TITLE (and Subtitle) 1 Oct 79- ₩ 30 Sep 8Ø Annual Progress Report (FY-80) Department of Clinical Investigation 5. PERFORMING ORG, REPORT NUMBER Walter Reed Army Medical Center. B. CONTRACT OR GRANT NUMBER(a) 7. AUTHOR(s) TIMOTHY M./BOEHM; LTC MC Chief, Department of Clinical Investigation 9. PERFORMING ORGANIZATION NAME AND ADDRESS PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS Department of Clinical Investigation Walter Reed Army Medical Center Washington, D.C. 20012 12. REPORT DATE 11. CONTROLLING OFFICE NAME AND ADDRESS Headquarters, Walter Reed Army Medical Center 13. NUMBER OF PAGES Washington, L.C. 20012 694 15. SECURITY CLASS. (of this report) 14. MONITORING AGENCY NAME & ADDRESS(II dillerent from Controlling Office) Commander, U.S. Army Health Services Command ATTN: HSPA-I Non-Sensitive Fort Sam Houston, Texas 78234 DECLASSIFICATION/DOWNGRADING SCHEDULE 16. DISTRIBUTION STATEMENT (of this Report) DISTRIBUTION STATEM Approved for builds release: Distribution U. drawed entered in Block 20, Il different from Report) 17. DISTRIBUTION STATEMENT (of the 18. SUPPLEMENTARY NOTES The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents. 19. KEY WORDS (Continue on reverse side if necessary and identify by block number)

20. ARSTRACT (Continue on reverse side if necessary and identify by block number)

Subject report identifies the approved clinical research activities conducted at WRAMC (during FY-80) that have been approved and annually reviewed by the Clinical Investigation and Human Use Committees. An annual progress report is enclosed for each protocol active during FY-80. Also, enclosed is a list of publications and presentations during FY-80 that reflect work accomplished in conjunction with approved clinical investigation protocols.

DD 1 JAN 73 1473 EDITION OF 1 NOV 55 IS OBSOLETE

3624.

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORTS CONTROL SYMBOL MED-300

ANNUAL PROGRESS REPORT (FY-80)
DEPARTMENT OF CLINICAL INVESTIGATION
WALTER REED ARMY MEDICAL CENTER
WASHINGTON, D.C. 20012

This report covers the period (1 October 1979 thru 30 September 1980).

APPROVED FOR PUBLIC RELEASE: DISTRIBUTION UNLIMITED

FOREWORD

The enclosed annual progress reports constitute documentation of continuing review by the WRAMC Institutional Review Board (Clinical Investigation and Human Use Committees) of ongoing research at WRAMC, which is required by DHHS, FDA, DOD, DA, HSC, and WRAMC regulations.

Requests for annual progress reports are sent to investigators in August, and annual progress reports are due 15 October.

When the annual progress reports are received by DCI, they are checked for accuracy and randomly sent to a institutional review board member who either will recommend approval of the annual progress report, request additional information, or propose scrutiny of the annual progress report by the entire board. The process of requesting additional information from the investigator and resubmittal of the information to the IRB member, in particular, is time-consuming but results in approval of the majority of the annual progress reports leaving few for review by the entire committee. All the individual annual progress reports in the current report have been approved by the committee and therefore represent the culmination of the review process for ongoing research.

Please note that there are several blank pages in the report. Blanks represent annual progress reports still in process of review by the WRAMC Institutional Review Board. A supplement containing these yet unapproved annual progress reports will be published later.

The compilation of this report and review of over 350 ongoing projects could not have been accomplished without the perseverance, patience, and proficience of Mrs. Ethel Ervin.

Accession For

NTIS GFA&I
DTIC TAB
Unannounced
Justification

Proposition of the control of the

Department of Clinical Investigation

During FY 80 the Clinical Investigation Program at Walter Reed Army Medical Center, already easily the largest in Health Services Command, continued to expand. At the beginning of the fiscal year there were 232 active work units, over 137 new research protocols were approved during the course of the fiscal year. There were more than 78 publications related to approved clinical investigation projects. Despite the increasing workload, the Department of Clinical Investigation provided improved support to the Clinical Investigation and Human Use Committees at Walter Reed Army Medical Center by refining the protocol approval process.

Primary and secondary review of research protocols, editorilization of consent forms and refusal to process protocols not reviewed by department chiefs were among the innovations that allowed the Walter Reed Army Medical Center Clinical Investigation Committee and Human Use Committee to subject Walter Reed Army Medical Center research to the highest standards of review for both scientific merit and adequacy of protection of human subjects.

The designation of a full time editorial assistant, Mrs. Iris Hepburn, played an integral role in the improvement in the protocol processing mechanism.

In FY 80 DCI was able to expand the type of support it could provide investigators. Thanks to the dedicated efforts of Mr. Mack Burton, the administrative officer, DCI was able to obtain additional space in outlying buildings, which have now become the Animal Research Facility and Gastroenterology Research Lab, finally providing support in two areas that historically had not had adequate facilities.

As FY 80 ended, DCI's first two allied health scientists, Major Lauren Reed and CPT Rudolfo Bongiovanni were approaching the end of their assignments at WRAMC. Both individuals have made substantial contributions to the clinical investigation program at WRAMC and are evidence that the allied health scientist can play a very important role working in conjunction with the MD investigator.

DCI continues to be fortunate to have outstanding command support, both from Major General Baker and his successor Major General Mittemeyer. Despite relatively austere resources, DCI has enjoyed an adequate budget for supplies and contractural services. The Commander, WRAMC approved the move of DCI to more spacious facilities on Ward 61, which DCI has been occupying since 1/80.

The Clinical Investigation Program at WRAMC has also been very considerably strengthened by the members of the CIC and HUC each of whom have unrelated busy duty assignments but nevertheless dedicate several hours of time monthly to the critical review of protocols, counselling investigators with regard to possible improvements in protocols, and protection of human research subjects at WRAMC.

The future of DCI holds challenges and excitement. From the current rate of protocol submittal, it is estimated that we will close FY 81 with over 500 active protocols. DCI has been tasked with supporting the Vietnam Head Injury Study, a four year recall study of head-injured Vietnam veterans funded by a 1.8 million dollar VA grant. It is clear that the Oncology program at WRAMC requires more personnel in order to fulfill all its responsibilities in clinical research. The Neurology Service wishes to enter the arena of Phase II evaluation of antiepileptic drugs. Finally, the new final DHHS and FDA regulations on clinical investigation will need to be implemented.

DEPARTMENT OF CLINICAL INVESTIGATION

TABLE OF CONTENTS

		PAGE
Unit Summ	ary Sheet	1
Table of	publications and presentations, FY-80	5
Work Unit	Numbers and Protocol Titles by Departments	13
	WORK UNIT NUMBERS AND PROTOCOL ELLES BY DEPARTMENTS	
DEPARTMEN	T OF MEDICINE	
General M	edicine	
1004	Stress blockation in a Medical ICU: Incidence and Possible Prevention with Cimetidine. (FY-77 I)	13
1005	Efficacy Trail Using Hydroxyurea (HU) in Thrombocytosis. PVSG Protocol 12. (FY-80 I)	14
1006	Efficacy Trial Using Hydroxyurea (AU) in Polycythemia Vera Study Group. Protocol 8. (FY-80)I	16
Nephrolog	y and Renal Dialysis Service	
1121	Combination Prednisone and Cytoxan Therapy Coupled with Plasma Exchange in the Treatment of Anti-Glomerular Antibody Membrane Mediated Renal Disease. (FY-76 IP)	18
1124	The Effect of Hyperuricemia on Chronic Renal Failure. (FY-78 I)	:,0
1125	State of Potassium Balance in the Adult Acute Leukemic Patient. (FY-78 F)	22
1127	Characterization and Response to Therapy in Mild Essential Hypertension. (FY-79 I)	24
1128	Evaluation of the Rehabilitation of End-State Renal Disease Patients by Hemodialysis and Kidney Transplantation Using Activity Recordings. (FY-79 I)	26
1129	Comparison of the Cardiopulmonary Variables in Patients Dialyzed Against Acetate or Bicarbonate Buffer. (FY-79 I)	28
1130	The Role of Hyperuricosuria in the Nephrotoxicity of Radiocontrast Agents. (FY-79 [)	31
1131	determination Anticongnisation Tourapy with Commadano. (FY-80 1)	99

DEPARTMENT OF MEDICINE continued

Cardiology Service		PAGE
1215	Double Blind Evaluation of Lopressor Vs Placebo in the Treatment of Angina Pectoria. (FY-80 I)	35
Endocrino	logy-Metabolism Service	
1308	Inderal Kinetics in Hyperthyroidism. (FY-74 T)	38
1310	TRH in Patients with Hypothalamic-Pituitary Thyroid Disease.	39
	(FY-72 P I)	
1311	Treatment of Thyroid Storm with Anion-Exchange Resin. (FY-74 I)	43
1334	The Regulation of Extrathyroidal Conversion of Thyroxine (T4) to Trilodothyroniue (T3). (FY-75 1)	45
1340	Use of Fluorescent Thyroid Scanning to Evaluate Iodine Kinetics during Prophylthiouracil Therapy of Graves Disease. (FY-76 P I)	48
1346	Thyroid Function Tests in Cord Blood, Material Sera and Aminotic Fluid. (FY-76 P I)	50
1347	Investigations into the Physiology of L-Reverse T-3 (rT3) and -3- - Dilothyronine (3-3 T2). (FY-76 P T)	52
1353	The Regulation of T4 Conversion. A Grant Proposal. (FY-77 SP I)	54
1354	Purification of Testosteroneestradiol Binding Globulin. A Grant Proposal. (FY-77 I)	56
1355	The Effect of Short-Term High-Dose Steroid upon Thyroidal Release in Thyrotexicomis. (FY-77 F)	58
1357	Effect of T3 and rT3 on Extracellular Cyclic Sucolotide Levels in Humans. (FY-77 F)	59
1358	The Effect of Obesity and Fasting on T3 Receptors in Circulating Mononuclear Cells. (FY-77 P 1)	60
1359	The Effect of Reverse T3 and 3, 3 T2 on Thyroid Gland Secretion, T4 Degradation, and Iodide Leak in Thyrotoxic Patients. (FY-77 F)	62
1360	Investigations Concerning T3 Production Rates. (FY-77 I)	63
1361	Postoperative Changes in Free Testostoron, at 1 Dex-Mormone-Binding Globulin. (FY-77 T)	65

DEPARTMENT OF MEDCINE continued

Endocrinology-Metabolism Service continued		PAGE
1362	Medical Treatment of Amenorrhea-Galactorrhea Syndrome with Vitamin B6 (Pyridoxine). (FY-77 SP I)	66
1363	Effect of T3 and rT3 on Plasma Cyclic Nucleotide Levels in Sheep. (FY-77 P I)	68
1364	Effect of L-Tryptophan on LSH and FSH Dynamics in Women. (FY-77 I)	70
1365	Insulin Resistance in Diabetes: Relative Effect of Glucose and Amino Acids. (FY-77 SP P I)	72
1366	The Effect of Glucagon on Thyroidal Economy. (FY-77 F)	74
1367	Effect of Methyldopa on Serum LH and Testosterone in Hypertensive Men. (FY-77 I)	75
1368	Effect of Dietary Phosphate on Serum Levels of Vitamin D Metabolites in Hypoparathyroidism. (FY-77 I)	77
1370	Sex Steroid Receptors in the Human Thyroid Gland. (FY-77 I)	49
1371	Glucose Regulation of Peripheral Thyroidal Economy in Fasted Sub- justs. (FT-77 7 I)	81
1372	Alterations in the Thyrotropin (TSH) Response to Thyrotropin-Releasing Hormone (TRH) Stimulation in Obesity and Fasting.(FY-77 PF)	82
1374 1376	Evaluation of Testosterone Reserve in Infertile Men.(FY-77 SP P I) Effect of Amitripyline and Amantadine on Growth Hormone Dynamics in Acroscogly. (Fr-77 P I)	83
1377	Effect of Dietary Trytophan Content on Food Intake in Obese Sub- jects. (FY-77 I)	87
1379	Effect of Post-Weaning Undernutrition on Reproductive Hormones in Rats. (FY-77 SP P I)	89
1380	• Effect of Thyroid Status on the Hormonally-Induced Cyclic AMP Responses of the Kidney. (FY-77 P I)	91
1381	Estradiol (E \hat{z}) Receptors in Rat Thyroid Glands. (FY-77 I)	93
1382	Neasurement of Storoids in Fluid Obtained by Micropuncture from Rat Seminiferous Tubules and Ep.a dymes. (FY-77 I)	05
1333	Measurement of Hemoglobin A_{1+C} in the assessment of the liftingly of Diabetic Treatment. (FY-77 Fig.	97

DEPARTMENT OF MEDICINE continued

Endocrino	ology-Metabolism Service	PAGE
1385	Serial Changes in Free Testosterone during Pregnancy Correlation with HCG Levels and Fetal Sex. (FY-78 SP I)	98
1386	The Effect of A -Testolactone (Teslac) in Male Infertility. (FY-78 P I)	1.00
1387	Acute Response to Estrogen in Men with Prostate Carcinoma (FY-80 I)	102
1388	The Development of a Radioimmunoassay for Thyronine and 3,5-T2. (FY-78 T)	
1389	The Effect of Dietary Carbohydrates on T3 Receptor Minetics. (MY-78 F)	104
1390	Investigations Concerning the Physiology of Todothyronines during Fasting (FY-78 P I)	106
1391	Regulation of the Initiation of Thyroid Horson Action. (27-78 SPI)	1.08
1392	Steroid Transfer across the Blood-Cerebrospinal Pluid Barrier in the Rhems Monkey. (FY-78 T)	1.1.0
1393	T3 Receptors in Normal and Fasting Rats. (FV-78 I)	1.1.1.
1395	T ₄ and T ₃ Conversion: Effect of Modulation of Glucose Metabolism. (FY-78 I)	1.13
1396	T ₄ to T ₃ Conversion: Effect of Somatostatin Administration. (FY-78 I)	115
1397	The Effect of Free Fatty Acids on Series Reverse T3 and T3 Levels. (1-78 P)	317
1398	Studies on the Pathogenesis of Hypocalcemia in Tumor Associated with Osteoblastic Metabolism. (FY-78 SP I)	11.9
1399	An Assessment of Parathyroid Hormone (PTH) Sevels in Hormal Sub- jects and in Patients with Disorders of Calcium Metabolism. (FY- 78 I)	121
1390-78	The Development of a Radioimmunoassay for 3-Monoiodothyronine (3-T1). (FY-78 P I)	1.23
1301-78	The Effect of Δ^{I} -Testolactone (Teslac) on 5 Peduchase in Rans. (FY-78 P I)	125

DEPARTMEN	IT OF MEDICINE continued	
Endocrino	ology-Metabolism Service continued	PAGE
1303-78	Studies on the Alterations in Drug Metabolism in Hyperthyroidism. (FY-78 I)	127
1304-78	Radionuclide Assessment of Cardiac Function in Patients with Acromegaly. (FY-78 P I)	J 23
1305-78	Breast Carcinoma and Thyroid Hormone Receptors. (FY-78 P I)	131
1307-78	The Effect of Fasting upon TSH Response to TRH. (FY-79 P I)	133
1300-79	Measurement of Serum Iodothyronines by High Pressure Liquid Chromatography (HPLC). (FY-79 I)	135
1301-79	The Effect of Various Metabolic Conditions on T3 Receptors in Circulating Mononuclear Cells. (FY-79 I)	137
1302-79	WRAMC #7810, Prevention of Gonadal Damage in Men Treated with Combination Chemotherapy for Hodgkin's Disease and Histiocytic Lymphomas. (FY-79 I)	189
1304-79	Thyroid Hormone in Cerebrospinal Fluid (CSF). (EY-79 SP I)	1 53
1305-79	Thyroid Function in Liver Disease. (FY-79 F)	134
1305-79	Thyroia Status in Ob/Ob Mice. (FY-79 T)	
1307-79	Offects of High Dose Dexamethasone on Subhuman Primates.(FY-79 PI)	146
1308-79	Stress-Induced Amenorrhea in Military Cadets. (FY-79 I)	148
1309-79	The Anti-Estrogenic Effect of Testolactone (Teslac). (FY-79 1)	Taro
1310-79	Pilot Investigation for the Treatment of Hirsutism with Gral Cimetidine. (FY-79 P I)	152
1311-79	Assessment of Thyroid Function and the Intrathyroidal Biosynthesis of Thyroid Hormone during the Acute Recovery Phases of Subacute Thyroiditis. (FY-79 I)	1 i i i
1312-79	The Effect of Long-Term High Fiber Diets in the Outpatient Management of Insulin Dependent Diabetes Mellitus. (FY-79 I)	156
1313-75	A Radioimmunoussay (RIA) for Human Thyroid Stimulating Hormone (TSH). (FY-79 I)	157
1314-79	Examination of the Effect of Ipodate (Gragnafin) on Thyroid Function. (FY-79 I)	159
1317-80	Sext of smaid the sproper on the force towns to the first of the	4.1

DEPARTMEN	I OF MEDICINE continued	D4 0 D
Encocrino	logy-Metabolism Service continued	PAGE
1316-80 1317-80	T3 Receptors in Human White Cells and Liver. (FY-80 I) Investigation of the Etiology of Idiopathic Hirsuitism.(FY-80 P I	163) 165
1318-80	Development of Fluorescent Immunoassay Procedures. (FY-80 L)	167
1319-80	Does Thyroid Hormone Administration Decrease the Size of Cystic Masses in the Thyroid Gland. (FY-80 I)	169
1320-80	Cyclic AMP Response to Glucagon in Bed and Fasting. (FY-80 J)	171
1321-80	Thyrotropin (TSH) Receptors in Physiologic States. (FY-80 I)	1.73
1322-80	The Relationship between Calcitonin, Nitropresside and T3. (FY-80 1)	1.75
1323-80	Thyrotropin (TSR) Receptors in Human Thyroid Tissue. (FY-80 I)	177
Gastroent	erology Service	
1415	Ecophageal Greating: Quantitated by Radiolsong . Ser . 17-77 R J) 180
1416	Esophageal Emptying in Achalasis: Quantitated by a Radioisotope Method. (F7-7/ P f)	1.82
1417	Plasma Ligandin in Liver Disease, (FY-77 I)	185
1419	Cricopharyngeal Bar: A Video Manometric Study. (FY-77 I)	187
1420	Adenyl Cyclase and Guanyl Cyclase and Guanyl Cyclase in the Cot. Esophagus. (FY-78 I)	188
1422	The Sequential Staging of the Liver in Hodgkin's Disease with Labaroscopy and Laparotomy. (FY-78 I)	1.89
1423	A Study of Trifluoroisopropyl Cyanoacrylate Polymer in the Control of Bleeding Peptic Ulders of the Stobach and Dundenum, (FY-78 F)	191
1424	A Double Blind Study of Long Term Maintenance Cimetidine Therapy on Gastroesophageal Reflux Disease. (FY-78 F)	194
1425	Pulmonary Aspiration from Gastroesophageal Reflux Defined by Pulmonary Aspiration from Gastroesophageal Reflux Defined by Pulmonary Scintiscan and Overnight Intraesochaseal pH Monitoring. (FY-78 P I)	195
1426	The Effect of Inodmethacia on Experimentally Induced Acid Stricture on the Cat Escapeages (FY-78 I)	1.97

DEFSET MENT OF DEDICESE continued

Gastroenterology Service continued		PAGE
1427	Mitroplycerine, Terbutaline and Aminophylias in the Treatment of Achalasis (FY-80 SP I)	199
1428	Maximal Rate of Urea Synthesis in Rats as a Peterminant of Functional Repatic Mass. (FY-80 SP I)	200
1429	Colchicine Therapy of Alcoholic Liver Disease - A Multicenter Randomized Controlled Trial. (FY-80 I)	202
1430	Investigation of the Potential of Various Pills to Induce Local Esophagitis. (FY-80 F)	203
Hematolog	y-Oncology Service	
1516	CALGB #7291, Role of Post Operative Padiotherapy, and Combinations of Dactinomycin, Vincristine, Cyclophosphamids and Adrianacin in Childhood Enabdomyosarcoma. (FY-73	204
1520	CALGB #7411, Combination Chemotherapy in Induction for Standard Risk and Combination Chemotherapy Plus Crainial Irradiation Plus Daunorubicin for Increased Risk Followed by Maintenance with Continuous Versus Intermitten 6-MP Plus Methotrexate Reinforcement and Subsequent Immunotherapy. (FY-74 1)	205
1528	CALGE #7391, Clinical Trial of Radiotherapy and Chemotherapy in Managing Non-Metastatic Ewing's Sarcoma. (FY-73	206
1532	CALGE #7451, Combination Radiotherapy and Chemotherapy of Stace III Hodgkin's Disease (Phase III) (FY-75 P I)	207
1534	CALGB #7521, A Comparative Study of the Value of Immunotherapy with MER as Adjuvant to Induction in Two Maintenance Chemotherapy Programs in Acute Myelocytic Leukenia. (FY-76 P I)	208
1535	CALGB #7351, Long Term Surgical Adjuvant Systemic Chemotherapy with or without Adjuvant Immunotherapy in Mammary Carcinoma: C Comparative Study of Cytoxan, Vincristine, Methotrexate, 5-Fluo-ouracil Versus Cytoxan, Prednisone Versus Cytoxan, Methotrexate and 5-Fluorouracil and MER. A Phase III Study. (FY-76 1)	209
1537	CALGB #7551, Combination Chemotherapy and Padiotherapy for Stage IV Hodgkin's Disease. (FY-76 P I)	211

DEPARTMENT OF MEDICINE continued

Hematolog	nematology-Oncology Service continued	
153ზ	CALGB #7552, Combination Chemotherapy and Immunotherapy for Previously Treated Stage IIIB and IV Hodgkin's Disease. (FY-76 P I)	212
1539	CALGB #7541, Combination Chemotherapy and Immunotherapy in Freviously Untreated Stage III and IV Neuroblastoma. A Phase III Study. (FY-76 I)	213
1541	CALGB #7542, Treatment of Non-Hodgkin's Lymphomas in Children. Methotrexate, Vincristine, Dexamethasone, Cyclophosphamide, 6-Mercaptopurine Plus Radiation Therapy to Involved Areas. A Phase III Study. (FY-76 F)	214
1542	CALGB #7584, Adjuvant Chemotherapy in Osteogenic Sarcoma. Adia-mycin Versus Sequential Adriamycin - Cyclophosphamide. (FY-76	215
1543	CALGB #7651, Combination Chemotherapy of Stage III and IV Lymphocytic Lumphoma (Lymphosarcoma) in Adults with or without Radiotherapy Consolidation. (FY-76 I)	216
1544	CALGB #7652, A Phase III Study. Combination Chemotherapy of Stage III and IV Histiocytic Lymphoma (Reticulum Cell Sarcoma) in Adults with or without Radiotherapy or Adriamycin Consolidation Induction: Vincristine, Streptonigrin, Prednisone Consolidation. Adriamycin Maintenance: Cyclophosphamide. (FY-76 P F)	217
1546	CALGB #7611, Treatment of Primary Untreated Acute Lymphocytic Leukemia in Patients under 20 Years of Age. (FY-77 SP I)	218
1547	CALGB #7682, Combination Chemotherapy or Chemoimmunotherapy for Metastatic Recurrent or Inoperable Carcinoma of the Breast. (FY-77 I)	219
1548	CALGB #7681, Investigation of the Effects of Adriamycin with and without Added MER in Soft Tissue Sacromas. (FY-77	221
1551	CALGE #7612, Therapy of Acute Lymphocytic Leukemia in Adults: A Comparison of Vincristine, Prednisone and L-Asparaginase. (FY-77 P I)	2 22
1552	CALGB #7632, Chemotherapy in Indolent Chronic Lymphocytic Leu-	223

DEFINITION OF HEDICIDE continued

Hematology-Oncology Service continued		PAGE
1554	CALGB #7691, Comparison of Involved Field Radiotherapy with Involved Field Radiotherapy with Adjuvant MOPP Chemotherapy and Extended Field Radiotherapy in the Treatment of Stage I and II Hodgekin's Disease in Children. (FY-77 F)	224
1555	CALGS Pilot Study #0702, Evaluation of Galactitol 1,2:5,6-Dianhydro in the Treatment of Advanced Carcinoma of the Lung and Melanoma. A Phase III Study. (FY-77 F)	225
1556	CALGB #7721, A Comparative Study of Adriamycin Versus Daunorubicin at Two Dose Levels for Induction and of 4-Week Cycle Versus 8-Week Cycle for Maintenance Chemotherapy in Acute Myelocytic Leukemis. (FY-77 F)	226
1558	CALGS \$7761, A Study to Determine the Affectiveness of Single Versus Multiple Alkylating Agents with or without Adriamycin in the Primary Treatment of Multiple Myeloma. (FY-78 I)	227
1559	CALGB #7781, Small Cell Carcinoma of the Lung: Localized Disease. A Phase III Study. Combination Chemotherapy Versus Alternating Chemotherapy Plus Radiotherapy with or without Immunotherapy. (FY-78 SP I)	228
1560	CALGB #7782, Small Cell Carcinona of the Lung. Extensive Disease. A Phase III Study. (FY-78 I)	229
1562	CALGB #7892, The Treatment of Advanced Non Small Cell Bronchogenic Carcinoma with Cytoxan, CCNU, Hexamethylmelamine, and Methotrexate. (FY-78 F)	230
1563	CALGB #7751, The Comparative Effectiveness of Combination Chemotherapy Alone and with Radiation Therapy by Involved Field or Extended Field in Poor Risk Patients with Stage I or II Hodgkin s Disease. (FY-78 I)	231
1564	CALGB #7772, Phase II Study of Chlorozotocin. (FY-78 I)	232
1565	CALGE #7804, Cyclophosphamide, Adriamycin, Vincristine, Prednisone in Combination with Low Dose 5-Day Infusion Bleomycin in the Treatment of Poor Histology Lymphonas and Modular Poorly Differentiated Lymphocytic Lymphomas. (FY-79 F)	233

DEFAITMENT OF MEDICINE continued

hematol	ogy-Oncology Service continued	PAGE
1566	CALGE #7811, Femission Induction and T-COAP Versus T-MOP Maintenance for the Treatment of Recurrent Childhood ALL. (FY-79 F)	2 34
1567	CALGE #0703, Cis-Platinum Diamminedichloride in Advanced Malignant Lymphomas. (FY-79 P F)	235
1568	CALGE #7892, Multimodal Therapy for the Management of Primary, Nonmetastatic Ewing's Sarcoma of Pelvic and Sacral Eones. (FY-79	236
1569	CALGE #7893, Multimodal Therapy for the Management of Primary, Nonmetastatic Ewing's Sarcoma of Bone, Pelvic and Sacral Sites Excluded. (FY-79	237
1570	CALGB #7851, Treatment of Advanced Diffuse Histiocytic Lymphoma. (FY-79 I)	238
1571	CALGB #7891, Intergroup Rhabdomyosarcoma Study II. (FY-79	239
1572	CALGB #7971, Phase II Study of M-AMSA. Treatment for Melanoma, Ovarian Carcinoma, Breast Carcinoma, Hypernephroma and Hepatoma. (FY-80 I)	240
1573	CALGE #7911, Treatment of Primary Untreated Acute Lymphocytic Leukemia in Patients under 20 Years. (F-79 F)	241
1575	CALCB #7972, A Phase II Trial of AMSA for Refractory Modgkin's Disease, Diffuse Histiocytic Lymphoma and Diffuse Poorly Differentiated Lymphocytic Lymphoma. (FY-30 I)	243
1576	CALCB #7982, Cherotherapy of Advanced Pancrestic Cancer. A Comparative Phase II Study. (FY-30 I)	244
1577	CALGS #7921, A Comparative Study of Three Remission Induction Regimens and Two Maintenance Regimens for Acute Myelocytic Leukemia. (FY-80 1)	245
1578	CALGE #3081, A Randomized Study Comparing the Combination of Hormonal Therapy and Chemotherapy with Chemotherapy Alone for the Treatment of Advanced Breast Cancer in Postmenopausal Women. (FY-80 I)	2 46
157 9	CALGE #7983, Surgical Adjuvant Systemic Chemotherapy with 5-Fluor-ourcil, Adrianycin and Mitromycin-C Versus Observation only in Castric Adenocarcinoma. (FY-80, I)	247

markers and or established and the are

destino y-oncho y corvice continue		PAGE
lous	with 0 +7200, the dae of Tethyl-CCTC $-1(2-6)$ forcettyl)-b-(a-Methylcyclohexyl)-l-ditrosoures in the Trethent of Prain Tumors. (FY-70 F)	248
1604	Michie w7205, rhase II, Combination Chemotherapy with Directly! Triazeno Imidazole Carboxamide and Adrianycin in Soft Tisque and Sone sarcosa. (FY-73 F)	249
1610	WRADC 97307, Phase 1-II Evaluation of Dibrosofulation in Fre- viously Treated Patients with Metastatic Carcinoma of the Breast. (FY-73 F)	250
1626	wRAMC #7405, Treatment of Advanced Penal Cell Carcinoma with a Combination 1-(Chlorethy1)-3-Cyclohexy-1-Mitrosourea (CC.'0) and Bleomycin. (FY-77 P F)	251
1627	WRANG 97404, Immunological Evaluation and Immunotherapy of Patients with Carcinoma of the Lung. (FT-75-1)	252
1628	WRAMC #7406, Chemoimmunotherapy of Carcinous of the Large Bowel. (FY-75 I)	253
1629	WRAAC #7407, Chemoimmunotherapy of Malignant Melanoma. (FY-75 F)	254
1630	WRAMC #7400, Comparative Trial of Tumoxifen and Fluoxymestrone Plus Tamoxifen in Metastatic Breast Cancer. (FY-75 I)	255
1643	The Use of Auto-Factor IX Concentrate (human) Dried in the in the Treatment of Patients with Eleeding Due to Factor IXI Inhibitors. (FY-76 F)	256
1644	WRAMC #7501, Evaluation of Adriamycin and Cis-Platinum Chemo- therapy in Treatment of Malignant Disease. A Phase Il Study. (FY-75	257
1649	WEAMC #7602, Chemoimmunotherapy of Prostatic Carcinoma. (FY-76	258
1651	WRAMS #7504, Combination Chemotherapy for the Treatment of Advanced Gastric Carcinoma with Either 1-(Tetra-bylro-2-Furany1)-5-Fluorouracil (Ftorafur), Adriamycin and Mitomycin-C Versus 5-Flurouracil, Adriamycin and Mitomycin-C. (FY-76 F)	259
1554	WEAMC 47601-A, The Treatment of Unresectable Bronchogenic Carcinoma with CCGO 2 (2-Colorethyl)-3-Cyclohexyl-1-Eitrosourea, Cyclophosphamide, Adriamycin, Procarbizine, Hexamethylemalamine, Methotrexate and Irradiation. (FY-77 F)	

DUFARTHER OF RESIDENCE

liematol	ony-Cheolosy Service	PAGE
1655	WEARC \$7697, Chemoimmunotherapy of Carcinoma of the Lung using High-Dose Methotrexate and Citrovorum Factor with or without BCC. (FY-77 F)	261
1657	WEATC #7701, Velban, Bleonycin and Cis-Platinum in the Treatment of Blead and Beck Malignancies. (FY-77 F)	262
1658	WEATC #7702, Adjuvant Chemotherapy of Prostatic Carcinoma with Adriamycin and Cis-Diamminedichloroplatinum II. (FY-78	264
1651	Polycythemia Vera Study Group Protocols 5,6,7 and 8. The Treat- ment of Thrombosis in Patients with Polycythemia Vera. (FY-78 I)	265
1654	VRAMC #7705, Metastatic Colo-Rectal Carcinoma. (FY-78 F)	267
1665	wKAMC #7706, Treatment of Refractory Gastrointestinal Tumors with Chlorambucil and Methotrexate. (FY-78 I)	268
1605	WRANC $\#7801$, Immunological Evaluation and Phase I Immunotherapy Trial of Patients with Various Carcinomas. (FY-78	269
1667	WRAMC #7503, Metastatic Breast Carcinoma. (FY-78 1)	270
1668	WRAMC #7807, Effect of N-Acetyl-Cysteine on Adriamycin-Induced Acute Cardiac Damage. (FY-79 I)	271
1669	WRAMC #7806, Chemotherapy of Carcinoma of the Urinary Bladder. (FY-79 F)	272
1670	WKAMIC #7902, Clinical Trial in Bronchogenic Carcinoma of Specific Immunotherapy as an Adjuvant to Surgery. (FY-79 F)	273
1671	WRAMC ± 7901 , Adjuvant Antiplatelet for Dukes "B2" or "C" Cancer of the Colon. (FY-79 I)	274
1672	Tumor Tissue for Extract Preparation. (FY-79 I)	27 5
1673	TC 179, Treatment of Stage I/II Testicular Carcinoma with Vinblastine, Actinomycin-D, Cyclophosphamide, Bleomycin and Cis-Platinum. (Testicular Cancer Intergroup Study) (FY-79 1)	276
1674	WRANC #7807A, Effect of Indocyanine Green Clearance on Plasma Levels of Adriamycin. (FY-79 I)	277
1675	WRAMC #7903, Mapatic Artery Adriamycin Infusion A Clinical and Pharmacokinetic Study. (FY-79 I)	27 8

DELIGIT OF MEDICAL continued

desatolog	y-Uncolory Fervice continue:	PAGE
1677	WRAIC #7905, Treatment of Acute Leukenia with Low bose Adriancein Infusion. (FY-79-1)	279
1673	MRAMC 07914, Metastatic Colonkectal Cancer. (FY-79 I)	2 80
1679	WRANG \$7907, Use of Nethyl CCNU in the Treatment of Melanoma, Colon and Castric Carcinoma (Group C brug). (FY-30 I)	281
1680	WRAMC #7908, Use of Streptozotocin in the Treatment of Metastatic Islet Call Carcinona (Group C Drug). (FY-80 I)	282
1681	WRAMC #7909, Use of Daunomycin in the Treatment of ALL, AML and Other Leukemias in Adults and Children (Group C Drug). (FY-80 I)	283
1682	WRANC #7910, Use of 5-Azacytidine in the Treatment of Acute Cranulocytic Leukemia in Adults and Children (Group & Drug). (FY-80 I)	284
1683	WRAMC #7911, Use of L-Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults and Children (Group C Drug).(FY- 80 I)	285
1684	WRANC \$7912, Use of Rexamethylmelamine in the Treatment of Ovarian Cancer (Group C Drug). (FY-80 \perp 1)	286
1685	WRAMC #7911, Use of VP-16 in the Treatment of Small Cell Carcinoma of the Lung (Group C Drug). (FY-80 I)	287
1696	WRANC #7915, Prevention of Conadal Damage in Nomen Treated with Combination Chemotherapy or Radiotherapy below the Diaphrasm. (FY-80 I)	289
1637	WRAMO #8302, Phase II Evaluation of Methyl Glyoxal Bis-Guanyl Hydrazone (Methyl-GAG) in Advanced Esophageal Carcinona, Mead and Beck and Cervix. (FY-30 I)	289
1688	WKA4C #8001, Feasibility Study of the Multidisciplinary Approach to Inoperable Lung Cancer Patients. (FY-80 I)	290
Pulmonary	Service	
1760	Sleep Apnea in Hypothyroid Patients. (FY-50 SP I)	291

The state of the s

PUPAST	MAN OF MADICINE continued	
Dermato	logy Service	PAGE
1601	Direct Temunofluorescence in Mixed Connective Tissue Disease. (FY-77 T)	
lniecti	ous Disease Service	
1903	Persistence of I Pallidum in Geurosyphillis. (FY-75 P I)	293
1905	Local Immune Response to Reisseria Gonorrhoeae in Humans.(FY-77 I)	295
1906	The Limulus Lysate Assay for the Determination of Gram Negative Meningitis Septic Arthritis and Contamination of Intravenous Fluids. (FY-78 +)	310
1908	Evaluation of Sodium Stibogluconate (Penhostam R) in the Treatment of Sutangous Leishmaniasis. (EY-78 $^\circ$ L)	312
1909	Immunological Evaluation of Patients with Cutaneous Leishmaniasis. (FY-78 1)	314
1911	In Vitro Inhibitory Activity of a Series of 2-Acetylpryridine Thiosemicarbazones toward a Group of Clinically Significant Bacterial Genera. (FY-79 I)	316
1912	Determination of Vancomycin Levels in Clinical Samples using High Press Liquid Chromatography. (FY-79 F)	318
1913	Laboratory Investigation of New Antibiotics. (FY-80 P I)	320
)FP∆PTMF	NT OF SURGERY	
nestnes	iology and General Surgery	
2000	The Effects of Gastric Surgery on the Release of Pancreatic Polypeptide. (FY-78 I)	322
2003	Use of Copolymer as a Lattice for the Growth of Neogut. (FY-80	324

present of Street

Periphera	l Vascular Service	PAGE
2104	Evaluation of the Efficacy of Suppressing Platelet Activity in Patients with Intermittent Claudication. (FY-77 T)	
2105	Rapid Screening for Coagulation Abnormalities. (FY-78 T)	
2106	Management of the Hemodynamically Significant, Asymptomatic Carotid Bruit. (FY-79 I)	326
2107	Perioperative Thrombosis Prophylaxis in Patients with Peripheral Vascular Disease. (FY-79 T)	
2108	Platelet Aggregation after Carotid Endarterectomy. (FY-79 T)	
2109	Etiologic Factors for Recurrent Carotid Stenosis. (FY-80 I)	3 28
2110	Participation of the Reticulo-Endothelial System in Shortening Platelet Survival. (FY-80 T)	330
Ophthalmo	logy Service	
2306	Clinical Quantification of Intraocular Malignant Melanoma Volume. (FY-76 P $$ F)	331
2308	Scleral Buckling for Retinal Detachment 1973 1976. A Retrospective View. (FY-78 F)	333
2309	A Study of Eye Trauma Treatment in the Military. (FY-78 I)	334
2310	Intraocular Lens. (FY-78 I)	335
2312	Corneal Endothelial Cell Loss Following Various Cataract Extraction Techniques. (FY-79 F)	33 6
Otolaryng	ology Service	
2516	The Effect of Amplification on Limited High-Frequency Hearing Loss. (FY-77 F P)	337
2517	Evaluation of a Specialized Technique for Training Audiovisual Integration in Hard-of-Hearing Patients. (FY-78 I SP)	342
2523	The Relationship between Electroacoustic Parameters and Perceived Sound Quality of Hearing Aids. (FY-78 I P SP)	344
2525	Generation and Evaluation of Synthetic Facial Images for Studying	346

DEPARTMENT OF SURGERY continued

Otolaryng	gology Service continued	PAGE
2 526	Development of Communication of Self-Assessment Inventory of the Hearing Impaired Soldier. (FY-79 I)	348
2527	Assessing Laryngeal Function Via Residue Inverse Filtering. (FY-79 I)	351
25 28	The Effects of Chronic Low Doses of Quinine in Tonic Water on the Electronystamogram (ENG) in Humans. (FY-80 P F)	353
2529	Effect of High Frequency Sensorineural Hearing Loss on the Latency of the Brain Stem Response. (FY-80 I)	355
2530	Test of the Assumptions Underlying the Comparative Hearing Aid Evaluation. (FY-80 $$ I)	357
2531	Maintenance of Speech Fluency Following an Intensive Stattering Therapy Program. (FY-80 I)	360
2532	The Effects of Age and Brain Damage on Fluid Intelligence in Aphasic Adults with Lesions in Dominant Hemisphere. (FY-80 F)	362
Organ Tra	ensplantation Service	
2610	Antilymphocyte Globulin (ALG) and Kidney Transplantation. A Controlled Double Blind Study. (FY-73 I SP)	364
2615	Immunological Monitoring of the Transplant Recipient. (FY-78 F)	367
2616	Obviating the Graft Versus Host Reaction. (FY-78 F)	368
2618	Intentional Donor Specific Pretransplant Transfusion. (FY-80 I)	369
2619	Histocompatibility Antigens and Interstitial Cystitis. (FY-80 I)	371
Urology S	ervice	
2805	Biochemistry Studies of Urinary Polyamines in Human Genitoruniary Carcinoma. (FY-76 T)	

DEPARTMENT OF SURGERY continued

Urology S	Urology Service continued	
2809	Relationships between Prostatic Cancer and excretion of Urinary Cholesterol. (FY-78 I)	375
2810	Comparative Study of High (5000 RADS) Versus Low Dose (2000 RADS) Preoperative Radiation to Radical Cystectomy for Control of Transitional Cell Carcinoma of the Bladder. (FY-78 T)	
2811	The Value of Excretory Urography, Cystography and Cystoscopy in the Evaluation of Adult Women with Urinary Infection. (FY-80 F)	376
2812	Human Chorionic Gonadotropin (HCG) Producing Cells in Seminomatous Germ Cell Tumors of the Testis: A Prospective and Retrospective Correlation with Tumor Histology and Response to Therapy. (FY-80 I)	377
2813	Alpha Fetoprotein (AFP) and Human Chorionic Gonadotropin (HCG) Producing Cells in Nonseminatous Germ Cell Tumors of the Testis: A Prospective and Retrospective Correlation with Serum AFP and HCG Levels, Tumor Histology and Response to Therapy. (FY-80 F)	378
2815	An Epidemiologic Investigation of Testicular Cancer. (FY-80 I)	379
Plastic S	Surgery Service	
2901	Survival and Critical Perfusion of Microvascular Free Flaps following Occulusions of Pedicle Vessels at Specific Time Intervals. (FY-80 I)	380
Allery ar	nd Clinical Rheumatology Service	
3138	Immunologic Mechanisms of Cutaneous Reactions to Inhalant Allergens. (FY-76 F P)	382
3144	Neurophysiologic, Immunologic and Biochemical Aspects of Bronchial Asthma. (FY-77 1 P)	384
3146	Immunotherapy Kit Potency Persistance. (FY-77 I)	387
3147	Hymenoptera Venom Safety and Efficacy Evaluation as Allergen Immunotherapy in Insect Sting Allergy Patients. (FY-77 SP P F)	389
3149	Investigation of Immunologic Imbalance in Atopic Dermatitis. (FY-78 F)	392
3151	Allergic Disease Center Study of Hymenoptera Insect Venom as an Agent for Diagnosis. (FY-78 F)	394
3152	Factors Affecting the Theophylline Half Life. (FY-78 F)	395

ALLERGY	AND CLINICAL RHEUMATOLOGY SERVICE continued	PAGE
3154	WRAMC #7802, Evaluation of Prostaglandin Secreting Suppressor Cells in Cancer Patients. (FY-78 I SP)	396
3155	Evaluation of Suppressor Immunoregulatory Cells in the Pathogenesis of Immunodeficiency Disease. (FY-78 I)	398
3 158	Evaluation of the Immunopathologic Mechanisms Operative in Dermal Reactions to Insulin in Diabetic Patients. (FY-79 P I)	400
3 159R	In Vivo Removal of Circulating Antibodies and Immune Complexes. (FY-79 I)	401
3160R	Study of Rheumatoid Arthritis and Sjorgen's Principitins in Rheumatoid Arthritis. (FY-79 I P)	412
3161	Evaluation of Immediate Hypersensitivity Skin Tosts in Uronic Patients. (FY-79 I)	415
3162R	Serial Study of Serological Parameters in Systemic Lupus Erythematosus. (FY-79 I P SP)	417
3163R	Histocompatibility Antigens in Acute Anterior Uveitis (AAU). FY-79 I P SP)	432
3164	The Comparison of Zaditen and Theophylline in the Prophylaxis of Bronchial Asthma. (FY-79 I)	435
3165	Clinical Trial of Skin Testing with Major and Minor Pencillin Derivatives in Hospitalized Adults. (FY-80 I)	436
3166	An Evaluation of Local Anesthetic Skin Testing and Progressive Challenge in Patients with a History of an Adverse Reaction to Local Anesthetics. (FY-80 I)	438
DEPARTMEN	T OF OBSTETRICS AND GYNECOLOGY	
4113	Cooperative Gynecologic Oncology Group. (FY-74 I)	440
4116	The Evaluation of Fetal Systolic Time Intervals and Beat to Beat Interval Variations in Fetal Heart Rate as Early Indicators of Fetal Maturity and Fetal Distress. (FY-75 I)	441
4124	Fetal Intensive Care Monitoring in a Long-Range Continuing Project	442

DEPART	FMENT OF OBSTETRICS AND GYNECOLOGY continued	PAGE
4129	Antepartum Fetal Evaluation of Noise Evolved Heart Rate Response an an Indicator of Fetal Well-Being. (FY-76 I)	443
4134	Treatment of Women with Cervical Cancer Stage IIB, IIIB, IVA Confined to the Pelvis and/or Para-Aortic Nodes with Radiotherapy Alone Versus Radiotherapy Plus Immunotherapy (Intravenous C-Parvum) (Phase II). (FY-77 I)	444
4135	A Randomized Comparison of Melphalan Alone Versus Adriamycin and Cyclophosphamide Versus Hexamethylmelamine and Melphalan in Patients with Ovarian Adenocarcinoma: Suboptimal Stage II, Stage IV and Recurrent, Equivalent to Stage III and IV (Phase III). (FY-77 I)	445
4136	A Randomized Comparison of Melphalan Alone Versus Melphalan Therapy Plus Immunotherapy (Corynebacterium Parvum in the Treat- ment of Women with Stage III (Optimal) Epithelial Carcinoma of the Ovary (Phase II). (FY-77 I)	446
4137	A Randomized Comparison of Pelvic and Abdominal Radiation Therapy Versus Pelvic Radiation and Melphalan Versus Melphalan Alone in Stage II Carcinoma of the Ovary (Phase III). (FY-77 I)	447
4139	A Randomized Comparison of Melphalan, 5-Fluorouracil and Megace Versus Adriamycin, Cytoxan, 5-Fluorouracil and Megace in the Treatment of Patients with Primary Stage III, Primary Stage IV, Recurrent or Residual Endometrial Carcinoma (Phase III). (FY- 77 I)	448
4140	A Clinical-Pathologic Study of Stage I and Stage II Carcinoma of the Endometrium. (FY-78 I)	449
4141	A Randomized Study of Adriamycin as an Adjuvant after Surgery and Radiation Therapy in Patients with High Risk Endometrial Car- cinoma Stage I and Occult Stage II. (FY-78 I)	450
4142	A Phase II Trial ICRF in Patients with Advanced Pelvic Malignan-cles. (FY-78 1)	451
4143	A Randomized Comparison of Local Excision Versus Cryosurgery in Patients with Limited Grade 1,2, or 3 Cervical Intraepithelial Reoplasia (CIN). (FY-78 I)	452

DEPAR	TMENT OF OBSTETRICS AND GYNECOLOGY continued	PACE
4144	A Randomized Comparison of Surgical Conization Versus Cryosurgery in Patients with Extensive Grade 3 Cervical Intraepithelial Neoplasis (CIN). (FY-78 I)	453
4145	A Randomized Comparison of Melphalan Versus No Treatment in the Treatment of Patients with Selected Stage IAi to IBi Ovarian Can- cer (Well and Moderately Differentiated). (FY-78 I)	454
4146	A Randomized Comparison of Melphalan Versus Radioisotopes in the Treatment of Patients with No Microscopic Residual Disease Having All Stages IC and II (A,B, and C) and Selected Stage IAii and IBii Ovarian Cancer. (FY-78 I)	455
4147	GOG #7711, Surgical-Pathologic Study of Women with Squamous Cell Carcinoma of the Vulva. (FY-79 I)	456
4148	GOG #7712, A Randomized Study of Radiation Therapy Versus Pelvic Node Resection for Patients with Invasive Squamous Cell Carcinoma of the Vulva Having Positive Groin Nodes. (FY-79 I)	457
4149	Automated Detection of Fetal Heart Pattern Abnormalities. (FY-79 I)	458
4150	On-Line Interpretation of Labor Curve Abnormalities. (FY-79 I)	459
4151	Early Reliable Detection of Fetal Heart Rate Variability by Adaptive Digital Filtering. (FY-79 I)	460
4152	GOG #26H. A Phase II Trial of Maytansine in Patients with Advanced Pelvic Malignancies. (FY-79 I)	461
4153	GOG #26, A Phase II Trial of "Baker's Antifol" in Patients with Advanced Pelvic Malignancies. (FY-79 I)	462
4154	GOG #7831, A Randomized Comparison of Cis-Platinum, 50 mg/m², IV, Every Three Weeks Versus Cis-Platinum, 100 mg/m², IV, Daily for Five Days Every Three Weeks Versus Cis-Platinum, 20 mg/m², IV, Daily for Five Days Every Three Weeks in the Treatment of Patients with Advanced Carcinoma of the Cervix. (Phase III). (FY-79 I)	463
4155	GOG #7863, Evaluation of Adjuvant Vincristine, Dactinomycin, and Cyclophosphamide Therapy in Malignant Germ Cell Tumors of the Ovary after Resection of All Gross Tumor (Phase III). (FY-79 I)	464
4156	GOG #7864, Evaluation of Vinblastine, Bleomycin and Cis-Platinum in Stage III and IV and Recurrent Molignant Germ Cell Tumors of the Ovary (Phase III). (FY-79 I)	465
4157	Prophylactic Antibodics in Abdominal Hysterectomy. (FY-79 I)	466
4158	Prophylactic Antibodies in Flective Cocarean Section (RV-70 E SD)	407

DEPAR'	TMENT OF OBSTETRICS AND GYNECOLOGY continued	PAG
4159	GOG #42, Treatment of Recurrent or Advanced Uterine Sarcoma. A Randomized Comparison of Adriamycin Versus Adriamycin and Cyclophosphamide (Phase III). (FY-79 I)	468
4160	GOC #7841, A Clinical-Pathologic Study of Stage I and II Uterine Sarcomas. (FY-79 1)	469
4161	GOG #7861, Surgical Staging of Ovarian Carcinoma. (FY-79 1)	470
4162	GOG #7862, A Randomized Comparison of Melphalan Versus Intraperitoneal Chromic Phosphate in the Treatment of Women with Stage I Exclusive of Stage IAi, GI, and IBi, GI) Epithelial Carcinoma of the Ovary (Phase III). (FY-79 I)	471
4163	GOG #26, A Phase II Trial of Cis-Platinum (II) Diamminedichloride. (FY-79 I)	472
4164	Study of Ovarian Cancer in Greater Washington, D.C. (FY-79 T)	
4165	GOG #26-I, A Phase II Trial of AMSA in Patients with Advanced Pelvic Malignancies. (FY-79 I)	473
4166	GOG #26-J. A Phase II Trial of Yoshi 864 in Patients with Advanced Pelvic Malignancies. (FY-79 I)	474
4167	GOG #7961, A Phase III Randomized Study of Adriamycin Plus Cyclophosphamide Versus Adriamycin Plus Cyclophosphamide Plus Cis-Platinum in Patients with Advanced Ovarian Adenocarcinoma. Suboptimal Stage III, Stage IV and Recurrent. (FY-79 I)	475
4168	Comparison of Two Antibotic Regimens for the Treatment of Soft Tissue Pelvic Infections. (FY-79 I)	477
4169	Effectiveness of Heat Lamps and Surgigators in Promoting Comfort and Healing of Median Episiotomies. (FY-79 I)	480
4170	A Phase II Trial of Chlorozotocin in Patients with Advanced Pelvic Malignancies. (FY-80 I)	483
4171	GOG #48, A Study of Progestin Therapy and a Randomized Comparison of Adriamycin Versus Adriamycin Plus Cyclophosphamide in Patients with Advanced Endometrial Carcinoma after Hormonal Failure. (FY-80 F)	484

DEPARTM	ENT OF RADIOLOGY	
Nuclear	Medicine Service	PAGE
4501	Clinical Evaluation of Fluorescence Scanning of the Tryroid with an Americium 241 Source. (FY-73 T)	
4514	Clinical Evaluation of Indium-DTPA. (FY-75 I)	485
4521	Technetium-99m-pyridoxylideneglutamate (99mTc-PG) for Diagnosis of Hepatobilary Disease. (FY-79 I)	490
45 2 2	Determination in Humans of the Effective Half-Life of Botulism, Immune Plasma (Human) Administered Intravenously. (FY-80 I)	493
4523	Determination of Glomerular Filtration Rate using Radiotracer Techniques. (FY-S0 $^{-1}$)	4 95
nadiati	on Therapy Service	
4601	Participation in the Cational Cooperative Study of Larly Hodakin's Disease. (EY-69 1)(transferred to Homatology-Oncology Carvica)	496
viagnos	tic Radiology Service	
4 7 56	Eye Tracking in Radiologists. (FY-10 1)	498
4701	Comparison of Test Chest Phantons with James Subjects on Sudjo-graphic Chest Unit. (PY-50 r)	49 9
4702	Video Transmissions, Storage and Diagnostic Evaluation. (21-5: 1)	501
$Di(PI \times I)$	ALIST OF PATHOLOGY	
blood 1	enk	
5504	Identification of Secretor Status in Group t Individuals by Lamanodiffusion. (FY-30-1)	
1 27 212	matt of Paulicialo	
,01.	comporm tost Defenses: 1. Covologiantal Aspects of weather - contropail Chesotoxis. (FY-77 β γ)	502
*; ** !	The cole of continizian horzone colorsine (b.c.) in evaluation of the dypothelia is situitary domain Acids in Children. ('r-7 ''') covour. Foot extensis II. (tulies of the econoral mass city of branchesia acception as colorator from s. (rh-7'' 1)	504 506
٠.	wasan a san was some till a farmountasis må sillias og grand	508

DEPAR	TMENT OF PEDIATRICS continued	PAGE
6025	Role of Surface Tension Measurement of Amniotic Fluid Lipid Extract in Prediction of RDS in the Newborn. (FY-78 1)	510
6026	Tracheal Aspirate Surface Tension as a Prognostic Indicator in Infants with Respiratory Distress Syndrome (RDS) (FY-78 1)	513
6027	WRAMC #7808, Combined Modality Therapy of Brain Tumors in Childhood. (FY-78 F)	514
6028	Application of Hemoglobin A_{1C} as an Indicator of Juvenile Diabetic Control. (FY-79 F P)	515
6029	Newborn Host Defenses III. Studies of Newborn Neutrophil-Neutrophil Interaction. (FY-79 I P SP)	516
6030	Studies of Adult and Newborn Neutrophil Chemotaxis under Agarose. (FY-79 I)	518
6101	SWOG #7834, Second Induction and Maintenance in Acute Lymphocytic Leukemia, Phase III. (FY-79 1)	520
6102	SWOG #7703, Radiation Therapy in Combination with BCNU, DTIC, or Procarbazine in Patients with Malignant Gliomes of the Brain. Phase III. (FY-79 I)	522
6103	SWOG #7919, Evaluation of m-AMSA in Children with Acute Leukemia and Non Hodgkin's Lymphoma in Relapse. Phase II. (FY-79 I)	523
6104	SWOG #7818, Evaluation of Rubidazone in Children with Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia. (FY-79 I)	524
6105	SWOG #7607B, Evaluation of Lithium Carbonate in the Amelioration of Hematopoietic Toxicity following Cancer Chemotherapy in Children with Solid Tumors being Treated AD-CON-FU, Phase II. (FY-79 I)	525
6106	SWOG #7604, Evaluation of Galactitol in Patients with Advanced Cancer, Phase II. (FY-79 F)	526
6107	SWOG #7810, Evaluation of Anguidine in Children with Acute Lymphoblastic and Non-Lymphoblastic and Non-Lymphoblastic Leukemia in Relapse, Phase II. (FY-79 I)	527
6108	SWOG #7621, MOPP Versus OPP in the Treatment of Children with Recurrent Brain Tumors, Phase III. (FY-79 I)	528
6109	SWOG #7709, Evaluation of Compliance in Children with Malignant Disease Treated with Prednisone. (FY-79 F)	529
6110	SWOG #7865, Acute Lymphoblastic Leukemia Classification Portion of Alinc 13. (FY-79 I)	530

DEPART	TMENT OF PEDIATRICS continued	PAGE
611 t	SWO: #7812, Evaluation of Anguidine in the Treatment of Central Nervous System Tumors, Phase 41. (FY-79 I)	531
6112	SWOG $\$7843$, Evaluation of Rubidazone in the Treatment of Children with Solid Tumors. (FY-79 I)	532
6113	SWOG #7617, Combination Chemotherapy with Vinblastine Sulfate and Bleomycin Infusion in Children with Metastatic Solid Tumors, Phase II. (FY-79 I)	533
6114	SWOG #7831, Evaluation of Neocarzinostatin in Children with Acute Lymphoblastic and Acute Non-Lymphoblastic Leukemia in Relapse, Phase II. (FY-79 F)	534
6115	SWOG #7376, Evaluation of the Natural History of Histiocytosis X. (FY-79 I)	535
6116	SWOG 7612, MOPP Plus Bleo and A-COP with IF Radiation Therapy in Stage III Hodgkin's Disease in Children. (FY-79 I)	536
6117	SWOG #7712, Comparison of Treatment Regimens for the First CNS Relapse in Children with Acute Lymphocytic Leukemia. (FY-79 I)	537
6118	SWOG #7905, A-COP Plus for Non-Hodgkin's Lymphoma in Children. (FY-79 I)	538
6119	SWOG #7796, Adjuvant Chemotherapy for Localized Unilateral Retinoblastoma, Reese-Ellsworth Group 5, Phase III. (FY-79 I)	539
6120	SWOG #7837, Evaluation of Systemic Therapy for Children with T Cell Acute Lymphatic Leukemia. (FY-79 I)	540
6121	SWOG #7799, Rare Tumor Registry. (FY-79 I)	541
6122	SWOG #7829, A Comparison of Two Dose Regimens of Intrathecal Methotrexate for Treatment of CNS Leukemia, Phase II. (FY-79 I)	542
6123	SWOG #7623, Evaluation of Systemic Regimens in the Treatment of Acute Leukemia of Childhood. Phase III. (FY-79 I)	543
6124	SWOG #8000, The National Wilms Tumor Study - 3 (FY-79 I)	544
6125	SWOG #7909, Evaluation of MOPP Adjuvant Chemotherapy in the Treatment of Localized Medulloblastoma and Ependymoma, Phase III. (FY-79 I)	545
6126	SWOG #7994, Therapy for Extraocular Retinoblastoma with Cyclo-phosphamide, Vincristine, Adriamycin and Irradiation. (FY-79 I)	546

DEPAR	TMENT OF PEDIATRICS continued	PAGE
6127	SWOG #7721, Evaluation of Induction, Remission Maintenance with and without Periodic Reinforcement, and CNS Prophylaxis in Acute Non-Lymphocytic Leukemia, Phase III. (FY-79 I)	547
6128	SWOG #7901, Rescue Therapy for Non-CNS Extra-Medullary Disease in Children with Acute Lymphoblastic Leukemia, Phase III. (FY-79 I)	548
6129	SWOG #7906, Multidrug Adjuvant Chemotherapy in Non-Metastatic Osteosarcoma, Comparison of Conpadri-I with Compadri-V, Phase III. (FY-80 I)	549
6130	SWOG #8002, Combination Chemotherapy with Adriamycin, Cis-Diamminedichloroplatinum, Vincristine and Cytoxan in Children with Metastatic Neuroblastoma. Stage IV. (FY-80 I)	550
6131	SWOG #8075, Circulating Immune Complexes in Pediatric Malignancies. (FY-80 I)	551
DEPART	MENT OF NEUROLOGY	
7111	Interruption of Maintenance Neuroleptic Therapy. (FY-77 F)	552
7115	Investigation of the Value of Brain Stem Auditory Evoked Response Test in Posterior Fossa Lesions. (FY-80 T)	
DEPARTM	MENT OF PSYCHIATRY	
7214	Pre- and Post-Discharge Assessment of Psychiatric Patients. (FY- $77\ \mathrm{F}$)	554
7217	Management of Impairment of Accomodations Secondary to Psychotropic Medication. (FY-78 F)	556
7218	Physotigmine Infusion and Lithium Responsitivity. (FY-79 I)	558
7219	Reliability of Serum Tricyclic Antidepressant Levels. (FY-79 F)	560
7220	The Developmental Significance of Transitional Objects. (FY-80 F)	562
7221	The Effect of Hypnotic Intervention on the Electroencephalogram of Low, Medium and High Hypnotic Capacity Patients. (FY-80 I)	563

Psychology		PAGE
/300	LSD Follow-Up Study (Establishment of Mormal Controls for Meuro-psychological Examination). (FY-79 1)	564
7301	Baseline MMPI Profile for an Active Duty Military Population. (FY-79 I)	566
DIVISION	OF HEMATOLOGY, WRAIR	
9010	Vitamin B ₆ Metabolism in the Hematopoietic System of Patients Receiving Isoniazid and Patients with Sideroblastic Anemia. (FY- 75 I)	568
9012	The Effect of Infectious Hepatitis on Erythroid Colony Formation by the Plasma Clot Culture Method. (FY-77 T)	570
9013	The Corbohydrate Dependence of Platelet Surface Interactions in Hypercoagulable Stress. (FY-77 T)	
9016	Investigation of Pyridoxine as a Treatment for Sickle Hemoglobinopthies. (FY-78 PI)	571
9019	Antisickling Agents: Alteration of Hemoglobin Oxygen Affinity. (FY-79 PI)	573
9020	The Effects of B_6 Aldehydes on Red Cell Oxygen Affinity. (FY-79 PI)	577
9021	Human-Marrow-in-Mouse Chimera. (FY-80 I)	579
9022	Iron Tolerance Test (ITT). (FY-80 I)	580
9024	The Effect of Microwave Exposure on Immune Regulatory Function. (FY-80 F)	581
GASTROEN	VIEROLOGY SERVICE, WRAIR	
9025-A	Functional Characterization of Human Intestinal Lymphocytes in Gastrointestinal Disorders. (FY-77 T)	
DIVISION	N OF SURGERY, WRAIR	
9030	Circulating Serum Isoenzymes in Mesenteric Infarction. (FY-77 I)	582
9031	Study of Control Mechanisms for Human Castric Parietal Cells. (FY-80 I)	587
9032	In Vitro Analysis of Human Colon Ion Transport Mechanisms. (FY-80 I)	588

AFIP	•	PACE
9035	Effects of Altitude, Mood and Dietary Habits on Performance of Choice-Reaction Time Task. (FY-77 I)	589
9036	Urease and Deaminases in Chemistry and Medicine. (FY-77 I)	590
9037	Localization of Lymphocyte Antigenic Markers in Fixed Paraffin-Embedded Sections. (FY-79 F)	593
DEPART	MENT OF NURSING, WRANC	
9036A	The Educational and Psychological Need Specific to Human Sexuality of Middle Aged Males Post Uncomplicated Myocardial Infarction. (FY-79 1)	591
90393	Nurse Controlled Factors that Influence the Development of Diarrhea in Tube-Fed Patients. (FY-79 1)	594
90403	Reducing Discomfort from Intramuscular Injections in the Dorsoguteal Muscle by Proper Body Positions. (FY-79 I)	596
90413	Attitudes of Health Care Workers toward the Occurrence of Violence in Close Realtionships. (FY-79 I)	601
PROTOC	COLS FROM OTHER MEDDAC FACILITIES	
9080	Coronary Artery Disease and Coronary-Prone Behavior. (FY-79 PI)	603
9082	Prevention, Treatment and Rehabilitation of Knee Injury at the U.S. Military Academy, West Point, N.Y. (FY-79 I)	607
9086	The Physical Fitness of Military Women Employed in Health Care Occupations. (FY-80 F)	609
9088	A Comparison of the Use of Cognitive Therapy and Hypnosis in a Group Setting for Treating Obesity. (USUHS & NNMC) (FY-80 1)	611
OTRER	DEPARTMENTS, WRAIR	
9100	Evaluation of Computer Assisted Drug-Drug Interaction Monitoring. (FY-80 I)	612
WRAMC	Regulation 70-1, Clinical Investigation Program	614
Author	Index	652
Code:	I = Interim Report F = Final Report P = Publications SP = Submitted Publications T = Terminated (a report had not been received by the time this report was collated, but a supplementary repuill be forthcoming.	ort
	xxvii	

Unit Summary Sheet

Department of Clinical Investigation Walter Reed Army Medical Center

This Annual Progress Report is for the Fiscal Year 1980.

1. Mission Changes

- a. Expansion. During FY-80, the Department of Clinical Investigation implemented a new Gastroenterology Research Laboratory in Bldg. T-2. With the help of a Veterinary Officer who is a collaborative investigator, this laboratory is already in full operation and has produced abstracts and publications to date.
- b. Currently there are thirteen (13) Clinical Investigation Laboratories at WRAMC with all but three (3) located in the new hospital.
- c. An animal procedures laboratory, formerly part of the Organ Transplant Service located at Forest Glen, and moved to Bldg #1 on main post in FY 79 is now in Bldg 7. Two portable containment systems for housing rodent size animals are on order thus providing us the ability to kennel rodents within our department. Surgical procedures and radioisotope injections are now carried out in this area. We continue to depend on WRAIR for kenneling and care of animals larger than rats.
- d. Through a \$1.8 million grant from the Veterans Administration, DCI WRAMC is supporting a study of Vietnam era veterans with projectile head wounds. The study, now in the data collection phase, will last approximately four years and will eventually accession about 1200 veterans which have been followed medically since their injury as early as 1967. CAT scanning will be used for the first time in a study of such size and scope. The project entitled, "Anatomical and Functional Sequelae of Head Injuries Incurred in Vietnam," was guided from its inception by Dr. William F. Caveness, M.D. until his death in January 1981. MAJ J.D. Dillon, MC, US Army, a neurosurgeon, has taken over as project manager and principal investigator. Term appointments for approximately ten people to conduct the project have been approved by HSC with hiring to proceed as soon as possible after the Presidential hiring freeze is lifted or further defined. We hope to begin accessioning patients in April 1981.
- e. Reference Interim change to HSC Reg 10-1, dtd 24 June 1980. The interim change establishes a Department of Clinical Investigation at WRAMC since WRAMC's activity consists of ten (10) or more personnel. The interim change also deletes the Clinical Investigation Service for such activities consiting of ten (10) or more personnel. The interim changes is effective until superseded by a formal printed change to HSC Reg 10-1; and as an interim measure, issued in other than page-forpage format.

2. Personnel Actions, Current Strength

 ${\tt a.}$ Personnel hired on temporary appointment to provide support to investigative projects.

Alston, Stephanie GS-02 0699 Wang, Elizabeth GS-13 0180

b. Current Manpower

Description	Grade	MOS	Br	Actual	Name
C, Clin Invest Dept. Asst C, Clin Invest Dept. Lab Officer (Admin)	05 04 04	61F9C 61F9B 68F9D	MC MC MSC	1 1 1	Boehm Schuster Reed
Biochemist Dietitian Med Lab NCO	03 03 E7	68COO 342O 92B	MSC AMS AMED	1 1 1	Bongiovanni Douglas Moody
Med Lab SP Med Lab SP Science & Eng	E5 E4 E6	92B 92B 01H3O	AMED AMED	1 1 1	Lambert Morgan Shelton
Supv Rsch Chemist Microbiologist Microbiologist Admin Officer Physiologist Physiologist	14 12 12 11 11	1320 0403 0403 0341 0413	GS GS GS GS GS	. 1 1 1 1 1	Bruton Dobek Ciak Burton Wright Lukes
Bio Lab Tech	09	0404	GS	2	Dickson Butler
Med Tech	09	0644	GS	2	Armstrong Burgess
Chemist	11	1320	GS	2	Dawson Rice
Chemist	09	1320	GS	1	Maydonovitch
Med Tech Bio Lab Tech Med Tech	09 08 07	0645 0404 0644	GS GS GS	1 1 2	Barnes Coleman Bongiovanni Londono
Secy Steno Edit Asst Supply Tech	07 07 06	0318 1087	GS GS GS	1 1 2	Ervin Hepburn Laster Kuffler

Clk, DMT	04	0316	GS	2	McAnnally
Bio Lab Tech	05	0404	GS	1	Martin

3. Investigation Program Summary

Number of Active Protocols	269
Number of Completed Protocols	66
Number of Terminated Protocols	32

4. Incentive

The Bailey K. Ashford Award medallion presented annually to the staff member at Walter Reed Army Medical Center whose research project was voted the most outstanding contribution to the WRAMC investigative program was Major Thomas G. Brewer, MC, Gastroenterology Service, for his paper entitled, 'Maximal Rate of Urea Synthesis Reflects Hepatic Cell Mass in Rats"; and Major Louis N. Pangaro, MC, on the metabolism of the thyroid hormones in health and disease.

5. Funding, FY-80:

Civilian Personnel	\$536,214.18
Military Personnel	\$327,094.34
Travel	\$ 21,500.00
Contracts	\$115,000.00
Supplies	\$472,800.00
MEDCASE	\$ 68,101.00

Total \$1,540,709.52

DEPARTMENT OF MEDICINE

- Johnson JP, et al. 'The Role of Plasmaphoresis in Anti-GBM Mediated Renal Disease Controversies in Nephrology 1979, Winchester and Schriener, eds., 1987.
- Pangaro L. Burman KD and Wartofsky L, et al. Thyroid Function Tests in Cord Blood Maternal Serum Fluid. JCEM 50:1075, 1980.
- Pangaro L, Burman KD. and Wartofsky L. Investigations into the Physiology of RT3 and 3,3'T2. JCEM 50:1075, 1980.
- Surman KD, et al. The Cffect of Obesit, and Fasting at T3 Receptors in Mr. or Cells. JCEM 51:106, 1980.
- Whay HE. Effect of Tg and rTg on Plasma Cycle Nucleotide Levels on Sherger Endocrinology 107:130-136, 1980.
- Glass AR. Insulin Resistance in Diabetes: Relative Effect on Glucose and Amino Acids. Presented at the American Diabetes Association Meeting and at the International Symposium, 1980. (Abstract)
- Pangaro L, et al. Glucose Regulation, Peripheral Thyroid Hormone Economy in Fasted Subjects. JCEM 50:1075, 1980.
- Burman KD, et al. Alterations in TRH Stimulation in Obesity and Fasting. Metabolism 29:46, 1980.
- Wray HL. Effect of Thyroid Status on the Hormonally-Induced Cyclic AMP Response of the Kidney. Endocrionlogy 106 (Suppl):122, 1980.
- Vigersky RA and Glass AR. "Effect of Delta-1-Testolactore (Teslac) in Oligospermic Men". J. Andrology 1:67, 1980.
- Wray ML, Burman KD, et al. Investigations Concerning the Physiology of Iccothyronicss. JCEM 107:130, 1980.
- Pangaro LP, Burman KD, et al. The Development of a Radioimmunoassay of Trilodotimus JCEN 50:130, 1980.
- Vigersky RA, Mozingo D, Eil E, Purohit V, and Bruton J. "Anti-Androgenic Property of Delta-1-Testolactone (Teslac). Presented at the Endocrine Society June 1980.
- Smallridge RC. Radioactive Assessment of Cardiac Function in Patients with Acromegaly. Clinical Research 28:198A, 1980.
- Smallridge RC. Breast Cardinoma and Thyroid Hormone Receptors. Clinical Research 28:421A, 1980.
- Burman FD, et al. The Effect of Fisting Upon TSH Response to TRH. Metabolic 29:46, 1980.

DEPARTMENT OF MEDICINE (continued)

- Smith C, Mehlman T, and Vigersky RA. 'Treatment of Hirsutism with Cimetidine'.

 Presented at the 62nd Annual Meeting of the Endocrine Society, June 1980.
- Raveche E, Vigersky RA, Tjio JH, and Steinberg A. 'Murine Thymic Androgen Receptors'. Presented at the Amer. Rheumat. Assoc., May 1980.
- Brewer TG, Dunn MA, Berry WR and Harmon JW. Urea Synthesis Reflects Hepatic Mass in Rats. Gastroenterology 79 1980.
- Tramont EC. <u>Treponema Pallidum</u> (Syphilis) in Principles and Practice of Infectious Disease. Chapter 180, 1979, Mandell, Ronnett and Douglas, McGraw Hill, eds), New York.
- Dobek A, Klayman L, Dickson E Jr., acovill J, and Trament EG. Inhibition of Clinically Significant Eacterial Organisms In Vitro by 2-Acatylpyridine Thiosemicarbazone. Antimicrobial Agents and Chemotherapy. 18 (1):27-36, 1980.
- Tramont EC, Clak J. McChesney D, Boslego JW, and Brinton CC. Cross Reactivity of Gonococcal Pili as Determined by Inhibition of Epithelial Cell Attachment. Presented at the ICCAC, Boston, Mass, 1979. (Abstract)
- Tramont EC, Boslego JN, Sadoff J, Zollinger W, Lolik A, Bryan J, and Brinton CC. Safety and Tamunogenicity Study of Gonococcal Pilos Maccine. Presented at the ICCAC, Boston, Mass, 1979. (Abstract)
- Tramont EC, Ciak J, Boslego JW, McChesney DG, Brinton CC, and Zollinger W. Anti-Genic Specificity of Antibodies in Vaginal Secretions During Infection with Neisseria Conorrhoeae. J Infect. Dis. 142:23-31, 1980.
- Tramont EC. Role of Adhesion of Neisseria Conorrhogon in Allegae . Presented at the City Toundation Symposica London, UK, 1950.
- Boslego JW, McChesney DG, Sadoff J, Ciak J, and Tramont EC. Funan Genital Antibody Response to a Gonococcal Pilus Vaccine. Presented at the ICCAC, New Orleans, 1980. (Abstract)
- Burman KD, et al. The Effect of Glucagon on Thyroidal Economy. JCEM, In Press.
- Burman KD, et al. Regulations if the Initiation of Thyroid Hormone Action. Hormone Metab. Res: In Press.
- Smallridge RC and Wray HL. Studies on the Pathogenesis of Hypocalcemia in Tumors Associated with Osteoblastic Metastases. Amer J Med, In Press.
- Glass AR, Dahms WT, and Swerdloff RS. Body Fat at Puberty in Rats: Alterations by Changes in Diet. Pediat Res 13:7-9, 1979

DEPAREMENT OF MEDICINE (Continued)

- Glass AR, Mellitt R, Vigeraky RA, and Swerdinff RS. Hypoandrogenism and Absormal Regulation of Cunadotropin Secretion in Rats Fed a Low Protein Diet. Endocrinology 104:438-442, 1979.
- Glass AR, Scheaf, and Dimond RC. Absent Greath Hormone Response to L-tryptophan in Acron-galy. J Clin Endocrinol Metab 48:664-666, 1979.
- Glass AR, and Smith CE. Stress-Induced Cortisol Release in Hypothalamic Hypoadcenalism. J.A.M.A 241:1612-1613, 1979
- Kidd GS, Glass MR, and Vigner / RA. The Hypothalamic-Pituitary-Testicular Axis in Thymotoxicusts J Clin Endocring Motab 43: 798-802, 1979.
- Glass AR, and Berenberg J. Gymecomestia after Chemotherapy for Lymphoma. Arch Int Med 139:1048-1049, 1979.
- Glass AR, Schaaf M, and Dimond RC. Amitriptyline-Induced Suppression of Growth Hormone in Acromagaly. <u>Psychoneumcendocrinology</u>: 5:81-86, 1980.
- Glass AR, and Swerdieff RS. Nutritional Influences on Sexual Materiation in the Rat. Four Proc 39:2360-2364, 1980.
- Raum WJ, Glass AR, and Swerdloff RS. Changes in Hypothalamic Catecholamine Neurotransmitters and Pituitary Gonadotropins in the Immature Female Rat: Relationships to the Gonadostat Theory of Puberty Onset. Endocrinology 106:1253-1258, 1930.
- Glass AR, and Vigersky RA. Correlation Between Acute and Chronic Increases in Serum Gon.dal Steroid Levels After HCG Administration. Fertil Steril: 34:41-45, 1980.
- Glass AR, and Vigersky RA. Leydig Cell Function in Idiopathic Oligospermia. Fortil Steril 34:144-148, 1980.
- Glass AR, Smallridge RC, Schaaf M, and Dimond RC. Absent Prolactin Remonse to L-tryptophan in Normal and Acromegalic Subject. Psychoneurocadocrinology 5:261-265, 1980.
- Vigersky RA, Mahlman I, Glass AR, and Smith CE. Treatment of Hirsute Women with Cimetidine: A Preliminary Report. N Engl J Med: In Press.
- Glass AM, and Vigersky RA. R siffration of Testosterone Production in Men After HCG-Induced Doses circuits. J Clin Engerisal Metab: In Press.
- Glass AR, Burman ID, Dahms WT, and Boehm TM. Endocrine Function in Human Obesity. Metabolism: In Press.

DEPARTMENT OF MEDICINE (continued)

- latham KR, Tseng YL, and Class AR. Nuclear Thyroid Hormone Receptors in ob/ob Mice. Clin Res 27:256A, 1979. (Abstract)
- Glass AR, Schaaf M, and Dimond RC. Amitriptyline-Induced Suppression of Growth Hormone in Acromegaly. Physiologist 22:70, 1979. (Abstract)
- Glass AR. HCC-Induced Block in Testosterone Production in Man. Proc. Endo. Soc. 61st Aum Mug, 1979, Abstract 832.
- Vigersky RA, and Class AR. Effect of Testolactone (Teslac) in Oligospermic Men. J Andrology 1:67, 1980. (Abstract)
- Tseng YL, Glass AR, and Latham KR. Thyronine Metabolism in Pat and Liver Homogenated from Rats and Genetically Obese Mice. Presented at the Endocrine Society 62nd Annual Meeting, 1980, Abstract 94.
- Smallridge RC, Glass AR, Wartofsky L, Ward KE, and Bouman KD. Investigations into the Ecology of Elevated Serum Tri-iodothyrocine (T3) Levels in Protein Malrourished Rats. Presented at the Endocrine Society 52nd Annual Meeting, 1930, Abstract 596.
- Glass AR, Bonglovachi R, and Boebm DM. Insulin Resistance in Obesity: Differential Effect on Glucose and Amino Acid Disposal. <u>Diabetes</u> 29 (Supp2): 20A, 1980.
- Burman KD, Smallridge RC, Osburne R, Dimond RC, Whorton NE, Kesler P, and Wartofsky L. Nature of Suppressed TSH Secretion During Undernutrition: Effect of Fasting on TSH Responses to Prolonged TRH Infusion.

 Metabolism 29:46-52, 1980.
- Smallridge RC. Want of May L., and Discondance Between the Suppressive Effects of Corticosteroids and Thyroid Homone. J Clin Endocrinol Metab 43: 00-705, 1979.
- Chernow B, Johnson IF, Janowitz WR, and Castell DO. Fulmonary Aspiration as a Consequence of Castroesophugeal Ceflux Congruentic Approach. Dig Dis & Sci 24:839-844, 1979.

DEPARTMENT OF SURGELY

- Harmon C.L. Use of Copolymer as a Lattice for the Growth of Reogut. Surgical Forum 30:365-366, 1979.
- Kramer KK. Eltrasonographic Measurement of Chorcdial Melanoma. Presented at the Angual Association in Research and Vision in Opthamology Meeting May, 1980. Orlando, Florida. (Abstract)
- Schwartz DM, and Surr RK. Three Experiments on the California Consonant Test. J. Speech Hear. Dis. February, 1979.
- Schwartz DM, Surr RK, et al. Performance of High Frequency Impaired Listeners with Conventional and Extended High Frequency Amplification. <u>Audiology</u> 18, 1979.
- Schwartz DM, and Surr RK. High-Pass and Conventional High Frequency Hearing Aids for Listeners with High Frequency Sensorineural Hearing Loss.

 Auditory and Hearing Prosthetic Research, Larson VD, Egolf D, and Hirlin L eds,.) Grune and Stratton 1979.
- Punch JL, Montgomery AA, Schwartz DM, Walden BE, et al. Multidimensional Scaling of Quality Judgments of Speech Stimuls Processed by Hearing Aids. J. Acoust. Soc. Am. 68, 2, 458-466, 1980.
- Montgomery AA. "Coarticulation and Lipreading: Comparison of Synthetic and Real Stimuli". Presented at the ASHA Convention, November 1979. (Abstract)
- Light JA. ALG Reverses Irreversible Rejection. Presented at the Transpl. Society July 1980. (Abstract)

ALLERGY AND RHELMATOLOGY SERVICES

- deShazo RD, Levinson HI, Dvorak HM, and Davis RW. Late Phase Skin Reaction. J. Immunol. 122:692, 1979.
- Smith JA, Mansfield LE, deShazo RD, and Nelson HS. An Evaluation of the Pharmacologic Inhibition of the Immediate and Late Outaneous Reaction to Allergen. J Allergy Clin Immunol 65:119, 1980.
- Smith L, Kaliner M, Davis P, Shelhamer J, and Hubbard V. Autonomic Nervous System Dysfunction in Patients with Cystic Fibrosis. J Allergy Clin. Imamol. 65:217, 1980.
- Shelhamer JH, Metcalfe DD, Smith LJ, and Kaliner M. Abnormal Adrenergic Responsiveness in Allergic Subject: Analysis of Isopro-Terenol-Induced Cardioviscular and Plasma Cystic AMP Responsed. J Allergy Clin. Immunol. 66:52-67 1980.
- Bookm TM, Kura : DA and Galloway JV. Permishent Levil Laccelons to Insulia, Evidence for Three Emmunologic Mechanisms. If esented at the American Academy of Allergy Meeting, 1980. (Abstract)
- Floyd M and Tesar JT. The Role of LgM Rheumatoid Factor in Experimental Vasculitis. Clin. Exp. Immunol. 36:165, 1979.
- Berne BH, and Lawless QJ. Re-evaluation of Anti-DNA Antibody Levels Detected by the Farr Technique and FIAX Immunofluorescence issay. Glinical Chemistry 26:1072, 1980.
- Ramirez DA and Evans R III. The Diagnosis of Hymenoptera Hypersensitivity. J. Allergy Clinical Immunol. In Press 1980.

DEPARTMENT OF PEDIATRICS

- Mease AD, Fischer GW, Humter KW, and Ruymann FB. Decreased Phytohemagg-Lutinin-Induced Aggregation and C5a-Induced Chemotaxis of Human Newborn Neutrophils. Pediatr. Res. 14:142-146, 1980.
- Mease AD, Burgess DP, and Thomas PJ. Differences Between Neonatal and Adult Complement-Induced Neutrophil Aggregation and Cellular Augmentation of Neutrophil Chemotaxis. Pediatr. Res. 14:549

DEPARTMENT OF PSYCHIALICY

Hunter JG. The Developmental Significance of Transitional Objects. Presented to the Annual Department of Psychiatry Research Symposium, June 1980.

DEPARTMENT OF HEMATOLOGY, MEALS

- Kark JA and Lossin LS. Sickle Cell Disease and Variants in Hematology and Oncology M. Lichtan, eds,.) Gruns and Stratton, Inc., New York, NY, pp. 89-97, 1980.
- Kark JA, Hannah JS, Hick CU, Rongi Wenni R, Lessin LS, and Hayes K. Vitamin B6 Aldehydes as Potential Antisickling Agents. Presented at the Fifth International Red Cell Conference, September 1980, Ann Arbor, Michigan.
- Kark JA, Hicks CU, and Bergiovanni R. Inhibition of Erythrocyte Sickling by Pyrideral Phosphate. Clin. Res. 28:315A, 1980.

USU II3

- Krantz DS, Schaeffer M, Davia JE, Dembrosk TM, MacDougall JM, and Shaffer RT. Investigation of Extent of Coronary Atherosclerosis, Type A Behavior and Cardiovascular Response to Social Interaction. Presented at the Suciety for Psychophsiological Research, Vancouver BC, October 1980.
- Krantz DS, Glass DC, Schaeffer M, and Davia JE. Behavior Patterns and Coronary Disease: A Critical Evaluation. J.T. Cacioppo and R.E. Petty eds.,) Focus on Cardiovascular Psychophysiology, New York: Gulford, In Press.

TITLE: Stress Ulceration in a Medical ICU: Incidence and Possible Prevention with Cimetidine

INVESTIGATORS:

Principal Investigator:

Dr. Lawrence F. Johnson Dr. Michael T. Keegan

DATE COMPLETION: Estimated January 1982

OBJECTIVE: To prove in a double blind randomized fashion if Cimetidine is effective in decreasing the incidence of stress induced gastrointestical homorrhage in the Medical Intensive Care Unit.

TECHNICAL APPROACH: See Protocol

PROGRESS and RESULTS: Since the last report, 2 patients have been added to the study. The double blind code has not been broken, so it is impossible to determine at this time the efficacy of Cimetidine vil placebo. Interim evaluation of the submitted data to Smith, Klein, French on 38 patients seems to indicate that there is some trend, but they are not willing to say that there is any significant difference between the two groups at this time. In patients studied so far, there have been no untoward side effects that could be related to the study drug or the protocol. Of note is that accession of patients to the study has been hampered somewhat by the wide spread use of Cimetidine in this hospital and outlying referral hospitals.

CONCLUSIONS: Forty patients have been studied to date under the protocol. Bocause it is a blinded coded protocol and the code has not been broken and no results are available at this time, it is anticipated that adequate data can be obtained with a total pool of 50 patients, it is asked that the study be continued until at least 10 more patients are accounted.

GUNDS UTILIZED: None

FUNDS REQUESTED, FY 80: Same as original protocol

PUBLICATIONS TO DATE: None

TYPE OF REPORT: Interim

ADDENDUM:

Forty patients have been studied under the protecol and there have been no untoward side effects noted that could be definitely related to the drug or to the protecol. On site inspection and drug inventory has been carried out as prescribed by EDA regulations by Chith, Klein, French. Company on a regular basis.

Date: 1 December 1980	Protoco	l No:	1005	Status: Interim X
Title of Project:				Final
Polycythemia Vera Study Gr the Treatment of Primary T			y Trial usin	ng Hydroxyurea (HU) in
Starting Date: 22 January 19	80 Estir	nated (Completion I	Date: Within the next fiscal
Principal Investigator: Dani	el B. Kimba	11, J	r., COL, MC	year.
Associate Investigators: Staff and Fellows of the B Oncology Service	lemato.logy-	Facili	ty: WRANC	
- Checology Service		Dept/	Svc Departs	ment of Medicine
Key Words:		al.		•
Accumulative MEDCASE Cost:			Contract	Accumulative Supply Cost:
FY-80 MEDGASE Cost	e Principalisano de Pala de La Septembra de Principalisa. Principalisa de La Septembra de Pala d	<u> </u>	Periodic Re	eview Results:
Technical Approach:				
" -			•	en de la companya de La companya de la companya del companya de la companya del companya de la c
$\frac{1}{2} \frac{1}{2} \frac{1}$				
en de la companya de La companya de la co			• •	
ng nghiệt được nhiều biểt thiết nhiều nhiều khi Thiết khiết họi nhiều nhiều khiết hiệt hiệt hiệt hiệt hiệt hiệt hiệt hiệ	r i rational La Caracteria			
Progress during FY-80:	malo i istore	••••		errore e e e e e e e e e e e e e e e e e
No patients from Walter Reprotocol. Nationally 43 p	atients hav	re beer	accrued to	been entered on this nations this study of whom 26 have evaluable patients 12 achie
Number of subjects to be student				
Serious/unexpected side effec				
Conclusions: Protocol 12 co	ntinues to	be one	en for patie	ent accrual and it is antici-
pated that 12 more patients to the prococol.	acquired r	ation	ally would p	provide for complete accrual
Publications or Abstracts, T	Y-80: Nor	ie .		

.

Progress during FY80 (Continued):

a complete remission as defined by a plateate count of less than 450,000. An additional 9 patients have had good partial responses with platelet counts being maintained in the normal range or less than 600,000 for periods of greater than one year in 12 of 21 patients. Only 2 patients have had no response to Hydroxyurea. Toxicity has been mild and consisted mostly of leukopenia. One patient has had pharyngitis and rash secondary to the Hydroxyurea. Three deaths on the study have occurred. One patient died after being in complete remission for a period of more than one year and after Hydroxyurea therapy was discontinued and the patient then relapsed. The Hydroxyurea was restarted in an inappropriately high dose, the patient developed pancytopenia and subsequently died of Candida septicemia. One patient with a history of a previous polycythemia vera developed herpes zoster infection and then went on to develop peripheral blasts and acute leukemia and died of pneumonia. The third death was an elderly patient who died in a nursing home of cardiac causes.

Date: 1 P	Protoco	J. No. 1006	1616		-
Date: 1 December 1980	[17/01060]	1 No: 1006	Status:	Interim X	_
Title of Project:			L	Final	_
Polycythemia Vera Study Gr	oup Protoco	ol #8, Efficacy Tr	ial Using Hyd	roxyurea (H	(ע
in Polycythemia Vera				•	
Starting Date: 22 January 1	980 Esti	mated Completion I	Dota: To do and	101-0-3 -1	_
		mateur Compretion 1	protocol wil	1 be closed	at the
Principal Investigator: Dan	iel B. Kimb	all, Jr., COL, MC	ally within	the next ye	ar.
Associate Investigators:					-
rosocime masminicis;		Facility: WRAMC			
Staff and Fellows of the H	ematology-				_
Oncology Service	0,7	Dept/Svc Departm	ent of Medici	ne	
Y					_
Key Words:					•
Accumulative MEDCASE	A =	3 // 6			_
Cost:		ulative Contract	Accumu	lative Supply	
	Cost:		Cost:		_
FY-80 MEDCASE Cost:		Periodic Re	view Results:		-
	•		ed in by DCI)		-
Progress suring FY-30: No been randomized to this pro-	patrients i	rea the Wilter witionally 65 patie	od Army Medic nos have been	entered in	to
this study. The study to had an initial response.	date has in The duratio	dicated that 100% n of the response	, of all pati however va	ents treated ried from b	d have rief
Kumber of subjects to be stud					(over
sricus/unexpected side effec					-
Conclusions: The study remains	ing onen f	or patient accrua	1 and chara b	hat Heda	
an effective agent for the	initial co	ntrol of newly di	L and Snows t	uat nydroxy(vthemia rub	irea ji
It will take further time t	o decide w	hether the leukem	ia risk is as	great with	this
Publication of Abstracts, F		nt as it is with			

Progress during FYSO: (Continued)

to greater than one year. With regard to toxicity slightly more than 50% of the patients had significant toxicity with thrombocytopenia being the most common and leukopenia the next most common as would be expected. Despite the frequency of leukopenia, no patient had a significant infection and evidence of clinical bleeding was rare despite marked thrombocytopenia in some patients. Anemia was of no clinical significance. Twenty-one of 46 patients achieved excellent control without need for any further phlebotomy. Eleven per cent had a satisfactory response with only one occasion per year where the patient was considered to be out of control, that is a hematocrit greater than 50% or a platelet count greater than 1,000,000. Forty-four per cent of the patients failed to achieve adequate control by the criteria mentioned above. Clinically, however, many of these patients who were categorized as failurer did very well. There were two deaths in patients in the study which occurred relatively early, but they were not due to inadequate management. There were also two major hemorrhagic apisodes, one case of Mallory-Weiss Syndrome which was thought possibly to be secondary to gastrointestinal upset resulting from the Hydroxyures therapy and there was one opisode of gastrointestinal bleeding. An analysin by .. group of the failure of the Hydroxyures regimen suggested the following contributing causes: (1) incorrect doses, (2) inadequate doses despite lack of toxicity, (3) reduction in dosage of Hydroxyurea to inadequate levels after an initial episode of toxicity, (4) inadequate phlebotomy before the patient was started on Hydroxyurea therapy, (5) excessive early iron replacement therapy, and (6) patient unreliability. One patient on the study has developed acute leukemia and the patient had a complete remission following its treatment. Recommendations to investigators within the group included that the patients be phlebotomized adequately before starting Hydroxyurea therapy in order to avoid inadequate hematocrit control in the face of white cell or platelet toxicity. In previously untreated patients, excellent control has been obtained with Hydroxymus In greater than 75% of the cases, however, in patients who have previously been treated the incidence of excellent control is only 35%. Iron replacement as indicated by serum iron and per cent saturation does occur in patients treated with Hydroxyurea and seems to parallel the increase in mean corpuscular volume. Patients on the Hydroxyurea do not need to be phlebotomized unless the hematocrit is greater than or equal to 50%. A subcommittee has been appointed in order to plan a second generation protocol to spaceed this current study.

Date: 25 Santumbar 1980	Protocol No:	1121	Status: Interim x
Title of Project: "Combines Project:	ednisone and (e in the Treat	ytoxan Therap	y glomerular Basement Membrane
Starting Date: November 1975	Estimated	d Completion D	ate: December 1981
Principal Investigator: John	P. Johnson, M	ID, LTC, MC, D	ivision of Nephrology, WRAIR
Associate Investigators: Jack Moore, Jr., MO, MAJ, MO	1	ility: WRAIR a	nd WRAMC
Today may may may may may may may may may m	i i	t/Svc Nephrol	ogy Service
Key Words: Anti-GBM Diseas Cytoxic Therapy		re's Sundrome	, Plasma Exchange,
Accumulative MEDCASE	Accumulati	ve Contract	Accumulative Supply
Cost: n	Cost: 0		Cost: 0
FY-SO MEDCASE Cost: 0		[eview Results: ed in by DCI)

Study Objective: To compare the effect of Cytoxan and Prednisone alone and in combination with plasma exchange on the rate of disappearance of circulatory antiglomerular basement membrane antibody and the effect of this in modifying disease course.

Technical Approach: Patients are randomized based on last SS# digit to receive Cytoxan-Prednisons vs. Cytoxan, Prednisone + 4 liter plasma exchange three times weekly plasma exchange require the use of the Blood Bank for plasma exchange use and fresh frozen plasma. Serum samples are serially gathered and analyzed for anti-GBM activity gratis by Contis Wilson, MD, Chief, Immuno-Pathology, Scripps Pesearch Clinic, LaGe ia, California.

Progress during FY-80: Two patients have been enrolled in the protocol during FY 80. One patient is now stable in with the nephrotic syndrome and serum creatinine of 2.2 and is off protocol, having completed the regimen. The second patient is currently on the protocol, is undergoing plasma exchange, and is stable with a serum creation of subjects to be studied before completion of study: 6 Additional (Total of 20)

Serious/unexpected side effects in subjects participating in project: One patient developed Hobag negative nephritis which necessitated removal of the patient from the protocol The relationship between the heratitis and plasma exchange remains unclear, but his Conclusions: hepatitis has completely resolved.

Conclusions: hepatitis has completely resolved.

Unly tentative conclusions can be reached at this time. The rate of disappearance of anti-GBM antibody appears to be similar between the two groups, but the numbers studied are too small to reach definite conclusions.

Publications or Abotracts FY-80: Johnson, J.P. et al: "The Role of Plasmaphoresis in Enti-GBM Maddated Begal Disease" Controversies in Nephrology, 1979. Winchester and

Funds Utilized, FY-80: None

Funding Requirements, FY-81:

Personnel: John P. Johnson, MD, LTC, MC, Department of Nephrology, WRATR

Jack Moore, Jr., MD, MAJ, MC, Nephrology Service, WRAMC

Funds. None

Equipment: None

Funds: None

Supplies: None

Funds: None

Travel: Presentation at National Meetings

Funds: \$600.00

Other: Reprint Expense

<u>Funds</u>: \$300.00

Total Funds Requested, FY-81: \$900.00

Date: 13 October 1980	Protocol	l No:	1124	Status: Interim	
Title of Project: "The Effec Renal Failure"			a on Chronic	Pinal	
Starting Date: December 197	7 Estir	nated (Completion D	oate: Undetermined	_
	iel A. Nash	, Jr.,	MD, LTC, M	C	_
Associate Investigators:		Facili	ty: WRAMC	Nephrology Service	
None		Dept/	S vc Departi Nephro	ment of Medicine/ logy Service	
Kay Words: Hyperuricemia,	Chronic Re	nal Fa	ilure		
Accumulative MEDCASE Cost:	Accumi Cost:		Contract	Accumulative Supply Cost:	r
FY-80 MEDCASE Cost:				ed in by DCI)	
Study Objective: To determine the control of the co	ine if hype auses is a	erurice delete	mia occurri prious facto	ng in patients with core or in the progression of	Mic their
•					
Technical Approach: Patic hyperuricemia will be prosof hemodialysis or kidney groups whose hyperuricemic normalized with the use of plotted using the reciprose used for a marrison he	transplants is untread a is untread fallopuring the control of the control of the transfer of transfer of the transfer of transfer	ation. ted or ol. TI creation	Such patie into groups to course of the course.	ents will be randomized where the hyperuriceming their renal failure will alinear relationship	into a is 11 be p that ca
Progress during FY-80:	One addition	nal pa	tient was fo	bund with a suitable deg	rec s incomi
hyperuricemia and chronic dual has been followed probeen a total of 4 entries	renal rails ospectively into this	for a protoc	pproximately ol observat	y eight months. There h	ave from
Number of subjects to be stu	died before o	comple	tion of study	• 20	
Serious/unexpected side effe	cts in subjec	ets par	ticipating in	project: NONE	
Conclusions: NONE					

MOME

Publications of A stracts FY 80:

Funds Utilized, FY-80: MONE

Funding Requirements, FY-81:

Personnel: None

Equipment: None

Supplies: None

<u>Travel</u>: \$600.00

Other: None

Date: 13 October 1980	Protocol No:	1125	Status: Interim
Title of Project: "State of Pot Acute Leukemic Patient"	assium Balance	in the Adu	final X
Starting Date: June 1978	Estimated C	ompletion D	ate: Project Discontinued
Principal Investigator: Suzann	ie M. Bergman, M	ND, MAJ, MC	
Associate Investigators: James D. Fitz, MD, CPT, MC	Facilit		ephrology Service, Weohrology Service
Donald E. Butkus, MD, COL, MC Daniel A. Nash, Jr., MD, LTC,		lvc Nepart Nephro	tment of Medicine blogy Service
Key Words: Total Body Potass	ium, Acute Leuk	cemia	•
Accumulative MEDCASE Cost:	Accumulative (Contract	Accumulative Supply Cost: C
	······	Davindia Da	view Results:
FY-80 MEDCASE Cost: Study Objective: The objective contents with unt	re was to determine the determ	(to be fille nine the fre	d in by DCI) equency of total body pota
Study Objective: The objective epletion in patients with untrown modulators of potassium Technical Approach: 15-20 patudied for total body potassi	re was to determine the determ	(to be fille nine the fre n, and to as voly diagnose otassium, an	equency of total hody pota ssess the effects of thera ed acute leukemia would be nd serum potassium. This
Study Objective: The objective	re was to determine the determ	(to be fille nine the fre n, and to as vly diagnose otassium, an indicated h	equency of total body pota ssess the effects of thera ed acute leukemia would be nd serum potassium. This by standard therapeutic me
Study Objective: The objective epletion in patients with untrown modulators of potassium. Technical Approach: 15-20 patudied for total body potassive performed prior to and after the performed prior to and after the epice. Becausing and a second to the performance of the perfor	e was to determine the week to determine the with new um, red cell point treatment as	(to be fille nine the fre n, and to as nly diagnose otassium, an indicated be	equency of total body potal seess the effects of theral ed acute leukemia would be not serum potassium. This by standard therapeutic meal, project had to be disc
Study Objective: The objective epletion in patients with untrown modulators of potassium Technical Approach: 15-20 particuled for total body potassium performed prior to and after the performance of the perfor	re was to dotern reated leukemia homeostasis. Itients with new um, red cell por treatment as	(to be fille nine the fre nine the fille nine the fre nine	equency of total hody potal seess the effects of theral ed acute leukemia would be not serum potassium. This by standard therapeutic meal, project had to be discontinued.

Funds Utilized, : Y-80:

Funding Requirements, FY-81:

Personnel: Project discontinued, no funding requested

Equipment: None

Supplies: None

Travel: None

Other: None

Date: 13 October 1980	Protoco	1 No: 1127	Status: Interim X
Title of Project: "Characte in Mild Essential Hypert		d Response to Ther	Time
Starting Daie: June 1979	Esti	mated Completion D	ate: June 1984
	niel A. Nasl	h, Jr., MD, LTC, M , RN, CPT, ANC	
Associate Investigators: Michael Dugar, Laborator	y Techni-	Facility: WRAMC N Outpatient Clini	ephrology Service; Medical c; Nephrology Laboratory
cian			tment of Medicine/ . cology Service
Key Words: Mild Essentia and Follow-up	1 Hypertens	ion, Borderline Hy	pertension, Characterization
Accumulative MEDCASE Cost:	1	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:		Periodic Re	view Results:
		(to be fille	d in by DCI)
techniques. To determing of fixed hypertension in	e which ongo patients w	oing therapy has a ith such labile hy	
changes and to isometric e diet, sodium restriction, patients will be followed	xercise wil and medicat prospective my presenta	be determined. I ions in accord wit ly for the develop tion companed for	sion will receive a complete ressure response to positional Patients will be treated with the standard practice. Such ment of fixed hypertension. The requency as
Progress during FY-80: Munder ongoing follow-up.	ineteen pat	ients have been er	niered and evaluated and are
Number of subjects to be stud	lied before o	completion of study:	20-40
Serious/unexpected side effec	cts in subjec	ts participating in p	project: NONE
Conclusions: Long-term fol conclusions.	low-up is r	equired in this st	cudy (5 year intervals) for
Publications or Abstracts, F	Y-80: NO	NE	

Funds Utilized, FY-80:

Funding Pequirements, FY-81:

Personnel: None

Equipment: None

Supplies: None

Travel: \$600.00

Other: " "C

In response to the Annual Report Review Committee question asking about the cost of adding more patients versus continuing with the current group, the following is applicable in reference to Protocol Work Unit #1127. A population demographic study of only nineteen patients is much too small a number, considering the variability of the questions being asked - e.g. incidence of morbidity, benefit of weight reduction, etc. At this point, there is no cost to speak of as all patients are simply being followed by the investigators as part of the ongoing particular patient population.

Date: 15 October 1990	Protocol	No:	1128	[5	tatus:	Interim	<u>x</u>
Title of Project: "Evaluati Stage Renal Disease Patie Activity Recording"					splanta	Final ation Usi	ng
Starting Date: June 1979	Estim	ated C	Completion D	ate: (June 19	982	
Principal Investigator: Dan	iel A. Nash,	Jr.,	MD, LTC, MC				•
Associate Investigators: Gregory Belenky, MAJ, MC Jimmy Light, MD, COL, MC			R Neuropsyc	chiatry	Divis		ransplant Svo e
Key Words: Rehabilitation Transplantation; Activity		age Ra				is versus	Kidney
Accumulative MEDCASE Cost:	Accumul Cost:	ative	Contract			lative Sup	ply
FY-80 MEDCASE Cost:	erani 3 i meni ini termadikendelesi		Periodic Re (to be fille		_		
Study Objective: To monito to and after being treated transplantation. Thereby modalities is clearly super	with convendetermining	lional if reh	hemodialys mabilitation	is or	receiv	ing kidne	y org
Technical Approach: A moved develop evidence of uremia imminant need of hemodialy be compared to repeat dete or transplantation. The dwill be compared to baseling this way, profiles of page.	as a consequesis or kidney rmination of ifferences in the contract of the cont	lence / trar activ l the also	of end-stag isplantation vity after i activity wi be compared	ge rena i. This institu ith each	disels base tion of there	ase and a line acti f either apeutic m atment mo	re in vity will hemodialysis odality dalitie
Progress during FY-80: For and repeat studies perform initial studies important of the activity conitoring Number of subjects to be studied.	our patients ed after hem steps were to device A no died before co	were odialy aken t ew and omolet	entered and sis was ini to improve t l improved r ion of study:	d had bitiated the sensonitor: 40-60	sline in eac sitivi has b	activiti ch. From ty and re	es recordes such producibilit
Serious/unexpected side effective	cts in subject	s part	icipating in p	project:	NON	E	
Conclusions: NOME				······································		 	 -

MONE

Publications or Abstracts, FY-80:

Funds Utilized, FY-80:

Funding Requirements, FY-81:

Personnel: None

Equipment: None

Supplies: None

[ravel: \$600.00

Other: \$1,800.00 - Computer rental time for deprograming activity monitor)

27

Date: 27 August 1980	Protoco	l No:	1129	Status:	Interim	X
Title of Project: "COMPARISO OF PATIENTS DIALYZED AGAIN					Final	
Starting Daie: November 19	79 Estir	nated (Completion I	Date: June 198	81	
Principal Investigator: Suza	anne M. Berg	man, M	D; Jack Mooi	re, Jr., MD		
Associate Investigators:	The state of the s	Facili	ty: Dialys	is Unit, WRAM , Surgical, Th	C horacic IC	יט
Mitchell M. Mutter, MD Barbara Smith, RN		Dept/	Svc Medic	ine/Nephrology	У	
Key Words: Acetate Dialys Resistance	sate, Bicarbo	onate	Dialysate, (Cardiac Output	t, Periphe	ral
Accumulative MEDCASE Cost:	Accumi Cost:	ulative	Contract		lative Supp	oly
FY-80 MEDCASE Cost:			i .	view Results:		
Study Objective: To determine the buffer in the di	nine if there	e is a for he	difference	in cardiopula	monary fun	ction
bicarbonate, and to provid dialysate buffers.	le physiolog	ic data	a on which 1	to base a mati	ional choi	e to ce of
Technical Approach: Swar used in determining cardia pressure. Hemodialysis waand once using a bicarbona pressure, arterial pressure	de physiological cather outputs by as performed te buffered res, plasma r	ters and the twice dialysterial	a on which in the contract of	terial lines and in monito the standard	were plac oring arte d acetate eart rate,	ed and rial dialysa right
dialysate buffers.	de physiological cather outputs by as performed te buffered res, plasma red every hour something we have the patients where the patients we have the patients of the patients	ters any therm twice dialys	a on which and radial and odilution; once using sate. Cardiactivity, cally studies	terial lines and in monito the standard in the	were placering arted acetate art rate, osmolali	ed and rial dialysa right
Technical Approach: Swar used in determining cardia pressure. Hemodialysis was and once using a bicarbona pressure, arterial pressurblood gases were determined. Progress during 11-80. Si	de physiological cather ac outputs by is performed tes puffered res, plasma red every hour a patients was periods	ters any them twice dialystenin arc.	nd radial among dilution; once using sate. Cardiactivity, cally studied id not compl	terial lines and in monito the standard in the standard in the standard in the coutput, he itechnologies in the protection the study	were placering arted acetate art rate, osmolali	ed and rial dialysa right ty and
Technical Approach: Swar used in determining cardia pressure. Hemodialysis was and once using a bicarbona pressure, arterial pressurblood gases were determined. Progress during 11-80. Sindled in between the dialy	de physiological cather to outputs by as performed tes, plasma relevery hour a patients was periods	ters any them twice dialystenin are and dialystenin are are and dialystenin are are and dialystenin are are are and dialystenin are	a on which and radial and dilution; once using sate. Cardiactivity, callly studied id not completion of study	terial lines and in monito the standard in the standard in technologies. I on the protected the study	were placed acetate art rate, osmolali	ed and rial dialysa right a ty and

Publications of the end to, 250-80:

Funds Utilized, FY-80:

Fundkng Requirements, FY-81:

Personnel: None

Equipment: Balloon flotation catheters - \$1,000.00

<u>Supplies</u>: \$600.00

<u>Travel</u>: \$600.00

Other: \$150.00

disposition form

For use of this form, see AR 340-15; the proponent agency is The Adjutant General's Office.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-MN

Investigational Drug Progress Report - Para 7 AR 40-7

TO C. Clinical Investigation SVC FROM Suzanne M. Bergman, MD DATE 26 August 80 CMT1 (ATTN: Timothy M. Boehm, MD)

- 1. Annual Progress Report on the Clinical Investigation Program, Work Unit #1129, Comparison of the Cardiopulmonary Variables in Patients Dialyzed Against Acetate and Bicarbonate Buffer. Investigators: Suzanne M. Bergman, MD, MAJ, MC; Jack Moore, Jr., MD, MAJ, MC;
- 2. The hemodialysis and hemodynamic monitoring are performed in the Dialysis Unit or the Medical, Cardiac, Thoracic, or Surgical Intensive Care Units located on the fourth floor of the Walter Reed Army Medical Center.
- 3. Seven critically ill patients were entered on the protocol and six survived to finish the study. One patient expired during the interim period between dialyses.
- 4. Maintenance of arterial blood gases and acid-base balances were not different with either dialysate. A small improvement in cardiac output and vascular resistance was noted with the bicarbonate containing dialysate in some patients. A statistical analysis has not yet been made. Determinations of plasma repis activity and catecholomines will be done it the end of the study period as a group.

The preparation of a bicarbonate dialysate is a laborious procedure. Dialysis with a bicarbonate containing dialysate is a safe procedure as long as dialysate pH is checked every hour and adjusted as necessary.

- 5. Additional information gained in conjunction with the hemodynamic monitoring are changes in endogenous vasoactive substances such as plasma renin and catecholamines. Future studies as an appendum to this protocol may include the measurement of opioid peptides (not available one year ago) and increasing the Na⁺ concentration of the dialysate (decreasing osmotic water shifts).
- 6. There have been no significant observations using a bicarbonate dialysate

SUZANNE M. BERGMAN, MD

MAJ. MC

Asst. Chief, Nephrology Service Walter Reed Army Medical Center

Date: 11 August 1980 Protocol No: 1130 Status: Interim X Final Title of Project: THE ROLE OF HYPERURICOSURIA IN THE NEPHROTOXICITY OF RADIOCONTRAST AGENTS Starting Date: 8 April 1930 Estimated Completion Date: July 1982 Principal Investigator: Jack Moore, Jr., MD, MAJ, MC, Staff, Nephrology Service Associate Investigators: Facility: Walter Reed Army Medical Center Daniel A. Nash, Jr., MD, LTC (P), Chief, Nephrology Service Department of Medicine Anthony Henry, MD, CPT, MC, Fellow James Hasbargen, MD, CPT, MC, Fellow Dept/Svc Nephrology Service Key Words: NEPHROTOXICITY, RADIOCONTRAST AGENTS, URIC ACID Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: 0 Cost:__ 0 Cost: 0 FY-80 MEDCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if the incidence of, or severity of, radiocontrastinduced acute renal failure (ARF) can be attenuated by pre-contrast exposure therapy with isotonic solutions, and if so, does bicarbonate solution add to the attenuation of ARF by increasing the solubility of uric acid in the urine. Technical Approach: All patients accepted for the study must meet "high risk" for contrast requirements. They are then sequentially randomized to one of three arms: 1.) Dextrese infusion, 2.) Normal saline infusion, or 3.) Isotonic bicarbonate infusion, followed by oral carbonic anhydrase inhibitors. Sequential blood renal function teles and urines for creatinine and unic acid are collected. Progress during FY-80: So far (11 August 1980) 4 patients have been studied. No conclusions can be reached as yet. Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: Conclusions: No conclusions can be reached as yet. This protocol has only been operative since 8 April 1980.

Publications or Abstracts, FY-80: None

mora unit mo.: 1130

funds btilized, FY-50: 0

Funding Requirements, FY-81:

Personnel: Jack Moore, Jr., MD, MAJ, MC, Principal Investigator
Daniel A. Nash, Jr., MD, LTC (P), MC, Chief, Nephrology Service

Anthony Henry, MO, CPT, MC James Hasbargen, MD, CPT, MC

Funds: 0

Equipment: None

Funds: 0

Supplies: ^Morte

Funds: 0

Travel: For presentation at Mational Meetings

Funds: \$600.00

Other: Reprint Costs

Funds: \$300.00

Total Funds Requested, FY-81: \$900.00

Date: 13 October 1980 Protocol No: 1131					s: Interim x		
Title of Project: "Hematuria With Coum	During Ant adin"	icoagu	lation Thera	ру 📙	Final		
Starting Date: November 197	9 Estin	nated C	Completion Da	rte: Novem	er 1381		
Principal Investigator: Dan	iel A. Nash	, Jr.,	MD, LTC, MC				
Associate Investigators:			Facility: Nephrology Service, Laboratory and Clinic Area				
James Hasbargen, MD, CPT, MC Anthony Henry, MD, CPT, MC Brian Copley, MD, MAJ, MC		Dept/	dicine/				
Key Words: Coumadin Thera		ia, Ur	ine Urokinas	- Activity			
Accumulative MEDCASE Cost:	Accumulative Contract Cost:				nulative Supply 125.85		
FY-80 MEDCASE Cost:			Periodic Review Results: (to be filled in by DCI)				
Study Objective: To determ eceiving standard Coumadin cours in such patients. To ith hemoturia. Technical Approach: Patient osages will be screed for ave hematuria on repeat excitl be further evaluated. Valuation for causes of hemotopies in this urine anticomparent.	therapy. To determine of the receiving the presence amination are this evaluation at the receiving of the receiving the received and the recei	ng County of County of mind in the county of	madin for standin for standin for standin for standing the absence of the absence	tiology of e is acnomi andard indi ematuria. of Coumadin urological inase activ	hematuria when it mal in such patien it such patien it such patien it seems and stands these determined it is a new tological will be determined it.		
Progress during FY-80: 84 our patients found to have valuations. Urines have been say is under development. Number of subjects to be stu	microscopio en stored fo	hemat or urin	curia underwe ne urokinase	ent urologi activity.	ical and hematolog The urine urokina		
Serious/unexpected side offe	cts in subjec	ts par	ticipating in p	project:	NONE		
Conclusions: NONE			 		·		

Publications or Abstracts, FY-80: NONE

In response to the Annual Report Review Committee question asking about the cost of adding more patients versus continuing at the present group level, the following is applicable in reference to Protocol Work Unit #1131. No more patients are being added to the study until those currently entered complete their evaluation (unine unokinase) and the data are analyzed. Depending on the results of these data, additional patients may at that time be considered in the interest of attaining statistical significance.

33

Funds Utilized, FY -80:

Funding Requirements, FY-81:

Personnel: None

Equipment: None

<u>Supplies:</u> \$800.00

Travel: \$600.00

<u>Other</u>: \$150.00

Date: 5 September 1980	Protoco	l No: 1	215		Status: Interim ;	
	lind Evaluat	tion of	locressor	5	Final	
Starting Date: 2 May 1980	Esti	mated Co	mpletion D	nte:	June 1981	
Principal Investigator:	Patrick K.C.	. Chun,	M.D., MAJ,	MC		
Associate Investigators:	Facility: Walter Reed Army Medical Center Dept/Svc Cardiology					
Fayaz Shawl, M.D., CPT, MC Clarion Johnson, M.D., CPT, MC Jamos E. Davia, M.D., COL, MC						
Key Words:	· · · · · · · · · · · · · · · · · · ·	-,				
lopressor, Couble Rlin Accumulative MEDCASE Cost:0	Accumulation Cost: C		; Contract		Accumulative Supply Cost: 0	
FY-SO MEDCASE Cost:	0	Periodic Revi				
Drug Lopressor for ang Technical Approach: 16 fashion at increasing graded exercise treadm	patients enr doses and fo	rolled i	n study, 1:			
Progress Auring MY-80: Study is progressing was the other centers p	ell without	complic			leted the study. at the same same	
Number of subjects to be stu Serious/unexpected side effe	died before ects in subjec	completi ets parti	on of study: cipating in I	: ló projec	t: None	
Conclusions: Study proc	eeding on so	chedule	with benef	icial	effects of	
Publications or Abstracts,	FT-80: Non-	૯				

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE STANL

SUBJECT

HSWP-ME

Protoco1

Clinical Investigation Svc

FROM Kenneth D. Burman, MD

2 Sep 80

CMT 1

K.D. Burman/ej/61416

- 1. Please allow protocols #1308, 1329,1331,1359,1366,1372, and 1389 to terminate.
- 2. Please keep the following protocols active for two (2) more years as explained below:
 - 1311 We require the use of this protocol because if a patient does enter the hospital in thyroid storm this protocol could be life saving.
 - 1334 We have made great progress on this protocol but would like it to thay active so that we could isolate and purify the enzyme responsible for T4 to T3 conversion.
 - 1346 We have developed new assays especially by BPLC for the measurement of thyronenes and would like this protocol to stay active so that we could measure these thyronenes in cord blood and ambient fluid.
 - 1347 We have not yet finished this protocol and would like to have its time period extended so that we could finish our studies investigating extrathyroid deiodenation.
 - 1353 We would like to finish this project by isolating and characterizing the T3 receptor.
 - 1360 Dr. Smallridge and I have sent one paper to be published comparing T2 production rates and would like to have this protocol open so that if the referres need more studies we could perform them.
 - 1390 We would like to measure thyronens by EPLC.
 - 1391 We would like to continue to measure scan lase activity in various conditions.
 - 1388 We are still in the process of developing a thyronine assay.

RENNETH D. BURMAN, NO

LTC, MC

Assistant Chief, Endocrine-Metabolic Svc

and Kyle Metabolic Unit

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

HSWP-ME

Response to Comments by Dr. Evans on Protocol 1308,

1311, 1359, and 1360

TO Clinical Investigation Svc

FROM Kenneth D. Burman, MD

DATE 4 Dec 80

Asst Ch, Endo-Metab Svc

Burman/eds/61416

- 1. 1308 As noted on detail summary sheet, this report is a final report. There are no abstracts on this protocol because Dr. Lowenthal left the service and there is no one to measure Inderal levels.
- 2. 1311 It is mandatory and important that this be minored so that this life threatening disease can be adequately treated when and if such a patient enters the hospital.
- 3. 1359 Dr. Buchm is presently writing up this manuscript.
- 4. 1360 The falst paper emanating from this projectal was so interesting and important it was rapidly accepted for publication (in press JCEM) and further, opened up new important questions relative to other iodothyronines. In short, we are the first to show that iodothyronine clearance rates can be performed with unlabelled hormones. This is an important contribution with wide spread implications

KENNETH D. BURMAN, MD

LTC, MC

Asst Ch, Endocrine-Metabolic Service

	mpletion D N, MD, L7 : WF c Me ontract	
D. BURMAN Facility: Dept/Svo	mpletion D N, MD, L7 : WF c Me ontract	Accumulative Supply
D. BURMAN Facility: Dept/Svo	N, MD, LT WF C Me ontract	Accumulative Supply
Facility: Dept/Svo	: WFc Me	Accumulative Supply Cost: 500
Dept/Svo	c Me	Accumulative Supply Cost: 500
idism umulative Co	oniract Periodic Re	Accumulative Supply Cost: 500
umulative Co	Per lodic Re	Cost: 500
: 0 P	Per lodic Re	Cost: 500
		officery Properties
~·—————	to be titte	å in by DCI)
Inderal le	evels in	patients with
. •		
is measur	red by ul	ltraviolet absorption
re completio	on of study	•
jects partic	cipating in	project: None
s do not o	correlate	with T4 levels.
	ojects partic	re completion of study ojects participating in s do not correlate

None

Title of Project: TRH in Patients with Hypothalamic Pituitary Thyroid Disease

Investigators:

A CONTROL OF THE PARTY OF THE P

Principal: Leonard Wartofsky, COL, MC

Associates: K. D. Burman, LTC, MC, R.C. Dimond, LTC, MC, M. Schaof, M.D.

Objectives: To assess the response to synthetic TRH (Thyrotropin releasing hormone) in various suspected endocrine disorders.

Technical Approach: Patients are studied on the metabolic ward. Blood samples are drawn for measurement of thyrotropin, prolactin, and other hormones, before and after this bolus injection or infusion of 100-500 mcg of synthetic TRH. Until Dec 1976, the latter agent was an injectional drug but has since been released for clinical use.

Progress & Results: Approximately 610 such studies have been completed in approximately 405 subjects. Although some data continues to accumulate with time and is yet to be analyzed, much already has appeared in the publications listed below. It is anticipated that additional studies on elucidation of abnormalities of the hypothalamic-pituitary-thyroid axis employing TRH as a probe will continue to be highly productive.

Conclusions: TRH has been found to be a useful agent for the assessment of disorders of the hypothalamic-pituitary-thyroid axis, with minimal or negligible side effects or problems associated with its use; and has also proved to be a valuable research tool.

Funds Utilized FY-80		Funds Requested FY-81				
1100	Personnel	-		1100	Personnel	2000
2100	Travel	-		2 6 0	Cons. Supplies	3000
2319	Rental	-		21 60	Travel	600
2400	Print & Repro.	-		2 400	Print & Repro.	400
2572	Contractual Svcs			2 572	Contractual Syca	800
2600	Cons. Supplies	3700			Total	6800
3100	Non-Exp. Equip.	-				
	Total	3700				

- Publications: (1) Noel, G., R.C. Dimond, L. Wartofsky, J.M. Earll, and A.G. Frantz.

 Continuous Infusion of TRH in Man. J. Clin. Endocrinol. 38:6-17, 1974.
 - (2) Wartofsky, L., R.C. Dimond, G.L. Noel, R.A. Adler, A.G. Frantz, and J.M. Earll. Effect of Water Loading on TSH and PRL Responses to TRH. J. Clin. Endocrinol. & Metab., 41:784-787, 1975.
 - (3) Wartofsky, L., et al., Failure of Propranolol to alter TSH and PRL Responses to TRH in Thyrotoxicoses, J. Clin. Endocrinol. Metab., 41-1884-490, 1975.

- (4) Wartofsky, L., et al, Estimates of Pituitary Stores of TSH and PRL in Normal and Hypothyroid Subjects by Use of Continuous TRH Infusion, Advances in Thyroid Research, Excerpta Medica, pp. 268-271, 1976.
- (5) Wartofsky, L., et al, Effect of Acute Increases in Serum T3 on TSH and PRL Responses to TRH, J Clin Endocrinol & Metab, 42:451-466, 1976.
- (6) Wartofsky, L., et al, Nature of Thyroidal Suppression and TSH and PRL Responses to TRH during Experimental Malaria in Man, J Clin Endocrinol & Metab, 44:85-90, 1977.
- (7) Burman, K.D., R.C. Dimond, F.D. Wright, J.M. Earll, J. Bruton, and L. Wartofsky, A Radioimmunoassay for 3,3'5'-Triiodothyronine (Reverse T3): Assessment of Thyroid Gland Content, Serum Measurements in Conditions of Normal and Altered Thyroidal Economy, and Serum Concentrations following Administration of TRH and TSH, J Clin Endocrinol & Metab 44:660-672, 1977.
- (8) Corrigan, D.F., K.D. Burman, R.C. Dimond, M. Schzaf, J.M. Earll, J.E. Rogers, F.D. Wright, and L. Wartofsky, Parameters of Thyroid Function in Patients with Active Acromegaly, <u>Metabolism</u> 27:209-216, 1978.
- (9) Burman, K.D., R.C. Dimond, Y-Y Djuh, J. Bruton, T.B. Washburn, C.D. Wright, and L. Warroleky, Falloce of 3, 24-72 Administration to Alter TSH and Prolactin Responses to TRH Stimulation, Metabolism 27:677-683, 1978.
- (10) Burman, K.D., R.C. Smallridge, R. Osburne, R.C. Dimond, N.E. Whorton, P. Kesler, and L. Wartofsky, Nature of Suppressed TSH Secretion During Undernocition Effect of Fasting on TSH Responses to Prolonged TRH Infusion, Metabolism 29:46-52, 1930.
- of TSH: Discordance Between the Suppressive Effects of Corticosteroids and Thyroid Hormone, J Clin Endocrinol Metab 48:700-705, 1979.
- (12) Corrigan, D.F., K.D. Burman, R.C. Dimond, M. Schaaf, J.M. Earli, J.D. Rogers, M.D. Wright, and L. Weil older, Parameters of Teyrold Euroction in Parisers with Active Acromagaly, <u>Metabolism</u> 27:209-216, 1978.
- (13) Burman et al: Failure of 3,3'-T2 to Alter Prolactin & TSH Responses to TRH Stimulation, Metabolism 27:677-683, 1978.
- (14) Boehm, T.M., R.C. Dimond, and L. Wartofsky, Isolated Thyrotropin Deficiency with TRH-induced TSH Secretion and Thyroidal Release, J Clin Endocrinol Metab 43:1041-1045, 1976.
- (15) Burman, K.D., R.C. Dimond, G.S. Noel, J.M. Earll, A.G. Frantz, and L. Wartofsky, Klinefelter's Syndrome: Examination of Thyroi Function, and the TSH and PRU Responses to TRH Prior To and After Testesterone Administration, J Clin Endocrinol Metab 41:1161-1166, 1976.

(16) Burman, K.D., R.C. Dimond, F.D. Wright, J.M. Earll, J. Bruton, and L. Wartofsky, A Radioimmunoassay for 3,3',5'-Trilodochyronine (Reverse T3): Assessment of Thyroid Gland Content, Serum Measurements in Conditions of Normal and Altered Thyroidal Economy, and Serum Concentrations following Administration of TRH and TSH, J Clin Endocrinol Metab 44:660-6/2, 1977.

Type of Report: Interim

Estimated Date of Completion: Two Years

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

LEFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-ME

Renewal of Protocols Previously Funded for Three Years

C, Dep Clin Invest

FROMC, Endo-Metab Svc

DATE 28 Jan 81

CMT 1

Wartofsky/bak/6-1416

- 1. The attached progress reports are submitted as addenda to maintain and renew protocols #1310 and #1340 for an additional 2-3 years.
- 2. Protoco! #1340 has been inactive since 1979 due to the departure of the former principal investigator, Dr. Charles Smith. These data have been reviewed and have considerable promise for publication but additional patients will be required. No modification to the prior protocol is anticipated.
- 3. Protocol #1310 is the umbrella protocol for the authorized investigative use of TRH in a variety of circumstances. Since it is anticipated that evaluation of the pituitary-thyroid axis will continue to be a relevant and important aspect of numerous related endocrine clinical studies, renewal is requested in order to facilitate such evaluation. It should be noted that this has been a highly productive protocol with 16 publications listed which involved TRH studies. Relative to the annual budget, this represents an unparalleled cost/efficiency ratio.

anad Wend Ly L. WARTOFSKY, M.D.

COL, MC

Chief, Endocrine-Metabolic Service and Kyle Metabolic Unit

Date:	Protoco	l No: 1311	Status: Interim X
Title of Project:			Final
Treatment of thyro	id storm	with anion Excha	nge Resin
Starting Date: 3-29-74	Esti	mated Completion Da	ute: ક 82
Principal Investigator: K	ENNETH D.	BURMAN, MD, LTC	, мс
Associate Investigators:	LTC MC	Facility:	C
LEONARD WARTOFSKY, MD,	ito, do	Dept/Svc Med/	Endo
Key Words: Resin/thyr	oid storm	- A	
Accumulative MEDCASE Cost: 0	Accum Jost:	ulative Contract 0	Acou: lative Supply Cost: 0
FY-80 MEDCASE Cost:			new Resulte: l in by DCI,
Study Objective: To hav when n	e availab eeded.	le a treacment	for thyroid storm
Technical Approach:	evchange	resin removes ci	rculating thyronines
, <u>.</u>			reduceding englosses
Progress during FY-80:	ient has	entered hospital	
Number of subjects to be stu			
Serious/unexpected side effe	cts in subje	cts participating in p	oroject: None
Conclusions: None ye	t		
Fublications or Abstracts,	FY-80:	None	

Funds utilized, FY-80: \$23,182

Funding requirements, FY-81:

Supplies: \$2,000

Other: \$400

Date: 22 Oct 80	Protoco	l No:	1334	Status: Interim
			T	XKirnk
Title of Project: The regul	lation or	1 ₄ to	T ₃ conver	sion
•				
Starting Date: 1 Aug 75	Esti	mater) (Completion Di	ite: 1 Aug 82
				1 AC 02
Principal Investigator: Kenn	neth D. Bu	ırman,	LTC, MC	
Associate Investigators:		Facili	ty: WRAMC	
_	TOTAL MAC		WRAMC	
Robert C. Smallridge,	DIC, NC	Dept/	Svc Kyle	Metabolic Unit
Key Words: T ₄ , T ₃		-k		,
Accumulative MEDCASE	Accum	ulativo	Contract	Accumació & Supply
Cost:	Cost:_			Cost:
FY-80 MEDCASE Cost:	L		Periodic Re	view Results:
			L .	l in by DCI)
Study Objective: To iso				1 - 6 - m + - m
conversion.	race the e	enzyme	responsib	le for T_4 to T_3
	•			
•	•			
Technical Approach: Aff	iinite ahu		aranbu	•
ALI	finity chr	Ollaco	Grabuy	
•				
Progress during FX-30:	Maria wat	icala		
riogress during in too.	nave noc	12019	ted it yet	
Number of subjects to be stu	idied hefore	compl-	etion of study	
Serious/unexpected side effe				
Conclusions:				
Publications or Abstracts,	FY-80:	None		

Funds utilized, FY-80: \$4,235

Funding requirements, FY-81:

Supplies:

\$5,000

Other:

2,000

College District			
PREFERENCE OF LIFEESTHOOL	Julius CT		
HSWP-ME	Renewal of Protocols Previous	sly Funded for Three Years	
TOC, Dep Clin Invest	FROMC, Endo-Metab Svc	9ATE 28 Jan 31 Wartofsky/bak/6-1416	CHT I

- 1. The attached progress reports are submitted as addenda to maintain and renew protocols: #1310 and #1340 for an additional 2-3 years.
- 2. Protocol #1340 has been inactive since 1979 due to the departure of the former principal investigator, Dr. Charles Smith. These data have been reviewed and have considerable promise for apublication but additional patients will be required. No modification to the prior protocol is anticipated.
- 3. Product #1310 is the ambrella protocol for the authorized investigative use of TRH in a variety of circumstances. Since it is anticipated that evaluation of the pituitary-thyrid axis we continue to be a relevant and important aspect of numerous related endocrine clinical studies of renewal is requested in order to facilitate such evaluation. It should be noted that this has been a highly productive protocol with 16 publications listed which involved TRH studies. Relative to the annual budget, this represents an unparalleled cost/efficiency ratio.

L. WARTOFSMY, M.D.

COL, MC

Chief, Endocrine-Metabolic Servic and Kyle Metabolic Unit

Title of Project: Use of Fluorescent Thyroid Scanning to evaluate lodine Kinetics during

Propylthiouracil Therapy of Graves' Disease

Principal Investigator: Leonard Wartofsky, COL, MC

Associate Investigators: Kenneth D. Burman, LTC, MC

Douglas Van Nostrand, MAJ, MC

Objective: To utilize the fluorescent thyroid scanner to quantitate and follow alterations

in thyroidal iodine content during antithyroid therapy of Graves' disease.

Technical Approach: 20-24 patients with Graves' disease are to be studied.

The following tests will be performed weekly throughout the study: serum thyroxine (T4), serum triiodothyronine (T3), resin untake of triiodothyronine (T3RU), serum iodine (I_s), thyroidal I_s by fluorescent scan. In addition, two 24 hour urines per week will be collected and 24 hour iodide excretion (I_s) determined. At the end of each study period a perchlorate discharge test ($C1_2$) will be performed.

Basal determinations of entry into study: Tr. T3, T3RU, $\mathbf{I_s}$, $\mathbf{I_t}$, $\mathbf{I_u}$, $\mathbf{Cl_2}$.

Study period (: Propylthiouracil 150 mg/day weekly: T4, T3, T3RU, I_s , I_t , I_u

Study period ends when weekly studies are stable; Cl₂ at end of study period.

Study Period II: Propylthiouracil 450 mg/day.

Study period ends when weekly studies are stable; ${\rm Cl}_2$ at end of study period.

Storly (region (ii) Propyl miourach, 1200 mg, day.

Study period ends when weekly studies are stable; Cl₂ at end of study period.

Study Period (V: Identical to Saury Period III except 5 drops SSK) tid.

Study ends at one week.

Progress & Results:

14 patients have been studied to date and the data is presently being re-evaluated. Attempts are being made to resume these studies in 1981 after a liquid in liquid ty prompted by the departure of the former principal investigator.

Conclusions: None as yet

<u>Side Effects/Complications</u>: There were absolutely no unexpected side effects or increased incidence of side effects related to any of the therapeutic manipulations detailed in the study protocol in any patients studied to date.

Funds Utilized FY-80: None	Funds	Requested FY-81	
	1100	Personnel	2000
	2100	Travel	600
	2319	Rental	200
	2400	Print & Reprod	300
	2572	Contract Svcs.	600
	2600	Cons. Supplies	1500
	3100	Non-Expend Equi	p
		Total	5200

Publications: () Thrall J. Corcoran R. Wartofsky L, et al: Quantitative Thyroid Fluorescent Scanning Technique and Chinical age and, Amer. J. Roentganol 130.517-522, 1978.

(2) The H J, Burman KD, Wartofsky L, et al: Solitary Autonomous Thyroid Nodules: Comparison of Fluorescent and Pertechnetate Imaging, J. Nucl. Med. 18:1064-1068, 1977.

Type of Report: Interim

Estimated Date of Completion: Three Years

			Stains:	
	:		L	Finol
				•
n Cord Bl	ood Matern	al Serum	Fluid	
Estin	rated Comple	tion Date:	8 -	-82
KENNETH D	. BURMAN,	MD, LTC,	мс	
•	Facility:	WRAMO	2	
COL MC	Dept/Svc	Endo	rine	
aternal \$	erum Fluid			· · · · · · · · · · · · · · · · · · ·
		i		ılative Supply 0
	Period	iic Review	Resuits	
and the same and t				
	s of thy to	nitus ia	್ರಂಥಾರೆ 1	slood and
		•	•	
				•
	• • • • • •			•
radioimm	unoassays	for vario	ous th	yronines
		•		
	•			
	•			
val ped R	.tA for fy	1		
ed before o	completion of	study:	10-15	
			et:	one
	COL MC TC, MC TC, MC Accumu Cost: ure level l fluid.	Estimated Comple KENNETH D. BURMAN, Facility: COL. MC Dept/Svc aternal Serum Fluid Accumulative Contra Cost: O Period (io b) ure levels of thy to 1 fluid. radioimmunoassays	Estimated Completion Date: KENNETH D. BURMAN, MD, LTC, Facility: WRAMO Dept/Svc Endoc aternal Serum Fluid Accumulative Contract Cost: O Periodic Review I (to be filled in b) ure levels of thy conices in I fluid. radioimmunoassays for various in calculative Contract Cost: O Periodic Review I (to be filled in b) ure levels of thy conices in a fluid.	Facility: COL NC Dept/Svc Endocrine aternal Serum Fluid Accumulative Contract Cost: Periodic Review Results: (to be filled in by DCI) ure levels of thy conicas in acted to find. radioimmunoassays for various the standard to find.

Publications or Abstracts, FY-80:

Pangaro, L., Burman, KD, Wartofsky, U et al 30EM 30:1075, 1980

Funds utilized, FY-80: \$20,000

Funding requirement, FY-81:

Supplies: \$5,000

Date:	Protocol	No:	1347	Status: Inter	
Title of Project:				Final	
Investigations into t	he physiol	ogy o	f RT3 and	3,3'T2	
Starting Date: 4-8-76	Estim	ated C	ompletion D	oate: 8-82	
Principal Investigator: K	ENNETH D.	BURMA	N, MD, LT	С, МС -	
Associate Investigators: LEONARD WARTOFSKY, MD		Facili	y: WRAMC		
Backing Waldight, 110		Dept/S	SycEndo		
Key Words:	T3				
Accumulative MEDCASE Cost:	Accumu Cost:	lative	Contract	Accumulative Cost:	Supply
FY-80 MEDCASE Cost:	erindikan propinsi perindikan berakan berakan berakan berakan berakan berakan berakan berakan berakan berakan Berakan berakan perindikan berakan ber			eview Results: ed in by DCI)	
Study Objective: To asciconver		fact	ors that	later extrathyro	oidal
	•				
Technical Approach: Developinfuse thyronenes to	specific fed and fas	radi sting	oimmunoas and pati	says and in some ents with thyro	e cases idal diseas
	•		·		
					•
Progress during FY-80:					
About 10 patien	ts have be	en in	fused wit	h 3 * 5 ° T 2	
Number of subjects to be stu	died hefore c	omple	tion of study	: 15	
Serious/unexpected side effe	cts in subject	ts part	icipating in	project: None	
Conclusions: Cadiolabel	led and un	label	led thyro	nenes five the	same MCR
Publications or Abstracts, I	Y-80:				
PANGARO, L, BURMAN, KD	, WARTOFSK	Υ, Ι,	JCEM 50:	1075, 1080	

Funds utilized, FY-80: \$360.00

Funding requirements: FY-81:

Supplies: \$1,000

Other: 1,000

Travel: 400

Date:	Protoco	l No:	1353	Stat	us: Interim x
Title of Project:					Final
					•
The regulation of T4 o	conversion	ı			
Starting Date: 12/30/76	Estir	maied (Completion I	Oate:	8/82
Principal Investigator:	CENNETH · D	D. BUR	MAN		
Associate Investigators: LEONARD WARTOFSKY, MD,	ITC MC	Facili	ty: Wramc		
ROBERT C. SMALLRIDGE, I Dr. KEITH LATHAM	TC, MC	Dept/	SvcDept of	Med/End	ocrine
Key Words: T4 Convers	ion	•			
Accumulative MEDCASE Cost:		ulative	Contract	3	umulative Supply
FY-80 MEDCASE Cost:	·		Periodic Re (to be fille	eview Resi	the same of the sa
Study Objective: To asce	rtain the	e fact	ors legul	ating T4	to T3 convers1
Technical Approach: Develop convers		in vi	vo and in	vitre t	o quantitate
	dies demo increase			carbonyd	rate content
Number of subjects to be stu Serious/unexpected side effe					None
Conclusions: Carbohydr	ates incr	ease	T4 to T3	conversi	
Publications or Abstracts, I	FY-80:				

SMALLRIDGE, RC, BURMAN, KD, WARTOFSKY, L et al. JCEM tentatively accepted.

54

Funds utilized, FY-80: \$20,000

Funds required, FY-81:

Supplies: \$5,000

Other: 400

Date: 15 October 1980	Protocol No	. 1354	Status: Interim X
Title of Project: Purification Binding Gl	on of Testoster		Final
J			
Starting Dute: 3 Nov 1976	Estimate	ed Completion D	ate: 30 Sept 1982
Principal Investigator: Ro	bert A. Vigersk	y, M.D. MAJ MC	
Associate Investigators:	Fa	cility: URAMC	
	De	pt/Svc Kyle Me	tabolic Unit
Key Words: Testosterone-	estradiol bindi	ng globulin	•
Accumulative MEDCASE Cost: 0	Accumulat	ive Contract	Accumulative Supply Cost: 0
		15	
FY-80 MEDCASE Cost:		 -	view Results:
Study Objective:	andrewijs, gay je umga waga wan dinang aga adalah ibig Mil	(to be fille	d in by DCI)
Study Objective: To purify, characterize a binding globulin. This p from their site of product controls the availability ment of this protein is in Technical Approach: Sequential use of Sephade temperature-dependent affigel electrophoresis. Quallectrophoresis and the seconted charcoal assay meaning the second charcoa	rotein is respondent in the got of sex steroids andirect; thus, ex G-100 chromatinity chromatoguitative analystonicoring of the	(to be filled addioimmunoassay on sible for the add to their takes to breast, sky the aim is to measure it tography, Conceptable, and pressis is by analytication and put fication.	for testosterone-estradion transport of sex steroids right tissues. It, thus, in, prostate, etc. Measure develop methods to directly it in biologic fluids. Smavilin A chromatography, eparative polyacrylamide rical polyacrylamide gel process is by a deviluant
Study Objective: To purify, characterize a binding globulin. This p from their site of product controls the availability ment of this protein is in Technical Approach: Sequential use of Sephade temperature-dependent affigel electrophoresis. Our electrophoresis and the seconted charcoal assay mean Progress during FY-80: Approximately 6000 fold in	rotein is respondent in the got of sex steroids adirect; thus, ex G-100 chromato dinty chromato ditative analystative analystative the total curification has	(to be filled addioimmunoassay on sible for the stand to their takes to breast, sky the aim is to measure in the standard property; and pressions by analytical binding of the been reached.	for testosterone-estradiol transport of sex steroids transport transport of sex steroids transport transport of sex steroids. In prostate, etc. Measure develop methods to directly it in biologic fluids. In an an an an accumulating and we are now accumulating and we are now accumulating transport of sex steroids.
Study Objective: To purify, characterize a binding globulin. This p from their site of product controls the availability ment of this protein is in Technical Approach: Sequential use of Sephade temperature-dependent affigel electrophoresis. Our electrophoresis and the ecoated charcoal assay ment approximately 6000 fold penough purified protein to	rotein is respondent in the got of sex steroids adirect; thus, ex G-100 chromator inity chromator inity chromator inity chromator in the total continuous the total conficution has to inject into	(to be filled addioimmunoassay on sible for the stand to their tands to breast, sky the aim is to measure in tography, Concastraphy; and presis is by analyticational binding of the standard binding	for testosterone-estradions transport of sex steroids arget tissues. It, thus, and prostate, etc. Measured develop methods to directly it in biologic fluids. Snavilin A chromatography, eparative polyacrylamide whical polyacrylamide gelen processes by a daythanethe process. and we are now accumulating antibodies and to iodinate
To purify, characterize a binding globulin. This p from their site of product controls the availability ment of this protein is i Technical Approach: Sequential use of Sephade temperature-dependent affigel electrophoresis. Qualicated charcoal assay mean Progress during FY-80: Approximately 6000 fold in	rotein is respondent in the got of sex steroids adirect; thus, ex G-100 chromator inity chromator inity chromator inity chromator inity chromator in the total control in the total conficution had inject into adied before comparing the condition of the condition in the conficution of the conficution had inject into adied before comparing the comparing the comparing the comparing the conficution had inject into addied before comparing the comparing	to be filled to the distribution of study of the state of	for testosterone-estradion transport of sex steroids transport the sex steroids transport that the probability of the

Publications or Abstracts, FY-80: None

work Unit do.: 1354

Funds Utilized, FY-80: None

Funding Requirements, FY-61: \$4550

Personnel: None

Equipment: None

<u> Supplies:</u> \$3000

<u>Trayel:</u> \$500

Other: (2572) \$750; (2400) \$500

Date: 1 October 1980	Protoco	l No: 1	355	SS	<u> SYZANIOZYZ</u>
Title of Project: The Effection upon Thy			igh-Dose Sterc Protoxicosis.	oid L	Final
Starting Date: 29 May 107	Esti:	mated (Completion Da	te: Unce	ertain
Principal Investigator: Ti	mothy M. Bo	ehm, I	TC MC		
Associate Investigators: Leonard Wartolsky, COL	MC	Facili	ty: WRAMC		
Kenneth D. Burman, LTC		Dept/		Metab Svo	· · · · · · · · · · · · · · · · · · ·
Key Words: 13 I, 125 I, thy	roxine, stero	id, thy	rotoxicosis, tl	hyroidal r	release
Accumulative MEDCASE Cost:	Accum Cost:		Contract		umulative Supply :: \$1,000
FY-S0 MEDCASE Cost:	none		Periodic Rev		
Study Objective: To asce in thyrotoxicosus.	rtain whether	r high ò	ose steroid in	hibits thy	roidal release
Technical Approach: In Introduction In Introduction and param no modifications to the originar amounts of 125 and 125	eters of peripual protocol,	pheral except	that some pat	ne m <mark>eta</mark> b lients rec	olism. There wer cived slightly sma
Progress during 197-30;	No progess	a ve	ry low priorit	y andy.	
Number of subjects to be st					None
Serious/unexpected side eff	ects in subjec	cts par	icipating in pr	roject:	None
Conclusions: Study is terminisher priority, and patient hospitalization required. Publications or Abstracts,	recruitment				ts have assumed ag inpatient

: :

MACHINA Date: 2 Oct 80 Protocol No: 1357 Status: Final Title of Project: Effect of T3 and rT3 on Extracellular Cyclic Mucliatide Levels in Humans. Starting Date: 6 April 1977 Estimated Completion Date: Principal Investigator: H. Linton Wray, LTC, MC Facility: WRAMC, Washington, D.C. Associate Investigators: Kenneth D. Furman, LTC, MC Robert C. Smallridge, LTC, MC Dept/Svc Leonard vartofsky, COL, MC Kyle Metabolic Unit Key Words: -hyroid hormones, cyclic AMP, cyclic GMP Accumulative Contract Accumulative MEDCASE Accumulative Supply Cost: None Cost: __None Cost: \$1,286.00 Periodic Review Results: FY-80 MEDCASE Cost: (to be filled in by DCI) Study Objective: To determine if, in humans, urine and plasma levels of cyclic AMP and cyclic GMP are changed by administration of 3,3,3 trijodothyronine (T_3) and 3,3',5'triindot vron ne (reverse Iz, rTz). Technical Approach: Hypothyroid patients will be studied before, during and after taking T_3 , rT_3 or both T, and rT. Hyperthyroid patients will be studied only with rT. Patients will be studied for 12 days; 3 days of baseline, 6 days of treatment and 3 days of post-treatment. Plasma cyclic AMP and cyclic GMP and serum T_2 , rT_3 and T_A will be measured on days 1-5 and 8-12. Progress during FY-80: No patients were studied in FY-80. Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: Nane Conclusions: This project is terminated as of 30 September 1980 because of difficulty in recruiting patients to be studied.

Publications or Abstracts, FY-80:

Status: Interim X Date: Protocol No: 1358 Final Title of Project: The effect of obesity and fasting on T3 receptors in mononuclear cells. Estimated Completion Date: Starting Date: 4-6-77 8-82 Principal Investigator: KENNETH D. BURMAN, MD, LTC, MC Facility: WRAMC Associate Investigators: LEONARD WARTOFSKY, MD, COL, MC Dept/SvcDept of Med/Endocrine Key Words: Obesity/fasting/T3 receptors Accumulative MEDCASE Accumulative Contract Accountilative Supply Cost: Cost: Cost: FY-80 MEDCASE Cost Poriodic Review Results: (to be filled in by DCI)

Study Objective:

To determine the physiologic factors that alter T3 receptors.

Technical Approach:

Develop a T3 radio receptor assay

Progress during FY-80:

T3 receptors were low in obesity and thyrotoxicosis and increased in fasting. We are now correlating T3/T4 receptors with acetylase activity in the receptor preparation.

Number of subjects to be studied before completion of study:

Serious/unexpected side effects in subjects participating in project:

Conclusions: T3 receptors are physiologically regulated

Publications or Abstracts, FY-80:

BURMAN, KD, et al JCEM 51:106,80

Funds utilized, FY-80: \$3%.45

Funding requirements, FY-81: \$2,000

Supplies: \$2,000

Travel: 8400

Starting Date: 4-21-77	Title of Project: The effect of reverse T3 on thyroid secretion. Starting Date: 4-21-77	e:	Protocol No:	1359	Status:	Interir	n
Starting Date: 4-21-77	Starting Date: 4-21-77 Estimated Completion Date: 8-80 Principal Investigator: KD BURMAN, MD,LTC,MC Associate Investigators: Facility: WRAMC Timothy Boehm, MAJ,MC Leonard Wartofsky,COL,MC Dept/Svc Dept of Med/Endocrine Key Words: Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: Cost: Cost: FY-80 MEDCASE Cost: (tc be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kind for the filled filled for the filled filled filled filled for completion of study: Progress during FY-80: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: 10	la of Duaissate					Х
Associate Investigators: Timothy Boehm, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulativa MEDCASE Accumulative Contract Cost: FY-80 MEDCASE Cost: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion of study: None	Principal Lovestigators: Associate Investigators: Timothy Boehm, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Accumulative Sup Cost: Cost: Cost: FY-80 MED ASS Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kine Reverse T3 ingested orally while I4 isotope give: Progress during FY-80: None Number of subjects to be studied before completion of study: 10	de of Project: The effect	of reverse	T3 on thyroi	d secreti	on.	•
Associate Investigators: Timothy Boehm, NAJ,NC Leonard Wartofsky,COL,NC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: FY-80 MEDCASE Cost: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion of study: None	Associate Investigators: Timothy Boehu, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Accumulative Sup Cost: Cost: Cost: FY-80 MEDCASE Cost: Periodic Review Results: (ic be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kine Technical Approach: Reverse T3 ingested orally while I4 isotope give: Progress during FY-80: None Number of subjects to be studied before completion of study: 10						
Associate Investigators: Timothy Boehm, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: FY-80 MEDCASE Cost: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion of study: None	Principal Investigators: Associate Investigators: Timothy Boehm, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: Cost: Cost: Cost: Cost: Cost: FY-80 MED ASS Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kine Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: 10		mati-atod	Completion Dat		^	
Associate Investigators: Timothy*Boehm, MAJ,MC Leonard Wartofsky,COL,MC Dept/Svc Dept of Med/Endocrine Key Words: Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: Cost: FY-80 MEDCASE Cost: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion of study: None	Associate Investigators: Timothy Boehm, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: Cost: Cost: FY-80 MEDCASE Cost: To determine if rT3 influences T4 levels and kind Reverse T3 ingested orally while I4 isotope gives Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: To determine if recompletion of study: Progress during FY-80: Number of subjects to be studied before completion of study: To determine if recompletion of study: Progress during FY-80: None				8-8	U	
Timothy Boehu, MAJ,MC Leonard Wartofsky,COL,MC Dept/Svc Dept of Med/Endocrine Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: Cost: Cost: FY-80 METCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: 10 Serious/unexpected side effects in subjects participating in project: None	Timothy Boehm, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: Cost: FY-80 MEDCASE Cost: FY-80 MEDCASE Cost: To determine if rT3 influences T4 levels and kind for the filled in by DCI) Study Objective: Technical Approach: Reverse T3 ingested orally while T4 isotope gives Progress during FY-80: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: To determine if rT3 influences T4 levels and kind for the filled in the	ncipal Investigator:	D BURMAN, MD	, LTC, MC			
Timothy Boehu, MAJ,MC Leonard Wartofsky,COL,MC Dept/Svc Dept of Med/Endocrine Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: Cost: Cost: FY-80 METCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: 10 Serious/unexpected side effects in subjects participating in project: None	Timothy Boehm, MAJ, MC Leonard Wartofsky, COL, MC Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: Cost: FY-80 MEDCASE Cost: Fy-80 MEDCASE Cost: To determine if rT3 influences T4 levels and kind for the filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kind for the filled in the f	sociate Investigators:	Facil	ity:			
Leonard Wartofsky, COL, MC Dept/Svc Dept of Med/Endocrine Key Words: Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Cost: Cost: FY-80 METCASE Cost: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: None Number of subjects to be studied before completion in project: None	Leonard Wartofsky, COL, MC Dept/Svc Dept of Med/Endocrine Key Words: Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Accumulative Sup Cost: Cost: Cost: FY-80 MEDCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kine Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: Number of subjects to be studied before completion of study: 10	mothy Boehm, MAJ, MC	L		-		
Accumulative MFDCASE Accumulative Contract Accumulative Supply Cost: Cost: Cost: Cost: FY-80 METHOASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: 10 Serious/unexpected side effects in subjects participating in project: None	Reverse T3/thyroid Accumulative MEDCASE Accumulative Contract Accumulative Sup Cost:		C Dept/	Svc Dept of	Med/Endoc	rine'	
Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: Cos	Accumulative MEDCASE Cost: Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kind Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: To determine if rT3 influences T4 levels and kind Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: To determine if rT3 influences T4 levels and kind Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: Number of subjects to be studied before completion of study:	Words:					٠.
Cost: Cost: Cost: Cost: Cost: Cost: FY-80 METCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: 10 Serious/unexpected side effects in subjects participating in project: None	Cost: Cost: Cost: Cost: Cost: FY-80 MEDICASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kine Reverse T3 ingested orally while I4 isotope give: Reverse T3 ingested orally while I4 isotope give: None Progress during FY-80: Number of subjects to be studied before completion of study: 10 Sections (progressed side effects in subjects participating in project)	. Reverse	T3/thyroid				
FY-80 MED CASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kineti Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	FY-80 METHASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if rT3 influences T4 levels and kind Technical Approach: Reverse T3 ingested orally while I4 isotope give: Progress during FY-80: None Number of subjects to be studied before completion of study: 10 Sections (presented side effects in subjects participating in project)	numulative MEOCASE	Accumulative	Contract			upply
Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: None None None	To determine if rT3 influences T4 levels and kind to determine if rT3 influences T4 levels and kind Reverse T3 ingested orally while I4 isotope gives Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study:	t:	Cost:		Cost:		
Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: None None None	Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: Number of subjects to be studied before completion of study: To determine if rT3 influences T4 levels and kind in the studied before the studied before completion of study: 10	-80 MEDGASE Cost:		Periodic Revi	ow Results:		
Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Technical Approach of the studied before completion of study:	-	And the state of t	• ;	•		
Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Technical Approach: Reverse T3 ingested orally while I4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: To determine if rT3 influences T4 levels and kind in the studied kind in the studied kind in project.	7.07		.1			
Technical Approach: Reverse T3 ingested orally while T4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Technical Approach: Reverse T3 ingested orally while I4 isotope given Progress during FY-80: None Number of subjects to be studied before completion of study: Topious Approach: None Topious Approach side affects in subjects participating in project:		mine if rT3	influences T	4 levels	and ki	neti
Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Reverse T3 ingested orally while T4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Foreigns (unsupported side effects in subjects participating in project)	. 10 46201		znazocneco z			
Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Reverse T3 ingested orally while T4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Foreigns (unsupported side effects in subjects participating in project)	•					• .
Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Reverse T3 ingested orally while T4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Serious (prespected side effects in subjects participating in project)	•	•		٠	•	
Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Reverse T3 ingested orally while T4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Foreigns (unsupported side effects in subjects participating in project)	·					
Progress during FY-80: None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Reverse T3 ingested orally while T4 isotope gives Progress during FY-80: None Number of subjects to be studied before completion of study: Foreigns (unsupported side effects in subjects participating in project)	chnical Approach:					
Name Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	None Number of subjects to be studied before completion of study: For ious (unexpected side effects in subjects participating in project)	Reverse	T3 ingested	orally while	. I4 isoto	pe giv	ren
Name Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	None Number of subjects to be studied before completion of study: For ious (unexpected side effects in subjects participating in project)					•	
Name Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	None Number of subjects to be studied before completion of study: Socious (unexpected side effects in subjects participating in project)						
Name Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	None Number of subjects to be studied before completion of study: Socious (unexpected side effects in subjects participating in project)						
None Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	None Number of subjects to be studied before completion of study: Serious (unexpected side effects in subjects participating in project)						• .
Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None	Number of subjects to be studied before completion of study: 10 Serious (unexpected side effects in subjects participating in project)	ogress during FY80:				•	
Serious/unexpected side effects in subjects participating in project: None	Number of subjects to be stilled before completion of stilly:	None					
Serious/unexpected side effects in subjects participating in project: None	Number of subjects to be stilled before completion of stilly:	•					
Serious/unexpected side effects in subjects participating in project: None	Samous Aurespected side affects in subjects participating in project.	nber of subjects to be studi	ed before comple	etion of study:	10		
Conclusions: RT3 does not affect T4 kinetics		ious/unexpected side effect	s in subjects par	ticipating in pr	oject: No	ne	
	Conclusions: RT3 does not affect T4 kinetics	nclusions: RT3 does no	c affect T4	kinetics			
·	•						
							•

Date:	Protocol No:	1360	Status: Interim X	
Title of Project: Investiga		iing T3 pr	Final oduction rates	
Starting Date: 1977	Estimated Co	ompletion Da	te: 8-82	
Principal Investigator: KEN	NETH D. BURMA	N, MD, LTC	, MC	
Associate Investigators: ROBERT SMALLRIDGE CHARLES SMITH	Facility	V: WRAMC	`	
LEONARD WARTOFSKY B.J.GREEN	Dept/S	vcDept of 1	1ed/Endocrine	
Key Words: Thyroid horm	one/T3.			
Accumulative MEDCASE Cost:	Accumulative (Cost:	1	Accumulative Supply Cost:	
FY-80 MEDCASE Cost:		Periodic Rev	iew Results:	
-		(to be filled	in by DCI)	
Study Objective: To determ identical clearance rate	S.	es ans un.	tabelied not mones had	-
'Technical Approach:				
Adminster calculate kinetics.	labelled and	unlabelle	ed hormones and	
Progress during FY-80: Aborinfusions with identical infusions to 10-15 other	clearance ra	tes. We t	vill now extend the	155
Number of subjects to be studied	before completi	on of study:	about 15	
Serious/unexpected side effects	in subjects parti	cipating in p	roject:	
Conclusions Unlabelled 3'5'				

Publications or Abstracts, FY-80:


SMALLRIDGE, RC, BURMAN KD, ETAL JCEM under consideration

Funds utilized: FY-80: \$1,000

Funding requirements, FY-81:

Supplies: \$5,000

Other: 400



Date: 10 Sept 80	Protocol	l No:	1361	Status: I	nterim
Title of Project:				I	Sinal X
Postoperative changes in f	ree testost	erone .	and sex-hort	none-binding-g	lobulin
Starting Date: 1977	Estir	nated C	omuletion D	ate: 30 Sept 8	0
Principal Investigator: Alla	an R. Glass,	M.D.,	MAJ MC		
Associate Investigators:		Facili	ty: WRAL	ic .	
		Dept/S	Svo Kyle Me	etabolic Unit	
Key Words: surgery, fr	ree testoste	rone			
Accumulative MEDCASE Cost: 0	Accumi		Contract	Accumula Cost:	ntive Supply \$2,400
FY-80 MEDCASE Cost:	0			view Results:_ d in by DCI)	
Study Objective:			(10 20 1120		
Technical Approach: Measurement of testoster	one and free	e testo	sterone bef	ore and after	surgery
Progress during FY-80: fiscal years, with one re-	~			y completed du is now termina	
Number of subjects to be stu	died before	comple	tion of study	: none	
Serious/unexpected side effe	ects in subjec	cts part	icipating in	project:	
Conclusions:					
Both total and free testo	sterone fall	l afte	r surgery u	nder general a	nesthesia.
Publications or Abstracts,	FY-80: No	one.			

Date: 15 October 1980	Protocol No:	1362	Status: Interim X		
-	Treatment of Am s with Vitamin		ctorrhea Final		
Starting Date: 21 Dec 1976	Estimate	d Completion i	Date: 30 Sept 1981		
Principal Investigator: Robe	ert A. Vigersky	, M.D. MAJ MC			
Associate Investigators:		Facility: WRAMC			
	Dep	t/Svc Kyle M	etabolic Unit		
Key Words: Amenorrhen-galac	ctorrhea; pyrid	oxine			
Accumulative MEDCASE Cost: 0	Accumulative Contract Cost: 0		Accumulative Supply Cost: 0		
FY-80 MEDCASE Cost:			eview Results:		
a co-factor in the synthes levels. Since dopamine is that prolactin levels would bromocriptine therapy or of Technical Approach: Pre-factorization, chlorpromazing whether or not chronic treaters.	is of dopamine a prolactin in decrease. This is ervation in the treatment and perform the present with pyr	which would thibitory facts would be an he treatment ost-treatment and suppressidoxine has a	or, it might be expected alternative to either of these syndromes. testing with provocative ive (L-Dopa) to determine		
or the dynamics of other pr	ituitary trophi	c hormones.			
Progres theolog SY-80; as in the blood of women reconvith MAJ R. Bongiovanni. The due to the failure to re	lving this ther Th <mark>e failu</mark> re <mark>of</mark>	apy have need the worldness	established in collaboratio		
Number of subjects to be stud	ied before comp	letion of study			
Serious/wexpected side effec	ts in subjects pa	urticipating in	project: None		

Conclusions: Pyridoxine has, to date, not been effective in lowering prolactin levels in amenorrhea-galactorrhea syndromes but has caused the resumption of menses in 2 of the 6 women so far treated with this regimen. Pyridoxine levels in plasma are currently being determined as well as those of pyridoxine metabolican. Publications or Abstracts, FY-80: Kidd, G.S., Dimend, R., and Vigersky, R.A., "Response of Hyperprolactinemic Women to Short Term and Long Term Pyridoxine Therapy," substitud.

Funds Utilized, FY-80: None

Funding Requirements, FY-61: \$1200

Personnel: None

Equipment: None

Supplies: \$1200

<u>Travel:</u> None

<u>Other:</u> #one

Date: 10 Oct 1980	Frotocol	No: 1	363	Status: Interim
	111000031	110		Bood
Title of Project: Effect of T ₃ and rT ₃	on Plasma	Cyclic	Nucleotida	e Levels on Sheep
Starting Date: 21 Dec 1976	Estin	nated Co	mpletion D	ate: 30 Sept 1982
Principal Investigator: H.	Linton Wra	y, ltc,	MC	
Associate Investigators: Kenneth D. Burman, LTC, MC		Facility	: WRAMC	•
John P. Alfred, CPT, MC Leonard Wartofsky, COL, MC		Dept/Svc Kyle Metabolic Unit		
Key Words: thyroid hormor	e, cyclic A	MP, c yc	lic CP	•
Accumulative MEDCASE Cost: None	Accumulative Contract Cost: None		ontract	Accumulative Supply Cost: \$7,413
FY-80 MEDCASE Cost: N	one	[F		view Results:
Technical Approach: The ar				
received one of the following high T_3 (4.5 $\mu g/kg$), 4) T_5 (1.5 $\mu g/kg$) in combination and the animals were studied indothyronines were measure	high r'I ₃ (4 .om. Treatm d throughou	l μg/kg) rents wo	, or 5) lo to admini	ow rT ₃ (2.5 µg/kg) plus low- ered every 8 \ for 4 days
accumulation and analysis of increase in plasma cyclic A subject of an addendum to the subject of an addendum to the subject of the subject o	of new data MP in respo rotocol.	during onse to '	the last y r ₃ require	es clarification and is the
Number of subjects to be students of subjects to be students of subjects to be students of subjects to be students.				
Conduciona Top results in	dicate that	in the	sheen 1)	T, markedly increases cAMP directive in both of 3; 3) degradation of rT3 is both T3 and rT3 contribute levels; and 5) T3 may enhance both 3,3'T2 and 3,5T2.

Funds utilized, FY-80: \$1,461 (2600)

Funding requirements, FY-81:

Personnel: Vincent M. Butler, GS-09

Equipment: Automated RIA System (81 MEDCASE)

Supplies: \$6,500

Travel: \$1,100

Other: \$3,500

Date: 10 Sept 1980	Protoco	l No:	1.354	Status: Interim X	
Title of Project: Effect of dynamics in women	L-tryptoph	nan on	LH and FSH	Final	
Starting Date: 1978	Esti	nated (Completion Da	ate: 1981	
Principal Investigator: All	Lan R. Glass	, M.D.	, MAJ MC		
Associate Investigators:		Facility: WRANC			
		Dept/Svc Kyle Met		abolic Unit	
Key Words: L-tryptophan,	LH, FSH	.	·	•	
Accumulative MEDCASE	Accum	ulative	Contract	Accumulative Supply	
Cost: 0	Cost:		0	Cost: \$100	
FY-80 MEDCASE Cost:			!	view Results: d in by DCI;	
To determine how L-trypto with the regulation of La				Recursor, Enceracts	
"Technical Approach:					
Assessment of pituitary go before and after administr				nd estrogen challenge	
Progres suring FY-80: in recruicing volunteers,				onnel as well as difficulty er this protocol during FY S	
Number of subjects to be stu Serious/unexpected side effe none					
Conclusions:					
Deferred					
Publications or Abstracts, I	FY-80:				

Funds utilized, FY-80: 0

Funding requirements: FY-81:

Supplies: \$2,000

Other: 4,000

Date: 10 Sept 80	Protocol No:	1365	Status: Interim X	
Title of Project: Insulin re effect on glucose and amin		etes: relativ	e Final	
Starting Date: 1978	Estimated	Completion Do	te: 1982	
Principal Investigator: All	an R. Glass, M.D.	, MAJ MC		
Associate Investigators:	Facil	Facility: WRAMC		
	Dept/	Svc Ky	le Metabolic Unit	
Key Words: L-valine, obe	esity, diabetes,	insulin resis	tance	
Accumulative MEDCASE Cost: 0	Accumulative Cost: \$13,90	į	Accumulative Supply Cost: \$2,500	
FY-80 MEDCASE Cost:		' 1	niew Results:	
Study Objective:			antender en	
To determine whether, in on amino acid metabolism metabolism.	states of insuli are blunted, as	n resistance, are the effec	the effects of insulin ts of insulin on glucose	
norma	nistration of IV il subjects and t n insulin resista	o subjects wi	f valine or glucose to th various disorders in ole.	
		~	· -	
-Progress during FY-80: half non-diabetic obese s subjects with insulin res	subjects.Plan is	to extend stu	ring FY 60- half normals, dy to other groups of	
Number of subjects to be stu				
Serious/unexpected side effeone syncopal episode probab	cts in subjects par oly related to ve	ticipating in p nipuncture (v	roject: vasovagal)	
Conclusions: Valine dispos disposal is		obese subject	s in whom glucose	

Publications or Abstracts, FY-80: Abstract presented at Amer Dialettec Assoc meeting, 1980, and also at International Symposium. Paper submitted for publication.

Funds utilized: FY-80: \$9,500

Funding requirements, FY-81:

Supplies: \$12,000

Travel: \$1,000

Other: \$4,400

Date:	Protocol	l No: 1366	Status: Interim		
Title of Project:	•.		Final X		
The effect of glucago	on on thyro	oidal economy	•		
Starting Date: 1/5/78	Estir	nated Completion l	Date: 8/82		
Principal Investigator:	KENNETH D.	BURMAN, MD, L1	C,MC		
Associate Investigators: LEONARD WARTOFSKY JOHN T. O'BRIAN		Facility: WRAMC			
ROBERT SMALLRIDGE LINDA JONES		Dept/SvcDept of Med/Endocrine			
Key Words: Glucag	on/thyroid	l hormone			
Accumulative MEDCASE Cost:	Accumi Cost:	ulative Contract	Accumulative Supply Cost:		
FY-80 MEDCASE Cost:	n fa nya, saasa oo shaasa mahkaadhaanaadhaa		eview Results:		
Study Objective: To asc					
Technical Approach: Admini glucagon by RIA	ster small	dose T3 durin	ig fasting and measure		
Progress during FY-80: A tota decreases glucagon cl			tudied and show that T		
Number of subjects to be st					
Serious/unexpected side effe	ects in subjec	cts participating in	project: None		
Conclusions: T3 regula	tes glucag	on ,			
Publications or Abstracts,	FY-30:				
BURMAN, KD. Et al JCEM	in press	٠			

Date: 10 Sept 1980	Protocol	No:	1367	Status: Interim x
				Final
Title of Project: Effect of a testosterone in hypertensis	methyldopa ve men.	on ser	um LH and	
testosterone in hypertensis				
Starting Date: not vet begun	Estir	nated (Completion E)ate: 1982
Deinging Laurentine	an R. Glass	, MD,	MAJ MC	
Associate Investigators:		Facili	ty:	
Nabil Gemayel MD CPT MC				
		Dept/	Svc K	yle Metabolic Unit
Key Words: clonidine, L	H. testoste	rone		
Accumulative MEDCASE			Contract	Accumulative Supply
Cost: 0	Cost:			Cost: \$436
FY-80 MEDCASE Cost:			Periodic Re	view Results:
			1	ed in by DCI)
in serum LH or testostero				iine produces changes
Technical Approach:				
Measurement of serum LH, and HCG, before and after				$vell_{ar{ar{I}}}$ as responses to LHRP.
Progress during FY-80:				
Due to an administrative formal approval to begin	mixup, the work on thi	princ: s prot	ipal investi locol, so no	gator never received thing has been done yet.
Number of subjects to be stud				
Serious/unexpected side effections	ets in subjec	its pur	ticipating in	project:
Conclusions:				
Deferred				
Publications or Abstracts, F	'Y-80:			

none

Work Unit #: 1367

Funds utilized, FY-80: \$436

Funding requirements, FY-81:

Supplies: \$4,000

Travel: \$1,000

Other: \$9,300

10 Oct 1980 1368 Protocol No: Date: Status: Interim No Wall Title of Project: Effect of Dietary Phosphate on Serum Levels of Vitamin D metabolites in Hypoparathyroidism. Starting Date: 26 April 1977 Estimated Completion Date: 30 Sept 1982 Principal Investigator: H. Linton Wray, LTC, MC WRAMC Associate Investigators: Facility: Joseph Bruton, Ph. D. Ira Mehlman, LTC, MC Dept/Syc Kyle Metabolic Unit Key Words: Phosphate, Vitamin D metabolism Accumulative Supply Accumulative MEDCASE Accumulative Contract Cost: None Cost: \$200.00 Cost: \$ 59,891 FY-80 MEDCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To determine if serum levels of 25-CH-D (25-hydroxy-vitamin D), 24, 25-(CH) 2-D (24, 25-dihyrdoxyvitamin D) and 1,25-(CH) 2-D (1, 25-dihydroxy-vitamin D) are changed by short-term manipulation of dietary phosphate intake in hypope athyroid patients. Technical Approach: The 15 day protocol consists of 2 days on normal phase intake (1.0 g of phosphorus), 10 days on low phosphate intake (0.5 g of phosphorus and 3 days on high phosphate intake (1.5 g of phosphorus). During the period of phosphate restriction, phosphate-binding antacids will be given. A patie : croup of phosphate-replete, antacid-treated will serve as a control group. Served inorganic phosphate, ionized calcium, total calcium, magnesium and creatinine and plasma 25-CH-D, 24, 25-(OH) D and I, 25-(OH) D will be determined.

Progress during FY-80: N:0 personnel have now set-up a chromatography system which appears adequate for the vitamin D assays in human serum. Control samples are now being processed to determine our normal ranges. Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None Conclusions: The experimental protocol has been shown to effectively lower urine

and serum phosphate in a manner which will provide the appropriate changes to allow correlations with the changes in the vitamin D metabolites.

Publications or Abstracts, FY-S0: None

Funds utilized, FY-80: \$26,400 (2600)

Funding requirements, FY-81:

Personnel:

Delbert Dawson (GS-11)

Vincent M. Butler (GS-09)

Equipment: Automated RIA System (FY-81) MEDCASE

Supplies: \$25,000

Other: \$2,800

Date: 15 October 1980	Protocol No:	1370	Status: Interim X			
Title of Project: Sex Stero Gland	id Receptors in	the Human Thy	roid			
Starting Date: 24 May 77	Estimated	l Completion i.	vate: 30 Sept 1982			
Principal Investigator: Rob	ert A. Vigersky,	M.D. MAJ MC				
Associate Investigators:		Facility: WRAMC				
	Dep	t/Svc Kyle Me	tabolic Unit			
Key Weels: Thyroid; Sex	steroids; Recept	ors				
Accumulative MEDCASE Cost: 0	Accumulative Cost:		Accumulative Supply Cost: \$699.15			
FY-80 MEDCASE Cost:	Q	 1	eview Results:ed in by DCI)			
in their thyroid glands. with respect to their phys receptors in more classic Technical Approach: Meas Scatchard analysis of cyto of thyroidectomy. Also, k	The additional ico-chemical ide target tissues is urement of affir sol made from thinectic analysis	aim is to cha entity and to or these ster nity constant nyroid glands s, size and ch	and binding capacity by obtained at the time			
Progress during FY-80: and the analysis of simila such as the thymus (human) Number of subjects to be stu	r parameters in to compare wi	other non-cl	10			
Serious/unexpected side effe	cts in subjects pa	articipating in	project: Rone			
Conclusions: Methods have to allow appropriate conclusions. Publications or Abstracts, 1	usions to be made		issues run for comparison ata obtained on the human			

nork Unit do.: 1370

runds Utilized, FY-80: \$699.15

Funding Requirements, FY-61: \$3700

Personnel: None

Equipment: None

Supplies: \$3000

Travel: \$500

Other: (2400) \$200

Date:	Protocol	No:	1371		Status: Interim
Title of Project: Gluc Economy in Fasted sub		tion,	Periphera	al Th	Final X yroid Hormone
Starting Date: 1-5-78	Estin	nated (lompletion D	ate:	8-80
Principal Investigator: K	ENNETH D.	BURMA	N, MD, LTC	,MC	
Associate Investigators: L. WARTOFSKY CO1,MC RC SMALLRIDGE,LTC,MC		Facili	ty: WRAMC	······································	
No omeened, gro, no		Dept/S	SvcDept of	Med/	Endocrine
Key Words: thyroid hormo	ne .				•.
Accumulative MEDCASE Cost:	Accumu Cost:	lative	Contract		Accumulative Supply Cost:
FY-80 MEDCASE Cost:			Periodic Re (to be fille		
Study Objective:			···		······································
To det	ermine the	effe	ct of gluo	ose	on T3/rT3 levels
•					
Technical Approach:					
	ster gluco	se du	ring feedi	ng a	nd fasting and
Progress during FY-80:					
About	30 patient	s stu	dieu		
Number of subjects to be stu	died before c	omple	ion of study:	0	
Serious/unexpected side effe	cts in subjec	ts part	icipating in I		t: None
Conclusions: Glucose/1	cresese and decr	eases	rT3		

Publications or Abstracts, FY-80:

PANAGARO, et al JCEM 50:1075,80

Date:		Protocol	No:	1372		Status:	Interim
Title of Project: A and fasting.	lterations	in TRH	sti	mulation	in obes	ity	Final X
Starting Date: 1	2-5-77	Estin	nated	Completion	Date:	8	3-80
Principal Investiga				RMAN, MD,			
Associate Investiga	tors.		Facil	lity: WRAMC			**************************************
•	e v		Dept,	/Svc Dept	of Med/	Endoc	rine
Key Words IKH Obesity	•						•
Accumulative MED Cost:	CASE	Accumi Cost:	lativ	Contract	1	Accumu Cost:	llative Supply
FY-80 MEDCASE (Post:			Periodic I (to be fil			
Study Objective:	To guanti	tate TS	η st	imulation	in fas	ting.	
Technical Approac	ch: TRH tests	in fee	ding	and fast	ing per	iods.	
Progress during I		if about	20	patients	ofu die d	Ъу Т	RH infusions
Number of subjects						0	None
Serious/unexpected	side effects	in subjec	ts pa	rticipating i	n project	: :	None
Conclusions:	TSH decre	ases in	fas	ting			
Publications or Ab	stracts, FY-	-80					

Burman, KD et al, Metabolism 29:46,1980

	Protocol	No: 1374	Status: Interimx
Title of Project: Evaluation infertile men.	on of testos	terone reserve in	Final
Starting Date: 1978	Estir	nated Completion I	Date: 1982
Principal Investigator:	Allan R. Cla	ss MD MAJ MC	
Associate Investigators:		Facility: WRAM	c ·
		Dept/Svc Kyle	Metabolic Unit
Key Words: testosterone,	HCG, infert	ility	
Accumulative MEDCA (Cost: \$1,000	Accumu Cost:	statico Contract	Accumulative Supply Cost: \$13,100
FY-80 MEDCASE Cost:	\$1,000	Periodic Re	eview Results:
Study Objective:		(to be fille	ed in by DCI)
Study Objective: To determine how the test	is responds		
		to single and mu	ltiple injections of HCG
Technical Approach: Measurement of serum leve of HCG administration.	els of gonad	to single and mu	ltiple injections of HCG.

may be related to a shift in the pathway of testosterone biosynthesis.

one paper in preparation. One abstract presented at National AFCR meeting.

Publications or Abstracts, FY-80: Two papers published in FY80, one paper in press,

33

Funds utilized, FY-80: \$44,000

Funding requirements, FY-81:

Supplies:

\$6,000

Travel:

\$1,000

Other:

\$18,000

Date: 10 Sept 80	(Protocol No:	1376	Status: Interim X			
Title of Project: Effect on growth hormone dynamic	of amitriptyline		ine Final			
Starting Date: 1978	Estimated	l Completion D	Oate: 1982			
Principal Investigator:	Allan R. Glass, N	TO MAIMO				
						
Associate Investigators:	Faci	Facility: WRAMC				
	Dept	:/Svc Kyle	Metabolic Unit			
Key Words: L-tryptophan, amitrip	tyline, acromega	ly, growth ho	rmone, prolactin			
Accumulative MEDCASE Cost:	Accumulativ	e Contract	Accumulative Supply Cost: 39,000			
FY-80 MEDCASE Cost:			eview Results:			
		(to be fille	ed in by DCI)			
Technical Approach: Measur and in response to pertur amitriptyline or amantadin	bation tests befo	prolactin and ore and after	growth hormone basally administration of either			
	revise protocol		y completed. Addendum to ding prior to beginning on			
Number of subjects to be stu						
Serious/unexpected side effe	ects in subjects pa	rticipating in	project:			
Conclusions: Amitriptyline suppresses stimulates growth hormone Publications or Abstracts,	in normals but	not in acrome	romegaly. L-tryptophan galy, and stimulates prolac			
Two papers published duri	r 1-30:					

Funds utilized, FY-80: \$435

Funding requirements, FY-81:

Supplies:

\$3,000

Other:

\$4,000

Date: 10 Sept 80	Protoco	l No: 1377	Status: Interim X
Title of Decises		ryptophan content	Final
Starting Date: 1978	Estir	nated Completion I)ate: 1982
Principal Investigator:	Allan R. Gla	ss, M.D., MAJ MC	
Associate Investigators:	4	Facility: WRAM	c
		Dept/Svc Kyle Me	tabolic Unit
Key Words: tryptophan, ob	esity, faod	.! intake	
Accumulative MEDCASE Cost: 0	Accumi	uistivo Contract 0	Accumulative Supply Cost: \$20
FY-80 MEDCASE Cost:	0	Periodic Re	eview Results:
			ed in by DCI)
Study Objective:	· · · · · · · · · · · · · · · · · · ·		
To determine whether the property food intake	proportion o	f tryptophan in f	ood can directly affect
Technical Approach:			
Measurement of food intak diet supplemented with va		_	nly a liquid formula
Progress during FY-80: Dust studied under this protoco			nel no subjects have beer
Number of subjects to be stu	died before d	completion of study	: 12
Serious/unexpected side effe			
Conclusions:		······································	
Deferred			
Publications or Abstracts, 1	FY-80:		
none			•

Funds utilized, FY-80: none

Funding requirement, FY-81:

Supplies:

\$1,000

Other:

\$3,000

Date: 10 Sept 30	Protoco	l No: 1379	Status: Interim X
Title of Project: Effect of reproductive hormones in a		g undernutrition	on
Starting Date: 1973	Esti	nated Completion	Date: 1982
Principal Investigator: Al	llan R. Glas	s MD MAJ MC	
Associate Investigators:		Facility:	TRAMC
		Dept/Svc Ky	r le Metabolic Unit
Key Words: undernutrition, puberty			
Accumulative MEDCASE Cost: 0	Accum Cost.	ulative Contract 0	Accumulative Supply Cost: \$3,800
FY-80 MEDCASE Cost:	0		eview Results: ed in by DCI)
Technical Approach:			
Determination of the resp to various perturbation t			
Progress during FY-80: @due to technical problems, additional studies. A majo	. Shortage o	f animal space ha	i; bith were unsuccessful as temporarily precluded is in preparation.
Number of subjects to be stu			
Serious/unexpected side effe	ects in subjec	ets participating in	project:
Conclusions:			
Undernutrition delays pub	berty in rat	s by means of go	nadotropin deficiency.
Publications or Abstracts, I submitted for publication.		parer published	in FY 30, one paper

Funds utilized: FY-80: \$1,862

Funding requirements, FY-81:

Supplies:

\$5,000

Travel:

\$1,000

Other:

\$9,000

Date: 10 Oct 1980	Protocol	l No: 1380	Status: Interim
		atus on the Horm Responses of the	
Starting Date: 19 Oct 1977	Esti:	nated Completion	Date: 30 Sept 1982
Principal Investigator: H.	Linton Wray,	LTC, MC	
Associate Investigators: Wayman W. Cheatham, MAJ, MC		Facility: WRA	MC
		Dept/Svc Kyle	Metabolic Unit
Key Words: Thyroid Hormo	ne, cyclic /	MP, cyclic GMP	
Accumulative MEDCASE Cost: \$1,000	Accumi Cost:_S	ulative Contract 600	Accumulative Supply Cost: \$17,264
FY-80 MEDCASE Cost: N	cne		eview Results:ed in by DCI)
To detar	nine if the	renal hormone re	centor - second messencer

Study Objective: To determine if the tenal normale re systems of two unrelated polypeptide hormones are affected by thyroid hormone. By measuring nephrogenous cyclic MMP during parathyroid and antidiuretic hormone infusions in hyper- and hypo- thyroid patients, it can be determined if thyroid hormone influence the renal cyclic AMP responses to these hormones.

Technical Approach: Hyperthyroid and hypothyroid patients will be admitted to Ward 47 for a 3 day study protocol and will be similarly studied after becoming euthyroid. During each admission the patient will undergo two 3-hour renal clearance procedures, one with PTH infusion and another with vasopressin infusion.

Progress during FY-80: Six pathents were studied this year with results simil to those reported in the FY-79 report. In addition, preliminary studies have shown that immunoreactive PTH levels during PTH infusion were higher in hypothyroid patients than in euthyroid patients.

Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: None

Conclusions: The delayed water excretion in hypothyroid patients and the decreased fractional excretion of phosphate in hyperthyroid patients are not associated with demonstrated changes in renal responses to vasopressin and parathyroid hormone. An addendum to the protocol has been submitted (attached). Publications or Abstracts, FY-80: Endocrinology 106 (Suppl): 122, 1980.

Work Unit #1380

Funds utilized: FY, 80:

\$3,061 (2600)

Funding requirements, FY-81:

Personnel:

Gerald M. Sheldon SP-6

Vincent M. Butler GS-09

Equipment:

Automated RIA System (FY-31 MEDCASE)

Supplies:

\$8,000

Travel:

\$1,100

Other:

\$5,000

Addendum to protocol, Work Unit #1380

1. This protocol, "Effect of Thyroid Status on the Hormonally -induced Cyclic AMP Responses of the Kidney", has resulted in three abstracts and three papers which are currently in preparation. One aspect of these investigations has demonstrated little effect of thyroid status on the renal responses to infused parathyroid hormone (PTH) when measured by nephrogenous cyclic AMP (NCAMP) and fractional excretion of phosphate (FE po4). However, preliminary studies have shown that immunoreactive PTH levels during PTH infusion were higher in hypothyroid patients than in enthyroid patients yet the measured renal responses were not significantly different (attached abstract). This suggested that hypothyroid patients had a decreased clearance of infused PTH and were in fact hyporesponsive to PTH.

2. We propose to continue to investigate the effect of thyroid status on PTH metabolism and responses by measuring biologically active as well as immunoreactive PTH in addition to McAMP and FE po4 during PTH infusion. Two bioassays will be employed. A cytochemical assay using rat renal tubules will be performed by Dr. James Posillico of Duke University and a adenylate cyclase assay using canine renal membranes will be performed by Dr. Robert Nissenson of University of California. Six patients with hyperthyroidism and six with hypothyroidism will be studied on a two day protocol which will not include the previously used anti-directic hormone infusion. These studies will determine whether biologically active PTH during PTH infusion is affected by thyroid status and will be important in the interpretation of the renal responses to PTH.

Date: 15 October 1980	Protocol	l No: ¹³⁸¹	s	status: Interim x
Title of Project: Estradiol Receptors in Rat Thyroid Glands				Final
Starting Date: 24 May 19	77 Estin	nated Completion i	Date:	30 Sept 1982
Principal Investigator: Ro	bert A. Vige	rsky, M.D. MAJ MC	;	
Associate Investigators:		Facility: WRAMC		
		Dept/Svc Kyle M	[etabolio	2 Unit
Key Words: Estrogen; rece	ptors; thyro	id		
Accumulative MEDCASE Cost:0	Accumu Cost:	lative Contract	i	ocumulative Supply
FY-80 MEDCASE Cost:	0	Periodic Re		
rat thyroid so that these receptors in the human. To and other non-classic target and other non-classic target. Technical Approach: Detesteroid specificity, net sistate kinectics of the receptate of varying ages.	echniques to et tissues s ermination o ize and char	be developed wil uch as the thymus f the binding cap ge, sedimentation	l be use	ed for these nd affinity, cient, and steady-
Progress during FY-S0:	d the alread as well as c	y accumulated dat lassic target tis	a has be sues for	een compared to
Number of subjects to he studential Serious/unexpected side effections.	cts in subject	s participating in p	project:	N/A
Conclusions: Estrogen red female rats are appear to b of other receptors. Publications or Abstracts, F	be similar i			

ŧ

work Unit do.: 1381

Funds Utilized, FY-80: \$426.20

Funding Requirements, FY-81: \$7300

Personnel: None

Equipment: None

Supplies: \$6600

<u>Travel:</u> \$500

Other: (2400) \$200

Data: 15 O. table 18 .	Promucol Nor	Premocol Nov. 1982			
Title of Project: Measure by Microp Seture from Rat	t wat of Storoids Sectiniferous Tub				
Starting Date: 24 May 1977		Completion D	te: 30 Sept 1983		
Principal Investigator: Rot	bert A. Vigersky	M.D. MAJ MC			
Associate Investigators:	Facil	Facility: WRAMC			
	D. 17	Svc Kyle M	etabolic Unit		
Key Words: Micropund	cture; sex steroid	3.			
Accumulative MEDCASE Cost: 0	Accumulative Cost: 0	Contract	Accumulative Supply Cost: \$2438.96		
FY-80 MEDCASE Cost:	0		riew Results: I in by DCI)		
Study Objective: To study	the control of s	permatogenes	is by sex steroids,		

Technical Approach: Testicular micropuncture using laboratory fabricated glass micropipets in adult male rats. Measurement of steroids by micro-methods of mailloimmunoussay. Infusion of various drugs and bormones intravenously and measurement of them as they appear in the seminiferous tubule.

particularly estradiol and testosterone. Also to investigate the nature of

the blood-testis barrier to these steroids and to other substances.

Progress during FY-80: Methods for simultaneous cannulation of the jugular and femoral vein have been developed so that constant infusion and blood sampling can be accomplished. A study of the ability of methotrexate, a commonly used about 10 the treatment of melimannies, has been completed showing 100 times lower leve No where of subjects to be attidied before completion of study: WA in the Totale. Serious/unexpected side effects in subjects positicipaling in project:

Conclusions: A blood-testis barrier exists for the drug, methotrexate. This may explain the reason that the testis is a frequent site of recurrence of leukepia.

Publications or Abstracts, FY-80: None

nork Unit do :

1382

funds Utilized, FY-60: \$2438.96

Funding featurements, FY-61: \$6700

Personnel: Susan Barnes, GS-09

Equipment: None

<u>Supples:</u> \$5000

Travel: \$500

Other: (25/2) \$1000; (2400) \$300

Date: 1 Octobre 1980	Protocol No:	1363	Status: 1.3.4.48 X			
Title of Project: Measureme Assessmen	ent of Hemoglobin of of the Efficacy o		Peatment			
Starting Date: 7/27/77	Estimated	Completion I	Date: present			
Principal Investigator:	Finiothy M. Boehn	a, LTC MC				
Associate Investigators:	facil	Facility: WRAMC				
P. Leapley, R.D.	Dept,	Abvo Depart	ment of Clinical law stigation			
Key Words: Clycos, lated	hemoglobin, diab-	tes, diabetic	diet			
Accumulative MEDCASE Cost: \$11,938.00	Accumulative Cost:	e Contract	Accumulative Supply Cost: \$16,821.53			
FY-50 MEDCASE Cost:		teriodic Re (to be fille	eview R. ofs:			
*Technical Approach: Second at the responses to diet to		·	an attempt was made to lated hermoglubins.			
*Progress during FY-80:	None. The distitis	in interested	in the study departed WRAMC			
Nomber of subjects to be stu Serious/unexpected side of the						
	liet the rapy withou romoting weight re	losing weigh luction. lorts are bo	est improvement in lighAlC ht, indicating that diet theraping made to gather the data			

Date: 10 Sept 80	Prof 100	1 No: 138	35	Status: Interim X	
Title of Project:	Final				
Serial changes in free tes	stosterone d	during p	regnancy		
Starting Date: 1978	Sstir	materl Co	mpletion D	nte: 1981	
Principal Investigator: Alla	n R. Glass	MD MAJ 1	·1C		
Associate Investigators:	Facility:				
Thomas Klein MD LTC MC Dept/Svc Kyle Metabolic Uni				tabolic Unit/ ObGyn	
Key Words: free testosterone, pregna	incy	l			
Accumulative MEDCASE Cost: 0		ulative C \$8,000	ontract	Accumulative Supply Cost: \$1,000	
FY-SO MEDGASE Cost:	Y-SO MEDCASE Cost: O Periodic Review Results: (to be filled in by DCI)				
Study Objective:					
To determine whether free pregnancy and whether such					
Technical Approach:					
Measurement of Fotal and I	ree testos	terone di	iring preg	nancy.	
Progress & ring UN-89:					
170 subjects studied. Ass completed.	says of tes	rost evon	e, free to	sterterone, and DHT	
Number of subjects to be sto	died before	completti	n of aludy:	30	
Serious/unexpected side offer none	cts in subjec	eis partic	epating in 1	oroject:	
Conclusions: Free testosterone falls mod not correlated with fetal s		increas	ing fetal	agn. Free testosterone is	
Publications or Abstracts, E One paper solutions for pu					

Funds utilized, FY-80: \$8,000

Funding requirements, FY-81

Supplies: \$3,000

Travel: \$1,000

Other: \$4,400

Date: 15 Catabar 1930	Protocol	No: 1	386	_] ;	Status: Interimx
Title of Project: The Effect of Male Inferti	f Delta-1-T			1	Eino!
Starting Date: 22 Nov. 1977	Estin	nated (Completion D	ate:	30 Sept 1983
Principal Investigator: Rober	t A. Vigers	ky, M.	D. MAJ MC		
Associate Investigators: Alla	1				
		Dept/S	Svc Kyle M	etabol	ic Unit
Key Words: Infertilit	y, male; Te	stolac	tone; Oligo	spermi	a .
Accumulative MEDCASE Cost: 0	Accumu Cost:		Contract		Accumulative Supply Cost: \$7262.20
FY-80 MEDCASE Cost:	0		Periodic Re (to be fille		
Study Objective: To improve idiopathic oligospermia. Trepect to normonal paramete the effect of lowering estrate basal and stimulated leading to the basal and stimulated lead	o study the ars and resp cogen levels	mecha onse t and b	inism of the to HCG and L blocking est	ou rgo BH and	spermia with to investigate
Technical Approach: LRH aperformed before beginning Semen and bormonal parameter are repeared at the time of ever is first.	on Teslac 1 ers are moni	Gm/da	y and Tamox monthly and	ifen 2 the H	CG and LRH tests
Progress during FY-80: Two a 100% increase in sperm comen have been begun on the	ounts (11 or	12 re	esponding) a	nd 4 p	regnancies. Five
Number of subjects to be stud Serious/unexpected side effect					: None
Conclusions: Blocking estro to have been effective in i men with idiopathic oligosy	increasing a	parm c	counts and p	romoti	ng fertility in

Publications or Abstracts, FY-80: Vigersky, R.A. and Glass A.R., "Effect of Δ^1 -Testolactone (Teslac) in Oligospermic Men,"J. Andrology 1:67, 1980.

100

Funds Utilized, FY-80: \$10765.20

Funding Requirements, FY-61: \$10,700

Personnel: Temporary hire, GS-07 to be named

Equipment: None

Supplies: \$2000

Travel: \$500

<u>Other:</u> (2572) \$8000; (2400) \$300

Date: 10 Sept 80	Protocol No: 1387	Status: Interim X
Title of Project: Acute reprostate carcinoma	esponses to estrogen in men wi	ith Final
Starting Daie: 1978	Estimated Completion I	Date: 1982
Principal Investigator:	Allan R Glass MD MAJ MC	
Associate Investigators:	Facility: WRAMO	3
	Dept/Svc Kyle	Metabolic Unit
Key Words: estrogen, LH, prostate of	carcinoma	•
Accumulative MEDCASE Cost:	Accumulative Contract Cost: 0	Accumulative Supply Cost: 0
FY-80 MEDCASE Cost:	· · · · · · · · · · · · · · · · · · ·	eview Results: ed in by DCI)
Study Objective:	er in de la company de la comp	-
administration different	with prostate carcinoma responding from normal men	ond to soute estrogen
Technical Approach: Measurement of serum LH a challenge	and estrogen after administra	tion of an acute estrogen
recently been published. <u>subject group, as per ranged</u> Number of subjects to be st	is study was essentially done Protocol is undergoing evalu cent addendum. Added before completion of studiects in subjects participating in	ation to study a different v: 15
Conclusions:		
Deferred		

Work unit no.: 1387

Funds utilized, FY-80: 0

Funding requirements: FY-81:

Supplies:

\$1,000

Other:

\$3,000

Date:	Protocol No: 1389 Status: Interim						
Title of Project:					l	Final	XX
The effect of Dietary	y Carbohyd	rate	on T3 Rec	eptor	s.		
Starting Date: 1978	Estin	nated C	ompletion I	Date:	198	0	
Principal Investigator:	KENNETH	D. BUI	RMAN, LTC	, MC		*****	
Associate Investigators: L. WARTUFSKY, COL, MC RC SMALLRIDGE, LTC,MC	Facility: WRAMC			AMC	-		
AR GLASS, MAJ,MC YVONNE LURES	Dept/Svc Dept of Med/Er				ndoer	Lne	
Key Words: Carbohydra	ate/T3 rec	eptors	5		-	•	
Accumulative MEDCASE Cost:	Accumi Cost:	ulative	Contract	L	Accurni Cost:		
FY-80 MEDCASE Cost:			Periodic Re (to be fille				
Study Objective: To asceptate if carbo	ohydrate i	nta k e	oleter '	îî re	ceptor	s leve	els.
Technical Approach:	•						
Isolate T3 receptors	from rat	liver	and solu	bíliz	e rece	ctor	
•							
Progress during FY-80: 25 rats studied by ea eceptors isolated.	ting 79%	or 64%	carbohy	irate	diet	and th	ien _.
Number of subjects to be stu Serious/unexpected side effe					rats ct:		
Conclusions: arbohydrates do not alt	er recepto	or lev	els				

Work unit no.: 1389

Funds utilized, FY-80: \$1,075

Funding requirements, FY-81:

Personnel: Lukes

Supplies: \$2,000

Other: 400

Travel: 1,000

Date:	Protocol No:	1390	Status: Interim X
Title of Project:			Final
•			
Investigations Concer	ning the Physi	ology of lo	odothyronines
Starting Date: 6-78	Estimated (Completion Da	te: 8-82
Principal Investigator:	Kenneth D. Bur		
Associate Investigators:	Facili	ty: WRA:	10
	Dept/s	Sve Dept	of Med/Endocrine
Key Words: Iodothyroni	nes		•
Accumulative MEDCASE Cost:	Accumulative Cost:	Contract	Accumulative Supply Cost:
FY-SO MEDCASE Cost:		Periodic Rev	iew Results: in by DCI)
Study Objective:			v manifestation in the community of the fill of the community of the commu
To guan onversions.	ititate the fac	tors influ	cing iodothyronine
•			
Technical Approach:	easurements by	RIA in var	cious states.
•			
			•
	-		
Progress during FY-80:		•	•
-	RIS for 3,5 T	2	•
Develop	RIS LOT 3,3 I	_	
Number of subjects to be stud	died before comple	tion of study:	30
Serious/unexpected side effect	cts in subjects par	icipating in p	roject: None
Conclusions: There is d	ecreased extra	thyroidal d	conversion in fasting
Publications or Abstracts, E	'Y-80:		
	1	200	·
Wray HL, Burman,	KD, et al JCE	M: 107:130	, 1980

Work unit no.: 1390

Funds utilized, FY-80: \$20,000

Funding requirements: FY-81:

Supplies: \$5,000

4 7 7

Date:	Protoco	l No: 1391	Status: Interim x		
Title of Project:		•	Final		
Regulations if the I	nitiation	of Thyroid Horn	none Action		
Starting Date: 1-78	Estir	nated Completion I	ate: 8-81		
Principal Investigator:	Kenneth D	. Burman, LTC,	мс		
Associate Investigators: Keith Latham		Facility:			
Wartofsky, L Yvonne Lukes		Dept/Svc Det	ot of Med/Endocrine		
Key Words: T3 rec	eptors		•		
Accumulative MEDCASE Cost:	Accumi	ulative Contract	Accumulative Supply Cost:		
FY-SO MEDCASE Cost:			view Results:		
To det	ermine how	thyroid hormon	nes work.		
Technical Approach: Isolate	e and puri	fy T3 receptors			
Progress during FY-80: alfhydryl oxidizing ago	Block T3 ents.	receptor activi	ty with Ipodate and		
Number of subjects to be stu					
Serious/unexpected side effe	cts in subjects none	ets participating in	project:		
Conclusions: THe receptor 50,000 Daltous	or has ace	tylase activity	and a MW of about		
Publications or Abstracts, 1	FY-80:		,		

Burman, KD et al, Hormone Metab Res: In press

Work unit no: 1391

Funds utilized, FY-80: \$20,000

Funding requirements, FY-81:

Personnel: Burman and Latham

Supplies: \$5,000

Date: 15 October 1980	Protoco	l No: 1392	Status: Interim
		cross the Blood-C e Rhesus Monkey.	erebrospinal Final X
Starting Date: 27 Dec 197	7 Esti	nated Completion I	Date: Completed
Principal Investigator: R	obert A. Vi	gersky, M.D. MAJ	мс
Associate Investigators:	:	Facility: WRAMC	
·	•	Dept/Svc Kyle M	etabolic Unit
Key Words: Blood-Cere	brospinal F	luid Barrier	
Accumulative MEDCASE Cost: 0	Accum Cost:_	ulative Contract 0	Accumulative Supply Cost:x 0
FY-80 MI'OGASE Cost:	0		eview Results:
Study Objective: To deter varying rates of entry int	o the CSF f	rom blood.	E gradocor Excorns have
Technical Approach: In cortisol into a vein and m and CSF via an Ommaya rese	easurement	unlabelled dexame	thasone, preinisone, and
Progress during FY-80: No	experiment	s were performed	in FY-80
Number of subjects to be stu Serious/unexpected side effe			
Conclusions: None of the into the GSF,	steroids me	easured had any ad	vantage in the rate of end

None

(

Publications or Abstracts, FY-80:

Date:	Protoco	l No: 1393	Status: Interim x
Title of Project: T3 Receptors in Nor	mal and Fas	ting Rats	Final
Starting Date: 1-78	Petis	nated Completion J	Date: 8-81
Principal Investigator:	Kenneth D	. Burman, LTC,	MC
Associate Investigators:		Facility:	AMC
		Dept/Svc De	pt of Med/Endocrine
Key Words: T3 r.e	ceptor/Fast	ing	
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			eview Results: ed in by DCI)
Study Objective: To me	asure T3 re	ceptors in rat	liver during fasting
Technical Approach: Isola	te T3 recep	to a in fed and	d fasting rat.
Progress during FY-80: We ar ecaptors decrease in		ocess of deter	mining why T3
Number of subjects to be serious/unexpected side e	studied before ffects in subje	completion of studets participating in	v: rats project:
Conclusions: T3 receptors dec	rease durin	g fasting	
Publications or Abstracts	, FY-80:	none	

Funding requirements: FY-81:

Personnel: Lukes, Burman

Supplies: \$2,000

. . .

٠.

Date:	Protocol	No:	1395	Status: Interim	X
Title of Project:				Final	 .
4 to T3 Conversion: Ef	fect of M	odula	tion of G1	ucose Metabolism	
Starting Date: 78	Estin	nated C	ompletion D	ate: 81	
Principal Investigator:	Kenneth D.	Burm	an, LTC, M	С	
Associate Investigators:		Facility: WRAMC		мс	
		Dept/S	lvc Dep	t of Med/Endocrin	
Key Words: Glucose /T	conversi	on			. ,
Accumulative MEDCASE Cost:	Accum Cost:		Contract	Accumulative Su Cost:	
FY-80 MEDCASE Cost:				view Results: d in by DCI)	
Study Objective: To stud 4 to T3 conversion in r		hanis	a by which	glucose increase	S
Technical Approach: Hepatic	: isolatio	n and	quantitat	ion of T4 convers	ion.
Progress during FY-80: Have starzyme activity	nown that	sulfh	ydyl group	s and glucose inc	reas
Number of subjects to be stu- Serious/unexpected side effe	udied before ects in subje	comple cts par	tion of study ticipating in	rats project:	
Conclusions: Glucose ent	nances T4	and T	3 conversi	on	

None

Publications or Abstracts, FY-80:

1 4 3

1395

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Yvonne Lukes, Kenneth D. Burman

Equipment:

Supplies:

\$3,000

Travel:

4.00

Other:

113

Date:	Protocol No:	1396	Status: Interim X			
Title of Project:			Final	•		
T_4 to T_3 Conversion:	Effect of S	Somatostatin	Administration			
Starting Date: 78	arting Date: 78 Estimated Completion Date: 81					
Principal Investigator:	Kenneth D. Bu	ırman, LTC,	MC			
Associate Investigators:		oility: WR	AMC	••		
	Dep	ot/Svc De	pt of Med/Endocrine			
Key Words: Somatos	station/T4 co	onversion .				
Accumulative MEDCASE Cost:	Accumulati Cost:	ve Contract	Accumulative Supply Cost:	-		
FY-80 MEDCASE Cost:			eview Results:ed in by DCI)	•		
Study Objective: To determ of T3 receptors and also altered by thyroid hormo	so to determi		alter T4 conversion ostation receptors are	e '		
Technical Approach: Somatos omatostatin RIA, T3/T4		or in thyro	id and pinuitary gland	d,		
			•	٠		
Progress during FY-80:						
Have de n thyroid and pituitary		ıy for measu	ring somatostatin rec	eptor.		
Number of subjects to be stu				-		
Serious/unexpected side effe	cts in subjects p	participating in	project:			
Conclusions: Thyroid bevels	iormone proba	bly alters	somatostatin receptor	-		
Publications or Abstracts, I	FY-80: None					

1 , 2

1396

Funds utilized, FY-80: \$1,554.94

Funding requirements, FY-81:

Personnel:

Yvonne Lukes

Equipment:

Supplies:

\$2,000

Travel:

400

Other:

1,000

Date:	Protoco	l No:	1397		Status: Interim x
Title of Project: The effect of Various		c Con	ditions or	n T3	Final Receptors in
Circulating Mononuclear	Cells.				
Starting Date: 79	Estir	nated C	ompletion T	ate:	8 2
Principal Investigator: Ke	nneth D. B	urman	, LTC, MC		
Associate Investigators:		Facili	y: WRA	AMC	
I. Wartofsky, COL Keith Latham		Dept/S	vc De	ot of	Med/Endocrine
Key Words: T3 recepto	rs	.			
Accumulative MEDCASE Cost:	Accumi Cost:	ulative	Contract		Accumulative Supply Cost:
FY-80 MEDCASE Cost:			Periodic Re (to be fille		
Study Objective: Measure quantitate and corre	e T3 recep late T3 re	tors	in various ractivity	s ill	nesses and
Technical Approach: Set up	T3 recept	or as	say and se	et up	acetylase enzym
Progress during FY-80: Develo	p acetylas	e act	ivity		
Number of subjects to be stu- Serious/unexpected side effe				·	0 :t:
O. a. A. a. i. a. a.	ably regul				

Burman, et al JCEM 51:106.80 Maxon, Premachandra NEJM, May 29 1980

Publications or Abstracts, FY-80:

1397

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Djuh, Latham, and Burman

Equipment:

Supplies:

35,000

Travel:

Other:

Onte: 10 October 1980	Protocol No: 1398	Status: Interim
		\$274041
litle of Project: Studies on in tumors a	the pathogenesis of hypocalogassociated with osteoblastic m	retastases
21. 04.625 0		
T 1079		te 30 Sep 1982
Starting Date: June 1978	Estimated Completion Da	its: 30 Sep 1902
	ert C. Smallridge, LTC, MC Linton Wray, LTC, MC	
Associate Investigators: Marcus Schaaf, M.D. John Horton, M.D.	Facility: WRANC	
Richard C. Dimend, LTC, MC	Dept/Svc Kyle Met	cabolic Unit
Key Words: Hypocalcemia, c	esteoblasts, cancer	•
Accumulative MEDCASE Cost: None	Accumulative Contract Cost: None	Accumulative Supply Cost: \$2,900
FY-80 MEDCASE Cost:	None Periodic Rev	riew Results:
T 00 MIDOLIDI COD.	(to be filled	
osteoblastic metastases is	ine whether the hypocalcemia so due to hypoparathyroid, second D metabolism, or an unidentic	seen in some patients wit ondary hyperparathyroidis
osteoblastic metastases is an abnormality in vitamin osteoblastic activity. Technical Approach: (1) 24 hour urines for ca (2) Serum for Ca, PO4, Mx (3) Calcium and parathor.	ine whether the hypocalcemia so due to hypoparathyroid, second D metabolism, or an unidentical alcium, phosphate, creatinine g, alkaline phosphatase, paramone infusions	seen in some patients wit ondary hyperparathyroidis fied humoral substance wi thyroid, vitamin D metabo
osteoblastic metastases is an abnormality in vitamin osteoblastic activity. Technical Approach: (1) 24 hour urines for ca (2) Serum for Ca, PO4, Mx (3) Calcium and parathor.	ine whether the hypocalcemia so due to hypoparathyroid, second D metabolism, or an unidentical alcium, phosphate, creatinine g, alkaline phosphatase, paramone infusions for tissue culture to test in	seen in some patients wit ondary hyperparathyroidis fied humoral substance wi thyroid, vitamin D metabo
osteoblastic metastases is an abnormality in vitamin osteoblastic activity. Technical Approach: (1) 24 hour urines for ca (2) Serum for Ca, PO4, Mg (3) Calcium and parathorm (4) Bone marrow biopsies to incorporate H-pro	ine whether the hypocalcemia so due to hypoparathyroid, second D metabolism, or an unidentical alcium, phosphate, creatinine g, alkaline phosphatase, paramone infusions for tissue culture to test in	seen in some patients with condary hyperparathyroidis fied humoral substance with the collar abilities according to utilize
osteoblastic metastases is an abnormality in vitamin osteoblastic activity. Technical Approach: (1) 24 hour urines for ca (2) Serum for Ca, PO4, Mg (3) Calcium and parathorm (4) Bone marrow biogsies to incorporate H-pro	ine whether the hypocalcemia so due to hypoparathyroid, second D metabolism, or an unidentical alcium, phosphate, creatinine g, alkaline phosphatase, paramone infusions for tissue culture to test in oline into collagen. itamin D metabolite assays are patient have been reported, or	seen in some patients with condary hyperparathyroidis fied humoral substance with thyroid, vitamin D metabola vitro the cells' abilities hearly ready to util we have article accepted for
osteoblastic metastases is an abnormality in vitamin osteoblastic activity. Technical Approach: (1) 24 hour urines for ca (2) Serum for Ca, PO4, Mg (3) Calcium and parathor. (4) Bone marrow biogsies to incorporate H-pro	ine whether the hypocalcemia so due to hypoparathyroid, second D metabolism, or an unidentical alcium, phosphate, creatinine g, alkaline phosphatase, paramone infusions for tissue culture to test in oline into collagen.	seen in some patients with condary hyperparathyroidis fied humoral substance with thyroid, vitamin D metabola vitro the cells' abilities hearly ready to util 26 the article accepted for 8
osteoblastic metastases is an abnormality in vitamin osteoblastic activity. Technical Approach: (1) 24 hour urines for ca (2) Serum for Ca, PO4, Mg (3) Calcium and parathor. (4) Bone marrow biogsies to incorporate H-pro	ine whether the hypocalcemia so due to hypoparathyroid, second D metabolism, or an unidentical alcium, phosphate, creatinine g, alkaline phosphatase, paramone infusions for tissue culture to test in oline into collagen. itamin D metabolite assays are patient have been reported, or added before completion of study:	seen in some patients with condary hyperparathyroidis fied humoral substance with thyroid, vitamin D metabola vitro the cells' abilities hearly ready to util 26 the article accepted for 8

Funds utilized, FY-80: \$2,255 (2600)

Funding requirements, FY-81:

Personnel: Delbert Dawson GS-11

Gerald M. Sheldon SP-6

Equipment: Automated RIA System (FY-81 MEDCASE)

Supplies: \$2,500

Travel: 500

Other: 1,000

level	ssessment of par ls in normal sub rders of calcium	jects and in	n patients	with
Starting Date: May 197	28 Est	imated Comp	letion Date:	30 Sept 1982
Principal Investigator:	Robert C. Smal H. Linton Wray	lridge, LTC	, MC	
Associate Investigators:		Facility:	WRAMC	
Marcus Schaaf, M.D. Richard C. Dimond, LT	C, MC	Dept/Svc ;	(yle Metabo	Plic Unit
Key Words: Parathon	mone			
Accumulative MEDCAS Cost: <u>None</u>	į.	Accumulative Centract Cost: None		Accumulative Supply Cost: \$1,200
FY-80 MEDCASE Cost: None			odic Review be filled in	v Results: by DCI;
and patients with met	abolic disorder	s.		els in normal subject easure PTH levels.
shortage of laboratory radioimmunoassay to da	y personnel has ate.	prevented t	he develop	
Number of subjects to l Serious/unexpected sid				100

Publications or Abstracts, FY-80: None expected. Reference ranges being established.

1399

Funds utilized, FY-80:

\$1,129 (2600)

Funding requirements, FY-81:

Personnel:

Vincent M. Butler, GS-09

Equipment:

Supplies:

\$2,500

Travel:

\$500

Other:

\$1,500

Date:	Protocol	No:	1300-78	Status: Interim X
Title of Project: The Development of a	Radioimmu	noas	say of Tri:	iodothyronine
Starting Date: 78	Estim	ated	Completion D	ate: 81
Principal Investigator: K	enneth D.	Bur	nan, LTC,	4C
Associate Investigators: L. Wartofsky, COL RC Smallridge, LTC		Facil		AMC
		Dept/	Svc De	pt of Med/Endocrine
Key Words: Radioim	munoassay			
Accumulative MEDCASE Cost:	Accumu Cost:	lative	Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			- 1	view Results:d in by DCI)
Study Objective: To deve	lop radio	immu	noassay fo	r thyroid hermones
Technical Approach: Conjuga ccasionally and check f			rabbits an	nd then bleed
Progress during FY-80: Antibod	y develop	ed f	or 3,5T2	
Number of subjects to be stud Serious/unexpected side effect None				
Conclusions: None yet				

Pangaro, LP, Burman, KD, et al JCEM 50:130, 1980

Publications or Abstracts, FY-80:

1300-78

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Burman

Equipment:

Supplies:

\$2,000

Travel:

Other:

: 01 : 01

Date: 15 October 1980	Protoco	l No!301-78	Status: Interim X
Title of Project: The Effect alpha Reductase in Rats.			Cinal
Starting Date: 24 Jan 78	Estir	nated Completion Di	ate: 30 Sept 81
Principal Investigator:	Robert A. V	igersky, M.D. MAJ N	1C
Associate Investigators:		Facility: WRAMO	
		Dept/Svc Kyle Me	tabolic Unit
Key Words: Teslac; Recept	ors; 5-aopl	ha Reductase.	
Accumulative MEDCASE Cost: 0	Accum Cost:_	ulative Contract	Accumulative Supply Cost: \$394.40
FY-80 MEDCASE Cost: 0			view Results:d in by DCI)
Study Objective: To determ Teslac in vivo is due to testosterone to dihydrotes	its abilit	or not the anti-a y to interact with	ndrogenic activity of the enzyme that converts
Technical Approach: Measurement Teslac. Also, measurement conversion of testosterone	s given eit of the in	her testosterone a vitro ability of T	eslac to prevent the
Progress during FY-80: I activity and that its antithe androgen receptor	t would app -androgenic	ear that Teslac do effect is via its	
Number of subjects to be stu			
Serious/unexpected side effe	cts in subje	cts participating in p	project: N/A

Conclusions: Teslac is an anti-androgen as well as inhibiting estrogen activity via anti-receptor activity. Further studies are in progress to characterize Teslac's ability to interact with the estrogen receptor.

Publications or Abstracts, FY-80: Vigersky, R.A., Mozingo, D., Eil, E. Purchit, V., and Bruton, J., "Anti-androgenic Properties of Delta-1-Testolactone (Teslac), "Endo. Soc.

nork Unit do.: 1301-78

funds Utilized. FY-80: \$394.40

Funding Requirements, FY-81: \$5600

Personnel: None

Equipment: None

Supplies: \$3800

<u>Travel:</u> \$500

Other: (2572) \$1000; (2400) \$300

Date: 15 October 1980	Protocol No:1303-78	Status: Interim X
Title of Project: Studies of		Final
· beddies ()	n the Alterations in Drug Met hyroidism.	abolism
In hypert	ny roidism.	
Starting Date: 28 Mar 78	Estimated Completion Da	ate: 30 Sept 81
	profile de de la control de la	10. 30 Sept 61
Principal Investigator:	Robert A. Vigersky, M.D. MAJ	MC
Associate Investigators:	Facility: WRAMC	
	Dept/Svc Kyle M	Metabolic Unit
Key Words: Hyperthyroidis	m; Methimazole, Dexamethasone	
Accumulative MEDCASE	Accumulative Contract	Accumulative Supply
Cost:0	Cost: 0	Cost: 0
FY-80 MEDCASE Cost:	n Periodic Rev	riew Results:
		in by DCI)
Study Objective: To deter	mine if changes in metabolism	of drugg used to treet
	the elevated thyroxine levels	
th rough beta-adrenergic e	ffects.	
•		
Technical Approach: The	half lives and plasma levels o	of devamethasone and
methimazole will be measur	ed after intravenous injection	while the patients are
hyperthyroid and after tre	atment with beta-adrenergic bl	ockade. They will be
studied again after being clinically indicated.	rendered euthyroid by the appr	opriate therapy as
,		
Progress during FY-80. N	a pardurka usus assessi dana k	Andrews and American
FY-80 due to the departure	o patients were accrued into to of the participating Fellow.	nis protocol during
·	, , ,	
Number of subjects to be stu	idied before completion of study:	10
Serious/unexpected side effe	ects in subjects participating in p	roject: None
Conclusions: The blood awa unavailable.	its analysis and therefore res	ults are currently
Publications or Abstracts, I	FY-80: None	

None

work Unit do.: 1303-78

Funds Utilized, FY-80: None

Funding Requirements, FY-61: \$3000

Personnel: None

Equipment: None

Supplies: \$3000

<u>Travel:</u> None

Other: None

Date:	Protocol No:	1304-78	Status: Interim	
	ve assessment o is with acromeg		tion.	
Starting Date: July 1978	Estimate	d Completion De	nte: 18 months	
Principal Investigator: Rob	ert C. Smallri	dge, LTC, MC		
Associate Investigators: Marcus Schaaf, M.D. Mitchell Mutter	Fac	Facility: WRAMC		
Wm. Oetgen Douglas van Nostrand	Dep	t/Svc Kyle Me	tabolic Unit	
Key Words: Acramegaly/car	diac function			
Accumulative MEDCASE Cost:	Accumulative Contract Cost:		Accumulative Supply Cost:	
FY-80 MEDCASE Cost:		_ Periodic Rev	view Results:	
			d in by DCI)	
left ventricular (LV) funct Technical Approach: LV fu scans, this procedure invol serum albumin		using gultiple ion of Tech	egated acquisition (MU GA) netium labeled human	
Progress during FY-80: A 38). The data are being co	n additional 19 mpiled now for	o patients have a manuscript.	e been studied (total of	
Number of subjects to be stud Serious/unexpected side effect				
Conclusions: Many acrome successful therapy for their		have abnormal	LV function, despite	

Publications or Abstracts, FY-80: Clinical Research 28: 198A, 1980

Work Unit No: 1304-78

Funds Utilized, FY-80:

Funding Requirements, FY-81:

Personnel: \$500.00 (McAnally, Kuffler, Bruton, Martin)

Fquipment: None

<u>Supplies</u>: \$400.00

<u>Travel</u>: \$500.00

Other: Reprints \$300.00

Date:	Protocol No: 13	3 05 –78	Status: Interim			
Title of Project: Breast car	cinama and thyroid	hommone re	ECEPTORS			
Stanting Duka and 1950	Takimetod Cov	nulation De	100			
Starting Date: July 1978 Principal Investigator: Robe	•		ete: 1 yr			
Associate Investigators:	Facility:					
Keith Latham, Ph. D.	- addity.					
	Dept/Svo	;				
Key Words: Thyroid hormo	ne/ breast cancer		•			
Accumulative MEDCASE Cost:	Accumulative Co Cost:	i	Accumulative Suppry Cost:			
FY-80 MEDCASE Cost:			riew Results: l in by DCI)			
in human breast carcinoma. Technical Approach: Eleas a receptor binding assay (L	t tumor is frozen i athan <u>et al</u> . J <u>Biol</u>	n liquid r . <u>Chem</u> 251:	nitrojan and processed in 17388, 1971).			
Progress during FY-80: Tabstract. Completion of the done in a tumor bearing str	e study is dependen	it upon sam	study was published in ar me parallel work being			
Number of subjects to be stud Serious/unexpected side effect						
Canalugiona	one receptors exist	s in human	n breast cancer. Their			
Publications or Abstracts, F	Y-80: Clinical R	<u>esearch</u> 28	3: 421A, 1980.			

Work Unit No:

1305-78

Funds Utilized, FY-80:

Funding Requirements, FY-31:

<u>Personnel</u>: \$500.00 (McAnally, Kuffler, Bruton, Martin)

Equipment:

None

Supplies:

\$400.00

Travel:

\$500.00

Other:

Reprints \$300.00

Date:	Protocol	No: 130	7-78	Status: Interim X
Title of Project: The Effect of Fasting	upon TSH	Response	ε το TRI	Final
Starting Date: 79	Estim	ated Comp	letion Da	te: 80
Principal Investigator:Kenne	th D. Burm	ian, LTC,	MC	
Associate Investigators: L. Wartofsky, COL RC Smallridge, LTC	·	Facility:	WRAN	10
RC Smallfluge, LIC		Dept/Svc	Dept	of Med/Endocrine
Key Words: TRH/fqst				•
Accumulative MEDCASE Cost:	Accamu Cost:	lative Conf	iract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:				riew Results:l in by DCI)
*Technical Approach:				ess is decreased in
*Progress during FY-80: 15 pati	ients studí	ied and e	esch had	i decreased TSP tempons
Number of subjects to be str Serious/unexpected side effe	died before c	ompletion ts particip	of study: ating in p	project:
Serious/unexpected side effe	died before c ects in subject ecrease TSF	ts particip	ating in p	roject:

Publications or Abstracts, FY-80:

BURMAN, KD et al Metabolism 29:46, 1980

Work unit no.: 1307-78

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Burman

Equipment:

Supplies:

\$2,500

Travel:

Other:

124

Date: 22 Oct 80	Protoco	l No: 1300-79	Status: Interim
Title of Project: Measureme	ont of Tod		y Kirak
and a solution Medant eme	sit of loa	ochyronines by	HPLC
Starting Date: 18 Aug 80	Estin	mated Completion L	rate: 15 Aug 93
Principal Investigator: Ke	enneth D.	Burman, LTC, MC	
Associate Investigators:		Facility: WRAMO	
Rudolph Bongiovanni, (CPT, MC	<u> </u>	
		Dept/Svc Kyle	Metabolic Unit
Key Words:	PLC	1	,
Accumulative MEDCASE	Accum	ulative Contract	Accumulative Supply
Cost:	Cost:		Cost:
FY-80 MEDCASE Cost:			view Results:
		(to be fille	ed in by DCI)
Technical Approach: U Progress during FY-80:	se of HCL We can a	P ccurately measu	re $ exttt{T}_{ extstyle A}$ and $ exttt{T}_{ extstyle 2}$
Number of subjects to be sta Serious/unexpected side effe	idied before	completion of study	· · · · · · · · · · · · · · · · · · ·
Conclusions:			
Publications or Abstracts,	FY-30:	none	•

Work unit no.: 1300-79

Funds utilized, FY-80: \$2,888.80

Funding requirements, FY-81:

Personnel: Bongiovanni

Equipment:

Supplies: \$4,000

Travel: 500

Other: 500

Date:	23 Oct 8	0	Protocol	No:	1301-79	Status: Interim
	Project:				ic conditions latory cells	
		a.a 13 10	ccpcoro o	CL 1. C		•
Starting	Date: 1	Jan 79	Estin	nated	Completion D	ate: 1 Jan 82
Princip	al Investig	ator: Ke	enneth D. Bu	rman,	LTC, MC	
Associate Investigators: Yin-Ying Djuh, GS-11			_	Facil	ity: WRAMC	
Leonard	d Wartofsk	y, COL, M	C	Dept/	Svc Kyle M	etabolic Unit
Key Wo	rds: T ₃ /	receptor	S	1		
	ulative ME		I		Contract	Accumulative Supply Cost:
FY-80	MEDCASE	Cost:			']	view Results:d in by DCI)
		· .	-		white cells.	ese activity in white ce
Progre		FY-80:	Have determ	uined	that T ₃ and	T ₄ receptors increas in
					etion of study ticipating in	
Conclus	sions:					
Publica	ntions or A	bstracts,	FY-80:	none		

1301-79

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Wartofsky, Burman, Djuh, GS-11

Equipment:

Supplies:

\$4,500

Travel:

500

Other:

Date: 15 October 1980	Protoco	1 No: 1302-79		Status: Interim X
Title of Projectivention of with Combinat Histiocytic L	Gonadál Da ion Chemot	mage in Men 1	Created odgkin's Di	Final
Starting Date: 7 Nov 1978	Esti	mated Complet	ion Date:	30 Sept ε3
Principal Investigator: Robert	: A. Vigers	sky, M.D. MAJ	MC	
Associate Investigators:		Facility:	vramc	
Ramona Chapman, M.D. MAJ MC Jeffrey Berenberg, M.D. LTC	MC	Dept/Svc	Kyle Metabo	olic Unit
Key Words: Azospermia; 400	lokio s di:	seaso; chemot	herapy	•
Accumulative MEDCASE Cost: 0	Accum Cost: \$	ulative Contra 4000	ct	Accumulative Supply Cost: 0
FY-80 MEDCASE Cost:)		ic Review : e filled in b	Results: by DCI)
for Hodgkin's disease and or diminished ability of the Lo of the therapy. The aim of the chemotherapy by the pre- with high dose testosterone	ther malig eydig cell this stud treatment. niferous twith chemo into a count at 200 mg uing throughout for the ction have the ction.	nancies. Dec to secrete t y is to prote suppression ubular and Le therapy. 22f ntrol or trea i.m. weekly ghout the dur tervals. been entered been assesse	reased lib estosteron of their p ydig cell ore beginning ation of their p into the ped in these	e are also side effects en from the ravages of ituitary-gonadal axis function are accessed fing the therapy, of the protocol. The 1 1-2 week before chemo- cheir therapy. Follow-u protocol; Leydig cell
Serious/unexpected side effect				ct: None
Conclusions: Men with Hodgk abnormalities of seminifero	in's disea us tubulan	ise have, in s and Leydig o	ome cases, cell functi	pretteatment lon.

None

Publications or Abstracts, FY-80:

DATE: 30 September 1980 PR	OTOCOL	NO: 1302-79	STATUS: Into	
TITLE OF PROJECT: WRAMC # 78	310		Fina	11
Prevention of Gonadal Dam				
Chemotherapy/Radiotherapy	for H	odokin's Disease	and Non-Hod	gkin's
Lymphoma STARTING DATE: NOV [079		ESTIMATED COMPLET	ON DATE: 198	3
PRINCIPAL INVESTIGATOR: R. C.	ipman			
ASSOCIATE INVESTIGATORS:		FACILITY: Walter	Reed Army Medic	al
3. Vi_ersky J. Berenberg		SERVICE: Hematol	new Occulous	
- Dazensezg		Denartme	ent of Medicine	
KEY WORDS:		1		
ACCUMULATIVE MEDCASE	ACCUMU	LATIVE CONTRACT	ACCUMULATIVE	SUPPLY
COST:	COST:		COST:	
FY-80 MEDCASE COST:	<u> </u>	PERIODIC REVIEW R	ESULTS:	
STUDY OBJECTIVE:				
		estosterone admi		
chemotherapy will proteac	t germ	cells from tota	il extinction	
in men with lymphoma			•	
			• •	
				. : .
TECHNICAL APPROACH: Men are rendomized to receive eith enanthate weekly until one Post-therapy, men are receive agents later.	her no e mont	h ; after the en	r or testoste id of chemoth	rone erapy.
PROGRESS DURING FY-80: 15 mer Disease and four of these Recause the declined for vasectomy (4). Four pat non-Hodokin's lymphoma arm	will ther f ients	i <mark>not be follow</mark> er olisw up (in ou have been places	l after thera Greause of	'S TV
NUMBER OF SUBJECTS TO BE STUDIO SERIOUS/UNEXPECTED SIDE EFFECTS	ED BEFO	RE COMPLETION OF ST BJECTS PARTICIPATIN	UDY:	
conclusions: It is too ear paper of abstract submitted		reach complusion ASCO for 1981.	ons. See att	ached
PUBLICATIONS/ABSTRACTS; FY-80:	Abst	tract submitted for v	ublication.	

work Unit do.: 1302-79

Funds Utilized, FY-80: \$4000

Funding Requirements, FY-61: 10,800

Personnel: None

Equipment: None

Supplies: \$1000

<u>Travel:</u> \$500

<u>Other:</u> (2572) \$9000.; (2400) \$300

Date:	Protocol No	1304-79	Status: Interim
Title of Project: Thyroid	hormones in cer	ebrospinal flu	uid YXXXK
Starting Date: 24 April 19 Principal Investigator: Pro-	79 Estimate	d Completion I	vate: September 1981
Associate Investigators: Kenneth D. Burman, LTC, MC Leonard Wartofsky, COL, MC Michael W. Potter, MAJ, MC	-	cility: WRAMC	etabolic Unit
Frances D. Wright, GS-11 Key Words:			•
Accumulative MFDCASE Cost:	Accumulati	ve Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			eview Results:
Study Objective: To deter hormones into the central in the CNS might play in varie	nervous system	(CNS), and what	s in the transport of thyrciat role thyroid hormones in
Technical Approach: CSF disease states (such as he will be studied. One to translational states of the collaboration of the collaborati	rniated disc di wo ml of CSF be	sease, pituita gond that requ	ary tumor, or meningitis) wired for noutine CSF
Progress during FY-80: For publication 26 Sept 80.	Preliminary tes	ults obtained	and m cript submitted
Number of subjects to be stu Serious/unexpected side effe			
Conclusions:			

Publications or Abstracts, FY-80: Submitted for publication 26 Sept 1980

4/0

Work Unit No: 1304-79

Funds Utilized, FY-80:

Funding Requirements, FY-81:

Personnel: \$500.00

Equipment: None

<u>Supplies:</u> \$2,500.00

<u>Travel</u>: \$500.00

Other: Contracts \$4,000.00

1 1 3

Starting Date: Estimated Completion Late: Terminated Principal Investigator: Prectice Thompson, LTC, MC Associate Investigators: Facility: WRAMC Accumulative MEDICASE		Protocol	No: 1305-79	Status: XXXXXX
Starting Date: Estimated Completion Date: Terminated Principal Investigator: Prentice Thompson, LTC, MC Associate Investigators: Kenneth D. Burman, LTC, MC Lawrence T. Johnson, COL, MC Robert C. Smallridge, LTC, MC Leonard Wartofsky, COL, MC Key Words: Accumulative MEDCASE Cost: None Cost: None Cost: None Periodic Native Results: (to be filled in by DCI) Study Objective: To determine whether alterations in binding proteins for serum normones are responsible for the abnormalities in thyroid hormone metabolism observed in patients with various liver diseases. Technical Approach: Ton patients each will be studied with (a) acute hepatitis (acute and during convalencemene); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary billiary cirrhosis. Measurements will be obtained in a baseline share and at intervals during follow-up for measurement of TI- TI2. The rT3, natural thin, TB7, GG, TH-G, and FTL terminous serum will be proved from a converse and after steroid therapy; and (c) primary billiary cirrhosis. Measurements of TI- TI2. The rT3, natural thin, TB7, GG, TH-G, and FTL terminous serum will be obtained to cortical, estrogen, and testosterone as well. TRI stimulation tests will be propressed uring FY-80: formed with measurement of TSH and prolactin responses the to the unavailability of the type of patients required, we have terminated the project - racts of which will be incorporated into protecol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None	Title of Project: Thyroid fu	nction in	liver disease	Final
Associate Investigators: Kerneth D. Burman, LTC, MC Robert C. Smallridge, LTC, MC Robert Results; (to be filled in by DCI) Study Objective: To dehemine whether alterations in binding proteins for serum Robert McBDCASE Co.t. Robert Results; (to be filled in by DCI) Study Objective: To dehemine whether alterations in binding proteins for serum Robert Results; (to be filled in by DCI) Study Objective: To dehemine whether alterations in binding proteins for serum Robert Results; (to	Title of Frageet. Suggested to			
Associate Investigators: Kerneth D. Burman, LTC, MC Robert C. Smallridge, LTC, MC Robert Results; (to be filled in by DCI) Study Objective: To dehemine whether alterations in binding proteins for serum Robert McBDCASE Co.t. Robert Results; (to be filled in by DCI) Study Objective: To dehemine whether alterations in binding proteins for serum Robert Results; (to be filled in by DCI) Study Objective: To dehemine whether alterations in binding proteins for serum Robert Results; (to				
Associate Investigators: Kenneth D. Burman, LTC, MC Lawrence W. Johnson, COL, MC Robert C. Smallridge, LTC, MC Leonard Wartofsky, COL, MC Key Words: Accumulative MEDCASE Cost: None Accumulative MEDCASE Cost: None Cost: None Periodic Daview Results: (to be filled in by DCI) Study Objective: To determine whether alterations in binding proteins for serum normones are responsible for the abnormalities in thyroid hormone metabolism observed in patients with various liver diseases. Technical Approach: Ten patients each will be studied with (a) acute hepatitis (acute and during convalencemen); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary biliary cirrhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of TI- T2, 11, 173, acute 114, 113, 113, 114, 114, 114, 115, 114, 114, 115, 114, 114	Starting Date:	Estir	nated Completion Da	te: Terminated
Kenneth D. Burman, LTC, MC Robert C. Smallridge, LTC, MC Record Wartofsky, COL, Mc Record Wartof	Principal Investigator: Preo	tice Thamps	son, LTC, MC	·
Dept/Svc Kyle Metabolic Unit Leonard Wartofsky, CCL, MC Key Words: Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: None Cost: None Cost: None FY-80 MEDCASE Cost: None Periodic Partiew Results: (to be filled in by DCI) Study Objective: To determine whether alterations in binding proteins for serum normones are responsible for the abnormalities in thyroid hormone metabolism observed in patients with various liver diseases. Technical Approach: Ten patients each will be studied with (a) acute hepatitis (sector and after steroid therapy); and (c) primary biliary circhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of TI- T2. My FT3, acute Tel, Tel, CEG, TeNG, and FTT. Terraining serve will be covered from at 40° product evaluation of the latter results for consideration of potential of cortisol, estrogen, and testosterone as well. Tel; stimulation tests will be progress during FY-80: formed with measurement of TSH and prolactin responses one to the unavailability of the type of patients required, we have terminated the project - parts of which will be incorporated into protecol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None	Kenneth D. Burman, LTC, MC	c	Facility: WRAMC	
Accumulative MEDCASE Cost: None Cost: None Cost: None Cost: None Cost: None FY-80 MEDCASE Cost: None Periodic Review Results: (to be filled in by DCI) Study Objective: To determine whether alterations in binding proteins for serum normones are responsible for the abnormalities in thyroid hormone metabolism observed in patients with various liver diseases. Technical Approach: Ten patients each will be studied with (a) acute hepatitis (acute and during convalencement); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary bilitary cirrhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of T1-T2. The TRA, normalist, TRA, CSG, TOSG, and FTT. Temaining server will be stored from at 400 pudding evaluation of the latter results for consideration of priential of cortisol, estrogen, and testosterone as well. TRB stimulation tests will be progress during FY-80: formed with measurement of TSH and prolectin responses due to the unavailability of the type of patients required, we have terminated the project - parts of which will be incorporated into protecol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None	Robert C. Smallridge, LTC, 1		Dept/Svc Kyle Me	tabolic Unit
Cost: None Cost: None Cost: None Periodic Deview Results: (to be filled in by DCI) Study Objective: To determine whether alterations in binding proteins for serum normones are responsible for the abnormalities in thyroid hormone metabolism observed in patients with various liver diseases. Technical Approach: Ten patients each will be studied with (a) scute hepatitis (acute and during convalencement); (b) shronic active hepatitis (before and after steroid therapy); and (c) primary biliary cirrhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of T1- T2, and -40 pending evaluation of the latter results for consideration of priential of cortisol, estrogen, and testosterone as well. TRH stimulation tests will be performed during FY-80: formed with measurement of TSH and prolactin responses to the unavailability of the type of patients required, we have terminated the project - parts of which will be incorporated into protocol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None	Key Words:		•	•
Study Objective: To determine whether alterations in binding proteins for serum hormones are responsible for the abnormalities in thyroid hormone metabolism observed in patients with various liver diseases. Technical Approach: Ten patients each will be studied with (a) acute hepatitis (acute and during convalencements); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary bilitary cirrhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of TI- T2. Ti, rT3, count will, TB), CSG, Te9G, and FTI. Remaining serum will be stored from at -40° punding evaluation of the latter results for consideration of potential of cortisol, estrogen, and testosterone as well. TRB stimulation tests will be performed during FY-80: formed with measurement of TSH and prolectin responses One to the unavailability of the type of patients required, we have terminated the project - parts of which will be incorporated into protocol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None				,
Study Objective: To determine whether alterations in binding proteins for serum hormones are responsible for the abnormalities in thyroid hormone metabolism observed in patients with various liver diseases. Technical Approach: Ten patients each will be studied with (a) acute hepatitis (acute and during convalencement); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary bilitary cirrhosis. Measurements will be obtained in a baseline state and at intervels during follow-up for measurement of TI- T2. Ti, rT3, count wil, TB), CSG, Te4G, and FTI. Remaining serum will be stored from at -40° punding evaluation of the latter results for consideration of potential of cortisol, estrogen, and testosterone as well. TRB stimulation tests will be performed during FY-80: formed with measurement of TSH and prolectin responses to the unavailability of the type of patients required, we have terminated the project - parts of which will be incorporated into protocol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None	FY-80 MEDGASE Cost: N	one	Periodic Rev	iew Results:
Technical Approach: Ten patients each will be studied with (a) acute hepatitis (acute and during convalencence); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary biliary cirrhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of T1- T2. If, rT3, recommend will be converted from the state and at intervals during follow-up for measurement of T1- T2. If, rT3, recommend will be characteristical for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the potential and continuous evaluation of the potential and continuous evaluation of the latter results for consideration of potential and continuous evaluation of the latter results for consideration of the potential and continuous evaluation of the potential and continuous evaluation of the latter results for consideration of the latter results for co	per data y aproblema pe		 [
(acute and during convalencence); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary biliary cirrhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of T1- T2, T3, Focus T31, T63, T63, T63, T63, T64, T73, Focus T31, T63, T64, T64, T64, T65, T65, T65, and F71. Remaining serum will be consideration of potential and polaring evaluation of the latter results for consideration of potential confiction, and testosterone as well. T86 stimulation tests will be performed using FY-80: formed with measurement of T64 and prolactin responses the to the unavailability of the type of patients required, we have terminated the project - parts of which will be incorporated into protocol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None				d hormone metabolism
(acute and during convalencence); (b) chronic active hepatitis (before and after steroid therapy); and (c) primary biliary cirrhosis. Measurements will be obtained in a baseline state and at intervals during follow-up for measurement of T1- T2. T3, require TMI, TB), CFG, TB+G, and FTI. Remaining serum will be obtained at -40 pending evaluation of the latter results for consideration of potential of cortisol, estrogen, and testosterone as well. TRH stimulation tests will be performed with measurement of TSH and prolectin responses the to the unavailability of the type of patients required, we have terminated the project - parts of which will be incorporated into protocol # Number of subjects to be studied before completion of study: None Serious/unexpected side effects in subjects participating in project: None		•		
Serious/unexpected side effects in subjects participating in project: None	The Paris Commence of the Comm			
Serious/unexpected side effects in subjects participating in project: None	(acute and during convalens steroid therapy); and (c) pin a baseline state and at 24, rT3, each wall, who, can -40 pending evaluation of cortisol, estrogen, and Progress during FY-80: to the unavailability of	nimary bili intervals of G; TemG, an of the latt testosteron formed with f the type	chronic active he ary cirrhosis. Mea during follow-up for differentiate statement of TS of patients require	patitis (before and after surements will be obtained in measurement of T1- T2, The error will be stored from sideration of potential mulation tests will be per H and prolectin responses, ed, we have terminated this
Conclusions:	(acute and during convalence steroid therapy); and (c) print a baseline state and at 21, rT3, exceptively (Er), CFC at -40 pending evaluation of cortisol, estrogen, and Progress during FY-80: Due to the unavailability of project - parts of which will	nimary bili intervals of G; Te4G, an of the latt testosteron formed with f the type ll be incor	chronic active he ary cirrhosis. Mea buring follow-up for defining size results for come as well. TRH stimulation as the astronoment of TS of patients requirement of porated into proto	patitis (before and after surgments will be obtained or measurement of T1- T2, Terms will be stored from sideration of potential mulation tests will be per H and prolectin responses. ed, we have terminated this col #
	(acute and during convalence steroid therapy); and (c) print a baseline state and at 124, rf3, ending evaluation of cortisol, estrogen, and repress during FY-80: 120 to the unavailability of coroject - parts of which will humber of subjects to be study.	nimary bili intervals of G; Te4G, an of the latt testosteron formed with f the type ll be incor	chronic active he ary cirrhosis. Meaduring follow-up foldow-up for a first state of TRI state of TRI state of patients required the protection of study:	patitis (before and after surements will be obtained or measurement of T1- T2, Terms will be stored from sideration of potential mulation tests will be per H and prolectin responses. ed, we have terminated this col #
	(acute and during convalence steroid therapy); and (c) print a baseline state and at 11, rT3, end of the product of cortisol, estrogen, and progress during FY-80: the to the unavailability of croject - parts of which will be strongen and subjects to be study. Serious/unexpected side effects	nimary bili intervals of G; Te4G, an of the latt testosteron formed with f the type ll be incor	chronic active he ary cirrhosis. Meaduring follow-up foldow-up for a first state of TRI state of TRI state of patients required the protection of study:	patitis (before and after surements will be obtained in measurement of T1- T2, Terms will be stored from sideration of potential mulation tests will be per H and prolectin responses. ed, we have terminated this col #

Work Unit No: 1305-79

Funds Utilized, FY-30: None

Funding Requirements, FY-81: None, Project terminated

Persurrel:

Equipment:

Supperes:

Travel:

Other:

Date: 10 Pec 80	Protocol	1 No:	1307-79	Status:	Interim x	
Title of Project: Errect of Subhuman P	High Dose De	exameth	nasone on		Final	
Starting Daie:	Estir	nuied (Joinpletion 1	Date: p c 19	81	
Principal Investigator: Ira	Mehlman, Ll	IC NC				
Associate Investigators: R. Smallridge, H. Williams, P. Perone		Facili	ty: WRAMC, I	WRAIR and USU	HS	
M. Schaaf, V. Armbrustmach	er	Dept/	Dept/Svc Hedicine/Endocrine			
Key Words:	الموادة				•	
Accumulativa MEDCASE Cost:	Accumulative Contract Cost:			ulative Supply		
FY-80 MEDGASE Cost:			i	eview Results ed in by DCI)		
Study Objective: Study efficience of Study eff	, bematologi	amethas ic char	some on thy igns, and m	roid hormone uscle patholo	metabolism, ਤ੍ਰਮ in	
Technical Approach: 6 for them sacrified after observed	ateot and 6 cving mulcip	treate Die blo	ed animals o	observed over and tissue.	180 daysand	
			 	·- ·		
Progress during FY-80: Mo of what appears to be a dif- are greatest appearing to a	fterence in	atroph	y greater	s compared (o in dex treate	r conlirmation d. The change	

Number of subjects to be studied before completion of study: tissue collected. but multiple Surjous/unexpected side offects in subjects participating in project: specimens to be challeted of muscle and pancreas.

Conclusions: install studies a basel and TRH responsive TRH potches and from controls.

Conclusions: Inyroid studies - basal and TRH responsive TSH notchas,ed from controls definite Type II atrophy 2 to dexamethasone - studies pending pancreatic changes observed present studies pending

Publications or Abstracts, FU-80:

abstracts

Protocol 1307-79

ξ.

į

- Muscle studies are ongoing particularly the time consuming aspects of evaluating ratio type II/I atrophy which has been definitely observed. Studies by self and Griffiths and Araba astmacher.
- II. Hematologic changes significant and currently evaluable by a router addition i.e. factor 8 antigen.
- Paneleatic changes noted, awarting slides and collaboration with Dr. Powers now at Letterman.

4 , 7

Date: 10 Sept 80	Protoco	l No:1303-79	Status: Interiry X
Title of Project: Stress-i cadets	nduced amend	orrhea in military	Final
Starting Date: 1979	Cati	nated Completion D	ain: 1983
Principal Investigator: All	an R Glass	DM LAM DE	
Associate Investigators: Leigh Wheeler MD LTC MC		Facility: WRAMC /	West Point
Thomas Klein MD LTC MC		Dept/Svc Kyle Me	tabolic Unit/ Ob Gyn
Key Words: stress, amenorrhea			
Accumulative MEDCASE Cost: 0	Accum Cost:	ulative Contract 0	Accumulative Supply Cost: 0
FY-80 MEDCASE Cost:	0	*****	view Results: d in by DCI)
Study Objective:			
To determine the etiology . Technical Approach: Measurements of pituitary and comparison with non-a	and goulda	L hormones in ลนลถ	
Progress ducing EV-80 w to obtain permission of h			
Number of subjects to be stu			
Sections/unexpected side offs	ects in subjec	ets participating in	project:
Conclusions:	······································		
Deferred		•	
Publications or Abstracts,	FY-80:		

' 🤈

Work unit no.: 1308-79

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Equipment:

Supplies: \$1,000

Travel:

Other: \$3,000

Date: 15 Oct 1980	Protocol	No:	1309-79	Status: Interim ×
Title of Project: The Anti-	Estrogenic	Effect	s of Δ^1 –Test	Final olactone (Teslac)
Starting Date: 24 April	79 Estin	nated (ompletion D	ate: 30 Sept 81
Principal Investigator: Robe	ert A. Viger	sky, M	.D. MAJ MC	
Associate Investigators:		Facili	ty: WRAMC	
		Dept/	Svc Kyle Me	etabolic Unit
Key Words: Teslac: Rece	eptors, estr	ogen		
Accumulative MEDCASE Cost: 0	Accumi Cost:	_	Contract	Accumulative Suppl Cost: \$331.75
FY-80 MEDCASE Cost:	0		i	view Results: d in by DCI)
being trested with Teslac an anti-estrogen. Technical Approach: Trested at the Teslac and Technical Approach: Trested at the Teslac and Teslac at the Tesla	eatment of c	astral	e immature	vats with estrogen
alone or estroyen plus Tes as an end point. In vitro with the cytosolic estroger	assessment	of the	ability of	Teslac to interact
	•			
Progress during FY-80: R estrogen receptor indicate results suggest that it ha	s that it ha	as no a	nti-estroge	n activity. Preliminar
Number of subjects to be stu	died before	comple	tion of study	: N/A
Serious/unexpected side effe	cts in subjec	ets par	icipating in	project: N/a
Conclusions: Teslac appear Further experiments for lothis result. Publications or Abstracts, 1	nger duratio	no ant in in i	i-estrogen r ·ivo will be	eceptor activity in vitable performed to confirm

work Unit No.: 1309-79

Funds Utilized, FY-80: \$331.75

Funding Requirements, FY-61: \$1200

Personnel: None

Equipment: None

Supplies: \$1200

Travel: None

Other: None

15 October 80 1310-79 Date: Status: Interim X Protocol No: Final Title of Project Pilot Investigation for the Treatment of Hirsutis with Cral Cimetidine. 30 Sept 1982 Starting Date: 22 May 1979 Estimated Completion Date: Principal Investigator: Robert A. Vigersky, M.D. WRAMC Associate Investigators: Facility: Kyle Metabolic Unit Dept/Svc Key Words: Cimetidine; hirsutism; androgen receptors. Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: \$13,207.00 Cost: \$1000 Cost: \$7500 FY-80 MEDCASE Cost: Periodic Review Results: \$1000 (to be filled in by DCI) Study Objective: To treat women with idiopathic hirsutism with a non-toxic meidication that acts by blocking the ability of androgen (testosterone and

Technical Approach: Measurement of the adrenal contribution of androgen by an ACTH stimulation test; the ovarian contribution by frequent sampling over 8 hours for pituitary and gonadal hormones; and the pituitary contribution by measurement of the response of prolactin to TRH. These studies done before and after 3-6 months on oral cimetidine treatment. Measurement of the rate of hair growth is accomplished by shaving a measured area on the face, chest or thigh and mighing the hair that has accomplished over the previous 1-1 maks. This is Progress during FX-80:

performed before and while on the cimetidine.

10 patients have been entered in to the study. The results of the first five indicate that there is a 50% or more decrease in the rate of hair growth and a marked subjective improvement without any significant changes in serum steroid levels.

Number of subjects to be studied before completion of study:

Serious/unexpected side effects in subjects participating in project: None

dihydrotestosterone) with the androgen receptor in the hair follicle.

Conclusions: Cimetidine appears to be a safe and effective treatment for idiopathic hirsutism and its action is most likely mediated by it anti-androgenic properties.

Publications or Abstracts, FY-80: Smith, C., Mehlman. J., and Tigersky: R. "Treatment of Hirsutism with Elmetidine," presented 62nd ann. meeting Endo. Suc., June, 1980.

work Unit No.: 1310-79

Funds Utilized, FY-80: \$21,707

Funding Requirements, FY-81: \$7000

<u>Personnel:</u> None

Equipment: None

Supplies: \$1200

<u>Travel:</u> \$500

Other: (2572) \$5000 ; (2400) \$300

Date:	Protocol	l No: 1311-79	Status: Interim
Title of Project: Assessmer) Doctor
intrathyr	coidal biosy	d function and the nthesis of thyroic hases of subacute	d hormone during the
Starting Date: November 19	79 Estir	nated Completion D	ate: 2 years
Principal Investigator: Reb	ert C. Smal	lridge, LTC, MC	
Associate Investigators: Leonard Wartofsky, COL, MC		Facility: WRAMC	
Kenneth D. Burwan, LTC, MC Richard C. Dimond, LTC, MC Nancy E. Whorton, GS-11	•	Dept/Svc Kyle	Metabolic Unit
Key Words: Subscute thyroi	ditis/biosy	nthetic defect	
Accumulative MEDCASE Cost:	Accumi Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:		and the second of the second o	view Results: d in by DCI)
in the resolution of the d this defect may have a dif Technical Approach: Blo (generally 6-8 months). F a 3 hour REAU with perchlo	ficult ultin od tests ob Luorescent (mate outcome. tained monthly unt thyroid scans mont	il disease resolves hly. At end of study,
		, go, a.u. o 2241 ooç	· · · · · · · · · · · · · · · · · · ·
Progress during FY-80: 3666666666666666666666666666666666666	Sev en (7) pa t least 6 m	atients have enrol onths.	led in protocol, and
Number of subjects to be stu			
Serious/unexpected side effe	ects in subjec	ets participating in	project: None .
Conclusions: Deferred			
Publications or Abstracts, 1	FY-80: N	Tona	

Work Unit No: 1311-79

Funds Utilized, FY-80:

Funding Requirements, FY-81:

Personnel: \$500.00 (McAnally, Kuffler, Martin, Bruton)

Equipment: None '

\$2,500.00 Supplies:

\$500.00 Travel:

Reprints Contracts \$300.00 750.00 Other:

Date: 1 October 1980	Protocol	No: 1312-79	Status: Interim XXX
	et of Long-Ter	rm High Fiber Die	ets in Final pendent Diabetes Mellitus.
Starting Date: 26 Sept 1979	Estim	ated Completion I	Oute: Uncertain
Principal Investigator: Time	othy M. Boeh	m, LTC MC	
Associate Investigators:]	Facility: WRAI	MC
	I	Dept/Svc Diabe	tes Service
Key Words: Fiber, Insulin	Dependent Dia	ibetes Mellitus.	:
Accumulative MEDCASE Cost:	Accumul Cost:	ative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			eview Results:
of insulin dependent diabetes; high fiber diet therapy. Technical Approach: If high in the ameliocation of postprotreatment of insulin dependent	a fiber diets a andial hypergl	re succespful on :	a long-term outpatient basis
Progress during FY-80:	Protocol has		due to departure of a
Number of subjects to be studentially students of subjects to be students. Serious/unexpected side effects of the subjects of the subject of the			
Conclusions: None			None
Publications or Abstracts. F	'Y-80: Nor	دير	

Date:	Protocol	No: 1	313-79	Status: Interim
Title of Project: A radioi	mmunoassay f	or hun	an TSH	EMNX
Starting Date: November 197	9 Estin	nated C	lompletion Di	nte: One year
Principal Investigator:	Robert C. Sm	allrid	ige, LTC, MC	
Associate Investigators: Richard C. Dimond, LTC, MC		Facili	ty: WRAMC	
Nancy E. Whorton, GS-11		Dept/S	Svc Kyle M	etabolic Unit
Key Words: TSH/RIA				
Accumulative MEDCASE Cost:	Accumu Cost:		Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:				view Results:
			(to be fille:	d in by DCI)
Study Objective:				
Technical Approach: ven	ipuncture			
Progress during FY-80:	Sera have	been o	obtained fro	m 5 volunteers
NT 1 C 1 to to be about	- 1: - 1 1 - C			five
Number of subjects to be stu Serious/unexpected side effe				
serious/unexpected side ene	cis in subjec	ts par	rerparing in I	project: None
Conclusions: None expect	:ed			

Publications or Abstracts, FY-80:

- 57

Work Unit No: 1313-79

Funds Utilized, FY-80:

Funding Requirements, FY-81:

Personnel: \$500.00 (Linda McAnally GS-05, Jesse Martin GS-05, Joseph Bruton GS-14)

Equipment: None

<u>Supplies</u>: \$1,000.00

<u>Travel</u>: \$500.00

Other: Contractual Svc \$500.00

Protocol No: 1314-79 Status: Interim Date: Final Title of Project: Examination of the Effect of Ipodate (Oragrafin) on Thyroid Function Estimated Completion Date: 8-80 Starting Date: 8-82 Principal Investigator: Kenneth D. Burman, LTC, MC Facility: Associate Investigators: WRAMC Dept/Svc: Dept of Med/Endcorine Key Words: Ipodate/thyroid function Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: Cost: Cost: FY-80 MEDCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To measure the effect of Ipodate on thyroid hormone levels. Technical Approach: TRH tests with or without ipodate and/or T3 in fed and fasting patients. Progress during FY-80: Just started Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: Conclusions: None yet Publications or Abstracts, FY-80: none

L. J

Work unit no.: 1314-79

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Djuh

Equipment:


-asilgqui-

\$4,000

Travel:

Other:

: E.



Date: 15 October 19.	Protoco	l No: 1315-80	Status: Interim v	
Title of Project: Sex-Steroid	Donantor de	u tha Manaa Physica	Final	
26X- 2461010	Receptor in	n the nouse inymus		
			and the second s	
Starting Date: 23 Oct 79	Esti	medad Completion	ote: 30 Sept 82	
Principal Investigator: Ro	bert A. Vigo	ersky, M.D. MAJ MC		
Associate Investigators: Elizabeth Raveche, Ph.D. (National Institutes of Health)		Facility: WRAMC		
		Dept/Svc Kyle M	etabolic Unit	
Key Words: Thymus; rec	eptors, est	l r. gea; receptors;	androgen	
Accumulative MEDCASE Cost: \$2850	Accum Cost:	ulative Contract 0	Accumulative Supply Cost: \$10,131.25	
FI -80 MEDCASE Cost:	()		view Results:	
in the thymus and to chara The basis for the marked s Systemic Lupus Erythematos of the thymus based on sex through receptor mechanism Technical Approach: Meas capacity, sex steroid spec column elution profile on of the receptors for andro between these parameters i Investigation of the relat "classic" receptors in pro Progness during FY-80:	cterize theorements, may be of steroids. steroids. curement, in ificity, six agarose 0.5 gen and estroids againship of the state and under the androgen cterized.	m physico-chemical ce in a variety of due to the differe These differences thymic cytosol, o ze, charge, sedime M, and kinetics o rogen. Determinat ges and the differ these receptor chaterus of the mouse a receptor has bee	immunologic disease, e.g. nce immunologic response are most likely mediated f the affinity, binding ntation coefficient, f association and dissociation ion of the differences ences between the two seres. racteristics to the more	

conclusions: Androgen receptors are present in the mouse thymus. Preliminary studies indicate the presence of estrogen receptors as well. The immune androgen resistance manifested by NZB mice may be explained by the failure to translocate the cytosol receptors to the nucleus, resolvents or Abstracis, resolvents. Raveche, E., Vigersky, "., Tjio, J.H. and Steinberg, A "Murin. Thymic Androgen Receptors." presented Amer. Rheumat. Assoc., May 1980

nork Unit do.: 1315-80

Funds Utilized, FY-80: \$10,131 + \$2850 = \$12,981

Funding Requirements, FY-61: \$8800 -

<u>Personnel:</u> Mary K. Rice, GS-11

Equipment: None

Supplies: \$7500

Travel: \$500

Other: (2572) \$500; (2400) \$300

Date:	Protocol No:	1316-80	Status: Interim X
Title of Project:			Final
3 receptors in human wh	rite cells and	liver	·
Starting Date: 2-12-80	Estimated	Completion D	ate: 8-83
Principal Investigator:	Kenneth Bur	rman, LTC,	мс
Associate Investigators:	Facil		AMC
	Dept/	Svc De	ot of Med/Endocrine
Key Words: T3 receptors	:/Liver/white o	cells ·	
Accumulative MEDCASE Cost:	Accumulative Cost:	Contract	Accumulative Supply Costs
FY-80 MEDCASE Cost:		1	view Results:
nd whether they correla	te with recept	ors in whi	kist in human liver ite cells.
Tochnical Approach:		•	
· ——	ize human live	er T3 recep	otors
•	:		
		•	
Progress during FY-80:			
No defi echnical problem with t	nite studies p he small amoun	erformed y it of liver	ret because we are hav. Tissue obtained.
Number of subjects to be stud			
Serious/unexpected side effections in a serious content of the serious for the	ts in subjects par	ticipating in p	project:
Conclusions: none yet			
Publications or Abstracts, F	Y-80: none yet		

none yet

Work unit no.:

1316-80

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel: Djuh and Burman

Equipment:

Supplies: \$5,000

Travel:

Other:

Date: 15 Oct 80	Protocol No:	1317- 80	Status: Interim X
Hirsutis	ution of the Etions. Determination al Metabolism		Final Partial Engyme Defects
Starting Date: 27 Nov 1979	Estimated	Completion D	ate: 30 Sept 82
Principal Investigator: Rob	ert A. Vigersky,	M.D. MAJ MC	
Associate Investigators:	Facil	ity: WRAMC	
	Dept,	/Svc Kyle Me	etabolic Unit
Key Words: Hirsutism; adm	enal; androgens.		•
Accumulative MEDCASE Cost: 0	Accumulative Cost: \$580		Accumulative Supply Cost: 0
FY-80 MEDCASE Cost:	0		view Results:
of the pituitary-adrenal as Technical Approach: Infus measurement of adrenal ster	sion of ACTH over		
incasarcinent of darchar over	,		
Progress during FY-80: The to have a subtle defect in	-		lyzed have not been found
Number of subjects to be stu	died before compl	etion of study:	. 10
Serious/unexpected side effect			
Conclusions: Though the sausually classified as idiog congenial adrenal hyperplas	pathic hirsutism		r to be few of the patier y have a mild form of
Publications or Abstracts, F	Constall C	, Mehlman, I	., and Vigersky, R., "Tro

more Unit no.: 1317-79

funds Utilized, FY-80: \$5800

Funding Requirements, FY-61: \$7800

<u>Personnel:</u> None

Equipment: None

Supplies: \$2000

Travel: \$500

Other: (2572) \$5000; (2400) \$300

Date: 23 Oct. 80	Protocol	No: 1318-80	Status: Interim
Title of Project: Developmen	t of Fluore	scent Innuncassay	Procedures.
Starting Date: April 1981	Estir	nated Completion i	nate: April 1983
Principal Investigator: Jos	eph Bruton,	Ph. D.	
Associate Investigators:		Facility: VRAY	
H. Linton Wray, LTC, MC Kenneth D. Burman, LTC, MC Robert A. Vigersky, MAJ, M		Dept/Svc Kyle	Metabolic Unit
Key Words: Immunoassay	; Radioimmu	noassay <u>ys</u> Fluore	escence Immunoassay
Accumulative MEDCASE Cost: \$15,000.00		ulative Contract 1,000.00	Accumulative Supply Cost: \$5,000.00
FY-80 MEDCASE Cost:	None		ed in by DCI)
Study Objective: To devel			sing a fluorescent molecule
dis dispersion for realization			
•			
	luorescein- e required, tiate this	tagged antigen ar Such an instru- study. In additi	
Progress during FY-80:			
Number of subjects to be stu Serious/unexpected side effe	died before cts in subjec	completion of students participating in	v: Normal subjects (N=25) for project: each procedure None
Conclusions: We anticipat testosterone, dihydrotesto			thyronines, cortisol, stradiol and prednisone.

None:

Publications or Abstracts, FY-80:

Work unit no.: 1318-80

Funds utilized, FY-80: None

Funding requirements, FY-81:

Personnel:

Equipment:

Other:

Supplies: \$5,000

Travol: 500

•

H. Linton Wray, LTC MC Kenneth D. Burman, LTC Robert A. Vigersky, MAJ MC Susan Barnes GS-09 Phyllis Kessler, GS-06 Vincent Butler, GS-09 Bio-Rad Fluoromatic System. A microprocessor based photo-counting fluorometer, consisting of a measurement and a data processing module and an automatic sampling module. (Cost, \$15,000)

(contracts for service): \$1,000 for RIA assays.

Date:	Protocol	No: 1319-80	Status: Interim		
Title of Project:		Final			
oes Thyroid Hormone Ad Masses in the Thyroi		on Decerase th	ne Size of Cystic		
Starting Date: 3-80	Estin	nated Completion	Date: 8-83		
Principal Investigator: Ke	nneth D. B	urman, LTC, M			
Associate Investigators:		Facility: WRAMC			
		Dept/Svc D	ept of Med/Endocrine		
Key Words: thyroid gl	and cysts	· · · · · · · · · · · · · · · · · · ·			
Accumulative MEDCASE Cost:	1	1. live Contract	Accumulative Supply Cost:		
FY-SO MEDCASE Cost:			eview Results:		
Study Objective:	ermine if		ed in by DCI) ne suppression alter		
Study Objective: To det yst size.	ermine if				
Study Objective: To det yst size. Technical Approach: All pa re divided into either	tients wit	thyroid hormon	ne suppression alter		
Study Objective: To det yst size. Technical Approach: All pa re divided into either ith thyroid hormone.	tients wit	thyroid hormon	ne suppression alter		
Study Objective: To detyst size. Technical Approach: All pare divided into either ith thyroid hormone. Progress during FY-80:	tients wit a no trea	thyroid hormon	ne suppression alter		
Study Objective: To detyst size. Technical Approach: All pare divided into either ith thyroid hormone. Progress during FY-80:	tients wit a no trea ents enter	thyroid hormon h thyroid glan tment group or ed into protoc	ne suppression alter and cysts are studied a a group to be treate		

Work unit no.: 1319-80

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Burman

Equipment:

Supplies:

\$1,000

Travel:

Other:

170

Date: 23 Oct 80	Protocol	1 No: 132	0-80	Status: Interim
Title of Project: Cyclic AM	P response	to Gluca	gon	kwick
Starting Date: 1 Jan 81	Estir	mated Cor	npletion D	ate: 1 Jan 84
Principal Investigator: Ken	neth D. Bur	man, LIC	, MC	
Associate Investigators: H. Linton Wray, LTC, MC		Facility:	. WRAMO	3
		Dept/Svo	: Kyle N	Metabolic Unit
Key Words: cyclic	AMP/Glucago	on .		
Accumulative MEDCASE	Accum Cost:	ulative Co	ontract	Accumulative Suppl Cost:
FY-80 MEDCASE Cost:				view Results: d in by DCI)
Study Objective: To determ glucagon.	ine if fast	ing alte	rs the cyc	clic AMP response to
				•
•		·		
Technical Approach: Glu	cagon infus	sion and m	measuremen	nt of cyclic AMP by RIA
•			•.	
Progress during FY-80:				
Number of subjects to be stu Serious/unexpected side effe				
Conclusions:				
Publications or Abstracts, I	FY-80: no	me yet		_

Work unit no.: 1320-80

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Equipment: \$3,000

Supplies: 400

Travel:

:rediO

Date:	Protoco	l No: 1321-80	Status: Interim X
Title of Project:			Final
TSH receptors	in physio]	logic States	
Starting Date: 5-80	Estin	nated Completion I)ate: 8-80
Principal Investigator:	Kenneth D.	Burman, LTC,	MC ·
Associate Investigators:		Facility:	АМС
		Dept/Svc De	pt of Med/Endocrine
Key Words: TSH rece	ptors		
Accumulative MEDCASE Cont.	Accum Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	ļ	Periodic Re	view Results:
		(to be fille	ed in by DCI)
issues and to see if t	ney are ne	,	regulateu.
			•
Technical Approach:			
Develo:	p TSH rece	ptor assay in	various tissue
	. '		
	•	•	
•			
"Progress during FY-80: None ye	et .	•	
	. .		
Number of subjects to be stu	diad buforo	acrapiation of chili	25
Serious/unexpected side effe			<u>• </u>
Conclusions:		والمساور والمساور والمساورة والمساورة والمساورة والمساورة والمساورة والمساورة والمساورة والمساورة والمساورة	
None			
Publications or Abstracts, I	FY-80· No	ne yet	

Work unit no.:

1321-80

Funds utilized, FY-80:

Funding requirements, FY-S1:

Personnel:

Lukes, Burman

Equipment:

Supplies: \$5,000

Travel:

500

Other:

Date: 22 Oct 80	Protocol No: 1322-80	Status: Interim				
Title of Project: The rel	ationship between cale	citonin, nitroprusside and				
Starting Date: 1 Aug 80	Estimated Completion	n Date: 1 Aug 83				
Principal Investigator: Ke	enneth D. Burman, LTC,	MC				
Associate Investigators: Phyllis Kesler, GS-07	Facility: WRAI	Facility: WRAMC				
	Dept/Svc Ky	Dept/Svc Kyle Metabolic Unit				
Key Words: Calcitoning	n, mitroprusside, T ₃	•				
Accumulative MEDCASE Cost:	Accumulative Contract Cost:	Accumulative Supply Cost:				
FY-80 MEDCASE Cost:	Periodic Review Results: (to be filled in by DCI)					
Study Objective: To see	if calcitonin inhibits	s T_4 to T_3 conversion				
•						
Technical Approach: In	vitro liver homogenato	es .				
•						
Progress during FY-80:	None	· ·				
Number of subjects to be stu	died before completion of st	udv: None				
Serious/unexpected side effe	cts in subjects participating	in project: None				

Publications or Abstracts, FY-80:

4 7 1

Work unit no.:

1322--80

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel:

Burman, Lukes

Equipment:

Supplies:

\$2,000

Travel:

Other:

Date: 22 Oct 80	Protocol	No: 132	23-80	Status: Interim
	ceptors in	n human	tissue	Rinks
Starting Date: Aug 1980	Estir	nated Con	npletion Date	: Aug 1983
Principal Investigator: Ke	enneth D. 1	Burman,	LTC, MC	
Associate Investigators: Facility: WRAMC Yvonne Lukes, GS-11				
		Dept/Svc	Kyle Met	abolic Unit
Key Words: TSH	······································	al.		•
Accumulative MEDCASE Cost:	Accumi	ulative Co	ntract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			eriodic Revie to be filled in	and the second s
				yroid tissue
Technical Approach: Bi	nding of	1 TS)	1.	· .
Progress during FY-80:	3 glands	studied		•
Number of subjects to be sto				3
Serious/unexpected side effe	ects in subjec	cts partici	pating in pro	ject: 0
Conclusions: None yet	•	· · · · · · · · · · · · · · · · · · ·		

Publications or Abstracts, FY-80:

Work unit no.: 1323-80

Funds utilized, FY-80:

Funding requirements, FY-81:

Personnel: Lukes, Burman

Equipment:

Supplies: \$4,000

Travel:

Ollow:

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-MGI

Clinical Investigation Protocol #1410

TO: Chief, Clinical Investigation Fred H. Goldner

DATE: 22 Sept 80 CMT 1

Service

Assistant Chief,

Gastroenterology Svc

Due to problems in patient acquisition, work on protocol #1410 is not proceeding at a satisfactory pace. It is, therefore, recommended that protocol #1410 be terminated.

Fred H. Goldner, LTC, MC

Assistant Chief

Gastroenterology Service

Onte: 4 September 1980 Protocol No: 1415				Interim X		
	1 Clearing: isotope Sca	Quantitated by		Final		
Starting Date: 13 April 197	7 Estir	nated Completion I	Oate: 3 years			
Principal Investigator: COL.	Lawrence F.	Johnson, M.D.				
Associate Investigators: Roy K.H. Wong, M.D.		Facility: Walter Reed Ammy Medical Center				
Donald O. Castell, M.D. Andre Dubois, M.D. Douglas Van Nostrand, H.D.	Dept/Svc: Gastroenterology Service					
Key Words: Esophageal Cle				•		
Accumulative MEDCASE Cost: N/A	Accumulative Contract Cost: N/A			ative Supply . N/A		
FY-80 MEDCASE Cost: Periodic Review Results: (to be filled in by DCI)						
Study Objective: To quant a measured bolus of fluid			y of the esopl	nagus to clear		
Technical Approach: Diluesophageal clearing profile						
adrethueue.						
Progress during FY-80: F have been evaluated with a that incorporated a metalic monitors within a catheter Number of subjects to be stu-	new monitor pH sensor system that	ing probe designon at the distal tipe is tapered down	ed by one of the and two transfor patient co	he authors (LFJ) sitorized pressure		

Conclusions: Data obtained from this protocol represents an advancement in the understanding of gastroesophageal reflux disease and supports our earlier published observations. Publications or abstracts, FY-80; none.

Publications or Abstracts, FY-80:

NONE

Continued.

Progress during FY-80:

oropharynx. This system obviates using a profusing system. To date our observation shows that bethanechol improves esophageal acid clearance as well as makes a more competent esophageal gastric junction to prevent reflux.

Two changes have been made in the plan section of this protocol. A commercially available transistorized esophageal catheter with pH and pressure functions is now used. This probe is tapered so that there is greater patient comfort in the oropharynx during the conduct of the protocol. This probe obviated the use of the borded catheter assembly referred to in the original protocol. Secondly, the alpaline bolus referred to in the plan section of the protocol has been omitted because it compromised accurate measurement of the acid bolus. Data obtained from this protocol represents an advancement in the understanding of gastroesophageal reflux disease and therefore this protocol needs to be renewed and completed.

Date: 4 September 1989	Protocol No	: 1416	Status: Interim x
Title of Project: Esophageal Emptying in Achalasia: Quantitated by Radioisotope Method			ISnal
Starting Date: 28 March 19	77 Estimate	ed Completion I	late: 3 years
Principal Investigator: Co	l Lawrence F. Je	ohnson, M.D.	
Associate Investigators: Roy K.H. Wong, M.D.		cility: WRAMC	
Douglas Van Nostrand, M.D	Dep	ot/Svc: Gastr	oenterology Sv
Key Words: Colon Esophag	eal Emptying		
Accumulative MEDCASE Cost: N/A	1	ive Contract /A	Accumulative Supply Cost: N/A
FY-80 MEDCASE Cost:	N/A		view Results:
Study Objective: To quant pneanumatic dilation.	itate esophagea	l emptying in	achalasia before and after
Technical Approach: To m with achalasia. Techneti esophageal emptying profi	um was tagged to	o <mark>con</mark> eflakes a	a solid meak in patients and milk and from this an
matic controlled voluntee	rs from asympto	matic patients	tory and distinguished asympto- with achalasia. This data was s, R.; Johnson, L.F.; Kaminsky, (see second page)
Number of subjects to be stu			A THE PARTY OF THE
Serious/unexpected side effe	ects in subjects p NON		project:
Conclusions: Sec énclose	d reprint.		
Publications or Abstracts,	FY-80:		

Continued: Progress during FY-80:

R.J.; Esophageal Emptying in Achalasia: Quantitated by Radioisotope Technique. Digestive Diseases and Sciences; Vol 24, P. 945, Dec. 1979.

2) Year Book of Nuclear Medicine, March 1981

There have been no modification in the plan section of the original protocol.

The undersigned investigator at a later date may modify protocol #1416 and use the esophageal emptying technique to determine which numatic dilation technique offers the best result in terms of esophageal emptying for achalasia. This will be done in collaboration with other investigators at the Medical College of Virginia, as well as possibly the National Naval Medical Center. If this endeaver is undertakened, the protocol will be modified and resubmitted through the appropriate committees.

Date: 1 October 1980	Protoco	I No: 141	1.7	Status: (Interim
Title of Project: PLASMA LIG	ANDIN IN L	EVER DISEAS	SE	Final
Starting Date: 1977	Esti	nated Com	pletion Date	e: 1983
Principal Investigator: LT	C Robert W.	Sjogren,	Jr., M.D.	
Associate Investigators: COL Lawrence F. Johnson, M.D.		Facility:	WRAMC	•
		Dept/Svc	Medicine/	Gastroenterology
Key Words:	hallipininggan i na hArafu ja ja visukstatutuse.		nadalitana, a. kan dalam kana a da a da kana.	*
Accumulative MEDCASE Cost: Rone	Accumi Cost:	ulative Con None	tract	Accumulative Supply Cost: Rone
FY-80 MEDCASE Cost: No.	ne		riodic Revis o be filled i	grant the contraction of the state of the st
Study Objective: This study potentially more sensitive available serum tests				
Technical Approach: Patie Center have blood drawn for frozen for plasma liganding sensitive and quantitative of Medicine in New York. and ligandin levels will have	or clinical n content. e radioimmu Correlatio	assessmen Plasna li noassay te ns between	nt. An ali Igandin con Ichnique at I pathologi	iquot is removed and ntent is determined by a Albert Einstein College ic diagnosis, enzyne valu
Progress during FY-80: Res Einstein College of Medici numbers of patients in each	ine in New ch diagnost	York have ic categor	been indet	terminate owing to small the past one year, an
Sumber of subjects to be stud Serious/unexpected side effec None	ied before d ts in subjec	completion	of study: I	Est 500
Conclusions: Not Availa	ble	and the state of t	demonto i reconsidente de segui segui segui	

Publications or Abstracts, FY-80: None

Work Unit Number: 1417

Funds Utilized, FY-80: None

Funding Requirements, FY-81:

Personnel: None

Equipment: None

Supplies:

(1) Freezer Vials
Nume vial, polypropylene with screw cap, 2.0 ml capacity
Landsel Cat #9015-7001
Three cases of 500 at \$80/case. Cost \$240
Landsel Cyrogenics
5303 46th Ave.
Hyattsville, MD 20781

(2) Bags for Freezer Vials Lab Tec Multi-Purpose Bag System, Series S Fisher Cat #1-812-50A One case of four packs of 250 bags each. Cost \$101 Fisher Scientific Co 7722 Fenton St Silver Spring, MD

Travel: None

Other: None

Progress during FY-80: additional 66 serum samples have been obtained. It is anticipated that continuation of the protocol allowing greater numbers of patients in each diagnostic category will yield results

Continued: Progress during TY-80:

split from apparatus that now affords televising the manometry record as elll as simultaneous photoscopic study all on the same TV screen. In onon-protocol clinically indicated use of this equipment we found the motility record did not project well. For this reason we are in the process of integrating a scilliscope, screen onto our existing motility equipment. This modification should afford the desired quality. Because the quality of the TV image of manometric events was not what we desired. We have not entered any patients to date into this protocol. This last technical challenge should be completed shortly, and the protocol initiated.

ADDENDUM: Cricopharyngeal Bar: A Video Manometric Study

An scilloscope will be attached to one existing manametric againment to better illustrate the tracing so that the TV camera can better clarify the manometric record. Officiwise, there have been no charges in the existing protocol.

Date: 4 September 1980	Protocol	No:	1419	Status: Interim: X
Title of Project: Cricopharmygeal Bar: A Video Manometric Study		ric Final		
Starting Date: 23 August 19	77 Estin	nated (Completion I	ote: 3 years
Principal Investigator: COL	Lawrence F	. John	son, M.D.	
Associate Investigators: Walter J. Kikendall, N.D.		Facili	ty: WRANC	·
David J. Curtis, M.D.		Dept/	Svc: Gasti	roenterology Service
Key Words: Cricopharynge	al Bar	1		•
Accumulative MEDCASE Cost: N/A			Contract	Accumulative Supply Cost: N/A
FY-80 MEDCASE Cost:	eriginasiya gara (mari) eriya yan (mari) eriya			eview Results:ed in by DCI)
Study Objective: To study shown on barium swallow.	the functi	onal s	ignificance	e of a cricopharyngeal bar
Technical Approach: This study of swallowing disord esophagus.				ic video tape fluoroscopic copharyngeal and upper
of Radiology and its inter has functioned well. This	face with be equipment	Valter has be	Reed Army Meen complime	chine procured by the Departmen Medical Center's TV Department ented by WRAMC-TV, acquiring a (See second page)
Number of subjects to be stu	died before	comple	etion of study	V:
Serious/unexpected side offe	cts in subje	cts pac	ticipating in	project:
Conclusions:				den en e
Publications or Abstracts, 1	FY-80:			

Work Unit: 1420

Title: Adenyl Cyclose and Guanyl Cyclose Activity in the Cat Esophagus.

Investigators:

Principal Investigator:

LTC Roy K.H. Wong, M.D.

Co-Investigators:

COL Lawrence F. Johnson, M.D. CAPT Donald O. Castell, M.D., USN Cpt. Ben H. Boedeker, DVM., WRAIR

Objective: To correlate adenyl cyclase and guanyl cyclase activity with lower esophageal sphincter contraction and relaxation.

Technical Approach: Same as initial protocol.

Progress and Results:

- 1. Over the past year we have received 3 opposites and have been able to study the anatomical location of the lower ecophagoal sphineter (188).
- 2. We have found that the opposum esophagi is an excellent model for extracting the LES without inflicting physical trauma to the LES prior to its removal.
- 3. The above requirements are essential to obtaining acceptable biochemical results when studying enzymes such as adenyl cyclase.
- 4. Also, we have recently obtained professional and technical support from Thomas Hickey, PhD in biochemistry in performing these assays.
- 5. Recently, we have acquired a room in building T-2 which will serve as a laboratory for these studies.
- 6. Here with the above facts we feel that at the present time continued support is essential and justified.

Funds Utilized FY 80: Approximately \$3,000.

Funding Requested FY 81: \$3,500

Type of Report: Interim.

Date: 24 September 1980	Protoco	l No:	1422	Status: Interim
	's Disease v		the Liver paroscopy a	
Starting Date:	Esti	nated (Completion D	Oute:
Principal Investigator: LTC	DAVID A. Pi	EURA		
Associate Investigators: CPT MORAKINYO OYEWOLE		Facili	ty:	•
COL LAWRENCE F. JOHNSON COL RICHARD M. HIRATA MAJ MARTIN WELTZ		Dept/S	Svc	
Key Words:				
Accumulative MEDCASE Cost:	A.cown Cost:	plative	Contract	Accumulative Suparty Cost:
FY-80 MEDCASE Cost: .				eview Results:
Progress during FY-80: Number of subjects to be stu	e Plan Secti	comple		
Serious/unexpected side offe	cts in subjec	ts parl	icipating in	Project:
Conclusions:	unitaria esperializar de la constitución de la cons		a nicelian and the age of the age according to	
Publications or Abstracts, 1	FY-80:			

WORK UNIT NO.:

1422

TITLE: The Sequential Staging of the Liver in Hodgkin's Disease with Laparoscopy and Laparotomy

INVESTICATORS:

Principal Investigator:

LTC David A Peura, M.D.

Assistant Chief, Castroenterology Service

Co-luvestigators:

CPT Morakinyo A. Oyewole, M.D. Fellow, Gastroenterology Service

COL Lawrence F. Johnson, M.D. Chief, Gastroesterology Service

COL Richard M. Hirata, M.D. Chief, General Surgery Service

MAJ Markin D. Walter, M.D.

Fellow, Hematology-Oncology Service

OBJECTIVE: To evaluate the role of laparoscopy in clinical Stage III or IV. Hodgkin's disease patients.

TECHNICAL APPROACH:

See Plan Section of orginal protocol.

PROGRESS AND RESULTS: No patients have been assessed under this protocol since the last report. Most patients with Stage III and IV Hodgkin's disease are undergoing laparotomy following their laparoscopic exam. So, their data cannot be included for study purposes. It is felt that continuation of the protocol is to be encouraged since an occasional patient will undergo laparotomy following his laparoscopic procedure.

CONCLUSIONS: No further conclusions can be reached at this time. Further evaluation of the data available seems to indicate that lapanoscopy is of benefit in patients with Stage III and Stage LV Hodgkin's disease as a staging tool.

FUNDS UTILIZED FY 80:

None

FUNDS REQUESTED FY 81:

None

PUBLICATIONS:

None

TYPE OF REPORT:

Interio

Date: 10 OCT 1980	Protoco	ol No:	1423	Status: Interim
Title of Project: A Study Polymer (MBR Ulcers of the	4197) in t	the Cont	ophyl Cyanoa rol of Bleed enum	acrylate Final
Starting Date:	Esti	imated C	ompletion D	nte:
Principal Investigator:	LTC DAVI	ID A. PE	URA, M.D.	
Associate Tuvestigators: LTC EDWARD L. BURKHALT	FP M.D.	Facilit	у:	
COL LAWRENCE F. JOHNSO		Dept/S	VC	
Key Words:	the second section and the second section is the second section of the sec		·	
Accumulative MEDCASE Cost:	Accum Cost:_	nulative	Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:				view Results:d in by DCI)
further blee	ding from	gastric protoco	and duodena	tive in preventing
Number of subjects to be stu Serious/unexpected side effe				
Conclusions:	nan da majandi vidur Britishi, "a siste d	annuari annuari annuari annuari		

Publications or Abstracts, FY-80:

191

*Progress during FY-80:

A total of 52 patients were studied under the national multi-center protocol. This study failed to show efficacy of MBR-4197 in stopping bleeding from gastric and duodenal ulcers or preventing rebleeding. Use of investigational drug as well as maintenance of drug inventory and the return of unused investigational supplies was monitored by 3M Corporation, in compliance with FDA regulations. There appeared to be no evidence of adverse affects related to the use of MBR-4197. All unused supplies were returned to 3M Corporation. This is a final termination report of the above protocol.

WORK UNIT NO.: 1423

TITLE OF PROJECT: A Study of Trifluoroisopropyl Cyanoacrylate Polymer (MBR 4197) in the Control of Bleeding Peptic Ulcers of the Stomach and Duodenum.

INVESTIGATORS:

Principal Investigator: LTC David A. Peura, M.D.

Assistant Chief, Gastroenterology Service

Co-Investigators: LTC Edward L. Burkhalter, M.D. Staff, General Medicine Clinic

.

COL Lawrence F. Johnson, M.D. Chief, Castroenterology Service

OBJECTIVES: To determine if the polymer is effective in preventing further bleeding from gastric and duodenal ulcers.

TECHNICAL APPROACH: See original protocol.

PROGRESS: This was a multi-center protocol and a total of 52 patients were assessed in the various centers. Analysis of data seem to indicate that MBR-4197 was no more effective than conventional therapy in stopping bleeding or preventing rebleeding episodes from gastric and duodenal ulcers. Because of the seeming lack of efficacy the study was terminated.

CONCLUSIONS: It was concluded from the compiled data of 52 patients that MBR-4197 was no more effective than placebo in controlling bleeding from gastric and duodenal ulcers or preventing rebleeding.

FUNDS UTILIZED FY 80: None

FUNDS REQUESTED FY 81: None

PUBLICATIONS: A manuscript is currently in preparation for submission to a national journal. In addition, the data from the study was presented by the principal investigator at the William Beaumont Gastroenterology Symposium in El Paso, Texas, in March of 1980.

TYPE OF REPORT: Final

WORK UNIT: 1424

TITLE: A Double Blind Study of Long Term Maintenance

Cimetidine Therapy on Gastro-Esophageal Reflux

Disease

INVESTIGATORS:

Principle: Roy K.H. Wong, M.D.

Co-investigator: Lawrence F, Johnson, N.P.

STARTING DATE: 1 February 1978

ESTIMATED DATE OF COMPLETION: Study has been terminated by SKF

PROGRESS AND RESULTS: Our participation in the protocol was very successful. We entered a total of 15 patients into the study and were ranked #2 in the USA when comparing ourselves with 8 other medical centers. The results of the study are negative and there is debate as to whether the data will be published.

DATE: 15 DECEMBER 1980

PROTOCOL NO.: 1425

STATUS: Interim

TITLE OF PROJECT: "Pulmonary Aspiration from Gastroesophageal Reflux Defined

by Pulmonary Scintiscan and Overnight Intraesophageal pH

Monitoring"

STARFING DATE: 15 FEBRUARY 1978

ESTIMATED COMPLETION DATE: Indeterminate

PRINCIPAL INVESTIGATOR: MAJ Steven S Shay, M.D.

ASSOCIATE INVESTIGATORS: COL hawrence C. Johnson, M.D.

LTC Mark R. Stein, M.D. MAI sebert W. Stein, M.D.

FACILITY: Walter Reed Army Medical Center

DEPT/SVC: Gastroenterology Service, Nuclear Medicine Service, Allergy/

Immunology Service

KEY WORDS: Pelmonary Aspiration

Gastroesophageal Reflux

ACCUMULATIVE MEDCASE COST: None

ACCUMULATIVE CONTRACT COST: None

ACCUMULATIVE SUPPLY COST: None

FY-80 MEDICASE COST: None

STUDY OBJECTIVE: To document the occurrence of pulmonary aspiration from noc-

turnal gastresophageal reflux.

TECHNICAL APPROACH: Patients with symptoms of nocturnal aspiration from pactroesophageal reflux are admitted on day 1 and a manometry/pH probe is placed in the esophagus to determine LES pressure and the presence of acid pH in the stomach (pH < 4). Later in the day (1600) the patients are started on prolonged intraesophageal pH monitoring according to the technique of Johnson et all; and this is continued overnight while they sleep. Reflux is defined as % time pH was < 4 for the duration of the night (minutes). Abnormal nocturnal reflux was defined as a value that exceeded 1.2% since this degree of acid exposure exceeded mean and 2SD for a previsouly defined asymptomatic control population. Prior to bedtime the patients are given 5mci of radioactive technetium (TC 99) sufur colloid. On the morning of day 2, the patients were questioned by two investigators (LFJ, SSS) regarding reflux and palmonary aspiration symptoms during the previous night. They then had a lung and abdominal scintiscan for location of the technetium.

PROGRESS DURING FY-80: The study population consisted of 13 patients; seven with abnormal gastressophageal reflux on the overnight pil record, and six with a normal pH record. Lower esophageal sphincter (LES) pressure confirmed the difference in LES competence between the two groups because those with abnormal reflux on the pH record had significantly less LES pressure (3mm Hg) than those with a normal record (10mm Hg, p < .05). Despite both the pH record and LES pressure showing a significant difference in reflux between the two groups, two experienced clinicians (LFJ, SSS) after interviewing the patients diagnosed reflux and pulmonary aspiration in 70% (5/7) of the abnormal reflux group; and a comparable 85% (5/6) in those with a normal overnight pH record. All 13 patients had normal pulmonary scintiscan without any evidence of aspiration of gastric contents. Despite the known delay in gastric emptying during sleep, only two patients had technetium present in the stomach the following morning.

CONCLUSIONS: We conclude the incidence of pulmonary aspiration due to reflux remains uknown. The presence of pulmonary aspiration from gastresophageal reflux is not accurately reflected by history. While the technolium scintiscan can document pulmonary aspiration from reflux², it is an incensitive test that is probably limited by the short duration the isotope memains in the storach; and secondly, the infrequency with which publishes actually aspirance area go trocoplageal reflux.

PUBLICATIONS OR ABSTRACTS, FY-80:

- 1. Johnson LF, DeMeester TR: Twenty-four hour pH monitoring of the distal esophagus, a quantitative measure of gastroesophageal reflux. Am J Gastro 62: 325-332, 1974.
- 2. Chernow B, Johnson LF, Janowitz WR, and Costell DO. Pulmonary aspiration as a consequence of gastroesophageal reflux Λ diagnostic approach. Dig Dis & Sci 24:839-844, 1979.
- 3. This data was presented at the Annual Fitzsimons Respiratory Disease Conference held in October 1979. MAJ Steven S. Shay, M.D. (presenter).

TYPE OF REPORT: Interim

COMMENT: The undersigned senior investigator (LFJ) will modify this protocol (CIS# 1425); and resubmit a modified plan to further pursue our investigation of pulmonary aspiration from gastroesophageal reflux.

Date:12/1/80	Protocol N	0: 1	426	Statu	us: Uttering X
Title of Project:	Title of Project:				Final
The Effect of Indo	methecin on	Exp	erimental	.ly Induc	ed Ac2d
Stricture on the R. Starting Date: 23 May 78	abbit Esoha	8419-	ompletion I	ote Tune	1000
Starting Date: 23 May 78-	Estima	tou d	ompremon a	inc. June	1983
Principal Investigator: Re	oy K.H. Won	g, M	I.D.	water committee and the applications are a page	and the second s
Associate Investigators: Facility: WRAMC WRAIR			•		
L.F. Johnson, M.D.	D	ept/S	Sve Castr	oenterol	ogy
Key Words: Indomethacin	, esophagea	1 st	ricture,		doscopy, barium ass
Accumulative MEDCASE			Contract	1 -	unulative Supply
Cost: 9,000,00	Cost:			Cost	2,000.00
FY-S0 MEDCASE Cost:					lts:
			(to be fille	ed in by DC	(1)
*Study Objective: This study examines the					
in the esophagus of ral	•		•		
whether stricture form	- -		•	ocusing	on the question of
*Technical Approach:					
of stricture for the previous pro-	cmation in otocol exce ere esophag HCl infusi degree of	the pt t itis on g stri	rabbit. hat we ar is induct astric ga cture for	This mode e able to ed. We a vages. N	d a model of strict el is similar to o keep the animals are able to do this We have also be abl by means of endoscoo
Similar to that					
Number of subjects to be stu- Serious/unexpected side effe	died before co ects in subjects	s par	tion of stud ticipating in	y: project:	
Conclusions: FY 80 has allowed is more suited this study failed Publications or Abstracts, in	for this st ed because	udv.	Previou	ıs attemp	mal model which ots at completing rate.

.

mork Unit do.: 1426

Funds Utilized, FY-80:

Funding Requirements, FY-61:

Personnel: (name and grade)

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase)

<u>Travel:</u> (mission oriented, training and presentation)

Other: (equipment rentals, contracts for service, animal care and reprints)

Personnel: Corrine Maydonavitch-GS9

Equipment: Newlett-Packard & channel recorder, hindorfer infunio pump, Olympus pediatric endoscope and light source, X-ray machine Harvard infusion pump, histologic fixing material and cassettes.

Cost: Light source and endoscopes-9,000.00 (Borrowed)

Travel: 1,200.00

Other: Light source-borrowed from dental research. Endoscope-borrowed from pulmonary medicine.

WORK UNIT: 1427

TITLE: Nitroglycerine, Terbutaline, and Aminophylline in the Treatment of Achalasia

STAPPING DATE: 22 August 1975

ESTIMATED DATE OF COMPLETION: August 1981

OBJECTIVE: To determine whether NTG, Aminophylline or Terbutaline change lower esophageal sphincter pressures and if these agents increase esophageal emptying.

KEY WORDS: Achalasia, Nitroglycerine, Aminophylline, Terbutaline, Esophageal Emptying, Lower Esophageal Sphincter

TECHNICAL APPROACH: No changes from previous protocol

PROGRESS AND RESULTS: Attached is a copy of an abstract submitted in Gastroenterology May 1980. Since the writing of the abstract 4 more patients have entered the study without significant differences in the results. We would like to study another 6 patients to make a total of 15 patients.

PROTOCOL NO.:

#1428

STATUS:

Interim

TITLE OF PROJECT:

Maximal Rate of Urea Synthesis in Rats as a Determinant

of Functional Hepatic Mass

STARTING DATE:

25 September 1979

PRINCIPAL INVESTIGATOR:

COL Lawrence F. Johnson, M.D.

ASSOCIATE INVESTIGATOR:

MAJ Michael A. Dunn, M.D.

STUDY OBJECTIVE:

To establish an accurate, reproducible whole animal model of maximal usea synthesis. To study the relationship of the meximal rate of usea synthesis to graded reduction in

hepatic sass.

TECHNICAL APPROACH:

sec original protocol.

PROGRESS DURING FY-80:

Urea synthesis was quantitated in rats, and reproducibility of this assay was established. Urea synthesis was found to reflect functional hepatic mass in normal rats and in rats with graded hepatectomy. ccl.—induced cirrhosis and portacaval shunts. The potential importance of variation on the composition substrate load was illustrated by marked increases in urea synthesis produced by arginine loading.

CONCLUSIONS:

Data from this protocol suggests that urea synthesis may be animportant new quantitavie liver function test. Optimal measurement conditions and methods are the subjects of further study.

PUBLICATIONS FY-80:

1. Brewer TG, Dunn MA, Berry WR and Harmon JW: Urea synthesis reflects hepatic mass in rats. Castroenterology 79 (1980); Abstract, in press.

WORK UNIT NO.: 1429

TITLE: Colchicine Therapy of Alcoholic Liver Disease: A Muli-Center Randomized Controlled Study

INVESTIGATOR:

Principal Investigator:

LTC David A. Peura, M.D.

Assistant Chief, Gastroenterology Service (assuming role in the absence of MAJ Michael

A. Dunna)

Co-Investigators:

STARTING DATE:

ESTIMATED DATE OF COMPLETION:

5 years

OBJECTIVE: To see if colchicine car product progression to circlesis and alcoholic liver disease, or affect already chabitabled alcoholic circumsta.

TECHNICAL APPROACH:

Please refer to original protocol.

PROGRESS AND RESULTS: The protocol was just approved and the investigational drug was just supplied by Eli Lilly Corporation. There have been no patients assessed in the protocol to date.

CONCLUSIONS: Because the protocol has not yet been started, no conclusions can be drawn.

FUNDS UTILIZED FY 80: None

FUNDS REQUIRED FY 80: None

ADDENDUM: The protocol has not officially begun. Therefore, no drug has been dispensed. Drug has recently been received in the form of coded vials containing placebo and colchicine. The supplies were supplied by Eli Lilly Company. These drugs will be maintained and dispensed in the Outpatient Pharmacy, and when the protocol begins the patients will be observed for any possible adverse reactions related to the medication.

Date: 10 OCT 80	Protoco	l No: 1429	Status: (Interim
Title of Project: Col	chicine Therapy fulti-Center Rand	of Alcoholic Live domized Controlled	er Disease: YOUNG
Starting Date:	Esti	mated Completion I	Outo: 5 Years
Principal Investigator:	LTC DAVID'A.	PEURA, M.D.	
Associate Investigators		Facility:	•
		Dept/Svc	
Key Words:	والمحافظة ويبيها من الأولى والمحافظة	.d	•
Accumulative MEDCASI	,	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	er degen er vert i var er være en er er være en er være en er være en være en være en være en være en være en		eview Results:
a nd alco	pholic liver dis ic cirrhosis.	ne can prevent process, or affect a	ogression to cirrhosis Tready established
Progress during FY-8 drug was just suppassessed in the pr	plied by Eli Lil	ly & Company. Th	and the investigational ere have been no patients
Number of subjects to b	,,,,,,,,,		the same of the sa
Serious/unexpected side	effects in subject	ets participating in	project:
Conclusions: Because can be c		is not yet been st	arted, no conclusions
Publications or Abstrac	ois, FY-80;		

Dote: 9 August 1930 Pr	otocol No: 1430	Stotus: Ankezira Final
	of the potential is vari Local esophagitis	cuo.
Starting Date: June 1980	Estimated Completion Da	de: Pilot project completes
Principal Investigator: James Walt	er Kikendall, MAJ, MC	· -
Associate Investigators: Ben Boedeker, CPT, VC	Facility: WICALI:	
Lawrence F. Johnson, COL, MC	Hept/Svc MED/GI VET. MEI	- WRAMC) WRAIR
K: Words: Esophogitis	or managed	
AND THE PARTY OF T	emicathil - Co	Cook: RA
FY-80 MEDCASE Cost: None	ق داخانطاندها دانین میشو با در در به این از این از از این این از از از این این از ا	view Results:lin by DCI)
Study Objective: To determine whether the opose the potential of pills to indu	num is a suitable model, ace local esophagitis.	for investigation of
Technical Approach: As outline	ed in approved protocol	
Progress during FY-80: Using was demonstrated that ascorbing calcium lactate in the tested other more extensive protocol.	e acid produced much mo animals. We have now to enlarge upon this w	re esophageal injury than received approval for an- ork.
Number of subjects to be studied be Serious/unexpected side effects in	efore completion of study:	
Conclusions: The experimental pro-	ocedures are valid for	study of this problem.

Work Unit No.:

1516

Title of Project:

CALGB #7291, Role of Post Operative Radiotherapy, and

Combinations of Dactinomycin, Vincristine, Cyclophosphamide

and Adriamycin in Childhood Rhabdomyosarcoma.

Principal Investigator: C, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 20 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

DATE: 30 September 1980 | PPOTOCOL NO: CALCE 7411 | STATUS: Interin X | Final

Combination in Childhood Acute Lymphocytic Leukemia

STARTING DATE: 14 April 1974		ESTIMATED COMPLETIO	ON DATE: Closed 12 Nov J
PRINCIPAL INVESTIGATOR: Dr.	Johannes	s Blom	
ASSOCIATE INVESTIGATORS:	1	FACILITY: Walter	Reed Army Medical
Dr. Frederick Ruyman		Center	·
		SERVICE: Hematolo	gy-Oncology
· · ·	- 1	Departmen	nt of Medicine
KEY WORDS: Cranial Radiation,	Lymphocy	tic Leukemia	
ACCUMULATIVE MEDCASE	ACCUMU	LATIVE CONTRACT	ACCUMULATIVE SUPPLY
COST: None	COST:	None	COST: None
FY-80 MEDCASE COST: None	\	PERIODIC REVIEW RES	BUL'IS:

STUDY OBJECTIVE:

- 1. To assess the role of early cranial radiation.
- 2. Determine role of more vigorous induction for high risk patients.
- 3. Compare three reinforced maintenance regimens.

TECHNICAL APPROACH: Standard risk patient were randomized to Reg I - Vincristine, Prednisone, Nethotrexate intrathecally & Lasparaginase Reg II - same plus cranial radiation. High risk patients were randomized to Reg II. Reg III - this arm is identical to Reg II but includes Dauremycin.

PROGRESS DURING FY-80: Note protocol closed in 1976. Six patients remain on study. Follow-up is pending on two. Four remain in complete remission.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: None
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:
None

CONCLUSIONS: See 1978-79 Annual Report

Dr. Ruyman has stated, he will provide subsequent fellow-up for annual report.

PUBLICATIONS/ABSTRACTS, FY-80:

Work Unit No.:

1528

Title of Project:

CALGB #7391, Clinical Trial of Radiotherapy and Chemotherapy in Managing Non-Metastatic Ewing's

Sarcoma.

Principal Investigator: C. Hematology-Oncology Svc

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 20 Feb 81, there has not been a response. This progress report request was for the period 30 Peptember 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

WORK UNIT NO. 1532

DATE: 30 September 1980 | PROTOCOL No.: (ALGB 7451 | STATUS: Interim X TITLE OF PROJECT. Combination Radiotherapy and Chase till)

STARTING DATE: 6/20/74 CALCB ESTIMATED COMPLETION DATE:
PRINCIPAL INVESTIGATOR: Jeffrey L. Berenberg, MD, LTC, MC
ASSOCIATE INVESTIGATORS: FACILITY: Walter Reed Army Medical Center

SERVICE: Hematology-Oncology
Department of Medicine

KEY WORDS: Combination Chemotherapy Hodgkin's Disease

ACCUMULATIVE MEDCASE | ACCUMULATIVE CONTRACT | ACCUMULATIVE SUPPLY
COST: None | COST: None |

FY-80 MEDCASE COST: PERIODIC NEVIEW RESULTS:

STUDY OBJECTIVE: Primary: To determine if combination induction chemotherapy followed by single agent maintenance therapy coduces different frequencies of veryone, a result of replacement of the property of

TECHNICAL APPROACH: Chemotherapy: Vincristine 1.4 mg/M²/week IV x2
Procarbazine 1.00 mg/M² day 1-14, DC
BCNU 80 mg/M² iv day 1
Prednisone 4C mg/M² po day 1-14

Total nodal irradiation ten out of 15 achieved a C.R.

PROGRESS DURING SY-80: Three of these patients relapsed. Overall - 4 are lost to followup. WRAMC is no longer entering patients on this study. No new patients during 1980.

MUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: CALGE 80
SERTOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICLPATING IN PROJECT:
None at WRANC, See below

CONCLUSIONS:

Chemotherapy followed by radiotherapy had increase bone marrow toxicity and this arm was dropped as CALGB.

PUTLICATIONS/ABSTRACTS, FY-80: Stuzman, L., Nisce, L. and Friedman, M. Increased Toxicity of Total Modal Irradiation Following Combination Chemotherapy, ASCO, Vol. 20, March 1979, page 391, #C411.

WORK UNIT : 1534 DATE: 30 September 1980 [PROTOCOL NO: CALCE 752] TITLE OF PROJECT: Comparative Study of the Value of STATUS: Bulerim X conventionapy with MER as Adjuvant to Induction and Two Maintenance hemotherapy Programs in Acute Myelocytic Leukemia STARTING DATE: 7 May 1975 ESTINATED COMPLETION DATE: 10 June 1977 Dr. Johannes Blom PRINCIPAL RIVESTICATOR: ASSOCIATE INVESTIGATORS: FACILITY: Walter Reed Army Medical Center Dr. Jeffrey L. Berenber, LTC, MC SERVICE: Hematology-Oncology Department of Medicine KEY WORDS: MER, Immunotherapy, Myleocytic Leukemia ACCUMULATIVE MEDCASE ACCUMULATIVE CONTRACT ACCUMULATIVE SUPPLY COST: None COST: None COST: None FY-80 MEDCASE COST: PERIODIC REVIEW RESULTS: None STUDY OBJECTIVE: To determine whether MER immunotherapy increases remission 1. rate or duration. 2. To compare monthly maintenance with ARa-C and 6-thioquanine (CTG) with alternating cycles of ARA-C and CTG with virtuistine VCR1, dexamethasone and ARA-C. TECHNICAL APPROACH: 1. Standard induction with ARA-C 100mg/H2/day by continuous infusion for 10 days plus Daunomycin 45 mg/N2/day IV push on days 1,2,3. 3. Three maintenance arms, two including MER 1 of these with cycling VCR and dexamethacone. PROGRESS DURING FY-80: Five patients remain alive. Four are still being followed on the protocol. One was transplanted and is still in CR. These patients will be followed for long term toxicity and survival. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: None SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

See 1978-79 annual report.

None observed in past year.

PUBLICATIONS/ABSTRACTS, FY-80: Cuttuer, J. et al, A Controlled Trial of Chemoismunotherpy in Acute Myelocyte Scukemia. Proceedings of NCI Immunotherapy Conference, April 1980.

CONCLUSIONS:

WORK UNIT NO. 1535 DATE: 50 September 1980 [P. Youcol Ho: CALCB 7581 TITLE OF FROMECT: Long Term Surgical Adjuvant Systemic Cherotherapy with or without Adjuvant Immunotherapy or Hammary Carcinoma. ESTABLED FOR LABOR DATE: 1981 STARTING DATE: 1975 PRINCIPAL INVESTIGATOR: LTC Jeffrey L. Bereaberg, M.D. MC ASSOCIATE INVESTIGATORS: Tractication of the food Army Medical 10.15 SERVICE: From regy-Oncology hope treat of Redicine KEY WORDS: Mammary Carcinoma ACCUMULATIVE CONFINCT ACCUMULATIVE MEDCASE ACCUMULATIVE SUPPLY COST: FY-80 MEDCASE COST: PERIODIC REVIEW BENDLTS:

STUDY OBJECTIVE: It is the specific aim of this study to ascertain if therapy with 3 active events plus nonspecific immunoclimulation. Superior to the 3 active agents, alone, or given in combination with vincriating and prednisons. The criteria for accessment will be the disease free interval of breast cancer patients with 4 or more positive axillary nodes discovered at the browy. A corollary comparison to the historial in the tipa in a patient group similarly staged and operated when followed by observation accessor by 3 active agent therapy in Milan will be utilized for an additional comparison.

TECHNICAL APPROACH: This study will compare the length of the disease free period and survival in female patients having operable breast carcinoma with 4 or more metastatic axillary nodes treated with a 5 drug combination, with a 3 drug combination, or with the 3 drug combination plus nonspecific immunotherapy with MER; the therapeutic choice being determined by random allocation. Following radical mastectomy (with, but preferably without, postoperative radiotherapy) and stratification, patients will be randomly assigned to receive induction treatment, followed by random chemotherapy. Patients should be proved to be free from metastatic disease by films and scans wherever possible. Chemotherapy (CONTINUED ON REVERSE SIDE)

PROGRESS DURING FY-80:

A total of 41 patients have been entered or study at WRAMC, of them; 4 have developed progressive disease, 2 have expired, and 35 remain stable with no evidence of disease.

NUMBER OF SUBJECTS TO BE STUDIED REFORE CONSTRUCT OF SERDY: 800 SERIOUS/CHEMPECTED SIDE EFFECTS IN SUBJECTS PARTICIPALING IN PROJECT:

CONCLUSIONS: As of April 1980 accrual is approaching 800 patients. Although the regimens have not yet been decoded, one regimen has a statistically significant better disease—free interval. This study is closed as of April 1980.

TUELICATIONS/ASSIRACIS, FY-80:

will begin 2 to 4 weeks after mastectomy. If postoperative radiotherapy is used cherotherapy must be delayed until 4 to 8 weeks after completion of radiotherapy is despite discouragement. Cherotherapy will be continued until either evidence of treatment failure has occurred or until 2 years have clapsed, whichever is earlier. Postoperative complications which force delay of chemotherapy beyond 4 weeks from mastectomy in the absence of radiotherapy, or beyond 16 weeks from mastectomy if radiotherapy is given, will render the patient incligible for study.

WORK UNIT NO. 1537 DATE: 30 September 1980 PROTOCOL NO: CALGE 7551 STATUS: Interin X TITLE OF PROJECT: Combination Chemotherapy and Final Radiotherapy for Stage IV and III B Hodgkin's Disease STARTING DATE: 8/5/75 activated | ESTINGLED COLUMNTER PRINCIPAL INVESTIGATOR: Jeffrey L. Berenberg, M.D., LTC, MC FACILITY: Walter Roed Army Medical ASSOCIATE INVESTIGATORS: Center SERVICE: Hematology-Oncology Department of Medicine KEY WORDS: Combination Chemotherapy, Hodgkin's Stage LV ACCUMULATIVE CONTRACT ACCUMULATIVE MEDCASE ACCUMULATIVE SUPPLY None COST: None COST: None COST: FY-80 MEDCASE COST: PERIODIC REVIEW RESULTS: None STUDY OBJECTIVE: 1. Compare remission frequency and duration of twelve versus six monthly cycles of CVPP. 2. To determine if radiotherapy augments efficacy six monthly cycles of CVPP. 3. To determine if rediotherapy given between cy-3 and 4 is preferable to that after 6 cycles. TECHNICAL APPROACH: Chemotherapy CCNU 75 mg/M2 p.o. day 1, Vinblastine 4 mg/M2 IV day 1 and 8, Prorabalie 100 mg/M² p.o. day 1-14, Prednisone 41 mg/M² pedal-14, Radiotherapy 2500 rads in 4 weeks to gross disease. PROGRESS DURING FY-80: WRAMC entered seven patients, six achieved a CR 3 patients remain in complete remission. No follow-up data available on the one at this; time. One of the two CR's have relapsed. CALGB entered 256 patients. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: Closed at WRAMC SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None

None of the treatment regimens appears superior to date.

PUBLICATIONS/ABSTRACTS, FY-80: 1. Gotlieb, AJ et al, Nitrosoureas in the Therapy of Lymphomas (manuscript in preparation) 2. Raila, S et al, Toxicity and Preliminary Results of Combined Radiotherapy and Chemotherapy in Hodgkin's Disease. ASTR, Oct 1979

CONCLUSIONS:

			WORK UNIT NO. 1538
DATE: 30 September 1980 P	ROTOCOL	NO: CALGE 7552	STATUS: Interior X
TITLE OF PROJECT: Combination	Chemoth	erapy and	Final
Immunotherapy for Previously To			lodghie's Disease
		•	
STARTING DATE: 7/28/75	·	Choresenen commit	PIPT ANT TARBUT
PRINCIPAL INVESTIGATOR: LTC Jet	Trey L.		
ASSOCIATE INVESTIGATORS:		FACILITY: Walte	er Reed Army Medical
		Cente	er
		SERVICE: Hemato	ology-Oncology
			tment of Medicine
KEY MORDS: Hodgkin's Disease		. Ar i amini	The second secon
ACCUMULATIVE MEDCASE	ACCUMU	LATIVE CONTRACT	ACCUMULATIVE SUPPLY
COST: None	COST:	None	COST:
FY-80 MEDCASE COST:	1	PERIODIC REVIEW	RESULTS:
None			. •
STUDY OBJECTIVE: 1. Compariso	n of two	different four	drug regimens
2. To explor	e altem	nating regimens	
3. Examine o			

TECHNICAL APPROACH: Reference appended schema. Note addendum #5 discontinued mainsengne chloigmbucil addendum #6 discontinued MER (methanal extractable residue BCG)

PROGRESS DURING FY-80: WRAMC entered six patients. 3 patients remain in complete remission. No new patients are being added. CALGB entered 21 patients in 1980.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: 80 CALGB SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

At MRAMO, one patient developed acute myelogoous leukemia, one patient developed chronic CONCLUSIONS: remai failure 2° to Steptozotocin.

- 1. MER is of no value in remission duration or maintenance.
- 2. Patients with prior chemotherapy have a worse readssion duration,

PUBLICATIONS/ABSTRACTS, FY-80: Cancer Clinical Trials - pending publication Coleman, N. et al, Combination Chemotherapy in Advanced Recurrent Hodgkin's Disease ASCO, Vol 20, March 1979, page 428 #C 568

. 7

WORK UNIT NO. 1539

DATE: 30 September 1980 PR TITLE OF FROJECT: CALCE Protoco Chemotherapy and Immunotherapy: Stage III and IV Neuroblastoma.	L 7541. in Prev	Combination Losly Untreated	STATUS: Interim Final	X
STARTING DATE: PRINCIPAL INVESTIGATOR: LTC ASSOCIATE INVESTIGATORS:	Joiney	ESTIMATED COMPLETS T. Berenberg, MC FACILITY: Walter Center SERVICE: Hematolo	Reed Army Hedical	
KEY WORDS:		1 Departue	it or realette	
ACCUMULATIVE MEDCASE COST:	ACCULE COST:	LATIVE CONTRACT	ACCUMULATIVE SUP	171.5
FY-80 MEDCASE COST:		PERIODIC REVIEW RE	SULTS:	
STUDY OBJECTIVE: To evaluate the	rote (of triple drug (Vinc	risting Cyclonhor	January S
and Adriauycin, combination chem neuroblastoma. To evaluate the ted neuroblastoma, both prior to (MER) thought capable of stimula patient's immunological reactivit to prolongation of median surviv	immunol and du ding in ity (to	logical responsivene uring therapy. To s mound up had respons	es of patients wit aluate the role of themeso lock in to	h disseminae fan aj 18 was oi 14
TECHNICAL APPROACH: Vincristing Cyclophosphamide, Adriamycin, an		ophosphamide, Adrian	nycın, versus Vincı	istin,
		•	•	-
•				
PROGRESS DURING FY-80: Five patineligible because of prior treaday 700. Follow-up is pending of	itment.	Two patients have	WRAEC. One patie expired on day 89.	nt was and
				•
		•	•••	- .e. *
		egger en i a a a a a a a a a a a a a a a a a a		n i i i i i i i i i i i i i i i i i i i
NUMBER OF SUBJECTS TO BE STUDIE SERIOUS/UNEXPECTED SIDE EFFECTS	None	SUECTS PARTICIPATING	n. Project:	•
CONCLUSIONS: Both regimens were meeting of CALGB.	effect	tive but no conclusi	ons made as of Apr	-03 11
PUBLICATIONS/ABSTRACTS, FY-80:				
None				

NORE UHLT NO. 1541 DATE: 30 September 1980 | PROTOCOL NO: CALGE 7542 STATUS: Interim TIPLE OF PROPERT Final X Treatment of Kon-Hodgkie's Lymphoma in Children ESTIMATED COMPLETION DATE: STARTING DATE: PRINCIPAL INVESTIGATOR: Dr. Johannes Blom ASSOCIATE INVESTIGATORS: FACILITY: Walter Reed Army Medical Center Dr. Frederick Ryman SERVICE: Hematology-Oncology Department of Medicine KEY WORDS: ACCUMULATIVE CONTRACT ACCUMULATIVE SUPPLY ACCUMULATIVE MEDCASE COST: COST: PERTODIC REVIEW RESULTS: FY-80 MEDCASE COST: STUDY OBJECTIVE: 1. To develop a combined radiotherapy/chemotherapy regimen ·of intent : To test contribution of high con well-strexate in concollidation. TECHNICAL APPROACH: See detailed outline in 1978-79 report. PROGRESS DURING FY-80: Study close with discontinging of padiatric asymptof CALCE. One WRAMC patient alive in remission will be followed for survival ... and toxicity.

NONE

RUMBER OF SUBJECTS TO BE SEUDIED BEFORE COMPLETION OF STUDY: None

SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

None

CONCLUSIONS: Study unable to be completed because of closeout of Pediatric CALCB.

FUBLICATIONS/ABSTRACTS, FY-80:

None

Work Unit No.:

1542

Title of Project:

CALGB #7584, Adjuvant Chemotherapy in Ostcogenic

Sarcoma. Adriamycin Versus Sequential Adriamycin-

Cyclophosphamide.

Principal Investigator:

Chief, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 20 Feb 31, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compiletien of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

WORK DELT 1:0. 1543

PATE: 39 September 1980				Interinax
TITLE OF PROJECT: Combination				Final
HII and IV Lymphocytic Lympho	oma In Adulti	s with or wit	hout	
Padiotherapy				•
NEARTING DATE: 1/20/76	E	STIMATED COM	LETION DATE: CI	osed 10/6/79
PRINCIPAL INVESTIGATOR: JOHN	ey L. Ferenl	berg, M.D., I	FC HC	tion or contrate the state of the same
ASSOCIATE INVESTIGATORS:	, F	ACILITY: Wal	ter Reed Army 1	dedical
		Cen	iter	,
	S	ERVICE: Hema	tology-Oacology	/
		Depa	ertment of Medic	cine
HUY WORDS: Lymphocytic Lymph	юпа			
ACCUMULATIVE MEDCASE	ACCUMULA"	TIVE CONTRACT	ACCUMULAT	TIVE SUPPLY
COST: None	COST:	None	COST:	
TY-80 HEDCASE COST:	- Pi	ERIODIC REVI	ES PRESIDES.	
None	' '	MULTIPLO MITTE	W MEJULIU.	•
COUNT OF TROOPT NO.		and the second s		

STUDY OBJECTIVE: 1. To confirm improvement in remission induction of lymphocytic lymphoma by adding Streptenigrinto Vincristine and Prednisone.

2. To examine the role of madiotherapy to bulky disease sites in improving remission rate and duration.

TECHNICAL APPROACH: Chemotherapy to all patients. Streptenigrin 1 mg/H 2 /week po x 6 weeks Vincristine 1 mg/H 2 IV x 6 weeks. Prednisone 40 mg/H 2 po x 6 week. Maintenance RT 3000-4000 rads to bulky sites followed by (CVP) Cytoxan, Vincristine, and Prednisone or only CVR.

PROGRESS DURING FY-80: 15 patients entered at WRANC. Seven achieved a C.R. 3 patients have had progression of disease. 1 new patient failed to attain C.R., 4 patients are in complete remission still. CALCB entered 251 patients.

ENTOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: Radiation hepatitis.

The patient developed radiation hepatitis? Enhanced by Vincristine.

ONCLUSIONS: 1. RT produced increased toxicity to bone marrow and liver without improving the number or duration of remission.

FUBLICATIONS/ABSTRACTS, FY-80:

See report on CALCS 7652.

			WORK UNIT NO. 1544
DATE: 30 September 1980	PROTOCOL NO:	CALGB 7652	STATUS: Interim
TITLE OF PROJECT:			Final X
Combination Therapy of Stag	e III and IV Hi	stiocytic Lympi	iona
			•
	ا بالوراد في التعلق للسلماء العاطماء	and a second construction of the contract of t	
STARTING DATE:	ESTIMATED COMPLETION DATE: Josed		
PRINCIPAL INVESTIGATOR: Dr	. Jeffrey L. Bo	reaberg, LuC, 1	MC
ASSOCIATE INVESTIGATORS:	FAC	FACILITY: Walter Reed Army Medical	
	ı [SERVICE: Heratology-Oacology	
	SE		
		Department of Medicine	
KEY WORDS: Histiocytic Ly	mphoma		
ACCUMULATIVE MEDCASE	ACCUMULAT	VE CONTRACT	ACCUMULATIVE SUPPLY
COST: None	COST:		COST:
None	PEi	RIODIC REVIEW R	ESULTS:
STUDY OBJECTIV.: 1. To det	rando de Carron	Anna describer describer	41
not not a self-time to time an	craice it strep A Dundadasus	courain rucues	ises the response
potention of Mineristine an			
 Explore consolidation r 	adi ation i hemad	V	

TECHNICAL APPROACH: 1. Induction with Vincristine 1 mg/M², Streptonigrin 11 m/M² and Predmisone 40 mg/M² po day 1-47
2. Consolidation varies with Cytoxan, Vincristine and Predmisone vs Adrianycin.

2. Consolidation varies with Cytoxan, Vincristine and Prednisone vs Adriamycin, Vincristine and Prednisone vs radiation.

Evaluate consolidation with Adriamycin,

PROGRESS DURING FY-80: Three patients entered, two failed therapy, 1 patient remains in complete remission. CALGB entered no dev patients.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: None

SERIOUS/CHEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

None at WRAMC, Vineristine potential Hepatic Toxicity of Radiotherapy in CALCB

CONCLUSIONS: This therapeutic regimen is inferior to current treatment experience methods. The remaining patients will be followed for survival and long term toxicity. Any toxicity will be reported.

PUBLICATIONS/ABSTRACTS, FY-80: Clickman, A., Vincristine Enhanced Hepatic Radiation Toxicity ASCC May 1979, Vol 20, page 318, #C114.

				WORK UN	U NO.	1546
DATE: 30 September 1980 [19 TYTE OF PROJECT: Treatment of	ROTOCOL 1 Acute Ly	mphocytic	1 7611 : Leukenia	STATUS	: Inter Final	III X
in Patients Under Twenty		•				•
PRINCIPAL INVESTIGATOR: Johanne			D COMPLECT	ON DATE:	Closed L	6 July 197
ASSOCIATE INVESTIGATORS:	1	FACILITY	: Walter	Reed Arm	y Medica	<u> </u>
Frederick K.B. Ruyman, M.D., LT	CHC		Center			
		SERVICE:		nt of Me	•	
KEY WORDS: Acute Lymphocytic L		·				
ACCUMULATIVE MEDCASE COST: None	ACCUMUI COST:	LATIVE CO None	NTRACT	COST:	LATIVE S	UPPLY
FY-80 MEDCASE COST: None	1	PERIODIC	REVIEW RE	SULTS:		
STUDY OBJECTIVE: 1. To test wh cranial irradiation in decreasi 2. To test whether consolidati	ng the i	ncidence	of CNS lea	skemia.	••	
duration of remission.						
				•		••
					· · · · · · · · · · · · · · · · · · ·	
		•			•	
TECHNICAL APPROACH: Induction of Patients will receive high d	with Vin	cristine, otrexate	Prednisor 500 mg/M2	ne an ≀. %3 du	Asparag	inase 50% idation.
		:				
		•				
			.•			
				.•		
No. 1320	•		2011		٠٠.	
PROGRESS DURING FY-80: WRAMC en out of 6 who achieved complete risk patients remain in complete	remissio	n. CALG	3 entered (534 patile	nts 7:5%	of low
are in remission of three years						or paracett
•			· .	•	•	
			•			: •
					•	· · · · · · · · · · · · · · · · · · ·
•			•		•	•
MEER OF SUBJECTS TO BE STUDIE					None ECT:	
Severe Mucositis sec						
CONCLUSIONS:		_				•
See 1978-79 rep	ort, unc	hanged.	•			
equalications/Abstracts, FY-80:	Abstrac	t will be	presente	d at spri	ng ASCO	meetings.

		WORK UNIT NO. 1547
DATE: 30 September 1980	[morocol. no: CALCE 7	682 SIA US: Interior X
TITLE OF PROJECT: Combinatio	on Chemotherapy or Cha	ro- I I I I I I I I I I I I I I I I I I I
Immunotherapy for Metastatic	Recurrent or Inoperable	le Ca. inc a of the Breast, 3 Treatment
Regimens: Cyclophosphamida, /	driamycin 5-Fluor ar	acil vs. Calophosphamide, Adriamycan,
5-Flourouracil, Vincristine,	Predmisona vs. Cyclop	hosphamide, Methotrexate, (CONT ON : 3
STARTING DATE: 1976	LESTITUTE I	contract (page:
PRINCIPAL INVESTIGATOR: LTC	Jeffrey L. Berenberg	, MC
ASSOCIATE INVESTIGATORS:	FACILITY:	Wal - Reed Army Medical
		However to gr-One alogy
	SERVI: H:	Here's in m-One olomy
		Department of Medicine
KEY WORDS:		•
ACCUMULATIVE MEDCASE	ACCUMULATIVE CONT	RACT ACCUMULATIVE SUPPLY
COST:	COST:	COST:
FY-80 MEDCASE COST:		EVIEW REMINES:
STUDY OF LECTIVE.		

and the CHF combination individually with the five draw combination, CAPVP, which appears to be the look combination program in CARCB study / Contribution the education of MER to each of the three combinations increases the remission induction frequency or prolongs the remission duration, or both.

. TECHNICAL APPROACH: Prior to randomization for treatment, patients will be stratified according to dominance of metastatic area, viscoral asseous soft tissue which develop either less than one year from diagnosis or equal to or greater than one year from diagnosis.

PROGRESS DURING FY-80: Of 12 patients entered on study at WRAMC only one remains free of disease. Three patients have expired and the remaining eight patients have all developed progressive disease.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE CONFERENCE OF STUDY: Closed SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

CONCLUSIONS: This study has been closed following the accrual of 429 patients. The CMF regimen is inferior to the adriamycin containing regimens except in patients who receive MER. All response frequencies are low probably because of the large number of patients with visceral disease.

PUBLICATIONS/ABSTRACTS, FY-80:

CONTINUATION OF TITLE

5-Fluorouracil, all 3 Regimens with or without MER. A Phase III Study.

1548

Title of Project:

CALGB #7681, Investigation of the Effects of Adriamycin

with and without Added MER in Soft Tissue Sarcomas.

Principal Investigator:

C, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 20 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

WORK UNIT NO. 1551 STATUS: Interim X Final.

PATE: 30 September 1930 | PROTOCOL NO: CALCE /612 TITLE OF PROJECT:

Therapy of Acute Lymphocytic Leukemia in Adults

STARTING DATE: 8/1/76 ESTIMATED COMPLETIO PRINCIPAL INVESTIGATOR: LTC Jeffrey L. Berenberg, N.D. MC ESTIMATED COMPLETION DATE: 9/29/80 Closed

ASSOCIATE INVESTIGATORS:

FACILITY: Walter Reed Army Medical Center

SERVICE: Hematology-Oncology Department of Medicine

KEY WORDS: Acute Lymphocytic Lymphoma

ACCUMULATIVE CONTRACT ACCUMULATIVE MEDCASE

ACCUMULATIVE SUPPLY COST:

COST:

None COST:

TY-80 MEDCASE COST:

None

PERIODIC REVIEW RESULTS:

STUDY OBJECTIVE: 1. To determine whether adding Daumomycin to Vincristine and Prednisone followed by Asparaginase will improve frequency and duration of . response. 2. To determine if MER will increase remission duration.

TECHNICAL APPROACH: Regimen T Vincristine 2 mg IV/week x3 Predaisone 40 mg/M2 pc x21 day

> L. Asparaginase 500 iu/ig IV daily x10d beginning on page 2. .

II As above Daumomycin 45 mg/M2 1V daily x3 orally (day

PROGRESS DURING FY-80: WRAMC entered 15 patients, 12 attained a complete remission (80%), eight of these have subsequently relapsed, of this group four remain alive and in complete remission. One of the partial remission patients remains alive. CALCH entered -164 patients 78% of these receiving Daunomycia achieved complete remission, 48% of. those did not. MER may have had an adverse effect on duration of complete remission.

HUBBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None

CONCLUSIONS: Dannomycin increases the complete remission rate in adults with acute. Tymphocytic leukemia. MER immunotherapy does not improve and may impair remission duration.

HUBLICATIONS/ADSTRACTS, FY-80: Abstract presented at American Society of Hematology . Metings December, 1979.

				WORK UNI	T NO. 1552	
DATE: 30 September 1980 [PI TITLE OF PROJECT:	OTOCOL.	NO: CALGE	7632	STATUS:	Interim X Final	·•
Chemotherapy in Indolent Chroni	c Lymph	ocytic Loui	cemia (CL	L)		
STARTING DATE: 30 Nov 1976	1.50	ESTIMATED	COMPLET	DATE:	1982	
PRINCIPAL INVESTIGATOR: De. ASSOCIATE INVESTIGATORS:	Jerirey	Berenberg FACILITY:	Walter Center	Peed Army	Medical.	~.
		SERVICE:	Hematolo	gy-Oncolo ent of Med		
KEY WORDS:				1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	And the Arman	
ACCUMULATIVE MEDCASE COST: None	COST:	None	TRACT	COST:	ATIVE SUPPLY None	
FY-80 MEDCASE COST:		PERIODIC	REVIEW RE	SULTS:	*	
_	if che	motherapy v	with colo	rambucil i	n indolent (TL.
will prolong surviva					•	
			. •			
				•		
	•		· . · .	•		
TECHNICAL APPROACH: After an in to Regimen I: No treatment, or						
q 28 days.						
			•			
		•			•	
				•		
		•				•
PROGRESS DURING FY-80: WRAMC the ineligible. One patient progres last call-up.						
		•			· .	
		÷				
			•		•	
•						
NUMBER OF SUBJECTS TO BE STUDIES SERIOUS/UNEXPECTED SIDE EFFECTS						
None CONCLUSIONS:						
Too early					•	
PUBLICATIONS/ABSTRACTS, FY-80:					···	
None				•		

		HORK HELT RO, 1554	· · · · · · · · · · · · · · · · · · ·
PATER OF PROBERT:	oregor No. CALOB 7591	STATES: Interim	
Companison of Involved Fie Charotherapy and Extended	Id Radiotherapy with	Adjuvant Morr	•
Stage 1 and II Hodgkins Di Stabilic Databer 1976	rubio mallownoraby ir sease in Childner	r rue llearment OI	·
STATUS MAIN Detaber 1926 FRUICLAN INVESTIGATOR: Dr.	Johannes Blom	HON DATE Closed Sept	ember 1980
PRESCRIATE INVESTIGATORS: ASSOCIATE INVESTIGATORS:	FACILITY: Walter	r Road Army Madicul	-
br. Frederick Ruymann	SERVICE: Remate	,	-
KEY MOSOS: Modeling Discours	Departs	cent of Medicine	-
KEY MORDS: Hodgkins Disease ACCEMULATIVE MEDICASE COST: None	ACCUMULATIVE CONTRACT COST: None	ACCOMULATIVE SUPPLY COST:	-
FY-80 MUDCASE COST:	PERIODIC REVIEW	Ţ	-
STUDY OBJECTIVE:			-
To compare the effectivene IF RT plus MOPP versus ext stage I and II Hodgkins Di	ended field radiother	radiotherapy versus apy in children wit	h
to examine the relative ta infections in the three di	terfecence of growth ffecent treatment arm	sta keoldinda of s.	
TECHNICAL APPROACH:			
All patients were laparoto or IF RT, lower limit of rapatients receive standard l	adiation being 3500 R	domized to either Mads. Half of IF	Ţ.·
•			
	•		
PROGRESS BURING FY-80:			
URAM C did not enter any pa- sect <mark>ion of CALGB was disso</mark>	tients on this study. Lyed, this study has	Since the Pediatric been closed.	-
	•		
NUMBER OF SUBJECTS TO BE STUDIE SERIOUS/UNEXPECTED SIDE EFFECTS None	D BEFORE COMPLETION OF ST LI SUBJECTS PARTICIPATE	HDY: None	-
CONCLUSIOUS:	The second section of the second seco	The state of the s	-
this study is closed.			
PUBLICATIONS/ASSTRACTS, FY-80:			

 $\mathcal{H}(\{\{1\}\})$

724

		WORK	UNIT RO. 15	55
FITTE OF PROJECT: Evaluation of G-Diambydro in the Treatment the Long and Melanoma.	of Galachitol 1. 2:	5, 1	US: Interi Final	X X
STARTING DATE:	LESTIMATED	COMPLETION DAT	<u></u>	n an andress of the second second
PRINCIPAL INVESTIGATOR LTC Jeff	rey L. Bereaberg, L.	IC Walter Reed A	rmy Medical	-
ASSOCIATE INVESTIGATORS:	;)	Center	· · · · · · · · · · · · · · · · · · ·	
	SERVICE:	Hematology-Onco Department of	ology Medicine	
KEY WORDS:				
ACCUMULATIVE NEDCASE COST:	ACCUMBILATIVE CONT		MULATIVE SU	PPLY
FY-80 MEDCASE COST:	PERIODIC F	EVIEW RESULTS:	-	
STUDY OBJECTIVE: To determine to cell, large cell, squamous an	the antitumor effected adenocarcinoma of			
TECHNICAL APPROACH: Galactico	ol Dosage: 60 mg/m	² as a slow int	ravenous pi	ish.
q 7 days.				
			,	
			•	•
				v
PROGRESS DURING FY-80: closed expired. One patient respond	to patient entry led temporarily.	1 June 1979.~ a	ill patients	s have
			•	
		•		
		-	·	•
NUMBER OF SUBJECTS TO BE STUDE SERIOUS/UNEXPECTED SIDE EFFECT	IS IN SUBJECTS PART	ICCPATING IN PI	ROJECT:	tient_entry.
CONCLUSIONS: Study closed - C/	M.CB. for poor respo	nse rate. Juno	1979.	

None

PUBLICATIONS/ABSTRACTS, FY-80:

225

				<u> - Mong unit no. 1550</u>
DATE: 30 September 1980	Profocol.	NO: CALGE 772		STATUS: Interin
		of Adriamycin v		. Final
Pagnerycin at Two Bush Levels			aek v	s &-week Cycle For
Maintenance Chemotherapy in A	cute Myel	ocytic Leukemia		
STARLING DATE: 10 June 77		ESTIMATED COMP	LETIC	ON DATE: 19 ROV 1979
PRINCIPAL INVESTIGATOR: Dr.	Jeffrey L	Berenberg		
ASSOCIATE INVESTIGATORS:		FACILITY: Wal	ter l	Reed Army Medical
		Cen	ter	•
	• •	SERVICE: Hema	tolog	gy-Oncology
·		Depa	rtmer	nt of Medicine
MEY MORDS: Acute Lyelogenous	Leukemia			
ACCUMULATIVE MEDCASE COST: None	ACCUMU COST:	LATIVE CONTRACT None	•	ACCUMULATIVE SUPPLY COST: None
FY-80 MEDCASE COST: None		PERIODIC REVIE	W RES	SULTS:
COUNTY OF TROP 100		and the state of t		and the second of the same and the second

To test whether remission duration and survival of is the same or different with Dannomycin CONRL 45 mg/M2 vs 30 m2 To test whether Adriamycin CADRI 30 mg/M2 can be substituted for DNR.

TECHNICAL APPROACH: 1) DNR 45 mg/M2 IV days 1-3 plus ARA-C 100 mg/M2 IV day 1-10

- 2) DNR 30 mg/M² IV days 1-3 plus ARA-C 100 mg/M² IV day 1-10. 5) ADR 30 mg/M² IV day 1-3 plus ARa-C 100 mg/M² IV day 1-10.

PROGRESS DURING FY-80: NRAMC entered 26 patients. 10 obtained a complete remission, partial remission and 13 no response. Only three of the responders remain alive. CLLGB entered 709 patients overall remission rate \$5%. [Twenty Live percent of those the achieved remission are alive in three years. High dose Dannomycin DNR appears nore toxic in patients over 60.

MAER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: RIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: See 1978-79 report. Bleeding and infection.

CLUSIONS: Elderly patients may benefit from low doses of DNR during induction.

UMICATIOMS/ABSTRACTS, FY-80:

Reported at ASCO sections, May 1980.

			WORK UNIT NO. 1558	
DATE: 30 September 1980 Ph	Ofocot	NO: TCAUCB: 7761 - TTT	STATUS: Interim X	
TITLE OF PROJECT: A Study to De				
of Single vs Multiple Alkylatic	ag Agent	s with or without A	Trianycin in	
the Princip Greatment of Modelin	p le Myel	, € 13/1FO.		
		Demonstrations was used was a	1. 1. 1. 1. 1. 1. 1	
STARTING DATE: PRINCIPAL INVESTIGATOR: Jeffrey		Charles Tree Me	DY DATE:	
ASSOCIATE INVESTIGATORS:	y 11. DEL	FAGILLTY: Walter	ced Army Medical	
W220CTRIE TRANSLIGGIOGE:		Conter	course may manage	
	•	SERVICE: Hematolog	ey-Oncology	
			it of Medicine	
KEY WORDS:		an na managana an		
ACCUMULATIVE MEDCASE	ACCUMU	LATIVE CONTRACT	ACCOMULATIVE SUPPLY	
COST:	COST:		COST:	
FY-80 MERCASE COST:	L	PERIODIC PEVIEW RES	1197.00	
ri-oo rayaan coni.	!	16K1ODIO POVERA KIS) () () () () () () () () () (•
STUDY COMECTIVE: To test the by	voothesi	s that bree alkyla	ing agents given some	ootd a
produce: Higher frequency of a				
than the same alkylating agents				
a combination of three alkyland				
and profess the duration of di				
duration of disease control are				
after treatment with triple all				(,,,,
	y	,		
TECHNICAL APPROACH: Combination	alkyla	iting agents plus pro	ednisone: L-PAM. Cvclo	no ho s
phamide, and BCNU versus Dequer				7
Cyclophosphamide, and BCNU vers				กโรส
prednisone: L-PAM, Cyclosphosp				
L-PAM.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		The part part partition	
•				
PROGRESS DURING FY-80: Eight pa	ntients	are on this protocol	l. Seven patients have	. had
PROGRESS DURING FY-80: Eight partial remissions, the other partial remissions.				
PROGRESS DURING FY-80: Eight partial remissions, the other presponses have relapsed at days	patient	is not evaluable. '	fwo patients with initial	
partial remissions, the other presponses have relapsed at days	patient	is not evaluable. '	fwo patients with initial	al
partial remissions, the other p	patient	is not evaluable. '	fwo patients with initial	al
partial remissions, the other presponses have relapsed at days	patient	is not evaluable. '	fwo patients with initial	al
partial remissions, the other presponses have relapsed at days	patient	is not evaluable. '	fwo patients with initial	al
partial remissions, the other presponses have relapsed at days	patient	is not evaluable. '	fwo patients with initial	al
partial remissions, the other presponses have relapsed at days	patient	is not evaluable. '	fwo patients with initial	al
partial remissions, the other responses have relapsed at days patients remain on study.	eatient s 348 an	is not evaluable. '	Iwo patients with initid have since expired.	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIES	eatient s 348 an	is not evaluable. 'd 436 of therapy and	Two patients with initial have since expired.	al
partial remissions, the other responses have relapsed at days patients remain on study.	eatient s 348 an	is not evaluable. 'd 436 of therapy and	Two patients with initial have since expired.	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIN SERIOUS/UNEXPECTED SIDE EFFECTS	eatient s 348 an GD BEFON S IN SUB Non	is not evaluable. ' d 436 of therapy and RE COMPLETION OF STU DECTS PARTICLEATING RE	Two patients with initial have since expired. DY: 440 IN PROJECT:	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIN SERIOUS/UNEXPECTED SIDE EFFECTS	eatient s 348 an GD BEFON S IN SUB Non	is not evaluable. ' d 436 of therapy and dE COMPLETION OF STU DECTS PARTICIPATING	Two patients with initial have since expired. DY: 440 IN PROJECT:	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIN SERIOUS/UNEXPECTED SIDE EFFECTS	eatient s 348 an GD BEFON S IN SUB Non	is not evaluable. ' d 436 of therapy and RE COMPLETION OF STU DECTS PARTICLEATING RE	Two patients with initial have since expired. DY: 440 IN PROJECT:	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIN SERIOUS/UNEXPECTED SIDE EFFECTS CONCLUSIONS: Regimens seen of the study of th	eatient s 348 an GD BEFON S IN SUB Non	is not evaluable. ' d 436 of therapy and RE COMPLETION OF STU DECTS PARTICLEATING RE	Two patients with initial have since expired. DY: 440 IN PROJECT:	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIO SERIOUS/UNEXPECTED SIDE EFFECTS CONCLUSIONS: Regimens seen effects	eatient s 348 an GD BEFON S IN SUB Non	is not evaluable. ' d 436 of therapy and RE COMPLETION OF STU DECTS PARTICLEATING RE	Two patients with initial have since expired. DY: 440 IN PROJECT:	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIN SERIOUS/UNEXPECTED SIDE EFFECTS CONCLUSIONS: Regimens seen of the study of th	eatient s 348 an GD BEFON S IN SUB Non	is not evaluable. ' d 436 of therapy and RE COMPLETION OF STU DECTS PARTICLEATING RE	Two patients with initial have since expired. DY: 440 IN PROJECT:	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIO SERIOUS/UNEXPECTED SIDE EFFECTS CONCLUSIONS: Regimens seen effects	eatient s 348 an GD BEFON S IN SUB Non	is not evaluable. And 436 of therapy and 436 of therapy and the completion of STU DECTS PARTICLEATING to but still too early	Two patients with initial have since expired. DY: 440 IN PROJECT:	al
partial remissions, the other presponses have relapsed at days patients remain on study. NUMBER OF SUBJECTS TO BE STUDIO SERIOUS/UNEXPECTED SIDE EFFECTS CONCLUSIONS: Regimens seen effects	eatient s 348 an ED BEFOL S IN SUB Non Tective	is not evaluable. And 436 of therapy and 436 of therapy and the completion of STU DECTS PARTICLEATING to but still too early	Two patients with initial have since expired. DY: 440 IN PROJECT:	al

WORK BAIN NO. 1559 Mail: 30 September 1980 [PROTOCOL NO: CALCE 778] TITLE OF PROJECT: Small Coll Carcinoma of the Lung: Localized Diseas Addendum 5 SHARFING DATE: 9/1/77 CALGE ESTIMATED COMPLETION DATE: 1980 PRINCIPAL INVESTIGATOR: Dr. Jeffrey L. Berenberg ASSOCIATE INVESTIGATORS: FACILITY: Walter Reed Army Medical Center Hematology-Oncology SERVICE: Department of Medicine 1984 WORDS: Small Cell Carcinoma ACCUMULATIVE MEDCASE ACCUMULATIVE CONTRACT ACCUMULATIVE SUPPLY None COST: COST: None . COST: None FY-80 MEDCASE COST: PERIODIC REVIEW RESULTS:

STUDY OBJECTIVE: 1. To determine whether CCV/AV plus radiotherapy (RT) gives a greater remission rate and duration than MACC plus RT.

None

2. To determine if NER immunostimulation increases response and duration of response.

VS CCNU 30 mg/M² plus Cyclophosphamide 400 mg/M² IV. Regimen 2: Cyclophosphamide 700 mg/M² IV plus CCNU 70 mg/M² po plus Vincristine 1.0 mg/M² with Adriamycin 50 mg/M² IV day 21 with Vincristine 1.0 mg/M² IV. Both regimens include 4500 rads to primary lung towor plus 3000 rad whole brain.

PROGRESS DURING FY-80: WRANG had entered 21 patients to date. Eight remain alive. Seven remain in remission. One has relapsed. CALG3 has entered 255 patients. About 50% have achieved a complete remission. 22% regain disease free at 24 months. The two treasurent arms appears comparable. MER is of no value.

SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

One patient died with wasting syndrome. No autopsy. One patient developed severe

CONCLUSIONS:

1. Complete remissions can be attained about 50% in small cell lung carcinoma at 50% in small cell lung carcinoma a

TERLICATIONS/ABSTRACTS, FY-80: Eaton, W. et al, Preliminary Results of Combined Radio-Thropy and Chemotherapy in the Treatment of Small Cell Cardinoma of the Lung (And litted to the American Radium Society for presentation)

			WORK UNIT K	0. 1560
PAGE: 30 September 1980 P.	korocoj. 1	O: CALGE 7782	STATUS: Li	nterim X
TITLE OF PROJECT:	- '		F	inal .
Small Jell Carolines, of Long	la Extens	due Oiseas .		
		TO COMPANY (CATALOG AND	108	Λ···-·································
STARTING DATE:	TEFFETTE	ESTIMATED COME Berenberg	LETION DATE: 198	
PRINCIPAL INVESTIGATOR: Dr. Jo ASSOCIATE INVESTIGATORS:			ter Reed Army Hee	dical
ASSOCIATE INVESTIGATIONS.			iter	
•	ļ.		tology-Oncology	
	1		ertment of Medicia	าย
KEY WORDS: Small Cell Carcino.	ia .			
ACCUMULATIVE MEDCASE	ACCUMU	LATIVE CONTRACT	ACCUMULATI	
COST: None	COST:	None	COST:	None .
FY-80 MEDCASE COST:	-l (PERTOILE A VIE	W RECOLTS:	The second secon
None				•
SIODY OBSECTIVE: 1. To a crain	ie whetha	er alternating	chemotherapy incr	eases response
rate or decasion. 2. To delete				
- mespoone mate over 3000 alies ell	ierapy sil	lang.		•
				•
			•	
		•		
		•		
TECHNICAL APPROACH: Regimen Lands of the CONU 30 mg/M ² po, Cytoxan (C + primary tumor and draining node 70 mg/M ² po + Cytoxan 700 mg/M ² + VCR 2 mg/M ² with Adria 75 mg/M ²	X) 400 r es. Regi	ng/M ² TV (terme imen 2. MACC. ristine 2 mg IV	d MACC) + RT 3000 Regimen 3, Altern	rads to ating CCNU
		•	· •	
PROGRESS DERING FY-80: WRANG a only one patient renains live				
with pulmonary texicity.		•		•
			•	•
				· •
			•	•
			•	
			company FO	TT TOTAL IN SINGLE SECURITY OF SINGLE SEC
NUMBER OF SUBJECTS TO BE STUDY SERIOUS/UNEXPECTED SIDE EFFECT				
One patient died of pulse			TEETH EN THOUGH	
CONCLUSIONS: 1. About 15% of pa			lete remission ((R) 2. Only 5%
overall are alive at 24 months.				
4. Those who do attain a CR have				
achieved CR ie 25% at 24 m.			•	
PUBLICATIONS/ABOTE OTS, FY-80:				
No publications to date.				

				FORK UK	12 NO. 1562	
DATE: 30 September 1980 Pi	COLOCOL	NO: CALGE	7802	STATUS:	Interim	
TITLE OF FROJECT: Treatment of	Advance	d Hon Small	CeJJ		Final X	-
Pronchogenic Carcinoma with Cyt	oxan, C	ONU, Hestina	ethylmeda	dine, and	Methotrezate	•
·						
STARTING PAGE:		ESTIMATED	COMPLETA	ON DATE:	June 79	••
PRINCIPAL INVESTIGATOR: Dr. Je	ffrey L	. Berenberg	;			*
ASSOCIATE INVESTIGATORS:		FACILITY:		Reed Army	Nedical	•
		SERVICE:	Center	gy-Oncolo	~	, •
•	.:	SERVICE:		nt of Medi		·. ·
KFY WORDS: Bronchogenic Carcin	oma	I			~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 	·
ACCUMULATIVE MEDCASE		LATIVE CON	TRACT		ATIVE SUPPLY	
COST: None	COST:	None	•	COST:	None	
FY-80 MEDCASE COST:	J	PERIODIC	REVIEW RE	surs:		-
None	and the second s					
STUDY ORJECTIVE:		F	•			
		se frequence ses of non-				- ,
плаколод с	c surcy)	bes or non-	romann, Cen	or ating ca.	CINOMA,	
	•			•		•
				-		-
			•			
						•
TECHNICAL APPROACE: Treatment of	vith Cyl	rosana CCPn	Mathota	cexe te and	Description.	
melamine.		,				
			•	•	يع.	
	•		•	· · · · ·	·	
				 .	•	•
•						
					•	
PROGRESS DURING FY-80: No path	ients <mark>e</mark> r	itered. No	patients	ະ ໓໙ສຄໂນ (ສ)	live at WRAMC	
		•		•		
			·			
	•	•		•	• .	
·						
				•	•	
				:		
NUMBER OF SUBJECTS TO BE STUDIE	D BEFOR	E COMPLETI	ON OF STU	IDY:		-
SERIOUS/UNEXPECTED SIDE DEFECTS					CT:	-
			غرد میاندند د درست			· ·
CONCLUSIONS: Low response rate,						,
The performance status appears a	o predi	ct sur vi va	J. This	жау Белип	related to ch	iemotheraj
PUBLICATIONS/ABSTRACTS, FY-80:	Manusc	ript being	prepared	. WRAMC T	vill include	
as a pi	imary a		- •			
			•			

Service and the service of the servi

 \mathbb{R}_{p}

			WORK UNIT ho. 1563	
DATE: 30 September 1930 Pi	lorocoi.	NO: CALGA 2751	Stants: Theoria X	
TITLE OF FROMECT:			* Final	
The Comparative Effectiveneral with Radiation Therapy	hu In	Wilver Brains or	State of a second secon	
Poor Rink Patients with Sta	age I c	in 13 - Lighting :	ox speca (leta, l). Gricar	
Poor Rink Patients with Str STARTING DAVE: 1977 PRINCIPAL INVESTIGATORS: Dr		ESTERVIOLE COMPLET	(0). L983	
PRINCE PAL INVESTIGATOR: Dr	<u>Jeffrey</u>	L. Berenberg,	Mrs., Mc	
ASSOCIATE INVESTIGATORS:	1	Contain	ne a menty amin car	
	1	SERVICE: Hematol	ogy-Oncology	
		Departm	nt of Medicine	
KEY WORDS: Hodgkins Disease		T LONG COM CONTRACTOR AND		
ACCUMULATIVE MEDCASE COST: None	1	LATIVE CONTRACT None	ACCUMULATIVE SUPPLY	
	1 0001.		COST:	
FY-80 MEDCASE COST: None		PERIODIC REVIEW R	ISULTS:	
STUDY OBJECTIVE:		and the second of the second o		
To determine if combination	ı chemo	therapy alone i	s as effective and	
less toxic than chemotherag	y plus	Involved Field	Reciation,	
TECHNICAL APPROACH:	1300 0 2			
Regimen I: Involved Field Procarbazine, a	nd Dec TOT	Lowed by Six cy	cles of CCNU, Vinblas	tine,
		and some.		
Regimen II: Chemotherapy al	.one.			
Addendum II (2/12/79) delet	ed the	arm with exten	של הופיר הפו	•
		501 III 1712 511 537 5511	acc ricino Mi.	
•			•	
PROGRESS DURING FY-80:			•	•
WRAMC has not entered any p	atient:	s on this study		
		· ·	•	
CALCB has entered 42 patien	ts. It	is too early to	examine results.	
			•	
			•	
NUMBER OF SUBJECTS TO BE STUDIE	n prropi	COMPLETE OF CT	102	
SERIOUS/UNEXPECTED SIDE EFFECTS	IN SUB	TECTS PARTICIPATING	E IN PRESSOR	
		- LOCK TAREFORE TA		
CONCLUSIONS:	and the second of	The state of the s		
Too early for analysis.				
· ·-				
PUBLACATIONS/ABSTRACTO, FY-80:				
None				

COTING DAIL: July 1978	1	ESTIMATED COM	T.ETION	DATE:		
THE INVESTIGATOR: GETTE		nberg, LTC, EC	ter Re	ed Army F	fedical	
		Cer	iter			
and the same of the second contract of the same of				-Oncology of Medic		٠٠ .
e Mords: Cunulative Medicasi; ST:	ACCUMUL COST:	ATIME CONTRACT		ACCUMULAT	IVE SUP	PLY
-30 MEDCASE COST:		PERIODIC REVII	W RESU	u.ts:		
eration of response while parality of response and its some in the design of a place atter up to 200 patients with strointestinal, pancreatic,	atient is r relationshi s III prote i advanced	ip to Whited: acol, should t neoplastic di	contin patiba Into pe sease	rors chio di colley da. III ab io the ca	rozotoci al. Tro udjeho j	in there ovide ex oresissio
eration of response while parelity of response and lie of the design of a plane ter up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will he tubing of a running intra	atient is a rebuiloush o III prote i advanced Lung tum Idministrat administrat administrat	maintained on in to within the ocol, should be neoplastic di ors, melanomation of Chloro red in a Johns fusion. The i	conting parties and ly cotocic over allure	cous chio at correct in the ca apploisa. a. Chlor a period to achie	rozotoci al. Tro udgube j tegorites ozotoci of 30. se ye a res	m there ovide expressions of 120.mg
wation of response while parallety of response and lie of the design of a plant term up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will he	atient is a rebuiloush o III prote i advanced Lung tum Idministrat administrat administrat	maintained on in to within the ocol, should be neoplastic di ors, melanomation of Chloro red in a Johns fusion. The i	conting parties and ly cotocic over allure	cous chio at correct in the ca apploisa. a. Chlor a period to achie	rozotoci al. Tro udgube j tegorites ozotoci of 30. se ye a res	m there ovide expressions of 120.mg
wation of response while parallety of response and lie of the design of a plane eter up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will he a tubing of a running intrallowing the administration.	atient is a rebuiloush o III prote i advanced Lung tum Idministrat administrat administrat	maintained on in to within the ocol, should be neoplastic di ors, melanomation of Chloro red in a Johns fusion. The i	conting parties and ly cotocic over allure	cous chio at correct in the ca apploisa. a. Chlor a period to achie	rozotoci al. Tro udgube j tegorites ozotoci of 30. se ye a res	m there ovide expressions of 120.mg
wation of response while parallety of response and lie of the design of a plane eter up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will he a tubing of a running intrallowing the administration.	atient is a rebuiloush o III prote i advanced Lung tum Idministrat administrat administrat	maintained on in to within the ocol, should be neoplastic di ors, melanomation of Chloro red in a Johns fusion. The i	conting parties and ly cotocic over allure	cous chio at correct in the ca apploisa. a. Chlor a period to achie	rozotoci al. Tro udgube j tegorites ozotoci of 30. se ye a res	m there ovide expressions of 120.mg
eration of response while partity of response and lie of the design of a place ster up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will be a tubing of a running intrallowing the administration ady.	atitent is a coloridations in advanced, lung tume ldministrate administrate administrate of times of t	maintained on in to white to cool, should be neoplastic di ors, melanoma tion of Chloro red in a holus fusion. The iddoses of the desire the de	conting particular par	cous chio at any of in the ca epholes. a. Chlor a poriod to achie ill he ca	rozotoci al. Tro udgilio j tegoriles ozotocir of 30. ac ve a res use for	in there ovide or ores in a contract of the co
cration of response while parallety of response and lie of the design of a plane ter up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will he tubing of a running intrallowing the administration ady. DORESS DURING FY-80: Fifteen	atitent is a coloridations in advanced, lung tume ldministrate administrate administrate of times of t	maintained on in to white to cool, should be neoplastic di ors, melanoma tion of Chloro red in a holus fusion. The iddoses of the desire the de	conting particular par	cous chio at any of in the ca epholes. a. Chlor a poriod to achie ill he ca	rozotoci al. Tro udgilio j tegoriles ozotocir of 30. ac ve a res use for	in there ovide or ores in a contract of the co
cration of response while parallety of response and lie of the design of a plane ter up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will he tubing of a running intrallowing the administration ady. DORESS DURING FY-80: Fifteen	atitent is a coloridations in advanced, lung tume ldministrate administrate administrate of times of t	maintained on in to white to cool, should be neoplastic di ors, melanoma tion of Chloro red in a holus fusion. The iddoses of the desire the de	conting particular par	cous chio at any of in the ca epholes. a. Chlor a poriod to achie ill he ca	rozotoci al. Tro udgilio j tegoriles ozotocir of 30. ac ve a res use for	in there ovide or ores in a contract of the co
cration of response while parallety of response and lie of the design of a plane ter up to 200 patients with strointestinal, pancreatic, ENICAL APPROACH: Dose and A 6 weeks. The drug will he tubing of a running intrallowing the administration ady. DORESS DURING FY-80: Fifteen	atitent is a coloridations in advanced, lung tume ldministrate administrate administrate of times of t	maintained on in to white to cool, should be neoplastic di ors, melanoma tion of Chloro red in a holus fusion. The iddoses of the desire the de	conting particular par	cous chio at any of in the ca epholes. a. Chlor a poriod to achie ill he ca	rozotoci al. Tro udgilio j tegoriles ozotocir of 30. ac ve a res use for	in there ovide or ores in a contract of the co

None

5

FUELICATIONS/ABSTRACTS, FY-80:

WORK	UNIT	MO^{\bullet}	1565

		11(1)(1) (1)(1)(1)(1)(1)(1)(1)
DATE: 3: September 1980 TITLE OF PROJECT:	Photocol not CA12B 780h	Figure 1 Storing Figure
Cyclophosphamide, Adrian,	. In. Vincrist as, Predr	uisone in Combination
with I was Dose 5-Doy I.V	nft on Plee voin in	Die Trantmert of Paar
Histology Lymphomus and I start: 1978	Rodulac Pearly Different	Lie Sed Amphocytic Compnosition (MRL: Closed 4 & pt. 79
PRINCIPAL INVESTIGATOR: Or	. Johannes Blen	
ASSOCIATE INVESTIGATORS:	FM HA W: Walter	Reed Army Hedical
	Center	
	SERVICE: Repartel	ogy-Oncology
	liopar tu	ent of Medicine
KEY WORDS: Bleomycin, Ly	yphomas	The state of the s
ACCUMULATIVE MEDGASE	LACCURULATIVE OUTERS	LACCUMULATIVE SUPPLY
COST: None	COST: None	COST:
KEY WORDS: Bleomycin, Ly ACCUMULATIVE MEDCASE COST: None FY-80 HEDCASE COST: None STUDY OBJECTIVE:	PERTODIC REVIEW B	ESPLIS:
STUDY OBJECTIVE:	man and the second of the seco	
To determine if aggressive	vo combination shemother	apy will implove
the meanagers mate and due	and the section of many the section with the	Transaction.

the response rate and duration in patients with lyphomas.

TECHNICAL APPROACH:

Cyclophosphamide 750_2 mg/m² I.V. bolus, Airiamycin 50 mg/m² I.V. bolus Vincristine 1.4 mg/m² I.V. bolus. All are given on day 1. Bleomycin 2 u/day continuous infusion 1.V. days 1-5. Prednisone 100 mg/day orally days 1-5.

PROGRESS DURING FY-80:

There were no new patients entered. One patient with nodular mixed lyphoma relapsed.

CALGB has entered 74 patients. 67% of the diffuse histiocytic patients achieved a complete response. only 20% of these have relapsed.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETEDE OF STUDY: None SERIOUS/UNEXPECTED SIDE EFFECTS HI SUBJECTS PARTICIPATING IN PROJECT: None CCHCLUS TORS ?

This regimen has substantial activity in aggressive lyphomas. It was incorporated into a group wide Phase III study.

PUBLICATIONS/ABSTRACTS, FY .O:

Ginsborg, S.J., Gottlieb, A.J., Bloomfield, C.D., Blom, J., Crooke, S.T.: Combination Chemotherapy with Continuous Infusion, Low Dose Blessycin in Lymphoma. ASCO, vol. 10, Match 1979, page 322.

DATE: 30 September 1980	PROTOCOL NO: CA	M CR 7911	STATES:	Interim
erell of Project:	1, workers were Ob	MOD 7 - C L		Final X
Remission Induction of Re	ecurrent Childhood	t ara.	I.—	
·				
STATESTAND NAMES TO TO	- Transfer	MOCEN CONTINUE	1.653 1.466	21.71
TARTING DATE: 1978 TRINGUPAL INVESTIGATOR: LT		ATED COMPLET	JON BATE:	Closed
SSOCIATE INVESTIGATORS:	C Jeffrey L. Berenl		Reed Army	Medical.
	ė <u> </u>	Center		
· ·	SERVIC		ogy-Oncolog	
EY WORDS:		Dapartm	ent of Medi	cine
CCUMULATIVE MIDCASE	ACCUMULATIVE	CONTRACT	LACCUMULA	TIVE SUPPLY
OST: None	COST: Non		COST:	None
Y-80 MEDCASE COST:	PERIOL	DIC REVIEW R	ESULTS:	
None			3	
TUDY OBJECTIVE: Effective	therapy for relap	sed childho	od ALL.	The property of the second sec
•				
• .				•
•				
			•	
		• .	•	
ECHNICAL APPROACH: Comparis	on of T. NOPP and	T-COAP (See	: : 1979 repor	+ 1
ECHNICAL APPROACH: Comparis	on of T. HOPP and	T-COAP (See	: 1979 repor	t)
ECHNICAL APPROACH; Comparis	on of T. HOPP and	T-COAP (See	: 1979 repor	t)
ECHNICAL APPROACH: Comparis	on of T. HOPP and	T-COAP (See	: 1979 repor	t)
ECHNICAL APPROACH: Comparis	on of T. HOPP and	T-COAP (See	: 1979 repor	t)
ECHNICAL APPROACH; Comparis	on of T. HOPP and	T-COAP (See	: 1979 repor	t)
ECHNICAL APPROACH; Comparis	on of T. HOPP and	T-COAP (See	: 1979 repor	t)
ROGRESS DURING FY-80: Prot	ocol closed becaus			
ROGRESS DURING FY-80: Prot				
OGRESS DURING FY-80: Prot	ocol closed becaus			
OGRESS DURING FY-80: Prot	ocol closed becaus			
ROGRESS DURING FY-80: Prot	ocol closed becaus			
ROGRESS DURING FY-80: Prot	ocol closed becaus			
OGRESS DURING FY-80: Prot	ocol closed becaus			
ROGRESS DURING FY-80: Prot	ocol closed becaus			
ROCKESS DURING FY-80: Prot Pedi	ocol closed becausatric group.	se of lack o	funding o	CALCB.
PROGRESS DURING FY-80: Protresh Pedi Pedi PEGER OF SUBJECTS TO BE STU- RIOUS/UNEXPECTED SIDE EFFI	ocol closed becausatric group. DIED BEFORE COMPLECTS IN SUBJECTS P	se of lack of the second secon	funding o	CALCB.
ROGRESS DURING FY-80: Prot Pedi PEBER OF SUBJECTS TO BE STU RIOUS/UNEXPECTED SIDE EFFI Anap	ocol closed becausatric group.	se of lack of the second secon	funding o	CALCB.
ROGRESS DURING FY-80: Prote Pedi Pedi MSER OF SUBJECTS TO BE STUBLETOUS/UNEXPECTED SIDE EFFI Anap	ocol closed becausatric group. DIED BEFORE COMPLECTS IN SUBJECTS P	se of lack of the second secon	funding o	CALCB.
ROGRESS DURING FY-80: Prot Pedi Pedi PRIOUS/UNEXPECTED SIDE EFFI Anap	ocol closed becausatric group. DIED BEFORE COMPLECTS IN SUBJECTS P	se of lack of the second secon	funding o	CALCB.
Pediametr of Subjects to be STUCKTOUS/UNEXPECTED SIDE EFFI Anap	ocol closed becausatric group. DIED BEFORE COMPLECTS IN SUBJECTS P	se of lack of the second secon	funding o	CALCB.
ROGRESS DURING FY-80: Prote Pedi Pedi Pedi RER OF SUBJECTS TO BE STU REROUS/UNEXPECTED SIDE EFFI Anap	ocol closed becausatric group. DIED BEFORE COMPLECTS IN SUBJECTS Phylaxis not experi	se of lack of the second secon	funding o	CALCB.

•			
		Silliaran aaya	WORK UNIT NO. 1567
DATE: 30 September 1980 (M.)	, (C. 11	MARCALIAN MANALL	Final X
Cis-Platinum Distamined Park	ovido	in Advance. Ret	ignem kyrphomas.
STARTING OMTE: PRINCIPAL INVESTIGATOR: Dr. 3	ohanne	5. B1 n	101 D. 10: 9 Rov. 1979
ASSOCIATE INVESTIGATORS:		FACILITY: Labor	Peed Army Hydical
		Center SERVice: Hematol Departs	
KEY WORDS: ACCUMULATIVE MEDCASE COST: None	ACCUMU COST:	LATIVE COMPRACT None	ACCUMULATIVE SUPPLY
FY-80 PUNCASE COST:		PERIODIC ROVIES I	ESULTS:
STUDY OBJECTIVE:		<u> </u>	
To determine the officacy	of cis	-platinum in 🙉	lignant lymphomas.
TECHNICAL APPROACH:			
Cisplatinum 70/m ² I.V. once	e a 21	davs.	•
This is given with mannito	l diur	esis.	
PROGRESS DURING FY-80:			
WRAMC did not enter any particular of CALGB entered 29 patients a	atient: and dei	s on this study monstrated mode	st activity.
			$_{ m e} = i \theta$
			÷. ´
NUMBER OF SUBJECTS TO BE STUDY SERIOUS/UNIXPECTED SIDE EFFECTS None	S IN SU	GE COMPLETION OF S EMECTS PARTICIPATE	NG IN PROJECT:
CONCLUSIONS:		ادار دران استعید منت استان ۱۳۰۰ در و پیوان در •	Company of the Compan
Cis-platinum may have some malignant lymphomas.	effec	tiveness in the	treatment of
PUBLICATION /ASSTRACTS, FY-80: Cavalli, F., et al.: Phase in Advanced Malignant Lymph Preliminary Results. Cancer No. 9-10, September-October	noma a o Trea	nd Small Cell L tmont Reprits 6	ung Cancer:
<u> </u>			and the second s

1568

Title of Project:

CALGB #7892, Multimodal Therapy for the Management of

Primary, Nonmetastatic Ewing's Sarcoma of Pelvic and

Sacral Bones.

Principal Investigator:

C, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 31, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

1569

Title of Project:

CALGB #7893, Multimodal Therapy for the Management of

Primary, Nonmetastatic Ewing's Sarcoma of Bone; Pelvic

and Sacral Sites Excluded.

Principal Investigator:

Chief, Tematology-Oncology Service

Associate investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

						nous min	т во. <u>15</u>	70
	[30] \$0 \ 1 cesbe	· · · · · · · · · · · · · · · · · · ·		NO: CALCE		STATES:	Interin	X
FIEL (pr PROJECU:	Treatment of			•		Fine)	
		e e e e e e e e e e e e e e e e e e e	nga jenda			•		
	 	es se etterani o tre i comme		,	ege e Oliveria			
	KG DATE: 4/ MAL INVESTIG	30/79 CALCE	ov I B	ESTIMATED		ON DATE: I	982	
	WE INVESTIG		ey u. n			Reed Army	Medical	
			•		Center	:		
	•	• • •	•	SERVICE:		gy-Oncolog at of Medi	•	
-Y 1/OF	RDS: Histio	cytic Lymphom			nepartine	are or near	CARE.	
	ATIVE NEDCA	SE		LATIVE CON			TIVE SUPI	'LY
.JST:	None	· ·	COST:	None	· · · · · · · · · · · · · · · · · · ·	COST:		<u>.</u> .
1-80 1	EDCASE COST			PERIODIC	REVIEW AN	SULTS:		
Juny r	DBJECTIVE: 1	None		1114	r			
		 Test wheth ase rate and 						
		HOP) 2. Tes						
ergres:	a in particu	The whether i						
clapse	2S	•				:	••	
		•		•		•		
					. •	• • •	•	
						•	•	
. CHO	therapy wi	:1. Treatment th and withou by standard o	t conti	nous bleom	ycin info	sion x 3 c	ourses wi	th rand
	•		•			•	• •	
:					. •	•	•	•
. •	•			•	•		•	•
								•
HOGRES	S DURING FY-	-80: 111 pati				mission.		
		CALCS ha	ve ente	red 56 pat	iots.			
	•			•			•	٠.
					•		•	
					· ·		•	
			•			·	•	
					•	•	•	
		TO BE STUDIE SIDE EFFECTS					Ţ:	
CLUS	IONS: Too e	arly for conc		•				
	•						-	. •
1.104	TIONS/ABSTRA	ACTS, FY-80:				•	*	
111 5373		,	None					
						•		
								•

1571

Title of Project:

CALGB #7891, Intergroup Rhabdomyosarcome Study II.

Principal hives gator:

Chief, Hematology-Cincology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no league delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

locuppression is encountered Other severe toxicities such toxicity may also be indicate PROGRESS DURING FY-80: Six no responses. Three patient SERIOUS/UNEXPECTED SIDE EVE.	Las extreme no cions for dose o cions for dose o company of the contract of th	ontered on this entry expired as	ng, mucositis, study. There nd three remai	and hepatic have been in on study.
Other severe Loxicities such toxicity may also be indicate PROGRESS DURING FY-80: Six no responses. Three patient	Las extreme no cions for dose o cions fo	medification. entered on this cutly expired a	ng, mucositis, study. There nd three remai	and hepatic
Other severe toxicities such toxicity may also be indicate PROGRESS DURING FY-80: Six	l as extreme na cions for dose a patients are	asea and vomiting the second s	ng, nucositis, study. There	and hepatic
Other severe toxicities such toxicity may also be indicate PROGRESS DURING FY-80: Six	l as extreme na cions for dose a patients are	asea and vomiting the second s	ng, nucositis, study. There	and hepatic
Other severe toxicities such toxicity may also be indicate PROGRESS DURING FY-80: Six	l as extreme na cions for dose a patients are	asea and vomiting the second s	ng, nucositis, study. There	and hepatic
Other severe toxicities such toxicity may also be indicate PROGRESS DURING FY-80: Six	l as extreme na cions for dose a patients are	asea and vomiting the second s	ng, nucositis, study. There	and hepatic
Other severe toxicities such toxicity may also be indicate PROGRESS DURING FY-80: Six	l as extreme na cions for dose a patients are	asea and vomiting the second s	ng, nucositis, study. There	and hepatic
Other severe toxicities such toxicity may also be indicat	las extreme na cions for dose :	asea and vomiti modification.	ng, xu c osítis,	and hepatic
Other severe toxicities such	Las extreme na	asea and vomiti		
hepatic dysfunction may star increased by 20 mg/m over t	ke previous do	se until 160 mg	/H is reached	wall be l, or untill mye
TECHNICAL APPROACH: The fir heavily treated with chemoth	ierapy_(expecia	lly nitrosourea	Lor radiother	apy or with
			0	
Determine the complete or pa (Sec. 4.2) to impatment with attitude responding to confinal laboratory data regard in	uctat response TM-AMS, Deter Inned todakk ad	rrequencies or mine the derate	ine various is or of nesponse	selected tamoxs— vin those
STUDY OBJECTIVE: This Roase.	II study of Me	AMSA (NSC 24999	2) is designed	to:
FY-80 MEDCASE COST:	PEF	CODIC REVIEW RE	SULTS:	-
ACCUMULATIVE MEDCASE COST:	at the same of the	VE CONTRACT	ACCUMULATIV COST:	L SUPPLY
KEY WORDS: M-AMSA, Melanoma,	Ovarian Carcii	Departmanoma, Breast Car	nt of Medicin	e iephroma. Rematow
	SEI	Center VICE: Hematolo	ogy-Oncology	
PRINCIPAL INVESTIGATOR: LTC ASSOCIATE INVESTIGATORS:	FAC	MATO: Valter	Reed Army Med	ica).
TOTAL STATE OF THE	Inffrage T Da	TEATED COSTLET	ON DATE: 198	53
STARTING PATE: Hay 1979	LEST	والمراجب المراجبين المراوم الممير والم	لتأثير المستدعين ويالجد	
Hypernephressa, and Hepatoss		•		and the second s
	arian Careir ma	, Bread Carnin	Office,	ent.

none

				and the second of the second o
			NORK BHI	T NO. 1573
DATE: 30 September 1980 P TITLE OF PROJECT: Treatment of Pelmary Untreated	ROTOCOL NO: C		STATUS:	Interia Final X
- Committee of the comm	www.	y i consecution		
STARTING DATE: 25 : pt 79 PRINCIPAL INVESTIGATOR: Dr. Je	ESTIMATION	MATED COMPLE	TION DATE: C	1050 4/12/80
ASSOCIATE INVESTIGATORS:	FACII	ATY: Walte Cente	r Rect Army	Medical
	SERVI	CE: Hemato	r logy-Oncolog ment of Medi	
KEY WORDS: Acute Lymphocytic	Leukemia	Depart	ment. Or Pretti	CIM
ACCUMULATIVE MEDCASE COST: None	ACCUMULATIVE COST: N	CONTRACT lone	ACCUMUL/ COST:	TIVE SUPPLY None
FY-80 MEDCASE COST:	PERIC	DIC REVIEW	RESULTS:	
And the same of th	response rat	o and durat	ion in acute	Lymphocytic
	•			•
				·
			•	
TECHNICAL APPROACH: Three arm and vs prednisone 40 mg/M ² plus vincristine 2 mg/M ² IV q week >	dexamethason	ring predni e 12 mg/M ² .	sone 40 mg/M All patien	2 with 120 mg/M 2 ts receive
·			•	· .
		• •		
•			•	•
	•	•	· .	
PROGRESS DURING FY-80: One pat Protocol closed because of lack				
				. •
			•	
·				•
NUMBER OF SUBJECTS TO BE STUDIE SERFOUS/UNEXPECTED SIDE EFFECTS	D BEFORE COMP	LETION OF ST	TUDY: N/	

CONCLUSIONS: The only patient treated will be followed for long term toxicity and survival. No subsequent reports will be submitted.

None

PUBLICATICES/ABSTRACTS, PY-80:

Investigator must answer his comments.

Reviewer did not approve this report.

1574

Title of Project:

CALGB #7981, Comparison of FAM Versus MA in Locally

Advanced or Metastatic Castric Cancer.

Principal Investigato . C, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compiletion of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

		UOREC UNIT NO. 1575
PATE: 30 September 1989 (P	korodój, ko: GALCB /972 Mal of AMSA for Metraci	ory Figal
Hodgkin's Disease, Diffuse His Diffuse Poorly Differentiated	Lymphocytic Lymphoma.	•
SVARTING PALE:	Гезатия го сомет	Action by the first
SPARTING PATE: PRENCIPAL INVESTIGATOR: LTC (ASSOCIALE LIVESTICATORS:	Toffmore to Possessions a RACS	er Beed Arry Medical
	SERVICE: Hemai	er elogy-Oncology Frent of Medicine
KEY WORDS: ACCUMULATIVE MEDCASE COST:	ACCUMULATIVE CONTRACT	ACCUMULATIVE SUPPLY COST:
FY-80 MEDCASE COST:	PERIODIC PEVIEW	
STUDY OBJECTIVE: This Phase II complete or partial response i histocytic lymphoma and poorly M-AMSA. Determine the duration netel of the continued it AM laboratory data regarding toxic	frequency of tell actory landifferentiated lymphogen of response to choose the decided and the control of the c	Hodghin's disease, diffuse ytic lymphoma to treatment wis Rode'da's and lymphome types
will be increased by 20 mg/82	th chemotherapy, especial netion, may start at 60 cover the previous dose countered. Myelosuppress such as extreme nausea a	lly nitrosoureas or radio- mg/M ² . Every 3 weeks the dose until 160 mg/H ² is reached, or ion will require dose modifica- nd vomiting, mucositis, and

PROCRESS DURING FY-80: Two patients entered on study. One had progressive disease but remains alive with decline after responding to another protocol. The other is not evaluable. She refused further therapy after 2 weeks and died with progressive effusions and pneumonia.

None

None

. ". . , 1Y-80;

Lone

		1938 UNIT 40, 1576	
DATE: 30 September 1980 P. ATTLE OF PROMECT: Chemotherapy Capper. A Comparative Phase I		STATUS: Interio X Final	
STARTING DATE: Decomber 1979	E to a treatment of the transfer of	CLASS WAGE	
	ESTIMATED CONPLET 'C Jeffrey L. Berenberg, MC		
ASSOCIATE INVESTIGATORS:		Reed Army Medical	
		logy-Oncology acnt of Medicine	
KEY WORDS:			•
ACCUMULATIVE NEDCASE. COST:	ACCUMULATIVE CONTRACT COST:	COST:	
FY-80 MEDCASE COST:	PERIODIC REVIEW)	ESULTS:	
(SMF vs. FAM) against advanced remission, and survival duration to patient marrival will be detailed and the diagrams of the frequency, severity patients with locally advanced	on. Moreover, the relation termined. To stody payolo this couche with mucinalist by and nature of symptoms,	uship of response and its qual duple distress in publicate wit welevence to depression in as compared to a group of	1155
TECHNICAL APPROACH: 5-Fluorou	uracil, Streptozotocim and	Mitomycin C versus	
5-Fluoroucil, Adriamycin, and M			
•			
. •			
			•
•			
PROGRESS DURING FY-80: One pati Patient expired on day 117 with	ient entered. No responsa progressive dekabilitati	of measurable disease.	•
	•		•
		•	
	•		. •
NUMBER OF SUBJECTS TO BE STUDIE SERIOUS/UNEXPECTED SIDE EVERCTS None			
CONCLUSIONS:	name and management of the source of the sou		
Too early for eve	duation.		•
diet totatene lacombacae av en-			
FUBLICATIONS/ASSTRACTS, FY-80: None			

DATE: 36 September 1980 IPI TITLE OF PROJECT: Comparative Study of Three is and Two Maintenance Regime as in	ssion l	nduction Regime	F	o. 1577 nterim X inal	
STARTING DATE: 20 Jan 80 PRINCIPAL INVESTIGATOR: Dr. Jef ASSOCIATE INVESTIGATORS:	frey L.	FACILITY: Walter Center	Reed Army Ee	The state of the s	
			ogy-Oncology ent of Medici	ne	
KEY WORDS: Acute Myelogenous I ACCUMULATIVE MEDCASE COST: Kone			ACCUMULATI COST: N	VE SUPPLY	
FY-80 MEDCASE COST: None	-}	PERIODIC REVIEW F	RESULTS:	*	
STUDY OF FOTIVE: 1. To determine increase comission rate. 2. To rate during remission induction	determ	erreasing intersiting in clothingsez	y of induction de pill deem	therapy will	
TECHNICAL APPROACH: Randomized Regimen B without CO-Trimoxazol 45 mg/M ² IV days 1,2,3 + AkA-C DNR 45 mg/M ² IV days 1, 2, 3 + 100 mg/M ² po days 1-7. Regiment infusion days 1-10.	e. Rai 100 mg/i	ndomize between Re M2 TV by continous OO mg/M2 IV by con	gimen 1) Daund infusion day tinuous infusi	omycin (DNR) 1-7. Regimen 2) Lon 6-Thoguainine	i •
				•	
		ents entered, both I not reported.	achieved a co	umplete remission.	
· · · · · · · · · · · · · · · · · · ·			•		
					,
NUMBER OF SUBJECTS TO BE STUDY SERIOUS/UNEXPECTED SIDE EFFECTS None					
CONCLUSIONS: Too early to eval	luate.	•	and the second s	as not been approve vaiting for the inves nts.	
, one was ready near the same of the same	None				

PAIR: 50 Fertenber 1980 (Pi TITLE OF FERRICE: A Rendomized Corbination of Horsonal Thorap Heat of Advanced Breact Cancer	Study Comparing the y and Chemotherapy with (dhemotherapy a	TROUDENCE X Timal Plone for the Treat-
STARTING DATE: July 1980 PRINCIPAL INVESTIGATOR: LTC Je ASSOCIATE INVESTIGATORS:	PASTINATED AND FACTOR IN THE FACTOR IN THE PASTINATE WAS TO SEE THE PASTINATE OF THE PASTIN	MC feed Gray Y	Sai al
REY WORDS: Advanced Breast Can	SERVICE: Herar Webser	copy-Oncology cont of Medic	ine
ACCUMULATIVE MEDCASE COST:	ACCUMULATIVE CONTRACT COST:		
FY-80 MEDCASE COST:	PERIODIC DEVIS	ide vers:	err egeter filmen halden film i 1 de gregorie geske geskelende et er
STUDY OBJECTIVE: To determine the combination chemotherapy plus I and survival in patients with a	hormonal therapy in impro	inst ion chemot Sving response	florapy versus to treatment
TECHNICAL APPROACH: Patients ent combination chemotherapy with a 28 day cycle or combination of tamoxifen.	cytoxan, adriamycin, 5-fl	luorouracil an	id tamoxifen in
	•		
PROGRESS DURING FY-80: Of three disease and two have had pautic	e patients entered on stu al responses.	idy in 1980, c	one has stable
	·	•	•
NUMBER OF SUBJECTS TO BE STUDIE SURTOUS/UNEXPECTED SIDE FFUECTS			
CONCLUSIONS: Too early.	. <u></u>	and the second second second second	
en se			•
PUBLICATIONS/ABSTRACTS, FY-80:			
None			

DATE: 30 Sentember 1990 (PROPOCOL TITLE OF FRANKE: Surgical Adjuvent Sy with 5-FU, Adriewycin, and Mitomycin-C	Not CALGE 7983 STATES SELECTED X
Adenocarcinoma.	C VS Observation only in Castric
STARTING DATE: 1979 PRINCIPAL INVESTIGATOR: LTC Jeffrey 1 ASSOCIATE INVESTIGATORS:	L. Berenberg, M.D. MC FACTION: Material Read Army Matter
KEY WORDS: Gastric Adenocarcinoma	SERVIEL: Section of Modicine
ACCUMULATIVE MEDCASE ACCUM	ULATIVE CONTRACT ACCUMULATIVE SUPPLY COST:
FY-80 MEDCASE COST:	COST: PERIODIC REVIOLA RESULTS:
standard surgical resection along, TECHNICAL APPROACH: Regimen 1: Obser 5-Fluorouracil 600 mg/H ² 1.v. days 1,	This study is to accertain if 6 two monthly cycle rain-C feelesing potentially cycle and a land advance in a comparison to a land a description of a land and a land a lan
PROGRESS DURING FY-80: Too early for	accual of patients.
	an degree in ten on shipy:

PUBLICATIONS/ASSIRACTS, FY-80:

comments.

			WORK UNIT	No. 1603
PATE: 30 September 1930 [P TITLE OF PROJECT: MRANG Protoco Mathyl-COMU (1-(2-chloroethyl): https://www.comu.com/pathyl/comu.com/pathyl/comu.com/pathyl/comu.com/pathyl/com/pathy	51 7206 ·	:Hyloyclobakyl),:l-		Interim Final X
STARTING DATE: PRINCIPAL INVESTIGATOR: Jeffrey ASSOCIATE INVESTIGATORS:		ESTIMATED COMPLET enberg, M.D., LTC, FACILITY: Walter	TON DATE: S AC Reed Army	
			ogy-Oncolog ent of Medi	
REY WORDS: ACCUMULATIVE MEDCASE COST:	ACCUM COST:	JLATIVE CONTRACT	ACCUMULA COST;	TIVE SUPPLY
FY-80 MEDCASE COST:		PERIODIC REVIEW 1	RESULTS:	
STUDY OBJECTIVE: To evaluate. CNS tumors as measured by tumor and duration of survival.		ectiveness of MeCC age with possible		
TECHNICAL APPROACH: Each patie cose every 6 weeks. The drug	eat will is give	receive: Me-CCNU a in one single do	150 mg/k ² p se on an emp	ou in a single ety stomach.
			•	•
PROGRESS DURING TY-80: Closed needian survival of 47 weeks we need natched bistorical control all patients entered on study i	thich was Ns. Even	s not sifnificantly the 5 years prior	y different in the onse	form and and at of this study
NOMBER OF SUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT None CONCLUSIONS: This study's resu Oproximately 3 months was added	S IN SU Lts ver	BJECTS PARTICIPATI e similar to those	from other	institutions.
TUBLICATIONS/ABSTRACTS, FY-80:	;			•
Kone				

1604

Title of Project:

WRAMC #72.05, Phase II, Combination Chemotherapy with

Dimethyl Triazeno Intidazole Carboxamide and Adriamycin

in Soft Tissue and Bone Sarcoma.

Principal Investigator:

Chief, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

The second secon				WORK UHI	T NO. 161	Ů	
DATE: 30 September 1980 (F TITLE OF PRODUCT: Phase I-II tol in Previously Treated Pati	Evaluati	on of Dib	comodulci	_ !	Final	- X	
STARTING DATE: 1973 PRINCIPAL INVESTIGATOR: LTC JOASSOCIATE INVESTIGATORS:	ESTERWIED (1976 First DATE: Jon 1979 Berenberg, M.D. NC FACILITY: Walter Reed Army Medical Center SERVICE: Senatology-Oncology Department of Medicine						
KEY WORDS: Metastatic Breast Cancer ACCUNULATIVE MEDCASE ACCUME COST: COST:		HATEVE CO	STEACT		ACCUMULATIVE SUPPLY COST:		
FY-80 MEDCASE COST:		PERIODIC REVIEW RE		usu lts:	SULTS:		
STUDY OBJECTIVE: Evaluation of with and are resistant to stand	t dibrom lard mod	odulejtol es of the	in patie	nts who hav	e been fr	eat e d	
TECHNICAL APPROACH: Dibromodu	deltol p	p.o. days	J- 10 cad	i 21. đay cj	rcle.		
PROGRESS DURING FY-80: This st	udy was	closed to	vatient	entry in I	lecember 19	978	
					-		
CONCLUSIONS: Despite responses ve developed progressive dise fectiveness in metastatic bre	S IN SUB observe ase or e	ed in 4 pa expired.	dictráci idionts, d	ic in Proje	CT:	ents, all little	
.UBLICATIONS/ABSTRACTS, FY-80:						• •	
	None						

1626

Title of Project:

WRAMC #7405, Treatment of Advanced Renal Cell Carcinoma with

with a Combination 1-(Chlorethyl)-3-Cyclohexy-1-Nitrosourca

(CCNU) and Bleomycin.

Principal Investigator:

Chief, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

WORK WILT NO. 1627 TTE: 30 September 1980 | PROTOCOL NO: WRANG 7404 Interim X Final THE OF PROJECT: Tertunological Evaluation and the ato with Cordinans of the way inotherapy of ESTIMATED COMPLETION DATE: TARGING DATE: HINCIPAL INVESTIGATOR: Dr. Jeffrey L. Berenberg SOCIATE INVESTIGATORS: FACILITY: Walter Reed Army Medical · Center SERVICE: Hematology-Oncology Department of Medicine Immunotherapy, Lung Carcinoma Y WORDS: COUNULATIVE MEDCASE ACCUMULATIVE CONTRACT . ACCUMULATIVE SUPPLY None None COST: COST: 031: 1-80 MEDCASE COST: PERIODIC REVIEW RESULTS: None TUDY OBJECTIVE: 1. To determine therapeutic efficacy of BCC given by scarefication to patients with lung carcinoma. 2. To determine if allogenic tumor cells benefit. . Correlation of in vivo and in vitro cellular immunity with clinical status. CHNICAL APPROACH: L. Stage I (A) pathents were mandomized between BCG; tumor cells

and ECG or follow-up alone. 2. Stage II - debulked surgically received radiotherapy 5000 and plus randomization we above. They also received Cytoxen 500 mg/M2 Methotrexate to mg/M2 iv + Vincristiae Z.0 mg EV on day 1 - 8 928d.

MOGRESS DURING FY-80: The single stage B patient left on study relapsed and died of progressive discuss. The stage A patients results from all discuss.

HER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: None

Mone in 1980

CLUSIONS: Immunotherapy may be of value to lung carcinoma patients with limited disease.

AT CATIONS/ABSTRACTS, FY-80:

See 17-79 report.

This report has not been approved. Waiting for investigator's comments in asswer to reviewer.

			FORK UNIT	NO. 1628			
DATE: 10 September 1990 (F) WITLE OF HIS JUST: Chemodemunot the Large Borel.			GIAIUJ:	(Internal Plant	X		
STARTING FAIL: 1976 PRINCIPAL ONESTICATOR: LTC Je ASSOCIATE DAVISTICATORS MAJ Salvetore J. Scialla, MC	ffrey Berenberg,	The time (Mileton DALE: May 1978) renberg, MC FACTOR Will be treed Army Modelat Con Stand D: Bourste g-Oncology bepartment of Medicine					
KEY WORDS: Carcinoma, Large B ACCUMULATIVE MEDCASE COST:	owel ACCUMULATIVE (OTTRACT	ÄÄÜÜÜÜÄÄ	afeve sum	i.Y		
FY-80 MEDCASE COST:	PERIOD	C BANDAN RI	Surs:				
STUDY OBJECTIVE: To investigat tion in patients with carcinom combination 5-FU/MeCCNI.	e the therapovida a al the color o						
TECHNICAL APPROACH: All patien Type II (Stage B ₁) - Extension to or through serosa; negative nodes. IV - Locally metastat removed, but with some tumor r or fixed so that surgery would	into but not the nodes. III (Stic disease beyon emaining. Canno	xough muse age C _l ∑=) id lymphatic of tolenate	nlaris. (St bimited to cs, the bul surgery,	age B ₂) serosa; p k of whic Tumor of	- Extension positive th can be such size		
PROGRESS DURING FY-80: No fur	ther accrual of	patients.		•			
					. •		
				<u></u> .	,6.		
NUMBER OF SUBJECTS TO BE STUDI SERIOUS/USENFACTED SIDE EFFECT	ED BEFORE COMMENS		P97: Closed	UT:			
CONCLUSIONS: Will be analyzed			5 year surv	ival info	rmation.		
PUBLICATIONS/ABSTRACTS, FY-80:							

! STAILS: Interio DVIA: 30 September 1950 Photocol, No. WRANG 7007 Figur X TITLE OF PROJECT: Chenoimmunotherapy of Malignant Melanomi | ISTEMBLED COMPLETION DATE: Closed May 1978" STARTING DATE: Nov. 1974 PRINCIPAL LEVESTICATOR: Dc. Johannes Blom FACILITY: Walter Reed Army Medical ASSOCIATE INVESTIGATORS: Center SERVICE: Hematelogy-Oncology Department of Medicine KEY WORDS: Melanoma ACCUMULATIVE COSTRACT ACCUMULATIVE SUPPLY ACCUMULATIVE NEGCASE cost: None cost: N ne COST: FY-80 MEDCASE COST: PERIODIC REVIEW RESULTS: Hone STUDY OBJECTIVE: To determine if nonspecific immunotherapy with BCG would prolonge disease free survival in melanoma both Stage I and advanced Stages II-IV. TECHNICAL APPROACH: CG was given by dermal scarification to Stage I patients. ore advanced patients received BCG and LCDT 700 mg/m every 21 days. PROGRESS DURING FY-80: This study was closed in 1978. Detailed analysis was performed last year. Since then one additional patient with Stage II disease has relapsed. Because of the small number of patients entered and the tack of a concurrent control group, this study is not suitable for aublication. DOMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: ากย CONCLUSIONS: Recommend that the follow up be for long term toxicity and hat this be the final report. BUBLICATIONS/ABSTRACTS, FY-80: 14950

		WORK Upd 5 R	0. 1630
PATER DI Serie or 1930 (PE TIME OF EM Vo. Comporative). Plaoxymesterone plus Tamoxifen (the of Therediton and		tos ta X
STARTING DATE: 1974 PRINCIPAL INVESTIGATOR: LTC JOF ASSOCIATE INVESTIGATORS:	Example to the first better FACTIFIED Laster) il lambe 1983	2 (i:a)
	SERVICE: Property Department	ogg~Opcology -	
KEY WORDS: Metastatic Breast Ca ACCUMULATIVE MEDCASE COST:	ncer L'Accussit Allawi contravet	z cörisin ka sv	er georga V
COST:	PERIODIC RIATES I.	reults:	Burn Burner - gamba rayara yangan rayan r
STUDY OBJECTIVE: Remonse rate relative therapeatic benefit of Prognostic importance of a varie challabed.		the quality of	Lampival.
		-	
TECHNICAL APPROACH: Regimen A terone 7 mg/m ² p.o. Bid, Tamoxife gradually be increased. Addendu	en 2 mg/m 2 p.o. bid. The ϵ	lose of tamoxid	3 - Fluoxymes- Ten will
	,		• .
PROGRESS DURING FY-80: A total No new patients entered in 1980. are not evaluable and twenty-mine		de. Of the ro	
	•		e e e
NUMBER OF SUBJECTS TO BE STUDIES SERIOUS/UNEXPECTED SIDE EFFECTS	ED BEFORD COMPLETED OF ST S IN SUBJECTS PAUL COPALES	UDY: C IN PROJECT:	
CONCINCTIONS.	disease control intervals	•	
PUBLICATIONS/ASSIRACTS, FY-80:			

Date: 1 December 1980	Protoc A No	2: 1643	Scalus: Interim
Title of Project:			leinal X
	Concentrate, lor VIII Inhibit	luman, Dried in tors and the Tr	n the Treatment of Patients reatment of Factor VIII
	5 Estimate	ed Completion I	Date: The study should be close
Principal Investigator: Dani			at this time.
Associate Investigators:	1	cility: WRAMC	
— — — — — — — — — — — — — — — — — — —	De	pt/Svc Departs	ent of Medicine
Key Words:	and and analysis of the same and the same an		
Accumulative MEDCASE Cost:		ive Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	بدینید به مدهند می میشونید که میشونید به میشونید به است. پدر و پا مهید به مید شهرسیمید که بیشونید را به میشونید که میشونید این است.	Pariodic Re (to be fille	view Results: d in by DCI)
Technical Approach:	u preživoji Populacija	· · · · · · · · · · · · · · · · · · ·	
			•
Progress during FY-80: Since the activation of the and an inhibitor to Factor comitant liver disease. Number of subjects to be student.	VIII. She wa	s ineligible f	as presented with bleeding or the study because of con-
Scrious/unexpected side effec			
	placement on		only one patient has presented therefore, I feel this study

WALTER REED ARMY MEDICAL CENTER WASHINGTON DC F/6 6/5
ANNUAL PROGRESS REPORT (FY-80) DEPARTMENT OF CLINICAL INVESTIGA--ETC(U)
SEP 80 T M BOEHM AD-A100 636 NL UNCLASSIFIED 4∞8 AO 2 00536

Work Unit No.:

1644

Title of Project:

WRAMC #7501, Evaluation of Adriamycin and Cis-Platinum

Combination Chemotherapy in Treatment of Malignant Disease.

Principal Investigator: Chief, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

Work Unit No.:

1649

Title of Project:

WRAMC #7602, Chemoimmunotherapy of Prostatic

Carcinoma.

Principal Investigator:

Chief, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

		WORK UNIT NO. 1651
DATE: 30 September 1920	120 Per OL 20: WRAMC 7604	A. W. F. Sterry
TITLE OF BELLEUT: Combination	Chemotherapy for the Tre	at- X
		a-Hydro-2-Furanyl-5-Fluorouraci
(Ftorafur), Adriamycin and M	itomycin-C vs.5-"Juoroura	cil, Adriamycin and Mitomycin-C
and the state of t		المتنفسين والمتعار الأمارة والماران وال
STARTING DATE: 1976	LENGTH TELEVISION	1978 I 1978
PRINCIPAL INVESTIGATOR: LTC Je	effrou Rorenhero MC	
ASSOCIATE INVESTIGATORS:	and theed Zirisy York of	
	Cent	
	SERVICE: Beach	Sign on One of the
•	Deg. e	Front of Wedl the .
KEY WORDS: Advanced Gastric		the same of the sa
ACCUMULATIVE MEDCASE	ACCUMULATIVE CONTRACT	Accessure the shally
COST:		COST:
FY-80 MEDCASE COST:	PERIODIC REVIES	OUNUAS:
STUDY OBJECTIVE: To study the	e efficacy of and compare	the results of treatment with
Ftorafur, adriamycin, and mit mitomycin-C.		

TECHNICAL APPROACH: Ftorafur 1500 mg/m 2 I.V. days 1-5 during week 1 and 5 of each 8-week cycle. Adriamycin 30 mg/m 2 I.V. days 1 and 29. Mitomycin-C 10 mg/m 2 I.V. day 1 of each 8-week cycle. 5-Fluorouraci1 600 mg/m 2 I.V. days 1 and 8 and days 29 and 36 of each 8-week cycle. Adriamycin 30 mg/m 2 I.V. days 1 and 29 of each 8-week cycle. Mitomycin-C 10 mg/m 2 I.V. day 1 of each 8-week cycle. Ftorafur was discontinued on 1 July 1977.

PROGRESS DURING FY-80: No further entries.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF SENDY: Closed to patient entry. SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARALICIPATING IN PROJECT:

CONCLUSIONS: Short responses in those evaluable patients however all evaluable patients had progressive disease by 18 months with 4 shortly thereafter - Awaiting group wide study with new Phase II agents.

DATE: 30 September 1980 | PROTOCOL NO: WRAMC 7404 | STATUS: Interim
TITLE OF PROJECT: | Final X

Treatment of Unresectable Bronchogenic Carcinoma

STARTING DATE:		ESTINATED COMPLET	ION DATE: Closed June 1977
PRINCIPAL INVESTIGATOR: Dr.	Johannes)	Blom	The second secon
ASSOCIATE INVESTIGATORS:		FACILITY: Walter Center	Reed Army Medical
Dr. Char		SERVICE: Hematol Departu	ogy-Oncology ent of Medicine
KEY WORDS: Lung Cancer			
ACCUMULATIVE MEDCASE COST: None	ACCUMO COST:	JLATIVE CONTRACT None	ACCUMULATIVE SUPPLY COST: reprints
FY-80 MEDCASE COST: None		PERIODIC REVIEW R	ESULTS:

STUDY OBJECTIVE: To determine whether combination chemotherapy with radiotherapy would prolong survival in unresectable bronchogenic cancer.

TECHNICAL APPROACH: Chemotherapy with CCNU, Cytoxan, Adriamyciu, Hexamethylmelamine, Procarbazine and Methetrexate befor radiotherapy/RT or after in those who failed RT.

PROGRESS DURING FY-80: Thirty-seven patients entered, three entered a complete remission. One patient remains alive and is being followed. She is stable without disease.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: None
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:
See 1978-79 Report

CONCLUSIONS:

See 1978-79 Report. Since only one patient remains alive this study should be closed. The remaining patient will be followed for long term toxicity.

				WORK UN	LT KO. 1655	
DATE: 30 September 1980 PR	OTOCOL NO	: WRAMC 760)7	STATUS:	Interim	•
TITLE OF PROJECT: Chemoimmunoth					Final X	
Lung Using High-Dose Nethotrexa	ite and Ci	trovorum Fac	tor vit	h or wit	nout BCC.	•
Bung osting hagh bone received					•	
						•
STARTING DATE: 27 July 1976		STIMATED CON	PLETIO:	N DATE: 2	Jan 1979	-
	hannes B.					-
ASSOCIATE INVESTIGATORS:			-	eed Army	Medical.	
LTC Charles Miller	, 		enter	y-Oncolog	.,	
	3	ERVICE: Her	Nartaros)	t of Medi	y cine	
KEY WORDS: Chemoimmunotherapy,	Jung Car		Jar Cuett	L OI Redi	C1.11C	-
KEY WORDS: Chemoimmunotherapy, ACCUMULATIVE MEDCASE		TIVE CONTRAC	יד:	ACCUMULA	TIVE SUPPLY	·
COST: None	COST:	None		COST:		•
						_
FY-80 MEDCASE COST: None	F	ERIODIC REV	LEW REST			_
STUDY OBJECTIVE: 1. Evaluate 1	2000000	htsined with	i high d	iose meth	otrexale and	•
radiation therapy in patient wi				للما ساداد. سا بدسا	with marchine City	
Taulation contapy in particular wa	cor acoad	ica. Simile Control	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	•	* •	•
2. Evaluate i	ole of in	munotherapy	with Bo	CG.		
•	• .		• .			
			•	•		•
macouract approach a second	• • •			· 11	200 2/2	
TECHNICAL APPROACH: 1. Escalat followed by radiation therapy I	ing doses L500 rads	with recycl:	ing to o	/ mg/kg chemother	300 mg/g apy.	٠.
0 77.75.41			. PCC			
Z. Hair tr	e patien	s will rece	rve bug	•		
		. •	٠.	•	•	
		•		•		
·				•		
					and radiati and survival	
				٠.	•	•
			•			
		•	•			
				• .		
* :			•		•	
				•		
NUMBER OF SUBJECTS TO LE STUDIO	ED REFORE	COMPLETION	OF STUD	Y: None		
SERIOUS/UNEXPECTED SIDE EFFECTS	S IN SUBJ	ECTS PARTICI	PATING	IN PROJE		~
OPERIOR OF STREET					None	
CONCLUSIONS:	·					-
Same as 79-80						
	•		•			
PUBLICATIONS/ABSTRACTS, FY-80:						
	Non	0				

WORK	URIT	NO.	1657
	ONTI	<i>310.</i>	. J.U.)/

DATE: 30 September 1990	Trrorecoi.	10: WRAMC 7701	STATUS: theerin
TILE OF FREJECT: Velban,	Bleomycin,	and Cis-Platinum	Cinel X
n the Treatment of Head and			
• .	•	•	•
STARTING DATE: 8 March 1977		ESTERATED COMPLE	TICN DATE: 30 Sept 1980
PRINCIPAL INVESTIGATOR: LT	C Jeffrey L	. Berenberg, MC	and the state of t
ASSOCIATE UNVESTIGATORS:			r tieed Army Fedical
MAJ Martin D. Weltz, MC.	*	Cente	ť .
MAJ David J. Perry, MC		SERVICE: Helanto	logy-Oncology
	• 1	Depart	rent of Medicine
KEY WORDS: Head and Neck M	alignancies	•	
ACCUMULATIVE MEDCASE	• ACCUMU	LATIVE CONTRACT	ACCUMULATIVE SUPPLY
COST:	cost:	ر ودرستان معامل معامل المعامل الم	cosr:
FY-80 MEDCASE COST:		PERIODIC REVIEW	KESULTS:
STILL OR IECTIVE . m			44 - F XI-31 - D7

STUDY OBJECTIVE: To evaluate the efficacy of the combination of Velban, Bleomycin, and Cis-Platinem in SCC of the head and neck recurring after radiation, surgery or previous chemotherapy. To evaluate the efficacy of this regime as preoperative or pre-radiation threatment in preventing recurrence.

TECHNICAL APPROACH: Pre-operative/pre-radiation induction: Velban 4.0 mg/m² I.V. day 1, Bleomycin 15 mg I.M. qd days 1-7, Cis-platinum 60 mg/m² I.V. day 8, plus manuated and fluids. Maintenance: Methotrexate 20 mg/m² p.o. twice weekly to begin on day 15 from onset of final induction course. Cis-platinum 60 mg/m² will be given every 29 days x3 courses then every 57 days x3 courses. Patients with recurrent disease after previous definitive treatment will be treated with the induction regimen every three weeks as long as there is continued tumor regression until the maximum dose of bleomycin (250 mg/m²) has been reached.

PROGRESS DURING FY 50: 119 patients have been entered on study; 109 with head and neck cancer, 7 with uterine cervical CA, 2 with esophageal CA and 1 with SCC anus. 2 records were not available for review. One hundred seven patients with Stage III and IV squamous cell carcinomas of the head and neck received combination chemotherapy consisting of Velban 4 mg/m² IV day 1, Bleomycin 15 mg in days 1-7 and cis-platinum 60 mg/M² IV with Mannitol diuresis day 8. Patients received from one to four cycles at three week intervals. Of 64 previously untreated patients, 14 (22.0%) achieved complete response, 30 (44.0%) were partial responders and 22 (34%) were less than partial responders. (CONTINUED ON REVERSE SIDE)

SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

Two creatinine 3.0; two with Bleomycin - related pulmonary infiltrates.

CONCLUSIONS: The combination regimen is effective in producing complete and partial responders who have superior survival to those who do not respond. Subsequent surgery and radiotherapy can be given without major morbidity. This regimen is planned for a randomized, prospective adjuvant trial.

PUBLICATIONS/ABSTRACTS, FY-89:

From AN Jr, Blom J, Garcia-Guerrero G, Richardson MF, Henderson RL: Combination chemo- therapy with viublastine, bleomycin, and cis-diamminedichloroplatinum (II) in squamous cell carcinoma of the head and neck. Cancer 45:2830-2835, 1980.

PROGRESS DURING FY 80 (CONT)

The response rate for all patients was 66%. 24 month actuarial survival for the complete responders was 83.2%, for the partial responder 39.3% and for nonresponders 0%. Of 42 previously treated or recurrent patients, 6 (14%) were complete responders, 13 (30%) were partial responders and 25 (56.5%) were nonresponders. The response rate was 44%. 24 month actuarial survival was 80% for complete responders, 12.8% for partial responders and 4% for nonresponders. Toxicity was mild with dermatitis, mild renal insufficiency and nausea and vomiting most commonly seen. Two patients developed renal insufficiency with creatinines of 3.0; two developed pulmonary infilatrates without symptoms; there were no drug related deaths. 24 month actuarial survival for the 64 previously untreated patients was 41.7%; 24 month actuarial survival for a retrospectively matched site and stage group was 34.5%. (Logrank test, p>0.10). This combination has activity in advanced head and neck cancer; no improvement in survival over historical controls was demonstrated.

Work Unit No.:

1658

Title of Project:

WRAMC #7702, Adjuvant Chemotherapy of Prostatic Carcinoma

with Adriamycin and Cis-Diamminedichloroplatinum II.

Principal Investigator:

Chief, Hematology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

Date: 1 December 1980 Proj	ocol No: 1661	Status: Interim x
Title of Project: Polycythemia Ver	a Study Croup (PVSG)	Final
TIOLOCOIS		· 1
Starting Date: FY 78	Stimated Completion Dat	e: Protocols 1 & 10 are closed to patient accrual, but pa-
Principal Investigator: Daniel B.	Kimball, Jr., COL, MC	tients randomized continue to be followed and protocol 5 com-
Associate Investigators:	Facility: WRAMC	tinues to be open for patient accrual with no near term completion date projected in the
Staff and Fellows of the Hematolo Oncology Service	Bept/Sve Departmen	national group. at of Medicine
Key Words:		
1	cumulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	Periodic Revi	ew Results: in by DCI)
Study Objective: To study the ther the myeloproliferative diseases.	apeutic medalities and	natural history of several of
the myeroprofficiative diseases.		
		•
Technical Approach:		•
Progress during FY-80: In FY 1980	WRANC followed pat	ients registered on polycythemia
vera study group Protocols 1, 5 a Protocol 01: Protocol 01 has bee WRAMC patient living in Fayettevi	en closed for several v	continues to be followed on this
Number of subjects to be studied before	ore completion of study:	(over)
Serious/unexpected side effects in su	bjects participating in pr	oject:

Conclusions: As noted previously, Protocols 1 & 10 are closed for further patient accrual. The patients currently randomized will continue to be followed and Protocol 5 remains

open for accrual.

Publications or Abstracts, FY-80: None.

Alkeran with no complications and good control of his platelet count. As noted above, the study has been closed. Patients who would be eligible for this study would now be appropriately randomized for Protocol 12. The advantage of Alkeran in this study was marginal compared to P32 and it was felt that inpart that it might be because of the lower dose used.

Progress during FY80: (Continued)

protocol having been last evaluated this post spring at the Neber Reed Army Medical Center and receiving a dose of P32 for control of her elevated platelet count. Followup continues in the national office on 431 randomized patients with the median followup being 5.3 years on phlebotomy, 5.4 years on Chlorombucil and 6.1 years on P32 as of the 15 February 1980. The median survival time is 7.8 years on Chlorambucil, 9.7 years on P32 and the median has not been reached on phlebotomy therapy. The differences in survival are not statistically significant. The excess incidence of loukemia in pationis treated with Chlorambucil which was identified previously continued with 16 documented cases from those patients treated with Chlorambucil as compared with I case on patients treated with phlebotomy and 9 on patients treated with P32. Also the increased incidence of cancer in patients treated with Chlorambucil continues although it is not statistically significant. There is as previously noted an excess incidence of thrombotic complications for patients treated on the phlebotomy arm as compared to those treated on the Chlorambucil or P32 arm. However, once the patients have been followed on any form of therapy for more than 3 years, the incidence of thrombotic complications appears comparable in all 3 groups.

Protocol 05: The three patients from Walter Reed continue to be followed on Protocol V and are all being followed without complications. Because of the previously noted incidence of Leukemia, this study was designed to test the role of phlebotomy plus anticaggregating agents as compared to P32 in the treatment of polycythemia rubra vera. Nationally 138 patients have been entered on the study with a median followup time of 42-56 weeks. Two deaths have been reported on the study, one due to suicide and a second due to a Budd-Chiari Syndrome at 86 weeks on the study. A total of 16 hemorrhese or thrombotic complications have been observed ranging from moderate to severe with both arms of the protocol having had recorded complications and at this point there appears to be no difference in incidence of the complications. As noted previously, the study continues to be open for patient accrual. It would certainly appear that if the arm of phlebotomy plus antiaggregating agents can be shown to be equivalent to the P32 arm that this may be the future treatment of choice for this disease.

Protocol 10: Two patients from WRANG have been randomized to this study which is designed to compare the therapeutic efficacy of P32 versus an oral akalating agent, phenylalanine mustard (Alkeran) for the control of primary thrombocytosis. Mrs. R.B. continues to be followed on the study although her therapy has had to be discontinued because of major cytopenia and a hypoplastic marrow. She has become significantly symptomatic because of the panocytopenia with anemia and has required transfusion. Whether this may evolve into a loukemic picture is unknown at the present time. The other patient who is randomized for the study at Walter Reed is receiving daily oral

(See aboyc)

WORK	UNLT	NO.	1664
------	------	-----	------

- -			
STARTING DATE: July 1977. PRINCIPAL INVESTIGATOR: LT ASSOCIATE INVESTIGATORS: MAJ Martin Weltz, MC MAJ Salvatore Scialla, MC	C Jeffrey Berenberg, MC FACTIONS: Walter SERVICE: House	er Feed Army Medical er ology-Oacology treat of Medicine	-
KEY WORDS: Metastatic Color ACCUMULATIVE MEDCASE COST:		ACCUMULATIVE SUPPLY COST:	
FY-80 MEDCASE COST:	PERIODEC PEVIES		-
mitomycin-C plus ICRF-159.i. evaluate the hypercoagulable			
TECHNICAL APPROACH: Regimen			
TECHNICAL APPROACH: Regimen progression after one dose, Regimen II - Mitomycin-C J every 3 weeks in divided do one course, the patient is tion. All patients will be	or stabilization after two mg/m ² I.V. every 6 weeks IC ses every 8 hours. If the to be taken off protocol.	o doses, switch over to R CRF-159.500 mg/m ² p.o. da re is objective progressi Addendum 1 changed the ra	egimen II y 1,2,3 on after ndomiza-
progression after one dose, Regimen II - Mitomycin-C J: every 3 weeks in divided do one course, the patient is tion. All patients will be	or stabilization after two mg/m ² I.V. every 6 weeks IC ses every 8 hours. If the to be taken off protocol.	o doses, switch over to R CRF-159.500 mg/m ² p.o. da re is objective progressi Addendum 1 changed the ra	egimen I y 1,2,3 on after ndomiza-
progression after one dose, Regimen II - Mitomycin-C J: every 3 weeks in divided do one course, the patient is tion. All patients will be	or stabilization after two mg/m ² I.V. every 6 weeks IC ses every 8 hours. If the to be taken off protocol.	o doses, switch over to R CRF-159.500 mg/m ² p.o. da re is objective progressi Addendum 1 changed the ra	egimen I y 1,2,3 on after ndomiza-
progression after one dose, Regimen II - Mitomycin-C J: every 3 weeks in divided do one course, the patient is tion. All patients will be	or stabilization after two mg/m² T.V. every 6 weeks To ses every 8 hours. If the to be taken off protocol. A entered on the ICRF-159 p	o doses, switch over to R CRF-159.500 mg/m ² p.o. da re is objective progressi Addendum 1 changed the ra	egimen II y 1,2,3 on after ndomiza-
progression after one dose, Regimen II - Mitomycin-C J: every 3 weeks in divided do one course, the patient is tion. All patients will be	or stabilization after two mg/m² T.V. every 6 weeks To ses every 8 hours. If the to be taken off protocol. A entered on the ICRF-159 p	o doses, switch over to R CRF-159.500 mg/m ² p.o. da re is objective progressi Addendum 1 changed the ra	egimen I y 1,2,3 on after ndomiza-
progression after one dose, Regimen II - Mitomycin-C J: every 3 weeks in divided do one course, the patient is tion. All patients will be	or stabilization after two mg/m ² T.V. every 6 weeks IO sees every 8 hours. If the to be taken off protocol, a entered on the ICRF-159 p. further entries.	o doses, switch over to R CRF-159.500 mg/m p.o. dare is objective progressinddendum 1 changed the rallus mitomycin-C regimen of the control o	egimen I y 1,2,3 on after ndomiza-
progression after one dose, Regimen II - Mitomycin-C J: every 3 weeks in divided do one course, the patient is tion. All patients will be PROGRESS DURING FY-80: No	or stabilization after two mg/m² T.V. every 6 weeks IO ses every 8 hours. If the to De taken off protocol. entered on the ICRF-159 p. further entries. UDIED BEFORE COMPLETION OF ECTS IN SUBJECTS PARTICIPA	o doses, switch over to R CRF-159_500 mg/m p.o. day re is objective progression Addendum 1 changed the rallus mitomycin-C regimen of the results of the resu	egimen I y 1,2,3 on after ndomiza- nly.
progression after one dose, Regimen II - Nitomycin-C J: every 3 weeks in divided do one course, the patient is tion. All patients will be PROGRESS DURING FY-80: No No SERIOUS/UNEXPECTED SIDE EFF CONCLUSIONS: Closed because	or stabilization after two mg/m² T.V. every 6 weeks IO sees every 8 hours. If the to be taken off protocol. A entered on the ICRF-159 pt further entries. BDIED BEFORE COMPLETION OF ECTS IN SUBJECTS PARTICIPAL of lack of therapeutic efficiency.	o doses, switch over to R CRF-159_500 mg/m p.o. day re is objective progression Addendum 1 changed the rallus mitomycin-C regimen of the results of the resu	egimen Ti y 1,2,3 on after ndomiza- nly.

			WORK UNI	y no. 1665
DATE: 30 September 1980	Paground No	WRANG 7706	I KOYUSE	The section X
TITLE OF PROJUCTS Treatment o	f Refractor	y Castr Intent:	call	_Hart
Tumors with Chlorambucil and				
• ,			•	
STARTING DATE: 1977	1	STIANIE COMPLI	2010.1 2.415;	June 1981
FRINCIPAL INVESTIGATOR: MAJ	Martin D. N	eltz, MC		
ASSOCIATE INVESTIGATORS:	ŀ	Wentler Bally	at Reed Army	Maded
		Cente		
•	5	ERVi CC: Hesiate	Hogy-Oncolo	ny :
·		Depart	nent of Hed	Leine
KEY WORDS: Refractory GI Tum	ors; chlora	mbucil; methotr	rexate	
ACCUMULATIVE MEDGASE	ACCUMULA	TIVE CONTRACT	ACCUMUL	ATIVE SUPPLY
COST:	COST:	and the state of t	COST:	
FY-80 MEDCASE COST:		PERIODIC REVIEW	UESULTS:	ومعالية بالمنصاب المناسب في ميسمالي. ال
STUDY OBJECTIVE: To test the	therapeut:	ic efficacy of	chlorambucil	and

TECHNICAL APPROACH: Chlorambucil 5.0 mg/m² days 1-14
Methotrexate 10 mg/m² days 1,4,8,12 (p.o.)

methotrexate in patients with advanced gastrointestinal tumors.

This course is repeated every 28 days. For patients who have had prior chemotherapy or radiotherapy, 75% of the dosage is given for the first cycle.

PROGRESS DURING IY-80: Bethesda Naval Hospital has not entered any further patients. WHAME entered two patients.

BUMBER OF DUBLECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

CONCLUSIONS: No efficacy seen as far as response and survival; will enter a total of six more patients; if 16 patients are without response, will close study.

Work Unit No.:

1666

Title of Project:

WRAMC #7801, Immunological Evaluation and Phase I

Immunotherapy Trial of Patients with Various Carcinomas.

Principal Investigator:

Chief, Hamatology-Oncology Service

Associate Investigator:

After numerous requests for an annual progress report on this project, as of 22 Feb 81, there has not been a response. This progress report request was for the period 30 September 1979 to 1 October 1980. We can no longer delay compilation of the reports submitted by those investigators who complied with the regulations, so a supplementary annual progress report will be compiled when this investigator submits his report.

		. WORK UN	IT NO. 1667
DATE: 20 September 1980 P TITLE OF PROJECT: Medastable B		803	Interim X Final
STARTING DATE: PRINCIPAL INVESTIGATOR: LTC JO ASSOCIATE INVESTIGATORS: MAJ Martin D. Weltz, M.D. MC KEY WORDS: Metastatic Breast of ACCUMULATIVE MEDCASE	ENTITY OF BERNICE: SERVICE: Carcinoma ACCUMULATIVE CONT	Walter Reed Army Center Limit clugg=Oncolog Department of Eedi	
COST:	cosr:	Cost:	and the second s
FY-80 MEDCASE COST:	PERIODIC R	EVITAL RESULTS:	
will be randomized to treatment of beapt to determine if BCNU are rate when compared to adrianyou CAF regimens and who have had plent regimen consisting of BCNU in an attempt to test the syner TECHNICAL APPROACH: Regimen I - BCNU 100 mg/m² I.V. Push This cycle will be repeated every co of 5% D5W over 30 minutes or Methotrexate 30 mg/m² I.V. push	ad mitomycin-C provi in. In the second gorior exposure to me U, methotrexate and rgism of BCNU and cy infusion day 1, Cy and day 1, Methotrexatery 28 days. Regimental day 1, Vincristine	de an equivalent of roup, patients who thousante will be vincristine, with toxan. Texan 400 mg/m ² I toxan 400 mg/m ² I.V. poin II - BCNU 100 mg 1.4 mg/m ² I.V. poin I.4 mg/m ² I.V. poin II.4 mg/m ² I.V. poin III.4 mg/m ² III.V. poin III.4 mg/m ² II	or improved response of have progressed or andomized to trop and without cytoxar. V. push day 1, ush day 21. g/m ² 1.V. in 30 ush day 1,
PROGRESS DURING FY-80: Of two follow-up, four patients have pand three patients have stable			
		•	
	• .		•
	· · · · · ·		
NUMBER OF SUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT			UT:

i w a

Continue to accumulate patients as present findings are inconclusive.

PUBLICATIONS/ABSTRACTS, FY-80: None

CONCLUSIONS:

WORK	UNIT	NO.	1668
------	------	-----	------

DATE: 30 September 1980 PR	OTOCOL NO: WRAMC 780/	STATUS: Interin X
TITLE OF PROJECT: Effect of N-A	cety1-Cysteine ou	Final
Adriamycin-Induced Acute Card.		
·		
		·
STARTING DATE: November 1978	ESTIMATED COMPLE	7100 DATE: June 1981
PRINCIPAL INVESTIGATOR: MAJ Mai	tin D. Weltz, MC	
ASSOCIATE INVESTIGATORS:		r Reed Army Medical
	Cente	r
	· SERVICE: Hemato	logy-Oncology
		ment of Medicine
KEY WORDS: Adriamycin-Induced	Acute Cardiac Damage	to comits a prompagana prompagana de administrativa de de designado de designado de de de de de de de de de de El comits de prompagana de
ACCUMULATIVE MEDCASE	ACCUMULATIVE CONTRACT	ACCUMULATIVE SUPPLY
COST:	COST:	cosr:
		DIVERSIT MA
FY-80 MEDCASE COST:	PERTODIC REVIEW I	RESULTS:
		·
STUDY OBJECTIVE: To test the ef	fect of N-acetyl-cystein	e on adriamycin's acu te
cardiac toxicity. The study w	vill provide information	on the development of acute
and chronic cardiomyopathy and		
ECG-gated cineangiography will		
receiving adriamycin with or w	rithout N-acetyl-cysteine	and the rate of progression
of the cardiomyonality will be	determined in "protecte	d" versus "non-protected" patients.
	decerment in propose,	a toubin how product products
	•	•
		•
TECHNICAL APPROACH: Randomizati	tour Decimon A Owell mil	anaba fallowed in 1 hours by
Randomizati	on: Regimen A - Oral pl	acebo lollowed in 1 hour by
adriamycin 60 mg/m 1.v. every	4 Weeks. Regimen s - U	ral N-acetyl-cysteine 5.6 mg/m ²
followed in 1 hour by adriamy	in 60 mg/m" 1.V. every 4	weeks.
•		
	· .	
PROGRESS DURING FY-80: This is	a joint study with the N	ational Concor Institute
PROGRESS DURING FY-80: III'S IS	a joint study with the h	arroad Cancer institute.
Approval was recently granted	for the use of N-acety1-	cysteine, inds iar, ine MCr
has entered 9 patients, four of		
adriamycin alone. Two patient	is on the adriamycin alon	e have developed congestive
heart failure; no patients on		
		ibility requirements, however,
several patients were consider	:e d.	
-		•
·		
NUMBER OF SUBJECTS TO BE STUDIE	D REFORE COMPLETION OF S	TUDY:
SERIOUS/UNEXPECTED SIDE EFFECTS		
SERIOUS/UNEXPECTED SIDE EFFECTS	None	MO IN TROOPOLY
coververove. In 2 years, no not		stitution, will close study for
CONCLUSIONS: In 2 years, no par	onthe if no accrual	ourderent warm crosse setting hor
our participation in next 9 m	nions in no decentar.	•
• = •		
PUBLICATIONS/ABSTRACTS, FY-80:		
	.,	
	None	
		•

		WORK UNIT NO. 1669
DATE: 30 Sentember 1980 PR TITLE OF PROJECT: Chemotherapy Uninary Blade	of Careinona of the	STATES: Interin Final X
STARTING DATE: PRINCIPAL INVESTIGATOR: Jeffrey ASSOCIATE INVESTIGATORS:	FACILITY: Wal Cen SERVICE: Hema	ter Reed Army Medical
KEY WORDS:		
ACCUMULATIVE MEDCASE COST:	ACCURULATIVE CONTRACT COST:	ACCUMULATIVE SUPPLY COST:
FY-80 MEDCASE COST:	PERLODIC REVIES	W RESULTS:
operative adjuvant therapy for of the urinary bladder who have to study the usefulness of coal (DDP), mitomycine-C (MTC) and me transitional cell carcinoma of study for eventual expansion in cooperative group (CALGE) if in TECHNICAL APPROACH: Adjuvant Chinfusion, every 28 days. Advant. Cis-diamninedichloroplatinu ol days 8 and 15.	had all gross disease ination chemotherapy without exate [NTX] in parties urinary bladder. It is a large clinical tribial results are promisemotherapy - Cis-diammaded or Recurrent Disease	removed at the time of surger ith cis-diamoinedichloroplatin thents with metastatic (stage to use this protocol as a pilo ial under the auspices of a ising. Inedichloroplatinus 60 mg/m² I
PROGRESS DURING FY-80: Two pat Study has been closed to patien of disease at day 7/0. The oth lost to follow-up.	t entry for poor accru	
	•	
	•	
		OMMUNE
NUMBER OF SUBJECTS TO BE STUDIE SERIOUS/UNEXPECTED SIDE EFFECTS N	D BEYORE COMPLETION OF IN SUBJECTS PARTICIPA one	TING IN PROJECT:
CONCLUSIONS:	one.	

PUBLICATIONS/ABSTRACTS, FY-80:

None

				WORK UNIT NO. 1670	
DaiE: 30 September	r 1950 : P	CYTOCOL	NO: WRANG 7902	STATUS: Interio	••
TITLE OF PROJECT:	Clinica: 'Cri	ial of S	pecific Immunothera	Firal X	
•	as an Adjuva			,	
	3			·	
STARTING DATE: No	t started	• • • • • •	LESTINATED COMPLET	ION DATE: Not formally a	ctivated
PRINCIPAL INVESTIG		ohannes	Blom	The section of the se	o Garage
ASSOCIATE INVESTIG	ATORS:	1		Reed Army Medical	
		}	Center		•
				ogy-Oncology	
KEY WORDS: Immune	otherapy, Lun	10 Cance	r Departm	ent of Medicine	
ACCUMULATIVE MEDCA			JLATIVE CONTRACT	ACCUMULATIVE SUPPLY	
COST: None		COST:	None	COST: None	
FY-80 MEDCASE COST		J	PERIODIC REVIEW R		
ri-ou repuise cosi	None		PERIODIC REVIEW R	ESOL15:	
STUDY OBJECTIVE:					. •
	To determine	af spe	offic immunotherapy	would improve	•
post-operative su	urvival in op	erable	lung carcinoma.		
•					
•					-
TECHNICAL APPROACH	•				
		ation of	f a tumor associate	d antigen with adjuvant	
controls, surgery	Administr	ation of vant alo	f a tumor associate	d antigen with adjuvant	
	Administr	ation of vant alo	f a tumor associate one.	d antigen with adjuvant	
	Administr	ation of want alo	f a tumor associate	d antigen with adjuvant	
	Administr	ation o	f a tumor associate one.	d antigen with adjuvant	
	Administr	ation on evant alo	f a tumor associate	d antigen with adjuvant	
	Administr	ation o	f a tumor associate	d antigen with adjuvant	
controls, surgery	Administr alone, adju	ation o	f a tumor associate	d antigen with adjuvant	
	Administr alone, adju -80:	vant al	one.		
controls, surgery	Administr alone, adju -80:	to cros	one.	d antigen with adjuvant	
controls, surgery	Administr alone, adju -80: Unable	to cros	one.		
controls, surgery	Administr alone, adju -80: Unable	to cros	one.		
controls, surgery	Administr alone, adju -80: Unable	to cros	one.		
controls, surgery	Administr alone, adju -80: Unable	to cros	one.		
controls, surgery	Administr alone, adju -80: Unable	to cros	one.		
controls, surgery	Administr alone, adju -80: Unable	to cros	one.		
controls, surgery PROGRESS DURING FY	Administr alone, adju -80: Unable activa	to cros	one.	refore protocol not	
controls, surgery PROGRESS DURING FY MUSSER OF SUBJECTS	Administr alone, adju -80: Unable activa	to crosted.	ss file on IND, then	refore protocol not	
controls, surgery PROGRESS DURING FY MUSSER OF SUBJECTS	Administr alone, adju -80: Unable activa	to crosted.	one.	refore protocol not	
controls, surgery PROGRESS DURING FY MUSSER OF SUBJECTS	Administr alone, adju -80: Unable activa	to crosted.	ss file on IND, then	vefore protocol not UDY: N/A G IN PROJECT:	
PROGRESS DURING FY HUSSER OF SUBJECTS SERIOUS/UNEXPECTED CONCLUSIONS:	Administr alone, adju -80: Unable activa	to crosted.	ss file on IND, then	vefore protocol not UDY: N/A G IN PROJECT:	

PUBLICATIONS/ABSTRACTS, FY-80:

None

WORK UNIT NO. 1671 1978: 30 September 1980 [PROCESS, NO: WRANG 7903. States: interio, X TITLE OF PROJECT: Protocol for Adjuvant Antiplatelet Therapy for Sukes 8, or C Cancer of the Colon STARTING DATE: ENTITION OF THE THE TOTAL June 1984 PRINCIPAL INVESTIGATOR: LTC Jeffrey L. Berenberg, M.D. MC FACILITY: Walter teed Army Fedical ASSOCIATE INVESTIGATORS: Company SERVICE: Sense logy-Oncology Department of Medicine KEY WOEDS: Cancer, Colon ACCUMULATIVE MEDCASE ! ACCUMULATIVE SUPPLY ACCUMULATIVE CONTRACT COST: COST: COST: FY-80 MEDCASE COST: PERIODIC REVIEW RESHLTS: STUDY OBJECTIVE: The aim of this study is to seek evidence for an increase in the disease-free period (or survival) in patients with Duke's "B2" or "C" colorectal cancer who are treated for a prolonged period with a platelet inhibitory agentaspirin. TECHNICAL APPROACH: A coagulation screen, Factor VIII complex, salicylate Level and platelet function tests (aggregation and membrane analysis) will be done prior to treatment and one month post treatment. The patients will then be followed according to the protocol with subsequent coagulation studies at 4-month intervals or whenever bleeding or thrombosis appears. PROGRESS DURING FY-80: 5 Patients were entered on protocol. One death 2° myocardial infarction post-op surgery for recurrence. MEMBER OF SUBJECTS TO BE STUDIED REFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: CONCLUSIONS: Need 30 patients in each of 2 Arms. Information is being combined

with Hershey Medical School same protocol. Too early to evaluate.

274

DATE: 33 September 1950 [P TITLE OF PROJECT: Tumor Tissu	DEVENIOUS NO.	WORK UNIT NO. 1672	
TITLE OF PROJECT: Tumor Tissu	176 c t 7 c 176 c 176 c 1	STATUS: Ince he X	-
Till of the store temperature	e for Extract Preparati		
	contract to the second	Carrier of the probability of the same	
•			
	The state of the s	1	
STARTLUS DATE: 1978		rector DATE: 1981	•
PRINCIPAL INVESTIGATOR: LTC Je	ffrey L. Berenberg, MC	cer Reed Army Medicat	
ASSOCIATE INVESTIGATORS:	FACILITY: Val	ter Reed Army Hadicat	
	Gen		
	SERVICE: Heter	telogy-Oncology	•
	Depa	attent of Medicine	
KEY KORDS: Tumor tissue; extra			
ACCUMULATIVE MEDCASE	ACCUMULATIVE CONTRACT	ACCUMULATIVE SUPPLY	•
	COST:		
COST:	0031;	COST:	
FY-80 MEDCASE COST:	PERIGDIC REVIE	M RESULTS:	
STUDY OLJECTIVE:		چەنچە دارات ئەنەندەر ئۇرىيى دارانىيى ئېزىنىڭ ھېنىكىنىڭ ئېزىكىنىڭ ئېزىنىڭ ئىلىنىڭ ئېزىنىڭ ئېزىنىڭ ئېزىنىڭ يېزىن 	:
Evaluation o	f immunotherapy in care	inoma of the colon using .	
an antigen prepared from human	colon tumor vissue.		
•			
	•		
	•		
		i de la companya del companya de la companya del companya de la co	建铁铁铁
•	_	·	
TECHNICAL APPROACH: Obtain tum	or tissue remaining att	er the Department of Pathol	logy
has obtained the necessary sam	ples for dia gnost ic pu r	poses. Tissue should not !	be :
deposited in formalin, should	be kept sterile, and ri	nsed with normal saline.	
Tumor tissue should be trimmed	l of fat and other tissu	e as much as possible.	
•			
		:	
No trio	sour ebtoired to date		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
PROGRESS DURING FY-80: No tis	ssue obtained to date.		
·			
NUMBER OF CUBJECTS TO BE STUDI	LED BEFORE COMPLETION OF		
·	LED BEFORE COMPLETION OF		
NUMBER OF CURJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT	TED BEFORE COMPLETION OF S IN SUBJECTS PARTICLES	NTING IN PROJECT:	
NUMBER OF CUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval	IED BEFORE COMPLETION OF S IN SUBJECTS PARTICLE, Luation. Study will be	NTING IN PROJECT:	
NUMBER OF CUMJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT	IED BEFORE COMPLETION OF S IN SUBJECTS PARTICLE, Luation. Study will be	Closed if no tissue is	
NUMBER OF CUMJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval	IED BEFORE COMPLETION OF IS IN SUBJECTS PARTICLE, Luation. Study will be	closed if no tissue is This report is not app	
NUMBER OF CUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval	IED BEFORE COMPLETION OF IS IN SUBJECTS PARTICLE, Luation. Study will be	Closed if no tissue is	
NUMBER OF CLAJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval obtained within next 6 months.	TED BEFORE COMPLETION OF IN SUBJECTS PARTICLE. Full be Investiga	Closed if no tissue is This report is not appart to the not and the result of the resu	
NUMBER OF CUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval	TED BEFORE COMPLETION OF IN SUBJECTS PARTICLE. Full be Investiga	closed if no tissue is This report is not app	
NUMBER OF SUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval obtained within next 6 months.	TED BEFORE COMPLETION OF IN SUBJECTS PARTICLE. Full be Investiga	Closed if no tissue is This report is not appart to the not and the result of the resu	
NUMBER OF SUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval obtained within next 6 months.	TED BEFORE COMPLETION OF IN SUBJECTS PARTICLE. Full be Investiga	Closed if no tissue is This report is not appart to the not and the result of the resu	
NUMBER OF CLAJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT CONCLUSIONS: No data for eval obtained within next 6 months.	TED BEFORE COMPLETION OF IN SUBJECTS PARTICLE. Full be Investiga	Closed if no tissue is This report is not appart to the not and the result of the resu	

DATE: 30 September 1980	rio ecor s	G: TC-179			10. 1673	•
TITLE OF PROJECT: Testicular C	ancer Into	ergroup Study	. :	• •	11101	
STARTING DATE: 1979 FREGIPAL INVESTIGATOR: LTC J	effrey L.		D. IIC			-
ASSOCIATE INVESTIGATORS:		FACILITY: Wi	di rde Mod	ed Army 1	(edleat	
		SERVICE: U.S.		Oncology of Medic		•
MEY WORDS: Testicular Cancer ACCUMULATIVE MEDCASE COST:	ACCUMUL.	AT IVE CONTRAC		ACCUMULAT	LVE SUPPLY	
FY-80 MEDCASE COST:		PERIODIC REVI	EU RESU	LTS:	· · · · · · · · · · · · · · · · · · ·	•
STUDY OBJECTIVE:		<u> </u>				•
To compare durgery plus early adjuvant che		ee and overall in patients				
	•	·			•	
	•				• .	
TECHNICAL APPROACH: Stage Tr	•	nith resectabl		: .	•	••
serum tumor markers will be r crsus adjuvant chemotherapy wi al Cis-platinum.	andomized th Vinblas	to treatment tine, Actinor	arms w aycin-D	ith no ad , Cycloph	juvant chemo osphamide, I	otherapy Bleomycin
	:	•		•		
			•	• • •	•	
PROGRESS PURING FY-80: 10 Pati	ents enter	ed on study.	Two pa	atients r	andomized to	no no
djuvant therapy have developed isease at surgery.	progressi	ve disease.	Both pa	itients h	ad bulky abo	lominal
The state of the s						
					4.	
	•					•
		•	•	• .	•	
NUMBER OF SUBJECTS TO BE STUD	IFD REFORE	COMPLETION (or stress	· · · · · · · · · · · · · · · · · · ·	•	· · ·
SERIOUS/UNEXPECTED SIDE EFFEC					r:	
CONCLUSIONS: Too early.						
,						•
FUBLICATIONS/ABSTRACTS, FY-80	•					
The state of the s	=					
				•		

WORK UNIT NO.1674 30 September 1980 | PROTOCOL NO: WRAMC 780/A Interim TITLE OF PROJECT: Effect of Indocyanine Green Final Clearance on Plasma Levels of Adriamycin ESTIMATED COMPLETION DATE: June 1981 STARTING DATE: 1978 PRINCIPAL INVESTIGATOR: MAJ Martin D. Weltz, M.D. MC ASSOCIATE INVESTIGATORS: FACILITY: Walter Reed Army Medical Center SERVICE: Hematology-Oncology Department of Medicine Adriamycin KEY WORDS: ACCUMULATIVE SUPPLY ACCUMULATIVE MEDCASE ACCUMULATIVE CONTRACT COST: COST: COST: FY-80 MEDCASE COST: PERIODIC REVIEW RESULTS: STUDY OBJECTIVE: To correlate indocyanine green (TCG) clearances in each patient with plasma levels of adriamycin. TECHNICAL APPROACH: Indocyanine green clearance is to be obtained prior to the first administration of adriamycin. If there is a change in adriamycin dosage and/or a 50% increase or decrease in LFT's it is to be repeated once again prior to a dose of adriamycin. A total of 50 indocyanine analyses should allow for all permutations of liver dysfunction, dosages of adriamycin, and clinical toxicity. It is expected that the study will be completed 12 months from the time of entry of the first patient. PROGRESS DURING FY-80: Patients only with liver disease who received adria are being studied - Accrual is slow 2° highly selected patients are needed. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: 100 SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: CONCLUSIONS: Require 6 more patients on adria alone to evaluate peak adria level with disease of liver - and toxicity. PUBLICATIONS/ABSTRACTS, FY-80:

1908. UNIT 10.1675

DATE:	30 Se	ptembe	r 1980	PRO	DIOCOL	NO: WI	RAMO) q 03
TITLE	OF FRO	JECT:	Pepatic	Artery	/ Adria	mycin	Infu	si.on
A Cli	inical	ar.! Ph	a macoki	nefic	Study	"		-

	·	
์ รางกับระ	Interin	
	linul	

ACCUMULATIVE NEDCASE	ACCUMULATIVE CONTRACT	ACCUMULATIVE SUPPLY
KEY WORDS: Hepatic Artery Ac	Depa	actment of Medicine
		ter vology-Oncology
ASSOCIATE INVESTIGATORS:	· • • •	lter Reed Army Medical
	Martin D. Weltz, M.C. NO	
STARTING DATE: 1979	ESTIMATED COM	"HETION DATE: June 1982

STUDY OBJECTIVE: To evaluate the efficacy of hepatic artery infusion of adriamycin in patients with metastatic liver disease. To evaluate the pharmacokinetics of adriamycin and its metabolites in patients with impaired liver function. To correlate the dose response with clinical toxicity. To evaluate radionuclide scan, angiogram, and liver-spleen scan as parameters of liver dysfunction in a comparative faction.

TECHNICAL APPROACH: special diagnostics will place hepatic antery catheter via axillary artery and hepatic vein catheter via femoral vein. Complete angiogram will be obtained at that time. Immediately thereafter the patient is sent to Nuclear Medicine for 99MTC-sulfur colloid infusion (rate: 1 ml/minute dose, 4 millicurles) into the hepatic artery to evaluate initial catheter placement and hepatic blood flow distribution. This information will help assess subsequent patterns of hepatic distribution of adriamycin. The patient, upon arriving on the ward, will next have assessment of hepatic function by indocyanine green clearance.

PROGRESS DURING FY-80: Two patients entered to date.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY:
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPALING IN PROJECT:

CONCLUSIONS:

Too early; need 12 evaluable patients to determine therapeutic efficiency.

		WORK UNIT NO. 1677
DATE: 39 September 1980 (PROTOCOL) TITLE OF PROJECT: Therapy of Acute L Dose Adriamycin Infusion	NO: WRAMC 7905 eukemia with lov	CTAPES: Interin X Final
STARTING DATE: 25 September 1979 PRINCIPAL INVESTIGATOR: H. Grant Tay ASSOCIATE INVESTIGATORS: Martin Weltz, N.D.	lor, M.D. FACILITY: Welter I Center	
	1	gy-Oncology nt of Madicine
KEY WORDS: ACCUMULATIVE MEDICASE ACCUMU COST: N/A COST:	JLATIVE CONTRACT N/A	ACCUMULATIVE SUPPLY COST: N/A
FY-80 MEDCASE COST: N/A	PERIODIC REVIEW RES	SULTS:
STUDY OBJECTIVE:		
 To determine if kinetic alteration chance it's efficacy in advanced leutherapy. Also to determine toxicity. 		
TECHNICAL APPROACH:		
TRN dose infusions of Adriamycin 10 if tolerated. With measurement of Adriamycin 10 if tolerated. With measurement of Adriamycin 10 if tolerated.		
	• •	·
·		•••
PROGRESS DURING FY-80: Four patients of the counts were lowered in all patients, all patients developed nucotoxicity being determined.	by day 10 of study.	a complete remission. Drug levels and
		•
NUMBER OF SUBJECTS TO BE STUDIED BEFORE SERIOUS/UNEXPECTED SIDE EFFECTS IN SUI Severe mucositis	RE COMPLETION OF STUI BUECTS PARTICIPATING	DY: 3-6 IN PROJECT:
CONCLESIONS: Too early. Plan to accur Depending upon toxicity a		
PUBLICATIONS/ABSTRACTS, FY-80:		

ROBL DRIT NO. 1678

					_ ~ ~		
DATE:	30 September	r 1980	PROTOCOL	NO: URAMC	7914	TTATUS: Into	rin X
	AN DEATHOR.	Metastalic			L.	Fine	

STARTING DATE: 25 September 19 PRINCIPAL INVESTIGATOR: MAJ Ma		ESTIMATED COMP	ETION DATE	January 1981
ASSOCIATE INVESTIGATORS:		FACILITY: Walt		my Medical
No.	- 1 C		cology-Onco	
KEY WORDS: Metastatic Colo-Re ACCUMULATIVE MEDCASE COST:		LATIVE CONTRACT	ACCUI- COST:	MULATIVE SUPPLY
FY-80 MEDCASE COST:		PERIODIC REVLES	KESULTS:	*

STUDY OBJECTIVE: To investigate the therapeutic efficacy of MOF-streptozotocin in advanced measurable colo-rectal carcinoma.

beginning on day 1. Repeat every 35 days. Methyl CCNU 30 mg/m² p.o. daily for 5 consecutive days beginning on day 2. Repeat every 72 days. Vincristine 1 mg T.V. push day 1. Repeat every 35 days. Streptozotocin 500 mg/m² T.V. weekly beginning on day 1. Two complete courses should be given to fully evaluate efficacy of regimen. If there is progression of measurable disease after 2 courses (see 11.4) or anytime thereafter the patient is removed from protocol and followed for survival information.

PROGRESS DURING FY-80: Excellent accrual; most patients followed at WRAMC with complete records.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: 36
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

CONCLUSIONS: Will need additional 10 patients because of NE & LFU patients to be able to evaulate 20% fully treated patients.

•		WORK UNIT NO. 1679	
DATE: 30 September 1980 PR TITLE OF TROJECT: Use of Methyl of melanoma, Colon and Gastric	COMU in the Treatment	STATUS: Interim Final	
STARTING DATE: October 1979 PRINCIPAL INVESTIGATOR: LTC J ASSOCIATE INVESTIGATORS:	effery L. Berenberg, MC	ETION DAGE: en Read Army Medical	
	Cent		
wall troung		ology-Oncology tment of Medicine	
KEY WORDS: ACCUMULATIVE MEDCASE	ACCUMULATIVE CONTRACT	ACCUMULATIVE SUPPLY	· ·
COST:	COST:	COST:	
FY-80 MEDCASE COST:	PERIODIC REVIES	V RESULTS:	
STUDY OBJECTIVE: The nitrosour			
synthesized anticancer agents.			
possess some biologic properties and are known to cross the bloom			
agents in a number of animal to			
heen ongoing since 1971. Methy	yl CCNU has shown activ	ity as a single agent in	the
treatment of melanoma. Minima			
Methyl CCNU as a single agent, the efficacy is increased.	but in combination wit	n 5-FU some trials repor	ted
TECUNICAL APPROACH.			
Methyl CCNU (Semustine): 200-	225 mg/m ² PO every 6-8	weeks.	
	•		
		•	
	•		
		÷ Î	
PROGRESS DURING FY-80: Two pat:	ients entered - one die	d on day 25 due to sepsi	s from a
perforated colonic cancer. The			
evaluate for response. This is with toxicity data for Class "	s a cooperative effort		
•			
	•	•	
·			
NUMBER OF SUBJECTS TO BE STUDIE SERIOUS/UNEXPECTED SIDE EFFECTS		make manager and the company and the same and an arranger and the same	
Diagonal Communication of the International	None	THO ME THOUSE	
CONCLUSIONS:	None		
	Notice		
		·	
PUBLICATIONS/ABSTRACTS, FY-80:			
	None		
	NOIN		

Work Unit 1689 Work Differed No. Market / 208 String String String	· · · · · · · · · · · · · · · · · · ·	Work His	:+ #100A		·
THE CO PASHET: See of Streptozotocia in the treatment First cardinoid STAX: IND DATE: Oct /2 ESTINATE CONSTITUTE DATE: PRINCIPAL INVESTIGATOR: LTC Josepy L. Berenberg, MC SENSICIATE INVESTIGATORS: FAILUTY Latter Rued Army Medical Center SENVICE: Hematolopy-Cacology Bepartment of Medicine EXEVICE: Hematology-Cacology Bepartment of Medicine EXEVICE: MEANT SENVICE: MEANT SERVICE:	The second secon		And with the contract of the c	1 STATES: Ceterin v	
OF Matastatic islet Cell Carcinose of the Pancress and Matastatic Cartinoid STAR 1.03 BNTE: Oct 72 PRINCIPAL INVESTIGATOR: LTC Joseph L. Berenberg, MC PROCLATE INVESTIGATOR: LTC Joseph L. Berenberg, MC PROCLATE INVESTIGATORS: PAULITY Watter Read Arey Medical Center SERVICE: Hematology-Oncology Department of Medicine KEY MORDS: ACCUMBLATIVE COUNTAGET COST: COST: PERIODIC REVIEW RESULTS: STUDY OBJECTIVE: Streptozotocinings shown a great degree of effectiveness in metastatic false cell carcinose of the pancreas and metastatic carcinoid, Clinical responses Enve Dean reported in patients with Cealingant islet cell immorg, Streptozotoch yields an overall response rate of approximately JOK. Even if an objective response does no occar, reading the of approximately JOK. Even if an objective response does no occar, reading the of approximately JOK. Even if an objective response does no occar, reading the of approximately JOK. Even if an objective response does no occar, reading the of approximately JOK. Even if an objective response does no occar, reading to the object of injudy to fact the object of the		• • • • • • • •	••		
ESTINATED EAST. DATE: Det 79 PRINCIPAL INVESTIGATORS: LTC Joffery L. Beromberg, MC SECTIANE INVESTIGATORS: LTC Joffery L. Beromberg, MC SECTIANE INVESTIGATORS: PAGE 18 PACHLITY Later Reed Army Medical Center SERVICE: Hematology-Oncology Department of Medicine REY MORDS: ACCUMULATIVE CO.TRACT COST: COST:				· · · · · · · · · · · · · · · · · · ·	
PRINCIPAL INVESTIGATORS: PACHATY Walter Reed Army Medical		11011. (1 17).			
PRINCIPAL INVESTIGATORS: PACHATY Walter Reed Army Medical	New York Name of the		L portagren complete	(A. DAGE	
ASSOCIATE INVESTIGATORS: FACILITY Watter Read Arey Medical Center		effery L.		VA DATE.	
SERVICE: Hematology-Oncology Department of Medicine REY NORDS: ACCUMULATIVE PROCASE COST: COST: PERIODIC REVIEW RESULTS: FY-BO MEDICASE COST: PERIODIC REVIEW RESULTS: STUDY OBJECTIVE: Streetocotocin has shown a great degree of effectiveness in metastatic islet cell carcinoma of the pancreas and metastatic carcinoma, Climical responses figure. Deem reported in patients withinal ignam islet cell tumors, Streptozotocin yields an overall response rate of approximately JON. Form if an objective response does not occur, malignation of regulate formation of regulate formed in this drug have not yet Been performed in other tumor types. TECHNICAL APPROACH: Streptozotocin is available for intravenous administration only. Both a five-day intensive course regimen and a weekly regimen have linearly by caployed using this drug, with current favor given to a schabule of 500 mg/m by caployed using this drug, with current favor given to a schabule of 500 mg/m by caployed using this drug, with current favor given to a schabule of 500 mg/m by caployed using this drug. These patients entered on study a all patients had climical At weeks. PROGRESS DURING FY-80: These patients entered on study all patients had climical At post mortem, one patient was found to have metastatic metanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NORCE ON SUBJECTS TO BE STUDIED BETORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: NORCE CONCLUSIONS:		inggany, gay.	FACILITY Walter	Reed Army Medical	
Department of Medicine ACCUMULATIVE MEDICASE ACCUMULATIVE COST: ACCUMULATIVE MEDICASE COST: PERIODIC REVIEW RESULTS: STUDY OBJECTIVE: Streptozotochu.hgs shown a great degree of effectiveness functional responses flave. Even reported in patients withingular islet cell tamous, Clinical responses flave. Even reported in patients withingular islet cell tamous, Streptozotochu ytelds an overall response. rate of approximately JON. Even if an objective response does not occur, madiciation of repaired for lateral producing tamors (insultanna and carefuned), may occur. Adequate clinical relate with this drug have not yet fleen performed in other tumor types. ECCHICAL APPROACH: Strptozotocin is available for intravenous administration only. Both a five-day intensive course regimen and a weekly regimen, have licen widely employed using this drug, with current favor given to a schedule of 500 mg/m² by holus daily x 5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROGRESS DURING FY-80: Those patients entered on study all patients had clinical diagnosis of carchold tumors. There were no responses and all patients had clinical At post mortem, one patient was found to have metastatic melanoma dusteed of carcimoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NOTE OF SUBJECTS TO BE STUDIED BETORE COMPLETION OF STUDY: NOTE OF SUBJECTS TO BE STUDIED BETORE COMPLETION OF STUDY: NOTE OF SUBJECTS TO BE STUDIED BETORE COMPLETION OF STUDY:					
REY MORDS: ACCUMBLATIVE MEDICASE ACCUMBLATIVE CONTRACT ACCUMBLATIVE SUPPLY COST: FY-80 MEDICASE COST: PERIODIC REVIEW RESULTS: STUDY OBJECTIVE: Streptozotocin.hgs shown a great degree of effectiveness in metastatic islet cell carcinosa of the pancreas and metastatic carcinoid, clinical responses have. Been reported in patients with cell immora, streptozotoch yields an overall response rate of approximately-JOX. Even if an objective response does ren occar, realization of hypothese does destroit of approximately-JOX. Even to state the constant of the pancreas and metastatic fater producing tumors (insultama and carcinoid, may occar. Adequate clinical relate with this drug have not yet Been performed in other tumor types. TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. Both a five-day intensive course regimen and a weekly regimen have line widely comployed using this drug, with current favor given to achieve for one widely comployed using this drug, with current favor given to achieve lost of one may be colour applications of carcinoid tumors. There were no responses and all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients had clinical At post mortem, one patient was found to have metastatic melacuma distead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. EUMSER OF SUBJECTS TO BE STUDIED BETORE COMPULTION OF STUDY: None. CONCLUSIONS:					
ACCUMINATIVE MEDICASE COST: ACCUMINATIVE CONTRACT ACCUMINATIVE SUPPLY COST: FY-BO MEDICASE COST: PERIODIC REVIEW RESULTS: STUDY OBJECTIVE: Streptomotoch.has shown a great degree of effectiveness in netastatic islet cell carchoma of the pancreas and metastatic carchomid, clinical responses have. Near reported in patients withing ignam islet cell tumors, streptomotoch. Welds an overall response rate of approximately JOX. Even if an objective response does not occur, smalleration of compliant Comploment Producing tumors (insultament and carchomot) hasy occur. Adequate clinical replace if this with this drug have not yet Been performed in other tumor types. TECHNICAL APPROACH: Streptomotoch is available for intravenous administration only.		····	Departme	nt of Medicine	
COST: COST: COST: COST: FY-BO MEDCASE COST: PERIODIC REVIEW RESULTS: STUDY OBJECTIVE: Streptozotochalas shown a great degree of effectiveness in metastatic islet cell carcinosa of the pancreas and metastatic carcinosa, clinical responses have been reported in patients withingligroun islet cell immors, streptozotocha yields an overall response rate of approximately-JOK. Even if an objective response according theoretical description of the pancreas and metastatic cell immors, insultment and carcinosal may occur. Adequate clinical trials with this drug have not yet been performed in other tumor types. TECENICAL APPROACH: Streptozotocin is available for intravenous administration only. both a five-day intensive course regimen and a weekly regimen have linear widely cuployed using this drug, with current favor given to a schedule of 500 mg/m by holus daily x-5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROCRESS DURING FY-80: These patients entered on study wall patients have clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma fusted of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. ENERGY OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: COCCURSIONS:) ACCUM	TOAGT'O GUTGA	ACCUMULATIVE SUPPLY	
STUDY OBJECTIVE: Streptomotocin.has shown a great degree of effectiveness in metastatic islet cell carcinoma of the pancreas and metastatic carcinoid. Clinical responses have. Hean reported in patients will impligative islet cell tumors, Streptomotocin yields an overall response rate of approximately JOK. Even if an objective response does not occur, madicative of approximately JOK. Even if an objective response and carcinoid inay occur. Adequate clinical trials with this drug have not yet been performed in other tumor types. TECHNICAL APPROACH: Strptomotocin is available for intravenous administration only. both a five-day intensive course regimen and a weekly regimen have here widely caployed using this drug, with current favor fiven to a schedule of 500 mg/m by holus daily x.5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x.4 weeks. PROGRESS DURING FY-80: Those patients entered on study a all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma distead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **EVENCE OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: **EXECUTION OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: **EXECUTION OF SUBJECTS TO PROJECT: **CONSTRUCTION OF STUDY: **CONSTRUCTION OF STUDY: **EXECUTION OF STUDY: **CONSTRUCTION OF STUDY: **EXECUTION OF STUDY: **EXECUTION OF STUDY: **EXECUTION OF STUDY: **CONSTRUCTION OF STUDY: **EXECUTION OF STUDY: **EXECUTION OF STUDY: **CONSTRUCTION OF STUDY: **EXECUTION OF STUD		•	JERTIVE CONTRACT		
STUDY OBJECTIVE: Streptomotocin.has shown a great degree of effectiveness in metastatic falet cell carcinoma of the pancreas and metastatic carcinoid. Clinical responses have. Hean reported in patients williamligrams islet cell tumors, streptomotocin yields an overall response rate of approximately JOK. Even if an objective response does not occur, amaliaration of type has formionately producing tumors (insultuma and carcinoid] may occur. Adequate clinical relate with this drug have not yet been performed in other tumor types. TECHNICAL APPROACH: Strptomotocin is available for intravenous administration only. both a five-day intensive course regimen and a weekly regimen, have linen widely caployed using this drug, with current favor fiven to a schedule of 500 mg/m² ly holus daily x.5 eyery 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROGRESS DURING FY-80: Those patients entered on study a all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma distead of carcinoid. This is part of a cooperative effort with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. EVENDER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY. SEREOUS/UNEXPECTED SIDE FFECTS IN SUBJECTS PARTICIPATING IN PROJECT: COMMUNICATIONS:	FY-80 MEDCASE COST:		PERIODIC REVIEW RE	SULTS:	
metastatic islet cell carcinoma of the pancreas and metastatic carcinoid, Clinical responses have been reported in patients will malignant islet cell tumors, streptozotocin yields an overall response rate of approximately 70%. Even if an objective response does not occur, madination of approximately 70%. Even if an objective response does not occur, madination of approximation for this drug tumors (insulinema and carcinoid) may occur. Adequate clinical trials with this drug have not yet been performed in other tumor types. TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. Noth a five-day intensive course regimen and a weekly regimen have been widely caployed using this drug, with current favor given to a schedule of 500 mg/m²/weekly schedule has usually been 1 gm/m²/weekly a weeks. PROGRESS DURING FY-80: These patients entered on study all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic medicama instead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **RUPDER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: **SURTOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: **CONCLUSIONS:**					
metastatic islet cell carcinoma of the pancreas and metastatic carcinoid, Clinical responses have been reported in patients will malignant islet cell tumors, streptozotocin yields an overall response rate of approximately 70%. Even if an objective response does not occur, madination of approximately 70%. Even if an objective response does not occur, madination of approximation for this drug tumors (insulinema and carcinoid) may occur. Adequate clinical trials with this drug have not yet been performed in other tumor types. TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. Noth a five-day intensive course regimen and a weekly regimen have been widely caployed using this drug, with current favor given to a schedule of 500 mg/m²/weekly schedule has usually been 1 gm/m²/weekly a weeks. PROGRESS DURING FY-80: These patients entered on study all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic medicama instead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **RUPDER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: **SURTOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: **CONCLUSIONS:**	STUDY OBJECTIVE: Streptomotoci	in.has s	hown a great degree	of effectiveness in	
Streptozotocin yields an overall response rate of approximately JOK. Even if an objective response does not seem, medicarbles of bypines from boronel producing twoors (insulthome and carchofd) may occur. Measure clinical trials with this drug have not yet been performed in other tumor types. TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. Both a five-day intensive course regimen and a weekly regimen have linen wheely coployed using this drug, with current favor given to a schiedule of 500 mg/m²/week, who weeks. The weekly schedule has usually been 1 gm/m²/week at weeks. PROGRESS DURING FY-80: These patients entered on study all patients had clinical diagnosis of carchold tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **EMPORT OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: **CONCLUSIONS:**	netastatic islet cell carcinoma	of the	pancreas and metas	tatic carcinoid,	•
projective response does not occur, residentian of experious for dotteral producing tumors (insulthone and carchoold may occur. Adequate clinical trials with this drug have not yet Been performed in other tumor types. TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. Both a five-day intensive course regimen and a weekly regimen have licen widely employed using this drug, with current favor given to a schedule of 500 mg/m²/week and bally x-5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROGRESS DURING FY-80: These patients entered on study a all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **EXPLORATION OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: **SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: **None.**	Clinical responses have been re	eported	in patients withing	lignant islet cell tumors.	
tumors (insulinema and carcinoid) may occur. Adequate clinical trials with this drug have not yet been performed in other tumor types. TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. both a five-day intensive course regimen and a weekly regimen, have been widely caployed using this drug, with current favor given to a schedule of 500 mg/m² IV bolus daily x.5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROGRESS DURING FY-80: These patients entered on study and all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **ENTIOUS/UNEXPECTED SIDE FFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: **Rone.** **CONCRUSIONS:**	Streptozotocim yields am overal	U respo	mse rate of approxi	estely John Even if an	
TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. Both a five-day intensive course regimen and a weekly regimen have linen widely caployed using this drug, with current favor given to a schedule of 500 mg/m² ly bolus daily x-5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROGRESS BURING FY-80: These patients entered on study and 1 patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma dustead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPULTION OF STUDY: SERIOUS/UNEXPECTED SIDE FFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: Kone.	onjective response does not our	nang angs	iljozatioa of tympio	an America control producting	
TECHNICAL APPROACH: Strptozotocin is available for intravenous administration only. Both a five-day intensive course regimen and a weekly regimen have linen widely caployed using this drug, with current favor given to a schidule of 500 mg/m TV holus daily x-5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week, x 4 weeks. PROGRESS DURING FY-80: These patients entered on study wall patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. RUMDER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.	tumors (insulinoma and carcinol	Ed Jamay	occur. Adequate ca	miter trists with rule	
Both a five-day intensive course regimen and a weekly regimen have linen widely caployed using this drug, with current favor given to a schedule of 500 mg/m²/ly bolus daily x-5 eyery 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROGRESS DURING FY-80: These patients eatered on study all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma dustead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. RUMDER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.	drug have not yet been personne	ed in ot	ner tumor types.		
Both a five-day intensive course regimen and a weekly regimen have linen widely caployed using this drug, with current favor given to a schedule of 500 mg/m²/ly bolus daily x-5 eyery 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROGRESS DURING FY-80: These patients eatered on study all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma dustead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. RUMDER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.					
both a five-day intensive course regimen and a weekly regimen have licen widely employed using this drug, with current favor given to a schedule of 500 mg/m² ly holus daily x-5 every 4-6 weeks. The weekly schedule has usually been 1 gm/m²/week x 4 weeks. PROCRESS DURING FY-80: These patients entered on study all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: NONE.		ocin is	available for intra	venous administration only.	
PROGRESS DURING FY-80: These patients entered on study all patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma fusted of carcinoid. This is part of a cooperative effect with NCR to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.	Both a five day intensive cours	e regû	en, and a weekly reg	iven have liven widely	•
PROGRESS DURING FY-80: These patients entered on study and patients had clinical diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.	bolus daily x 5 every 4-6 week	s. The	weekly schedule has	usually been 1 gm/m²/week.	•
diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.			,		
diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.			, ·		:
diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.	•				•
diagnosis of carcinoid tumors. There were no responses and all patients have expired. At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.					٠
At post mortem, one patient was found to have metastatic melanoma instead of carcinoid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.	PROGRESS DURING FY-80: Those I	patients	entered on study s	all patients had clinical	•
At post mortem, one patient was found to have metastatic melanoma distead of carcinold. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None.	diagnosis of carcinoid tumors.	There	were no responses a	na all patients have expired.	
noid. This is part of a cooperative effect with NCE to study response with toxicity of class "C" drugs. This report has not been approved. Investigator has not answered reviewer's comments. **RUNDER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None. **CONCLUSIONS:	At post mortem, one patient was	found a	to have metastatic -	melanoma instead of carci-	
This report has not been approved. Investigator has not answered reviewer's comments. **RUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None. CONCLUSIONS:	noid. This is part of a cooper	rative ϵ	affect with NCE to s	tudy response with toxicity	٠.
Investigator has not answered reviewer's comments. RUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None. CONCLUSIONS:	of class "C" drugs.				
Investigator has not answered reviewer's comments. RUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None. CONCLUSIONS:				••	
Investigator has not answered reviewer's comments. RUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None. CONCLUSIONS:			This rep	ort has not been approved.	
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None. CONCLUSIONS:					ıls.
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None. CONCLUSIONS:	SIDE TO OF CUDITIONS DO BE CHURC	ED REFO	OF COMPLETION OF ST	my ·	•
CONCLUSIONS:	SERTOUS / UNEXPECTED SIDE EFFECT	S IN SUF	SJECTS PARTICIPATING	IN PROJECT:	
	None.			•	
None	CONCLUSIONS:		anteriorina de la companya de la co		
	None				

None.

			MORK UNIT NO. 1681	
DATE: 30 September 1980 PR TITLE OF PROJECT: Use of Douno ALL, AML, and Other Leubersin:	mydin in the	Treatment of	STATUS: Leterim X Final	
STARTING DATE: October 1979 PRINCIPAL INVESTIGATOR: LTC JOASSOCIATE INVESTIGATORS:	Sfory I Bor	MATED COMPLETE enberg, MC LITY: Walter Center	0.4 DATE: Reed Army Hedical	-
	SERV	TCE: Hematolo Departme	gy-Oncology at of Madicine	
KEY WORDS: ACCUMULATIVE MEDCASE COST:	ACCUMULATIV	E CONTRACT	ACCUMULATIVE SUPPLY COST:	→
FY-80 MEDCASE COST:	PERI	ODIC REVIEW RE	SULTS:	
STUDY OBJECTIVE: Daunomycin i purposes they include daunomub and NSC 82151.	s known by s icine, rubid	everal other n onvein, nubony	ames. For information cin C, Cerutidine ^R	
TECHNICAL APPROACH: The current used as a single agent is 60 m repeated at intervals of three marrow and peripheral counts.	g/m²/day IV	ior three days	 The course is usual 	.1y
PROGRESS DURING FY-80: Two pat relapsed on day 111 and subsect therapy. This is a cooperative toxicity data on Class "C" dru	e effort wit	The other pa	tient died on day 31 d	of
NUMBER OF SUBJECTS TO BE STUDIO SERIOUS/UNEXPECTED SIDE EFFECT	ED BEFORE CON S IN SUBJECTS None	PLETION OF ST	UDY: G IN PROJECT:	
CONCLUSIONS:		,		
·	foo early for	conclusions.		
PUBLICATIONS/ABSTRACTS, FY-80:	None			

WORK UNIT NO. 1682

DATE: 30 September 1980 Profession of S-Azac	ro rocol.	NO: WRAMC 7910		STATUS:	Interim X	
of Acute Granulocytic Leukenia	услатие ибА ст	in the freatmen Its and Children	1.		l'inal	 -
,	211 1144	2,00 441 010 110 01				
STARTING DATE: October 1979	CTATE	ESTIMATED COMP		N DATE:	· · · · · · · · · · · · · · · · · · ·	
PRINCIPAL INVESTIGATOR: LT ASSOCIATE INVESTIGATORS:	C Jener	y L. Berenberg,			(c. 15 1	
V220CIVIE TALESTICATORS:	i,	FACILITY: Val.		cea Army	egren1	
•				y-Oncolog		
	:			t of Medi		
KEY WORDS:	·					
ACCUMULATIVE MEDCASE		JLATIVE CONTRACT		6	LIVE SUPPL	Y
COST:	COST:		-	COST:		
TY-80 MEDCASE COST:	-	PERIODIC REVIE	W RES	ULTS:		
STUDY OBJECTIVE: At this point	er er er					
effectiveness for the induction	na de roi	e, 5-azzeytidine	eemen	aemonstra loovusa	ted clinic	al •
adults and children previously	refract	corv to other ac	tive	antileuke	njo ganas Renkemia O	Ι
Response rates in bolid temors	and otl	er types of lea	dien.io	have not	Been sama	t.
enough to wantant the use of 5	-azacyti	idine.			.5	
				• •	,	
			•			
•		•	• • •			
TECHNICAL APPROACH: 150.200 mg/	/m ² /day	intravenously f	or fi	ve davs a	e a ranid	
injection. This drug course carecovery from myelosuppression	in be re	peated every 14	-21 d	ays. deper	nding upon	
			······································			
						٠.
		•			•	
•			•	• .		•
PROGRESS DURING FY-80: Two patient responses, however both patient is a cooperative effort with MC	s had f	ailed standard	thera	by for lea	ikemial T	f, i c
"C" drugs.						
			• .	•	••	٠.
				•		
		,				
NUMBER OF SUBJECTS TO BE STUDIE SERIOUS/UNEXPECTED SIDE EFFECTS					r: ,	
None.		an indicated the second of the second				:
Too early.						
•						
				•		
PUBLICATIONS/ABSTRACTS, FY-80:						
T ione:						

•		WORK UNIT NO. 1683
DATE: 30 September 1989 P TITLE 0 PROJECT: Use of L-As; Treatment of Acute Lymphoblast		STATUS: Interim X Final Pictures.
STARTING DATE: October 1979 PRINCIPAL INVESTIGATOR:	ESTIMATED (67) LTC Jeffery L. Berenber	FIJON DATE:
ASSOCIATE INVESTIGATORS:	FACULITY: Walt	er Reed Army Medical
	SERVICE: Herait Depar	ology-Oncology tacht of Medicine
KEY WORDS: ACCUMULATIVE MEDCASE COST:	ACCUMULATIVE CONTRACT COST:	ACCUMULATIVE SUPPLY COST:
FY-SO HEDCASE COST:	PERIODIC REVIEW	RESULTS:
STUDY OBJECTIVE:		entigenically noncross-reactive
animal tumor systems and in hu is qualitatively and quantitat alternative to E. Coli asparag	man ALL. Compared with cively the same. Thereio ginase in those situation	
TECHNICAL APPROACH: Intravenou Intramuscularly 6,000 IU/m ² t.	isly 1,000 IU/Kg 30,000 I i.w. x 3 weeks (9 doses)	N/m ² per day x 10-20 days.
	•	
PROGRESS DURING FY-80: No pa	itients entered.	
	This repair	t has not been approved.
	Investigator has not answer	
NUMBER OF SUBJECTS TO BE STUDY	ED BEFORE COMPLETION OF	STUDY:
SERIOUS/UNEXPECTED SIDE EFFECT	S IN SUBJECTS PARTICIPAT None	ING IN PROJECT:
CONCLUSIONS:	promise and the control of the contr	amender fine fine fine fine of the contract of
	None	
PUBLICATIONS/ABSTRACTS, FY-80:		
- communication processing at the		

WORK UNIT NO. 1684

DATE: 30 September 1980 PROTOGOL NO: MRAME 7612 | STATUS: Interim > TITLE OF PROJECT: Use of Hexamehtylmelamine in the Treatment of Ovarian Cancer. ESTIMATED COMPLETION DATE: STARTING DATE: October 1979 PRINCIPAL INVESTIGATOR: LTC Jeffery L. Berenberg, MC FACILITY: Walter Reed Army Medical ASSOCIATE INVESTIGATORS: Center SERVICE: Hematology-Oncology Department of Medicine KEY WORDS: ACCUMULATIVE CONTRACT ACCUMULATIVE SUPPLY ACCUMULATIVE MEDCASE COST: COST: COST: PERIODIC REVIEW RESULTS: FY-SO MEDCASE COST: STUDY OBJECTIVE: Cancer of the ovary is the tumor in which HAM has been shown to have definite antitumor activity. Its uses may be indicated in patients who have become refractory to therapy with alkylating agents, or in patients where therapy with alkylating agents is contraindicated (e.g. compromised bone merrow function due to prior radioth rapy,. TECHNICAL APPROACH: The currently recommended dosage of hexamethylemelamine when used as a single agent is 8 mg/kg/day (300 mg/m²) X 90 or indefinitely if tolerated. The total dose is usually divided into four equal parts and given after meals and at bedtime. An intermitteent regimen; i.e., 21 days (8 mg/kg/day), on and 21 days off drug, may be better tolerated and required if gastrointestinal or neurotoxicity becomes prohibitive. A reduction of the dose to 6 mg/kg/day may also be necessary. Therapy shold be stopped in the presence of severe leukopenia (less than 2,000/mm3) or severe thrombocytopenia (less than 75,000/mm3), until marrow function has recovered. PROGRESS DURING FY-80: No patients entered as of 1 July 80 - This is a cooperative . effort with the NCI to gather response with toxicity data from Class "C" drugs, NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: CONCLUSIONS: Too early PUBLICATIONS/ABSTRACTS, FY-80: Hone

WOPY UNIT NO. 1685

DATE: 30 September 1980 PI TITLE OF PROJECT: Use of VP-16 Small Cell Carcinoma of the In	in the	NO: WRAMC 79	113. of		terim X tal
STARTING DATE: October 1979 PRINCIPAL INVESTIGATORS: L ASSOCIATE INVESTIGATORS:		FACTURY:	berg, MC Walter I Contai Hematolog	teed Army Med y-Oncology t of Medicin	ical
KEY WORDS:					
ACCUMULATIVE MEDCASE COST:	ACCUME COST:	JLATIVE CONT	RACT	ACCUMULATIVE COST:	
FY-80 MEDCASE COST:		PERIODIC R	EVIEW RES	SULTS:	
patients with a frequency rang carcinoma of the lung. Although the limited to patients refract mental data suggest that the repatients may be considerably in TECHNICAL APPROACH: VP 16-213 period. Two dose schedules had 2-3 weeks or 125 mg/m²/day 1,3 sequent courses is modified, detoxic manifestations.	gh the cory to be sponse igher. should be been, 5, ever	standerd the rate rode be administed used successry 4-5 weeks	ommendath derapy" for deced in pro- ered intra ssfully: s. The ex	on is that it or this disea di	n use should no, expeni- meated wa a 30-minute x 5 every between sub-
toxic manifestations.					
PROGRESS DURING FY-80: Two pa VP-16 - one pediatric patient tumors are alive inthout evide not evaluable at this time (cn effort with the NCI to gather	with red nce of d tered J	current Sard disease. Th une 80) - Th	coma. Bo ne patien nis study	t with recurr is part of a	dth Testicular ent Sarcoma is cooperative
NUMBER OF SUBJECTS TO BE STUDI SERIOUS/UNEXPECTED SIDE EFFECT NO	ED BEFO	RE COMPLETION BUECTS PART	ON OF STU ICIPATING	DY: -	
CONCLUSIONS;		·			
PUBLICATIONS/ABSTRACTS, FY-80:					
No	ne	· · · · · · · · · · · · · · · · · · ·			- Committee of the last on the last supporting

STARTING DATE: PRINCIPAL INVESTIGATOR: Rame	ona Chanmar	ESTIMATED	<u> Completi</u>	ION DATE:		
ASSOCIATE INVESTIGATORS: T. Klein		FACILITY	: Walter Center	Reed Army	Medical	r ing grap graphens
R. Vigersky J. Berenberg		SERVICE:		ogy-Oncolo ent of Med		
HER WORDS:	LACCING	LATIVE CO	CCP A CP	LACCING	ATIVE SU	PPIV
ACCUMULATIVE NEDCASE COST:	COST:	MATIVE CO.	NI RICI	COST:	211111111111	
FY-80 MEDCASE COST:	A DESCRIPTION OF THE PROPERTY	PERIODIC	REVIEW R	ESULTS:		
GTUDY OBJECTIVE: To protect	: women fro	om ovarian	failure :	2° chemoth	erapy fo);
Hodgkin's disease or non-H						
	•		•			
				• •		•
					· •	
	•					•
					•	•
"CCHNTCAL APPROACH"						
TECHNICAL APPROACH: Randomiz	ions of or	ived combin	ned oral	contracept	ives or	serve as
TECHNICAL APPROACH: Randomiz a control with no hormonal	o to recei agents du	ived combin	ned oral a	contracept	ives or	serve as
TECHNICAL APPROACH: Randomiz a control with no hormonal	o to recei agents dur	ived combinations chemo	ned oral a	contracept	cives or	eerve as
TECHNICAL APPROACH: Randomiz a control with no hormonal	co to recei agents du	ived combining chemo	ned oral a	contracept	cives or	eerve as
TECHNICAL APPROACH: Randomiz a control with no hormonal	co to recei agents du	ived combin	ned oral a	contracept	cives or	eerve as
TECHNICAL APPROACH: Randomiz a control with no hormonal	co to recei agents dur	ived combining chemo	ned oral a	contracept	tives or	eerve as
a control with no hormonal	co to recei agents dur comen che	ring chemo	therapy,			
PROGRESS DURING FY-80: Three randomization. Name are of	agents du	ring chemo	therapy,			
e control with no hormonal PROGRESS DURING FY-80: Three	agents du	ring chemo	therapy,			
PROGRESS DURING FY-80: Three randomization. Name are of	agents du	ring chemo	therapy,			
PROGRESS DURING FY-80: Three randomization. Name are of	agents du	ring chemo	therapy,			
PROGRESS DURING FY-80: Three randomization. Name are of	agents du	ring chemo	therapy,			
PROGRESS DURING FY-80: Three randomization. Name are of	agents du	ring chemo	therapy,			
PROGRESS DURING FY-80: Three randomization. None are of	agents dur e women che k therepy,	ose to tak	e oral con	ntraceptio	ves witho	
PROGRESS DURING FY-80: Three randomization. None are of randomization. None are of randomization. None are of randomization. The randomization of the random	agents dur e women che k therepy.	ose to tak	e oral con	ntraception UDY: 20 UDY: PROJ	ves witho	ut
PROGRESS DURING FY-80: Three randomization. None are of	agents dur e women che k therepy.	ose to tak	e oral con	ntraception UDY: 20 UDY: PROJ	ves witho	ut
PROGRESS DURING FY-80: Three randomization. None are of minors/unexpected Side Efficiency (No. 1005/UNEXPECTED SIDE EFFICIENTIAL AREA are	DIED BEFO	ose to tak	e oral con	ntraception UDY: 20 UDY: PROJ	ves witho	ut
PROGRESS DURING FY-80: Three randomization. None are of subjects to be still through the still through	DIED BEFO	ose to tak	e oral con	ntraception UDY: 20 UDY: PROJ	ves witho	ut

DATE: 30 September 1980			STATES: Ince	ria X
TITLE OF PROJECT: Phase IT			Fina	1
Bix-Guanyl Hydrazone (Methy: Jarcinoma, Head and Neck, an		Advanced Esophageai		
arcinoma, nedu and neda, a	nd Cartvin			
STARTING DATE:		TESTELVIER COMMERCA	MOS DATE:	
PRINCIPAL INVESTIGATOR: MA	J Martin D	. Weltz, MC	and the same of th	
SSOCIATE INVESTIGATORS:		FACILITY: Walter		r:]
		SERVICE: Hematol	ogy-Onco logy	
	ı		ment of Medicine	
CEY WORDS:		The second secon		
ACCUMULATIVE NEDCASE		ULATIVE CONTRACT	ACCUMULATIVE	SUPPLY
COST:	COST:		COST:	
FY-80 MEDCASE COST:		PERIODIC REVIEW F	RESULTS:	
TUDY OBJECTIVE: To define	the roope	l rot a rad vorda	ulan duration uti	14.3
eakly schedule of methyl-Ga				
lead and neck cancer, or cen			(100)	
		,		
			•	
TECHNICAL APPROACH: Methyl-	500 mo/M	to he civen as a	n intravanana inf	
in D5W or normal saline over	r no less i	than 30 minutes, in	to a freely moni	ng TV
			ar a area y suma	
				•
		•		
		•		
		1.6. 4		
ROGRESS DURING FY-80: Six ad squamous cell tumors.		entered from April one partial remissi		
o disease" for variable per				
tudy with decrease.		ino politico (ile ver enjoure en en en	7 1010311 (
•		,		• •
			•	
				•*
		•		•
NUMBER OF SUBJECTS TO BE ST	TIDIED BEFO	RE COMPLETION OF ST	rupy:	
SERIOUS/UNEXPECTED SIDE EFF				
. Expected N				
CONCLUSIONS: Too early			,	
•				
· •••		•		•,
PUBLICATIONS/ABSTRACTS, FY-	80:			•
. Danie Com Louis I I I I I I I I I I I I I I I I I I I	None			
	-			
	rena e en e		and the state of t	

				WORK URIT	NO. 1688	,
DATE: 30 September 1980 [P] TITLE OF PLONINGY: Feasibility S nary Approach to Inoperable Lur	study of	the Multi	8001 discipli-	FSTATES.		×
• ,						
STARTING DAFE: April 1980 PRINCIPAL HIVESTIGATOR: WRAMC ASSOCIATE INVESTIGATORS:		y Hultidis	ciplinary Walter	O'l DATE: A Team Reed Army I		
				gy-Oncology nt of Media		
KEY WORDS: Lung cancer; psychos ACCUMULATIVE MEDGASE COST:	ocial a ACCUMU COST:	spects of LATIVE COM	illness;	multidiscip ACCUMULAT COST:	linary ap	proach Y
FY-80 MEDCASE COST:		PERIODIC	REVIEW RE			~
	-					-
STUDY OBJECTIVE: To conduct a	descrip	tive study	to deter	wine the fe	asibility	and
utilization of a multidiscipling of inoperable lung cancer paties			oach to t	he treatmen	t and man	agemen
inoperage. Img cancer page	Tribo cre			•		
			•			•
TECHNICAL APPROACH: A resource opportunity to work with skille psychosocial aspects of illness	ed inciv	iduals in	order to	deal with s	ionie of th	c
					•	\$ 1100 \$
		,	•	•		
				•	•	
			to to Kair			
PROGRESS DURING FY-80: Eight p	arienro	were ente	rea on st	uoy .	er en	
	- - - -		•			
•		•			-	:
			•		•	
						, · · •
NUMBER OF SUBJECTS TO BE STUD!! SERIOUS/UNEXPECTED SIDE EFFECTS					ſ:	
CONCLUSIONS: Team approach is discharge planning (social world	benefic k and co	ial to pat	ients for alth purs	pain conti	col and	
***				•		•
PUBLICATIONS/ABSTRACTS, TY-80:				,		
					•	
					•	_

Date: 9 December 1980	Project No: 1700	Status: Interim XX
Title of Project:		Final
Sleep Apnea in Hypothyroi	d Patients	
Starting Date: 15 June 80	Estimated Completion Date	: 31 May 82
Principal Investigator: Kri	Ishnan R. Rajagopal	
Associate Investigators: Sarkis S. Derderian	Facility: WRAMC Pu	lmonary Clinic
Claude J. Tellis Kenneth D. Burman Bahman Jabbari Keith K. Hunt, Jr.	Dept/Svc Medicine/F	ulmonary
Key Words: Apnea, Hypoth	yroid	
Accumulative MEDCASE Cost: N/A	Accumulative Confinct Cost: N/A	Accumulative Supply Cost: N/A
FY-80 MEDCASE Cost:	Periodic Revis	
nypothyroidism (decreased T	; standard polysonochographic te '4 and/or increased TSH) will be lative frequency and type of ap	e monitored and the .
Progress during FY-80: Fi episodes of obstructive sle	ve hypothyroid subjects studied p apnea.	have shown several
	died before completion of study:	10
Scrious/unexpected side effec	cts in subjects participating in pro	oject: N/A
Conclusions: Work in satis	factory progress - will be comp	leted after monitoring
Publications or Abstracts, E Society Meeting in May 198		he American Thoracic

work Unit do.: 1700

Funds Utilized, FY-80:

Funding Requirements, FY-61:

Personnel: N/A	<u>Total</u>
Equipment: (Maintenance) \$500.	\$500.00
Supplies: (consumable) EEG paper @\$13.63 per box with 1 patient per box, for 10 patients \$140.	\$140.00
H.P. Paper @ \$53.00 per box with one patient per box \$530.00	\$530.00
Travel: For presentation at Annual Meeting \$700.00	\$700.00
Other: Preparation, publication costs and reprints \$500.00	\$500.00
Miscellaneous \$200.00	\$200.00
Total	\$2.570.00

Annual Report and Request for Continuation (Protocol in force since 1978)

Work Unit No.: 1903

<u>Title of Project</u>: Detection of \underline{T} . pallidum in the CSF in patients with neuro-syphilis.

Investigators:

Principal Investigator: S.M. Harrison, CPT MC

Associate Investigators: Charles N. Oster, MAJ MC

W. J. Herald

E. C. Tramont, LTC MC

Starting Date: (Approved Nov 1976) Patients not entered until microbiologist became available Sept78.

Estimated Date of Completion: Sept 1981.

Objective:

- 1. To determine the frequency with which <u>Treponema pallidum</u> can be isolated from the CSF of patients who have received an inadequate course of treatment for primary or secondary syphilis (see Reference 1).
- 2. To attempt isolation in patients with late latent syphilis or apparent asymptomatic neurosyphilis.
- 3. To explore and improve procedures for Treponemal antigen detection as an indication of neurosyphilis, and an indication for therapy.

Technical Approach: T. pallidum isolation (as modified by DF Dec 1979). Patients from the Military District of Washington who have latent syphilis will have a lumbar puncture for determining therapy. If cerebrospinal fluid exam is positive for VDRL, FTA-absorbed, FTA-unabsorbed or if there is abnormal protein, glucose, or cell count suggestive of possible neurosyphilis, then the CSF will be passed into two experimental rabbits and one control rabbit. (Negative RPR and FTA virgin male rabbits will be used). The two experimental rabbits will be carried for 40 days, sacrificed and testicular homogenates passed in second rabbits. At the end of 80 days, the rabbits will be sacrificed, testes homogenized, and examined for Treponemes by darkfield and direct fluorescent antibody. RPR, VDRL and FTA will be determined on all test rabbits.

T. pallidum antigen detection. The Nichols' strain of T. pallidum passed in rabbits will be used for simulating infected CSF. After extraction, pooled CSF will be infected with T. pallidum, and antigen will be determined by gas chromatography, limulus lysate, or solid phase radioimmunoassay.

Progress and Results: Although 19 more patients have been examined this year, no rabbit syphilomas nor serologic changes have been identified. Preliminary studies on antigen determination have begun.

Conclusions: There is insufficient data for conclusion at this point.

Funding Requirements FY-79: \$10,000.00

Funding Requirements FY-80: \$12,000.00

Funding Requirements FY-81: \$11,000.00

Within Funding Requirements:

Personnel: W. J. Herald, GS-9

S. M. Harrison C. N. Oster E. C. Tramont

Equipment: Already available through the Infectious Disease Labs, CIS.

Consumables:

Animals and care \$ 9,000.00 Chemicals, reagents & glassware 1,500.00 Travel 500.00

Publications:

Tramont, EC, Chapter 180, Treponema pallidum (syphilis) in PRINCIPLES & PRACTICE OF INFECTIOUS DISEASE, 1979. Editors Mandell, Bennett and Douglas, McGraw Hill, New York.

Type of Report: Interim.

References:

Tramont, EC. Persistence of Treponema pallidum in Cerebrospinal Fluid Following Recommended Penicillin G Therapy. JAMA 236:22-6-2207, 1976.

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OF GEFICE SYMBOL

SUBJECT

HSWP-MI

Continuation of Protocol #1905

TO C, Clinical Investigation Svc FROM C, Infectious Dis Svc

DATE 18 Sept 80

CMT 1

- 1. Request continuation of Protocol #1905 entitled "Local Immune Response to <u>Neisseria gonorrhoeae</u>".
- 2. The objectives of the original protocol were as follows:

"The objective of this research is to study the kinetics of local immunity as it pertains to bacterial infections, in particular, N. gonorrhoeae, such that a well-tolerated local immunogen capable of inducing protection in man might be developed in the future.

Briefly, our hypothesis holds: 1) that the initial event of many infections is implantation on mucosal cells of the offending agent to which a local immunological response develops. General infection is provided a local disease and, therefore, well suited for studying local immunity; 2) that there are associated with genococcal organisms, antigenic determinants which when isolated, purified and concentrated will upon local administration induce significant protection to infection.

The specific objectives were to

- (1) Development of New Techniques to Determine Inhibition of Epithelial Cell Attachment (IEA) of Gonococci
- (2) To determine which antigenic determinants against which the human local immune response is directed the following antigens will be isolated, characterized and purified: acetone or formalin killed whole organisms, native outer cell wall complex, lipopolysaccharide (endotoxin), and pili. These antigens in turn will be used to block inhibition of epithelial cell attachment.
- (3) An attempt will be made to better understand the kinetics of local and parenteral antibody formation by determining concurrently the ability of serum and local antibodies obtained concurrently to inhibit epithelial cell adhesion of the homologous infecting organisms.
- (4) An attempt to shed some light on the mechanisms of recurrent gonococcal infections will be undertaken by examining the ability of antibody raised in rabbits to inhibit epithelial cell attachment of recidivistic strains isolated from the same patient at different times.
- 3. The majority of these objectives have been met, and can be summarized as follows:
 - (1) Attempts to develop new techniques to measure IEA have been unsuccessful so far (Annual Report 1976).
 - (2) The SPRIA has been modified for measuring local antibody (Annual Report 1978).
 - (3) The principal antigen mediating attachment of gonococci to epithelial cells are pili (Annual Report 1978, 79, 80) but other antigens are also involved (Annual Report 1979).

33ECT: Continuation of Protocol #1905

- Tramont EC, Ciak J, Boslego JW, McChesney DG, Brinton CC and Zollinger W. Antigenic Specificity of Antibodies in Vaginal Secretions During Infection with Neisseria gonorrhoeae. J Infect Dis 142:23-31, 1980.
- Tramont EC. Role of Adhesion of N. gonorrhoeae in Disease, Ciba Foundation Symposium, London, UK, 1980.
- Boslego JW, McChesney DG, Sadoff J, Ciak J, Tramont EC. Human Genital Antibody Response to a Gonococcal Pilus Vaccine (Abstract). ICCAC, New Orleans, 1980.
- o. Projected costs: FY-81
 - Equipment: new gamma counter \$20,000. Old equipment is in need of constant repair secondary to heavy use.

consumable supplies: \$15,000.

SUBJECT: Continuation of Protocol #1905

- (4) Recurrent gonococcal infections may be due to antigenic heterogenicity of gonococcal pili (Annual Report 1978).
- (5) Parenteral immunization with a gonococcal pilus vaccine induces local antibody capable of inhibiting attachment (Annual Report 1980).

4. Future directions

- (1) The kinetics of this local response will be studied by examining the serum and local responses concurrently.
- (2) The response to local vaccination with a gonococcal pilus vaccine will be studied.
- (3) The response to parenteral followed by local immunization and vice versa will also be studied.
- (4) Other attachment antigens besides pili involved in attachment will be determined and studied.

5. Bibliography (1978-1980)

- Tramont EC, Ciak J. Antigonococcal antibodies in Genital Secretions. 1978 in Immunobiology of Neisseria gonorrhoeae, pp 274-276.
- Tramont EC. Human Immune Response to Neisseria gonorrhoeae Prospectives for Vaccine Development. Presented at 32nd Arnual Meeting, Soc. Med. Consultants to the Armed Forces. Nov. 1977. (Abstract)
- Tramont EC, Ciak J, Gilbreath M, Brinton C (Abstract) Blockage of Local Antigonococcal Antibody by Gonococcal Antigens. ICCAC, Atlanta, Georgia, 1978.
- Tramont EC, Hodges W, Ciak J. Importance of Antigenic Differences in Gonococcal Reinfection. (Abstract) Clin Res. 1978.
- Tramont EC, Hodges W, Ciak J, Gilbreath M. Importance of Differences in Attachment Antigens in Gonococcal Reinfections. J Clin Lab Med 93:730-735, 1978.
- Tramont EC, Ciak J, McChesney D, Boslego JW, Brinton CC. Cross Reactivity of Gonococcal Pili as Determined by Inhibition of Epithelial Cell Attachment. (Abstract) presented ICCAC, Boston, Mass. 1979.
- Tramont EC, Boslego JW, Sadoff J, Zollinger W, Lolik A, Bryan J, Brinton CC. Safety and Immunogenicity Study of Gonococcal Pilus Vaccine. (Abstract) presented ICCAC, Boston, Mass. 1979.

Date: 20 September 1980	Profoc	ol No: 1303	Status: Interim
Title of Project: Local Immu in Humans	ne Respons	e to <u>Neisseria goner</u>	rhoede BAXXX
Starting Date: 27 Sep 77	F'ct	imated Completion Da	nte: 1983
But a final stream of the first and	Inst	intaled Completion Da	ne. 1300
Principal Investigator: E	dmund C. T	ramont	
Associate Investigators: John Boslego, MAJ MC Jennie Ciak, GS 12	Facility: Walter Reed		ed Army Medical Center
dennie Clak, do 12	. •	Dept/Svc Infecti	ous Disease
Key Words: Neisseria gono	rrhoeae, 1	ocal immunity	
Accumulative MEDCASE Cost: \$20,000.00		nulative Conteact \$1,000.00	Accumulative Supply Cost: \$15,000.00
FY-80 MEDCASE Cost: \$36	00.00,		riew Results: Lin by DCI)
a gonococcal vaccine.			
*Technical Approach:		•	
The immune response is to phase radioimmunoassay (se	be studied e previous	lusing an inhibitic annual reports).	n of attachment and soli
Progress during FY-80:			
See attached sheets.			
Number of subjects to be student Serious/unexpected side effects.			roject;
Conclusions: See attached sheets			
Publications or Abstracts, E	TY-80: Se	ee attached sheets	

Progress during FY-80

 A parenterally administered genococcal pilus vaccine was shown to induce local antibody.

A prototype gonococcal vaccine manufactured at the University of Pittsburgh and in collaboration with WRAIR, was tested for safety and immunogenicity in volunteers at WRAMC and at Fort Bragg, North Carolina. Vaginal washings and seminal fluid were obtained and tested for local antibody by the standard inhibition of attachment assay developed by us and the standard Solid Phase radioimmunoassay developed by Dr. Wendell Zollinger at WRAIR.

Eleven female volunteers were given two intramuscular injections of 100, 200. 50s, at 1000 up of a garachecal personative (PCR 3-2, Lot 001) one month apart. Antipilus antibodies (IgG, IgA) were measured in vaginal secretions by solid phase radioimmunoassay (SPRIA) and expressed as micrograms (ugs) of specific antipilus antibody/ugs of total IgG in the vaginal secretion. Measurements were made for 8 weeks after the initial vaccination. All 11 volunteers had antibody rises; 10/11 within 2 weeks after the initial vaccination. The geometric mean of the maximal fold rises were: IgG 4.6, IgA 7.6. The antibody rises appeared to be dose dependent, although individual variation was seen.

Four male volunteers were given 2 mg subcutaneous booster injections of PCH 3-2 vaccine one year after initial vaccination. Antipilus antibodies were measured in seminal fluid by SPRIA and standardized for total IgG as above. Measurements were made for 6 weeks after vaccination. All volunteers demonstrated an antibody response within 2 weeks. The geometric mean of the maximal fold rises were: IgG 9.4, IgM 2.7, IgA 4.4. The secretory antibody responses appeared to parallel that seen in the serum (Fig 1, Fig 2, Fig 3).

The local genital antibodies were also capable of functional activity, namely in vitro inhibition of attachment of the gonococcus to epithelial cells (Table 1).

- 2) A prototype gonococcal pilus vaccine PGH 3-2 was previously shown to be safe and imagingatio. The probable functional aspects of a gonococcal vaccine were demonstrated by the ability of these antibodies to block attachment of the gonococci to human buccal epithelial cells. The antigenic determinant responsible for blocking attachment was shown to be pili (Table 3). The antibodies also blocked attachment of heterologous strains (Table 4).
- 3) The cross reactivity of antibodies from patients with naturally occurring

 N. gonorrhoeae infections to homologous and heterologous GC pili were studied in the SPRIA. All patients studied showed antibody rises to the homologous strain. Three of the six strains demonstrated significant levels of antibody against several of the heterologous strains.

Five of six normal controls demonstrated low levels of antibody against all pili tested. One of the normal controls had high levels of antibody against 6 of the 7 pili strains.


4) An IgA protease was isolated from liquid GC media in which N. gonorrhoeae was grown. This protease was capable of splitting serum IgA isolated from a IgA myeloma patient into two fragments. The activity of this enzyme on local secretory antibody from patients infected is being studied or from volunteers who received the PGH 3-2 gonococcal pilus vaccine.


TABLE 1


INHIBITION OF ATTACHMENT OF PGH 3-2 GONOCOCCI WITH GENITAL SECRETIONS FROM VOLUNTEERS IMMUNIZED PARENTERALLY WITH PGH 3-2 GONOCOCCUS PILUS VACCINE

	WEEKS					
_{Vol} (1)	preimm	2	4	6	8	
2	< 1:1	< 1:1	< 1:1	< 1:1		
4	< 1:1	1:4		< 1:1	< 1:1	
25	1:4	1:8	1:16	1:16	1:32	
28	1:2	1:8	1:8	1:4	1:2	

⁽¹⁾ Volunteers ? and 4 were men given a booster injection one year after a similar vaccination. Volunteers 25 and 28 were women given a booster vaccination at the 4th week.







Post vaccination sera absorbed with PGH 3-2 LPS and PGH 3-2 pili

Table 2

		SPRIA		
Serum	[EA	LPS/µg/ml	pili/ug/ml	
pre-immunization	< 1:1	0.51	4.56	
post-imm. unabsorbed	1:16	0.75	17.41	
post-imm. absorbed LPS	1:32	0.59	16.93	
post-imm. absorbed pili	< 1.1	0.41	4.90	

Serum from volunteer #4 (1 mg dose) was absorbed with Pgh 3-2 LPS, then with vaccine pili. Absorption with LPS did not effect the IEA titer, while absorption with pili reduced the titer to pre-immunization levels.

Inhibition of attachment of heterologous strains

	(-		•		
Serum (wk)	Pgh 3-2 ⁽²⁾	Ph 1 3 (2)	Ph1 5(2)	Phi 8(2)	Phi 19(2)	135(3)	135(3) 222(3) 769(3)	769(3)	339 (4)
Vol 1 (prc)	1:1	7: F	7: F						
Vol 1 (7wk)	1:8	1:2				-1 -1		1:1	
		!	t -1			7:7		1:2	
Vol 9 (pre)	1:2				; ;				.·•
Vol 9 (7c-le)	1.16			7.	T:7		1:1		1:2
	07:7	•		3:8	1:8		1:2		1:4
Vol 4 (pre)	1:1	< 1:1 >		, · · ·				٠	
Vol 4 (423)	1:8	:: -		٠ ١ - ١				다. 다.	1:1
				7		-		7:7	1:4

(1) vaccine strain

(2) Philippine strain

(3) U.S. strain

(4) Korean strain

Conclusions

- (1) A parenterally administered pilus vaccine was shown to induce local antibody.
- (2) This local antibody was capable of functional activity, namely inhibition of attachment.
- (3) This antibody appears to be cross-reactive against other strains.

Publications and Abstracts, FY-80

- Tramont, EC, Ciak J, Boslego JW, McChesney DG, Brinton CC and Zollinger W.

 Antigenic Specificity of Antibodies in Vaginal Secretions During Infection
 with Neisseria gonorrhoeae. J Infect Dis 142:23-31.
- Tramont EC. Role of Adhesion of N. gonorrhoeae in Disease, Ciba Foundation Symposium, London, UK, 1980.
- Boslego, JW, McChesney DG, Sadoff J, Ciak J, Tramont EC. Human Genital Antibody Response to a Gonococcal Pilus Vaccine. ICCAC, New Orleans, 1980.

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-MI

Justification of fund

TOC, Dept of Clin Investigation FROM Principal Investigator Protocol $\#_{*}\#\mathbb{C}5$

DATE 5 Jan 1981

CMT 1

1. A new gamma counter is needed for the following reasons:

- a) The principle antibody test employed by us is the solid phase radioimmunoassay (SPRIA). This test is sensitive enough to quantitate local antibodies, a major technical problem in conducting these studies.
- b) The SPRIA will also be adapted for measuring antigens, similar to tests now employed in the Virus Department, WRAIR, for measuring hepatitis A & B antigens.
- c) The present games counter which we have at our disposal is outmoded, outdated and has been down a total of four months in the past twelve resulting in interruption in study and lost man hours. Also it does not have the computer capabilities which we need for storing and correlating our data. This requires many man hours to calculate the data by hand.
- d) Finally, it is only partially automated and has a limited sample capacity; productivity is greatly enhanced when samples can be run automatically overnight.

2. Supplies

\$ 2,000.00 isotopes purified GC pili 4,000.00 monocional antibodies 4,500,00 animals 1,500.00 (rabbits housed at WRAIR) expendible misc. supplies 3,500.00 i.e. collection cups vaginal tampons Kellogg's GC culture media liquid nitrogen silk labels Calgiswabs minitek CTA's flexible microtiter plates pipette tips teletype paper for gamma counter teletype ribbons Wheaton vials etc.

\$15,000.00

August Compelling EDMUND C. TRAMONT, M.D. LTC . , MC

Chief, Infectious Lisease Service

DA 2496

REPLACES DD FORM 96, WHICH IS DESOLETE.

4 GPO -- 1975 -- 665-422/1063

Date: 7 October	1930	Protocol	No: 1	906	Stains:	Final
Title of Project:	tion of Gr	us Lysate As ram Negative Intravenous	e Menir	igitis Septi	rmina- ic Arthritis a	
Starting Date:		Estir	nated C	Completion I	Date: 10/80	
Principal Investig	gator: Charl	les Oster, M	MAJ MC		•	
Associate Investi	gaiors:		Facili	ty: NRAMC		•
Arthur Dobek, Edmund C. Tram			Dept/:	Svc Med/Infe	ectious Diseas	se .
Key Words:			1			
Accumulative ME Cost:		Accumi Cost:		Contract		lative Supply
FY-80 MEDCASE	Cost:				eview Results: ed in by DCI)	
Study Objective: of bacterial en cases chosen by Technical Appro	doloxin in the Infec	fluids, esp tious Diseas	peciall se Serv	y cerebrosp vice.	oinal fluid, 1	from clinical
were done by to procedure was vious year all	he improvedused for a	i procedure Il specimens	descri s analy	bed in last zed in the	t years annual current year.	l report. Thi . As in the pr
Progress during the current fi	FY-80: Ti scal year.	ne following (See Cont	g data inuatio	in Table l on Sheet)	represent the	e analyses for
Number of subject						
Serious/unexpect	ed side ette	cts in subjec	ets par	ncipating in	project: N/A	
Conclusions: (Sec attache	d page)			AND THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS	
Publications or I	Unitracta, I	EY-80: None	e			

Patient Designation	Endotoxin (ng/ml)	Time interval with multiple specimens
A B C	.052	
В	.074	_
С	.055	Day 1
	.084	Day 3
ט	.023	
£	.400	
F	0*	
ti	.265	
D E F G H I J	0	
	0 0	
v	.060**	
L	0	
М	038	
N		
0	0	
0 P	0	Day 1
·	0 0 0 0	Day 7
Q	.048	Day 1
	.195	
	.038	Day 7
R	.038	
R S T U	0	
T	.070	
U	.094	
V	0	
	.034***	
W	.220	Day i
	.200	Day 6

OD reading below standard baseline of graph and, therefore, considered as 0 $\,\mathrm{ng/ml}$ of endotoxin.

dialysate pleural fluid

Conclusions: The limulus lysate assay is a sensitive test for the detection of endotoxin in body fluids. No further research is needed. This assay should now be done in the Department of Pathology Clinical Laboratory in direct support of patient care.

Date: 8 Oct 1980 Protocol No: 1908 Status: (Interim Final Title of Project: Evaluation of sodium stibogluconate (Pentostam) in the treatment of cutaneous leishmaniasis 4 Apr 78 Estimated Completion Date: 1983 Starting Date: Principal Investigator: Charles N. Oster, M.D., MAJ MC Associate Investigators: Edmund C. Tramont, MD, LTC(P)MC Facility: WRAMC Craig J. Canfield, MD, COL MC Larry D. Hendricks, Ph.D., MAJ MSC Charles Pamplin, MD, MAJ MC Jeffrey D. Chulay, MD, LTC MC Dapt/Svc Medicine/Infectious Disease Key Words: Leishmaniasis; pentavalent antimony Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: \$4,000.00 Cost: FY-SO MEDUASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: (a) To evaluate the efficacy of different regimens of sodium stibogluconate (Pentostam) for the treatment of cutaneous leishmaniasis. (b) To observe for long term sequelae of leishmaniasis and its treatment is military personnel. Technical Approach: Unchanged Progress during FY-SO: 10 patients with leishmaniasis were seen during the period 1 Oct 79 to 30 Sep 80. Three had been previously treated at WRAMC and were readmitted for treatment of recurrent disease; one was treated with a fourth course of sodium stihogluconate with apparent resolution; the second was treated with Number of subjects to be studied before completion of study: 60 Serious/unexpected side effects in subjects participating in project: None Conclusions: See following sheet

Publications or Abstracts, FY-30: Chulay JD, Tranont EC, Hendricks, LD, Takafuji E. Clinical manifestations of cutaneous leishmaniasis. Manuscript in preparation.

Progress during FY-80:(Continued)Amphotericin-B, one gram total dose, but still had positive post-treatment cultures; the third had continued disease involving skin graft sites on an old burn wound. He had had three courses of sodium stibogluconate and overthree grams of amphotericin-B previously; therefore he was treated with local heat therapy with improvement.

Two patients were treated previously elsewhere, one in Panama, and the other in Colombia. The first was retreated at WRAMC using the standard regimen of sodium stibogluconate. The second, a civilian Peace Corps volunteer was referred to the National Institutes of Health for treatment.

The remaining six patients were enrolled in the experimental limb of the protocol. Two were treated in Group A (600 mg I.V.once a day for 10 doses), three in Group B (600 mg I.V. loading dose followed by a continuous I.V. infusion of 600 mg per day for 9 days), and one in Group C (600 mg I.V. loading dose followed by 200 mg I.V. every eight hours for 27 doses). All healed after their treatment; however, since the follow-up period has been short, it is premature to consider these patients cured.

Sodium stibogluconate has been well tolerated by all patients. We have not had to curtail its administration due to an adverse reaction. Side effects, including headache (1 patient), chest pain (1 patient), and paresthesias (1 patient), were minor and transient.

Conclusions: It is clear that sodium stibogluconate is effective for the treatment of cutaneous leishmaniasis. However, 25-30% of the patients treated at WRAMC have not been cured with the initial ten day course, and there is no apparent difference, at this time, in the failure rate of the experimental treatment groups. Our data suggests that higher dose or longer treatment regimens using sodium stibogluconate will be required.

Work Unit No.: 1908

Funds Utilized, FY-80: \$2,000.00

Funding Requirements, FY-81: \$2,000.00

Personnel: None

Equipment: None

Supplies: \$1,500.00

Travel: \$500.00

Date: 9 October 1930	Protoco	ol No: 1909	Status: (Interim)
Title of Project: Immunologi cutaneous	cal evalua leishmania	tion of patients wi sis	th XXXXXX
Starting Date: 21 Feb 1978	Esti	imated Completion D	ate: 30 Sep 1981
Principal Investigator: Ch	arles N. O	ster, M.D., MAJ MC	
Associate Investigators: Franklin A. Neva, M.D., NI	H	Facility: WRAMC	•
Eskild A. Petersen, M.D. Edmund C. Tramont, M.D. [T Jeffrey D. Chulay, M.D., L	C(P) MC TC MC	Dept/Svc Medicir	ne/Infectious Disease
Key Words: Leishmaniasis/	immunology,	/1 ymphocyte	•
Accumulative MEDCASE Cost:	Accun Cost:_	ulative Contract	Accumulative Supply Cost: \$5,000.00
FY-80 MEDCASE Cost:	!	Periodic Re	view Results:
		(to be tille	d in by DCI)
Study Objective: 10 study immune responses in patien			specific humoral and cellulations.
Technical Approach: No c	hange in tl	nis fiscal year.	
			•
studied in FY80. One pati leishmanial antigens in vi	ent was stu tro, with	udied twice. 7/8 p lymphocyte transfor	rmation responses 4-56 (Contid)
Number of subjects to be stu			
Serious/unexpected side effe	ects in subje	ots participating in	project: None
Conclusions: Most patients cell mediated immunity, as responsiveness may prove u	seful as a	a by in vitro lymph	nocyte responses. This

Protocol No: 1909

Progress during FY-80: (Cont'd) times control levels. The eighth patient had levels only 1.3-2.0 times control; this patient has continued active disease despite three coursesof sodium stibogluconate and over 3 grams of amphotericin B. The other patient who is unresponsive to therapy (two courses of sodium stibogluconate and one gram of amphotericin B) has the next lowest in vitro lymphocyte responses, ranging 1-4.6 times control. The other patients who responded to therapy had responses 9-56 times control. These data are provocative and suggest that immunodeficiency may be contributing to these two patients prolonged, unresponsive disease.

Passage of the peripheral blood mononuclear cells (PBM) over nylon wool columns abolished the antigen-induced transformation of lymphocytes of all patients, suggesting a role for macrophages in antigen-processing or presentation. Culture of the PBM's in the presence of indumethacin had no effect on the transformation responses of five of eight of these patients. One patient's response decreased, and two patient's responses increased with assumethacin. One of these latter patients was a poor responder initially. With indomethacin his responses were 30 times control levels, suggesting the possibility of a prostaglandin-mediated suppression.

<u>Conclusions</u>: (Cont'd) responsiveness of lymphocytes from two patients with recalcitrant disease suggests that an immunodeficiency may prevent resolution of leishmaniasis. These interesting preliminary findings will be pursued.

Funds Utilized, FY-80: \$3,000.00

Funding Requirements, FY-81: \$5,000.00

Equipment: Multiple-channel automated sample harvester \$1,500.00

Supplies: \$3,000.00

Travel: \$500.00

Date: 4 October 1980	Protoco	ol No:	1911	Status: Interim x
Title of Project:				Final
In Vitro Inhibitory Acti	vity of a S	Series	of 2-Acetyl	pyridine thiosemicarbazone
Starting Date: 27 Feb 79	€sti	mated (Completion I	late: Oct 81
Principal Investigator: Art	hur Dobek,	Ph.D.		
Associate Investigators:		Facili	ty: Walter R	eed Army Medical Center
Edmund Tramont, M.D., LTC Daniel Klayman, Ph.D.	МС	Dept/	Svo Departme	nt of Clinical Investigati
Key Words:	 	-al		•
Accumulative MEDCASE Cost:	Accum Cost:	ulative	Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			1	eview Results:
a collecti	on of clini	ically	significant	d related compounds toward bacterial organisms.
Technical Approach: The mincluded 50 of 2 acetylpyr 6N ⁴ , N -disubstituted (nonc 9 derivatives of other 2-acompounds related to 2-acyfoliowing chinical isolated 5 Staphylo-occus aureus,	idine thios yelic), and cylpyridine	semicar i 18N ⁴ , e thiosem	bazones [26] N ⁴ -disubsti enicarbazon nicarbazones land mapro-h coccus, 5 <u>Pe</u>	N ⁴ monosubstituted, tuted (azacyclic)], es and 6 miscellaneous
Progress dering FY-80: MICs of 0.002 to 0.062 ug/	ml were obt	tained		
gonorchoese and 0.016 to 0			.7% of the c	
Number of subjects to be stu			tion of study	:
Serious/unexpected side effe	cts in subjec	ets part	ticipating in	project:
Conclusions: Thirty additional available for testing. The for the enteric and Pseudo	ie major em;	phasis	various che will be on	mical structure have become finding potential inhibito
Publications or Abstracts, I	TY-80: (3ee	r a ticad	thed page:	

Technical Approach - (Continuation): 5 Klebsiella - Enterobacter spp.,

4 Shigella spp., 1 Escherichía coli (invasíve), 5 Proteus mirabilis and 5 Neisseria meningitidis. The standard agar dilution method was used with 30 M. gonorrhoeae isolates.

Progress during FY-80 (Continuation): N. meningitidis. S. aureus was inhibited in the MIC range of 0.125 to 0.5 ug/ml by 18% of the compounds, whereas 26% inhibited group D interococcus with an MIC of 0.025 to 2.0 ug/ml. Poor antibacterial activity was shown toward gram-negative bacilli. These data have

Publications or Abstracts, FY-80:

1. Dobek, Arthur, D. Klayman, E. Dickson Jr., J. Scovill, and E. Tramont: Inhibition of Clinically Significant Bacterial Organisms In Vitro by 2-acetylpyridine thiosemicarbazone, Antimicrobial Agents and Chemotherapy,

Date: 9 October	1980	Protocol	No:	1912	Status: Interim			
Title of Project:		ation of var using high p			r clinical (Final) promatography (HPLC)			
Starting Date: 27	March 1979) Estir	nated C	ompletion L	Date: 30 Sep 80			
Principal Investig	cator: Char	les N. Oster	, M.D.					
Associate Investigators: Rudolfo Bongiovanni, CPT MSC				Facility: WRAMC				
Edmund C. Tramo	ont, MD LT(C(P)MC	Dept/S	vc Medicine	/Infectious Disease			
Key Words:	comycin/ant	ibiotic ass	: ay		•			
· · · · · · · · · · · · · · · · · · ·				Contract	Accumulative Supply Cost: \$12,000.00			
FY-80 MEDCASE Cost:					eview Results:			
Study Objective: vancomycin. uing HPLC.				-	shic characteristics of mycin in clinical samples			
Technical Approach the fiscal year	ach: There	have been	no char	nges in the	technical approach in			

Progress during FY-80. The technical aspects of sample preparation and chromato-

graphy were described in the FY-79 report.

Further studies were designed to develop an internal standard and to determine if componly used clinical pharmaceuticals would interfere with this assay. (Cont. d)

Number of subjects to be studied before completion of study: 0

Serious/unexpected side offects in subjects participating in project:

Conclusions: The first objective, defining vancomycin's HPLC characteristics, has been achieved. However, limited availability of HPLC time prevented further assessment of this assay method for vancomycin in clinical samples. This technique Publications or Abstracts, FY-30: McClain JBL, Bongiovanni R. (continued)
Guantitation of vancomycin by high pressure liquid chromatography. Manuscript in preparation.

Progress during FY-80: (Continued). Unfortunately, we were unable to secure access to the HPLC equipment, and work on this project was necessarily curtailed.

Conclusions: (Continued) (HPLC) is potentially extremely useful, not only for the rapid assay of vancomycin, but also for other antibiotics. Strong consideration must be given to allocating more access to HPLC equipment for this work.

Funds Utilized, FY-80: #1,000.00

Funding Requirements, FY-81: 0

Personnel: None

Equipment: .!one

Supplies: None

<u>Travel</u>: None

Date: 13 October 1980	Protocol	l No:	1913	Status:(Interim)	
Title of Project: Laborat	ory Investi	gation	of New Ant	Final ibiotics	
Starting Date: 22 January	/ 1980 Estir	nated (Completion D	ate: January 1983	
Principal Investigator: Char	les N. Oste	r, MAC	MC; Alan S	. Cross, LTC MC	
Associate Investigators: Edmu Tramont, MD: Arthur S. Dobek	, Ph.D.;	Facili	ty: WRAMC		
John F. Keiser, MD; Dennis & Ronald K. Porpatich, M.S.	ореско,Рпи;	Dept/	Sve Medic	ine/Infectious Disease	Svc
Key Words: Antibiotics/Bac	terial susc	ı eptibi	lity/resist	ance mechanisms	•
Accumulative MEDCASE Cost: 0	Accumi Cost:		Contract	Accumulative Suppl Cost: \$5,000.00	y .
FY-80 MEDCASE Cost:	0			view Results: d in by DCI)	
Study Objective: 1. To inve			· · · · · · · · · · · · · · · · · · ·		
Technical Approach: In vitusing standard agar-dilution	ro antibact	erial		cterial antibiotic resi	
		·	•		
Progress during FY-80: In drugs piperacillin (P), cefo determined for two collection of recent consecutive isolated Number of subjects to be sto	ntaxine (H), ons of bacte es from WRA	moxal rial i MC's C	actam (L), o solates. O linical Mic	and cefoperazone (I) were ne collection was a ser robiology Laboratory.	e ies
Serious/unexpected side effe	cts in subjec	its piur	Holpating in	project: N/A	
Conclusions: Only cefopera have sufficient in vitro act potentially useful clinicall	ivity again	st ant	ibiotic-res	istant <u>Pseudomonas</u> to b	e ainst
Publications or Abstracts, i Cefoperazone, and Piperacill					(Cont'd) ive_bacteria

Progress during FY-80: (Cont'd): second collection was a group of antibiotic-resistant gram-negative bacteria gathered at WRAMC over the last several years. Sensitivity of these bacteria to carbenicillin (CB), gentamicin (G), tobramycin (N) and amikacin (A) were also determined for comparison with the investigational antibiotics.

Consecutive recent bacterial isolates

	Number Percent Susceptible								
	Isolates	Н	L	I	Р	CB	G	N	Α
Escherichia coli	124	98	77	99	98	73	97	9 <u>8</u>	100
Klebsiella-Enterobacter	97	100	91	94	92	44	93	92	99
Proteus species	93	97	92	100	98	78	85	94	99
Pseudomonas aeruginosa	122	84	84	93	98	52	63	90	93

Antibiotic-resistant bacteria

	Number		Percent Susceptible							
	Isolates	H	L	I	Р	CB	G	N	Ā	
Escherichia coli	98	10 <u>0</u>	99	100	91	53	8 <u>9</u>	85	99	
Klebsiella-Enterobacter	74	95	99	84	26	12	16	12	91	
Pseudomonas aeruginosa	102	59	53	94	93	35	17	39	92	

Conclusions: (Cont'd):Enterobacteriaceae, but are less active against Pseudomonas.

<u>Publications or Abstracts, FY-80:(Cont'd): C.N. Oster, A.S. Dobek, A.S. Cross, E.C. Tramont.</u> Submitted to ASM Annual Meeting, March 1981.

Funds Utilized, FY-80: \$6,000.00

Funding Requirements, FY-81: \$7,500.00

Media	\$1,000.00
Disposable plastic ware	3,500.00
Other consumables	2,500.00
Travel, publications	500.00

Date: 27 October 1980	Protocol No:	2000	Status: Interim x
Title of Project: The Enfect of Pancres	s of Gastric Sur utic Polypeptide	gery on the	Final Release
Starting Date: 1978	Estimated	Completion I	Oate: 1033
Principal Investigator: Joh	in Harmon		
Associate Investigators: Lawrence Johnson MD	Facil	ity: _{Walter} Ro	eed Army Medical Center
Richard Hirata MD Ian Taylor MD	Dept/	Svc Sur	gery
Key Words: Pancreatic polype	ptide, ulcer, ho	rmone	
Accumulative MEDCASE Cost:	Accumulative Cost:		Accumulative Supply Cost:
FY-80 MEDCASE Cost:			eview Results:
Study Objective:			
To determine the roles of release of pancreatic pol			rrum of the stomach in the a the parcreas
Technical Approach:			·
To compare meal stimulate before and after surgery		ic polypepti	ide values in patients
patients have had surgery	of whom 8 have	had repeat o	icipation of surgery. Thirteen collection of serum samples. pancreatic polypeptide in Apr 8
Number of subjects to be stud			
Serious/unexpected side effec	cts in subjects par	ticipating in	project:
	l has not interf		rimens. No unexpected proble a licantly with patient care.

FUNDING REQUIREMENTS

CLINICAL INVESTIGATION PROGRAM

OUT THO	T NO.: 2000 T	ITLE:	Use of Co-F	olvmer as a La	ttice for the Growth of	FY-		
PO: PRI			Neogut RINCIPAL INVESTIGATOR:					
		Col	HARMON	·	·			
MENT OF PENSE			FY 81	FY 82	REMARKS We were authorized 50%			
·) - 1200	Personnel:		` .		a technician but we have able to implament this this date.	e not bee		
.1100	Travel:				this date.			
	Mission		·		· · · · · · · · · · · · · · · · · · ·			
	Conference		600 .	600				
•	Patient							
2319	Rental Equip:					·		
- 100	Printing and Reproduction:							
1572	Contractual Svc Lab Contracts:							
:500	Consumable Suppliand Experimental Animals	ies	4000	4000	Rubbit acquisition o	hoarding		
Officer:			"					
Total:			7.					
Require	ment Ranks		No	No	WORK UNITS:			

Date: 27 Galaine 1980	Protocol no:	2003	Status: Interim x	
Title of Project: Hea of Con-			Final	
of Neogut	olymer as a Latti	ce for the	Growth	
or Reogut			•	
Starting Date: March 1980	Estimated C	Completion I)afa: 4 1000	
			Jate: March 1982	
Principal Investigator: John	W. Harmon, LTC	MC		
Associate Investigators:	Facili	TV: Walter F	leed Army Institute of Re	cearah
William Berry CPT MC		o Harrer I	teed samy inscitable of he	3ean ch
Keith Lillemoe CPT MC	Dant/S	ivo n		- .
	Debija	DIVISIO	on of Surgery	
Key Words:				• ;
Small intestin	e, surgery			
Accumulative MEDCASE	Accumulative	Contract	Accumulative Supply	
cst:	Cost:	,	Cost:	-
FY-SO MEDCASE Cost:			view Results:	-
		(to he fille	ed in by DCI)	
Study Objective:		Na programma programma (con programma programma)	بالمتعارضة والمتعارض والمتعارضة والمتعارض والمتعارضة والمتعارضة والمتعارضة والمتعارضة والمتعارضة والمتعارض والمتعارض والمتعارض والمتعارض والمتعارض والمتعارض والمتعارضات والمتعارض والمتعارض والمتعارض والمتعارض والمتعارض والمتعارض وا	
•	-6 13 47-		on of the coall bound out	
To investigate methods	or expanding the	Sullace are	ea of the small bowel muc	.038
		•		
				•
Technical Approach:	•		•	
Rabbits are studied. A	nimal surgary is	performed o	on the ileum	
rogress during 1/4-80:				
Dacron and dexon polyme	r have been studi	ed with sin	nilar mendita (ase disced	c attache
- , , , , , , , , , , , , , , , , , , ,				
er of miliecis to be stud				- ~
us/unexpected side effec	ts in subjects purti	cipating in	project:	
				•
Currently autogenous me with foreign naterial.	scle grafts seen	to be a su	perion lattine, as compan	:ed
contions or Abstracts. F	Y-80:			
(Surgical Forum: 30:36				
			•	<i>:</i>

FUNDING REQUIREMENTS CLINICAL INVESTIGATION PROGRAM

N. UNI	T NO.: 2003 TIT	LE: The Effects of	Gastric Surg	ery on the Release of	FY				
		Pancreatic Pol	Pancreatic Polypeptide						
'C:	<u>eri</u>	ncipal investiga	CIPAL INVESTIGATOR: John W Harmon						
		Cre. Harmon							
MENT F ENSE		FY 81	FY 82	REMARKS	3				
- 1200	Personnel:	None	None						
100	Travel:								
	Mission	800	800	Confer with collaborat	ors				
	Coalerence	60v ·	600	Present material	-				
	Patient								
19	Rental Equip:								
99	Printing and Reproduction:								
::	Contractual Svc Lab Contracts:	50	50	Freight transport of	speci ens				
<i>(1)</i>	Consumable Supplies and Experimental Animals								
·:		r,							
1:		3.							
_i ni-o	ment Ranks	No	Жо	WORK UNITS:	an a				

Work Unit Number: 2106

Management of the Hemodynamically Significant, Title of Project:

Asymptomatic Carotid Bruit

Investigators:

Principal: LTC G. Patrick Clagett

Associates: COL George J. Collins, Jr.

COL Norman M. Rich ITC James M. Salander MAJ Michael J. Spebar

Objectives:

(1) To determine the most appropriate management of patients with asymptomatic, hemodynamically significant carotid bruits, (2) To determine the natural history of asymptomatic extracranial vascular disease; (3) To determine the role of noninvasive diagnostic techniques in the management of patients

with asymptomatic extracranial vascular disease.

Technical Approach: Consenting patients who are asymptomatic for cerebrovascular disease who have hemodynamically significant carotid stenoses (as determined by non-invasive studies) are eligible for randomization into two groups. Patients ineligible for candomization include those who have had carotid endarterectomy on the side in question, those judged too frail to undergo carotid endarterectomy, and those who don't consent. Patients randomized into the surgical group will undergo arteriography and carotid endarterectomy if an operable lesion is found. Patients. randomized into the second group will be treated with aspirin, 650 mg twice daily, and followed closely (every 3 months). It patients in the second group developsymptoms, they will then undergo arteriography and carolla endarterectomy.

Progress and Results:

Since initiating this project, 22 patients have been identified with hemodynamically asymptomatic carotid bruits. Of these, 14 have consented to join the study and 8 have refused. Of those who have entered, 8 have been randomized into the aspirin group and 6 have been allocated to the surgical treatment group. The mean follow-up period for all patients entered is 10 month. In the aspirin group, there was one death from a cardine cause. Two patients in the aspirin treatment group developed symptoms. The first patient developed nonfocal global symptoms of cerebrovascular insufficiency manifested by dizziness and disequilibrium. This

technically was considered a failure of aspiring therapy and the patient underwent arteriography which demonstrated two critical stenoses, one at the carotid bifurcation and one in the siphon region. Because of the tandem lesions, the latter of which was not amenable to surgical therapy, the patient was considered inoperable. The second aspirin failure patient developed amaurosis fugax and underwent arteriography which demonstrated a tight stenosis of the internal carotid artery which was reconstructed with a carotid endarterectomy. His course and follow-up have been uneventful.

Of the 6 patients allocated to the surgical group, 4 have undergone uneventful prophylactic carotid endanterectomies. One of these patients died in the follow-up period because of complications of another vascular procedure. The remaining three patients have had uneventful follow-up following carotid endarterectomy. One patient developed anaphylaxis and a subsequent myocardial infarction during angiography. At present, he is considered too poor an operative risk and is being followed by medical therapy. The final patient in the surgical group has steadfastly refused arteriography after being allocated to the surgical group. She also is being followed on medical therapy. The 8 patients who refused entrance into the study comprise any interesting group from which valuable information may be obtained. All of these patients declined entrance into the study because they did not want to have a 50% chance of having surgery. All of these patients have been followed on aspirin therapy. One of these patients developed a mild stroke and underwent arteriography and operation which demonstrated an occluded internal carotid artery which could not be reopened. Another patient, although remaining asymptomatic, was seen at another hospital and underwent bilateral carotid endarterectomies there.

Conclusion:

As with the annual report last year, the number of patients is too small and the follow-up period too brief to draw firm conclusions.

The study will have to be continued for another 2-3 years to reach meaningful conclusions.

Funding Requirements: None.

Publications: None.

Type of Report: Interim.

Work Unit Number: 2109

Title of Project: Etiologic Factors for Recurrent Carotid Stenosis

Investigators:

Principal: LTC G. Patrick Clagett

COL Norman Rich

Associates: LTC George J. Collins, Jr.

LTC James M. Salander MAJ Michael J. Spebar MAJ Waltiam L. Eddleman LTC Salverio Cabellon

(1) To determine risk factors for the development of recurrent Objectives:

carotid stenosis following successful carotid endarterectomy

Technical Approach.

dations with surgically or anglegraphically proven carotid restenosis comprise the study group. These patients are age and sex matched with patients who underwent carotid endarterectomy during the same year. The second group of patients comprises the control group. On all patients, the following information is obtained: symptoms and other indications mandating first procedure, angiographic findings, operative details, immediate postoperative morbidity and mortality, histopathologic findings, and presence of atherosclerotic risk factors. In addition to these data, study patients and control patients will have blood drawn for determination of cholesterol and triglyceride levels as well lipid fractionation studies to determine the relative amounts of HDL, LOL and VLDL cholesterol. Furthermore, both groups of patients will undergo threshold dose response platelet

aggregometry to ADP epinephrine and collagen.

Progress and Results:

To date, 25 patients have been identified with recurrent carotid stenosis following successful carotid endarterectomy. Ten patients with restenosis have been matched with control patients and all have had their studies completed. The data have not been analyzed. We are waiting from complete follow-up on all patients with carotid restenosis, as well the necessity for finding matched controls for these patients. It is anticipated that one more year of surgery will be necessary to meet these requirements and complete the study.

Conclusions: The study is incomplete and no definite conclusions can be drawn. The one striking finding that has surfaced is that greater than 50% of the patients with carotid resterosis have been females. Because thus does not parallel the natio of nole to female (4:1) in

our population undergoing carotid andarteractomy, sex difference appears to be an obvious etiologic factor for carotid restenosis.

Funding Requirements: There have been no funding requirements. The clinical laboratory has performed the lipid determinations and Dr. George J. Collins' laboratory has performed the platelet

aggregometry.

Publications: None

Type of Report: Interim.

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN-

REFERENCE OR OFFICE SYMBOL

SUBJECT Work Unit #2110

Protocol: Participation of the Reticuloendothelial

HSWP-SPV

System in Shortening Platelet Survival

ro

FROM

DATE

CMT 1

C, Clinical Investigation

Acting C, Per Vas Surg Svc

15 Jan 1981

- 1. The protocol, Participation of the Reticuloendothelial System in Shortening Platelet Survival, has been withdrawn from those supported by the Clinical Investigation Service. This protocol is now being carried out in the Division of Surgery at Walter Reed Army Institute of Research with support from OMA funds.
- 2. This protocol involved no human subjects.

G. PATRICK CLAGETT, M.Y.

LTC, MC, USA

Acting Chief, Peripheral Vascular

Surgery Service

Date: 28 August 1930	Protocol	No:	2306	St	atus: Interim				
Title of Project:					Final XX				
CLINICAL QUANTIFICATION OF	- INTRAOCULA	R MALIC	SMANT MELANC	DHA VOLU	ΜE				
•		•							
Starting Date: 20 March 1975	5 Estir	nated C	ompletion D	nte: 2	2 August 1980				
Principal Investigator:	LTC KENYON	K. KRAI	MER, MC						
Associate Investigators:		Facilit	y: VRAMO	`					
None	•	Dept/Svc Cphthalmology							
Key Words: Ultrasound, I	ntraocular	Tumor	Malignant N	le Lanoma	•				
Accumulative MEDCASE			Contract	,	cumulative Supply				
Cost: Unknown	Cost:	None		1 -	osi: None				
FY-80 MEDCASE Cost:	None		Periodic Re (to be fille						
The following abstract was Vision in Ophthalmology me	eting, Orla	ndo, FI	orida, 4 Ma	iy - 9 Ma	y 1980.				
•			-						
Technical Approach:									
See above		•							
•				•					
				,					
Progress during FY-80: See above		•			•				
Number of subjects to be stu	died before	comula	ion of study	. 19	<u> </u>				
Serious/unexpected side effe									
Conclusions:			······································		·				
See above									
Publications or Abstracts, 1	FY-SO: See	above							

ULTRASONOGRAPHIC MEASUREMENT OF CHOROLDAL MELANOMA

Kenyon K. Kramer, M.D. Walter Reed Army Medical Center Washington, D.C.

The size of choroidal malignant melanomas continues to be important clinically, influencing managment in many cases. Nineteen melanomas have been measured in three dimensions with ultrasound in vivo and the results compared to histopathology dimensions. Both the "Coleman" apparatus and the Bronson Turner were used. The height measurements were the most accurate but one tumor was overestimated by 3.5 mm and one underestimated by 2.5 mm. Tumor base size estimates showed considerably more scatter. Lesions posterior to the equator were generally overestimated. (One tumor by 7 mm by one method.) Tumors located on the equator were generally more accurately measured and the errors better centered about a zero error line (one mass underestimated by 4 mm). These differences in errors depending on the location were statisdically significant at the .01 level for one diamter of the tumor base. These data suggest that empirically derived correction factors may offer improved accuracy in ultrasound size estimations of choroidal tumors in vivo.

ARVO abstracts
1900, Octood, Stonests

Date: 15 October 1980 Protocol No: 2308 Status: Interim Final XX Title of Project: Scleral Buckling Experience at WRAMC 1973 - 1976: A Retrospective View Starting Date: 1978 Estimated Completion Date: 1980 Principal Investigator: Cary L. Burton, MAJ, MC Facility: Walter Reed Army Medical Center Associate Investigators: Paul V. Whitmore, COL, MC Fleming D. Wertz, LTC, MC Ophthalmology Service Dept/Svc Department of Surgery Key Words: Scieral buckle, silicone Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: Cost: 0 Cost: 0 FY-80 MEDCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: To review surgical results of Retina Service, Ophthalmology, concerning scieral buckling operations. Technical Approach: Chart review Progress during FY-80: Scleral buckling procedures using solid silicone elements results in an outcome with no statistical difference as compared to using expandable silicone elements. Number of subjects to be studied before completion of study: Serious/unexpected side effects in subjects participating in project: Conclusions: Expanding silicone buckling elements are not necessary to achieve good results, as claimed by some authors. Furthermore, our results compare favorably with other reported series. Publications or Abstracts, FY-80: None

Date: 10 October 1990	Protoco	l No: 2309		Status: Int	terim XX
Title of Project: A Study of Eye Trauma and					nal
Starting Date: 27 Dec 77	Esti	nated Com	pletion D	ate: June 1980	
Principal Investigator: Ho	oward P. Cup	oples, CAP	T, MC, U	SN	
Associate Investigators:		Facility:		l Naval Medical Reed Army Medica	
Paul V. Whitmore, COL, MC,	, UṢA	Dept/Svc	Ophthalm	ology Service, D	Jept of Surgery
Key Words: Vitreous surgs	ery, ocular	i trauma			.•
Accumulative MEDCASE Cost: 0	Accum Cost:	ulative Co 0	ntract	Accumulati Cost: 0	ve Supply .
FY-80 MEDCASE Cost:	0			eview Results:ed in by DCI)	
Study Objective: To deter ocular trauma. To compar surgery with the results methods. To develop plan based upon the adalysis of	e the resul of ocular t s for the e	ts of ocu rauma cas fficient	la trau es manag manageme	ma cases managed ed in the past b nt of ocular com	by vitreous v conventional
Technical Amproach: A series of cases of ocul compared with a similar s WRAMO during the Vietnam	eries drawn	retrospe	ctively	from records of	NNMC and
		-			•
Progress during FY-80: To combined series at WRAMC and the retrospective studene 1980.	and NNMC.	The prosp	ective se	eries is therefo	re completed
Number of subjects to be stu					
Serious/unexpected side effe No serious unexpected sid				•	J in the manageme
Conclusions: Conclusions a will be reviewed at this by conventional surgery. Publications of Alexands	s to the ef time, until	fectivene	ss of vi	of t	hese frauma cases fechniques

Interim XX Date: 14 August 1980 Protocol No: 2310 Status: Final Title of Project: INTRAOCULAR LENSES Estimated Completion Date: 12 August 1931 Starting Date: 13 April 1978 (Final termination of this protocol will be determined Principal Investigator: MC by the FDA) Facility: Walter Reed Army Medical Center Associate Investigators: None Dept/Svc Conthalmology Service Key Words: Intraocular Lenses Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: None Cost: None Cost: \$4300 FY-79 FY-80 MEDCASE Cost: None Periodic Review Results: (to be filled in by DCI) Study Objective: To evaluate intraocular lenses with regard to safety in the treatment of aphakia

Technical Approach: Intraocular lenses will be implanted in selected patients either at the time of cataract extraction or in a second operation following cataract extraction. This is part of a nationwide collaborative study to determine the incidenc of adverse effects.

Progress during FY-80: 53 patients have had lens implants or attempted lens implants. One adverse result mentioned in the preceding report has been corrected with a final visual acuity of 20/20. A second adverse result is not directly attributable to the intraocular lens.

Number of subjects to be studied before completion of study: Unknown (FDA will determine) Serious/unexpected side effects in subjects participating in project:

None

Conclusions: The generally good results indicate sufficient value to continue with this protocol.

Publications or Abstracts, FY-80: None

20 June 80 Date:

Work Unit No. 2312

Status: Final

litle of Project: Corneal Endoth Hall Cell Lose Ferlowing Various Cataract

Extraction Techniques.

Starting Date: May 1979

Completion Date: 20 June 1980

Principal Investigator: R. Jeffrey Bergquist, MAJ, MC

Service: Ophthalmology

Facility: WRAMC

Hey Words: Corneal Endothelium

Asso. Investigators: None

Aboum. MEDCASE

Accum. Contract

Accum. Supply

Cost: None

Cost: None

Cost: \$64.80

FY 80: None

FY 80: None

FY 8C: None

Objectives: To compare the amount of corneal endothelial damage resulting from the "standard cataract" extraction versus the "small incision extraction.

lachnical Approach: Corneal endotholial cell counts were teasured pre and iost op in each group of patients.

Progress during FY 80: 14 patients from the "standard catamact" group were studied of which 4 were eliminated due to post operative scaplications, trauma or cancellation of storgery. 3 patients from the "small incision" group were studied. Greater numbers were not obtained in this group because of the relative infrequency of nontraumatic cataracts in young persons who are old enough to cooperate for the andsthalial call these and the ultimately reserve a small inclision extraction is opposed to one of one other techniques. Recause of my transfer to Fort Polk, LA, I am terminating this project.

Conclusions: Since the study is incomplete, no conclusions can be drawn.

Colications: None

He Effects: There were no side effects or complications with any of the patients.

Date: 6 October 1980	Protoco	1 No.: 2	516	Status: Final			
Title of Project: The Ef Hearin	fect of Ampl g Loss	ification	on Limi	ted High-Frequency			
Starting Date: August 19	76 Esti	mated Comp	oletion	Date: October 1980			
Principal Investigator:	Rauna K. Sur	r, M.S.					
Associate Investigator: Daniel M. Schwartz, Ph.	D.	Facility: Army Audiology and Speech Center, WRAMC					
		Dept/Svc:	Depart laryng	ment of Surgery, Oto- ology Service			
Key Words: California Co fusions, high				nition, consonant con-			
Accumulative MEDCASE Cost:	Accumulative Supply Cost:						
FY-80 MEDCASE Cost:		Period	dic Revi	ew Results:			
Study Objective: 1) Ass tool in clinical hearing frequency hearing loss. individuals with hearing	<pre>aid evaluati 2) Assessme</pre>	on on the nt of bene	populat fit of	ion with limited high- amplification for			
Technical Approach: Comp	leted.						
Extended High Frequency A sented in Atlanta, Georgi appeared in ASHA, Sept. 1 Association. The pilot study imme for publication in EAR an	mplification a, last Nove 979, a journ diately prec d HEARING. his project	for Heari mber. The al of the eeding the will be pr	ing Loss abstraction Americal above	er this protocol entitled Above 2000 Hz was pre- ct for this paper n Speech-Language-Hearing paper has been accepted on of the fourth paper			
Number of subjects to be	studied befo	re complet	ion of	study: n/a			
Serious/unexpected side e	ffects in su	bjects par	ticipat	ing in project: n/a			

Conclusions: The research by us as well as by others over the past four years has been very fruitful and has demonstrated the sensitivity of the CCT to the phoneme recognition problems associated with high frequency sensorineural hearing impairment. Superiority of the CCT, however, in conventional comparative hearing aid evaluations over other speech test materials currently in use has not been demonstrated.

Future clinical applications of the CCT will probably be in aural rehabilitation through analysis of phonemic changes achieved with training and amplification.

Publications or Abstracts, FY-80:

Schwartz, D.M. and Surr, R.K. Three Experiments on the California Consonant Test. J. Speech Hear. Dis., February, 1979.

sonant Test. J. Speech Hear. Dis., February, 1979.
Schwartz, D.M., Surr, R.K. et al. Performance of High Frequency Impaired Listeners with Conventional and Extended High Frequency Amplification. Audiology, 18, 1979.

tion. Audiology, 18, 1979.

Schwartz, D.M. and Surr, R.K. High-Pass and Conventional High Frequency Hearing Aids for Listeners with High Frequency Sensorineural Hearing Loss. Auditory and Hearing Prosthetic Research, Larson, V.D., Egolf, D. and Kirlin, L. (Eds.), Grune & Stratton, 1979.

*Note: Copies of the first two publications have been forwarded to DCI; a copy of the third publication is attached.

WORK UNIT NO.: 2516

FUNDS UTILIZED, FY-80: \$159.00 to present results at national meeting

\$260.00 for reprints

FUNDING REQUIREMENTS, FY-81:

REPRINTS: \$100.95

WORK UNIT NUMBER: 2516

TITLE: The Effect of Amplification on Limited High-Frequency Hearing Loss

INVESTIGATORS: Principal: Rauna K. Surr, M.S.

Associate: Daniel M. Schwartz, Ph.D.

OBJECTIVES: 1. Assessment of the California Consonant Test (CCT) as a clinical tool. 2. Assessment of benefit of amplification for individuals with limited high-frequency sensorineural hearing loss.

TECHNICAL APPROACH: Speech audiometry is considered one of the more important measurements in clinical audiology. Because research has shown that pure tone audiometry provides limited information about the speech processing characteristics of the auditory system, clinicians have long been interested in evaluating an individual's ability to hear and understand speech. Ideally, speech testing should reflect the communication handicap created by the hearing loss and should differentiate between normal hearers and those with sensorineural impairment. The most widely used word recognition test is the CID W-22 lists (Hirsch et al., 1952). It has been shown to be relatively insensitive to high-frequency sensorineural hearing impairment, which is very prevalent in the U.S. Armed Forces secondary to noise exposure. Several new speech materials have been developed because of the problems associated with CID W-22. Among them is the Northwestern University Auditory Test Number 6 (NU-6) by Tillman and Carhart (1966) which is now used routinely within the United States Army and Air Force audiology clinics. More recently (1977) Owens and Schubert introduced a consonant discrimination test, the California Consonant Test (CCT), which is purported to be highly sensitive to high-frequency hearing impairment. Over the past four years we have completed several studies to evaluate the CCT as a clinical tool.

PROGRESS AND RESULTS: Initially, performance-intensity functions were obtained for both normal hearers and those with high-frequency sensorineural hearing loss. The results demonstrated almost a linear function for both subject groups, approaching asymptote at 50 dB SL, as compared to the typical sigmoidal function obtained with conventional (CID W-22 and NU-6) word recognition tests. CCT scores were also compared to scores on MU-6 lists in 60 subjects with high frequency noise-induced hearing loss. Consistent with previous findings, relatively high word recognition scores were obtained for the NU-6 materials, whereas the range of scores on the CCT approximated a normal distribution.

The second phase was designed to examine the sensitivity of the CCT in differentiating among hearing aids. We sought to determine if a high-pass hearing aid can provide increased improvement in word recognition and consonant discrimination over that of a conventional high frequency emphasis hearing aid in laners with hearing loss limited to frequencies above 1000 Hz. Word and consonant discrimination were assessed in quiet and in the presence of 12 talker speech babble for ten subjects under three listening conditions: 1) unaided; 2) wearing a conventional high frequency emphasis hearing aid; and 3) wearing an experimental high-pass instrument. The speech testing materials included: 1) NU-6; 2) CCT; and 3) eight voiceless English consonants. The results indicated that both instruments provided similar benefit in quiet. For the noise condition, however, the experimental high-pass

aid provided a considerable advantage, as suggested by mean data. No notable difference was observed in the mean percent improvement between the NU-6 and the CCT scores. Effect of noise at different signal-to-noise ratios needed further examination.

The third phase examined the effects of multi-talker competing speech and half vs. full-list usage on the variability of the CCT scores in sound field in an effort to establish some guidelines for a significant difference between scores when comparing different hearing aids for individual patients. Phoneme recognition was assessed in a sound field in quiet and under four message-to-competition ratio conditions for normal hearing subjects and in three MCR conditions for listeners with bilateral high-frequency sensorineural hearing loss. Noise interference functions for both subject groups were characterized by a gradual decline in recognition performance as the signalto-noise ratio decreased. The slope of the function for the two groups was parallel with the mean scores for the hearing-impaired subjects approximately 30% lower than that for the normal hearers. Test-retest reliability across conditions was examined via correlational analysis and by computing testretest difference scores for individual subjects. Increased test variability with half-lists and with the introduction of a competing message makes the CCT under these two conditions of questionable value in routine bearing aid evaluation procedures.

The final phase of this protocol assessed the usefulness of the CCT in predicting aided benefit for individuals with hearing loss limited to frequencies above 2000 Hz. In addition to assessment of phoneme recognition by the CCT, Social Hearing Handicap Index (SHI) developed by Ewentsen and Birk-Nielsen (1973) and follow-up hearing aid use questionnaires were used. The results indicated that despite the sensitivity of the CCT to the phoneme recognition problems associated with high-frequency sensorineural hearing impairment, no appreciable aided improvement was demonstrated with this measure for his group of subjects. On the other hand, the follow-up accessment was somewhat more encouraging. Usage and subjective reports of improved daily communication suggested that many of these hearing aid fittings for the limited high frequency hearing loss group can be considered successful.

CONCLUSIONS: The research here as well is elsew one to the nest Jour mians has been very fruitful and has demonstrated the sensitivity of the CCT to the phoneme recognition problems associated with high-frequency censorineural hearing impairment. Superiority of the CCT, however, in conventional comparative hearing aid evaluations over other speech test materials currently in use has not been demonstrated.

Future clinical applications of the CCT will probably be in aural rehabilitation through analysis of phonemic changes achieved with training and amplification.

REFERENCES:

Evertsen, h. G., and Birk-Hillson, H., Sacial Investigate Tidez. Audiology, 12, 180-187, 1973.

Hirsch, I. J., Davis, H., Silverman, S. R., Roynolds, E. G., Elbert, E., and Benson, R. H., Development of materials for speech audiometry. <u>J. Speech Hearing Dis.</u>, 17. 321 237, 1952.

Owens, E., and Schubert, E. D., Development of the California Consonant Test. J. Speech Hearing Res., 20, 463-474, 1977.

Tillman, T., and Carhart, R., An expanded test for speech discrimination utilizing CNC monosyllabic words (Northwestern University Auditory Test Number 6) SAM-TR-66-55, 1966.

FUNDS UTILIZED: FY-77: Travel to Chicago, Illinois, for paper presentation

FY-78: None FY-79: None

FY-80: Travel to Atlanta, Georgia, for presentation of paper

and purchase of reprints.

FUNDING REQUIREMENTS, FY-81: Purchase of reprints, requested.

PUBLICATIONS:

Schwartz, D. M., and Surr, R. K., Three experiments on the California Consonant Test. J. Speech Hearing Dis., February, 1979.

Schwartz, D. M., Surr, R. K., Montgomery, A. A., Prosek, R. A., and Walden, B. E., Performance of high frequency impaired listeners with conventional and extended high frequency amplification. Audiology, 18, 1979.

Schwartz, D. M., and Surr, R. K., High-pass and conventional high frequency hearing aids for listeners with high frequency sensorineural hearing loss. Auditory and Hearing Prosthetic Research, Larson, V. D., Egolf, D., and Kerlin, L. (Eds.), Grune & Stratton, 1979.

Surr, R. K., and Schwartz, D. M., Effects of multi-talker competing speech on the variability of the California Consonant Test. Manuscript accepted for publication, Ear and Hearing, November, 1980.

TYPE OF REPORT: Final

DATE PREPARED: 24 October 1980

Date: 7 October 1980	Protoco	1 Mo.:	2517	Stat	us: Interi	i m		
Title of Project: Evaluation	tion of a Sp Integration		ed Techni	que for T	raining Aud	dio-		
Starting Date: 22 August	1977 E	stimated	d Complet	ion D ate :	January	1981		
Principal Investigator: /	Allen A. Mon	tgomery	, Ph.D.					
Associate Investigators: Brian E. Walden, Ph.D. Daniel II. Schwartz, Ph.I	o	Facil		y Audiolo ter, WRAM	gy and Spee C	ech		
Robert A. Prosek, Ph.D. Earl Wilkinson, MD, MAJ	, MC	Dept/S	Svc: Depo lar	artment o yngology	tment of Surgery, Oto- gology Service			
Key Words: Aural rehabilintegration	itation, reh	abilitat	tion, lip	reading,	euditory-vi	isual		
Accumulative MEDCASE Cost:		ative Co		Ac Co	cumulative st:	Supply		
FY-80 NEDCASE Cost:		Per	iodic Rev	iew Resul	ts:	-		
Study Objective: This stunewly-developed training paudible and visible aspect (AVI)].	udy is desig procedure fo is of speech	ned to e r improv simult:	evaluate ving pati ineously	the effec ents' abi [zudio-vi	tiveness of lity to use small integr	f a e the		
Technical Approach: Third and experimental groups are tional rehabilitation or findividually in 10 and-hos before and after testing audiovisually in noise, are (t-tests and ANACOVA). In were tested at a similar	nd tested be the AVI tech ur sessions consisted of nd the data n addition,	fore and nique. by train a 100- were and a group	d after r The AVI ned rehub item sent alyzed wi of 12 no	eceiving training ilitation ence test th parame rmally-he	either tradwas done ists. The presented tric statisaring peop	di- stics le		

Progress during FY-80: All data have been collected and analyzed, and very encouraging results have been obtained. Foth groups show significant improvement following training, and the experimental group shows significantly more improvement than the controls. No learning was evidenced by the normals.

Number of subjects to be studied before completion of study: none

(cont.) - #2517

Conclusions: The technique appears to be a useful and efficient way to improve new hearing aid users' ability to use the visual (lipreading) component and the auditory component of speech simultaneously.

Publications or Abstracts, FY-80: Manuscript in preparation for submission to J. Speech & Hearing Disorders.

WORK UNIT NO .: 2517

FUNDS UTILIZED, FY-80: None

FUNDING REQUIREMENTS, FY-81:

REPRINTS/PAGE CHARGE: \$300.00

Date: 6 October 1980 Protocol No.: 2523 Status: Interim Title of Project: The Relationship Between Electroacoustic Parameters and Perceived Sound Quality of Hearing Aids Starting Date: June 1978 Estimated Completion Date: November 1980 Principal Investigator: Daniel M. Schwartz, Ph.D. Facility: Army Audiology and Speech Associate Investigators: Allen A. Montgomery, Ph.D. Center, WRAMC Brian E. Walden, Ph.D. Robert A. Prosek, Ph.D. David H. Layland, MD, MAJ, MC Dept/Svc: Department of Surgery, Otolaryngology Service Key Words: Hearing aid processed speech, multidimensional scaling, hearing aid sound quality, electroacoustic characteristics Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: \$18,650 Cost: Cost: \$256.40 FY-80 MEDCASE COST: Periodic Review Results:

Study Objective: To determine the relationship between various perceptual dimensions and the physical characteristics of hearing aids in judging the sound quality of hearing aid processed speech.

Technical Approach: A single 20 second type records' passage tentisting of an interpretate reading from "The Adventures of Tom Seager" was hearing aid processed through each of 20 commercially available hearing aids in a paired comparison format. The recording procedure was accomplished using KEMAR equipped with Zwislocki-type ear simulators.

For the playback phase 10 normal hearers, 10 subjects with high frequency hearing loss, and 10 with flat loss were each instructed to furnish two types of responses; ratings of similarity and judgments of preference based on the quality of the hearing aid processed speech. Similarity ratings were made on a 7-point equal appearing interval scale, where 1 represented very similar and 7 dissimilar. Preference judgments consisted of identifying the aid within each pair which had preferable sound quality.

Progress during FY-80: This research has culminated in the presentation of two papers at the 1972 and 1979 annual meetings of the Grenican Steech-Language-Hearing Association. The abstract of each of these papers appearing in ASHA, Sept. 1978, 1979.

(cont.) - #2523

The first paper dealing with results obtained on normal hearing subjects was recently published in the <u>J. of the Acoustical Society of America</u>, 68, 2, 458-466 (1980). The second paper reporting results for 20 patients with hearing loss (10 sloping, 10 flat configuration) is in the process of being submitted for publication to the <u>J. Acoust. Soc. Am.</u>

Results of this investigation revealed that one perceptual dimension, low cut-off frequency (LCO) dominated the judgment of hearing aid sound quality for both normal hearing and hearing impaired subjects. That is, listeners

strongly preferred hearing aids with relatively low LCO's

Number of subjects to be studied before completion of study: 30

Serious/unexpected side effects in subjects participating in project: n/a

Conclusions: The finding that LCO dominates listener judgments of hearing aid sound quality is in direct contrast to the amplification needs of hearing impaired patients. That is, an extensive pody of research literature suggests that amplification of low frequency speech sounds and noise may create an upward spread of masking and thus degrade the intelligibility of speech. Hence, the data of the present study reveals that the electroacoustic characteristic that results in the best sound quality, i.e., low low-cut-off frequency, may not be the one that results in improved speech understanding with a hearing aid.

Publications or Abstracts, FY-80:

Punch, J.L., Montgomery, A.A., Schwartz, D.M., Walden, B.E. et al. Multidimensional scaling of quality judgments of speech signals processed by hearing aids. J. Acoust. Soc. Am., 68, 2, 458-466, 1930. Schwartz, D.M., Montgomery, A.A., Punch, J.L., Walden, B.E. et al. Electroacoustic correlates of hearing aid quality judgments (submitted for publication - J. Acoust. Soc. Am.).

WORK UNIT NO.: 2523

FUNDS UTILIZED, FY-80: \$256.40 - case of 4 rolls of hardcopy paper

FUNDING REQUIREMENTS, FY-81:

REPRINTS/PAGE CHARGES: \$500.00

Date: 7 October 1980

Protocol No.: 2525

Status: Interim

Title of Project: Generation and Evaluation of Synthetic Facial Images for

Studying and Training Lipreading

Starting Date: 21 August 1978

Estimated Completion Date: September 1981

Principal Investigator: Allen A. Montgomery, Ph.D.

Associate Investigators:

Brian E. Walden, Ph.D. Robert A. Prosek, Ph.D. Daniel M. Schwartz, Ph.D.

Kweon I. Stanbaugh, MD, CPT, MC

Facility: Army Audiology and Speech

Center MRAMC

Dept/Svc: Department of Surgery, Oto-

laryngology Service

Key Words: Lipreading, synthetic speech, computer graphics, aural rehabili-

tation

Accumulative MEDCASE Cost: \$7,595.00

Accumulative Contract

Accumulative Supply

Cost:

Cost: \$622.60

FY-80 MEDCASE Cost: \$7,595.00

Periodic Review Results:

Study Objective: This study is designed to evaluate the feasibility of simulating on a computer graphics system, the information-bearing elements of the talker's mouth and face during speech, for the purpose of studying lipreading in hard-of-bearing patients.

Technical Approach: The third year of this project has been devoted to refining the algorithm (in the form of a FORTRAN program) that produces sequences of up to five consonants and vowels. The primary approach has been to incorporate a mechanically-based model of coar iculation with linear interpolation between primative images and experimentar - controlled amounts of furward and backward coarticulation.

Progress during FY-80: The basic algorithm has been completed and is in the process of being debugged. One subroutine, designed to blank invisible portions of the upper teeth coincident with upper lip movements, is completed but not yet incorporated into the main program.

Number of Subjects to be studied before completion of study:

Serious/unexpected side effects in subjects participating in project: n/a

(cont.) - #2525

Conclusions: Progress this year has been substantial, with successful generation of simple coarticulated lip shapes (see abstract referenced below). The final evaluation of the system will take place this fiscal year.

Publications or Abstracts, FY-80: "Coarticulation and lipreading: comparison of synthetic and real stimuli", presented at ASHA Convention, November 1979, Abstract in ASHA, Nov., 1979.

WORK UNIT NO.: 2525

FUNDS UTILIZED, FY-80: \$5,000.00 - Camera, compact video color

\$2,595.00 - Video Tape Recorder/Reprod. Editor \$ 452.60 - (20) 1/2", 2400' reel-to-reel videotape

on 7" reel

\$ 170.00 - Front loading disk cartridge for RKO5, DEC

disk drive

FUNDING REQUIREMENTS, FY-81:

TRAVEL: \$582.00 (to present results at national meeting)

SUPPLIES: \$160.00 for magnetic storage medium for data

REPRINTS/PAGE CHARGES: \$500.00

Date: 3 October 1980 Protocol No.: 2526 Status: Interim Title of Project: Development of a Communication Self-Assessment Inventory of the Hearing Impaired Soldier Starting Date: January 1979 | Estimated Completion Date: September 1981 Principal Investigator: Brian E. Walden, Ph.D. Facility: Army Audiology and Speech Associate Investigators: Marilyn D. Hang, Ph.D. Center, WRAMC Sue A. Erdman, M.A. Roy K. Sedge, Ph.D., MAJ, MSC Dept/Svc: Department of Surgery, Oto-Daniel E. Speilman, M.D., MAJ, MC laryngology Service Key Words: Self-assessment, inventory, hearing impaired, communication Accumulative Supply Accumulative MEDCASE Accumulative Contract Cost:____ Cost:____ FY-80 MEDCASi Cost: Periodic Review Results: Personnel Cost: \$7,243.00

Study Objective: The objective of this project is to develop a communication self-assessment inventory to be used in the inpatient Aural Rehabilitation Program of the Army Audiology and Speech Centers (MAND). The spacific purposes of this inventory are:

a. To assess progress in environmental control, and in emotional, social, familial, and vocational adjustment to the handicap as a result of the Aural Rehabilitation Program (i.e., a quantitative index of improvement provided by pre- and post-program scores).

b. To establish a baseline for planning a patient's environmental control training and adjustment counseling in the Aural Rehabilitation Program.

c. To provide prognostic indicators of short-term success in the Program (pre-program administration).

d. To provide prognostic indicators of long-term success in communication after returning to duty station (post-program administration).

Technical Approach: The original Application for the held desearch Project proposed that the Government contract for the development of a self-assessment inventory of communication ability. Following the approval of the original protocol by the Department of Clinical Investigation, requests for funding were made to the Medical Research and Development Command and to the Health Services Countries of the Medical Research and Development Command and to the Health Services Countries of the Medical Research and Development Command and to the Health Services Countries of the Medical Research and Development Command and to the Health Services Countries of the Medical Research and Development Command and to the Health Services Countries of the Medical Research and Development Command and to the Health Services Countries of the Medical Research and Development Command and to the Health Services Countries of the Medical Research and Development Command and the Health Services Countries of the Medical Research and Development Command and the Health Services Countries of the Medical Research and Development Command and the Health Services Countries of the Medical Research and Development Command and the Health Services Countries of the Medical Research and Development Command and the Health Services Countries of the Medical Research and Development Command and and

In May, 1979, a new communication self-assessment inventory appeared in the literature. The Hearing Performance Inventory (T.C. Giolas, E. Owens, S.H. Lamb and E.D. Schubert, <u>Journal of Speech and Hearing Disorders</u>, 1979) appeared to have potential for use with a military population. Given that funding was not obtained for the original proposal, the project was modified to be an evaluation of the Hearing Performance Inventory (HPI). Among the specific goals of this evaluation were the following:

a. To determine the clinical applicability of the HPI for a military

population;

b. To accomplish a detailed statistical analysis of the reliability of the HPI; and

c. To determine the prognostic value of the HPI for the military

population.

As a result of the work accomplished during FY-80 (see "Progress during FY-80"), it became apparent that the HPI could not be modified to fulfill each of the purposes of a self-assessment inventory outlined in the original protocol. It appears, therefore, that the original proposal - to develop an inventory tailored to the specific needs of the Army - is the only viable

option remaining.

Since the initiation of this project, considerable technology in test design, construction and evaluation has been acquired. As a result, it is probable that a communication self-assessment inventory can be developed inhouse that will meet all of the Army's major needs. It will be essential, however, that an experimental psychologist be available part-time for a period of one year to provide technical guidance in test construction, data acquisition and statistical evaluation.

Progress during FY-80: Work during the past year focused on an assessment of the HPI as a potentially suitable self-assessment communication inventory of the hearing impaired soldier. The complete 158-item inventory was administered to a total of 254 patients entering the Army Audiology and Speech Center's Inpatient Aural Rehabilitation Program. Extensive analyses of the scales and subscales of the HPI were accomplished via computer. The major findings of this work were:

a. The Speech Scale items could be drastically reduced in number, with virtually no loss of reliability.

b. The Intensity Scale items could be reduced in number to produce a scale containing equal numbers of items in two subscales: Detecting Common Sounds and Detection and Loudness of Speech.

c. Although the Reaction to Auditory Failure Scale is closely concerned with one of the goals of the project, items of this type are under-

represented in the Inventory as compared to other Scales.

d. The Personal Adjustment Scale, while <u>potentially</u> useful as predictors of adjustment and program evaluation, proved to be too general in nature and not sufficiently applicable to the military population.

e. The Social Scale may be eliminated since it is completely redun-

dant with the Speech and Reaction to Auditory Failure Scales.

f. The Occupational Scale items should be eliminated because the structure of these items mirrors that of the Speech, Reaction to Auditory Failure and Personal Scales.

As a result of item and factor analyses of the original 158-item inventory, an 80-item revision was developed. The basic strategy for item selection/elimination was to select items for the shortened scales so as to maximize coefficient α . (In general, this means selecting the items with the

highest item-total correlations.) The revised 80-item inventory was administered to an additional 75 patients as they entered Program and at the conclusion of the two weeks. Additional data obtained include a) testing at the soldier's duty station 2-4 weeks prior to entering program and retesting at beginning of program (25 patients; as estimate of test-retest reliability), and b) testing with complete 158-item inventory at least six months following program (75 patients; as estimate of long-term effect of program).

While the analyses of these data are not yet complete, it is clear that:

a. The 80-item inventory has acceptable test-retest reliability.
b. Those items most applicable to the AA&SC's inpatient program and military population show potential for prognostic applications and program evaluation.

c. A large percentage of the items appear largely irrelevant to the purposes outlined in the original protocol.

d. There is a high degree of redundancy among items.

While the basic approach utilized by the HPA (e.g., Likert-type scale, subscale organization, etc.) appears reasonable and the test has good internal consistency it is not likely to fulfill our basic requirements. We have been forced to return to the original proposal to develop a communication self-assessment inventory tailored to the military population. A working outline of the invactory has been developed, a pool of possible items is being generated, and a preliminary experimental design has been constructed to assess reliability and validity. Work has been slowed since August because the Experimental Psychologist working on the project has not yet been rehired.

Number of subjects to be studied before completion of study: Approx. 600

Serious/unexpected side effects in subjects participating in project: n/a

Conclusions: n/a

Publications or Abstracts, FY-80: Not applicable at the present time.

WORK UNIT NO.: 2526

FUNDS UTILIZED, FY-80: \$7,243 (salary - Experimental Psychologist)

FUNDING REQUIREMENTS, FY-81:

PERSONNEL: \$12,000 (Dr. Marilyn Mang. GS-13 Dyeniacatal Poychologist), 40% time)

TRAVEL: \$312.00 to present HPI analysis to Annual Convention of American-Speech-Language-Hearing Association, Detroit, November 1930

REPRINTS. \$200.00

PAGE CHARGES: \$500.00

Date: 30 September 1980	Protoc	01 10 : 252	./	Status: Interim		
Title or Project: Assess	ing Laryngeal	Function vi	a Resi	due Inverse Filtering		
Cost: Cost: \$800.00	: 31 December 1980					
Principal Investigator: F	Robert A. Pro	sek, Ph.D.				
Allen A. Montgomery, Ph.		Facility:				
)., COL, MC	Dept/Svc:				
				Accumulative Supply Cost: \$800.00		
FY-80 MEDCASE Cost:		Period	lic Rev	riew Results:		

The state of the s

Study Objective: To establish the relationship between voice severity ratings and acoustic measurements obtained by means of Linear Predictive Coding for patients with voice disorders.

Technical Approach: Patients with various vocal complaints who were seen at the Army Audiology and Speech Center and the Otolaryngology Service, WRAMC, were the subjects for this experiment. Each patient recorded the vowel /a/ at a comfortable pitch and loudness. Each vowel was digitized, inverse filtered to obtain a residue signal, and measured to obtain the following residue features: pitch perturbation quotient, amplitude perturbation quotient, pitch amplitude, coefficient of excess, spectral flatness of the residue signal. These six measures constitute the primary independent measure of the study.

Two-second samples of the vowels were randomized on audio tape and presented to a panel of nine speech-language pathologists who judged the severity of each sample on a seven-point, equal-appearing interval scale. The nine severity judgments were averaged for each sample, and the mean severity judgments constitute the dependent variable of the study.

Two changes have been made in the procedures. First, a two-second sample has been digitized, instead of a 400 msec sample, in order to determine if the residue feature values change significantly across time. Second, the speech-language pathologists have been asked to judge the severity of the voice

disorder, rather than voice quality. Severity judgments are more amenable to an equal-appearing interval scale than quality judgments which are basically nominal. Also, judging severity is a routine clinical procedure familiar to all the judges.

Progress during FY-80: Forty-eight male and forty-two female patients with vocal complaints have been recorded. The mean age of the subjects is 44.3 years with a range of 18 years to 76 years. The following disorders were represented in this sample: laryngitis (16 patients), vocal nodules (14 patients), unilateral vocal fold paralysis (12 patients), vocal polyps (10 patients), vocal papilloma (5 patients), spastic dysphonia (4 patients), contact ulcers (one patient), and undetermined pathology (28 patients). This latter category included those patients whose diagnosis was not complete at the time of the recording, or patients who had no visible pathology of the larynx. Each of the ninety patients recorded the vowel /a/, and the residue features were measured using the Speech and Hearing Data Acquisition System (SHDAS).

The perceptual judgments of severity were obtained from a panel of nine speech-language pathologists. The judges were instructed to rate the severity of each sample on a seven-point, equal-appearing interval scale where "l" represented normal voice. The judgment procedure was repeated on three consecutive days, with the data of the first session to be disregarded in subsequent analyses. The average correlation between the second and third sessions, across the nine judges, was 0.90 (range: 0.86 - 0.93). The interjudge reliability, calculated with the data obtained in the third session, was 0.35. These numbers indicate that the judges were consistent between and within themselves.

The analysis of the data has just begun. One multiple linear regression, using the six residue features as predictors and the mean severity ratings as the criterich, has been completed. The multiple correlation coefficient for this analysis was 0.80, indicating that 64% of the variability in the severity ratings was accounted for by the residue features. Additional analyses to be performed include separate regression analyses for all combinations of the residue features, significance tests to determine which features contribute heavily to the regression, split-half rultiple regressions, and a multiple discriminant analysis of the detail

Number of subjects to be studied before completion of study: 90

Serious/unexpected side effects in subjects participating in project: n/a

Conclusions: While firm conclusions cannot be drawn at the present time, the magnitude of the multiple correlation coefficient is certainly encouraging. The residue features appear to provide quantitative information which characterizes, at some level, the functioning of the voice.


Publications or Abstracts, FY-80: Not applicable at the present time.

FUNDS UTILIZED, FY-80: 5400.00

FUNDING REQUIREMENTS, FY-81:

TRAYEL: 5600.00 (to present results at a regime -

REPRIST AND THE STATE OF



Work unit number: 2528

Title: The Effects of Chronic Low Doses of Quinine in Tonic Water on the Electronysagmogram (ENG) in Humans.

Principal Investigator: Joan T. Zajtchuk, COL, MC, USA

Associate Investigators: Michael J. Dunne, CAPT, MC, USN, Rebecca A. Merriken, Capt, USAF, BSC, John S. Jewell, MAJ, MSC. USA, Earl V. Wilkinson, MAJ, MC, USAF, Susan G. Chadwick, & Hollis J. Nosler

Starting date: 5 November 1979

Completion date: 31 July 1980

Status: Final

Facility: Otolaryngology Service and Audiology/Speech Center, Walter Reed Medical Center; Toxicology Department and Forensic Pathology, Department of Pathology, Armed Forces Institute of Pathology, Washington, D.C. 20012

Service: Otolaryngology

Key words: low dose quinine, tonic water, electronystagmogram

Objective: The object is to quanitate the ENG response in humans after daily ingestions of low doses of quinine in tonic water over a two week period.

Technical approach: Four control subjects, nine test subjects drinking 52.5 mg of quinine in tonic water daily and test subjects drinking 105 mg of quinine in tonic water daily were tested using 5 serial ENG's on days 1,3,7,10 and 14. ENG testing consisted of horizontal and vertical gaze OKN, tracking, positionals, positioning bi-thermal calories and fixation supression with interpretation under double blind conditions.

Conclusions: The pilot project was completed using the above test groups. All controlled subjects had five normal ENG's, and showed no habituation to calori stimulation. The nine subjects drinking 52.5 mg per day of quinine in tonic water over a two week period showed no ENG abnormalities. Three of four subjects in the high dose group (105 mg per day) showed positional abnormalities in at leas one ENG. Random blood quinine levels cannot be used to predict the incidence of symptomatology or ENG abnormalities in persons drinking chronic low doses of quinine in tonic water. Transient positional abnormalities may occur in persons drinking 105 mg of quinine in tonic water daily.

Number of subjects to be studied before completion of study: 15

None

ablications or Abstracts, FY 80: The Effects of Chronic Low Doses of Quinine Tonic Water on the Electronysagmogram (ENG) in Humans, is being presented as a poster presentation for the American Academy of Otolaryngology at their national meeting in September 1980 in Anaheim, California. Additionally the homed Forces Institute of Pathology is presenting the data at the Joint Committee on Aviation Pathology in the next fiscal year.

Funds utilized, FY 80: Approximately \$400.00 worth allocated out of the clinic investigation services for consumerable supplies. Susan G. Chadwick and Hollis J. Nosler had travel expenses funded for the poster presentation in Anaheim, California for this fiscal year.

Funding requirements, FY 81: None

Date: 6 October 1980	Proto	col	No.:	2529			Stat	tus:	Int	erim	
Title of Project: Effect Latend	t of High Fr cy of the Br					al l	Hearin	ng Lo	ss o	n the	
Starting Date: upon pure instrume		Est	imated	Comp	letio	n Da	ate:			fter date	
Principal Investigator:	Daniel M. S	chw	artz, P	h.D.							
Associate Investigators: Don B. Blakeslee, MD, MAJ, MC Roy K. Sedge, Ph.D., MAJ, MSC			Facility: Army Audiology and Speech Center, WRAMC								
Robert L. Henderson, M), COL, MC		Dept/Sv				nt of ogy Se		rgery, Oto- ice		
Key Words: Auditory Bra- ing Loss and				V L	atenc	y, I	iigh f	requ	ency	Hear	
			ative Contract Accumulative S Cost: \$25.00								
FY-80 MEDCASE Cost:		Periodic Review Results:									
Study Objective: To calc of latency delay on the a of varying degrees of hig	auditory bra	in	stem re	spon	nt fo se cr	or pi reate	redicted by	ting the	the pres	degree ence	
Technical Approach: Audwith surface disc electro to acoustic clicks at 60 60.3 and 80.3 per second	odes attache dB SL are r	d to	o the v	erte	x and	i ear	rlobes	s. R	espo	nses	
Progress during FY-80: No instrumentation necessary not purchased in FY-80.	lo progress , to record	has and	been m store	ade the	on th brain	nis p n ste	orojed em res	it si spons	nce e da	the ta wa:	
Number of subjects to be	studied bef	ore	comple	tion	of s	tud	<u>/: 1(</u>	00			
Serious/unexpected side e	effects in s	ubj	ects pa	rtic	ipati	ng ·	in pro	oject	: n	/a	
Conclusions: Not applica	able at this	ti	ne.								
Publications or Abstracts	s, FY-80: N	ot a	applica	ble -	at th	nis t	time.				

WORK UNIT 110 .: 2529

FUNDS UTILIZED, FY-80: \$25.00 for gold disc electrodes

FUNDING REQUIREMENTS, FY-81:

EQUIPMENT: \$35,000 for a versatile microprocessor based auditory brain

stem response unit

SUPPLIES: \$200.00 for electrodes, recording paper, electrode paste

TRAVEL: \$450.00 to visit the Kresge Hearing Research Lab, New Orleans, LA

REPRINTS/PAGE CHARGES: \$650.00

Date: 7 October 1980 Protocol No.: 2530 Status: Interim Title of Project: Test of the Assumptions Underlying the Comparative Hearing Aid Evaluation Starting Date: May 1980 Estimated Completion Date: December 1981 Principal Investigator: Brian E. Walden, Ph.D. Associate Investigators: Facility: Army Audiology and Speech Joanne M. Crowley, M.A. Center, WRAMC Daniel M. Schwartz, Ph.D. Dennis L. Williams, M.A., CPT, MSC Michael H. Mayer, MD, CPT, MC Dept/Svc: Department of Surgery, Otolaryngology Service Key Words: Comparative Hearing Aid Evaluation, hearing aids, validity, reliability Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: Cost: Cost: FY-80 MEDCASE Cost: Periodic Review Results:

Study Objective: The purpose of this research is to test the assumptions which underlie the comparative hearing aid evaluation (CHAE). Among the questions to be answered are: a) Do clinically and statistically significant performance differences exist among hearing aids preselected to be appropriate to the patient's hearing loss? b) Does the same instrument tend to be best for all patients? c) Are available test materials sufficiently reliable for use in hearing aid selection? d) Are the results of a CHAE stable over time? e) Do the results of a CHAE predict patient performance in the real world?

Technical Approach: Hearing-impaired subjects selected from the Aural Rehabilitation Program of the Army Audiology and Speech Center are administered a modified comparative hearing aid evaluation (CHAE) using three behind-the-ear instruments. The binomial model (at .95 confidence) is used to determine if significant differences exist among the aided monosyllabic word recognition in noise scores. In those cases where the inter-aid differences exceeded chance performance, two additional steps were taken. First, the patient was allowed to wear each of the three instruments for an extended period of time during the week following the initial CHAE. At the end of this trial use period, the patient indicated which aid was most acceptable and which was least acceptable. Second, following the trial use period, the CHAE was repeated.

Andread Comment of the Comment of th

Progress during FY-80:

Experiment #1 - Initially, three electroacoustically similar hearing aids were selected for use. All three were appropriate for use with high frequency noise induced hearing loss. Of the 75 total inter-aid comparisons, only seven difference scores exceeded the .95 confidence level. Since this number of significant differences could occur due to chance alone, there was no basis for concluding that any of the differences among aids represented actual sig-

nificant performance differences.

Experiment #2 - Data collection has begun on a follow-up experiment, identical to the first in design, but utilizing three instruments that are electroacoustically quite dissimilar. The three aids are all housed in identical cases and a double-blind paradigm is being employed to avoid subject or experimenter bias. To date, six subjects have been run on the follow-up experiment. Of the 18 possible pre-trial inter-aid differences, 12 exceed statistica? Significance. Ten of these, however, were between Aid C and either Aids A or B. For the post-trial CHAE, seven of the 18 differences were significant. Six of the seven were between Aid C and either Aids A or B. The data (to date) for the trial use judgments reveal that the subjective acceptance ratings were consistent with the word recognition scores for 11 of the 12 significant inter-aid comparisons. That is, when two scores were significantly different, either the aid that scored higher was the most preferred aid, or the aid that scored lower was the least preferred aid. Of the seven significant inter-aid differences on the post-trial use CHAE, four were confirmed by the subjective judgments.

A comparison of the pre-trial and post-trial CHAE word recognition scores revealed that, of the 18 significance pre-trial differences, only five were replicated on the post-trial testing. From a clinical perspective, the aid of choice on the initial CHAE (i.e., the highest score irrespective of statistical significance) would also have been the aid of choice on the post-trial CHAE for only three of the six patients. Further, the aid of choice on the initial CHAE was the aid preferred by the patient in four of the six cases. The aid of hoice on the post-trial CHAE was the preferred aid in two of the

six cases.

Number of subjects to be studied before completion of study: 50

Serious/unaspectual side offects in subjects participating in project: n/a -

Conclusions: The following tentative conclusions are supported by the data
1. For hearing aids preselected to be appropriate to the patient's
hearing impairment (i.e., electroacoustically homogeneous), the frequency with
which statistically significant inter-aid differences occur does not exceed
chance.

2. For electroacoustically dissimilar aids, significant inter-aid differences in word recognition occur frequently. In general, however, relatively few interactions between aids and patients are observed. Specifically, the same aid was generally poorest for all patients.

3. There is not a high degree of agreement between relative word recognition scores and subjective preference ratings.

Publications or Abstracts, FY-80: Mot applicable.

WORK UNIT NO.: 2530

FUNDS UTILIZED, FY-80: none

FUNDING REQUIREMENTS, FY-81:

EQUIPMENT: \$10,000 for a two-channel diagnostic audiometer

TRAVEL: \$607.00 (to present results at a national meeting)

<u>REPRINTS</u>: \$200.00

PAGE CHARGES: \$500.00

Date: 30 September 1980 | Protocol No.: 2531 Status: Title of Project: Maintenance of Speech Fluency Following an Intensive Stuttering Therapy Program Starting Date: 2 September 1980 | Estimated Completion Date: 31 August 1982 Principal Investigator: Marcia D. Bond-Liebertz, M.A. Associate Investigators: Facility: Army Audiology and Speech Pamela Silverwood, M.A. Center, MRAMC Patryce F. Thompson, M.A. Brenda W. Lohsen, M.A. Dept/Svc: Department of Surgery, Oto-Joyce Gurevich-Uvena, M.A. laryngology Service Christine Fair, M.Ed. Gloria Ch^{*}, M.A. Robert A. Prosek, Ph.D. Key Words: Stuttering, follow-up, disfluency, speech Accumulative Contract Accumulative MEDCASE Accumulative Supply Cost: \$251.60 Cost: Cost: FY-80 MEDCASE Cost: Periodic Review Results:

Study Objective: To determine the extent to which fluency improvement is maintained by adult stutterers participating in the Precision Fluency Shaping Program during a nine-month period following release from treatment.

Technical A proach: Therty stubterers who are participating in the Precision Fluency Shaping Program at Walter Reed will be the subjects for this study. Tape-recorded telephone monologues will be obtained from each subject on five occasions: 1) prior to the initiation of therapy (baseline), 2) immediately after completing the program (four weeks after baseline), 3) three months nost-therapy, 4) six morths post therapy, and 5) sine months post-therapy. After giving permission to record the monologue, the subject will be instructed to speak for five minutes about his speech, or his hobbies, or about any topic that interests him (the specific content of the monologue is not important).

Two general measures of fluency, percent syllables stuttered (%SS) and syllables per minute (SPM), will be obtained for each of the 150 monologues. The improvement in each of these measurements relative to the baseline session will be calculated for each subject for each post-therapy recording. Appropriate statistics will be applied to these data to determine if the figurey gains made by the program are retained when the subject finishes treatment.

350

(cont.) - #2531

Progress during FY-80: Data acquisition has just begun. Four subjects have been recorded in the baseline and immediate post-therapy conditions.

Number of subjects to be studied before completion of study: 30

Serious/unexpected side effects in subjects participating in project: n/a

Conclusions: Not applicable at the present time.

Publications or Abstracts, FY-80: n/a

WORK UNIT NO.: 2531

1

FUNDS UTILIZED, FY-80: \$251.60

FUNDING REQUIREMENTS, FY-81:

EQUIPMENT: Stop watches with independent reset capability, as per

original protocol (qty, 2; cost, \$55.00 each).

SUPPLIES: Cassette tapes as per original protocol (qty, 88; cost,

\$4.50 each).

TRAVEL: \$750.00 (to present results at a national meeting).

Work Unit No.: 2532

Title of Project: The Effects of Age and Brain Damage on Fluid Intelligence

in Aphasic Adults with Lesions in Dominant Hemisphere.

Principal Investigator: Barbara C. Sonies, MA

This protocol has been terminated due to lack of acceptable patients for the project.

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-SOT

Progress Reports on Work Units 2610, 2615, 2616, 2618,

H24F-201

C, Dept of Surgery

FROM C, Transplant Svc

DATE 24 NOV 80

CMT 1

T0:

C, Dept of Clin Invest

1. Progress reports on the above numbered work units are attached.

2610 - ALG

2615 - Immunological Monitoring

2616 - Graft Vs Host · Terminated

2618 - Intentional Donor Specific Transfusion

2619 - Histocompatibility, Antigens : d Interstitial Cystitis.

- 2. The progress report on 30 2615 is expanded, reviewing the past three years performance. Ropefully it will serve as a final report for this work unit, established in 1977, which has provided most of the funding for transplant research. This year, transplant immunology laboratory work supporting the remaining approved protocols (ALG, Transfusion, and Thoracic duct drainage HSC approval pending) has been charged to the appropriate work unit.
- 3. Current immunological monitoring work bears little resemblance to the 1977 protocol. Therefore individual protocols covering the seven aspects of present monitoring research are being finalized for presentation and approval at the January, 1981 C.I.S. meeting. Please bear in mind that this research is presently in progress under the expiring WU #2615.

5 Enc

JIMMY A. LIGHT, MD

COL, MC

Chief, Transplant Service

D.te: 11 October 1930	Protoco	ol No: 2610	Status: Interim X	
Title of Project: ALG and	Kidney Tra	nsplantation	Final	
Starting Date: 1973	Esti	mr ted Completion I	Date: Open: present addendy	
Principal Investigator: J	. A. Light	•	expires 1982	
Associate Investigators:	one	Facility: Walter Reed Army Medical Center		
	·	Dept/Svc Surgery	/Transplant	
Key Words: Immunosuppress	sion; Reject	⊣ tion; Rejection Re	versal; ALG	
Accumulative MEDCASE Cost: None	Accum Cost:_	ulative Contract None	Accumulative Supply Cost: None	
FY-80 MEDCASE Cost: Kone			eview Results:ed in by DCI)	
Study Objections To botter	defire the	ora of ALC to kid	na / twansolardation	

Technical Approach: Transplant recipients experiencing severe allograft rejection which had failed to respond to standard antireted for therapy received ALG as a therapy instead of removing the kidney. Throsettes were measured during treatment scheluled which varied in length from 6 to 05 days and in dose from 5-30 mg/kg/day.

Progression of EX-80: A. Steroid resistent regards rejection - ALO is officers

B. Short vs. long treatment schedules - Short course may be as effective

C. Correlation of results with T-rosette suppression - no correlation (See

D. Correlation of results with ALG serum levels and rosettes - pending (attached shedy

Number of subjects to be studied before completion of study: Approx. 50

Serious/weekploted side effects in subjects participating in project:

Serious/weekploted side effects in subjects participating in project:

Serious/weekploted side effects in subjects participating in project:

Conclusions: Although original objectives of this protocol were never achieved, useful original work has been accomplished. New objectives identified altering approaches under protocol addendum during this fiscal year.

Publications or Abstracts, FY-80: ALG Reverses Irreversible Rejection. Abstract accepted; presented July 80 to Transpl. Society Ms to be published Mar 81.

Progrèss (continued)

ALG had been previously thought to be effective only as prophylaxis in the early post transplant period. We showed that ALG effectively reversed rejection episodes resistant to standard antirejection therapy. These kidneys would have been lost to rejection without ALG. Our work defined parameters when ALG should be used for rejection, helped define duration of therapy needed, and showed that monitoring assays (performed under WU 2615) failed to predict a successful outcome.

Work was presented at the VIII International Transplantation Congress in 1980. The manuscript will appear in the Transplant Proceedings, March, 1981. Serum collected from patients receiving ALG is being analyzed for ALG levels and will be compared with T-rosette levels, biopsy or nephrectomy pathology, and antibody eluates of rejected kidneys where appropriate. This will be original work and should result in publication.

New work under this protocol is detailed in the addendum submitted and approved recently. Briefly the thrust of that work is to randomize cadaveric transplant recipients into two treatment groups:

- A. Prophylaxis ALG given for 20 days starting on the first postoperative day.
- B. Nonprophylaxis These patients will receive ALG only if they experience graft rejection and will be treated for only 8 days.

The hypothesis is that ALG given only for rejection will lead to results equivalent to those achieved with ALG prophylaxis. This type of study has not been performed elsewhere to date.

T-rosettes will continue to be measured. They serve two purposes. Failure to produce rosette suppression with ALG may be associated with a poor response to ALG, whereas profound T-rosette suppression may be associated with increased opportunistic infection.

mora unit Ho.: #2610

Funds Utilized, Fi-60: \$5,822.54

Funding Requirements, FY-61: \$7,970.92

<u>Personnel:</u> (name and grade) Faith May, GS-7 PFC Donna Morgan

Equipment: (describe in detail including cost)

Supples: (consumable, animal purchase) ALG - operating funds

Travel: (mission oriented, training and presentation) \$750

FUNDING REQUIREMENT Clinical Investigation Program

Juck U	mit No: 26	sio fit	le: Organ Transp Antilymphocy	lant Clinica te Globulin	(ALG) and
.PC:	A24P	Principal Investiga	Kidney Transplantation		Date Work Unit Approved:
leman of Expens			FY- 81	FY- 82	Remarks
2100		ssion oference	650.00 375.00	750.00 425.00	
2400	Reprints rep	and production	250.00	290.00	
2600	Consumat	ole Supplies	6695.92	7700.31	
3100	Non-Expa				
2372	Lab Cont	uipment tracts	-00-		
			7,970.92	9,165.31	

THIS REQUIREMENT RADRS NO 3 OF 5 WORK UNITS.

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-SOT

Termination of MU 2615, Immunological Monitoring of the Transplant Recipient.

......

xx THRU: C, Dept Surgery (1004 FROM C, Transplant Svc

DATE 29 Sep 80 CMT1 COL Light/fs/61462

TO:

C, Clin Invest Syc

- 1. The above mentioned work unit is scheduled for termination 30 September 1980, unless an addendum justifying continuation is submitted prior to that date.
- 2. There has been extensive research in nearly all areas specified in the protocol which have yielded negative results in general, documented in an abstract earlier this year. These results and other unpublished results will be presented in the annual report. An additional abstract on monitoring has been accepted for presentation in November, 1980, and publication in 1981. Older data is being re-examined using newer statistical methods and may be helpful in explaining the lack of predictability of the monitoring assays.
- 3. Meanwhile related work has been initiated examining new culture techniques and new assays for cell mediated immunity and rejection activity. These tests look very promising. The present protocol is being extensively revised and can be submitted as an addendum in October along with the annual report. It will not be ready by the above mentioned deadline.
- 4. Research conducted under the support of this work unit supports research under Work Units 2610, 2617, and 2618. Request continuing support for WU 2615 for one month until appropriate addendum is created.

JIMMY A. LIGHT, MD

011 MC

Chief, Transplant Service

	Protoco	1 No: 2	2616	Status: Interim			
Title of Project: Obviating	the Graft	Vs Host	Response	Final			
Starting Date: 1977	10041		Completion D	late: 1980			
Diatric Date.				ate: 1900			
Principal Investigator: A	innable, C.R	· CUL,	, MC				
Associate Investigators: None			Facility: Walter Reed Army Medical Center				
		Dept/	Svo Surger	y/Transplant			
Key Words:		-4		•			
Accumulative MEDCASE Cost: None		umulative Contract		Accumulative Supply Cost: None			
FY-SO MEDCASE Cost:	None			view Results: d in by DCI)			
Study Objective: GVH is the objective of this experimentating this response to bility barrier.	ental animal	proto	col was to	determine a means of ob-			
Technical Approach: Histoi antigen at intervals prio	r to transpl	lanting	their bone				
appropriate antigen dose successfilly inconstitute	d with allog g. work was	penaid Buspen	bota marrow ded when th	ed recipients could be without any GMA. Although a primary investigator wa			
appropriate antigen dose successfilly inconstitute the results were promising	d with allog g. work was	penaid Buspen	bota marrow ded when th	ed recipients could be without any GMA. Although a primary investigator wa			
appropriate antigen dose successfelly inconstitute the results were promisin reassigned. No abstracts	d with allog g, work was , publicatio None	penaid Buspen	bota marrow ded when th	ed recipients could be without any GMA. Although a primary investigator wa			
appropriate antigen dose successfully inconstitute the results were promisin reassigned. No abstracts Progress during FY-80:	d with allog g, work was , publicatio None 4,800	phaic duspen ons nor	bore marrow ded when the final repo	ed recipients could be without any GM. Although primary investigator was no was written. N/A			

None

Publications or Abstracts, FY-80:

Date: 6 November 1980	Protocol No: 2618	Status: Interim			
Title of Project: Intentiona Transfusion	l Donor Specif & Pretransplan	t Final			
Starting Date: Approval date	e Estimated Completion D	ate: 1983			
Principal Investigator:	ight, J.A.				
Associate Investigators: Kumar, Oddenino, Biggers	Facility: Walter	Facility: Walter Reed Army Medical Center			
	Dept/Svc Surgery	/Transplant			
Key Words: Transplant, Т	ransfusion				
Accumulative MEDCASE Cost:	Accumulative Contract Cost:	Accumulative Supply Cost:			
FY-SO MEDCASE Cost:		view Results: d in by DCI)			

Study Objective: 1. Decrease incidence of rejection and improve long term results of transplantation.

2. Determine which type of blood is most efficient.

3. Determine antibody production to T and B lymphocytes and red cell antigens with the types of transfusion.

4. Measure MLC and CML responses before and after transfusion.

Technical Approach: Recipients receive either fresh or stored donor specific blood transfusion at two week interval prior to transplantation. Frequent antibody screens and crossmatches are performed. MLC and CMC assays are performed before and after transfusion.

Progress during FY-80: 5 patients have been entered in the study. Preliminary observations suggest that both types of blood are effective. Sensitization rates may be decreased, by using stored blood rather than fresh blood. The will be a significant contribution since presently about 35% of recipients are ser Number of subjects to be studied before completion of study: 20-30 /tized by the trans Serious/unexpected side effects in subjects participating in project: /fusion process.

Conclusions: None

Publications or Abstracts, FY-80:

None

CLINICAL INVESTIGATION PROGRAM

work unit do :: 2618

tI/A Funds btil and, FY-80:

Funding Requirements, FY-61: \$19,562.00

<u>Personnel:</u> (name and grade)

Equipment: (describe in detail including cost)

Supplies: (consumable, animal pucchase) consumable: \$18,400.00

Travel: (mission oriented, training and presentation) Mission: \$362.6

Conference: \$300,00

Other: (equipment rentals, contracts for service, animal care and reprints) Reprints and reproduction: \$500.00

MLC. CML 40 x \$150.00 Ab Screen 80 x 80.00 Crossmatch 40 x 150.00

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN. REPERENCE OF OFFICE STWOOL

SUBJECT

HSWP-SOT

Response to Reviewer Comments on W/U 2618

TO C. Dept of Clin. Invest.

FROM C. Transplant Svc

DATE 29 Dec 30

- 1. This protocol was approved in July 1980 and details of the work to be performed are in the referenced protocol. The funding request for 1981 represents the costs the experimental studies to be performed. This work was previously done under the funding for W/U 2615 which has now expired.
- 2. Our present plans are to change our funding requests from one large work unit (as it was for the past several years under W/U 2615) to specific funding for each protocol The funds requested to support W/U 2618 reflect that administrative change. Further description of the specific funding requirement is attached.

Chief, Transplant Service

Date: 6 November 1980	Protocol	l No: 2619	Status: Interim,	
Title of Project: Histocompa Interstiti	atibility Ar ial Cystitis		Final	
Starting Date: 1980	Estir	nated Completion I	Date: 1981	
Principal Investigator: Fowl	ler/Light			
Associate Investigators:		Facility: Walter Reed Army Medical Center		
		Dept/Svc Surger	ry/Transplant	
Key Words: HLA, cystitis	,	1		
Accumulative MEDCASE Cost:	Accumu Cost:	plative Contract	Accumulative Supply Cost:	
FY-80 MEDCASE Cost:			eview Results:ed in by DCI)	
Technical Approach:	patients w	ere tissue typed	for HLA - A, B, C and Dr.	
, ·			, , , , , , , , , , , , , , , , , , ,	
		g has been comple completed in this		
Number of subjects to be student Serious/unexpected side effections				
Conclusions: Pending				
Publications or Abstracts. F	TY-80.	None		

CLINICAL INVESTIGATION PROCESS

ork Unit do.:

2619

Funds Utilized, FY-80: New Project - No funds used in 80

Funding Requirements, FY-61: \$4,198

Personnel: (name and grade)

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase) consumable: \$3,173 (19 typings x \$167.00

mission: \$475

Travel: (mission oriented, training and presentation) conference: \$200

Other: (equipment rentals, contracts for service, animal care and reprints)

Reprints and reproduction: \$350

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-SOT

Response to Reviewer of APR W/U #2619

TO C, Dept of Clin Invest

FROM C, Transplant Svc

DATE 29 Dec 1980

CMT 1

- 1. This protocol was approved 24 June 1980, but funds were apparently not allocated. Nonetheless tissue typing studies were completed on 19 patients, since the primary investigator was leaving WRAMC shortly thereafter. Twelve of these patients' typings were included in the statistical analysis. A manuscript has been drafted and is being revised prior to submission for publication. The abstract is attached.
- 2. Funding request submitted for FY 31 represents the cost of the work already performed in FY 80 and publication/presentation costs.

JIMMY A. KIGHT, ME

COL, MC

Chief, Transplant Service

Abstract

We studied the histocompatibility profiles in 12 Caucasian patients with convincing clinical and cystoscopic evidence of early interstitial cystitis. There were no statistically significant increases in HLA - A, B, C, or DR in these patients when compared with a control population. Susceptibility to early interstitial cystitis does not appear to be associated with HLA.

Date:	14 Octobe	r 1930	Profosol	No:	2809	Status:	Interim xx
Title of	f Project:		thip between of Urinary		atic Cancer sterol	and .	Final
Starting	g Date:		Estir	nated (Completion D	ate:	
Princip	oal Investig	ator: Ha	rry Y.C. Wo	ng, Ph	<u>d</u>		
Associa	ate Investig	gators:		Facili	ity:		•
David G. McLeod, MD, COL, MC, USA Eustus Nelson, MD, CPT, MC, USAF			Dept/	Svc Urolog	Jy		
Key Wo	ords:	state, CA	and non-est	erfied	cholesteral		•
	ulative ME		Accumi Cost:		Contract		ulative Supply
FY-S0	MEDCASE	Cost:	Ö .		i .	view Results:	
Study	Objective:	·			<u> </u>		
car ele hor and Techn	rcinoma of evated uri pefully ut d as a prod ical Approa	the prost nary level ilize this gnostic in ach: 24	ate; Attempts of N.E.C. method as a dication.	ot to in va mean	establish a rious stages s to earlt d	terol in pat correlation of Prostati liagnosis of ained on pati	between c CA, and the disease,
Progr but we	ess during got behind	FY-80: Se d due to o	veral sample ther protoco	es wer	e obtained a	and sent to H	oward Universi
					tion of study		
						N/A	
Conclu	sions:	None					
Publica	ntions or A	bstracts, I	FY-80:	None			

Dale: 5 December 1930	Protocol 1	No:	2811	Status: Interim
man to the state of				Final X
Title of Project: The value o	f excretory	urograp	hy, cys	tography and cystoscopy
in the evaluation of adu	It women wi	th urina	ry infe	ction.
Starting Daie: ?	Estim	ited Com	plation I	Oute: Completed
Principal Investigator: MAJOR	JACKSON E.	FOWLER,	JR. MD	, MC, USA
Associate Investigators:	_T	Cacility:	Walter	Reed Army Medical Center
_]^	. a.o.z.z.z.		gton, D.C. 20012
llone	-) L/C	····	
		ept/Svc	Urolog	y Service
Key Words:				
•	Infections			
Accumulative MEDCASE	Accumul		tract	Accumulative Suppl
Cost:	Cost:			Cost:
FY-S0 MEDCASE Cost:				eview Results:
r 1-00 mm orton oost.				ed in by DCI)
Study Objective:		`		
Technical Approach.				•
•	•			•
			٠.	

·-				
Progress during FY-80:				
Doctor Fowler left the Se project before he left.	ervice in S	eptember	1980, sc	o I assume he completed t
Number of subjects to be studie	- 7 l C	muletion	of study	/:
Million of Daniego to we begin	ed before co			
Serious/unexpected side effects				project:
Serious/unexpected side effects Conclusions:	s in subjects	s particir	ating in	
Serious/unexpected side effects	s in subjects this proje	s particin	ating in	

Fitle of Project: Human Chorionic Gonadotro Tumors of The Testis: A P			2812	Dettett	s: Interim	^
Human Chorionic Gonadotro					Final	
Histology and Response to	rospective a	oducing nd Ret	g Cells in rospective	Seminomatou Correlation	s Germ Cel with Tumo	ſ
Starting Date: 25 Mar 19	80 Estin	nated C	ompletion D	ate: 1 yea	r	
Principal Investigator:	DAVID G. M	cLEOD,	MD, COL, M	C, USA		
Associate Investigators:		Facilit	y: WRAMC			• .
CHARLES DAVIS, COL, MC, USA						
SUSAN KERN, CPT, MC		Dept/S	ve Urology	, Pathology	, AFIP Gen	ito-uri B:
Key Words: Testis T	umor (Semino	ma)				•
ccumulative MEDCASE Accum		lative Contract		Accumulative Su		
ost: <u>n</u>	Cost:	0_		Cost:	0	
FY-80 MEDCASE Cost:	ost: <u>0</u>			eview Result		
	-		(to be fille	ed in by DCI)	
Study Objective:						 ;
To see if there is any comalignancy in seminomas. Technical Approach: We	are trying t	o coll	ect.for exa	mination, t	-	
To see if there is any co malignancy in seminomas.	are trying t	o coll	ect.for exa	mination, t	-	
To see if there is any comalignancy in seminomas. Technical Approach: We	are trying t l. No funds	o collo asked	ect,for exa and no fun	mination, t ds needed.	issue bloc	ks,
To see if there is any comalignancy in seminomas. Technical Approach: We soutlined in the protoco Progress during FY-80: In a warehouse at Fort Mea	are trying t 1. No funds Little progr de, Maryland	o colla asked ess has	ect,for exa and no fun s been made Doctor Kern	mination, t ds needed. as most ti is pressin	ssue blocks g ahead.	ks,
To see if there is any comalignancy in seminomas. Technical Approach: We soutlined in the protoco Progress during FY-80: In a warehouse at Fort Mean tissue blocks Tumber of appreciation be structured.	are trying t l. No funds Little progr de, Maryland	o collo asked ess has but l	ect, for exa and no fun s been made Octor Kern	mination, tds needed. as most tiis pressin	issue bloc	ks,
To see if there is any comalignancy in seminomas. Technical Approach: We soutlined in the protoco Progress during FY-80: In a warehouse at Fort Mea	are trying t l. No funds Little progr de, Maryland	o collo asked ess has but l	ect, for exa and no fun s been made Octor Kern	mination, tds needed. as most tis pressin 50-60 On-cproject:	ssue blocks g ahead.	ks,

Date: October 1000	Protoco	l No:	2813	Status:	Lutorim
					Final X
Title of Project: Alpha feto	protein (AF	P) and	i human chor	ionic	
gonadotropin (HCG) produci					
tumors of the testis; a r	retrospectiv	e con	relation wit	h serum AFP ar	nd HCG levels
tumor histology and resper		15y	Completion I	ate: N/A	
Starting Date: 25 Mar 80	រុះស្រុក	ilmen.	COMPLETION	i.s. Fi/A	
Principal Investigator: FO	LER, JACKS	ON E.	JR. MD, MAJO	R, MC, USA	
Associate Investigators:		Facili	ity:	LIDANO	•
RAY E. STUTZMAN, MD, COL.,	MC HSA			WRAMC	
MAIL. STOTZERRS NO. COL.,	. OJA	Dept/	GU BRANCH OF		
Key Words:	a turnosa	7		•	•
	c tumors				
Accumulative MEDCASE			Contract	Accumul	lative Supply
Cost: 0	Cost:	<u> </u>	and the state of t	Cost:_n	
FY-80 MEDGASE Cost:	<u> </u>		Poviodic Re	view Results:	
F 1-80 MED (MSE COSE				ed in by DCI)	
			100 80 2		
To see if there is any	correlation	n betw	een kumor ma	rkers and degi	ree of
malignancy.					
Technical Approach:					
			•		
				•	
Progress during FY-80:					
Number of subjects to be sta	died before	comple	Hon of shide	· 	
Serious/unexpected side effe					
perions/mexpected and erre	crs m subjec	ors bur	ticipating in	More No.	ne
Conclusions:					
Complete			•		
Publications or Abstracts, 1	FY-80:	None			

Associate Investigators: Key Words: testi tumor	Estimated STUTZMAN, M	Completion D C, COL, MC, I lity: Walter N Washing	
Starting Date: 22 May 1980 Principal Investigator: RAY E. Associate Investigators: Key Words: testi tumor	Estimated STUTZMAN, M	Completion D C, COL, MC, I lity: Walter N Washing	JSA Reed Army Medical Center
Principal Investigator: RAY E. Associate Investigators: Key Words: testi tumor	STUTZMAN, M	C, COL, MC, U lity: Walter N Washing	JSA Reed Army Medical Center
Associate Investigators: Key Words: testi tumor	Facil	ity: Walter I Washing	Reed Army Medical Center
Key Words: testi tumor		Washingt	
testi tumor	Dept,		
testi tumor		/Svc Urology	Service
	`S		
Accumulative MEDCASE Cost: 0	Accumulative Cost: 0		Accumulative Supply Cost:0
FY-80 MEDCASE Cost:	0	Periodic Re (to be fille	eview Results:ed in by DCI)
To determine epidemilogical of the control of the c	ontrol study	- Interview	ving patients both as re is no funding needed.
port	ive and pat researchers	ients are int . Approximate	Staff has been very sup- terested in cooperating ely 20-30 patients studied day
Serious/unexpected side effects in None			
Conclusions:			

None

Date: Nov. 15 1080	Protocol	No: 2	ana	Sto	tus: Inter	ini	×
			J U		Fina		
Title of Project: Neovasc	ularizatio	n of	the Micro	vascula	r Free-	Elaj	5
Starting Date: Aug. 1 1	980 Estim	nated C	ompletion D	ate: Tar	31 10	982	
Deinoinal Investigators	A. Chow, M						
Associate Investigators: H.D. Peterson, COL, MC Sp 4 M. Callahan		Facilit	y:Walter alter Ree	Reed Ared Ared Area	my Media Institu	cal te	Center of Research
		Dept/Svc Plastic and Reconstructive Surg					tive Sorgo
Key Words: Neovasculariza	tion Micro	vascu	lar Free	,			
Accumulative MEDCASE Cost:	Accumu Cost:	evital	Contract	I -	cumulative st:	Sup	oply
FY-S0 MEDCASE Cost:			Periodic Re (to be fille				
perfectives To study perfect the study is mission-indicate when the sec maybe safely performe erage for traumatic greenity.	Free-flaps n (ligatio orientated ondary bon d on patie	, so n) of l beca le gra ents f	as the fleton the feed use the ifts, nervolving	ap will ling ver informat ve graft success	l continuous sels of tion obtained the content of t	ue the ain ndo:	to sur- e flap, ed will n grafts flap cov
Technical Approach: epigastric vessels ar							
Progress during FY-80: data indicates that t lipetion of the vesse	he microva	scula	r free-fl	ap may	survive		
Number of subjects to be stu Serious/unexpected side effe							
Conclusions: Final conc study on all canine m	lusion may odels. Th	not e pre	be drawn liminary	until d	completi s promis	on ing	of the

Addendum to FY-80 Annual Progress Report (APR) for Work Unit #2901 Funding Budget Justification for FY-61

This research project was designed to be carried out during the latter portion of FY-80 and the entire portion of FY-81, and may possibly extend to the first 2 months of FY-82.

According to the protocol, neovascularization (the specific post-operative time intervals required) on 60 (ccessful microvascular free flaps of dogs will be studied, so as to estain the necessary statistically significant data.

During FY-80, Satisfactory results were obtained from the work performed on 8 dogs. Therefore, during FY-81, further research work is necessary to be performed on the remaining 52 dogs.

From the allocation on the FY-60 Buget Funding, consumable supplies were acquired for the work on 20 dogs. (This is the only money or funding spent on this project.) Therefore, during the FY-81, further funding budget is necessary so as to obtain the consumable supplies for the operative investigation of the other 40 dogs. (This had been previously checked out with Mr. Burton and MAJ Reed, and was considered to be correct.)

The continuation of this research project is highly desirable, because it is directly applicable to clinical situations, and is mission essential in the surgical care of military personnel sustained with gun-shot or shrapnel wounds of the lower extremities as well as in the management of soldiers with open fractures of the tibia and/or fibula (motor-cylcle or jeep accidents).

It is planned that the findings and conclusions of this clinical research project will be presented in the national meeting of the Plastic Surgery Research Council in the Spring of 1982.

Funds requested: \$3,930.

Work Unit No.: 3138

Title of Project: Immunologic Mechanisms of Cutaneous Reactions to Inhalant

Allergans

Investigators:

Principal: Richard D. deShazo, M.D.

Associate: H.M. Dvorak, M.D.

Objectives: To define the immunologic mechanisms responsible for untoward cutaneous reactions seen with the injection of inhalant allergens

Technical Approach: Immediate hypersensitivity skin tests, punch skin biopsy, light and fluorescent microscopy, RAST IgE.

Progress and Results: During the last year we have concluded the originally initiated work in collaboration with investigators at FAMC, extending our observations on the etiology of late cutaneous allergic responses to antigen. This protocol has involved the use of H₁ and H₂ antihistimines and aspirin in an attempt to block the late cutaneous allergic response. In addition, we have observed the effects of these antihistamines on insulin reactions, which we are studying under a separate protocol. The work of last year has been extended by observing the histology of blocked late cutaneous reactions using punch biopsy and I micron distant state sections. These sections, obtained on 3 patients, revealed that reactions which appeared to be blocked clinically by common antihistamine combinations, are indeed blocked histopathologically as well.

To summarize, during this protocol we have been able to entablish that late in time dermal reactions to antigens which occur after intradermal injection of ragweed are IgE-mediated. These reactions may be blocked by combinations of \mathbb{H}_1 and \mathbb{H}_2 antihistamines. We have further established that histamine itself is unable to induce such late reactions. Therefore, a pharmacologic mediator other than histamine appears to be acting either alone or in conjunction with histamine at histamine receptors to provide the vasopermeability event necessary for subsequent late reactions. Since aspirin has no effects on these responses, the mediator is probably not prostaglandin. These important findings form the basis for further received being carried on by a number of intestigators to further

characterize IgE-mediated late in time reactions.

Funding Requirements for FY 81:

The principal investigator for this protocol has left service and therefore the protocol is to be terminated at this time.

Publications:

- 1. deShazo RD, Levinson HI, Dvorak HM, Davis RW. Late phase skin reaction.
 - J Immunol 122:692, 1979.
- 2. Smith JA, Mansfield LE, deShazo Rd, Welson MS. An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen. J Allergy Clin Immunol 65:119, 1980.

Presentations:

Presentations were made on the basis of the work at the American Academy of Allergy in 1979 and in 1980.

Complications: None

Type of Report: Termination

Date: 20 October 1980	Protocol No:	3144	Status:	Interim X	• •
Title of Project: Neurophysi Aspects of Bronchial Asthm		ogic and Bioch		Finel	• ·
•					
Starting Date: 8 March 1977	Estimate	d Completion I	Date. October	1981	,
Principal Investigator: L	aurie J. Smith,	M.D.			•
Associate Investigators:	Fac	ility: Allergy-	Immunology Se	rvice	·
Richard Evans III, CGL MC Richard Summers, LTC MC	Dep	t/Svc			٠
Key Words:	الميد المستحد والما المداد المرازي المستحد المستحد			•	
Accumulative MEDCASE Cost:	Accumulati Cost:	ve Contract	Accumu Cost:	lative Supply	-
FY-80 MEDCASE Cost:		Periodic Re	view Results:		
		(to be fille	d in by DCL,		
Study Objective: To charact beta adrenergic as well as cholinergic imbalance.	erize a group of cholinergic rea	atopic asthm sponses, looki	natics by thei ing in particu	r alpha and lar for a	•
Technical Approach: All p skin testing to inhalant a tests will be performed at to saline mechalicated pro Carbachol and Thenylephrin of very low domes of isup Clinic: 1) Metholyl brone lenge with air and He/O2.	Llergens and an NIH: 1) Oral a prauolol; 3) Pupa; 4) Response of L. The follow hial challenge of	antigen brond aspirin challe sillometry to of cyclic nucl ing tests will with air and h	chial challeng enge; 2) Eccri measure pupil motides to in be performed Me/U2; 2) Hist	ne sweat reng recomment of travenous in at WRAMO All amine bronchi	owing ponses jections lergy ial chal-
Progress during F7-30: We with cystic fibrosis, 4 parand 10 nonallergic normal undergone studies of alpha gone studies of beta adren	tients?with fat; control and 23 a adrenergic and	r/nsic as?lula, allergic asthm cholinergic r	, 9 patients whatics. These nervous system	ith allergic subjects hav	rhinitis ve all ve under-
Sumber of subjects to be stud	lied before comp	letion of study	<u>studied: 2</u>	ground: 1) alexercise asth	ilergia — ma
Serious/unexpected side effect					,
Conclusions:					
	ttached sheet.				
Publications or Abstracts, F	Y-80. See at	tached sheet.	•	· •	

Conclusions:

In summary:

- 1) Allergic asthmatics show increased sensitivity to alpha adrenergic and cholinergic stimulation and decreased sensitivity to beta adrenergic stimulation.
 - 2) Intrinsic asthmatics show these defects similarly but to a greater degree.
- 3) Patients with cystic fibrosis and their parents, with and without asthma, also demonstrate these abnormalities.
- 4) These studies suggest autonomic nervous system abnormalities are not enough alone to result in bronchial asthma.
- 5) There have been no serious or unexpected side effects or complications in subjects participating in this study.

Publications or Abstracts, FY-80:

- 1. Abstract: Autonomic nervous system dysfunction in patients with cystic fibrosis. L. Smith, M. Kaliner, P. Davis, J. Shelhamer. V. Hubbard, J. Allergy Clin. Immunol. 65:217, 1980.
- 2. The cholinergic nervous system and immediate hypersensitivity II. An analysis of pupillary responses. L. Smith, J. Shelhamer, I. Kaliner, accepted for publication, J. Allergy Clin. Immunol.
- 3. Autonomic nervous system abnormalities in allergy, asthma and cystic fibrosis. Michael Kaliner, James Shelhamer, Pamela Davis, Laurie Smith, J. Cray Venter, accepted for publication, Annals of Internal Medicine.
- 4. Abnormal adrenergic responsiveness in allergic subjects: analysis of isoproterenol-induced cardiovascular and plasma cystic AMP responses, J. H. Shelhamer, D. D. Metcalf, L. J. Smith, and M. Kaliner, J. Allergy Clin. Immunol. 66:52-61, 1980.

.ork Unit 10:: 3144

Funds Utilized, FY-80: \$800.00

Funding Requirements, FY-61: \$1700.00

Personnel: (name and grade) No additional requirements.

Equipment: (describe in detail including cost) No additional requirements

Supplies: (consumable, animal purchase) No additional requirements

Travel: (mission oriented, training and presentation) \$1000.00

Other: (equipment rentals, contracts for service, animal care and reprints) \$700.00

Work Unit No.: 3146

Title of Project: Immunotherapy Kit Potency Persistence

Investigators:

Richard J. Summers, M.D. LTC MC Principal:

Associates: Richard Evans III, M.D. COL MC

Michael S. Edwards, CPT MSC

Objective: The study is designed to determine the persistence of biological

potency of allergy extracts during shipment and use.

Technical Approach: RAST (Radioallergosorbent Test) will be performed to

determine potency persistence.

Progress & Results: The extracts have been shipped and returned. Aliquots

are being taken at intervals. Final results are awaiting

standardization of RAST inhibition.

Conclusions: No conclusions can be made until all results are in.

Funds Utilized, FY-78: \$500 of estimated total cost of protocol.

Funds Utilized, FY-79: \$500 of estimated total cost of protocol.

Funding Requirements, FY-80:

Personnel: One GS-7 technician, currently employed, 2 weeks/year Equipment: No new equipment is required

Supplies: Consummable - needles, syringes and

RAST testing \$4,000.00

Travel: None

> Total \$4,000.00

Publications: None

Type of Report: Interim

Addendum:

Principal Investigator: Richard J. Summers, M.D. LTC MC

Associate Investigator: Richard Evans III, M.D. COL MC

Associate Investigator: Michael S. Edwards, CPT MSC

WODERDOW

NORK UNIT # 3146
TITLE OF PROJECT: Immunotherapy Kit Potency Persistence.
<u> </u>
PRINCIPAL INVESTIGATOR: Richard J. Summers, LTC MC
DATE OF APPROVAGE AT WRANC: 26 April 1977
DATE OF APPROVAL AT COST (NOT REQUIRED)
COPY OF ANNUAL PROGRESS REPORT FY-79 IS ATTACHED: YES

ADDENIUM: Continuation of this protocol is desired. It was not possible to complete standardization of RAST inhibition during FY-80 due to lack of standards from Bureau of Biologics at FDA. Hopefully these will become available during FY-S1 and the project can be completed over the name 6-9 months. An increase in funding is requested because the price per RAST inhibition is now up to \$400.

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

HSWP-QAI

Termination Request for Work Unit #3147

TOC, Clin Inv Svc

FROM C, Allergy-Immuno Svc

DATE 30 July 1980

Dr Evans/ma/6-1853/4

- 1. This is a termination request for Work Unit #3147 entitled: "Hymenoptera Venom Safety and Efficacy Evaluation as Allergen Immunotherapy in Insect Sting Allergy Patients."
- 2. Insect venoms for diagnostic and treatment of insect sting allergy were approved for use in the general population in April 1979.
- 3. We have continued to follow approximately 14 patients in this protocol with specific IgG and IgE antibody liter until the beginning of this calendar year. These patients continue to receive insect venom immunotherapy but this treatment is not considered investigative.

as Em RICHARD EVANS III, M.D.

Chief, Allergy-Clinical Immunology Service

Date: 14 0-5 80	Protocol No: 3147		Status: Interim
Title of Project: Hymenopt Immunotherapy in Insect	era Venom Sa Sting Allerg	fety and Efficacy ly Patients.	Final V Evaluation as Allergen
Starting Daie:	Esti	mated Completion D	ate:
Principal Investigator: Dan	iel A. Ramire	ez, MAJ MC	
Associate Investigators:		Facility: Walter Reed Army Medical Center	
		Dept/Svc Clinical Investigation	
Key Words:		.i	•
Accumulative MEDCASE Cost:	Accumulative Contract Cost:		Accumulative Supply Cost:
FY-80 MEDCASE Cost:			view Results: d in by DCI)
Study Objective: To estab	lish the safe	ety and effectivene	ess by hymenoptera venom

preparations in the prevention of anaphylactic reactions following hymenoptera

Technical Approach: Patients with history of having systemic reactions following a hymenoptera sting are evaluated by skin testing using a skin test titration technique from 10^{-3} ug/ml up to 1 ug/ml. Concordant venom RAST titers are also obtained. Routine chemistries, CBC, with sedimentation rate urinalysis, C3, C4, FANA and venom specific titers of IgE and IgC have been followed every 3 months.

Progress during FY-80: Of the 24 selected patients for venom immunotherapy, 19 patients have moved from the area and are no longer in the study. These patients are on clinical allergy treatment with licensed materials. Five patients who had reached the 100 ug of venon per month continue attending to periodical follow up visits as to 14 Oct 80. (contd) Number of subjects to be studied before completion of study: Completed 30 July 1980 Serious/unexpected side effects in subjects participating in project:No patients have experienced a systemic reaction; no abnormalities of the laboratory parameters have thus far been detected Conclusions: Hymenoptera venom extracts have so far been shown to be safe for use in immunotherapy. Efficacy in preventing anaphylactic reactions upon subsequent stings has also been demonstrated. The specific IgE titer increased with immunotherapy in approximately bull of the matients and the specific IgG antibody increased with immuno-Publications or Abstracts, FY-80:

therapy in all patient

See continuation sheet

stings.

Progress during FY-80:

The protocol was terminated 30 July 1980. On 18 August 1980 an FDA inspector reviewed this project. No significant deficiencies were found.

Publications or Abstracts, FY-80:

- Ramirez, D.A. and Evans III, R: The diagnosis of Hymenoptera hypersensitivity, J. Allergy Clinical Immunol. (Abstract).
- 2. Ramirez, D.A. and Evans III, R: The diagnosis of Hymenoptera hypersensitivity. J. Allergy Clinical Immunol. In press 1980.

Presentations:

- 1. An abstract for presentation by Dr. Ramirez of part of these data regarding diagnosis has been accepted for the scientific section of the American Academy of Allergy meeting in Merch -379.
- 2. An abstract for presentation by Dr. Evans of part of these data regarding treatment has been accepted for a scientific workshop of the American Academy of Allergy meeting in March 1979.
- 3. Presented to Penn Allergy Society June 1980.
- 4. Accepted for presentation AACIA, Las Vegas, Nevada, November 1980.

Date: psc 1 1030	Ibrotocc	ol No: 3	149	Status: Interim
Title of Project:				Final X
Investigation of Immunolog	gic Imbalanc	e in Ato	pic Derma	titis.
Starting Date:	Esti	maled Co	ompletion	Date:
Principal Investigator: por	NNA LYNN SCH	HUSTER		
Associate Investigators: RICHARD EVANS III. COL MC CONSULTANT: ARNOLD I. LEVINSON UNIVERSITY OF PENN PHILA PA		Facility	/: WALTE	R REED ARMY MEDICAL CENTER
		Dept/Svc Allergy - IMMUNOLOGY SERVICE		
Key Words:		4	,	
Accumulative SIEDCASE Cost:	Accumulative Contract Cost:		Accumulative Supply Cost:	
FY-80 MEDCASE Cost:				eview Results:

Study Objective:

The purpose of this study is to further delineate the immunologic imbalances found in atopic dermatities and to study the collular regulation of Icl in this patient population.

Technical Approach:

Peripheral bloodmonous par colls from both normal and atopic demastitis patients were cultured for 1 hour with a B adrenergic agonist (Isuprel). B adrenergic antagonist propanolol) alpha adrenergic agonist (phenylenhrine), alpha antagonist (atropine) or aminophyllane. After an hour's incubation with these agents the cells were then washed and lymphocype subpopulations were determined. The resulting technique used for characterizing these subpopulations tonsisted of rising CMRBC sensitized with either rabbit IqN or rabbit IqG anti-CMCRC to identify Tu (helper cells) or T (suppressor cell) respectively.

In addition, we have developed a sensitive assive for the measurement of extremely low levels of IqE by a modification of the Phadibas IqE PRIST. This direct radio-labelled anti IqE (DE $_2$ specific) antibody obtained from the phadibas IqE FAST for the less specific PRIST anti IqE I 125 . This method proved useful in quantitating in vitro IqE synthesize by human blood mononuclear cells after 7 days in culture with or without pokeweed mitogen stimulation.

Progress during FY-80:

This decrease could be reversed with prior incubation with atropine before the addition of methacholine. In the atopic dermatitis copulation studied there was no change in the levels of T—cells after incubation with any of the above agents.

Our new sensitive method for the measurement of IGE has been found to be sensitive to 40 ph/ml of IGE and reproducible with different lot numbers of reagents. The coefficient of variation among multiple experiments was 11% at 220 pg/ml of IGE and 21% at 40 gy/ml of IGE.

This new method allowed us to quantify in vitro IGE synthesized by human blood mononuclear cells. Atopic nations were found to synthesize significantly more IGE than normal subjects. The addition of tokewest mit, in to the cultures did not significantly enhance IGE synthesis by either the atopic or non-atopic cells.

Conclusions:

The second of the second secon

Atopic dermatitis may be related to a B adrenergic blocade.

In addition, we have found that atopic patients were found to synthesize significantly more IgE than normal subjects. IgE synthesis in either normal or atopic cells was not simulated in the immunologic aberrancies and cellular regulation if IgE in atopic dermatitis will be carried out at a different institution.

Date: 14 00- 80	Protoco	l No: 2151	Status: Interim	
Title of Project: Allergic I Study of Hymenoptera Venom			Final X	
Starting Date:	Estimated Completion Date:			
Principal Investigator:	Richard Evan	s III, COL MC		
Associate Investigators:	f	Facility: Walter R	eed Army Medical Center	
Michael S. Edwards, CPT MSC		Dept/Svc Clinical Investigation		
Key Words:		≟	•	
Accumulative MEDCASE Cost:	Accumi	ulative Contract	Accumulative Supply Cost:	
FY-80 MEDCASE Cost:			eview Results: ed in by DCI)	
Study Objective: To establ agents in making the diagr			enoptera venoπs as testing	

Tachmical Approach: Patients with a history of allergic reactions to hymenopters stings were skin tested with the commercially available whole body extracts and with insect venoms using a skin test titration of 10^{-3} ug/ml up to 1 ug/ml. Venoms from Honey Bee, Yellow Jacket, Yellow Hornet, White Faced Hornet and Wasp were provided by the MINID, NIH. Catalog was A(6301635,-002-585, recaived November 1978. Venom materials were given FDA approval for human use in April 1979. These materials have therefore not been investigative since that date.

Progress during FY-80: 395 patients have been skin tested with insect venoms. 3 groups with positive skin test reactions have been identified; 1) systemic reactions, 2) large local reactions, 3) either of above with patients previously treated with whole body extracts.

Number of subjects to be studied before completion of study: Completed 30 July 1980 Serious/unexpected side effects in subjects participating in project: None

Conclusions: Direct skin tests with insect venoms clearly separate patients with a history of previous systemic reaction from the control population. Patients with a history of large local reaction to an insect sting have positive direct skin tests to vanom with a surprisingly large frequency. Considerable cross reactivity or (contd) Publications or Abstracts, FI-SU: none

multiple sensitivity was found to the insect venoms of the vespids (yellow jacket and hornets). There is also an unexpectedly high incidence of positive skin tests to venoms in the previously whole body extract fronter group. It is concluded that skin tests with venoms alone do not identify the parient at risk for a sub-parametrization.

Date: 15-10-30	[Protocol No: 3152	Status: Interin			
Title of Project: Factors af	fecting theophylline half life	Final X			
Starting Date:	Estimated Completion Date	· ·			
Principal Investigator: Paul					
Timolpai investigator. Paul					
Associate Investigators: Rodolfo Bongiovanni, CPT MS	Facility: Dept. of Cl Biochemi	Facility: Dept. of Clinical Investigation Biochemistry Lab.			
Richard Evans, COL MC		Dept/Svc Department of Clinical Investigat:			
Key Words: Aminophylline, Solu-medrol	, terbutaline, clearance, pharm	ecokinetics			
Accumulative MEDCASE Cost:	Accumulative Contract Cost: N/A	Accumulative Supply Cost: \$7,500			
FY-80 MEDCASE Cost: \$3	,750 Periodic Revie	ew Results:			
	(to be filled i				
Technical Approach: Pharma population. The patient poclinically stable and acute	acokinetics studies will be car opulation will be studied under o asthma.	ried out on a norma! conditions of			
Progress during FY-80: The Seven patients were studied	e normal volunteer population h I under conditions of clinicall	ave been completed. y stable and acute asthma			
	lied before completion of study: ets in subjects participating in pro	None None			
Conclusions: In all cases so clearance and in the T $\frac{1}{2}$ Be	so studied, there is no differe	nce in the rate of			
Publications or Abstracts, F	Y-S0: None				

Date: 10 October 1930	Protoco	l No: 315	4	Status			
Title of Project: Evaluation	of Prostagla	andin Secr	eting Sup	ressor	NAZK		
	ancer Patien						
		:		. •			
Starting Date: 14 Apr 78	Esti	nated Con	pletion D	ate: 1 Oct	ober 1981		
Cyr	nthia H. Ewe						
Principal Investigator: An	thony J. Deu	itsch, MA	I, MC				
Associate Investigators: Barbara Bongiovanni, 1	BS	Facility:	WRAMO	5			
Sonnya Londono, BS		Dant/Sug		ology Experi			
		Dept/Svc	Allergy	-Immunolog	y Service		
Key Words: Hodgkin's Dis	sease, prost	aglandin,	entioxidar	nt	•		
Accumulative MEDCASE Cost: NA	Accumi	ulative Co	ntiract		nulative Supply \$36,673.72		
FY-80 MEDCASE Cost:	NA	TP _C	riodie Re	view Result	equita:		
11-00 114470.001	2172			d in by DCI	·		
Study Objective:	·			···			
establish their in vivo and in inhibitor (indomethecia) and Technical Approach: In vitro lymphocyte culture indomethecia. Cocultures v	certain inhi (catalase a s were set u vere also do	bitors of t nd a-tocop p with the ne with inc	oxic oxyg herol) mitogen i lomethaci	en metaboli PHA with and in and catala	te production divithout se or		
a-tocopheroi. Delayed hype anergy.	ersensitivity	skin tests	were per	rformed to s	creen for		
Progress during FY-80:							
Peripheral blood mononucle stimulated in culture with the				-			
Number of subjects to be stu							
Serious/unexpected side effe	cts in subjec	ets partici	pating in	project: N	one		
Conclusions: Abnormal lym	phocyte prol	iferative r	esponses	seen in Hod	gkin's Disease		
may result in part from the	excessive p	roductiou	of toxic o	xygen metab	olites as well		
es prostaglanding by adhere							
Toblications or Abstracts, I Toxic Oxygen Me'sbolites in	こま 一つひこ ときたび						

(continued from front sheet)

the second secon

prostaglandin inhibitor indomethacin and the antioxidants catalase or a-tocopherol. Patient lymphocytes showed significant increases in PHA induced proliferation at all PHA doses when cultured with indomethacin. Further augmentation of lymphocyte proliferation was achieved with the addition of catalase or a-tocopherol to indomethacin in the culture system. The increase in proliferation was greatest in patients with more depressed PHA responses; and was abrogated by removal of adherent cells from the culture system.

Data: 10 Nov 80	librotoco	l No:	01.00		Status:	interni AA	
Title of Project: Evaluation	of Suppress	or Imm				Final	
Cells in th	e Pathogensi	s of De	ficien cy Dis	ease.			
Starting Date: 18 March			ompletion I	Date:	1 Octobe	er 1981	
	thia N. Ewel nony J. Deut			·			
Associate Investigators: Tami Hase, BS		Facilit	y: Experim WRAMC		mmunolo	ogy Lab .	
Talk Hase, 20		Dept/S	vc Allerg	mology i	y Service		
Key Words: chemotaxis, hi	istamine	4				•	
Accumulative MEDCASE Cost:	Accumi Cost:	ulativa	Contract			lative Supply \$12,986.24	
FY-80 MEDCASE Cost:	· · · · · · · · · · · · · · · · · · ·		Periodic Re (to be fille		-		
Study Objective:							
		•					
•							
Technical Approach:							
					-		
Progress during FY-80;							
Number of subjects to be stu	died before	complet	ion of study				
Serious/unexpected side effe	cts in subjec	ets part	icipating in	projec	t:		
Conclusions:			<u></u>		······································		

TITLE OF PROJECT:

Project # 3155 Evaluation of Suppressor Immunoregulatory
Cells in the Pathogenesis of Deficiency
Disease

OBJECT:

To detect the etiology of abnormal leukocyte chemotactic responses associated with recurrent infections in patients with atopic dermatitis.

TECHNICAL APPROACH:

The chromium-labelled radiochemotactic assay was used in this study.

PROCRESS IN FY 80:

During FY 80, fifteen patients with atopic dermatitis and 25 normal controls have been studied. Patients were bled and their white cells fractionated by density gradient methods into monocytes and neutrophils. These cells were placed in the upper chamber of Boyden chambers after being labelled with chromium 51 isotope, and subjected to 3 to 4 hour incubation across a chemotactic gradient. This gradient was produced with partially purified G3A. Chemotaxis was performed in the presence of various concentrations of histamine phosphate from 10⁻⁶ to 10⁻⁸ molar.

There was no evidence of inhibition of either monocyte or polymorphonuclear leukocyte chemotaxis in the normal control subject chemotaxis on exposure to varying concentrations of histamine. Likewise, no inhibition of leukocyte chemotaxis was noted in atopic dermatitis patient assays when chemotaxing cells were exposed to histamine. However, histamine inhibited patient monocyte chemotaxis in a dose-response fashion. This was seen in each of the patients studied, but was not noted in any control.

CONCLUSION:

Histamine seems to selectively inhibit monocyte chemotaxis in patients with atopic dermatitis. The specificity of this inhibition (as to which distamine receptor is stimulated) is under further investigation. Histamine release in the skin of patients with atopic dermatitis may form the basis for recurrent dermal infections in these individuals. This may occur by inhibition of the ingress of mononuclear phagocytic cells into infected sites.

PLAN:

- A) The manuscript for this data is being prepared.
- B) We hope to study the specificity of this response by performing chemotactic assays in the presence of various $\rm H_1$ and $\rm H_2$ anatagonists.

Date: 1 October 1980	Protocol	No: 31	53	Status: Interim					
Title of Project: Evaluation Operative	of the Immu in Dermal R		-	anisms					
Starting Date: 18 June 1979	Estin	nated Com	oletion D	ate: 1982					
	nothy M. Bo	ehm, LTC	MC						
Associate Investigators:		Facility: WRAMC							
Richard deShazo, MD		Dept/Svc	Dept of	Clinical Investigation and Allergy Service					
Key Words:		-							
Accumulative MEDCASE Cost:		ulative Con \$7,250.00	tract	Accumulative Supply Cost: \$1,856.20					
FY-80 MEDCASE Cost:				view Results: d in by DCI)					
*Study Objective: To determi	ne the mech	anism unde	rlying de	ermal reactions to insulin.					
Technical Approach: Skin of reaction sites with light an				parations and skip biopsies py.					
Progress during FY-80: I cent microscopy was comple			vere stud	lied and the immunofluores-					
Number of subjects to be stu- Serious/unexpected side effe									

Conclusions: (See attached abstract.) There are at least 3 distinct types of local reactions to insulin: 1) IgE dependent "late phase"; 2) "Arthus" local vasculitic; 3) delayed hypersensitivity.

Publications or Abstracts, FY-80: Persistent Local Reactions to Insulin. Evidence for Three Immunologic Mechanisms. (Abstract) R.D. deShazo. T.M. Boehm, D.D. Kumar, and J.A. Galloway. American Academy of Allergy meeting, 1980.

100

*Uncertain. Although the present study is complete, an addendum may be submitted as new insulable to become available with potentially differ of types of reactions.

Starting Pater	Estimage	l Comus (Ign I)	stu:
Principal in estigator: Bernar	d H. Berne, M	D, PhD.	
Associate Investigators:	Tad	ilizy: WRAMC	
	Dep	t/Svc Medicin	ne/Rheumatology Service
Key Words:	antibodies, I	mmune complexe	·
Accumulative MEDCASE Cost:	Accumulativ		Accumulative Supply Cost. \$1,284.50
FY-80 MEDCASE Cost: \$650.0	00		view Results:d in by DCI)
Study Objective:			
See attached sheet.			
Technical Approach:			
See attached sheet.			
Progress during FY-30:			
Progress during FY-30: See attached sheet.			

Tallego and a state Cas, my see none

Objectives:

- a. To develop systems containing immunoadsorbents capable of removing proteins from the blood of rabbits by extracorporcal circulation.
- b. To remove circulating antibodies and immine commisses (IC) from rabbits and to determine their clearance and reappearance rates during and after their removal.
- c. To develop a procedure for removing circulating antibodies and IC that is devoid of adverse clinical and hematological effects and which can serve as a protocype for human use.

Technica 1 Approach:

Phase I - Infital experiments will test the albu-in-anti-albumin system, since this has been extensively investigated already by others. We will immunize rabbits with a subcutaneous and an intranuscular injection of 5 mg of bovine serum albumin (BSA) in complete Freund's adjuvant. Antibodies to BSA should develop within two weeks; their appearance will be accertained by radio-immunoassay. Following the appearance of antibodies, a dose of BSA will be given intravenously. This should result in the formation of immune complexes between the BSA and the anti-BSA. These will be detected by an assay for IC that we have already developed.

The amount of BSA to be injected intravenously for 10 induction will have to be determined ampirically, and will probably differ for each animal since each will most likely develop different antibody levels. The radiofamunoassay for anti-BSA antibodies will provide the titer of antibodies in each a food. By adding BSA to the antibody in vitro, we will be able to determine the amount of BSA necessary to form soluble complexes detectable by the immune complex assay. Taking into account the blood volume of the rabbit, we will then calculate the amount of BSA to be injected to form soluble immune complexes in vivo. We will then inject this amount of BSA into the rabbits and determine whether the in vivo formation of account requires requires the same or a different autigm/antibody ratio as compared to the in vitro model. If the in vivo formation of requires a different ratio, this will be used in future trials.

Technical Approach Continuation:

Five adult male rabbits housed at MRAIR will initially be immunized with ESA. The appearance of antibodies will be wonitored by bleeding from an ear vein once every three days. After the intravenous injection of antigen, the animals will be bled daily until it is ascertained that the induced immune complexes have been cleared from the circulation. The animals will then be sacrificed and autopsied. Histological elimination of the Eudneys will be performed with the assistance of the Veterinary Pathology Division of WRAIR. Personnel of this division will perform autopaies on all animals that are sacrificed or die during the experiments.

Gross pathological examinations of all organs and hemotoxylin-ecoin staining of rabbit kidneys will be performed, and the pathological findings will be interpreted in light of the experiments performed. Antigen, antibody and IC deposition in the kidneys will be detected by immunofluorescent microscopy for the presence of albumin, IgG, IgM, C3 and C4. Kidney slices will be incubated at low pH to elute complexes which can be detected in radioismunoassays for albumin, anti-albumin, and IC.

With each group of five animals tested in the study, 2-5 rabbits will be set aside as untreated controls. These will be sacrificed after 4 weeks and autopsied for evidence of renal immune complexes deposited as a result of infectious processes. Complement fixation assays for agents (primarily protozoal) causing such deposits will be performed on sera from all animals in the test and control groups, and only

rabbits that appear free from these agents will be used in the studies.

If none of the original five rebbits develope detectable immune complexes after the intraverous injection of CSA, these animals will be sacrificed and a cose of BSA three times as high will be injected into a second group of five immunized rabbits. Although unlikely, it is possible that we will not succeed in inducing TC formation in either of the first two test groups. If no complexes form after ten animals have been tested, we will inject complexes formed in vitro into five unimmunized rabbits and will study the kinetics of their disappearance in these animals, as well as the pathological sequelae of the injection.

As a part of Phase I, several radioimmunoacceys will be developed. We will design an assay for BSA and for anti-BSA using a double antiboly technique. BSA will be labelled with 125-I by the Chloramine T or the Bolton-Hunter method, depending upon reagent availability and labelling efficiency. A commercial rabbit antiserum to BSA will be reacted with this, and a goat antiserum to rabbit immunoglobulin will be used as a second antibody. In the test for BSA as an antigen, the BSA circulating in rabbits and present in serum will act as an unlabelled inhibitor of the precipitation of labelled BSA. In the test for antibodies to BSA, rabbit serum suspected of containing anti-BSA will be substituted for the commercial antiserum to BSA; the amount of labelled BSA precipitated will increase as the titer of anti-BSA antibody rises.

We have already developed an assay for monitoring immune complex levels based on the binding of IC by iodinated Clq and the precipitation of the bound Clq by 25g/L of polyothylene glycol (MW 6000). This assay will be applied to the measurement of IC in tested and control vabbles.

Some IC may not be detectable by the Clq binding assay, although this is one of the more sensitive tests for these. It the assay detects no IC in any rabbits which develop circulating antibodies, we will develop an IC assay based on precipitation with remoderable chemnatoid C. show or boving conglutinin.

Phase 2 - After we establish a method for monitoring the development and persistence of anti-ESA antibodies and IC, we will begin the second phase of the study. We estimate that this will start four months efter the beginning of the project. In this will establish a method for attaching BSA to immunes isorbent columns and for monitoring the effluent from these columns.

In the initial studies of this phase, BOA will be attached covalently to Sepherose books with cyanogen browing. After the BSA is attached

and the boods are riased, norms collabiling and reflect to 20A city be passed through the colors. The turn's like to 10A will be adsorbed by the colors, and will be eluted as pil 3.6. There partified nationalism will then be labelled with 125-7. The labelled antibodies will then be used to determine the adsorption expactly of this and other columns. Labelled antibodies will be proved through the column with a buffer at pil 3.0. New accesses of the labelled antibodies will be performed with a gamma scintillation counter.

Columns containing bound BSA will be tested for antigen leakage by binding 125-I labelled BSA to the Sepharose. After the adsorber has been thoroughly riused with beffer, it will be proved through a column and normal rabbit serum will be passed through it. The amount of radioactivity escaping from the immunoadsorbent will be monitored and will determine the leakage rate of the advorbent in the presence of rabbit serum. Similar stables will be performed with columns containing bound human Clq which will be designed to remove IC from serum.

Phase 3 - In this phase, we will study the effects of removing circulating antibodies to BSA and IC from the same of rabbits as part of an extracorporeal circulation system. These studies should begin six to nine months after the start of the project and are dependent upon the successful completion of the first two phases.

Eight rabbits will be injected with ESA or in Phase 1. All eight will be treated by extracorporeal circulation. Five of these will be connected to an immunoalsorbest column containing BSA linked to Sepharose beads and their blood will be perfected through the column. The remaining three will act as controls and will be connected to a column containing rabbit serum albumin linked to the beads. It is expected that the column containing DSA will remove circulating anti-DSA antibodies, while the column containing rabbit serum albumin will not.

The abount of albumin on the columns will be determined by the studies done praviously in Phase 2. Refure will be enlarged if there is little antibody removal in the first perfusion studies.

Since these experiments will be dire too primarily toward testing the perfusion apparatus, rather than toward the perfusioned alterration of the fraude response, such rability will value only a single perfusion. The perfusion will be took to occur when a high level of anti-RSA antibodies are detestable in the second BSA, anti-RSA and IC levels will be monitored inmediately leader and after the perfusion, and every three days there after for a period of two weeks. Robbits will then be sacrificed and outopsied.

Phase 4 - This phase will begin after the conclusion of the previous studies, probably 9-12 months after the start of the project. Studies in this phase will be similar to those in Phase 3, except that immune complexes will be removed, rather than antibolics.

In eight rabbits, IC will either be induced or injected, as determined by the earlier Phase I studies. Blood from five of the eight rabbits will be perfused through a column containing human Clq bound to Sepharose beads, while blood from the remaining three will be perfused through a column containing only Sepharose beads. As in the Phase 3 studies, BSA, anti-BSA and IC levels will be measured before and after the perfusions, and the animals will be sacrificed and autopsied two weeks after the perfusions.

Animal Treatments: All rabbits will be fed and watered ad libidum and will be treated in a humane manner designed to minimize pain and discomfort. Before perfusion studies, rabbits will be premedicated by injections of atropine (2 mg) and heparin (1000 U/kg) intravenously into an ear vein. Thirty minutes later, they will be anaesthetized by a slow intravenous injection of sodium pentoleculated (30 mg/kg), which will be repeated if the animals appear to regain consciousness or show discomfort.

Bleeding of rabbits for routine testing will be performed by incining a peripheral car wein with a scalpel after a local application of xylene to induce vacodilation. Animals will be sacrificed by an overdose of Somethal injected intravenously.

Immunoadsorption and Perfusion Techniques: We have arranged a collaborative investigation with Dr. Franco Castino of the American Red Cross Blood Research Laboratory in Bethesda, Maryland for our extracorporeal perfusion studies. Dr. Castino has developed a plasma-pheresis system which flaters plasma proteins through a membrane with 0.6 micron peres. Filtration of plasma through this membrane is said to be less destructive of platelets than is plasmapheresis with a centrifugal cell separator. A small model of the apparatus is available for our use in rabbit experiments.

Dr. Cast no is currently isolating Tactor Will from plasma using an immunoadserbent containing antibodies to the factor that are bound covalently to Sepharose Ch beads with cyanogen bromide. Purified Factor VFII is removed from the immunoadserbent by 1 H nACl or 0.22 M CaCly. We half use these techniques, with a coopsians modified cutions, for sinding and ciuting BSA from the immunoadserbent.

We plan to routinely bouse our rabbits at WATE, which will allow us to observe and study them once our laboratory. We will transport the raibits to the American Rad Cross Laboratory for each perfusion and will return them to WRAIR after the inent.

The relieve while be entirely sleen both reserves as the first Cropp

laboratory in bost instances, although in some cases the rubbit may be precedicated at SMAIR before transportation to have time during the precidented at SMAIR before transportation to have time during the precidented phase of encenthesia. After the rubbits are felly anaesthetized, a feweral art by and velouable to included and connected to the plasmapheresis system. Analytically a periotaltic pump, blood will flow through the periodical system and plasma will pass through the pores in the system's media. The separated plasma will then pass through an on-line is namendableat colors containing a specific protein bound covalently to Sepharose brads. Antibolies to BSA will be removed by binding 85A to the beads, as outlined above. It is expected that IC will be removed by both the columns containing BSA and those containing Clq, as the will determine which of the two methods is more efficient for this either in the studies described above or in later ones.

After the plasma has passed through the immunoalsorbeat, it will then be returned to the rabbit together with the wills, which will have bypassed the loop containing the edsorbent. This bypass will spare the cells may possible travma or removal which right occur if they were allowed to come into contact with the resorbent.

After the perfusion is coupleted, the cannels will be removed and the rounds will be repared. Rabbits will be allowed to receiver from their amoesthesia and will be returned to MAAR for studies of their post-operative clinical state. The immunitarient will be recycled by removing bound antibodies and immunically leads with high reducity salt solution and buffers with low [1]. The perfusion system will be cleaned, sterilized, and used in later modies.

Several investigators have previously perfused rabbits with exerct corporeal immunoadsorption devices. Indicate anticongulated with doses of heparin similar to those that we will use. It did not appear necessary to neutralize the anticongulant after treatment. In our inital studies, we will not attempt to neutralize the anticongulant and will rely on meticulous surgery to prevent post-operative bleeding from the wound. If excessive bleeding does occur, we will neutralize the heparin with protonine, but it seems likely that this will not be necessary as rabbits tend to be hypercompulation. Protonomia times will be menitored to follow the effects of the anticongulant and any added protonine. Poster the operation is specifically designed to minimize platelet loss, we expect to have few bleeding problems referable to this, perfectable the rabbits will only be perfused on one occasion.

Leskage of Sepharose beads from the apparatule will be prevented by inserting a nitrocallulose filter with 0.0 miles pores into the effluent line. This filter will allow proteins to pass through it, but will retain the beads and any other particles that adult embolization.

Because this is only a preliminary study, and future perfusion apparatus will likely have a different design, we will not routinely test the column effluent for pyrogenicity or sterility, although all apparatus will be sterilized by heat, ethylene oxide and/or merthiolate prior to use. Should a problem develope in the studies that are referable to a failure in sterility or to pyrogenicity, appropriate studies will then be conducted. In such a case, sterility would be determined by taking samples for bacterial cultures and pyrogenicity would be measured by the Limulus amebacyte lysate test.

PROGRESS DURING FY-80:

The nature of the rabbit immune response to BSA has been explored. I found that rabbits responded to an injection of BSA in Freund's adjuvant by producing antibodies and immune complexes. Both of these were detected by radioimmunoassays.

The response to BSA was determined by a double antibody RIA using iodinated BSA. Antibody was detected in six rabbits within 3-5 days. Antibody levels rose rapidly at first, and then more slowly for a period of five months. After a booster injection, antibody levels rose still further, followed by a small decrease.

Immune complexes detected by a Clq binding assay appeared within 3 days after primary immunization. They reached a peak within 14 days, and changed little after this. Three of the six rabbits received a booster injection of BSA, but this did not affect the level of immune complexes.

It became necessary to determine whether the immune complexes were derived from the injection of BSA or from constituents of the Freund's adjuvant. Complete Freund's adjuvant contains mycobacteria in oil, while incomplete Freund's adjuvant contains only oil.

Three rabbits were injected with complete Freund's adjuvant, while two were injected with incomplete adjuvant. After six weeks the rabbits were boosted with incomplete adjuvant. The animals were bled once per week for three weeks. These will be analyzed for IC in the near future.

Pathology studies of tissues from sacrificed animals revealed lymphocytic infiltrates in the lungs and kidneys. These were not intense, however, and were suggestive of a chronic protozoal infection. This had been anticipated since many rabbits in the WRAIR colony show similar lesions. No severe signs of serum sickness appeared in the rabbits.

CONCLUSIONS:

Initial studies suggest that immune complexes appearing after injecting ESA and Freund's adjuvant may be predominantly composed of antigen and antibodies related to Freud's adjuvant, rather than to BSA. In order to remove specific immune complexes, as required by the protocol, it must be determined whether these complexes result from the BSA or the adjuvant. After analyzing the results of immunizing rabbits with only the complete or incomplete adjuvant, it will become apparent whether we should direct our efforts to removing complexes containing BSA or to removing those with adjuvant constituents. Thus, the future direction of this work depends upon the resulting of these studies now being performed.

CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 3159-R

Funds Utilized, FY-80:

Funding Requirements, FY-81:

Personnel: An additional person is needed to complete Phase II. This person would spend 50% of time on this protocol, as follows:

> Rabbit bleeding and serum shortage 5 hrs/wk Preparing immunosorbents 5 hrs/wk Performing radioimmunoassavs IC hrs/wk TOTAL TIME 20 hrs/wk

Equipment: None

Supplies: Metabolic animal cages 500.00

Radioisotopes for immunoassays 1,000.00

(125-I Bolton-Hunter Reagent; 5 orders

per year at \$200 per order) Chemicals (Cyanogen bromide-activated

Sepharose, antisera, anesthetics, buffers, antigens, others) 2,000.00 Chromatography colums 500.00

Glassware, Plastiware and

pipette tips for immunoassays

(1000) and general use 1,500.00 Miscellaneous supplies 1,000.00 TOTAL 6,500.00

Travel: 400.00

Publication Costs: 400.00

Other:

Rabbits - Purchase: 30 rabbits 3 \$25.00 750.00 1000 rabbit days @ \$0.55 550.00

TOTAL \$ 8,600.00

<u> 11-25-80</u> Protocol No: 3150-R Status: Interim X Date: Final Title of Project: Study of Rheumatoid Arthritis and Sjogren's Syndrome Precipitins in Rheumatic Diseases. Starting Date: Summer, 1979 Estimated Completion Date: June. 1981 Principal Investigator: Joseph T. Tesar, MD Facility: Walter Reed Hospital Associate Investigators:
Oliver Lawless, MD Dept/Svc Medicine-Rheumatology Rheumatoid Factor Key Words: Rhematoid Arthritis Precipitins, Sjogren's Syndrome precipitins Accumulative MEDCASE Accumulative Contract Accumulative Supply \$6,499.27 Cost: \$1,430.38 Cost: Cost: Periodic Review Results: FY-80 MEDCASE Cost: \$1,430.38 (to be filled in by DCI) Study Objective: Investigation of rheumatoid arthritis and Sjogren's syndrome precipitins. Technical Approach: Examination of rheumatoid and Sjogren's disease sera by agar gel precipitin technique using antigens obtained from thymus. Sera from patients with other recumatic diseases used as controls. Progress during FY-80: Clinical and immunological data from 65 patients

Progress during FY-80: Clinical and immunological data from 65 patients were obtained. It was demonstrated that certain rheumatoid arthritic sera form an additional precipitin line with a thymus antigen. This is probably a RF with dual specificity, i.e. toward ANA and LeG.

Number of subjects to be studied before completion of study: 35

Serious/unexpected side effects in subjects participating in project:
None

Conclusions:
These data suggest a diagnostic application of these precipitins in rheumatoid arthritis and Sjogren's syndrome.

Publications or Abstracts, FY-80: See annual progress report.

CLINICAL INVESTIGATION PROGRAM

work Unit wo .:

3160-R

Funds Utilized, FY-80:

\$3000

Funding Requirements, FY-81: TOTAL: \$4490

<u>Personnel:</u> (name and grade)

<u>Equipment:</u> (describe in detail including rost)
Sonicator

\$990

\$2500 Supplies: (consumable, animal purchase)

<u>Travel:</u> (mission oriented, training and presentation) \$500

Other: (equipment rentals, contracts for service, animal care and reprints)

Scientific publications

\$500

Work Unit No.: 3160-R

Study of Rheumatoid Arthritis and Sjogren's Syndrome Precipitins in Rheumatic Diseases.

Investigators:

Principal: Joseph T. Tesar, M.D., Staff Rheumatologist

Associate: Oliver Lawless, M.D., Section of Rheumatology

Starting Date: Summer, 1979

Objectives: The study was designed to evaluate the diagnostic value and the biological properties of rheumatoid arthritis and Sjogren's syndrome precipitins.

Technical Approach; Reference antisera with known precipitating antibodies to RAP and SS-A/B antigens are used for the identification of precipitin lines present in sera of patients with wheumatic diseases. The antigen used is a thymus or B-lymphocyte (tissue culture line) extract. No modification of protocol has been made.

Since the start of investigation we have Progress Report. examined approximately 65 sera of patients with rheumatoid arthritis, Sjogren's syndrome and appropriate rheumatic disease controls.

> We have reference sera for RAP and Sjogren's syndrome precipitin determination. We have [6] rheuma⊷ made the observation that certain Iqu rhauma-toid Icobors induce and additional precipitin . line using the method for demonstration of RAP precipitins.

M. Floyd and J.T. Tesar: The role of IgM Publications: rheumatoid factor in experimental vasculitis. Clin Exp. Immunol 36: 165, 1979.

> R. Raskin, J.T. Tesar and O.Lawless: Sjogren's syndrome and hypokalemic paralysis. Accepted for publication, Arch Int. Med. 1980.

Date: 20 October 1980	Protoco	1 No: 3161	Status: Interim X
Title of Project: Evaluation Skin Tests in Uremic Patient		ate Hypersensitiv	ity Final
Starting Date: June 1979	Estir	mated Completion	Date: December 1980
Principal Investigator: Rogh	ava V. Char	ya, M.D.	
Associate Investigators: Richard Evans III, COL MC	f	Facility: Walter	Reed Army Medical Center
Jim Baker, CPT MC		Dept/Svc Allergy	-Immunology
Key Words:			
Accumulative MEDCASE Cost:	Accumi Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:		eview Results:	
		(to be fill	ed in by DCI)
Study Objective: To determi and flare skin testing is allergic reactions in pati	a reliable m	method of determin	nsitivity as assessed by wheal ning potential IgE mediated
			tivity skin tests by prick test nd morphine are to be used as
Progress during FV-20. So	far 5 uremig	c natients have b	een studied. Two patients had
positive skin tests to inh positive skin tests and al	alant aller	gen. There was o	nly one patient who had both

Publications or Abstracts, FY-80: None

Conclusions: None can be drawn at this time.

Number of subjects to be studied before completion of study: 50

Serious/unexpected side effects in subjects participating in project:
The other three patients had negative histories and skin tests.

CLIMICAL INVESTIGATION PROGRAM

Mork Unit No.: 3161

Funds Utilized, FY-80: None

Funding Requirements, FY-61: \$2500.00

Personnel: (name and grade)

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase)

Travel: (mission oriented, training and presentation) \$1,000.00

Other: (equipment rentals, contracts for service, animal care and reprints)

IgE Prist test and Rast for each patient \$1,500 probably more than once)

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-MR

Clinical Investigation Protocol, Work Unit #3162-R

- TO C, Dept of Clin Invest
- FROM C, Rheumatology Svc

DATE 3 December 1980 CMT I

- 1. In response to your DF dated 22 August 1979, the protocol has been modified in the following manner.
- 2. The normal range will be defined using sera from Rheumatology Service Staff and from apparently normal patients evaluated in the Rheumatology Clinic. Consent will be obtained from normal subjects.
- 3. The consent form has been modified. The new consent form is attached.

oliver J. LAWLESS, MD

Colonel, MC

Chief, Rheumatology & Clinical

Immunology Service

D.to: 13 October 1980	rational No. 3162-R		Status: In	
Title of Profess.			E	Inal
Serial Studies of Serological	Parameters in Syst	emic Lupus	Erythemato	sus
Starting Date: 22 August 1979	literiment et Countie	Ci a Datas	30 Conto-1	1002
Starting Date: 22 August 1979	Estimated Comple	11 41 17 1131	30 Septemb	er 1982
Principal Investigator: Col Oliv	er J. Lawless, Maj	Richard C	. Welton	
Associate Investigators:	Facility:	WRAMC		
Sernard H. Berne, MD, PhD.				
	Dept/Svc 1	Medicine/R	Cheumatology	y Service
Key Words:	· · · · · · · · ·	-		
Systemic lupus erythematosus, D Accumulative MEDCASE		·····		(2 ()
1	Accumulative Contr Cost: 0	101	Cost: \$13	live Supply ,820.18
FY-80 MEDCASE Cost:	Perio	dic Review		
		oe filled in		~~~~ <u>~~~</u>
Study Objective:	managa a managangan yang a			ere lengto i y as gue
See attached sheet.				
Technical Approach:				
* *				
Sec attached sheet.				-
Sec attached sheet.				
Progress during FY-50:			•	
Progress during EY-90: See attached sheet. Number of publicits to be sinded.	agans copy Wijar - S	- 1 1 1 1 1 1 5		
Progress during PY-90: See attached sheet. Number of subjects to be studied.	ogano com Selio () Paulyottis perioly ()	i (m) (v) — 5 (n), se proje	ect:	
Progress during FY-50:	angung dagay bajar () Sadiyadis jagahalya l	.: (** kg;5 hg, :6 proj:	00 cet: none	

Clinical Chemistry 26:1072, 1980.

3. OBJECTIVES:

- 1) To assess the value of serial testing of DNA birdings and immune complex determinations by all bindings in systemic lupus crythematosus (SLE).
- 2) To ascertain in a prospective study whether rapid improvement in the above parameters can be found in the first weeks of steroid therapy in nephritis, and whether they can be used to regulate steroid dosage.
- 3) In a retrospective study, to relate changes in these parameters to the long-term course and prognosis in SLE.
- 4) To correlate the DNA binding and Clq binding assays with complement levels (C3, C4) and determine which of these tests are the best for short-term and long-term follow-up in SLE and related diseases.
- 5) To maintain the DNA binding assay as a routine procedure on the Rheumatology and Clinical Immunology Service and to standardize it to meet the requirements of the Joint Commission on the Accreditation of Hospitals (JCAH).
- 4. MEDICAL APPLICATION AND STATUS: Several investigators have shown that DNA binding levels correlate well with disease activity in SLE with diffuse proliferative glomerulonephritis (1-4). The correlation in other forms of SLE appears weaker. Recently, studies with several different assays for immune complexes, including Clq binding activity, have suggested that these also can serve as useful parameters in SLE, although their actual prognostic role has not yet been defined (5-7).

Measurements of DNA binding and immine complexes reported in the literature are usually performed on a mouthly basis with occasional studies utilizing weekly measurements. At present, most physicians treat SLE complicated by diffuse proliferative glomerulonephritis with approximately 60mg of prednisone per day for at least three menths, before making a final assessment of the degree of steroid responsiveness in each patient. Improved assays may be able to reduce this time. For studies of DNA binding and immune

tipes a sure will also be purfered; the second as active since the house, deposit upon but a scintillation counting with a copill leconductor could tuil.

The mean and standard deviations will be determined at each level. Quality control sera at each level will be placed in one or more positions on each run depending upon its length. If the quality control sera show a greater than 25D deviation from the expected between-run mean at a given level, all assays near that level will be discarded.

If the Clq binding assay for IC proves to be useful and can be standardized, it will also be upgraded to meet JCAH criteria. Until that time, it will not be used in patient management, but will be utilized in research studies with appropriate cautions and controls used for interpreting data.

Phase II.

After quality control standards for DNA binding are established, we will begin Phase II of this study. In this phase, we will determine whether rapid changes in DNA and Clq binding occur during therapy of SLE.

If rapid changes are found, we will attempt to correlate these with changes in clinical status, with particular emphasis on diffuse proliferative glomerulonephritis, one of the most serious manifestations of SLE. We shall also determine whether these are better markers for acute changes than are C3 and C4 levels. Correlations with skin test reactivity (intermediate PPD, Candida, SKSD, mumps, Trichophyton) will also be determined, as will be changed in fluorescent antinuclear antibody titers.

Patients dulited to WRAMC with SLE and active dephcitis will be entered into this study, provided that they have not been previously treated acutely with steroids or immunesuppressive agrees. These patients will fulfill four or more American Pheumatism Association Preliminary Classification Politoria for SLE (including dephritis) and must give their informed consent for participate a in this study which will intend on that the manifold risks.

We estimate that 20 patients fulfilling requirements outlined above will be available for this study during the first year of this project, including 12 whose seca has already been stored but not tested for all necessary components. All patients entered into this study will have 15 ml of blood drawn once every 2-3 days.

Sera will be stored in 500 ul aliquons at -20°C unril tested. Each aliquot will be frozen and thawed only once. DNA bindings will be performed by the Farr assay. This test consists of: (1) Incubating sera with a standard preparation of tritiated double stranded DNA, with denatured DNA previously removed by endonuclease treatment. This preparation has been used in the Rheumatology Laboratory for two years; (2) Precipitation of complexed DNA by ammonium sulfate at 50% saturation; (3) Centrifugation at 3000 RPM an 4°C; (4) Removal of hill of the invented trip (1. Transfer of both helpes of the remation mixture to intrillation misler (b) Counting of railous strip in a beta sofic (1) action state to the residence.

(7) Calculation of percentage of DNA round and the precision of the assay; (8) Where the percentage of DNA bound exceeds 50%, sera are diluted and tested to determine the concentration that gives a 50% binding. The "DNA binding capacity" of the serum, expressed as grams of DNA bound per liter of serum is then calculated. Binding capacities at 50% DNA binding are used for high binding sera because assay provisions vary inversely with DNA binding percentage above this level.

An aliquot of each specimen will be tested for Clq binding capacity. This measures levels of immune complexes and aggregated immunoglobulins. Patients with SLE often have elevated Clq binding levels, but the correlation with disease activity is not yet clear. The Clq binding assay is performed with the following steps:

- (1) Clq, the first component of complement, is isolated from pooled human plasma, obtained from outdated whole blood in the WRAMO Blood Bank. Three units (1500 ml) of blood yield sufficient Clq for approximately 10,000 tests.
- (2) The Clq is aliquoted and stored at -70° C. It is frozen and thawed only once.
- (3) When ready for use, an aliquot is thawed and iodinated with 125-I. Either the Bolton-Hunter or Cloramine T method is used for iodinations, depending upon availability of reagents and efficiency of binding.
- (4) Unbound iodine is removed by dialysis.
- (5) 125-I Clq is incubated with serum in the presence of EDTA.
- (6) The Clq binds to immune complexes and aggregated IgC.
- (7) The total radioactivity added is determined in a gamma scintillation cocktail.
- (8) Bound 1251 Clq is precipitated by 25 g/liter of polyethylene glycol, molecular weight 6,000.
- (9) Reaction tubes are centrifuged at room temperature at 3000 RPM.
- (10) The supermatant is poured off and discarded.
- (11) The radioactivity in the precipitate is counted.
- (12) The percentage of Clq bound and the assay precision is calculated.
- (13) Using a standard curve with aggregated human gamma globulin (HGG), the gram equivalents of aggregated HgG precipitated in each serum is calculated.

The Clq binding assay has been performed in this service for over a year. Although within-run precisions are with a an acceptable level, run-to-run

variations are still for great to allow samples tosted in different runs to be routinely peoplited. Therefore, ten normal same are included in each run to give a normal range. All tests are done in duplicate. In serial studies on single patients, all samples are tested on the same run, or divided between no greater than two runs.

As we gain more experience with the Clq binding assay, we may be able to reduce run-to-run variation to a small enough level to allow exclusion of the 10 normal sera, now placed in each run. When this occurs, we will test the assay to determine whether it can fulfill JCAH criteria. In addition to the tests outlined above, the following tests will be performed as part of the routine care given to SLE patients:

Pre-Study:

- 1) CBC with platelet and reticulocyte counts
- 2) Westergren sedimentation rates
- 3) SMAC-20
- 4) Serum protein electrophoresis
- 5) Rh factor
- 6) Urinalysis
- 7) 24 hour usine for questionine clearance and probabil
- 8) Chest x-ray
- 9) Electrocandiogram
- 10) Renal biopsy where clinically indicated.

The following parameters will be followed on a routine basis:

- 1) Clinical parameters for classification of SLE see flow sheet #1
- 2) Serial lab data: See flow sheet #2; these include:
 - a) DNA binding and Clq binding once every 2-3 days for four weeks or more until stable, then weekly.
 - b) Urinalysis every 2-3 days for protein (Dipstick) and sediment.
 - c) Creatinine clearance, serum creatinine, BUN and 24 hour urine pro-
 - d) Weekly CBC with Westergren erythrocyte sedimentation rate.
 - e) FAMA with titers weekly.
 - f) C3, C4 weekly or more often if indicated.
 - g) Weekly skin tests if negative at outset.

CRITIFRIA FILE INE COMMUNICATION OF THE CONTROL OF

(,

7

	CRITERIA	(+) IN PART	1 11 12 12 1	ī			TE.			ILEY!	<u>y</u> 5
1.	. Facial crythema (butterfly resh)					<u>:</u> : · .		- -	j.==		
2.	Discoid Lupus										
3.	Raynaud's phenomenon				<u> </u> 						
<u>1</u> ;.	Alopecia										
5.	Photosensitivity				į		! !				
6.	Oral +/or hasopharyngeal ulcers		<u> </u>								
7.	Arthritis without deformity										
٤.	LE Cells (2 or more) (FANA > 1/160)										
9.	Chronic false-positive (+) STS 6 months										
10.	Profuse proteinuria 3.5 gm/day										
11.	Cellular casts in urine										
12.	Pleuritis +/or Pericarditis										
13.	Psychosis +/or convulsions in the absence of uremia										
14.	Hemolytic anemia, +/or leuko- penia (< 4,000), +.or thrombocyto- penia (< 100,600)										
15.	Miscellaneous										

(. .

Scale:	0 =	absent		
	1-5	s - m13.4	to	0000

1-5 = mild to severe List mushers for 166 receive Man.

423

and the second of the second o

(....

	TEST	NEE.	54	P#3 P#3] n 5 17/3	j j	 ن	10	12		18	2.	125	28,	35	<u>;</u> :
1)	MA Binding S .	 		===				(-		===				1	Ħ
5)	DNA Binding Capacity															T
	Clq Binding		<u> </u>		<u> </u>			<u> </u>								
	FAT		L		<u> </u>	<u> </u>										L
	Serum C'3	ļ			<u> </u>											L
6)	C.7														 	
7)	U/A - WBC's/			ĺ												
8)	U/A - REC's/			İ												-
9)	U/A - CASTS															
Ō)	U/A - PROTEIN															-
	24 HR. Protein															r
2)	Creat. CJ,							·							·	
3)	Serum - EUN												·			; !
1,)	" - CR								1						-	j –
5)	Hematology - WBC						- 1									-
5)	% Polys/ % Lymphs															
7)	Het/Hgb						-									-
(8.	Sed Rate			#-				• • • • • • • • • • • • • • • • • • • •	<u> </u>	<u> </u>						
9)	Predmisone Dose	·				}		}								
3)	MISCELLANEOUS															
<u>.)</u>																
?)																_
3)										·						-
·.)														-	İ	
(ر										ļ						
:-=	= 100 C.C	,				L		TT, I	tari u	====			==::!	. ======	<u> </u>	

The same of the property of the same of th

(_-:

Fig. (a) if the LM constant of the LM constant is a performance of part of the tout and the last the LM part of the study will therefore price or widitional terkload on the Main Laboratory or other Services. The case essential to totitoring the course of sLE for both research and a last 1 care.

It is empected that the above study will take one year to complete. At its termination we shall know whether the Olq and DNA binding assays are useful adjuncts to clinical management of SLH on more than an occusional basis, and if either of these is a better parameter than those routinely followed in cases where nephritis appears.

Since SLE is a variable disease with many patterns of symptomatology, it is possible that we may determine that serial studies of Clq binding are most useful in some types of disease, DNA binding in other, and routine testing in still other cases. The elucidation of such types of disease may lead to important insights into the pathogenesis of SLE and related disorders.

Phase III

Phase III of this study will at first be performed concurrently with Phase II, but will last longer. This will be a retrospective investigation of DNA and Clq bindings in SLE patients and their correlation with long term prognosis. Few such studies exist in the literature because of the relative newness of these techniques (4), and those studies that have been done suggest that the correlation is not perfect. Since we use a different DNA preparation than do other investigators, our results for this assay may differ from theirs.

Our serum bank currently contains over 3000 specimens from SLE patients. More than 100 patients have been followed for a year, with some being followed for five years. We shall select for our analysis at least 30 patients who have shown at least one exacerbation and who have been followed for at least three years.

All sera from each of the selected patients will be tested for DNA and Clq binding. A sera from an individual will be rested on a single run to minimize assay variation. Sera will also be tested for C3 and C4 by radial immunediffusion with appropriate quality controls.

Results will be correlated with the clinical course of each patient, as determined by chart review by a Rheumatology fellow. Where the clinic's charts are incomplete, we will attempt to retrieve the permenent imputient chart and outpatient charts from the Walter keed Patient Administration Division, from another military installation, or from the patient. Only those cases that can be completely documented will be analyzed. No test will be performed until the fellow is satisfied that the patients records are adequate for use in a publication. While it is not possible at this time to determine the number of patients with adequate retrievable records that can be used in this study, we expect it to be more than 30. Such a number would make possible a much larger study than has yet been published.

Harrie III

This study will involve taking an additional 40 ml of blood on a occasion from healthy people denating 500 ml for medical purposes. No additional venipunctures will be required. Denors will be identified only by age and sex. Informed consent will be obtained from donors, who will obtain no direct benefit from this study.

Patients with SLE and other diseases seen in the Rheumatology Clinic and on the medical wards will be asked to donate up to 30 ml on up to three occasions per week during acute phases of their illnesses and less for an indefinite period thereafter. Some of these patients may be anemic. This study must utilize anemic patients, since this is one of the common complications of SLE. Where the hematocrit is below 35, reduced amounts of blood will be obtained. Because the requirement for the use of an anemic patient, this protocol carries more than a low risk, as defined by WR 70-1, 8 January 1979.

All adult patients, and persons responsible for minor patients and for those incapable of consenting themselves, will be asked to give full informed consent. Children under legal age will be asked to give assent in writing if capable of understanding the risks and benefits involved.

This protocol may benefit some patients who are part of this study. The results of DNA binding assays and Clq binding assays may be used in making therapectic decisions concerning individuals participating in this study. Within WRAMC, these assays will only be available to persons participating in this protocol. The tests will not be offered to WRAMC patients who have not given their consent to participate, as there are no funds allocated for performing the test on a routice basis.

Copies of consent forms are attached. There are three forms:

- 1) Blood donor form.
- 2) WRAMC patient form.
- Guardian form for WRAMC patients not competent to consent or under legal age.

These forms are appended at the end of the protocol.

Data Anny sin Plan: 3D W and Clq binding levels in SLE patients will be compared with those in normals and in other diseases. Changes in levels in individual patients will be displayed graphically in longitudinal studies. All parameters measured (clinical, therapeutic and serological) will be plotted on the same graph.

Correlations of levels of different constituents in the same individual will be statistically analyzed by the Pearson correlation coefficient, including p values for their significance. It is recognized that correlations obtained in longitudinal studies are often imprecise, because trends of one parameter can change while those of another do not until a later time. To obtain a significant number of data points in such studies, one must compare the same parameters at the same times in more than two individuals, or one must group similar data points obtained at different times in the same individual, providing all of these points are following the same trends.

Fign. framer of differences between normal and discusse groups, and differences before and after therapy, will be analyzed by the Student t test. A \underline{p} < 0.01 will be considered as the minimum significant level. The normal range will be defined as ± 2 standard deviations from the mean.

If data points in any group appear to be abnormally distributed, non-parametric statistics will be used. These will include the Wilcoman matched pairs test, the Mann-Whitney U test for significance of differences of ungrouped data, and the Spearmann rank correlation test to find the correlation coefficient. Appropriate adjustments will be made for groups with large numbers of ties obtained in ranking data.

PROGRESS DURING FY-80:

We directed our efforts toward refining and evaluating methodology for measuring immune complexes and antibodies to DNA. These are involved in the pathogenesis of SLE.

Our present assay for immune complexes utilizes the precipitation of 125_T labelled Clq (part of the first complement component) by immune complexes in the presence of polyethylene glycol. This assay detects a high percentage of patients with SLE, but is subject to inferfering substances and the hazards of radioactivity. To avoid the use of radioactivity, we tried to develop an immune complex assay using anti-antibody. This unique IgM is found in occasional normal and diseased people. It reacts with the antibody in immune complexes present in several diseases, but not with unbound antibody. Using the anti-antibody, we attempted to devise a hemagluttination-inhibition technique to detect i mune complexes. The results of these trials were not definitive, however, and the attempt was temporarily postponed until further background studies could be conducted.

Our assay for antibodies to DNA, the Farr technique, involves the precipitation of tritiated DNA by ammonium sulfate after it has bound to anti-DNA antibodies in patient sera. In 3,000 tests, we showed that SLE could be monitored with this assay. However, the assay is not very reproducible, involves the use of radioactivity and toxic chemicals (xylene), and is very time consuming.

We therefore tested a recently marketed fluorescent immunoassay system (TTAX) for antibod/es to DNA. Over 1,000 tests were performed with this system. We found that the FTAX system while not exceedingly reproducible was equally reliable as the Farr assay, and had the same specificity for SLE. Further, results could be obtained within 3 hours of the receipt of a specimen with a smaller technician time than the Farr assay. Unlike the Farr assay, the FTAX method was no radioactive or chemical hazards.

If funds become available to purchase the FIAX system, we plan to replace our Farr assay with the FIAX method. This would add an important new capability to our laboratory, and the FIAX method could be extended to other assays involved in the diagnosis and management of 55%.

Clinical parameters and serial laboratory testing as outlined in the protocol have been collected on 27 patients over the past one year.

Through Trimervice Medical Information System, the computer program, "Clinflow" was used to enhance the evaluation of the large amount of data collected. Approximately 65,000 bits of data were entered and analyzed through various worksheet panels. The computer analysis has been completed and the information derived is presently being organized and will be placed in written form for publication and Aperican Rheumatism Association National Meeting submission by mid January 1981.

Since normal blood bank donors could not be used in this study, the normal range was determined using sera from normal hospital staff and patients without significant disease that were referred to the Rheumatology Clinic.

A revised consent form was prepared to meet requirements of MSC. This is appended to this report.

CONCLUSIONS DURING FY-80:

We have validated the Farr and FIAX assays for antibodies to DMA to conform to JCAH standards. Because of its simplicity, speed and safety, we found the FIAX method to be superior to the Farr assay. It seems to be the best method currently available to measure these antibodies, although its reproducibility needs improvement.

We are continuing to evaluate new assays for immune complexes and anti-DNA antibodies. We are also currently using these to determine the significance of these substances in SLE and related disorders.

Publications or Abstracts, FY-80: (Continued)

- Lindsey SM, Berne BH, Snyder KL, Lawless OJ: Circulating Immune Complexes (CIC) Response to Standard Steroid Therapy in Acute Systemic Lupus Erythematosus. 43rd Annual Meeting of the American Kheumatish Association. 1979.
- Lawless OJ, Lindsey S, Snyder K and Berne B: Circulating Immune Complexes (CIC) Response to Standard Steroid Therapy in Acute Systemic Lupus Erythematosus Nephritis. IXth European Congress of Rheumatology, 1979, Wiesbaden.

CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 3162-R

Funds Utilized, FY-80:

Funding Requirements, FY-81:

Personnel: One full time military (Sp 4) or civilian (GS-09) technician is required for this project. There is no Clinical Investigational personnel currently available for this protocol. We request the assignment of a CIS technician to complete this project. This additional person was authorized by the most recent manpower survey, but has not been assigned to the Rheumatology Service.

Equipment: FIAX Fluorometric System (Medcase Request)

Beckman Refrigerated Centrifuge (Medcase Request)

Supplies:

Radioimmunoassay:

<pre>Isotopes (125-I Bolton Hunter Reagent) 6 Orders at \$200.00 per order</pre>	1,200.00	
Scintillation Cocktails (for 5000 assays)	1,500.00	
Scintillation Vials (for 5000 assays)	1,000.00	
Polystyrene Tubes (for 10,000 assays)	2,000.00	
Pipette Tips	1,500.00	
- Serum vials for storage (1500 vials)	500.00	
Other Glassware and Plasticware	1,000.00	
Chemicals (buffers, radiac wash, etc)	500.00	
Miscellaneous Supplies TOTAL SUPPLIES	1,000.00	\$10,200.00
Travel:		500.00
Publication Costs:		500.00

11-23-30 Protocol No. 3163-R Status: Interim Date: Final Title of Project: Histocompatibility Antigens in Acute Uveitis. Starting Date September, 1979 Estimated Completion Date: April-May 1981 Principal Investigator: Joseph T. Tesar, M.D. Associate Investigators: D.M. Strong, Facility: Walter Reed Hospital Chief, Histocomp. Lab. Paul Killian, Rheumatologist, F. Wergeland, Chief, Opth. Serv. Dept/Svc Medicine-Rheumatology Key Words: Hla, Acute Anterior uveitis Accumulative Supply Accumulative NEDCASE Accumulative Contract Cost: \$8+9.10 Cost: \$5,587.33 Cost: \$5,587.38 Periodic Review Results: FY-80 MEDCASE Cost: (to be filled in by DCI) Study Objective: To determine the frequency of HLA-C scries antigens and HLA-B? crossreactive antigen (B-7, B-27, B-22, B-40, B-42) in acute anterior uveitis. Technical Approach: Complete histocompatibility typing of all patients presenting in the opthalmology clinic with the diagnosis of acute non-granulomatous uveitis. See also the protocol annual progress report appended. Progress during FY-80: See annual progress report. Number of subjects to be studied before completion of study: 12-15 Serious/unexpected side effects in subjects participating in project: Conclusions:

See annual progress report.

Publications or Abstracts, FY-80: See Annual progress report. Work Unit No.: 3163-R

Title: Histocompatibility Antigens in Acute Uveitis (AAU)

Investigators:

Principal: Joseph T. Tesar, MD, Staff Rheumatologist WRAMC

Associate: Paul J. Killian, MD. Formerly Asst Chief Rheumatology Svc

D. Strong, MD, Chief. Histocompatibility Laboratory

F. Wergeland, MD, Chief, Ophthalmology Svc.

Starting Date: September 1979

Completion Date: April 1981

Objective: To determine the frequency of HLA-C Series of antigens and HLA-B7 Crossreactive antigens (B-27, B-7, B-40, B-42, B-22) in acute anterior uveitis.

Key words: HLA-C1, HLA C-2, B-7 CREG antigens, acute anterior uveitis.

Technical Approach: No modifications

Progress Reports (Conclusions):

- 1) The HLA-C2 an antigen whose association with uveitis has not yet been described was found to be present in this study in 70% of 34 patients with acute anterior (non-granulomatous) uveitis (AAU). This is in contrast with a 39% incidence of HLA-B27 antigen in the same population (nl population = 8% HLA-B27, 10% HLA-C2)
- 2) The relative risk for occurrence of AAU in persons with HLA-C2 antigen was calculated to be 27.0 and those with B-27 antigen 7.1.
- 3) The incidence of rheumatic disease (ankylosing spondylitis and Reiter's Syndrome) was 17.6% in this population (5/34).

Publications: Joseph T. Tesar, MD, Paul Killian MD, David Strong PhD et al:
Acute anterior uveitis, strong association with a new
histocompatibility antigen, HLA-C2. In Preparation, 1980

J. T. Tesar et al: Histocompatiblity antigens in acute anterior uveitis. Submitted to the Am. Transplant Soc. meeting 1981.

ork Unit No.: 3163-R

ands Utilized, FY-80: \$2000

sinding Requirements, FY-81: \$1800 (including supplies, travel and publications).

<u>Personnel:</u> (name and grade)

Equipment: (describe in detail including cost) None

Supplies: (consumable, animal purchase) \$1300

Travel: (mission oriented, training and presentation) \$500

<u>Other:</u> (equipment rentals, contracts for service, animal care and reprints) None

Date: 10/9/80	Protocol N	o: 3164	Status: Interim X
Title of Project:			Final
R	•		
The Comparison of Zaditen	and Theophyll	ine in the Prop	hylaxis of Bronchial Astim
Starting Date: 1/18/80	Estima	ted Completion I	Date: 12/81
Principal Investigator: D	or. Anthony J.	Deutsch	
Associate Investigators:	. F	acility:	AMC
Dr. Ana Ortiz Dr. Richard Summers Dr. Richard Evans	D	ept/Svc Dep	t. of Allergy
Key Words: Prophylactic	Therapy in A	sthma; Ketotif	en .
Accumulative MEDCASE Cost: 0	Accumula Cost:	tive Contract	Accumulative Supplicate: 0
FY-80 MEDCASE Cost:	0		eview Results:
Study Objective:			
To evaluate the long term so of asthma; to compare its e. Technical Approach: See original protocol.			
Progress during FY-80: female patient terminated s recurrence of pre-study med	tudy at third	month. Reason	(12 male, 3 female); one for discendinuation:
Number of subjects to be stud	lied before cor	nnletion of study	: 30
Serious/unexpected side effect			
Conclusions: Satisfactor	ry progress;	no complication	ns to date.
P. W. es or Abstracts, F		ono.	

Status: Interim Protocol No: 3165 Date: 15 October 1030 Final Title of Project: Clinical Trial of Skin Testing with Major and Minor Penicillin Derivatives in Rospitalized Patients. Estimated Completion Date: July 1982 Courting Date: June 1980 Richard Evans III, COL MC Principal Investigator: Associate Investigators: Facility: Walter Reed Army Medical Center Lelia T. Gaines, MAJ MC Dept/Svc Allergy-Immunology Hey Words: Accumulative MF:DCASE Accumulative Contract Accumulative Supply Cost: Cost: 0 Jost: TY-SO MEDCASE Cost: Pariodic Pariso Results: (to be filled in by DCI) Study Objective: To determine whether current penicillin determinants are adequate to predict patient's response to penicullin and derivatives. Technical Approach: Skin heat history positive and negative patients who will be given penicillin and record reactions, if any. Progress during FY-80: To date, we have tested 12 patients with a history of penicillim allergy. Two Totalds had positive shin tests and were not diven pericillin. The remainder were given penicillin or derivatives without reaction. We have begun to lest history negative patients. rabor of subjects to be studied before completion of study: clous/unexpected side effects in subjects participating in project: None omelusions: None can be drawn at this time.

Imblications or Abstracts, FI-80: Non

nora unit no.: 3165

Funds Utilized, FY-80: None

Funding dequirements, FY-81: \$1500.00

<u>Personnel:</u> (name and grade) No additional requirements 10 hours week/med

tech <u>Ecuipment:</u> (describe in detail including cost) No additional requirements

Supplies: (consumable, animal purchase) No additional requirements

Travel: (mission oriented, training and presentation) \$1500.00

Other: (equipment rentals, contracts for service, animal care and reprints) No additional requirements

Date: 8 September 1980	Protocol No:	31 66	Status: Interim X	
Title of Project: An Evalua	in Patients with		Final Testing and Progressive of an Adverse Reaction to	
Starting Date: 25 March 1980			Oate: Fall 1981	
Frincipal investigator: H.	chard J. Summers, S. Nelson, COL M thael Schatz, H.D	C		٠
Associate Investigators: Richard Evans III, COL MC	Facil			
Bonnie Baswell, MAJ MC Richard Weber, LTC MC Clarence Virtue, COL MC	Dept/	Svc Allergy	y-Clinical Immunology Servic	ce
Key Words: Local Anesthet:	ic; Skin Tests; C	hallenge; Ad	dyerse Reaction .	
Accumulative MEDCASE Cost: N/A	Accumulative Cost: N/A	Contract	Accumulative Supply Cost: N/A	-
FY-80 MEDCASE Cost:N/		Periodic Re (to be fille	rdew Resultar ed in by DCI)	
Technical Approach: Skin is reacted (by history) is pagradually increased until local anesthetic has been	erformed at low continuous either a positiv	oncentration	ns. The concentration is	
Progress during FY-80: To be negative at full str	date 2 patients		mpletely tested and found 500 patients at 4 major me	
Serious/unexpected side effe	cts in subjects par	ticipating in	project.	edical nters.
Conclusions: Insufficient of	lata at present			
Publications or Abstracts, F	Y-80: None			

CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 3166

Funds Utilized, FY-80: N/A

Funding Requirements, FY-81: N/A

Personnel: Richard J. Summers, LTC MC and Associate Investigators

Equipment: N/

Supplies: Consumable supplies utilized are those utilized in

normal patient care

Travel: Presentation of paper at one national meeting - \$800.

Other: N/A

Profocol No: 4113 Interim Date: 7 October 1980 Status: Figal Title of Project: "Cooperative Gynecologic Oncology Group" Estimated Completion Date: Starting Dule: N/A N/A Principal Investigator: Robert C. Park, COL, MC, USA Facility: Walter Reed Army Medical Center. Associate Investigators: Ward 67, Outpatient Clinic Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA Department of OB-GYN, GYN Oncology Dept/Svc Service Geoffrey Weisbaum, LTC, MC, USA William Neglia, MAJ, MC, USA Key Words: M/A Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: N/A Cost: N/ACost: N/A FY-30 MEDCASE Cost: Periodic Review Results: N/A (to be filled in by DCI) Study Objective: The Walter Reed section of Gynecologic Oncology is involved with nationally organized Gynecologic Oncology Group which contains 23 of the major medical centers in the country which are interested in the area of gynecologic tumors and treatment. GOG is recognized and funded through the National Cancer Institute. Technical Approach: Walter Reed is active in 23 GOG protocols. Presently, there are 36 protocols either continuing to collect data or active. These protocols involve typetment of ovicien calcinous, cervisely continuous, a thouse the two andometrium and uterine parcoma. To date over 816 patients have been registered in this group from Walter Reed. About 292 have been placed in specific protocol studies. Progress during PA-50: About 292 patients have been placed in GOG protocolo from falter Reed. Number of scheets to be studied before completion of study: Unknown Serious/unexpected side offices in subjects participating in project: Detailed in previous reports. Conclusions: Detailed in previous reports.

440

•						
Date: 17-Dec 30	Protocol No:	4151 4116		Status: Interim y		
Title of Project: The Eva	iluation of Fetal	Fetal Systolic Time Final				
Intervals and Beat to Bea Indications of Fetal Matu	at interval Varia	tions In Feta		rt Rate as Early		
Starting Date: FY 15	Estimated	Completion D	ate:	undetermined		
Principal Investigator:	JAMES HADDOCK					
Associate Investigators: H. KLAPHOLZ		Lity: WRAM	С			
H. SKIBA-POWELL	Dept,	/Svc OB ob				
Key Words:				•		
Accumulative MEDCASE	Accumulative Cost:			Accumulative Supply Cost:		
FY-80 MEDCASE Cost:		Periodic Re	view l	Results:		
		(to be filled				
Technical Approach: Systophono cardiography.	·	ls is determí	ned b	y EKG and		
	th development of this accurately I fetal EKG signa	f protocol 41 by totally n I. Hopefully	51 we on in , we'	ll have this		
Number of subjects to be stu Serious/unexpected side effe				60		
perional merbacian ains effe	ere in emlaces bar	, iii giiingioii.	v ojeo	· · ·		
Conclusions:						

The additional new feature of the technology is to derive the fetal EKG signal by a non invasive means, namely from the maternal abdomen rather than from a fetal scalp lead. This is being done under an approved research protocol. An amendment to 4116 is in order but we would prefer to submit this at a time when we have this ability in hand and have a specific procedure in mind.

Date: 17 Dec 80	Protocol N	0: 4124	Status: Interim x
Title of Project: Felal In- Continuing Project	tensive Care M	enitoring in a	Long-Banga
Starting Daie: 1973	Estimat	ed Completion D	Oute: On going
Principal Investigator:	JAMES B. HADDO	OCK	5 5
Associate Investigators: T. FRANK A. PRESBYLICK	Fa	acility: WRAM	c ·
H. SKIBA-POWELL	D,	rat/Svc 08	
Key Words:			
Accumulative MEDCASE Cost: \$435	Accumula Cost:	tive Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			eview Results:
Study Objective: To accume to fetal heart rate abnormance.			al outcome in relation rmalities.
Technical Approach: Eac reviewed and classified. infomration on a disk or o	We currently i	nave available	nd labor curve is technology to put this
Progress during FY-80: a	s above	- :	
Number of subjects to be stu Serious/unexpected side effe none			
Conclusions:			
Currently we have colle initiation of this prot and difficult. Shortly into a computer memory for analysis.	ccol. Review , we will have	of these curre the ability to	ntly is time consuming put these directly

Date: 17 Dec 80	Protocol No: 4129	Status: Interim y
	um Fetal Evaluation of Noise f Fetal Well-being.	Final Evolved Heart Rate
Starting Date: 1976	Estimated Completion I	Date: May 82
Principal Investigator:	JAMES HADDOCK	
Associate Investigators:	Facility: WRAM	•
T. FRANK A. PRESBYLICK H. SKIBA-POWELL	Dept/Svc CB	
Key Yords:	The state of the s	•
Accumulative MEDOASE	Accumulative Contract	Accumulative Supply Cost:
Cost:	Cost:	· —
FY-80 MEDCASE Cost:	Periodic R. (to be fill	eview Results:ed in by DCI)
FY-SO MEDCASE Cost: Study Objective: To test to accelerations in response to teal well being as are the accelerations.	Periodic Ro (to be fill) the validity of the concept	eview Results: ed in by DCI) nat Fetal Heart Rate s good a predictor of us fetal movement and
Study Objective: To test the accelerations in response the accelerations. Technical Approach: Feta second tone pulse 90 to 121 in is has proven to be an experience a computer program to	Periodic Ro (to be fill) the validity of the concept the oan external stimulus are as	eview Results: ed in by DCI) nat Fetal Heart Rate s good a predictor of s fetal movement and etandard techniques a five- the fetus and response note others as well. When we
Study Objective: To test the accelerations in response the accelerations. Technical Approach: Feta second tone pulse 90 to 121 in is has proven to be an experience a computer program to	Periodic Rate (to be fill) the validity of the concept the concep	eview Results: ed in by DCI) nat Fetal Heart Rate s good a predictor of s fetal movement and etandard techniques a five- the fetus and response note others as well. When we

Note additional Co Investigator on this protocol is John Read. Initial work accomplished on this protocol in 1976 was promising. However, the initial investigator left and in the Interim several papers were published on this technique which is now accepted as standard practice in current ante partum testing. We are developing a computer technology to accomplish spectral frequency analysis of FHR variability under an approved protocol. We intend to use the same set up as proposed but - simply analyze the data obtained with a computer program.

Date: 7 October 1980	Protoco	1 No: 4134	Scatus: Interim XX
Title of Project: "Treatmen Stage IIB, IIIB, IVA, Conf Radiotherapy Alone Versus (Phase III) GOG #24. Storting Date:	t of Women ined to the Radiothera	with Cervical Cance Pelvis And/Or Para	a-Aortic Nodes With by (Intravenous C-Parvum)
Principal Investigator: Rob	ert C. Parl	k, COL, MC, USA	
Associate Investigators: Paul B. Heller, LTC, MC, USA		Facility: Walter R	eed Army Medical Center
Terrel J. Michel, LTC, MC, USA William Neglia, MAJ, MC, USA		,	nt of OB-GYN, GYN Oncolog
Key Words: Cervical cance	er, radiothe	erapy, and immunother	erapy
Accumulative MEDCASE Cost: None		ulative Contract None	Accumulative Supply Cost: None
FY-80 MEDCASE Cost:	None		iew Results: in by NOI)
Carda Old Alaman Balana			t for actionts with almost

Study Objective: Radiotherapy is the standard treatment for patients with advanced cervical carcinoma. The goal of this project is determined if the addition of immunotherapy will enhance the radiation response rate.

Technical Applicach: The patients are randomized to one of the areatment regiment:

1) Radiotherapy alone, or 2) Radiotherapy plus C-Parvum. Afterdment to the protocol states that patients who have clinical Stage IB found to have disease extending out to the pelvic side walls at surgery are eligible.

Progress Juring FY-80: One hundred and minety-two patient group-wide have been evaluated as eligible. Ten patients have been submitted from Malter Reed.

Number of subjects to be studied before completion of study: Annual accrual: 150 patients Serious/unexpected side effects in subjects participating in project: Adverse effects that were seen were basically those expected.

Conclusions: It is too early to draw any conclusions with regard to improve survival.

Date: 7 October 1980	Her made		4135	dinas: Corto XX
Title of American: "A Random Alone Versus Adriamycin ar	nized Compar d Cyclophos	ison o	f Melphalan e Versus Ne	Fire
Principal Investigator: Rot	ert C. Park	, COL,	MC, USA	and the same of the same of the same of the same of the same of the same of the same of the same of the same of
Associate Investigators: Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Facili	Facility: Walter Reed Army Medical Center Ward 67, and GYN Outpatient Cli	
		Dept/Svc Department of OB-GYN, GYN Oncolog Service		
Key Words: Melphalan ver Melphalan in			Cytoxan, ve	rsus Hexamethylmelamine and
Accumulative MEDCASE Cost: None		:lative	Contract	Accumulative Supply Cost: None
1Y-80 MEDCASE Cost:	N/A			view Results: d in Ly DCI)
Study Objective: Single a in patients with epithelia determine if adding Adriam rate.	l ovarian c	ancer.	The object	
Technical Approach: Pati 1) Alkeran; 2) Alkeran plu				of three treatment arms. Cytoxan plus Adriamycin.

Progress during PV-50: The total number of patients entered into this study was 432. The total number of patients from Walter Reed was 22.

Namel or of subjects to be stalled betwee completion of study: Approximately 430. Serious/unexpected side effects in subjects proficienting in project: There were no serious side effects in any Walter Reed patients.

Constrainers: The combination regimens appear to be more active than Melphalan alone in producing complete responses in these stages of ovarian cancer. Adriamycin and Cytoxan has a slightly higher response rate. Melphalan and hexamethylmelamine is oral, and avoids cardiac risk and alopecia. Functions or classificate, (1-50):

Date: 7 October 1980	מהטוחבין [No: 4136	Status: Industria XX
Title of Project: "A Random Versus Melphalan Therapy P (Optimal) Epithelial Carci	lus Immunot	herapy in the Tre	atment of Women with Stage III
Starting Daie:	Listi	nated Completion I	lace. Unknown
Principal investigator: Rob	ert C. Park	, COL, MC, USA	
Associate Investigators: Paul B. Heller, LTC, MC, U	S 4		Reed Army Medical Center, , and GYN Outpatient Clinic
Terrel J. Michel, LTC, MC,		Dept/Svc Departm Service	ent of OB-GYN, GYN Oncology
Key Words: Epithelial ov	arian carci	.! noma treated by M	Melphalan and immunotherapy
Accumulative MEDCASE Cost: None		ulative Contract None	Accumulative Supply Cost: None
FY-80 MEDCASE Cost:	None		eview Results:
Study Objective: Nelphala epithelial cancer. The ob of an immunotherapy agent	jective of	this study is to	determine if the addition
Technical Approach: Patiliovary are randomized to on alone and Regimen 2 is Mel	e of two tr	eatment regimens.	Trithelial varcinema of the Regimen I is Melphalan
	• •		
The second secon			
Progress during AV-80. Of into this protocol.			eatients have been entered entered three potients in
			150 patients annual accumal
Surrous/une spected side chies have been noted in either			project: No severe reactions
Conclusions: None at this			

Date: 7 October 1980 Protoco	l No: 4137	Stalus: Corini XX
Title of Project: "A Randomized Compar Abdominal Radiation Therapy Versus Pe Alone in Stage II Carcinoma of the Ox	Radiation at	nd Melphalan Versus Melphalan
Storting O.Co. 11 February 1977 Cati	mited Completion	Date: November 1978
Principal Investigator: Robert C. Park	e, COL, MC, USA	
Associate Investigators: Paul B. Heller, LTC, MC, USA		r Reed Army Medical Center, 67, and GYN Outpatient Clinic
Terrel J. Michel, LTC, MC, USA William Neglia, MAJ, MC, USA	Dept/Svc Depart	tment of OB-GYN, GYN Oncology ce
Roy Words: Stage II ovarian cardino	ma, pervic radia	tion, Alkera
•	ulative Contract None	Accumulative Supply Cost: None
TY-to DieDCASE Cost: None		eview Results:ed in by DCI)
Study Objective: The standard treats cinoma has been postoperative irradia data supports that single alkylating objective of this study is to determine or the combination of the two are the	etion to the abdor chemotherapy is o ine if radiation a	men and the pelvis. Recent equally effective. The alone, chemotherapy alone,
Tochnical Approach: Patients are rea total abdominal hysterectomy and be of the endocervix, the diaphragm, the then are randomized to 1) Pelvic and diation and Melphalan, or 3) Melphala	llateral salpingo- e iliac, and para- abdominal radiat:	-oophorectomy plus evaluation -aortic nodes. The patients
Progress during 19-50. Patients are treatment. However, the GOG withdres Therefore, no firm conclusions have to	v from this proto	col as of November 1978.
Notice () There is a subject to the subject or unexpected side effects in subject	on portioner in the	245 were hopefully studied. project: There were no serious in the project.
Co. Chaicher None.	y e, a mayanda say Albania yakanian a saasi	

Table: 7 October 1930	Imeteco	UNO: 4139	Status: Lateria XX		
Title of Project: "A Randor 5FU, and Magace Versus Addratients with Primary Stag (Phase III)" GOG # 28. Starting Date: 4 January 1	riamycin, Cy ge III, or I	toxan, 5FU V Recurren	, and Me it or Res	gace in the Treatment of idual Endometrial Carcinon	
Principal Investigator: Rob	ert C. Park	COL, MC,	USA		
Associate Investigators: Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Facility: Walter Reed Army Medical Center, Ward 67, GYN Outpatient Clinic			
		Dept/Svc Department of OB-GYN, GYN Oncolog Service			
Key Words: Endometrial o	earcinoma, S	tage III a	ind IV, t	reated with chemotherapy.	
Accumulative MEDCASE Cost: None	Accomulative Contract Cost: None		Accumulative Supply Cost: None		
PV-30 MEDCASE Cost:	None Pe		iodio Re-	dow Results: Lin by DCI)	

Technical Approach: Patients with advanced or recomment endometrial carcinoma are randomized to one of two treatment regimens: 1) Melphalan, 5FU, and Megace, and 2) Adriamycin, Cytoxan, 5FU, and Megace.

Frogress during FY-80: Three hundred and fifty-eight patients were entered into this protocol. Two were entered from Walter Reed.

Number of subjects to be studied before completion of study: 358

Serious/unexpected side offects in subjects participating in project: There were some hemotologic toxicities in ten patients and three drug-related deaths.

Conclusions: The overall objective response rate was 36.8%. The activity of Melphalan and 5FU for the first time the treatment of this disease has been established. There is suggestion that there is a better response to combination chemotherapy in patients with poor prognosis endometrial carcinena in companion to a single agent thorapy. They will be a follow-up on patients entered in the content of the content

superior.

WALTER REED ARMY MEDICAL CENTER WASHINGTON DC F/6 6/5
ANNUAL PROGRESS REPORT (FY-80) DEPARTMENT OF CLINICAL INVESTIGA--ETC(U)
SEP 80 T M BOEHM AD-A100 636 NL WNCLASSIFIED 6≠8 AD 4.00630

Date: 7 October 1980	Pretoco	1 : 12:	4140		Archest la	·	
Title of Project: "A Clinic and II Carcinoma of the En				ge I	Fi	imal	
Starting Date: 25 November	1980 Esti	nated (Completion	Date:	Unknown		
Principal investigator: Robe	rt C. Park,	COL,	NC, USA				
Associate Investigators:	·ca	Facili	ty: Walter Ward		rmy Medic Outpatien		
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Dept/	Svo Depar Servio		OB-GYN,	GYN Onc	olog
Key Words: Endometrial ca	rcinoma, St	age I	and II, s	urgical	investiga	tion	•
Accumulative MEDCASE Cost: None	Accumi Cost:		Contract		Accumulat		ply
FY-80 MEDCASE Cost:	None		Periodic . (to be fi	Review I lled in by			
Study Objective: To determetastasis and the relation factors in Stage I and II	nship of th	ese no	de metasta	asis to	other pro	gnostic	

Technical Approach: The patient will have a total abdominal hysterectomy, bilateral salpingo-oophorectomy, selective pelvic and para-aortic lymphadenectomy and peritoneal cytology sampling. Thereafter, the patient will be followed up or entered onto an additional Gynecologic Oncology Group Protocol. Patients with Stage I, Grade 1 disease are not eligible for this protocol. All patients are to be entered to the protocol after the surgery has been performed.

Stage I and II endometrial carcinoma can be admitted to this protocol which

will involve a surgical procedure and pathologic follow-up.

Progress during FY-S0: There have been 673 entries to this protocol. Walter Reed has entered 46 patients into this protocol.

Number of subjects to be studied before completion of study: Unknown
Serious/unexpected side effects in subjects participating in project: Four patients had pulmonary emboli. One patient was noted to have died. Seventeen patients had homorrhage greater than 1000 cc.

Conclusions: It would appear that this study could define the surgical procedure required for optimal evaluation of this stage or stages of endometrial carcinoma.

throughout made that a great a speciment greater that the second of the second		anne de la companya del companya de la companya del companya de la	
Date: 7 October 1980	Protoco	Ro: 4141	Status: Interim xx
Title of Project: "A Random Adjuvant After Surgery and metrial Carcinoma, Stage I	Radiation	Therapy in Patien	ts with High-Risk Endo-
Storting Date: 22 August 1	978 Estin	mated Completion L	late: Unknown
Principal Investigator: Rob	ert C. Park	, COL, MC, USA	
Associate Investigators:			Reed Army Medical Center, , GYN Outpatient Clinic, OR
Paul B. Heller, LTC, MC, U. Terrel J. Michel, LTC, MC,		Dept/Svc Departm Service	ent of OB-GYN, GYN Oncology
Key Words: Stage I and O	ccult Stage	I endometrial c	arcinoma treated by
Accumulative MEDCASE Cost: Mone	Accum Cost:_	ulative Contract None	Accumulative Supply Cost: None
FY-80 MEDCASE Cost:	None		eview Results:
as functions of various tweendometrial carcinoma.			
determined at surgery. The pelvic or para-aortic node ment will receive radiation to Adrianycin or no furthe	involvement therapy. r treatment therapy. o date, 83	e greater than 1/s t or microscopic of Following this, patients have been	evidence of cervical involve there will be randomization
Number of subjects to be size Serious/unexpected side effections of bowel obstruct relief of bowel obstructions of conclusions: None at pres	its in subjection in one on, possibl		e: Approximately 75/year for project: There has been you died after surgery for n therapy.
Publications or Abstracts, F		ie	

Date: 7 October 1980	Protoco	180:	4142		Interim		
Title of Project: "A Phase Advanced Pelvic Malignane	II Trial of	TCRF		With	Final		
Starting Date: 27 September	er 1978 desti	mated C	'a spletion I	ule: Unknown)		
Principal Investigator: Rol	ert C. Park	c, COL,	MC, USA				
Associate Investigators:		Facil	Facility: Walter Reed Army Medical Center Ward 67, GYN Outpatient Clinic				
	errel J. Michel, LTC, MC, USA		Department of OB-GYN, GYN Oncol Service				
Key Words: ICRF-159 in ac	dvanced pelv	.: ∕ic mal	ignancies.			•	
Accumulative MEDCASE Cost: None	Accumulative Cost: Non				ılative Suj None		
FY-80 MEDCASE Cost:	None			view Results: ed in by DCI)	-		

Technical Approach: Patients with histologically advanced and recurrent and persistent metastatic or local gynecologic cancer with documented disease progression will be entered into this treatment.

Progress during FY-80: Sixty patients have been entered to this protocol in the entire GOG. Five patients have been entered from Walter Reed. The patients with squamous cell carcinoma of the cervix as of November 1978 are no longer eligible for entry. Patients with epithelial carcinoma of the ovary as of June Number of subjects to be studied before completion of study: 25 patient per site. Serious/unexpected alle of reis in subjects participating in project: No serious or unexpected side effects have been noted.

Concommions: ICRF appears to have a moderate activity in squamous cell carcinoma of the cervix at the dose and schedule tested, despite significant myelosuppression.

Publications or Abstracts, FY-80: None

PROGRESS DURING FY-80: 1989, are no longer eligible for entry.

Stabus: Interina XX 7 October 1980 | Protocol No: 4143 Date: Title of Project: "A Randomized Comparison of Local Excision i Versus Cryosurgery in Patients with Limited Grade 1, 2 or 3 Cervical Intraepithelial Neoplasia." COC #31. 1 November 1978 Estimated Completion Date: 1982 Starting Date: Principal Investigator: Robert C. Park, COL, MC, USA Walter Reed Army Medical Center, Facility: Associate Investigators: GYN Outpatient Clinic Paul B. Heller, LTC, MC, USA Department of OB-CYN, GYN Oncology Terrel J. Michel, LTC, MC, USA Dept/Svc Service Geoffrey Weisbaum, LTC, MC, USA Key Words: Local excision, cryotherapy, CIN-1, 2, 3. Accumulative Contract Accumulative MEDCASE Accumulative Supply Cost: None None Cost: Cost: Periodic Review Results: TY-80 MEDCASE Cost: None (to be filled in by DCI) Study Objective: To evaluate and compare the immediate and long-term effectiveness of outpatient cryosurgery and outpatient local excision in the treatment of limited

Technical Approach: Patients are randomized to one of two treatment arms:

cervical intraepithelial neoplasia (CIN) Grade 1, 2, or 3. Patients are then

1) Outpatient cryosurgery, or 2) Outpatient surgical excision.

Progress during FY-S0: To date there have been 296 patients entered from the entire GOG. Twenty-three patients have been entered from Walter Reed. It is too early to draw any statistical conclusions.

Number of subjects to be studied before completion of study: 300 annually. 660 total Serious/unexpected side effects in subjects participating in project: At this point, none have been noted.

Conclusions: None.

Publications or Abstracts, FY-80: None.

randomized to prospective studies.

Date: 7 October 1980				
Title of Project: "A Randor zation Versus Cryosurgery Epithelial Neoplasia (CLN)	in Patients	with Exce	rgical nsive G	Coni- First Intra-
Starting Dafe: September I	1978 lösti.	nded Com	detion L	Date: 1981
Principal Investigator: Rol	ert C. Park	, COL, MC,	USA	
Associate Investigators: Paul B. Heller, LTC, MC, I	JSA	Facility:		Reed Army Medical Center, tpatient Clinic
Townel I Mighel ITC MC HCA		Dept/Svc	Depart Secvic	ment of OB-GYN, GYN Oncolo e
Key Words: Surgical conf	ization, cry	osurgery,	CIN-3	•
Accumulative MEDCASE Cost: None	j.	ulative Contract None		Accumulative Supply Cost: None
FY-80 MEDCASE Cost:	None_	Per (to	iodic Re be fille	eview Results:
neoplasia Grade 3 would be	e in-hospita nis study is coutpatient nt of extens ized prospec patient is	l conizati to evalua cryosurge ive surgic tive study randomized	on or in te and or ry to that intra to one	aepithelial neoplasia of two treatment arms.
Progress during FY-80: To evaluable are 33. Four has for analysis at this point Number of subjects to be six Serious/unexpected side of the state of	ded before.	ered from	Walter l	Reed. It is too early Approximately 310
Complisions: It is too eacontinue.	irly to draw	conclusio	ns. The	e patient accession will
Publications or Mistracts. I	°Y~89: Non	e.		

Date: 7 October 1980	Prefece	No. 414		Status; be	iorimxx
Title of Project: "A Random Versus No Treatment in the IIBi Ovarian Cancer (Well	Treatment	of Patien	ts with S	Selected Stage I	
Starting Dafe: 22 August 1	978 Esti:	naled Con	pletion D	Date: 1983	
Principal Investigator: Rob	ert C. Park	, COL, MC	, USA		
Associate Investigators:	•	Facility:		Reed Army Medica GYN Oncology S	
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA Geoffrey Weisbaum, LTC, MC, USA		Dept/Svc	Departme Service	ent of OB-GYN, G	YN Oncology
Rey Words; Early ovarian	carcinoma,	Melphalan	versus r	no treatment	•
Accumulative MEDCASE Cost: None	1	ulafive Co. None		Accumulat.	
FY-80 MEDCASE Cost:	None			eview Results:ed in by DCI)	مودود ودودودودودودودودودودودودودودودودود
Study Objective: Scatterr chemotherapy. Have report Stage I ovarian carcinoma. numbers, and the unavailab definitive conclusions of present study to determine after surgery in definitive Technical Approach: Stage	ed five-year Unfortunatility of dethese studion the value of	r survival tely, the tailed pares es imposs of chemotion n patients	ls as hig non-rand thologic ible. It nerapeuti s with St	gh as 90% in pat domized nature, information mak t is the purpose ic prophylactic tage IAi and IBi	tients with the small te the of the therapy
hysterectomy and bilateral patients are randomized to	salpingo-o	phorector	ny is per	cformed after wh	
a service of the re-		and the same of th	Arikan, wis	e Demonstration of the second	ಕ
Progress during FY-80: Walter Reed. It is too ea				e been randomize analysis.	d from
Number of subjects to be stu Serious/unexpected side effe none noted.				~ 	
Conclusions: None.	a die aktiviglingdischen unter 2 diese gestallt geb		and age, in a particle department by		

Publications or Abstracts, FY-50. None.

4.,6

Dute: 7 October 1980	Prefere	1/92 4146		
Title of Project: "A Random Versus Radio-Isotopes in t Disease, Having all Stages and IBii Ovarian Cancer." Storting Date: 22 August 19	the Treatmen IC and IT NCL Protoc	t of Patio (A, B and o1 #7602.	nts wit! C), and	of Selected Stages TAii,
Principal Investigator: Rob				
Associate Investigators:	IC A	Facility:		Reed Army Medical Center, 7, GYN Outpatient Clinic
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA Geoffrey Weisbaum, LTC, MC, USA		Dept/Svc	Departm Service	ment of OB-GYN, GYN Uncology
Key Words: Melphalan ver	sus radio-i	sotopes in	sclecto	ed early ovarian cancer.
Accumulative MEDCASE Cost: None	1	alative Con None	tract	Accumulative Supply Cost: None
PY-80 MEDCASE Cost:	None			view Results: d in by DCI)
scopic residual disease, isotope. In the case of i	ral for those patients we recent of the subsequent ass of Melphatable Stage ents who have distincted to 1) Pel A total of the	e treated ith minima he patient radiother alan chemo II and power had stag salpingo on will be sease in Sivic radiotics.	with open of residual	eration alone in Stage II all disease. In some recurrent ovarian care purpose of this study in intra-abdominal radio-acsis Stage I patients, arotomy including total tomy if there is no micro-elphalan or 2) Radio-and IIC lesions, the and Melphalan or 2) Melphala been entered from Walter
Number of scheets to be stu Surjous/unexpected side offe no severe toxic reactions	ets in subjec	ts particip		
Conclusions: None.			British and a separate framework	er en plantate de l'una accusar para l'accion de l'accion de l'accionne de la company de la company de la comp

Publications of Abstracts, TY-89: None.

STEDY OBJECTIVE: and to determine if an addition of palvic radiotherapy to standard surgical and chemotherapoutic treatment of incompletely resected Stage II improves curvival.

Pata: 7 October 1980	Protocol	():o: 4147		Stabast Interio. xx
Tible of Project: "Surgical Squamous Cell Carcinoma of				With
Starting Date: 15 November	1978 Buti:	nated Com	detion D	Date: 1983
Principal Investigator: Rob	ert C. Park	, COL, MC,	USA	
Associate Investigators: Paul B. Heller, LTC, MC, U	ICA	Facility:		Reed Army Medical Center, 7, GYN Outpatient Clinic
Terrel J. Michel, LTC, MC, Geoffrey Weisbaum, LTC, MC,	USA	Dept/Svc	Departi Servic	ment of OB-GYN, GYN Oncology e
Key Words: Surgical path	ologic stud	y, squamou	s cell	carcinoma of vulva
Accumulative MEDCASE Cost: None		ulative Con None	tract	Accumulative Supply Cost: None
FY-SO MEDCASE Cost:	None			eview Results:
logic prognosis factors of of tumor in mm., histologi Stage I-IV carcinoma of th	size of le c rate, sit e vulva. T pment of fu	sion, loca e, and num o rapidly other prot	tion of ber of p accumula	
confirmed invasive squamou to be Stage I-TV, that rad Patients will have radical	s cell carcical vulvec vulvectomy	inoma of tomy suffi plus bilather they	he vulvaces to retail grant teral grant have neg	remove all of the lesion. roin node dissection and gative groin nodes to follow-
Progress during FY-80: T				entered from the entire evaluation from this study.
Number of subjects to be stu Serious/unexpected side offe				
Conclusions: None at this	time.	me e elementente arma apparazione p		
Publications or Abstracts, A	₹¥-80; Non	e.		

Date: 7 October 1980	Protocol	No: 414	8	St.dus: '. Ceria: xx
Title of Project: "A Random Versus Pelvic Node Resecti of the Vulva Having Positi	on For Pati	ents With	Invasivo	
Stortio, Onic: 15 November	1978 Liste	nded Com	defina D	1983
Principal Investigator: Robe	rt C. Park,	COL, MC,	USA	·
Associate Investigatora: William Neglia, MAJ, MC, U	l'acility:		Reed Army Medical Center, Radiation Therapy Dept.	
Terrel J. Michel, LTC, MC,	Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA Geoffrey Weisbaum, LTC, MC, USA		Departme Service	ent of OB-GYN, GYN Oncology
Key Words: Randomized stu	dy, squamou	s cell, v	ulva card	cinoma, positive grown nodes.
Accumulative MEDCASE Cost: None		ılative Cor None		Accumulative Supply Cost: None
TY-so MEDCASE Cost:	None	Pe (t	riodic Re o be fille	view Results:d in by DCI)
Study Objective: To deter radiotherapy to pelvis and radical vulvectomy and bil	groin in p	atients v	ith posit	y of adding adjunctive cive groin nodes at
confirmed invasive squamous vectomy suffices to remove in the groin on one or both	s cell carc all the lo h sides con cal vulvect tive nodes nt is to be uring FY-80	inoma of cal lesio taining m omy plus the pat randomiz , a total	the vulvan and who etastation bilateralient will ed to report of 33 parts.	ose surgery revealed nodes carcinoma. Patients will largery nodes dissection to laken off the study. Simen 1 including pelvicationts have been entered
Number of subjects to be sin Serious/unexpected side offer in six patients. Fistula				
Co; chasions: No definitive				one pattent.

Publications or Abstracts, PY-80: None.

TECHNICAL APPROACH: node dissection or regimen 2 including bilateral groin and polytic node irradiation.

Date: 17 Dec 80	Protocol	No: 4149	Status:	Interim X		
Title of Project: Automate Abnormal		f Fetal Hearl Pat	tern	Pinal		
	•		•	•		
Starting Date: 1979	Estim	ated Completion D	ate: Undetermi	ned .		
Principal Investigator:	HADDOCK, Jame	s				
Associate Investigators: A. PRESBYLICK		Facility: WRAMC				
T. FRANK H. SKIBA-POWELL		Dzak/Svc OB				
Key Words:			•			
Accumulative MEDCASE Cost:	1	lative Contract		lative Supply		
FY-80 MEDCASE Cost:	ر در	Periodic Re (to be fille	view Results: d in by DCI)	magastic is come est con postanogamente per esta con postanogamente per esta con		
Study Objective: To dev		er program to rec edical staff.	ognize fetal	heart rate		
	· •					
Technical Approach:	Same as abovo					
Progress during FY-80: time consultant this yea (2)connection to the res developed these at a sop	r because (I) earch compute histicated Le	other items have r still has not b yel. Modificatio	e been more i een made (3) ns of existin	mportant others have g technology		
Number of subjects to be st Serious/unexpected side eff				ar		
Progress Cont		plication of thes	e techniques	are still		

The technology to read FMR Traces is still in its infancy No program developed to date is at all satisfactory. Any application here would involve further development and modification. I believe this can be done with local personnel.

Date: 17 Dec 80	Protocol No:	4150	Status: Interim X
Title of Project: On-Line In Abnormalit		abor, Curve	Final
	V	1	•
Starting Date: Sep 80	Estimated	Completion 1	Date: Mar 81
Principal Investigator: HAD	DOCK, James		
Associate Investigators: A. PRESBYLICK		ity: WRAM	C .
T. FRANK H. SKIBA-POWELL	Dept/	Svc OB	
Key Words:			•
Accumulative MEDCASE Cost: \$1435	Accumulative Cost:	Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost: \$	1435		eview Results:
Study Objective: To cor and to investigate the ef or abnormal.	relate labor curv fect of therapy w	e abnormali hare uterin	ties with uterine activity activity has been normal
		•	. ·
		•	•
Technical Approach: Uter automatically and by hand to be programmed to perform	on line to the 0	B Research (and therapies are entered Computer. The computer is
Progress during FY-80: The Mr. Presbylick for the part	ne development of st 2 months. Com	the program puter connec	n has been the chief task of ctions will be made shortly.
Number of subjects to be stu Scrious/weexpected side effe tione			The state of the s

Dalo: LL Doc.		Photoco	ol No:		telus; Inte	
Mile of Project Rate Variabi	sk: Early Re Lity by Adap	aliable Data Liv⊹ Digilal	ection of fetal (Filtering	Heart Raic	Fin:	1
Starting Date:	· JAN 80	Esti	mated Completio	n Dale:	UN 82	
Principal Inve	sügator: JAM	ES HADDOOK				
Associate Investigators: T. FRANK		Facility: WRAMC				
A. PRESBYLIC H. SKIBA-POW			Dept/Svc OB			
Key Words:			-A			
Accumulative l Cost: \$870		3	ulative Contract	. 1	ecumulativ	
FY-80 MEDCA	SE Cost:			Review Re illed in by	osulta: DCI)	
Study Objection o maternal al to-beat varia	bdominal wal	l EKG signal	ouler program to . This will the tal condition by	en be used	i to comput	e beat-'
		•		•	•	
Technical App	roach:		•	•		
		As above	•			•
			•			•
				· · · · · ·		-
Progress diag			rable progress h	as been ma	nde in the	develop
					•	•
Number of sub	ects to be st	eroled beibu	completion of sh	udy: See a	ttached	
Scrious/watcos None	ected side off	ects in subje	ets participating	iu project		-
Conclusions:	ramania <u>na any</u> amin'ny fivondronana amin'ny fivondron-desimalana ao ao ao ao ao ao ao ao ao ao ao ao ao			and the second second second second second second second second second second second second second second seco		teriform on anthonormal actions

⁽a) Initially 30 - 50(b) If technically feasible, to be evaluated for broader epplication of testing fetal condition

Date: 7 October 1980	Protogo	1.34 415	2 2	Status	: Interim XX
Title of Project: "A Phase With Advanced Pelvic Malig				tients	Find
Specting Date: 21 November	1978 Esti	nested Cons	olrion D	Date Unknow	n
Principal Investigator: Rob	ert C. Park	, COL, MC,	USA		
Associate Investigatore:		Facility:			dical Center, tient Clinic
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Lept/Svc	Departi Service		YN, GYN Oncology
Key Words: Phase II, Nayt	ansine, pel	a vic malign	ancies		•
Accumulative MEDCASE Cost: None		Mone			wlative Jupply Nonc
TY-80 MEDCASE Cost:	None			view Results ed in by DCI)	
Study Objective: To deter whose advanced malignancie treatment. A rejection ty size of 25 evaluable patie allows replacement of inef	s have been pe of desig nts per dis	resist <mark>e</mark> nt n will be ease site	to high used inv per drug	r priority m volving a fi g studied.	ethods of xed sample The design
Technical Approach: Mayta affecting DNA synthesis in of tubulin prolimerization tumor models. Three sched bolus every three weeks is maligancy was included in which one response was see Progress during FY-89: S from the entire GOC.	arresting Maytansiules have b convenient the 20 pati	cells in me has sho een studice dose for ents. Thi atients.	etaphase wn activ s in Pha patients s was at Other ro	e of mitosis vity against ase I trials s. Only one n ovarian ca esponses wer	by inhibition many animal Single gynecologic reinoma in e confined to
Technical Approach: (contin	med) non-gy	necologi <mark>c</mark> m	nalignanc	ies.	

Number of schieds to be studied before a troletion of similar 25 patients in each categor Scrious/unexpected side effects in subjects participating in project: None. of disease

Conclusions: Maytansine is insignificant against squamous cell carcinoma of the cervix and epithelial tumors of the ovary. Other areas have yet to be evaluated.

Publications or Abstracts, IV So: None.

Datober 1980	Drareco	l No:	4153	Status: informs xx		
"Gile of Projec": "A Phase Patients With Advanced Pel	II Trial of	Baker	's Antifol i	ln lied		
Starting Order 21 November	1978 Esti	materi s	Cornulation D	ate: Unknown		
Principal Investigator: Rob	ert C. Park	, ool,	MC, USA			
Associate lavestigators:		Facility: Walter Reed Army Medical Center, Ward 67, GYN Outpatient Clinic				
Paul B. Heller, LTC, MC, U Terrel J. Michel, LTC, MC,		Dept/	ept/Svc Department of OB-GYN, GYN Oncolog Service			
Rey Words: Phase II, Bak	er's antifo	⊥ 1, adv	anced pelvic	e malignancy .		
Accumulative MEDCASE Cost: None	Accumulative (Cost: None			Accumulative Supply Cost: None		
FY-80 MEDCASE Cost:			1	view Results:d in by DCI)		

Study Objective: To determine the efficacy of Baker's Antifol in patients whose palvanced malignancies have been resistent to high priority methods of treatment. A rejection type of design will be used involving six sample size of 25 cvaluable patients per disease site per drug.

Technical Approach: Baker's autifol, also known as triazinate, is an antagonist of folate metabolism which acts by blocking dihydrofolate reductase. This drug is believed to diffuse passively into the cells by active transport mechanism. The drug is able to penetrate the CNS in quantities reaching CNS levels of 1-5% of blood levels following IV administration. It is excreted mainly by the liver and much lesser extent by the kidney. Toxicities include myocutaneous and gastrointestinal effects. Moderate myelosuppression has been observed. Responses have Progress during FY-80: Sixty-nine patients have been entered into this protocol from the entire COG.

Number of subjects to be studied before completion of study: 25 patients per disease site Serious/unexpected side effects in subjects participating in project: Some Grade 3 mucocytis has been observed in two of the patients.

Conclusions: There is some limited activity noted in the sites studies. This drug is probably not as useful as more conventional drugs.

Publications or Abstracts, FY-89: None.

TECHNICAL APPROACH: been observed in adenocarcinoma in the lung, breast, and sarcomas, and acute myelogenous leukemia. Patients not eligible for higher priority studies who have advanced pelvic malignancies will be entered into this protocol when the drug is suggested by the GOC office. The drug will be given as 500 mg/m² and 500 cc. of D-5 and normal saline as an infussion every 39-60 minutes. This drug will be repeated weekly as toxicity permits. The patient will be followed to progression of disease.

Versus Čis		of Cis-platin	Final		
63. 979 lästi	of Pat	num, t00 mg/ lients Vith A	m ² Versus Cis-platinum, dvanced Carcinoma of the		
	7		and the control of th		
Associate investigators: Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Facility: Walter Reed Army Medical Center, Ward 67, GYN Outpatient Clinic			
		Dept/Sve Department of OB-GYN, GYN Oncolog Service			
advanced	ન carcir	oma of cervi	x, Stage III		
	3		Accumulative Supply Cost: None		
0 MEDCASE Cost: None		Periodic Review Results: (to be firled in by DCI)			
	A USA advanced Accum Cost: None	979 Listimated of the C. Park, COL, A Dept/ advanced carcin Accumulative Cost: No.	Pariodic Rev		

*Study Objective: To confirm the effectiveness of Cis-platinum in advanced and recurrent squamous cell carcinoma of the cervix, no longer responding to radiation therapy or surgery. To compare the frequency and duration of response, and adverse effect of DDP therapy using three different doses and treatment schedules. To evaluate the roles of serial determination of serum carcinoembryonic antigen (CEA) levels and determining extent of disease, response of treatment, and in predicting treatment failure. To access re-treatment with Cis-platinum of patients *Tochnical Approach: Patients who have histologically confirmed local, advanced, recurrent, persistent, or metastatic squamous cell carcinoma of the cervix which is resistent to curative treatment with surgery or radiotherapy are eligible. All patients must have lesions which are measurable or evaluable by a physical exam. For patients who are being re-treated with Cis-platinume, the patient must have a measurable recurrent or progressive disease noted during follow-up after completion of initial therapy. Patients must demonstrate a 50% or greater increase *Progress during FY-50: Two hundred and sixty-one patients were entered to this protocol. One hundred and sixty-two patients were considered evaluable.

Number of subjects to be studied before completion of study: Approximately 135 Serious/unexpected side effects in subjects participating in project: None known.

Conclusions: There are no significant differences in response when three regimens are compared. The study is progressing satisfactorily and it is anticipated that additional patient entries will be acquired to meet the objectives of this study. Abstracts, FY-50: None.

TECHNICAL APPROACH: of the tumor size over the size of completion of initial therapy. Patients must admit all previous Cis-platinum therapy for at least three weeks. These patients will be randomized depending upon treatment status to Regimen 1: 50 mg/m² IV every three weeks X eight courses. Regimen 2: 100 mg/m² IV every three weeks X four course. Regimen 3: 20 mg/m² IV for five days every three weeks X four courses. The patients will be followed up every four weeks after the courses are completed. If progression occurs, the patients will be re-treated until progression after the re-treatment begins.

Dale: 7 October 1980	Protocol	No: 415) 	Status: Interim xx
Title of Project: "Evaluati	on of Adjuv	aat Viner	istine,	Final
Dictinomycia, and Cyclophe Ovary After Resection of a				
Starting Dale: 9 February	1979 Estir	nated Com	pletion D	inter 1982
Principal Investigator: Robe	rt C. Park,	COL, MC,	USA	
Associate Investigators: Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Facility: Walter Reed Army Medical Center, Ward 67, GYN Outpatient Clinic		
		Dept/Svc Department of O3-GYN, GYN Oncology Service		
Key Words: Vincristine, A ovary	ctinomycin-	D, Cyclop	hosphaat	de, germ cell tumors of
Accumulative MEDCASE Cost: None		lative Cor		Accumulative Supply Cost: None
FY-80 MEDCASE Cost:	Noue	Po	riodic Ro o be fille	eview Resulte:
Study Objective: To evalue Dactinomyc in and Cyclophos dermal sinus tumor, embryo choriocarcinoma, and malig I and II after removal of markers, especially alphaf (beta HCG) when these are Technical Approach: Hist the ovary, Stages I or II, excluding patients with pustage III disease will be resection of all tumor, no patients will be placed on by protocol. At the end of Progress during FY-SO: The patients who have had secon whether negative or position.	phamide (VA nal carcino nant mixed all gross tetoprotein present in ologically if previouse dysgermatice dysgermative biop Vincristin f 24 weeks ere have be nd-look ope ve at secondied before of the second tetoprotein teto	c) chemotima, immating and cell umor. To (AFP) and predicting confirmed ally untremona are all grossy of one e, Actino of therapien 27 entrations, id-look large completion	tumors of evaluate human of study are terms of study for study of study for study of	n patients with endo- toma (Grade 2 and 3), of the ovary, Stages e the role of serum horionic gonadotrophin se and relapse. To nt germ cell tumors of completely resected, . Patients with early is resected. After gros gative peritoneal vashin nd Cytoxan as described atient will have a secon this protocol. Of 10 negative. All patients are presently alive:
Serious/unexpected side effe three Grade 3 WBC toxociti neurologic toxicities.	ets in subjects, three G	ts partici) rade 3 Gl	alingin toxicit	project: There have been tes, and nine Grade 3
Conclusions: It is too ear	ly for any	conclusio	ns.	

Publications or Abstracts, FY-80: None.

STUDY OBJECTIVE: determine the role of re-staging laparotomy in determining response, predicting relapse, and planning further therapy.

TECHNICAL APPROACH: Jook Laparotomy performed. If there is no evidence of disease, the patient will have three more cycles of VAC. If no progression, VAC will be stopped. If progression, the patient will be entered in a protocol for recurrent disease. If at re-staging Laparotomy the recurrence is noted, the patient will be entered in a protocol for recurrent disease.

Tibe of Project: "Evaluation of Vinblastiac, Bleodycin, and 1-Cis-platinum in Stage III and IV and Recurrent Malignant Germ Cell Tumors of the Ovary (Phase III)." GOG #45. Starting Date: 29 June 1979 Waterated Complete in Date: July 1982 Principal Investigator: Robert C. Park, COL, MC, USA Associate Lavestigators: Facility: Walter Reed Army Medical Center, Ward 67, GYN Outpatient Clinic Paul B. Heller, LTC, MC, USA Department of OB-GYN, GYN Oncology Terrel J. Michel, LTC, MC, USA Dept/Syc Service Key Words: Advanced germ cell tumors of the overy treated with Vinblastine, Bleomycin, and Cis-platinum Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: None Cost: None Cost: None Periodic Review Results: FY-80 MEDCASE Cost: (to be filled in by DCI)

Study Objective: To evaluate the effect of four cycles of combane? Vinblastine. Electrycia, and Cis-platinum (VBP) chemotherapy in the management of patients with endodermal sinus tumor, embryonal carcinoma, immature teratoma (all grades), choriocarcinoma, and malignant mixed germ cell tumors of the ovary with advanced or recurrent disease, incompletely resected. To evaluate the role of serum markers, especially alphafetoprotein and human chorionic gonadotrophin when these are present in predicting response and relapse. To determine the role Technical Approach: Histologically confirmed malignant germ cell tumors of the ovary with advanced (Stage III or IV) or recurrent disease, incompletely resected, excluding patients with pure dysgerminoma (mature anaplastic) are cligible. Patients with incompletely resected Stage II disease are eligible. Patients previously treated with VAC are eligible. After the surgery, the patients are placed upon four course of Velban, Bleomycin, and Cis-platinum. With progression of the disease, the patients are switched to 12 cycles of Progress during FY-80: There have been 21 patients entered to this protocol from the entire GOC.

Number of subjects to be studied before completion of study: Approximately 15 per year. Serious/unexpected side effects in subjects participating in project: There has been one Grade 4 WBC toxicity, six Grade 3 WBC toxicities, and three Grade 3 GI toxicities.

Conclusions: As expected, toxicities are considered manageable. Early results are encouraging.

Publications or Abstracts, FY-80: None.

STUDY OBJECTIVE: of re-staging laparotomy in patients in clinical remission in assessing completeness of response and then planning further therapy. To evaluate and compare the effect of Vineristine, Dactinomycin, and Cyclophosphamide (VAC) chemotherapy in patients found to have persistent disease at the time of re-staging laparotomy. To determine the need for maintenance Vinblastine therapy in patients found free of disease at re-staging laparotomy.

TECHNICAL APPROACH: Vincristine, Actinomycin-D, and Cytoxan. With complete or partial response, the patient will have a re-staging laparotomy. If there is no evidence of disease, the patient will be placed on Vinblastine for 18 nonths. If there is persistence of the disease, the patient will be placed on Vincristine, Actinomycin-D, and Cytoxan.

Dute: 26 Nov 80	Protocol No: 4157	Status: Interim X		
Title of Project		Final		
	in Abdominal Hystoroctomy			
Prophylactic Antibiotics	In Modulinal hysterectomy			
Starting Date: Apr 79	Estimated Completion	Date: Mar 80		
Principal Investigator: Pa	trick Duff, M.D., LTC, MC			
Associate Investigators:	Facility: WRAM	Facility: WRAMC Dept/Svc OB-GYN		
None	Dept/Svc OB-GY			
Key Words: Antibiotic P				
Accumulative MEDCASE Cost: None	Accumulative Contract Cost: None	Accumulative Supply Cost: None to date		
FY-80 MEDCASE Cost:	the state of the s	Beview Results:		
	(to be fil	led in by DCI)		
	ly is to determine whether post of operative site infection			
	ned in the complete protoco double-blinded.	of on file with GYS.,		
		•		
*Progress during FY-80: 8	35 patients have been carol	led fir the study to date.		
Number of subjects to be stu	died before completion of stu	dy: 100		
Number of subjects to be stu Serious/unexpected side effe	died before completion of stu- ets in subjects participaling i	dy: 100 n project:		
Number of subjects to be stu Serious/unexpected side effe No adverse reactions to a	died before completion of stu	dy: 100 n project:		
Number of subjects to be stu Serious/unexpected side effe	died before completion of stu- ets in subjects participating i idministration of Cefoxitin	dy: 100 n project:		

Date: 26 Nov 80	Protocol No:	4158	Status: Interim
Title of Project:			Final XX
Antibiotic Prophylaxis in	Low Risk Cesare	an Section	
Starting Date: Apr 79	Estimated	Completion Da	te: Jun 80
Principal Investigator: LTC	Patrick Duff, M	C.	
Associate Investigators:	Faci	lity: WRAMC	
CPT Paul N. Smith John Keiser			
Susan Strong	Dept	/Svc ob-gyn	
Key Words: Antibiotic Pr	ophylaxis in Ces	arean Section	
Accumulative MEDCASE	Accumulativ		Accumulative Suppl
Cost: None	Cost: None		Cost: \$450.00
FY-80 MEDCASE Cost: N	lone	}	iew Results:
		(to be filled	in by DCI)
Study Objective:			
Technical Approach:			
		•	
Progress during FY-80:	Investigation Co	mpleted	
Number of subjects to be stu			82
Scrious/unexpected side effe	cts in subjects pa	rticipating in p	roject: NONE
Conclusions:			
Manuscrip has been written			
<u>Unit 40.:</u> 4158			
: btilized, FY-80: \$45	50.00		
no Readingments. FY-6			

Date: 7 October 1980	Profess	: 80: 4159	Status: Interim xx	
Tille of Project: "Treatmen Sarcoma. A Randomized Com Phosphamide (Phase III)."	parison of			
Strating Dide: 6 April 197	9 Esti	nated Completion D	ate: Unknown	
Principal Investigator: Robe	rt C. Park,	COL, MC, USA		
Associate Investigators: Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Facility: Walter Reed Army Medical Center; Ward 67, GYN Outpatient Clinic		
		Dept/Svo Department of OB-GYN, GYN Oncolog Service		
Key Words: Chewotherapy	for recurre	ant or advanced uto	erine sarcoma.	
		ulative Contract None	Accumulative Supply Cost: None	
FY-80 MEDCASE Cost:	llone	Periodic Re (to be fille	view Results: d in by DCI)	

Study Objective: To determine if Adrianycin alone is more effective than Adrianycin and Cyclophosphamide in producing reponses in advanced or recurrent uterine sarcoma. The second objective is to determine if the duration of response for each treatment arm is different.

Technical Approach: Patients with primary Stage III, primary Stage IV, or recurrent uterine sarcoma are eligible. Both patients with non-measurable and measurable disease are eligible but they may be analyzed separately. Patients with all cell types of uterine sarcoma are eligible. Patients previously treated with radiotherapy to the pelvic bed are eligible but they must have completed this radiation more than three months prior to entry on this study. The patients will have an exploratory laparotomy, TAH/BSO, omentectomy if feasible. The patient Progress during FY-SO: A total of 56 patients have been entered into this protocol.

Number of subjects to be studied before completion of study: 75 patients
Serious/unexpected side effects in subjects participating in project: There have been none.

Conclusions: Regimens are well tolerated by patients entered. There is not enough accrual at this point to draw any permanent conclusions. To date there have been no complete responses. There has been one partial response and several progressions. Publications or Abstracts, FY-80: None.

TECHNICAL APPROACH: will then either have radiation or not. After that, they will be stratified by regimen 1 to receive Adrianycin, 60 mg/m^2 IV every three weeks, or regimen 2 to receive Adrianycin, 60 mg/m^2 IV plus Cyclophosphamide, 500 mg/m^2 IV, both every three weeks.

Date: 7 October 1980	Proloce	1 301 4160		Status:	Interim XX
Tiffe of Project: "A Clinic and II Uterine Sarcomas."	al Patholog COC #40.	ic Study o	E Stage	1 1	Final
Sporting Pulch 6 August 197	9 [2.13	mited Comp	1- Gr. <u>0.1</u> 1	late: Unknown	and the second second second second
Principal Investigator: Rob	ert C. Park	, COL, MC,	USA		
Associate lavesligators:	CA	Facility:		Reed Army Med 7, CYN Outpat	dical Center, ient Clinic
Paul B. Heller, LTC, MC, U Terrel J. Michel, LTC, MC,		Dept/Svc	Departi Service		N, GYN Oncology
Key Words: Clinical path	ologic stud	y, Stage I	and II	, uterine sar	coma .
Accumulative MEDCASE Cost: None		Mone		1 .	lative Supply None
FY-80 MEDCASE Cost:	None			view Results:	entre de la composition della
Study Objective: The purp and aortic lymph node meta The relationship of these such as mytotic indexes, t	stasis asso node metast	ciated with asis to oth	n Stage er impo	I and II ute ortant progno	rine sarcomas. stic factors
Technical Approach: All clinical Stage I and II wh adenectomy are eligible fo a simple extrafacial abdom selective pelvic and para-obtained. Omental biopsy logic types of uterine sar Progress during FY-80: to the entire GOG.	o are medic r this stud inal hyster aortic lymp is recommen comas are a	ally suitaly. All part ectomy, bil hadenectomy ded as an occeptable.	ole for tients v tateral v. Peri optional	hysterectomy will undergo, salpingo-ooplitoneal cytole procedure.	and lymph- at a minimum, horectomy, ogy will be
Number of subjects to be stu- Serious/unexpected side effe					e
Conclusions: There are no	conclusion	s at this 1	ime.		

Publications or Abstracts, TY-80: None.

ويوسوهما للمعافي والمرابع مروعه العالما يداري		المائيس عمران الماران	غيد عرسه	First	
Title of Property "Surgical GOG #41.	Staging of	Ovarlan	Carcinoma	16 Value of the state of the st	
Storling Pode: 6 April 1979			171.641	ne Uninova	
Principal Davestigator: Robe	rt C. Park,	COL, MC	USA		
Associate Investigators:	A		Ward, 67	teed Army Medical Center, , GYN Outpatient Clinic	
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Dept/Svo Department of OB-GYN, GYN Oncology Service			
Key Words: Surgical stag	ing, ovaria	an carcin	oma	•	
Accumulative MEDCASE Cost: None	i	nulative Co	entract	Accumulative Supply Cost: None	
FY-SO MEDCASE Cost:	None			view Results:	
structures and retroperito	neal lymph establish a ovarian ca	uodes by a <mark>surgica</mark> ancer tro	direct ex L protocol	ercineme to intraperitoner aumination, cytologic for patients entered into otocols. To determine the	
Technical Approach: All and found to have Stages I All histologic types of over for entry into this protocoreferral institutions are criteria are met. Patient	t, II or II darian care col. Patien eligible for with all	I (optima inoma and nts whose or entry listolog	differen procedur provided ic types	tiation are acceptable es were performed at that the eligibility	

for entry into this protocol. Patients whose procedures were performed at referral institutions are eligible for entry provided that the eligibility criteria are met. Patients with all histologic types of primary ovarian cancer are eligible including epithelial tumors, germ cell tumors, stromal tumors, and Progress during FY-80: Fifty-seven entries have been made from the entire GOG into this protocol. No analysis has been made of this data yet.

Number of subjects to be staded before completion of study: unknown Serious/unexpected side effects in subjects participating in project: None of note.

Conclusions: None.

Publications or Abstracts, FY-80: None.

TECHNICAL APPROACH: all others. Tumors metastatic to the ovary are not eligible for inclusion. A total abdominal hysterectomy, bilateral salpingo-ophorectomy, except in young patients with a unilateral disease, are performed. Selective pelvic and para-aortic lymphadenectomy are performed. Omental biopsy and peritoneal cytology sampling in addition are performed. The diaphragm is examined and a Pap smear and biopsy are performed in this area. The patient then would be entered into an appropriate treatment protecol and followed for five years.

Date: 7 October 1980	Project No.	4162	Steine: Interim XX		
Title of Project: "A Randomize Intraperitoneal Chromic Phosp of Stage IAi, Gl; and IBi, Gl GOG #46.	hate in the trea	stment of V	Women with Stage I (Exclusive -		
Starting Date: 21 August 1979	Estimated Co	mplettin D	December 1983		
Principal Investigator: Robert	C. Park, COL, 1	MC, USA			
Associate Investigators:	Facility	Facility: Walter Reed Army Medical Center Ward 67, GYN Outpatient Clinic			
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, US	A Dept/Sy	o Departi Service	ment of OB-GYN, GYN Oncology e		
Key Words: Melphalan, ICP-3	2, epithelial ca	arcinoma o	f ovary ·		
Accamulative MEDCASE Cost: None	Accumulative (Cost: None	Contract	Acommulative Supply Cost: None		
FY-80 MEDCASE Cost:	None]		eview Results:ed in by DCI)		
Study Objective: The purpose of Melphalan versus peritonea in Stage I, exclusive of IAi, a randomized prospective stud Stage IAi, G2, G3; IAii; IBi, FIGO classification, who have will be total abdominal hyste Technical Approach: Patient IBii or IC epithelial cancer those who have undergone opti	1 radioactive cl Gl and IBi, Gl y. Patients who G2, G3; IBii; undergone option rectomy, bilate s with Stage IA: of the ovary are	epithelia epithelia epithelia ere eligiand IC epithal stagingral salpingral, G2, G3;	l cancers of the ovary in ible are those with surgical thelial cancer of the ovary, g. The surgery performed go-oophorectomy, partial IAii; IBi, G2, G3; or		
Progress during FY-50: Six is too early to analyze this	patients have be	een entered	d into this protocol. It		
Number of subjects to be studied Serious/unexpected side offsets			to the trade of the state of the		
Conclusions: It is too early	to form any co	nclusions.			

STHOT OBJECTIVE: omentectomy, and staging examination. These patients will then be randomized to either Regimen 1: Melphalan, 7 mg/m²/day X five days every four weeks for 10 course or 18 months. Or Regimen 2: chromic phosphate 15 millicurries intraporitoneally as a single dose.

Publications or Abstracts, FY-80: None.

Date: 7 October 1980	Projece	UNO: 4163	Section Unterior XX		
Title of Project: "A Phase Treatment of Advanced Gyne					
Starting lade: 6 April 19	79 Weti	mated Completion I	Date: Unknown		
Principal Investigator: Rol	pert C. Park	, COL, MC, USA			
Associate Investigators: Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Facility: WalterRoad Army Medical Center, Ward 67, GYN Outpatient Clinic			
		Dept/Sve Department of OB-GYN, CYN Oncolo Service			
Key Words: Phase II, Cie	s-platinum,	advanced gynecolo	gic malignancy -		
Accumulative MEDCASE Cost: None		ulative Contract None	Accumulative Supply Cost: None		
FY-80 MEDCASE Cost:	None		eview Itesults:		

Study Objective: To determine the efficacy of Cis-platinum in the treatment of advanced or recurrent gynecologic sancers. A rejection type design will be used involving a fixed sample size of 25 evaluable patients per disease site per drug or a combination of drugs studies. The design allows replacement of ineffective regimens by never agents or combinations.

Technical Approach: Cis-platinum appears to exert its cytotoxic action by cross linking DNA and thus acting in a manner similar to the bifunctional alkylating agents. Cis-platinum has demonstrated activity in animals studies against transitional cell carcinoma in mice. Toxicity tricls in animals reveals myelosuppression, lymphoid atrophy, hemorrhagic introcolitis, renal tubular necrosis, and cocclear damage, as well as some degree of immunosuppression. Reports have been made on Phase I and broad Phase II studies with this agent. Responses have Progress during FY-80: Two hundred and one patients have been accessed to this protocol. Combinations of Cis-platinum and other regimens will be tested in future trials. Tumor categories, except epithelial ovarian carcinoma and squamous cell carcinoma of the cervix continue to accrue cases for consideration.

Number of subjects to be studied before completion of study: 25 cases per disease site. Serious/thexpected side effects in subjects participating in project: There have been some Grade 3 CI toxicity and some Grade 3 hypokalemia noted.

Conclusions: Cis-platinum has marked activity as a first-line chemotherapeutic in squamous cell carcinoma of the cervix and is active as a second-line therapy for advanced adenocarcinoma of the ovary. The drug appears to be active against endometrial carcinoma but may have limited activity in therapy of sarcomas and Phonocarcinoma or Abstracts, 11-80:

cervical adenocarcinoma.

TECHNICAL APPROACH: been noted in testicular tumors including germ cell tumors. Ovarian carcinoma, bladder carcinoma, squamous cell carcinoma of the head and neck, and squamous cell carcinoma of the cervix. Patients with histologically confirmed gyaccologic cancer, either recurrent or advanced, on initial presentation are eligible. Cis-platinum will be given as 50 mg/m² IV every three weeks. Hydration will be given at each course. Once enough patients in any disease category have been treated with Cis-platinum, the entire group will nove on to the next drug recommended in this GOG protocol.

D.to: 7 October 1980	The oracles	1 1,000	1165	Model Litter n. XX	
Till: of Phojeotr "A Phase Advanced Pelvic Malignanci	Tl Trial of	: AMS.A :	n Patients	With Fire	
Spring Die: 21 August 1	979 (33)		gr piction ()	e e. Unknown	
Principal overligator: Rob	ert C. Park	COL,	MC, USA		
Associate investigators:		Facili	-	Reed Army Medical Center, 7, GYN Outpatient Clinic	
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Dupt/Svc Department of OB-GYN, GYN Onco Service			
Key Words: Phase II, AMS	A, advanced	 l pelvi	e malignanci	ies	
Accumulative MEDCASE Cost: None				Accumulative Supply Cost: None	
IY-80 MEDCASE Cost:			Pariodic No Go be fille	ed in by DCI)	
Study Objective: To deter malignancies have been res rejection type design will patients per disease site	istent to l be used ir	iigh pr	iority metho	ods of treatment. A	
It has particular affinity	e drug inhinds the DN/ for adenired a case of tive because	lbits D A throu ne-thya E lymph se its	NA synthesis The intercal and incertain pairs. The inglosar comments is activity is	s but has little effect ation and external binding. In a Phase I trial a and in a case of ovarian about the same as Adria-	

Number of subjects to be studied before completion of study: 25 patients per disease Serious/wavpected side offects in subjects participating in project: Essentially none.

Progress during FY-80: There have been a total of 11 entries to this protocol.

Conclusions: It is too early for any definitive conclusions.

Publications or Abstracts, FY-50: None.

TECHNICAL APPROACH: as a dose of 120 mg/m 2 intravenously, repeated every four weeks as toxicity permits. Patients who have received pelvic and/or abdominal radiation previously will get 90 mg/m 2 at the same interval.

Inte: 7 October 1980	Profoco	io: 4	1.66	Status:	Interin	XX
With Advanced Felvic Mali	El Trial of gnancies."	Yoshi-8 GOC # 2	64 in Pati 6-J.	i e	Final	
Starling Dale: 21 August 1	979 Estir	nated Co	appletion I.	late: Unknown		
Principal Investigator: Rob	ert C. Park	COL, N	C, USA	·		
Associate Investigators:		Facility		Reed Army Ye 7, GYN Outpat		
Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Dept/Svc Department of OB-GYN, GYN Oncolog Service				
Key Words: Phase II, Yos	hi-864, adv	anced pe	lvic malig	gnancy		•
Accumulative MEDCASE Cost: None	Accum Cost:	ulative Contract None		Accumi Cost:	ulative Sup None	ply
FY-80 MEDGASE Cost:	Mone]	Periodic Re (to be fille	eview Results: ed in by DCI)		
Study Objective: To determalignancies have been restype design will be used in per disease site per drug.	istent to h	igh prio	rity metho	ods of treatm	ent. Ar	ejectio
Technical Approach: Yosh by EL-merzabinisakurai as a resistent to nitrogen must but it is active against the Exact mechanism of action the drug shows no cross reanimal tumbes. First of Progress during FY-80: The state of the s	an alkylationed derivitioned L1210 symbols bet been sistance to injury stud	ng agentives. Some in a clucid natural testings.	active as tructurall mice where ated. It -occurring -Yoshi-86	gainst experi ly it is simi c busulfan is may have alk g alkylating h were cooluc	mental tu lar to bu not acti ylating a agent-res ted in Ja	mors sulfan ve. ctivity istent

Number of subjects to be studied before completion of study: 25 per disease site. Serious/unexpected side effects in subjects participating in project: None.

Conclusions: It is too early to draw any conclusions.

Publications or Abstracts, FY-80: None.

at doses of 5-100 mg, per day. In a COO study, there have been six partial responses reported in 16 patients with ovarian cancer. Patients who have hardlogically confirmed advanced recurrent resistent metastatic or local synecologic cancer with documented disease progression are eligible for this study. Yoshi-864 will be administered at 2.0 mg/kg/day for 5 days impravenously and repeated every six weeks as forficity peculis.

Date: 7 October 1980	Profess	l Ro: 4167	in the second se	Status: Interim XX	
Title of Project: "A Phase Plus Cyclophosphamide Vers in Patients with Advanced and Recurrent." COC #47. Procless Onle: 21 August 1:	us Adriamyc Ovarian Ade	in Plus Cy nocarcino:	clopi ospia: a, Supoptii	aide Plus Cis-platinum aal Stage 147, Stage 1V,	
Principal Investigator: Robe	ert C. Park	, COL, MC,	USA		
Associate Investigators: Paul B. Heller, LTC, MC, USA Terrel J. Michel, LTC, MC, USA		Facility:	ty: Walter Rood Army Medical Center, Ward 67, GYN Outpatient Clinic		
		Dept/Svc	Department of OB-GYN, GYN Oncology Service		
Key Words: Adriamycin, Conf the ovary.	ytoxan, Cis	-platinum	treatment i	in advanced adenocarcinc…a	
Accumulative MEDCASE Cost: None		ulative Con None	Accumulative Supply Cost: None		
FY-80 MEDCASE Cost:	N	Per (to	iod a Ravie o be filled in	w Results:	
Study Objective: To determ plus Cyclophosphamide impre in Stage IV, suboptimal Sta	oves remiss age III, an	ion rate, d recur <mark>re</mark> n	remission d t ovarian a	ndenocarcinoma. To	

in Stage IV, suboptimal Stage III, and recurrent ovarian adenocarcinoma. To determine the frequency and duration of true complete remission using these regimens as judged at a second-look laparotomy.

Technical Approach: Patients who have been diagnosed as Stage IV and suboptimal

Stage III primary cases or recurrent cases are eligible. Suboptimal Stage III

is defined as those Stage III patients with at least one residual lesion at the time of surgery equal to or greater than 3 cm. in the largest diameter in the abdomen or pelvis. Histologic types cligible are serous adenocarcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma, endometroid adenocarcinoma, undifferentiated carcinoma, or mixed epithelial carcinoma. Patients with measurable Progress during FX-80: Two hundred and eight patients have been entered into

Progress during FX-80: Two hundred and eight patients have been entered into this study.

Number of subjects to be studied before completion of study: 400

Serious/unexpected side effects in subjects participating in project: Renal toxicity was was observed in 42.6 patients in cases who received Cis-platinum; all were mild toxicities except for one case. Fourteen who and 3 platelet toxicities of severe grade Conclusions: None.

Publications or Abstracts, FY-80: None.

PROTOGOL NO. 4467 CONTINUED

TECHNICAL APPROACH: disease and patients without measurable disease is a separate category and will be evaluated. The patients will be stratified by performance and measurable versus non-measurable disease entered into the protocol and then randomized to Regimen 1: including Adriamycin, 50 mg/m² IV, Cyclophosphamide, 500 mg/m² IV every two weeks for eight courses versus Regimen 2: Adriamycin, 50 mg/m², Cyclophosphamide, 500 mg/m², and Cisplatinum, 50 mg/m², all given IV every three weeks for eight courses. After these course, a second-look laparotomy will be performed. Patients with complete response will be maintained on Cyclophosphamide, 500 mg/m² every three weeks for an addition of 12 months. Patients with partial response or stable disease will be taken off the study.

Date: 26 Nov 80	Protocol	No: 4168	Status: Interim X
Title of Project: Comparison of Two Anti Soft Tissue Pelvic Inf	blotic Reginections	mens for the Treat	Final Final of
Starting Date: Apr 79	Estin	nated Completion D	ate: Apr 80
Principal Investigator: Patr	ick Duff, M	.D., LTC, MC	
Associate Investigators: No	one	Facility: WRAMC	
		Dept/Svc 0B-GYV	
Key Words: Antibiotic Tre	eatment of P	l elvic Infections	
Accumulative MEDCASC Cost: None	Accumu Cost:	dative Contract None	Accommutative Supply Cost: None to Date
FY-80 MEDCASE Cost: N	lone		eview Results:ed in by DCI)
The purpose of the study combination of Penicillin infections. Technical Approach: The entire treatment prot	and Gentam	icin for treating	
Progress during FY-80:	75 patient	s have been enrol	led in the study to date.
Number of subjects to be stu- Serious/unexpected side effe			
Conclusions: At the pres difference between the tw		here is no statis	tically significant
Publications or Abstracts,	FY-80: None	to date	

work bult no.: 4168

runds Utilized, Fi-60: None

Funding Requirements, FY-61:

Personnel: (name and grade)

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase)

Travel: (mission oriented, training and presentation) \$500

Other: (equipment rentals, contracts for service, animal care and reprints)

Dute: 17 October 1080	Protoco	ol No: 4	169	Status: Intering	
Title of Project:				Final	
Effectiveness of Heat Lamp of Median Episiotomies.	s and Surg	igators	in Promo	ting Comfort and Healing	
Starting Date: Oct 1979	Esti	mated (Completion	Date: Dec 1980	
Principal Investigator: MAJ	Clifford Si	mons, A	NC		
Associate Investigators:		Facili	ty: WRA	MC, Units 43,44	
LTC Reuben B. Bowie, ANC CPT Marcia Kossman, ANC		Dept/Svc Nursing Research Service			
Key Words: Median Episiotomies, Heali	.ng				
Accumulative MEDCASE			Contract	Accumulative Supply	
Cost: 0	Cost:_	0		Cost: 0	
FY-80 MEDCASE Cost:	0			Review Results: led in by DCI)	
Study Objective: To determine whether there the patient's expression or regime used.					
				•	
Technical Approach:					
No change from protocol su	bmitted.		· .		
			e ja vede ta	Salanderi (1 a.a. 1757) a seculado Caractería	
Progress during FY-80:					
88 subjects accured.					
Number of subjects to be stu Scrious/unexpected side effe					
None Conclusions: None at this time. Data a	malysis is	being	conducted		

disposition form

For use of this form, see AR 340-15; the proponent agency is The Adjutant General's Office.

HILFERENCE OR OFFICE SYMBOL

C, Dept Clin Invest

SUBJECT

Response to reviewer comments on FY 80 APR

HSNP-NR

10

for worl: Unit # 4169

FROM

C, Nsg Rsh Svc

DATE

CMT 1

8 Dec 1980 MAJ Southby/ab/2026

- It is understood that no money was spent on this work unit in FY80.
- The original budget request of \$800 (\$300 for data analysis and \$500 for presentation and reprints) was insufficient considering current costs.
- The funding request for FY81 added the following to the original budget request:
 - \$100 for consumable supplies
 - \$150 for reprints (Reprints may be a separate charge for example \$200 for Milt Med).
 - \$500 for travel for an additional investigator (3 people are conducting the study).
- This request is \$750 above the orginal amount requested.

MAJ(P), ANC

C, Nursing Research Service

WRAMC

	CILNICAL INVESTIGATION PROGRAM						
ONE UNIT NO.: 4169	HTTLE: Effectiveness of Heat Lamps and Surgigators in Promo-						
*	ting Comfort and Helling of Medien Emisictomies.						
	PRINCIPALINVESTIGATOR: MAJ Clifford M.B. Simons						
•	Co-investigators: MAJ Bowie, CPT Kossman .						
MENT .							

		Co-i	investigators: MAJ Bowie, CPT Kossman .				
MENT H INSE			FY 81 -	FY 82	REMARKS		
- 1200	Personnel:		•				
.00	Travel:						
	Mission						
	Conference		1000.00		2 persons		
	Patient						
119	Rental Equip:	and the second of	•				
700 -	Printing and		150.00				
	Reproduction:						
72	Contractual Svc						
•	Lab Contracts:						
99	Consumable Suppleand Experimental Animals		100.00				
11 Service	Data Analysis		² 300.09				
idel:			1550.00				
•			3.				
leguirement Ranks		No,	No	WORK UNITS:			

Date: 7 October 1980	Protoco	No:	4170		Status:	Interim	хх
Title of Project: "A Phase Patients with Advanced Pelv				•		Final	
Starting Dale:	Dstir	nated	Completion D	0.00:	Unknown		
Principal Investigator: Rot	ert C. Park	, COL	, MC, USA				
Associate Investigators:		Facil	ity: Walter 1 Ward 67			ical Cen ent Clin	
Paul B. Heller, LTC, MC, I Terrel J. Michel, LTC, MC,		Dept/	Svc Department Service	ent o	E OB-GYN	, GYN On	colo
Key Words: Phase II Chlor	ozotocin, a	dvanc	ed pelvic ma	lignar	ncies.		
Accumulative MEDCASE Cost: None	Accum Cost:_		Contract		Accumu Cost:	lative Sur None	ply
FY-80 MEDCASE Cost:	None		Periodic Re (to be fille				·
Study Objective:							
Technical Approach:							
Progress during FY-50: from the entire GOG.	To date, no	patie	ents have bee	en pla	aced in	this prot	coco:
Number of subjects to be sto Serious/unexpected side off					:t:		
Conclusions:	* # * * * * * * * * * * * * * * * * * *		· · · · · · · · · · · · · · · · · · ·				

Publications or Abstracts, FY-80:

493

Ditte. 7 occoner 1700	1210000	(130). 417.	<u></u>	(1):11.43.	31/20 23111 XX	
Title of Project: "A study Comparison of Adriamycin V Advanced Endometrial Carci	ersus Ädria	mycin Plu	s Cyclop:	osphamide in	First Facients with	
Starting Date: 10 July 193	o Zati	unted Com	olstion D	ute: 1983		
Principal Investigator: Ro	bert C. Par	k, COL, M	C, USA			
Associate Investigators:		Facility: Walter Reed Army Medical Center, Ward 67, CYN Outpatient Clinic				
Paul B. Heller, LTC, MC, U Terrel J. Michel, LTC, MC,		Dept/Svc Department of OB-GYN, GYN Oncolog Service			, GYN Oncology	
Rey Words: Advanced endom	etrial carc	inoma, hor	cmonal fa	ilure, Adrian	nycin, Cytoxan	
Accumulative MEDCASE Cost: None	Accum: Cost:	ulative Cor None	tract	Accurau Cost:	lative Supply None	
FY-S0 MEDCASE Cost:	None			view Results: d in by DCI)		
carcinoma to oral progesticherapy. To compare a compare a compare as therapy which no longer responds to who have received no prior response rate of advanced Technical Approach: Patie Stage IV recurrent or residence quamous carcinoma. Suppread are eligible as non-hormonal therapy will be ortherapy will be of therapy will be of therapy of Progress during FY-80: The Number of subjects to be studyed. Number of subjects to be studyed. Serious/unexpected side offer. Conclusions: It is too ear	bination of y for advan- o or has fare cytotoxic or recurrents must had all endome Those patientered directly, 50 mg to three we have better the control of	Adriamyciced or reciled to reddrugs. Control adernation with particle and the control and the	in, and (current easpond to onfirmaticial card print occurrent eases. To see patient the current to of shuly of shuly	endometrial control progestins in progestins in the reprince of the reprince of the reprince of the reprince of the reprince of the reprince of the reprince of the reprince of this protocol of the reprince of this protocol of the reprince	ide or arcinoma in patients port at 37% iamycin. I, primary athoma, or evidence of swith prior crior hormonal ease. Patient ized to	

Publications or Abstracts, FY-30: None.

STUDY OBJECTIVE: Confirmation of survival benefits responders to cytotoxic drugs.

TECHNICAL APPROACH: Regimen 1: Adriamycin, 60 mg/m² IV every three weeks for eight courses or Pogimen 2: Adriamycin, 60 mg/m² IV every three weeks for eight courses plus Cyclophoophamide, 500 mg/m² IV every three weeks for eight courses. Responders will be followed up at the completion of therapy. Patients with progression will be placed on another prototol.

Date: 18 SEPT 80 Protocol No: 4514 Status: Interim x Final Title of Project: Clinical Evaluation of Indium 111 DTPA 25 JUN 74 Estimated Completion Date: Indeterminate Starting Date: Principal Investigator: DOUGLAS VAN NOSTRAND, M.D., MAJ, MC Associate Investigators: Facility: Walter Reed Army Medical Center Asaf Durakovic, M.D., MAJ, MC Dept/Svc Nuclear Medicine Service James Corley, MAJ, MSC Richard Stotler, MAJ, MSC Key Words: Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: NONE Cost: NONE Cost: NONE FY-80 MEDCASE Cost: Periodic Review Results: NONE (to be filled in by DCI) Study Objective: The purpose of this study is to evaluate the efficacy and safety of the radiopharmaceutical Indium 111 DTPA in the evaluation of cerebral spinal fluid flow. Technical Approach: No modifications have been made to the original protocol. Progress during FY-80: During the period of 1 October 1979 through 18 September 1930, a total of 14 patients were studied. Number of subjects to be studied before completion of study: 40 Serious/unexpected side effects in subjects participating in project: (See attached shegt) Conclusions: (See attached sheet.)

435

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE STHEOL

HSWP-XN

Annual Progress Report - Work Unit #4514

TO Clinical Investigation

FROM C, Nuclear Medicine Svc. DATE 5 DEC 80

CHT 1

WRAMC

WRAMC

MAJ Van Nostrand/msm/61186

1. No other conclusions can be obtained from the 14 patients who have been studied to date.

2. It is important to emphasize that the purpose of this protocol is two fold. (a) A protocol must be in effect in order for Walter Reed Army Medical Center to obtain FDA Phase III IND radiopharmaceuticals. (b) The objective of the Phase III study is for evaluation of the safety of the radiopharmaceutical Indium 111 DTPA as noted in the Annual Progress Report.

DOUGLAS VAN NOSTRAND, M.D.

MAJ, MC

C, NUCLEAR MEDICINE SERVICE

disposition form

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

HSWP-XN

REQUEST FOR EXTENSION OF PROTOCOL #4514

TO CLINICAL INVESTIGATION COMM. FROM C, NUCLEAR MEDICINE SVC. DATE 18 SEPT 80 WRAMC WRAMC msm/61186

CMT 1

- 1. TITLE OF PROJECT: Clinical Evaluation of Indium 111 DTPA.
- 2. INVESTIGATORS: Douglas Van Nostrand, M.D., MAJ, MC
- 3. STATUS: The present protocol is subject to termination on 30 September 1980 since it has been in effect for three years. This request is to continue this protocol for an additional extension of 3 years. Indium 111 DTPA is still under Phase III investigation with the Food and Drug Administration. Presently, it is still considered the radiopharmaceutical of choice for studying the physiology of cerebrospinal fluid flow. The progress report to date is as noted on appendix C. Only one adverse reaction has been noted in the last year. As noted, the conclusion was the reaction was not due to the product.
- 4. IMPACT: As previously, there is no impact on any other service or department.
- 5. FUNDING: There is no requirement for funding. The radiopharmaceutical is purchased from the Nuclear Medicine supply funds.

DOUGLAS JAN NOSTRAND, M.D.

MAJ, MC

C, NUCLEAR MEDICINE SERVICE

DA 161, 2496

RUPLACES DO FORM DA, MMICH IS CHEOLETE.

RIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECT PARTICIPATING IN PROJECT:

adverse reaction was reported. A meningitis type reaction 14 hours postjection in a 5 year old female patient was noted by the attending physician.
Injection was difficult with several attempts made to place the spinal
addle intrathecally. Subsequent evaluation revealed negative cultures of the
rebrospinal fluid. The pyrogen test (limulus lysate 0.125 ng/ml level) of
the product was negative. Blood agar plates of the product were negative.
The reaction was felt not to be due to the product, however, the specific
tology was undetermined. Another patient received a dose from the same lot
cawn at the same time and injected within 30 minutes of this patient. This
atter patient experienced no adverse reactions.

ne results of the 14 patients studied over the above interim are described a follows:

- a. 8 normal studies.
- b. 1 suboptimal.

,:

- c. 1 normal pressure hydrocephalus.
- d. 3 abnormal tracer distribution with blockage of CSF flow.
- e. 1 communicating hydrocephalus.

INVESTIGATIONAL PROGRESS REPORT/RCS MED-254

- 1. The following is an interim progress report for investigational drugs according to Paragraph 1, AR 40-7.
- 2. IDENTIFICATION OF STUDY: Glinical Evaluation of Indium 111 DTPA.
- 3. INVESTIGATOR: Douglas Van Nostrand, M.D., MAJ, MC
- 4. LOCATION OF STUDY: Walter Reed Army Medical Center, Nuclear Medicine Service.
- 5. NUMBER OF SUBJECTS INVOLVED: 14
- 6. NARRATIVE OF PROCRESS: The results of the 14 partents studied over the above interim are described as follows:
 - a. 8 normal studies.
 - b. 1 suboptimal.
 - c. I normal pressure hydrocephatus.
 - d. 3 abnormal tracer distribution with blockage of CSF flow.
 - e. 1 communicating hydrocephalus.
- 7. ADVERSE REACTIONS: One adverse reaction was reported. A meningitis type reaction 24 hours post-injection in a 5 year old female patient was noted by the attending physician. The injection was difficult with several attempts made to place the spinal needle intrathecally. Subsequent evaluation revealed negative cultures of the cerebrospinal fluid. The pyrogen test (limulus lysate 0.125 ng/ml level) of the product was negative. Blood agar plates of the product were negative. The reaction was felt not to be due to the product, however, the specific etiology was undetermined. Another patient received a dose from the same lot drawn at the same time and injected within 30 minutes of this patient. This latter patient experienced no adverse reactions.
- 8. DISPOSITION OF UNUSED SUPPLIES: No supplies were unused.

Date: 14 889 80	Protoco	l No: 4521	Status:	Interim x
		loxylideneglutamat nosis of Hepatobil		Final .
Starting Date: 7 NOV 78	Esti	nated Completion I	Date: NOV 81	
Principal Investigator:	UGLAS VAN NO	OSTRAND, MAJ, USA,	МС	
Associate Investigators: Asaf Durakovic, MAJ, USA	, MC	Facility: Walter	Reed Army Hed	ical Center
	· :	Dept/Svc Nuclear	Medicine Ser	vice
Key Words:	erredikan keringan di rengan seperaturah keringkan dan pertembanan dan pertembanan dan pertembanan dan pertemb	3	• ,	•
Accumulative MEDCASE Cost: MONT)	ulative Contract	i .	ative Supply
FY-80 MEDCASE Cost: NO.	VE	Periodic Refice to be filled	eview Results: ed in by DCI)	
Study Objective: The purpo of To 99m PG as a diagnos				cal efficacy
Technical Approach: No min regard to technical app	roach.			al protocol
	Burn de Traggio de April de La Carlo de		egan, germen er men ger er er er flattat. Men germen er	en y y maam en de se en een een een een een een een een
Progress during FY-80: Du total of 28 Tc PG studies			through 14 Sep	о 80, а
Number of subjects to be stu	died before	completion of study	7: 25	
Serious/unexpected side efferenctions have been noted Conclusions: (See attached	in any of t			adverse

CONCLUSIONS: A total of $28\ \text{Tc}\ PG$ studies were performed. The distribution of studies were as follows:

(1) 16 Normal studies, (2) 3 studies with decreased liver function and dilated ducts, (3) 1 study with non-visualization of the gallbladder with prominent ducts [pancreatic carcinoma], (4) 7 studies with non-visualization of the gallbladder with acute cholecystitis, (5) 1 study with decreased liver function and normal ducts.

DOGGLAS ... NOSTRAND, M.D.

HAJ, MC

CHIEF, NUCLEAR MEDICINE SERVICE

ASSUAL PROGRESS REPORT IN CONCORDANCE WITH PARAGRAPH 7 AR 40-7.

- 1. <u>Study Title</u>: Technetium 99m Pyridoxylideneglutamate (Tc99m PG) for Diagnosis of Hepatobiliary Disease.
- 2. Location of Study: Walter Reed Army Medical Center
- 3. Number of Subjects Studied: 28
- 4. Progress Report: A total of 28 patients have been studied with TCPG. No adverse reactions have been noted in any of the studies. The distribution of studies were as follows:
 (1) 16 normal studies, (2) 3 studies with decreased liber function and dilated ducts, (3) 1 study with non-visualization of the gall-bladder with prominent ducts [pancreatic carcinoma], (4) 7 studies with non-visualization of the gallbladder with acute cholecystitis, (5) 1 study with decreased liver function and normal ducts. This information was reported to the IND holder who is Dr. Robert Lull at Letterman Army Medical Center.
- 5. Project Future: It is anticipated an additional Sepatianas will be studied before the protocol is completed.

6. No unused supplies of investigational drug require disposition.

DOUGLAS VIN MOSTRAND, M.D.

HAJ, MC

C, NUCLEAR MEDICINE SERVICE

Date: 13 Oct 1980	Protocol No:	4522	Status: Interim X		
Title of Project: Determina Half-Life of Botulism Immu Administered Intravenously	ne Plasma (Human)		ve Final		
Starting Date: Nov 1979	Estimated (Completion Da	uta: Nov 1981		
Principal Investigator: MA	J James H. Anders	on, USAMRIID	, Ft Detrick		
Associate Investigators: MAJ George E. Lewis COL Joseph F. Metzger		Facility: USAMRIID, Ft Detrick			
LTC Clarence J. Peters Peter B. Jahrling LTC Robert J. Kaminski WRAMC	Dept/	Sve			
Key Words: Botulism, Immune Plasma	, Antitoxin, BW				
Accumulative MEDCASE Cost: None	Accumulative Cost: No		Accumulative Supply Cost: \$500		
FY-80 MEDCASE Cost: N	one	i	riew Results: l in by DCI)		
a therapeutic and a proph Technical Approach: Admin Intravenously. Routine b technique, assay of seque bodies to botulinal toxin	istration of 3 lood volume deter ntial blood sampl	00 ml of Bot mination usi	ulism Immune Plasma (Human) ng standard radioisotopic		
	predicted recipie	nt titer and	antity and titer of immune the passively aquired titers		
Number of subjects to be stu-	died before comple	tion of study:	ien		
Serious/unexpected side effe	cts in subjects part	icipating in p	roject: None		
Conclusions: Half-life val averaged 21-27 days. In 4 equaled or exceeded the pr feasibility of making such Publications or Abstracts, 1	of 5 volunteers, edicted period of	the actual	period of "protection"		

nork Unit no.: 4522

runds Utilized, FY-80: None

Funding Requirements, FY-61: Yes

Personnel: (name and grade) None

Equipment: (describe in detail including cost) None

Supplies: (consumable, animal purchase) Supplies for 5 blood volume determinations

Travel: (mission oriented, training and presentation) None

<u>Other:</u> (equipment rentals, contracts for service, animal care and reprints) None

Date:	Protoco	l No: 4523	Status: Interim XX
	tion of Glome otracer Tech	rular Filtration Ra	te .
Starting Date: Indefinite	Estic	nated Completion I	Date:
Principal Investigator:			
Associate Investigators:		Facility: WRAMO	
MAJ D. Van Nostrand, M COL J. Light, MC	vIC ·	Dept/Svc Nuclear	Medicine Service
Key Words:			
Accumulative MEDCASE Cost: 0	Accumi	ulative Contract	Accumulative Supply Cost: 0
FY-80 MEDCASE Cost:	0		eview Results:ed in by DCI)
Study Objective:			
	•		
Technical Approach:			
• •	·		
Progress during FY-80: protocol. Funds to purch pected to be activated upo	nase this equi	pment are being so	quipment as described in the bught, and the project is ex-
Number of subjects to be stu Serious/unexpected side effe			miniant.
Conclusions:			project: None

Publications or Abstracts, FY-80:

Work Unit No. :4601

Title of Project: Participation in the National Cooperative Study of Early Hodgkin's Disease.

Investigators :

Principal Investigator: George B. Hutchison, M. D. Project coordinator at Harvard School of Public Health.

Associate Investigator: Jeffrey Berenberg, M. D. and William Neglia, M. D. at Walter Reed Army Medical Center.
29 associate investigators at other collaborating centers.

Objectives: To determine the effects on survival, disease expension, and complications of therapy of differing irradiation volumes in treatment of early staged Hodgkin's disease.

Technical Approach: This clinical trial study was randomized and prospective, comparing localized irradiation to clinically involved region with extended field irradiation to clinically involved region plus regions suspected of being sites of sub-clinical disease.

Progress and Results: An interim report was distributed August, 1970. Localized recurrences have appeared in significantly greater frequency in patients receiving localized treatment than in those given extended field therapy. Extensions to extra-nodal sites on the same side of the diaphragm as the initial disease are also more frequent with localized treatment, but the excess is smaller, and transdiaphragmatic extensions are only slightly reduced by extended field therapy. There is no significant survival difference between the two therapy groups for the total collaboration, and for the Walter Reed series there is a non-significant reduction in mortality in the group given localized therapy.

Entry of patients into this study was terminated in 1971 at Walter Reed and in 1973 for the entire collaboration. At a meeting of all participating institutions held in Chicago, July, 1976, it was decided that follow-up of 10 years or more might be needed to conclude the study. The survival of both groups is substantially better than projected in 1967, at the outset of the study and based on reports available at that time.

Conclusions: To date, comparison of localized fields with extended fields of therapy of early Hodgkin's disease has not shown a clear superiority of either technique within 11 years of follow-up. The study suggests that extensions following extended field therapy may routinely carry a poor prognosis but that local extensions following local field therapy may be followed by cure in a substantial proportion of cases.

Publications:

- 1. Hutchison, G. B. Progress report. Hodgkin's Clinical Trial, 1972. National Cancer Institute Monograph No. 36:387-393. 1975.
- 2. Nickson, J. J. and Hutchison, G. B. Hodgkin's disease clinical trial. Sixth National Cancer Conf. Proc. 1968. Pages 77-81. Lippincott Philadelphia. 1970.
- 3. Nickson, J. J. and Hutchison, G. B. Extension of disease, complications of therapy, and deaths in localized Hodgkin's disease; preliminary report of a clinical trial. Am. J. Roentg., Rad. Th., Nuc. Med. 114:564-573. 1972.
- 4. A collaborative study. Report prepared by Hutchison, G. B. on behalf of Steering Committee. Survival and complications of radiotherapy following involved and extended field therapy of Hodgkin's disease, stages 1 and 2. Cancer 38: 288-305. 1976.

Funding requirements:

Estimated January to December, 1980

T-ravel: \$1,200

Date: 27 Oct 80	Protoco	1 No: 4700	Status: Interior X	
Title of Project: Eye T	racking in Rac	liologists	Final	
	,	*		
Starting Date: Estimated Completion Da			ito:	
Principal Investigator: SI	nerry L. Brahm	nan, MD, LTC, MC		
Associate Investigators:		Facility: Walter Reed General Hospital		
		Dept/Svc Radiolo	gy/Diagnosis	
Key Words:				
Accumulative MEDCASE Cost:	nulative MEDCASE Accumula Cost:		Accumulative Supply Cost:	
FY-80 MEDCASE Cost:			riew Results: I in by DCI)	
Study Objective:				

No work on this protocol to date.

Project awaits decision concerning funding for equipment which may be procured in 80-81.

Funding requirements: Actual requirements for FY-83 uncontain as decision concerning funding to thecessary equipment remains outstanding.

Site visit was performed by principal investigator. Funds were to be provided by the Chlef, dept. Radiology. These have not naterialized due to many budget Constraints. The principal investigator is separating from service 1 October 1980. This protocol and further work lie in the hands of Chief, Dept. Radiology.

David J. Eurtis, LTC,MC

30 September 1980

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

Sua.ECT

HSWP-XD

Protocol No. 4701 Final Report

TO THRU: C, Dept of Radiology, FROM

Robert Golden, M.S.

DATE 10 Oct 1980

CMT 1

Thru: C, Diagnostic Svc 45

Physicist

TO: C, Dept of Clinical Investigation, WRAMC

Timothy M. Boehm, LTC, MC

1. Attached is detail summary sheet (Appendix C) for protocol No. 4701 and a final report prepared for publication entitled "Patient Exposure Estimates using a Chest Phantom."

Robert Golden, M. S.

Physicist

Diagnostic Radiology Svc Department of Radiology

k !

Date: 9 Oct 1982 Protocol No: 4701 Status: Interim Final XX Title of Project: Comparison of Test Chest with Human Subjects on Radiographic Chest units. Starting Date 26 Feb. 1980 Estimated Completion Date: Principal Investigator: Robert Golden, M. S. Associate Investigators: Facility: WRAMC E. Thomas Pulaski, M. D. Dept/Svc Diagnostic Radiology Svc. Priscilla F. Butler, M. S. (Bureau of Radiological Health) Key Words: Patient exposure, humanoid phantom, Automatic exposure control Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: None None None Cost: Cost: FY-80 MEDCASE Cost: Periodic Review Results: None (to be filled in by DCI) Study Objective: to determine whether humanoid phantoms are reasonably analogous to human patients in terms of performance of automatic exposure controls of dedicated chest x-ray units. Technical Approach: Measure for routine patient chest exposures, the exposure, KVP, milliamperes and time of exposure and compare to corresponding data for humanoid phantoms. Compare patient exposure data to humanoid phantom data, considering sex, weight, and pattent thickness. Progress during FY-80: Please see attached report. Number of subjects to be studied before completion of study: 26 Serious/unexpected side effects in subjects participating in project: Conclusions: Humanoid phantoms are reasonable patient analogs in terms of their

AEG performance on one x-ray unit for a single technique for a small patient

To be submitted to Health Physics Journal for Pulication.

population.

Publications or Abstracts, FY-80:

Date: 27 Oct 80	Protoco	l No: 4702	Status:(Interim)			
Title of Project:			Final			
Video	Transmission,	Storage of Diagr	ostic Evaluation			
			•			
Starting Date:	farting Date: Estimated Completion Date:					
Principal Investigator: S	herry L. Brahm	an, MD, LTC, MC				
Associate Investigators: E. Thomas Pulaski, MD,	•	Facility: Walter Reed General Hospital				
David J. Curtis, MD, (USUHS)	Dept/Svc Radiology/Diagnosis				
Key Words:		- -	•			
Accumulative MEDCASE Cost:	Accum Cost:_	ulative Contract	Accumulative Supply Cost:			
FY-80 MEDCASE Cost:			eview Results:ed in by DCI)			
Study Objective: Termin	nate this stud	y. Equipment wil	l not be procured.			

The Microlese radiographic machine required for this project is on the property books of WRAMC, but is not serviceable at this time. Funds for refurbishment of the Microdose are in doubt and the fate of the project lies in the hands of the Chief, Dept. Radiology. The principle investigator is separating from service 1 October 1980.

Date: 20 October 1980	Protoco'	No: 6018	Status: Materim		
Title of Project: Newborn Ho	st Defenses	: I: Developmental	Final		
Aspects of Newborn Neutrop	hil Chemota	ixis			
	 				
Starting Date: 20 June 77	Estin	nated Completion Date:	20 June 80		
Principal Investigator: Pau	1 J. Thomas	, MD, LTC, MC			
Associate Investigators:	OT MC	Facility:			
Frederick B. Ruymann, MD, COL, MC Doris Burgess		Dept/Svc			
Key Words: Newborn neutrop	hil, chemot	axis			
Accumulative MEDCASE	Accum Cost:	ulative Contract	Accumulative Supply Cost:		
FY-80 MEDGASE Cost:		Periodic Review			
Study Objective: Confirm	and charact	erize the cellular ch	emotactic defect of		

the newborn neutrophil and to correlate this Cherease with gestational age.

Technical Approach: Modified 51 Cr labelled neutrophil chemotexis assay using Boyden chambers comparing cord clood neutrophils to normal adult volunteer neutrophils. Preliminary studies on the effect of chemotaxis of certain drugs such as vinblastin and the effect of concentration of the neutrophils on chemotaxis, also done wing same technique.

Progress during FY-80: Due to difficulties in obtaining cord blood neutrophils, only 2 newbones were studied on this protocol. Because of the slow accrual and because of the higher priority of other studies on the newborn neutrophil, this study has been closed.

Number of subjects to be studied before completion of study: Projected: 100, Actual: 52 Serious/unexpected side effects in subjects participating in project: NONE

Conclusions: Decreased newborn neutrophil chemotaxis has been confirmed as statistically significant. The correlation with gestational age has yielded no statistical differences noted. The conclusions have been published in the following.

Publications or Abstracts. FY-80:

Mease, A.D., Fischer, C.W., Hunter, K.W., and Ruymann, F.B.: Decreased thytological produced appropriation and Commissional American problems newborn neutrophils. Pediatr Res 14:142-146 (1980).

FUNDING REPORT CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 6018

Funds Utilized, FY-80: \$2000

Funding Requirements, FY-81: NONE

Personnel: NONE

Equipment: NONE

Supplies: NONE

Travel: NONE

Other: NONE

1. Work Unit N.: 6021

2. Title of Project: The Role of Leutinizing Hormone Releasing Hormone (LHTH) in Evaluation of the Hypo-

halamic Pituitary Gonadal Axis in Children

3. Principal Investigator: LTC Chandra M. Tiwary, MC

Objective: To develop a test for assessing hypothalamo-hypophysealgonadal axis in children which can be used on an outpatient basis.

- 5. Progress and Results: 57 children were studied; of these 4 can not be included in the protocol lecause these receive only one injection of LHRH (the protocol requires 3 injection to be given to each child), the gonadotropin results on six children are not available yet. The conclusions based upon the analysis of 17 thildren are as follows.
 - A. Girls with precocious puberty can be differentiated from those with premature adrenanche.
 - B. The pool serum IH and serum FSH value is directly correlated with the mean and the peak serum IH and FSH value. This suggests that for most clinical purposes analysis of the gonadotropin in one serum cample may be sufficient. This would reduce the cost.
 - C. Comadotropin response to LHRH is different in children with malignancy treated with chemotherapy and/or radiation. Thus the LHRH test can be used to detect subtle derangement of hypothalamo-hypophyseal-gonadal.axis.

6. Funds requested for FY 1981:

Paper publication
Travel for presentation
of paper

\$200.00

600.00 \$300.00

7. Publication: Three abstracts published

5. Type of report - Final

DISPOSITION	FORM
For use of this form, see AR 340-15, the propo	onent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

Reply to your comments on the protocol # 6021

TO THRU: C, Dept of Peds. 91 /

FROM C, Peds Endoc. Section DATE 2 Feb. 1981

CMT 1

TO:

C, Clinical Investigation

- 1. According to the protocol each child receives 3 injections of LHRH. Each of the four children received only one injection (non compliance) therefore, they are not included.
- 2. We did not observe any ill effects in any subjects due to participation in the study specifically IHRH injection did not produce any observable ill effects.

Articles CHANDRA M. TIWARY, M.D.

LTC, MC

Chief, Pediatric Endoc. Section

Date: 20 Oct 80	Protoco	l No:	6023	:	Status: Interim
Title of Project: Newborn H Newborn Neurophil Membrane	ost Defenses Using Lect	s II: S ins as	Studies of Molecular 1	the Probes.	Final.
Starting Date: 24 January 7	8 Esti	nated (Completion 1	Date: 24	June 81
Principal Investigator: Paul	J. Thomas,	MD, LT	c, MC		
Associate Investigators: Gerald W. Fischer, MD, LTC, MC Frederick B. Ruymann, MD, COL, MC Doris Burgess		Facility:			
		Dept/Svc			
Key Words: Newborn neutr	ophil, neur	a ophil a	nggregation		
Accumulative MEDCASE Cost:	SE Accumul		Contract		ccumulative Supply
FY-SO MEDCASE Cost:			Periodic R (to be fill		
Study Objective: Study of in ability to form aggrega activated serum.	differences tes in resp	b:twee	en adult an o plant lec	d newbortins, C	ch neutrophils Se, and Zymosan

Technical Approach: Using a standard platelet aggregometer, study of aggregation of cord blood neutrophils and adult neutrophils at a standard concentration (5X10 cells/mi)using phytohemagglutinin (PEA), column purified C5a, and zymosan activated serum (ZAS). The effect of vinblastin and cytochalasin B on aggregation of both adult and newborn neutrophils were also studied.

Progress Caring FY-80: Only 2 newborns were scudied too to the lack of cordblood available for study.

Number of subjects to be studied before completion of study: Projected: 100, Actual: 32 Serious/unexpected side effects in subjects participaling in project: NONE

Conclusions: Newborns have statistically poorer aggregation of neutrophils in response to PHA, C5a, and ZAS. The addition of vinblastin decreased the adult aggregation but did not significantly change the newborn aggregation. The addition of cytochalasin B resulted in the disappearance of the normal adult neutrophil aggregation - deaggregation but did not significantly affect the newborn aggregation. Further study is warranted in working at the effect of concentration of C5a or ZAS on the aggregation since other investigators have reported different newborn aggregation problems with differing concentrations.

(Con't) #6023

Publications or Abstracts, TY-80:

Mease AD, Fischer CW, Hunter RW, Ruymann FB: Decreased phytohemagelutinininduced aggreation and C5a-induced chemotaxis of human newborn neutrophils. Pediatr Res 14:142-146 (1980).

Mease AD, Burgess DP, Thomas PJ: Differences between necestal and adult complement-induced neutrophil aggregation and cellular augmentation of neutrophil chemotaxis. Pediatr Res 14:549 (abstract #740), (1980). - Presented at the 1980 APS-SPR neeting, San Antonio, Texas, 2 May 1980.

House AD, surgess DP, Thomas FT: Rechard differences in complements induced neutrophil aggregation and cells an augmentation of neutrophil chemotaxis. (Submitted for publication)

FUNDING REPORT CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 6023

Funds Utilized, FY-80: 52000

Funding Requirements, FY-81: \$500

Fersonnel: Doris Dargess, CC-9, 10%

Equipment: NONE

Supplies: \$500

Travel: NONE

Date: 20 October 1980	Protocol No	: 6024	Status: Interim
Title of Project: Newborn H and Killing of Group B Str		II: Phagocytos	is XXXX
Starting Date: 24 January 7	8 Estimate	ed Completion Da	ate: 24 January 81
Principal Investigator: Pau			
Associate Investigators: Gerald W. Fischer, MD, LTC		oility:	
George Lowell Frederick B. Ruymann, MD, (James W. Bass, MD, COL, MC	COL, MC Del	ot/Svc	
Key Words: Newborn neutro	phil, group B s	treptocci	•
Accumulative NEDCASE Cost:	Accumulati Cost:	ve Contract	Accumulative Supply Cost:
FY-SO MEDCASE Cost:			view Results:
Study Objective: Study phanewborn neutrophils. Technical Approach: Assay specific anti-streptoccal established and reported. this assay.	for 5 strains	of group Best Jement, and adj orn (cord) new	:1t neutrophils been
Progress during FY-80: No accural of newborn cord blo	new newborns od samples for	have been studies.	led because of the low
Number of subjects to be stud Serious/unexpected side effect		~ 	
Conclusions: None as yet.	·	ng to complete	study by 24 January 81.
Publications or Abstracts. F	Y-80: None.	•	•

FUNDING REPORT CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 6024

Funds Utilized, FY-80: NONE

Funding Requirements, FY-81: \$1000

Personnel: Doris Burgess, GS-9, 10%

Equipment: NONE

Supplies: \$500

<u>Travel:</u> \$500

) Work Unit Number: 6025

) Title: Role of surface tension measurement of amriotic fluid lipid extract in Prediction of RDS in the newborn.

) Investigators:

Principal: Chandra M. Tiwary, M.D., LTC, MC. Associates: James Haddock, M.D., LTC, MC Dale Landes, M.D., LTC, MC

Doris Burgess

- i) Starting date: The apparatus was not available till June 1979 and then the layestigation was started.
- (a) Estimated date of completion December 1981
- 1) Objective: To measure surface tension of amniotic fluid lipid extract prior to all during labor, and to correlate it with the subsequent development of FDS in newborn.
- g) Key words: None
- ে) Technical ্যুগ্ডিবল: No changes
- 1) Progress and Results: We have studied the administic fluid from \$3 patients. The sults show that a high surface tension of the amniotic fluid lipid extract predicts the development of RDS in the newborn or (b) an unusual course in the immediate about period requiring observation in the special care nursery. The analysis of the stients studied so far is given in the attached abstract.
- () Conclusion: We would like to confirm our data by analysing more patients (we had niy one child with RDS); approximate number would be 300.
- (k) No complete ion or side effect occured during the study.
- (1) Copy of the distract submitted for presentation at the forth coming pediatric diservice conference is enclosed.

181: Chemicals and supplieds \$300.00
Papers publication etc 200.00
Travel 600.00
TOTAL \$1,100.00

Surface Tension of Amniotic Fluid Lipid Extract as a Predictor of Immediate Neonatal Course

Chandra M. Tiwary, D. Landes and James B. Haddock with the technical assistance of D. Burgess. Department of Pediatrics Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, D. C. 20012 and Uniformed Services University of the Health Sciences, Bethesda, Maryland.

Surface Tension (ST) of Amniotic Fluid (AF) lipid extract correlates with the AF L/S ratio and predicts the fetal pulmonic maturity. We measured the ST in AF to predict the development of RDS in the neonate. Serendipitously we observed that a high ST was associated with a variety of complications (other than RDS) during the immediate neonatal period. We report the value of ST measurement in AF.

Amniotic fluid was collected during the 24 hours period of delivery and was frozen at -70° C till analyzed. A chloroform methance lipid extract was made of the AF and ST lowering property of the lipid extract was measured in an autotensiometer (Fisher Lab). The minimum amount of the lipid extract (in microliters) required to maximally lower the ST (dynes/cm) was recorded. These two values were added. This figure (the ST sum) was analyzed relative to clinical condition of the baby.

We studied 42 AF from 42 mothers, 27 delivered vaginally, 13 by Cesarean Section and 2 by forceps. The pregnancy was normal in 33 and complicated in 9 (pre eclamptic toxemia - 3, Diabetes Mellitus - 2, hypertension - 2, and one each with anemia, appendicitis). Twenty eight babies had a normal course, 14 had a complication(s) (Rh disease - 4, hypoglycemia - 3, meconium staining -3, ABO incompatability - 2, multiple congenital anomalies - 1, RDS -1). Thirty six babies were 2,500 gm or over and 6 were less than 2,500 gm, (3 were premature, less than 37 weeks gestation).

The ST sum was 45 or less in 28 babies and all but three (hypo-glycemia - 1, meconium staining - 1, ABO incompatability - 1) had a normal course, in 14 babies the ST sum was > 45 and all but 3 had an abnormal course requiring close observation and/or treatment (RDS+- multiple congenital anomalies - 1 meconium staining 2, Rh disease, multiple exchange transfusion - 4, sepsis and/or hypoglycemia - 2, ABO incompatability - 1). The Apgar score was normal (<5 at 1 min & 5 min) in all except 3 babies in the group with ST sum of >45, and it was abnormal in one baby in the < 45 ST sum group.

To determine the effect of prematurity on the surface tension we selected babies with gestational age of 37 weeks or less, or birth weight of 2,500 gm or less, in three babies the ST sum was less than 45 and in 8 it was greater than 45. Significantly, the highest ST sum of 87 was in a 2,769 gm, 37 weeks gestation and the lowest value of 31 was also in a 2,765 gm, 38 weeks gestation baby.

Conclusion:

- 1. A ST sum of more than 45 particularly if it is more than 50 predicts an abnormal course in the immediate neonatal period requiring dose observation and intervention.
- 2. A ST sum of less than 45 especially if it is less than 40-is associated with an uncomplicated neonatal course.
- 3. Maternal conditions such as anemia, hypertension, pre eclampsia do not effect the ST.
- 4. The ST is effected by factors other than low birth weight or gestational age.

Speculation:

A raised ST sum signifies pulmonic immaturity which may be associated with immaturity of the other organs. This may explain the increased number of babies with nonpulmonic complications in the high ST sum group.

(a) Work Unit Number: 6026

(b) Title: Tracheal Aspirate surface tension as a prognostic indicator in infants with Respiratory Distress Syndrome (RDS)

(c) Investigators:

Principal: Chandra M. Tiwary, M.D., LTC, MC
Associates: Richard D. Landes, M.D., LTC, MC
Doris P. Burgess, Medical Technologist

(d) Starting date: September 1979

(e) Estimated date of completion: June 1982

(f) Objective: To measure the surface tension of the lipid extract of trachael aspirate at various periods and to use this data in evaluating the prognosis of newborn with respiratory distress syndrome (RDS).

(g) Key words: None

(h) Technical approach: No modifications

- (i) Progress and results: We analysed 52 trachael aspirate samples from six babies. All these babies were intubated and had RDS. As the ST of the trachael aspirate decreased the respiratory status improved. In some cases the babies developed other complications ie bleeding episodes, seizure disorder, renal failure or intestinal obstruction or heart failure etc and died. Respiratory status occasionally during the complication one but usually it remained unchanged Once the ST decreased, it did not rise again except transiently in a few samples.
- (j) Conclusion: The preliminary data are very encouraging with respect to prediction in the improvement of respiratory status of intubated babies. We need to study more babies (about 30) to confirm the preliminary results.
- (%) No unexpected or serious side effects in subjects participating in this study.

(1) Publications: No

FY dl: Chemical and supplies \$500.00
Paper Publication 120.00
Travel 600.00
Total \$1,220.00

Date: 20 October 1960	Protocol	No:	6027	Status: Alegie
Title of Project: WRAMC #7	808 - Combi Childhood	ined M	odality	Final
Starting Date: 26 September	78 Estim	nated C	Completion D	Date: October 1980
Principal Investigator: Fred				
Associate Investigators:		Facili	ty:	
aul J. Thomas, MD, LTC, MC		Dept/S	Sve	
Key Words: Brain tumor, h	igh dose met	hôtre	xate	•
Accumulative MEDCASE Cost:	<u> </u>		Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	Antife Stragelymenta area provincial against			eview Results:ed in by DCI)
Study Objective. To determ vincristine, high dose met and radiation will increase tumors.	hotrexate, V	P-16,	CCNU, and g	procarbazine following surger
Technical Approach: Strainduction phase followed by	tification for non-random	nto hi ized u	gh & stands maintenance.	ard wish with non-randomized
Progress during FY-80:	o additiona available t	l paci hrough	ents have a	ccrual. High dose
Number of subjects to be stu Serious/unexpected side effe				
Conclusions: 2/3 patients not enough patients to evalue because of unavailability of	luate effect:	ivenes	s. Recomme	r recurrence. There are nd closing this study
Publications or Abstracts. I			. O L CAGLE,	

k i

1. Work Unit N.: 6028

2. Title of Project: Application of Ho, A1C as an indicator of juvenile disbetes control.

3. Investigations: Chandra M. Tiwary, LTC, MC R. Bongiovanni, CPT, MC

- 4. Objective: To determine if measurement of Ho. A_1C is an effective means of assessing diabetic control and to determine the optimal time for its measurement. To determine if the HB A_1C in obese children correlates with the insulin level.
- 5. Progress and Results: We analysed Ho. And in approximately 20 children, most of the children had analysis performed more than once. From the analysis of the data we conclude that
 - A. Hb, A1C measurement is a good indicator of the degree of diabetic control during the previous 2-4 weeks.
 - B. The change in Hb. A₁C is rapid in newly diagnosed diabetic as opposed to those with diabetes of long duration. In dew diabetic the fall in Hb. A₁C can be monitored every week while in others the change is apparent in 3 weeks.

Conclusion: We suggest that in children with established diabetes mellitus, the Hp. $A_1\mathcal{C}$ should be measured at 3-4 weeks interval to assess the degree of diabetic control. Hb. $A_1\mathcal{C}$ is in normal range in obese patients and is not related to serum insulin level.

Funds utilized in FY 1980 \$1,472.00

Funds requested in FY 1981

Paper publication \$200.00

Travel to meeting 600.00

TOTAL 800.00

Publication: One abstract published

Type of Report: Final

de land to be de la conte

Date: 20 603 80/19 JAN 81 Protocol No: 6029 Title of Project: Newborn Host Defenses IV: Study of Newborn Newtrornil-Meutrophil Interaction. Starting Date: 22 OCT 1979 Estimated Completion Date: 22 OCT 1981 Principal Investigator: Paul J. Thomas, MD, LTC, MC Associate Investigators: Facility: Frederick B. Ruymann, MD, COL, Doris P. Burgess Dept/Svc Key Words: Newborn neutrophil, chemotaxis, neutrophil aggregation Accumulative MEDCASE Accumulative Contract Accumulative Supply Cost: Cost: · Cost: FY-SO MEDCASE Cost: Periodic Review Results: (to be filled in by DCI) Study Objective: Investigate differences between adult and newborn neutrophil by a. studying the effect of cell concentration on chemotaxis; b. studying the kinetics of concentration effect on chemotaxis; and, c. studying the C5a-induced aggregation of newborn and adult neutrophils. Technical Approach: Using the established ⁵¹Cr-labelled neutrophil Eoyden c'amber cherotaxis assay and the neutrophil aggregation assay, the concentration of newborn and adult neutrophils is varied in the chemotaxis assay and the aggregation of newborn and adult neutrophils is evaluated using C5a as the aggregation stimulus. Preincubation of cells with vinblastin and cytochalsin-15 Newborn -adult neutrophil pairs were studied with varying concentrations of neutrophils. 8 newborn adult neutrophil pairs were studied with respect to C5a aggregation. Number of subjects to be studied before completion of study: Projected: 50: Actual Serious/unexpected side effects in subjects participating in project:

Conclusions: Newborn neutrophils have augmented chemotaxis with increased cell concentration; however, the augmentation is only about half that seen with the adult. Newborn neutrophil aggregation appears to be irreversible, similar to that seen with adult aggregation after preincubation of the neutrophils with cytochalasin-B. Further study of the aggregation and chemotaxis is needed. New studies suggested by this study will be forthcoming.

The corrected portion of the study is presided. The lactoferrin posmoibility was only listed as an example of further studies suggested by this study. If this possibility turns out to have some merit, a new protocol will be written.

116

(Con't) #6029

Publications or Abstracts, FY-80:

Mease AD, Burgess DP, Thomas PJ: Differences between neonatal and adult complement-induced neutrophil aggregation and cellular augmentation of neutrophil chemotaxis. Pediatr Res 14:549 (Abstract #740) (1980). Presented at the 1980 APS-SPR meetings, San Antonio, Texas, 2 May 1980.

Mease AD, Burgess DP, Thomas PJ: Neonatal differences in complement-induced neutrophil aggregation and cellular augmentation of neutrophil chemotaxis (Submitted for publication).

FUNDING REPORT CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 6029

Funds Utilized, FY-80: \$700

Funding Requirements, FY-81: \$2000

Personnel: Doris Burgess, CS-9, 20%

Equipment: NONE

Supplies: \$1500

Travel: \$500

Date: 20 October 1980	Protoco	1 No: 6030	Status: Interim
Title of Project: Studies of Chemotaxis under Agarose	Adult and	Newborn Neutrophi	1 Minut
Starting Date: 22 Oct 79	Esti	mated Completion 1	Date: October 81
Principal Investigator: Paul	. J. Thomas,	MD, ITC, MC	
Associate Investigators: Frederick B. Ruymann, MD, COL, MC		Facility:	
Doris P. Burgess		Dept/Svc	
Key Words: Newborn neutro	phil, chemo	ltaxis under agaro	se
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	l	Periodic R	eview Results:
-	,,		ed in by DCI)
chemotaxis under agarose.			
	•	.44 4	
Technical Approach: Usin of chemotaxis of adult and concentration of neutrophi	newborn ne	utrophils under v	arying conditions of atim
of chemotaxis of adult and	newborn ne	utrophils under v	arying conditions of atim
of chemotaxis of adult and concentration of neutrophic Progress during FY-80: with reproducible results projector & the obtaining	newborn ne ls, and pre ls, and pre ls ls ls ls ls ls ls ls ls ls ls ls ls	utrophils under vesence of compound technique was es neutrophils obtain	arying conditions of atims such as Winblastin . tablished in our laboratomed. Lack of the Tri-Sim
of chemotaxis of adult and concentration of neutrophic Progress during FY-80: with reproducible results projector & the obtaining this protocol.	newborn ne ls, and pre ls, and pre ls agarose with adult of only 1 c	utrophils under vesence of compound technique was es neutrophils obtained blood for students.	arying conditions of stimes such as Vinblastin . tablished in our laboratomed. Lack of the Tri-Simedy have impeded progress of
of chemotaxis of adult and concentration of neutrophi Progress during FY-80: with reproducible results.	newborn ne ls, and pre ls, and pre ls agarose with adult of only 1 c	utrophils under versence of compound technique was es neutrophils obtained blood for study	arying conditions of stimes such as Winblastin . tablished in our laboratomed. Lack of the Tri-Simely have impeded progress of the Projected: 50, Actual:

Publications or Abstracts. FY-80: None.

The listing of one patient studied was an error. Only one newborn was studied using the agarose technique; however, 35 adult samples were studied while attempting to firmly establish this technique in our laboratory. As of this time, the technique is still not reliably reproducible and an estimated 5-10 more adult studies will need to be done before any more newborns will be studied.

Work Unit No.: 6030

Funds Utilized, FY-80: \$2500

Funding Requirements, FY-81: \$2500

Personnel: Doris Burgess, GS-9, 20%

Equipment: NONE

Supplies: \$2000

<u>Travel:</u> \$500

Date: 20 002 80	Protocol	No: 6101	Status: Interim
Title of Project: SWOG PRO second Induction and M shase III.	TOCOL # 78 aintenance	334 e in Acute Lymp	hocytic Leukemia,
Starting Date: 2 MAY 80	Estir	nated Completion I	Date: APR 81
Principal Investigator: Fre	derick B.	Ruymann MD, CO	L MC
Associate Investigator:: Paul J. Thomas MD, LTC	мс	Facility:	
Conald Karcher MD, LTC	MC	Dept/Svc	
Key Words: Acute lympho	cytic leuk	temia, relapse	· · · · · · · · · · · · · · · · · · ·
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost: Periodic Review Results: (to be filled in by DCI)			
Study Objective: To invest vincristine, adriamycing therapy with methotrexal in relapse acute lymphoness of maintenance the rabinoside; cytoxan, with vincristine, adriamycand prednisone with all cytosine arabinoside in CNS prophylaxis with indetween two maintenance of Standard Progress during FY-80: No Number of subjects to be studied.	n, and preate, hydrocytic leverapy with vincristing cin, preduction, preduction case of attrathecal earms.	ednisone follow cortisone, and kemia; to inverse, cycles of 6-the, cytosine arisone. It is with vinction with 6 induction fails three drug the citients were entitients were entitients.	ed by intrathecal cytosine arabinosido stigate the effective-hioguanine, cytosine abinoside, prednisone; ristine, adriamycin—thioguanine and ure with VAP; erapy; randomization tered on this study.
Serious/unexpected side effe			
and closed by the group	p to patie systemic	nts with marro	s treatment, this study we relapse only; the ients with extra-medul-

The protocol was indeed properly amended. Reports from the group ith respect to all group protocols are published twice per year and a copy will be furnished to your office should you desire them.

FUNDING REPORT CLINICAL INVESTIGATION PROGRAM

Work Unit No.: 6101 - 6131

Funds Utilized, FY-80: NONE

Funding Requirements, FY-81: NOW:

Personnel: NOWE

Equipment: NONE

Supplies: MONE

Travel: NONE

Dute: 20 CCT 80	Protocol No:	6102	Status: Interim
			Final
Title of Project: SWOG PRACTICATION Therapy in in Patients with Hal	Combination	with BCNU,	DTIC, or Procarbazine rain, Phase III.
Starting Date: 3 MAR 80	Estimated	Completion I	Date: JAN 81
Principal Investigator: Fre	derick B. Ruy	nann MD, CO	L MC
Associate Investigators:	• 1	lity:	
Paul J. Thomas MD, L William Neglia MD, L Eugene George MD, CO	TC MC Dept	:/Svc	namen of antiferror to the second control of the second control of the second control of the second control of
Key Words: Malignant gl	ioma		•
Accumulative MEDCASE	Accumulativ		Accumulative Supply Cost:
FY-80 MEDCASE Cost:		Periodic Re	eview Results:
			ed in by DCI)
Study Objective: To study drugs to radiation the glioma.	y the effect onerapy after r	of adding oneurosurger	ne for three shemotherapy
Technical Approach: Dane			<u>.</u>
following surgery and	lomized study laradiation the	between BC nerapy.	NU, DIIC, or procarbazine
April 1 a. gardina distribution April 1 a. gardina distribution			
Progress during FY-80: No	VRAMC patien	its were en	tered on this study.
	•		
Number of subjects to be stu	died before comp	letion of study	75
Serious/unexpected side effe			
Conclusions: This is prin by the pediatric grou of SWOG in January 19	ip when the pe	t SWOG prodiatric gro	tocol and will be dropped oup becomes independent
Publications or Abstracts.	FY-80:	. بر	

Date: 20 007 80	Protocol	No: 6103	Status: Interim
			Final
Title of Project: SWOG PRO Evaluation of m-AMSA : kin's Lymphoma in Rel	in Childr	en with Acute	Loukemia and Non-Hodg-
Starting Date: 3 HAY 80	Estir	nated Completion	Date:
Principal Investigator: Fred	erick B.	Ruymann MD, CO	I, MC
Associate Investigators:		Facility:	
Paul J. Thomas MD, LT	C MC	Dept/Svc	
Key Words: Acute leukem	ia, relap	1 se; non-Hodgki	n's lymphoma, relapse
Accumulative MEDCASE Cost:		ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:		Periodic R	eview Results:ed in by DCI)
Study Objective: To study agent for acute leuke			
Technical Approach: Non and acute non-lymphoc schedules for acute l	ytic leuk	emia; randomiz	
peripheral blood blas response. Number of subjects to be stu Serious/unexpected side effe	after two t count d died before ets in subje	courses, the ecrease but no completion of studets participating in	patient had a transient detectable marrow y:
····	ns open w	ith precaution	s of continuous cardiac

Publications or Abstracts. FY-80:--

		والمنافية والمنافية والمنافية والمنافية والمنافية والمنافية والمنافية والمنافية والمنافية والمنافية والمنافية	and the second second second second second second second second second second second second second second second		
Date: 20 00 Protocol No: 5104			Status: Interim		
Title of Project: SUOG PROTOC Incluation of Rubidazon Acute Myelogenous Leuke		cute Lymphoblastic and			
Sarting Date: 11. 1111, 80	Estimate	ed Completion	Date:		
Principal Investigator: Frede	rick B. R	uymann MD,	COL MC		
Associate Investigators: Facility:					
Paul J. Thomas MD, LTC		pt/Svc			
Key Words: Acute leukemia	, relapse		•		
Accumulative MEDCASE Cost:		ive Contract	Accumulative Supply Cost:		
FY-80 MEDCASE Cost:	د چې د د د د د د د د د د د د د د د د د د		Review Results:		
remissions in children Technical Approach: Random Rubidazone given intrav	ized stud	y of two do	sage schedules of		
	·				
was placed on study; ho	wever, he cause of d before con in subjects	expired wideath not not not not not not not not not not	dy: n project: See progress-		
Conclusions: Study remains	open unti	l supply of	Rubidazone is exhausted		
Conclusions: Study remains open until supply of Rubidazone is exhausted The one death within 12 hours was initially thought to be a possible trug related death. The child developed progressive coma and heart rate and rhythm disturbances culminating in a cardiac arrest. At autopsy, the child had massive leukemic infiltrations in the abdomin- al organs, the CNS, and the heart, including an infiltration of the reart around the A-V·node. The pathologists were content to call the cause of death massive leukemic infiltration and it was their opinion that the drug played little or no role in the death.					

Date: 20 OCT 80	Protoco	No:	6105	[Status: In	erim
	mo oo t '' ra	'Agr			湖	Kalk
Title of Project: SWOG PRO Evaluation of Lithium Toxicity Follocing Con- Treated with AD-CON-	m Carbonat ancer Cher	te in· nother	the Ameli capy in Ch	oratio ildre	on of He n with Se	matopoieti olid Tumor
Starting Date: 14 JUL 80	Estir	nated (Completion D	ate:		A
Principal Investigator: Free	derick B.	Ruyma	ann MD, CO	L MC		
Associate Investigators: Paul J. Thomas MD, L	TC MC	Facili	ty:	·	tern priliminasjon upirk pamanasisk ramp	
		Dept/	Sve	**************************************		
Key Words: Solid tumor	s, pediati	i cic, c	chemothera	ъу.		•
Accumulative MEDCASE Cost:	Accum Cost:		Contract		Accumulati Cost:	~ ^ *'
FY-80 MEDCASE Cost:			Periodic Re (to be fille			
Study Objective: To study neutropenia caused by AD-CON-FU (adriamyci on various pediatric other protocols of h	y AD-CON-I n, cytoxa solid tur	FU; to n, vir	o study th cristine, in patient	eff and	ectivene 5-flurou	ss of racil)
Technical Approach: Rand not of lithium carbo by tumor type.	omized strate to the	idy wi he for	ith respec ir drug ch	t to emoth	the addi erapy; s	tion or tratified
Progress during FY-80: No	WRAMC pa	tient	s have bec	en ent	ered on	this study
Number of subjects to be stu	died before	comple	tion of study	:		
Serious/unexpected side effe	cts in subjec	ts parl	ticipating in	project	t:	·
Conclusions: Study remai	ns open					
Publications or Abstracts. I	FY-80:					

Date: 20 001 80	Protoco	1 No: 6106	Status: Titlerim'X	-
Tytle of Project: SWOG PR			Final Vanced Cancer, Phase	II.
Starting Date: 2 MAY 80	Estin	mated Completion I	ate: OCT 80	~ ~
Principal Investigator: Fre	ederick B.	Ruymann MD, CO	L MC	_
Associate Investigators: Paul J. Thomas MD, I	TC MC	Facility:		-
	•	Dept/Svc		
Key Words: galactitol,	Phase II	1	•	
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accumulative Supply Cost:	_
FY-SU MEDCASE Cost:			oview Results: ed in by DC()	•
Study Objective: To stude malignancies and to			ol on advanced childh	ood
				•
Technical Approach: Mon- for liver, kidney or	randomized bone marr	l study with in row impairment.	itiel dosage modifice	tion
		· · · · · · · · · · · · · · · · · · ·		
Progress during FY-80: 1	IO WRAMC pa	atients were en	tered on this study	•••
Number of subjects to be st	udiad before	completion of study		- .
Serious/unexpected side eff revealed serious hem				īls Lients
Conclusions: Study clos	sed by Grou	up because of s	erious side effects a	and

Publications or Abstracts, FY-80:

Date: 20 OCT 80	Protocol	No: 6107	Status: Interim
			Fynak
Title of Project: SWOG PROTE Evaluation of Anguida Non-lymphoblastic Lev	ne in Chi	ldren with Act	ate Lymphoblastic and
Starting Date: 14 JUL 80	Estin	nated Completion	Date:
Principal Investigator: Free	lerick B.	Ruymann MD, C	DI, MC
Associate Investigators:	ac Mc	Facility:	
Paul J. Thomas MD, Li	ro Mo	Dept/Svc	
Key Words: Acute leukemi	a, relaps	€ .	:
Accumulative MEDCASE Cost:	Accumi Cost:	dative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			Review Results:led in by DCI)
remissions in childrent Technical Approach: Non-	n with ac	ute Loukemia :	
modification depending	g on degr	ee of toxicity	y
		· ·	
Progress during FY-80: On leukemia had a transi	e patient ent respo	with juvenile nse but quick	e chronic granulocytic ly relarsed.
Number of subjects to he stu Serious/unexpected side effe			
Conclusions: Study rema	ins open	for monocytic	and monomyelocytic
Dublications on Abstracts	EV20.		

Date: 20 GCP 60	Protoco	l No: 6108	Status: Interim
Title of Project: SWOG MOPP versus OPP in the Tumors, Phase III.	PROTOCCI ne Treatme		with Recurrent Brain
Starting Date: 24 HAR 80	Estir	nated Completion I)ate:
Principal Investigator: Fre	ederick B.	Ruymann MD, CC	OL MC
Associate Investigators:		Facility:	
Paul J. Thomas MD, LI Engene George MD, COL		Dept/Svc	
Key Words: Brain tumor,	recurren	t	
Accumulative MEDCASE	Accum Cost:	dative Contract	Accumulative Supply Cost:
FY-S0 MEDCASE Cost:	annesen a erinadiske f. s. den er en av sælet hens mag		eview Results:
Technical Approach: Rando nustard to vincristin	omized stu	dy for the addi	tion of nitrogen
Progress during FY-80: No	WRAMC pa	tients were ent	ered on this study
		i	:
Number of subjects to be stu Serious/unexpected side effe		******************************	
Conclusions: Study remai	ns open		
Dublications or Abstracts 1	FV80.		

Date: 20 OCT 80	Protocol	l No:	6109	St	atus: Interim
Title of Project: SWOG PRO! Evaluation of Complian with Prednisone	rocol # 77 nce in Chi	709 Lldren	with Mal	Lignant	Final Disease Treated
Starting Date: 24 MAR 80	Estir	nated C	ompletion D	ate: 0	CT 80
Principal Investigator: Free	derick B.	Ruyma	nn MD, CO	L MC	
Associate Investigators:		Facilit	y:		and the second s
Paul J. Thomas MD, LT	C MC	Dept/S	Svc		
Key Words: Compliance,	prednisor	10 1			•
Accumulative MEDCASE Cost:	Accum Cost:		Contract		coumulative Supply
FY-80 MEDCASE Cost:			Periodic Re (to be fille		sults:
Study Objective: To evaluation is one for malignant of the malignant of th	liseases.				
Progress during FY-80: 110	o WRANC pa	ationt	s entered	on th	is study
Number of subjects to be stu Serious/unexpected side effe					
Conclusions: Study close patients entered.	ed by Grou	nb pcc	ause of a	dequat	c numbers of
Dublications or Abstracts 1	TV80.				•

1:10: 20 00m PO	Protoco	l No: 6110	Status: Interim
Tile of Project: SWOG PRO Scute Lymphoblastic L	TOCOL # 7 eukemia C	865 Lassification I	Portion of ALinC 13
Carting Date: 20 JAN 80	Esti	mated Completion I	Date:
Principal Investigator: Fre	derick B.	Ruymann MD, CC	DL MC
'ssociate Investigators:		Facility:	
Paul J. Thomas MD, LT Bonald Karcher MD, LT Barbara Detrick-Hooks	C MC	Dept/Svc	rassanda gapana para Mandapa ta ar ar ar ar ar ar ar ar ar ar ar ar ar
Cay Words: Acute Lymphob	lastic le	wkemia, classit	fication
Accumulative MEDCASE		ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	ar o e e e e e e e e e e e e e e e e e e		ed in by DCI)
leukenia by studying teristics of the blas	cytochemi ts	cal staining a	nd immunologic charac-
Technical Approach: Evaluuse of cytochemical s	ation of tains and	the blasts in timmunologic st	the bone marrow by the tudies.
	Salation (Salation) Salation (Salation) Salation (Salation)		
with 2 T-cell and 6 "	non-T, no	n-B cell" leuke	n entered on this study emias identified. d in the pathology lab
Number of subjects to be studerious/unexpected side effections			
Conclusions: T-cell and lymphoblastic leukemi on the ability to mak	as and se	parate treatmen	nt protocols are based
Publications or Abstracts. I	Y-80:		

Date: 20 OCT 80	Protocol	No:	6111 .	Statu	s: Interim
Title of Project: SWOG PRO Evaluation of Anguidi Tumors, Phase II.			tment of C	Central II	/Fitak// ervous System
Starting Date: 3 MAR 80	Estir	nated C	ompletion D	ate:	
Principal Investigator: Fre	derick B.	Ruyma	ann MD, CC	L MC	
Associate Investigators:		Facilit	ty:		
Paul J. Thomas MD, LT Eugene George MD, COL		Dept/S	Svc		
Key Words: CNS Tumors,	recurrent	4			
Accumulative MEDCASE Cost:			Contract		mulative Supply
FY-80 MEDCASE Cost:			i	view Resuled in by DC	ts:I)
Study Objective: To stud weekly in children wi					idine given
Technical Approach: Non- impaired liver, kidno	randomize ey, and bo	d stu ne ma:	dy with do rrow funct	sage adj	ustments for
Progress during FY-80:	lo WRAMC p	atien	ts have be	een enter	ed on this stu
Number of subjects to be stu Serious/unexpected side offer	idied before ects in subje	comple cts par	ction of study ticipating in	project: _	
Conclusions: This study	remains	open	for non-a	strocytom	!as
Publications or Abstracts.	FY-80 -				

Date: 20 007 80	Protoco	1 No: 6112	Status: Interim
Title of Project: SWOG PRO Evaluation of Rubidazo	TOCOL # 7 ne in the	843 Preatment of	Children with Solid
Starting Date: 11; JUL, 80	Esti	mated Completion	Date:
Principal Investigator: Fred	erick B.	Ruymann MD, C	OF MC
Associate Investigators:		Facility:	The control to the co
Paul J. Thomas MD, LTC	MC	Dept/Svc	
Key Words: Brain tumor,	recurren	ı t; solid tumo	r, recurrent
Accumulative MEDCASE		ulative Contract	Accumulative Supply Cost:
FY-S0 MEDCASE Cost:	energi en annoneni e ere a en en en en en en en en en en en en en		Review Results:
Study Objective:To study tumors and brain tumor. Technical Approach: Non-impaired liver, kidney	s in chil randomize	dren. d study with	dosage adjustments for
		•	
		-	
Progress during FY-80: No	WRAMC pa	tients were e	ntered on this study.
		•	
Number of subjects to be stud Serious/unexpected side effect			
Conclusions: Study remain	ns open u	ntil supply o	f rubidazone is exhauste
Publications or Abstracts. A	э. -80:		

Date: 20 OCT 80	Protocol	No:	6113	Status: Interim
Title of Project: SMOG PRO Combination Chemothers in Children with Metas	apy with V	inbla		
Starting Date: 24 MAR 80	Estin	nated (Completion D	ate:
Principal Investigator: Fre	ederick B.	Ruyn	ann MD, C	OL HC
Associate Investigators:		Facili	ty:	
Paul J. Thomas MD, LT	C MC	Dept/	Svc	
Key Words: Solid tumors.	, pediatri	c, me	etastatic	
Accumulative MEDCASE Cost:			Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:				view Results:d in by DCI)
Study Objective: To study solid tumors with vint	the effe clastin en	ct of d ble	treatmen	t of metastatic pediatric
Technical Approach: Non- impaired liver, kidney	-randomize , or marr	d stu ow fu	dy with denction.	osage adjustments for
Progress during FY-80: No	o WRAMC pa	tient	s were en	tered on this study.
Number of subjects to be stu Serious/unexpected side effe				
Conclusions: Study remai	ins open		The second second second second second second second second second second second second second second second se	
Publications or Abstracts. I	FY-80:			·

Date: 30 OCT 80	Protoco	I No: 6114	Status: Interim
Title of Project: SWOG Pi	ROTOCOL # '	7831	Final
Starting Date: 24 MAR 80	Estir	nated Completion I	Date: 1 007 80
Principal Investigator: Fre	ederick B.	Ruymann MD, CO	DL MC
Associate Investigators: Paul J. Thomas MD, IM	I'C MC	Facility:	
•	•	Dept/Svc	
Key Words: Acute leuken	nia, neoca	rzinostatin	
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accumulative Supply Cost:
EX-80 MEDCASE Cost:	all in the contract of the con		ed in by DCI)
Study Objective: To stud ducing remissions in Technical Approach: Non-intravenously daily f	acute leul randomize	temia in relaps	:e.
Progress during FY-80: N		n de la companya de la companya de la companya de la companya de la companya de la companya de la companya de Salanggia de la companya de la comp	tared on this study
Progress during ri-ou:	or minus pro		wered on this study.
Number of subjects to be stu Serious/unexpected side effe my elosuppression and	cts in subjec	ts participating in	project: Severe
Conclusions: Study close			
Publications or Abstracts.	FY-80:	. g	

Date: 20 00T 80	Protoco	l No:	6115	Status	s: Interim
Title of Project: SNOG PROS Evaluation of the Natu	POCOL # 73 ural Histo	576 Ory of	Histiocy	tosis X	Binak .
Starting Date: 21 MAR 80) Estin	mated (Completion D	ate:	
Principal Investigator: Fre	ederick B.	Ruym	ann MD, Co	OL MC	
Associate Investigators:	a Ma	Facili	ty:	manifer de de la companya de la companya de la companya de la companya de la companya de la companya de la comp	
Paul J. Thomas MD, LTG Donald Karcher MD, LTG		Dept/	Svc		
Key Words: Histiocytosis	s X	٠.			
Accumulative MEDCASE Cost:	j		Contract		nulative Supply
FY-80 MEDCASE Cost:			Periodic Ra (to be fille	view Result d in by DCI	3:
Study Objective: To chara children who have not	been pre	viousl	y treated	•	
Technical Approach: Stude effects of disease, as	nd effect	s of t	oi disease Cherapy at	yearly i	gic competence ntervals.
Progress during FY-80: No	o WRAMC pa	atient	s have be	en enterc	d on this stud
Number of subjects to be stu Serious/unexpected side effe					
Conclusions: Study remains	ins open			***	
Publications or Abstracts. 1	FY-80:				

Date: 20	OCT 80	Protoco	l No:	6116	St	atus: Interi	m
MOPP plus	et: Sweg Pro Bleomycin ar II Hodgkin's	id A-COPP	with	Involved	Field	Minak Radiation	
Starting Date:	2 MAR 80	Estin	nated C	ompletion I	Date:	Politica Company	
Irincipal Inve	stigator: Fred	erick B.	Ruyma	unn MD, Co	OL MC		
Associate Inve	stigators: omas MD, LTC	MC	Facilit	y:		-	
Donald Kar William Ne	cher MD, LTC glia MD, LTC ine MD, LTC	MC MC	Dept/S	ve			
77 337 3 -	Hodgkin's di	•	tage I	II			: •
Accumulative :	MEDCASE	Accurate Cost:	ulative	Contract		cumulative s	~ ~ ~
SY-80 MEDCA	SE Cost:	د د د د د د د د د د د د د د د د د د د		Periodic Re (to be fille		sults: OCI)	
Technical App	th MOPP-Bleomisone, processione, processione, procession on coving the second second second according to the second secon	arbazine a-vincri mized str ollowed)	, and stine, idy be ov rad	bleomycir prednisc	n) versione, and	us ACOPP (d procerba	(adria azine)
							· ·
•						ران المرافع المادية. الشكائل المادية المادية	
Progress durappear to l	ing FY-80: Two	patient omplete :	s wer respon	e entered se to the	l on stu erapy.	idy and bo	th
	iects to be studi						
Conclusions:	Study remain	is open					
Publications o	r Abstracts. FY	?80: -	-				

Date: 20 005 80	20 005 80 Protocol No. 6117			
Title of Project: SWOG PRO	madat # ##	110	·	Final
Comparison of Treatment Children with Acute Li	nt Regimer	is fo:	r the Firs cemia, Pha	t CNS Relapse in se III.
Starting Date: 14, JUL 8	O Esti:	mated	Completion D	Date:
Principal Investigator: Fr	ederick B	. Ruyi	nann MD, C	OL MC
Associate Investigators:	a .v.a	Facil	ity:	
Paul J. Thomas MD, LT William Neglia MD, LT		Dept/	Svc	
Key Words: CNS leukemia		4		•
Accumulative MEDCASE Cost:	1	Accumulative Contract Cost:		Accumulative Supply Cost:
FY-80 MEDCASE Cost:			Periodic Re	eview Results:
intra thecal therapy the effect of mainten in duration of respon	ance intra	eatmen athec	nt of CNS al therapy	leukemia; to study versus no maintenance
trexate, hydrocortiso between no further th	the skull ne, and c erapy ver	and : ytosi: sus i:	intratheca ne arabino ntrathecal	d therapy with metho- side. Randomization
Progress during FY-80: N	o WRAMC pa	atien [.]	ts have be	en entered on this study
Number of subjects to be stu	died before	comple	tion of study	-
Serious/unexpected side effe				· · · · · · · · · · · · · · · · · · ·
Conclusions: Study remai	ns open			
Publications or Abstracts. 1	FY-80:			

Date: 20 OCT 80	Protoco	1 No: 6118	Status	: Interim
Title of Project: SWOG PRO ACON-plus for Non-Hog	TOCOL # 79 gkin's Lyn	005 liphoma in Chi	Lldren, Phase	Mind
Starting Date: 14 JUL 80	Esti	mated Completio	n Date:	
Principal Investigator: Fr	ederick B.	Ruymann MD,	COL MC	
Associate Investigators: Paul J. Thomas MD, LT	C MC	Facility:		
Donald Karcher MD, LT William Neglia MD, LT	C MC	Dept/Svc		
Key Words: Non-Hodgkin	's lymphom	a, therapy	•	•
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accum Cost:	ulative Supply
FY-S0 MEDCASE Cost:	. De cambrane, ann an cambrane an combana an combana an cambrane an cambrane an cambrane an cambrane an cambrane	COMPANY AND ADDRESS OF LEGS	Review Results illed in by DCI)	
ACOP-plus chemotherapy therapy in obtaining therapy in obtaining Hodgkin's lymphoma. Technical Approach: RanchCOP-plus (adriamycin, purine) and LSA2-L2 (ab-thioguanine, cytosim methotrexate, intratherapy in the progress during FY-80: and both have achieved	y versus rand mainta domized st cytoxan, daunomycin ne arabino ecal metho	adiation ther aining remission adving remission adving remission vincristine below, hydro side, vincristine trexate) pathents were tory remission	chemotherapy prednisone extine, prednisone entered on ons on the A	A2-L2 chemo- dhood non- regimens , 6-mercapto- sparaginase, isone, cytoxa
Number of subjects to be stu Serious/unexpected side effe	. 7			
Conclusions: Study remai	ins open			
Publications or Abstracts.	FY-80:			· · · · · · · · · · · · · · · · · · ·

Date: 20 OCT 80	Protoco	ol No:	6119		Status:	Interim
Title of Project: SWOG PRO Adjuvant Chemotherapy Reese-Ellsworth Group	for Loca	lized	Unilatera	al Ret	Linobla	Final
Starting Date: 14 JUL 80	Esti	mated (Completion :	Date:		
Principal Investigator: Free	derick B.	Ruyma	nn MD, CO	OL MC		
Associate Investigators: Paul J. Thomas MD, LT	C MC	Facili				
Paul Whitmore MD, LTC	FIG	Dept/Svc				
Key Words: Retinoblasto	oma, unil	₄ ateral	, chemoth	nerapy	,	•
Accumulative MEDCASE Cost:		-	Contract		Accumu Cost:	dative Supply
FY-80 MEDCASE Cost:	and the second s		Periodic R (to be fill	eview]	Results:	ernar en en en en en en en en en en en en en
Study Objective: To study therapy after enucleat Ellsworth Group 5.	the efficion of u	ect of nilate	chemothoral retir	erapy noblas	versus stoma,	no chemo- Reese-
•						
Technical Approach: Rand cristine and cytoxan	lomized s versus no	tudy b chemo	etween ch therapy.	iemoth	ierapy	with vin-
Progress during FY-80: No	WRAMC pa	atient	s have be	een en	tered	on this st
Number of subjects to be stu- Serious/unexpected side effe					t:	
Conclusions: Study remain	s open		man, a rendi selm quideque de milli, qui d _e			

Publications or Abstracts. FY-80: --

Date: 20 (CCT 80	Protocol No:	6120	Status: Interim
Title of Project: SHOG PR Evaluation of Systemi Lymphocytic Leukenia,	OTOCOL # 7837 c Therapy for Phase III.	Children w	ith T-cell Acute
Starting Date: 14 JUL 80	Estimated	Completion I	ate:
Principal Investigator: Fre	derick B. Ruyı	nann MD, CO	L MC
Associate Investigators:		lity:	
Paul J. Thomas MD, LT Donald Karcher MD, LT Barbara Detrick-Hooks William Maglia, MD, I	C MC Dept	/Svc	
Key Words: T-cell leuk			•
Accumulative MEDCASE	Accumulativ	e Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			view Results: d in by DCI)
Study Objective: To eval	uate "Duke" c	nemotherapy	regimen versus LSA2-L2
regimen in the treatm			· • (
prednisone, L-asparig arabinoside, 6-thiogu with methotrexate, hy versus LSA2-L2 regime ase, daunomycin, cran 6-thioguanine, BCNU, Progress during FY-80: Tw	inase, adriam anine, methot drocortisone, on (cytoxan, vidal radiation hydroxyurea) o WRANC patienty remission;	ycin, crani rexate, cyt and cytosi incristine, intrathed in the trea ats were en however, o	ked regimen (vincristing al radiation, cytosine oxan, intrathecal therapne arabinoside (ARA-C)) prednisone, L-asparaginal methotrexate, ARA-C, tment-of t-cell loukemiatered on study and both ne developed a testicula ed.
Number of subjects to be st	died before comp	letion of study	organizacione della compositiona
Serious/unexpected side effe			
Conclusions: Study remai	ns open	· · · · · · · · · · · · · · · · · · ·	
Tublications on Abstracts	EV80•		


Date: 20 OCT 80	Protoco	l No:	6121	Status: Interim
Title of Project: SNOG PRORE Rare Tumor Registry.	OTOCOL # 7	'79 9		12.02K
Starting Date: 1: Fob 80) Estir	mated C	Completion D	ate:
Principal Investigator: Fre	ederick B.	Ruym	ann MD, CO	OL MC
Associate Investigators:		Facili	ty:	
Paul J. Thomas MD, LTO Donald Karcher MD, LTO		Dept/S	Sve	
Key Words: Rare tumor	registry	1		•
Accumulative MEDCASE Cost:	Accumi Cost:	ulative	Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:				view Results: d in by DCI)
Study Objective: To accurand rare tumors of chi	nu⊥ate dat ildhood	a on	unusual, i	incommon, infrequent,
Technical Approach: Registrare tumors.	stry with	patho	logy revie	ew of patients with
			-	
Progress during FY-80: No study.	o WRAMC pa	atient	s have bed	en registered on this
Number of subjects to be stu Serious/unexpected side effe				
-				
Conclusions: Study remain	ins open			
Publications or Abstracts. 1	FY-80:			

Date: 20 002 80	Protoco	1 No: 6	122	Status: Interim
Title of Project: SUOG F A Comparison of Two Do Treatment of CNS leuke	cal Methotrexate for			
Starting Date: 14 JUL 80	Esti	mated Co	ompletion I	Date:
Principal Investigator: Fre	derick B.	. Ruyna	nn MD, C	CL MC
Associate Investigators: Paul J. Thomas ND, LTC	: ис	Facilit	7 :	
•	_	Dept/S	vc	
Key Words: Leukemia, CN	ís,			
Accumulative MEDCASE Cost:	ve MEDCASE Accumulative Contract Cost:		Accumulative Supply Cost:	
TY-SO MEDCASE Cost:	entere de la constante de la c		Poriodic Re (to be fills	eview Results:
Study Objective: To evalue methotrexate dosages gleukemia. Technical Approach: Rand and low doso methotrex	iven intr comized st	ratheca	lly for	the treatment of CNS andard dose methotrex
CIIS loukemia,	ace grven	i Tilcia		vol the flexbuent of
		· · · · · · · · · · · · · · · · · · ·	•	
Progress during FY-80: No	WRAMC pa	atients	have be	en entered on this st
Number of subjects to be studential students of subjects to be students. Serious/unexpected side effects of the students of th				
Conclusions: Study remai	ns open			•
Publications or Abstracts, I	Y-80:			

Date: 20 00% 80	Protoco	l No: (5123	Status: Interim	
Title of Project: SWOG PROF Evaluation of Systemic of Childhood (ALinC 1	c Rogimens	523 s in t	the Treatm	Ent of Acute Leukemia	
Starting Date: 14 JUL 8) Estir	nated (Completion D	ate:	
Principal Investigator: Free	derick B.	Ruyma	ann, MD, C	OL MC	
Associate Investigators:		Facili	ty:		
Paul J. Thomas MD, LTC MC Donald Karcher MD, LTC MC Barbara Detrick-Hooks Filliam Neglia MD, LTC MC			Svc		
Key Words: Acute lymphob	lastic lev	ukemia	2	•	
ccumulative MEDCASE Accumulative ost: Cost:			Contract	Accumulative Supply Cost:	
FY-SO MEDCASE Cost:			Periodic Review Results: (to be filled in by DCI)		
Technical Approach: Rando 1) vincristine, prednt intrathecal methoto during maintenance 2) same as 1) 4xcept n 3) vincristine, prednt therapy with methoto	omized stuisone, L-a rexate, 6- adjusted maintenance isone, L-a trexate, h intravered on stu	idy be aspara merca to ke ispara aydrous ady, 1	etween thraginase, captopurine was the was aginase, captisone, methotrexadied duri	ee arms ranial radiation with , methotrexate, drugs C at 3000-4500; 500-3000; ytoxan, intrathecal and cytosine arabinoside, ate, oral 6-mercaptopuring	
Number of subjects to be stu- Serious/unexpected side effe					
Conclusions: Study remain (ALinC 13) is activate	ns open un ed in late	til t	he second or early	Generation study	
Publications or Abstracts, I	Y-80:				

Date: 20 009 80	Protoco	l No: _6124	Status: Interi	in
Title of Project: SWOG PR The Nationa	OTOCOL# { 1 Wilms! !	8000 Tumor Study - 3	• XFINEAY	
Starting Date: 24 MAR 8	o Esti	mated Completion I	Oate:	
Principal Investigator: F	rederick l	B. Ruymann MD,	COL MC	
Associate Investigators: Paul J. Thomas MD, LT	C MC	Facility:		
David McLeod MD, LTC William Neglia MD, LT	MC C MC	Dept/Svc		
Key Words: Wilms! Tumor		ل.	•	•
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accumulative (
WY-80 MEDCASE Cost:			view Results: ed in by DCI)	
Study Objective: To inves histology Wilms! tumo: therapy.	tigate the r with sur	e therapy of dirgery, radiatio	fferent stage and c	d hemo
Technical Approach: Rando (favorable or unfavorable	cin-D for no radiot ensive vir sus 2000 I av)- radia mycin-D, a	10 weeks versu therapy; vincri acristine and a R radiotherapy; ation therapy w adriamycin,c	s 6 months. Stag stine, actinomyc ctinomycin-D. St Chemotherapy sam ith vincristine, ytoxan.	e II in-D, age e as I actin
Number of subjects to be stu Scrious/unexpected side effo				
Conclusions: Study remain	ns open	بيود مستند بيجاف وبينو موافعت في يند في بيدون بيدون	·	
Dublications or Abstracts	FY-80·			

Date: 20 007 00	Protoco	l No: 6125	Status: Interim
Title of Project: SWOG PROSE Evaluation of MOPP Adju Redulloblastoma and Epo	uvant Chei	motherapy in th	FivalX he Treatment of Localized
Starting Date: 18 SEP 80	Esti	nated Completion 1	Date:
Principal Investigator: Fre	ederick B	. Ruymann MD, O	COL MC
Associate Investigators: Paul J. Thomas MD, LTC MC		Facility:	
William Neglia MD, LTC Eugene George MD, COL l		Dept/Svc	
Key Words: Medulloblasto	oma, open	dymoma, chemotl	herapy .
Accumulative MEDCASE Cost:	· ·	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:		Periodic R	teview Results: led in by DCI)
Study Objective: To evaluation therapy plus MOPP (musprednisone, and procarlocalized medulloblasto	targen - i bazine) cl	nitrogen musta hemotherapy in	rd, oncovin - vincristin
Technical Approach: Randoradiaition therapy plus		udy between rad	diation therapy and
Progress during FY-80: No protocol	o WRAMC p	atients have bo	een entered on this
Number of subjects to be stu Serious/unexpected side effe			
Conclusions: Study remain	ins open		
Tablications on Abstracts	UV 9 0-		



Date: 20 OCT 80	Protocol	No: 6126	Status: Interim
Title of Project: SWOG PROTECTION OF Extra-ocul cristine, Adriamycin a	lar Retino	blastoma with (Jinak Cyclophosphamide, Vin-
Starting Date: 14 JUL 80	Estir	nated Completion D	ate:
		Ruymann MD, CC	
Associate Investigators: Paul J. Thomas MD, LTC	. MC	Facility:	
Paul Whitmore MD, LTC William Neglia MD, LTC	MC	Dept/Svc	
Key Words: Retinoblaston	ia, extra-	cular	·
Accumulative MEDCASE Cost:	Accumi Cost:	dative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	enganisa nasasa kan interpreta per se se encanas di na nova antere in septembara antere se sa entanas in	and a second a second and a second a second and a second	view Results: d in by DCI)
Study Objective: To study therapy in the treatme (degree and type of sp	nt of ext		
Technical Approach: Non-managerified for each classified for each classified cristine and cytoxan; cytoxan, adriamycin, itherapy; class 3, 4, a but vary the length of if there is danger of	ss (1-5). class 2 - ntratheca nd 5 use therapy a spread to	Class 1 - chem chemotherapy was the character of the char	otherapy with vin- ith vincristine, erapy, and radiation ents used in class 2 rathecal therapy only id.
Progress during FY-80: On is tolerating the ther	e patient apy very v	has been enter	ed on this study and
Number of subjects to be stu Serious/unexpected side effe			
Conclusions: Study remai	ns open		

Publications or Abstracts. FY-80:

Date: 20 OCT 80	Protocol	No:	5127	Statu	s: Interim	
Title of Project: SWOG PRO Evaluation of Inductio Periodic Reinforcement Loukemia, Phase III. Starting Date: 2 MAY 80	n, Remissi , and CHS	ion Ma	aintenance nylaxis in Completion D	Acute No	NimalX l without on-Lymphocytic	
Principal Investigator: Fre	derick B.	Ruyma	enn, MD, C	OL MC		
Associate Investigators:		Facili	ty:			
Paul J. Thomas, MD, LTC MC William Neglia, MD, LTC MC Donald Karcher, MD, MAJ MC		Dept/Svc				
Key Words: Acute Non-Lym	phocytic I	- Leuk <i>er</i>	nia		•	
Accumulative MEDCASE Cost:			Contract		mulative Supply	
FY-80 MEDCASE Cost:			Periodic Re (to be fille	view Result d in by DCI		
Study Objective: To inves leukemia of vincristin vestigate the effective and intrathecal therap sine arabinoside; to i (VAP) on maintenance t	e, adriamy eness of (y with met nvestigate	ycin, CNS pi thotro	and predn rophylaxis exate, hyd	isone (VA with rad rocortisc	AP); to in- diation therapy one, and cyto-	
Technical Approach: Stand with 6-thioguanine and fails. CNS prophylaxis drug therapy. Randomi 6-thioguanine and ARA-t vincristine, adriamy	cytosine with radi zed mainte C; cytoxar	arabi iatior enance n, vir	noside (An therapy conscription)	RA-C) if and tripl sisting c	VAP induction le intrathecal of cycles of	
Progress during FY-80: Tw died of overwhelming v has achieved a satisfa	aricella i	infect	cion durin	g inducti	on; the other	
Number of subjects to be stu Serious/unexpected side effe						
Conclusions: Study remai						

Publications or Abstracts, FY-80:

the: 20 OCT 80 Protocol No: 6128 the of Project: 5.006 PROTOCOL # 7901 scue Therapy for Non-CHS Extra-medullary Disease the Lymphoblastic Loukemia, Phase III ecting Date: 16 MAY 80 Estimated Completion Date: pincipal Investigator: Frederick B. Ruymann MD, COL Manual J. Thomas MD, LTC, MC filliam Neglia MD, LTC, MC Cey Words: Extra-medullary leukemia	
acue Therapy for Non-CNS Extra-medullary Diseas ute Lymphoblastic Leukemia, Phase III acting Date: 16 MAY 80 Estimated Completion Date: Ancipal Investigator: Frederick B. Ruymann MD, COL Massociate Investigators: aul J. Thomas MD, LTC, MC Illiam Neglia MD, LTC MC Dept/Svc	
sociate Investigators: Frederick B. Ruymann MD, COL Manual J. Thomas MD, LTC, MC Llliam Neglia MD, LTC MC Dept/Svc	
ssociate Investigators: aul J. Thomas MD, LTC, MC Illiam Neglia MD, LTC MC Dept/Svc	ic
aul J. Thomas MD, LTC, MC Illiam Neglia MD, LTC MC Dept/Svc	•
Illiam Neglia MD, LTC MC Dept/Svc	•
Words. Pytra-madullary laukamia	
Jy Words. Extra-modulately reducinta	
ccumulative MEDCASE Accumulative Contract ost: Cost:	Accumulative Supply Cost:
2-30 MEDCASE Cost: Periodic Review (to be filled in	Results: by DCI)
Study Objective: To determine the effectiveness of rolocal areas of extra-medullary, non-CNS leuken	
Pechnical Approach: Non-randomized standard therapy extramedullary leukemia — including kidneys, test cular sites, and bone. Systemic therapy also re	stes, mediastinum,
Progress during FY-80: One patient with T-cell leuke clapse responded well to the radiation therapy tuffered a systemic relapse and died.	emia with a testicul to the testes but
imber of subjects to be studied before completion of study:	
rious/unexpected side effects in subjects participating in proj	
onclusions: Study remains open	The second secon
Francisco (Francisco	•
ublications or Abstracts. FY-80:	

Date: 20 OCT 80	Protoco	l No: 6129	Status: Interim
	FiralXX		
Title of Project: SWOG PRO Multidrug Adjuvant Che Comparison of COMPADRI	motherapy	in Non-metasta	tic Osteosarcoma,
Starting Date: 30 MAY 80	Estir	nated Completion I)ate:
Principal Investigator: Fr	ederick B.	. Ruymann, MD,	COL MC
Associate Investigators: Paul J. Thomas MD, LTC	MC	Facility:	
Monroe Levine, MD, LTC	PC .	Dept/Svc	
Key Words: Osteosarcoma	, chemotho	a erapy	•
Accumulative MEDCASE Cost:	Accumi Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	<u> </u>	Periodic Re	view Results:
			ed in by DCI)
Study Objective: To comp the treatment of osteo	sarcoma (r	non-metastatic)	•
Technical Approach: Rand CONPADRI-I chemotherap adriamycin) versus hig by surgery followed by mycin.	y (cytoxar h dose met	, vincristine, thotrexate for	melphalan, and 7 courses followed
Progress during FY-80: No protocol	o WRAMC pa	atients have be	en entered on this
Number of subjects to be stu	died before	completion of study	• • • • • • • • • • • • • • • • • • •
Serious/unexpected side effe	ects in subjec	ets participating in	project:
Conclusions: Study remai	ins open		
Publications or Abstracts	FV80+	_	

nte: 22 CCT 80	Protoco	ol No: 6 130	Status: Interim
title of Project: SHOG PROT	Final		
Combination Chemothera Encristine, and Cytox	an in Chi	ildren with Ke	s-diamminedicloroplatin tastatic Neuroblastoma,
Marting Date: 1 OCT 80	Esti	mated Completion	Date:
Principal Investigator: Fred	lerick B.	RUymann, MD,	COT JIC
Associate Investigators:	•	Facility:	
aul J. Thomas, MD, LE	C, MC	Dept/Svc	
Key Words: Neuroblastom	a, Stage	IV, chemother	apy .
Accumulative MEDCASE Cost:	Accum Cost:	ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:		a transmission per removal.	Review Results: Ued in by DCI)
four drug chemotherapy			ic neuroblastoma, vincristine, cytoxan,
Adriamycin, and cis-pleatient must have a me	atinum ir	children wit	n stage IV neuroblastom
	· · · · · · · · · · · · · · · · · · ·		
Progress during FY-80: Norotocol.	o WRAMC p	· ~	been entered on this
Number of subjects to he stu			
Scrious/unexpected side effe	cts in subje	ects participating i	in project:
Conclusions: Study rema	ins open		
Publications or Abstracts. 1	FY-80:	but ges	

Date: 20 OCT 80	Protocol	No: (5131	Status: Interim		
Title of Project: SWOG PRO Circulating Immune con	TOUOL # 80	075 Pedia	atric Mali	gnancies		
Starting Date: 1 OCT 80	Estir	nated (Completion D	ate:		
Principal Investigator: Fre	derick B.	Ruyma	ann, MD, C	OL MC		
Associate Investigators: Paul J. Thomas, MD, LTC MC Barbara Detrick-Hooks		Facility:				
		Dept/	Svc			
Key Words: Immune compl	exes, mal	ignan	су			
Accumulative MEDCASE Cost:	Accumulative Contract Cost:		ľ	Accumulative Supply Cost:		
FY-80 MEDCASE Cost:				view Results: d in by DCI)		
Study Objective: To measure before therapy, during in pediatric patients acute non-lymphocytic	the cour with acut	se of e lym	therapy, phocytic 1	and after therapy eukemia, neuroblastoma		
Technical Approach: Serum for presence of circul with type of disease, with the immune complete	ating imm therapy g	une co	omplexes.	and correlation		
Progress during FY-80: No study.	yRAMC pa	tient	s have yot	been entered on this		
Number of subjects to be stu						
Serious/unexpected side effe	ects in subjec	ets parl	icipating in p	project:		
Conclusions: Study rema	ains open					

Publications or Abstracts. FY-80:

***************************************	Protocol	No: 7111	Status: lotturion
Title of Project: Interrupti			Final Final
Starting Date: 15 Oct 77	Estim	ated Completion I	Date: 30 Sep 80
Principal Investigator: R. F	arlan Briden	oauch, COL, MC	
Associate Investigators:	1	Facility:	
Jamas G. Hunter, MAJ, MC Robert L. Bank, MAJ, MC		Walter Reed Arr	ny Medical Center
Robert L. Bank, MAO, HC	· [1	Dept/Svc Psychia	atry
Key Words: Prolactin; ileur	oleptic Thera	npy; Discontinua	nce
Accumulative MEDCASE		ative Contract	Accumulative Supply
Cost:	Cost:		Cost:
FY-80 MEDCASE Cost:		Periodic Re	eview Results:
		(to he fills	ed in by DCI)
logical functioning by sta	atic evaluati ndardizēd rai	ion of patient's ing scales. Ho	mental status and psycho-
ievers during tapering and		icinuance of mate	itenance neuroleptic therapy.
ievels during tapering and		itinuaner of matr	itenance neuroleptic therapy.
			itenance neuroleptic therapy.
		continuation she	itenance neuroleptic therapy.
Progress during PY-80:	See attached	continuation she	See attached continuation shee

Protocol No: 7111 "Interruption of Maintenance Meuroleptic Therapy"

Progress during FY-80: Three (3) more patients were entered into the study during FY-80, bringing the total number of subjects to six (6). Two patients were unable to maintain remission without neuroleptics (one was hospitalized and the other was re-started on neuroleptic therapy as an outpatient). The third patient became hypomanic and responded to lithium carbonate. Prolactin levels for patients from FY-80 are pending on samples that had been kept frozen at -70° C. Values from patients studied in FY-73 were within the normal range but did show a small decline, within the normal range, in relationship to tapering doses of neuroleptics. The sample of subjects is too small to compare different rates of tapering medication. The project was of heuristic value in that prolactin level determinations are now routinely used within the department to assess patient compliance and/or degree of bioavailablility of prescribed neuroleptics.

Number of subjects to be studied before completion of study: NA; project terminated due to reassignment of Principal Investigator.

Date: 6 Oct 30	Protoco	l No: 7214	Status: x'h g'agiga
Title of Project: Pre- and	P ost-Di schar	ge Assessment of F	Psychiatric Patients
Starting Date: Jan 77	Estir	mated Completion D	late: Sop 80
Principal Investigator: Don	ald W. Morga	n, COL, MC	
Associate Investigators:	L, iic	Facility: Walter Reed A	rmy Medical Center
Enmanuel G. Cassimatis, L Charles R. Privitera, LTC		Depi/Svc Psychia	atry
Key Words: psychiatric	patients; ME	ם B; follow-up	
Accumulative MEDCASE Cost:	ľ	ulative Contract	Accumulative Supply Cost:
FY-S0 MEDCASE Cost:	, and an estimate of the state		eview Results:
structured method of asse function of psychiatric p compare pre-discharge mor patients seen by an HEB. Technical Approach: From HEB were entered into the were obtained while still every three months by mai vocational functioning after departing WRAMC. Progress during FY-80:	atients seen bidity with Jan 77 to Au study. Bas on an inpat led question Follow-up fo	by a Medical Evaluation post-discharge fur grand	luation Board (MEB); to action of psychiatric tive patients seen by an all and demographic data ients have been followed enotional and social-t was terminated two years
Number of subjects to be st	udied before	completion of study	r: 200
Serious/unexpected side ell			
Conclusions: It is feasib specific information conc are systematically assess	erning outco	patients by mail me will be availab	questionnaire. Hore ble when the questionnaire

Protocol No.: 7214 "Pre- and Post-Discharge Assessment of Psychiatric Patients"

Progress during FY-80: The return rate for the questionnaire has been approximately 85%. Three patients have committed suicide. A ride range of outcomes are thus far apparent with about one-third of the group expaniencing rehospitalization thus far. We have completed the operational phase and the periodic mailing of questionnaires. Examination of the information obtained is approximately one-third completed. Preparation of final report is planned in the next 12 months.

Date: 6 Oct 80	Protoco	No:	7217		Status: Liveulia	i
Title of Project: Management Secondary	of Impairm to Psychotr			ion	Pinel	
Starting Date: 15 Apr 78	elstin	unted C	Completion 1)ate: 3	0 San 80	
Principal Investigator: R. H	arlan Bride	nbaugh	, COL, NC			
Associate Investigators: Richard J. Sapolis, MAJ, A	!IC	Facili	ty:	eed Ar	my Nedical Center	
Daniel L. LaDuke, CPT, ANC Hary Barbara Papineau, CPT		Dept/S	Svc Psychia	atry		
Key Words: Blurred Vision	; Anticholi	l nergic,	/Psychotrop	ic Med	ication	
Accumulative MEDCASE Cost:	Accum Cost:	ulative	Contract		Accumulative Supply Cost:	
FY-SO MEDCASE Cost:			Periodic Re (to be fille		Results: y DCI)	
secondary to the anticholicants, and anti-Parkinson a management of such impairm (3) to examine the relation impairment of accommodation. Technical Approach: Patienticholinergic action were If blurring of vision was patient was tried on the diofinal strength of glasses of medication was recorded intervals. Progress during FY-80: Number of subjects to be studential strength of glasses of medication was recorded intervals.	gents; (2) ent seconda nship between. Ints who were e evaluated noted at a pter eyegla dispensed w and monito See attack died before	to evalue to to en dosa e receiby meanormal sses in as detered and comple	luate the entry above partial payents of a new reading distribution of a new partial patients within attion of study	ffecti sychot cation otropi ar vis stance g incr patien were r sheet.	veness of optical ropic agents; and and degree of agents that have ion reading card. (16" to 20"), then ements of +0.5 dipoter. t choice alone. Level a-evaluated at weekly	
Conclusions: Blurring of tropic agents is very previous mediate management is the reading glasses. Publications or Abstracts, line.	same as for	the ar acute presby	nticholinero treatment p vopia, i.e.	gic ac psychi , the	tion of certain psycho- atric ward. The im- application of +dipoter	

Protocol No: 7217 "Hanagement of Impairment of Accompodation Secondary to Psychotropic Hedication"

Progress during FY-30: dineteen (19) patients were formally entered into the project in 1978 and a large number of patients, oaver 30, were issued eyeglasses but not entered into the study. Screening was completed in June 1978 on Ward 198 on all patients receiving psychotropics with anticholinergic effect. Two-thirds of this sample showed evidence of impairment of accormodation. The results of this study were presented to the annual Department of Psychiatry Research Symposium in June 1978. Also, the results of this study have been used by the Principal Investigator in the teaching of psychopharmacology. A final report is being prepared at the present time and will be submitted through appropriate channels upon completion of same.

Number of subjects to be studied before completion of study: Wineteen (19) patients were studied in 1975. No further study is planned.

Date: 6 Oct 80	Protocol	l No: 7213	Status: Interim
Title of Project: Physostigm	ina Infusio	n and Lithium Res:	ponsivity
			•
Starting Date: 25 Feb 30	Estir	nated Completion L	Date: Jun 31
Principal Investigator: Pau	l Hevinouse,	CPT, HC	
Associate Investigators: R. Harlan Bridenbaugh, COL	, i1C	Facility: Walter Reed Arm	ny Medical Center
Robert Watson, COL, MC		Dept/Svc Psychi	atry
Key Words: Physostigmine-	lithium resp	ponsivity	
Accumulative MEDCASE Cost:		ulative Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:	and the state of the state decreases the desire of the state of the st	Periodic Re	eview Results: ed in by DCI)
*Study Objective: To examine infusion and to determine istatus changes.	e the menta if lithium i	l status changes i responsivity is re	nduced by physostigmine lated to such mental
*Tochnical Approach: patier for 43 hours with no neurol (one placebo, one physostic ized, double-blind, crossov ade while undergoing the i	ieptic medic gmine - 4 mo ver design.	cation. Patient t J.) on two separat Systematized rat	dien receives two infusion te days utilizing a randon tings of mental status are
*Progress during FY-80: Se	ee attached	continuation shee	et.
Number of subjects to be stu Serious/unexpected side effe			
Conclusions: None.	-		
			. •
That it was an Abrit of the	est en. Hor	10	

Protocol No.: 7213 "Physostigmine Infusion and Lithius Responsivity"

Progress during FY-80: One patient has been entered into the study. Two patients nave declined participation. Hultiple factors, including recent reassignment of an Associate Investigator (RHB), have impeded progress on this protocol, and as of this date it is doubtful that further work is feasible. However, the Principal Investigator desires to keep protocol extant in the event other associate investigators can be obtained.

Date: 6 Oct 80	Protocol	l No: 7219	Status: XX40	1957.54
Title of Project: Reliabili	ty of Serum	Tricyclic Antidep	ressant Lavels	nol
Starting Date: 6 Oct 79	Estir	nated Completion 1	Date: "Inv /9	
Principal Investigator: Robe	ert L. Bank,	MAJ, MC		
Associate Investigators: R. Harlan Bridenbaugh, COI		Facility:	my Medical Cente	<u> </u>
		Dept/Svc Psvchia	trv	
Key Words: Antidepressant	, tricyclic	~4		•
Accumulative MEDCASE Cost:	į.	alativo Contract	Accumulati Cost:	
FY-80 MEDCASE Cost:		Periodic Refuse fills	oview Results: ed in by DCI)	
Study Objective: To examine of serum tricyclic antide	e the reliabi pressant leve	ility and validit	y of laboratory i	reporting
Technical Approach: 20 co line. 4-5 ml. serum sampl laboratories offering anal	es were main	rea simurcaneousi	rom patients taki y to two differer	ing amitript nt commercia
	e de la companya de l			
Progress during FY-80:	See attached	l continuation sh	eet.	•
Number of subjects to be str Sections/unexpected side effe				
Conclusions: Until further ing tricyclic antidepressatith caution. Publications or Abstracts,	nt blood lev	els, such blood	ovided by laborat levels should be	cories offer interpreted

Protocol No: 7219 "Reliability of Serum Tricyclic Antidepressant Levels"

Progress during FY-30: Seven (7) patients were entered into the study. Levels determined by each of the two labs were in fair agreement in the lower range (50 to 150 ng/ml). However, one patient's levels were returned as 553 ng/ml vs. 191 ng/ml (both these are in the higher therapeutic range). The second part of the study (i.e., to send sequential, identical serum samples to the same lab) was not undertaken because of the relatively poor correlation of results noted between the two labs.

Date: 6 Oct 80	Protocol	No:	7220	Status: XXXVIII
Title of Project: The Davelo	pmental Sign	nifica	nce of Trans	Final sitional Objects
Starting Date: 3 Har 30	Estin	rated C	Completion D	nte: 31 Jun 30
Principal Investigator: Jame	es G. Hunter,	, MΛJ,	!1C	
Associate Investigators: R. Harlan Bridenbaugh, COL	., MC	Facili <u>!</u> al	•	nv Medical Center
		Dept/	Sve Psyc	chiatry
Key Words: Transitional of		tric c	linic/child	psychiatry clinic
Accumulative MEDCASE Cost:			Contract	Accumulative Supply Cost:
FY-80 MEDCASE Cost:			Periodic Re	wiew Results:
		a pa pro aalla l-	(to be fille	ed in by DCI)
Study Objective: (a) to co in a general pediatric pop objects in the same age gr (b) to correlate the prese assessment of problem beha- Behavioral Rating Scale.	oulation, age roup in an ou ence or absen	es 6-1 utpati- nce of	O, with the ent child ps transitiona	sychiatric population; and all objects with maternal
Technical Approach: Nother either the pediatric or chaires that polled demogra	rild psychiat	ry cl	inic were as	ked to complete question-
Progress during FY-80: Que pediatric clinic and by 25 were placed on flow sheets coxon Rank Sum Test was us Investigator presented research Symposium on 13 G	mothers in and statisticed to compare sults of the	the c tical re the	hild psychia evaluation w two clinic	atry clinic. Results was completed. The Wil-
Nursher of subjects to be sh	ulied before	comple	ction of study	: See "Progress during EV.80"

Conclusions: The presence or absence of a transitional object, as reported by maternal polling, has no relationship to the presence of psychopathology as measured by the behavior symptom checklist employed in this study.

Publications or Abstracts, FY-80:

ilone

Paper presented to Annual Department of Psychiatry Research Symposium

Serious/unexpected side effects in subjects participating in project:

Date: 12/1/80	Protoco	1 No:	7221	Status: In	terim X
Title of Project:				Fi	nal
"The Effect of Hypr of Low, Medium and				etroencephalogra	ım
Starting Date: June 1980	Estir	nated (Completion I	ode: February 19	181
Principal Investigator: Har	old J. Wain	, PhD			
Associate Investigators: - Glenn Harper, MD		Facili	ty: WRANC		
Bahaman Jabbari, MD		Dept/	````	ment of Psychiat ogy Service	ry
Key Words:	and the second s	4			•
Accumulative MEDCASE Cost:	Accumi Cost:	Motive	Contract	Accumulati Cost:	
FY-80 MEDCASE Cost:				eview Results:ed in by DCI)	
Study Objective:	**************************************				
To explore the effects of of low, medium and high hy induction of a hypnotic tr	pnotic capa				
Technical Approach:					
Each subject is to be eval then placed in low, medium taken on one occasion before	and high h	ypnoti	c groupings	. BEG recording	s are then
Progress during FY-80:					•
Six subjects have been eva	luated as o	f this	date.		
Number of subjects to be stu- Serious/unexpected side effe					
Conclusions: Cannot draw c	onclusions	at thi	s time.		*******

Publications or Abstracts, FY-80:

Date: 10 OCT 1980	Protocol No: 7300	Status: Interim X
Title of Project: LSD Follo Normal	ow-Up Study (Establishment of Controls for Neurophyscholog	f <u>Final</u> gical Examination)
Studing Date: October 197	8 Estimated Completion	Date: Uctober 1983
Principal Investigator: Fra	ncis J. Fishburne, Jr., LTC,	MS
Associate Investigators:	Facility: Walter	Reed Army Medical Center
	Dept/Svc Psycho	logy Service
Key Words: Neuropsycholo	gical Examination, Normal Co	ntrols
Accumulative MEDCASE Cost: \$0	Accumulative Contract Cost: \$0	Accumulative Supply Cost: \$0
FY-30 MEDCASH Cost: So		eview Results:
	n approximately seventy-five valuation to compare with LSD	
· .		
examination, electroence (CATSCAN). Computerized	ects were to be screened wite phalography, and computerize laxial tomography support pain of the screening has bee	daxial tomography rovided by NIH has been
Progress during FY-80: T a current total of 37 no	en volunteer subjects have b ormal control subjects evalua	een evaluated providing ted.
Number of subjects to be st	udied before completion of stud	v: 75
Scrious/unexpected side effe	ects in subjects participating in	project: NONE
Conclusions: N/A	and a reason that the section of the	and the second s

Publications or Abstracts, FY-80: NONE

1.34

Work Unit No.: 7300

Title of Project: LSD Follow-Up Study (Establishment of Hormal

Controls for Neuropsychological Examination)

Investigators: Francis J. Fishburne, LTC, MSC

<u>Objectives</u>: To obtain base rate values of a neurologically screened normal adult population with respect to the Halstead-Reitan neuro-psychological battery.

Technical: Volunteer subjects are first screened using a clinical neurological examination, electroencephalography, and computerized axial tomography (CAT scan). Subjects who are normal on all screening procedures are then administered the Halstead-Reitan neuropsychological battery.

Progress and Results: Thirty-seven (37) subjects have been evaluated to date.

Conclusions: Deferred.

Funds Utilized: None

Funding Requirements, FY-81: None.

Publications: None.

Type of Report: Interim.

9 October 1930 Protocol No: 7301 Interira Date: Wille of Project: Baseline MMPI Profile for an Active Duty Military Population Estimated Completion Date: October 1931 Starting Date: 3 January 1980 Principal Investigator: Francis J. Fishburne, Ph.D., Chief, Psychology Service Facility: Walter Reed Army Medical Center Associate Investigators: Bruce R. Lockwood, Ph.D. Thomas W. Waddell, Ph.D. Psychology Service Dept/Svc Department of Psychiatry Key Words: MMPI, Military Norms Accumulative Supply Accumulative MEDCASE Accumulative Contract Cost: NONE Cost: \$1,550 Cost: \$1,574 TY-80 MEDCASE Cost: MONE Pariodia Review Results: (to be filled in by DCI) Study Objective: To obtain normative data for an active duty military population on the various scales comprising the Minnesota Multiphasic Personality Inventory, an objective personality assessment device frequently used by mental health professionals. It is expected that the normative data will be collected from approximately 5,000 active duty military personnel. Technical Approach: The technical approach remains unchanged in terms of the experimental instruments being utilized; however, some modification has been made in the order in which the instruments will be administered. Following the explanation of the research project and the subjects' signing of the volunteer agreement form, each subject will be administered the MMPI, the Shipley Institute of Living Scale, and a background information questionnaire, in that order. The experimental data will be collected in one session of approximately two hours in Forderess during FY-80: Experimental procedures have been devised in detail and the testing materials necessary for the project have been acquired. Two pilot projects, totaling 50 subjects, have been conducted to test the feasibility and

practicality of the research design, with the experimental procedures being (see next

NONE

MONE

Serious/unexpected side effects in subjects participating in project:

Number of subjects to be studied before completion of study: 5,000

Conclusions: Undetermined

Publications or Abstracts, FY-80:

Progress during FY-80: (Continued)

determined to be effective, with minor alterations in the details of the administration of the materials. A contract with a civilian service provider has been made for the scoring of the MMPI data to be collected during the study. It is anticipated that actual data collection will be begun in approximately one month.

CLINICAL INVESTIGATION PROGRAM

7301 Work Unit No.:

Funds Utilized, FY-80: \$3,124

Funding Requirements, FY-81:

Personnel: NONE

Equipment: NONE

Supplies: Xerox paper, pencils, and other miscellaneous costs: \$1,000

Presentation of paper at American Psychological Association Travel:

convention in Los Angeles, California: \$1,000 approximately

Contracts for service (MMPI scoring by computer): \$1,550 Other:

Publication and reprints: \$500

Date: 10 Oct '80	Protoco	l No:	9010		Status:	Interim	X
Title of Project: Villegic Patients with sides	6 actabolism Oblastic and		atients res	elving	Tivri erro	Finel i	
Starting Date: Sep 7h	Estin	mated	Completion	Date:	Dec ! 81		
Principal Investigator:	John A. Karl	k, LTC	, MC .				
Associate Investigators: MJ Haut, LTC, MC retir	ed.	Facil	ity: Hematol WRAIR,	ogy, I WRAMC	nternal	Medicine	:
GS Schechter, MD, Chie Washington V.A. Hosp.	f, Hem-Onc.	Dept/	Svc 1. Hem	/Med W	RAIR, C	.I.S., WR	AMC
Key Words: Vitamin Bo, Re	d Cells, Iso	1 oniazi	d, Siderobl	astic	Anemia		•
Accumulative MEDCASE Cost: none	Accumi		Contract e		Accumu Cost:	lative Sur none	ply
FT-80 MEDCASE Cost:	none	ده مدین اور اور اور اور اور اور اور اور اور اور	Periodic II (to be fill				*******
1. To improve to 2. To identify anemia.						sideroble	stic
Technical Approach: 1. P. chromatography and the ef 2. Previous data was coldrafted. 3. Plans were made to put. Plans were made to put anemias. Progress during FY-80:	fects of her lated, analy rsue measure	moglob yzed, ements	in binding illustrated of INH met	on kind, and abolit	etics wo manuscr: es in pa	ere defin ipts were atients.	!
1. The effect of pyrid	oxal binding ajor papers					inase kin	etics
Number of subjects to be stu							
Serious/unexpected side effe Patient involvement is	only to do:	ns par nate s	ticipating in mall venous	projec blood	et: L sample	s. None	
Conclusions:	<u></u>						

1. A rapid method of analysis of crythrocyte pyridoxal kinase activity was diveloped. 2. Dissociation of biochemical and hematologic responses to B6 were Publications or Abstracts, FY-80: found in the sideroblastic anemias.

see next page.

9010

John A. Kark, LTC, MC

Publications: none completed in FY '80.

The following manuscript has been completed and will be submitted in the next month: Kark, J.A., Haut, M.J., et. al. A rapid flurometric assay for erythrocyte pyridoxal kinase activity.

The following manuscripts are written in draft:

- 1. Dissociation of erythrocyte pyridoxal phosphate levels and hematologic response to vitamin B6 in the sideroblastic anemias.
- 2. Erythrocyte metabolism of vitamin Bg in the sideroblestic anemias.

(Authors: Kark, J.A., Haut, M.J., and Schechter, GS.).

Funding:

Funds utilized, FY-80: none

Funding requirements, FY-81:

Personnel:

GS-09 10 hours

Supplies:

\$1,000

			Wo	ork Unit #	9012	
DATE: 30 september 1980 Properties of FECSECT: The Effect of Erythroid Colony Formation in t	Infect	ious Hepati	tis on [literi. Final X	
STARTING BATE: PINGIPAL INVESTIGATOR: MAJ AUG ASSOCIATE INVESTIGATORS:	ust J.	FACILITY:	D. MG Water Le			
MAJ William M. Butler, M.D. MC LTC Jeffrey L. Berenberg, M.D. Nancy Josza		SERVICE:			g cine	
KEY WORDS: Infectious Hepatitis ACCUMULATIVE MEDUASE COST:	, Plasm	a Clot Cult PLATIVE CONT	ore System	ACCUMULA	TIVE SUPPI	<u>.Y</u>
FY-80 MEDCASE COST:		PERIODIC I	HATTE BEST			interestant agg
STUDY OBJECTIVE: To determine progenitors (CFU-E and BFU-E) i of this injury.	whether n the b	the hepati	tis virus and to cla	injures arify the	erythroid mechanism	3
TECHNICAL APPROACH: The plasma used to determine colony growth acute hepatitis. Normal controllaving marrows done as part of	of CYU 1 marro	-K and BFU- w is obtain	K from man ed as an e	now of particle asp	atients wi	th :
						•
PROGRESS DURING FY-80: This pr problems with erythropoietin su hepatitis had been studied, the with no evidence of a secum sup and continues to be followed in	pply an s patie pressor	d loss of one showed not showed not be the had not be the had not be the had not be the best of the best of the had not be the best of the had not be the best of the had not be the best of the best	ur technic ormal BC o problems	ian. On progenit with th	e patient or growth:	in culture
NUMBER OF SUBJECTS TO BE STUDIE SERIOUS/UNEXPECTED SIDE EFFECTS						
CONCLUSIONS:						-

570

None

None

PUBLICATIONS/ABSTRACTS, FY-80;

Date: 10 Oct 185	Protocol	l No: 9016	Status: Interim X
Title of Project: Pyridoxine	e as a treat	ment for sickle he	Final
Starting Date: June '77	Estir	nated Completion Da	te: Aug 81
Principal Investigator:	John A. Karl	c, LTC, MC	
Associate Investigators: L.S. Lessin, MD, Pro		,	ol lab, WRAIR en. lab, WRAMC
R. Bongiovanni, CPT	, MSC	Dept/Svc 1. Hem/Me	ā WRAIR, C.I.S., WRAMC
Key Words: Sickle Cell Dis	sease, Pyrid	Noxine, Red Blood C	ells .
Accumulative MEDCASE Cost:	Accumi Cost:	ulative Contract	Accumulative Supply Cost: \$6,194.25
FY-30 MEDCASE Cost:		Perfection Red (to be filled	iew Ite, olts: in by DCI)
Study Objective:			
1. To define the eff	fect of pyri	doxine on erythroc	yte sickling in vitro.

'Technical Approach:

- 1. Antisickling effects of pyridoxal were contrasted with pyridoxine.
- 2. Most of the active work on this project, in vitro, was transferred to protocol #9019.
- 3. LS Lessin studied the effect of pyridoxine on red cell filterability.

Progress during FY-80:

1. Increased filterability was demonstrated for pyridoxine-treated sickle cells.

Number of subjects to be studied before completion of study:

Serious/unexpected side effects in subjects participating in project:

None: at present, only participation is donation of small venous blood samples. Conclusions:

1. Pyridoxine has some antisickling activity by an unkown mechanism.

Publications or Abstracts, FY-80:

1. Abstract. 2. One publication 3. Patent application award.

Abstract: Kark, JA, Hannah, JS, Hicks, CU, Bongiovanni, R., Lessin, LS, and K. Hayes. Vitamin E6 aldehydes as potential antisickling agents. Fifth International Red Cell Conference, Ann Arbor, Michigan, Sep. 80. not published.

Publications: Some of our data was included in a review: Kark, J.A. and Lessin, L.S. Sickle Cell Disease and Variants in Hematology and Oncology, M. Lichtman, editor. Grune & Stratton, Inc., New York, N.Y., pp 89-97, 1980.

Patent application. A US Gov. patent was submitted by the Military patent office. An award for a supported patent application was received by John A. Kark. The patent application has not yet been acted upon.

Funding:

Funds utilized, FY-80: \$6,194.25

Funding requirements, FY-81: GN 00 ideas/ok

Supplies: \$1,000

Travel: 500

	Protocol	No: 9019	Siatus:	Interim	<u>X</u> .
Title of Project: Antisickl	ing agents:al	teration of hemo	globin oxygen	Final affinity	
Starting Date: Aug. 1979	Estima	ated Completion D	atu: Aug 82)	
	hn A. Kark, L	TC, MC	•		
Associate Investigators:		Facility: Hematol Biocher	l. lab, WRAIR n. lab, WRAMC		
R. Bongiovanni, CPT L.S. Lessin, MD, Prof. Me		Dept/Svcl. Hem/Me	ed WRAIR, C.I	.s., WRAM	C
Key Words: Antisickling	agents, red c	ells, hemoglobin,	, oxygen affi	nity, Sic	kle C
Accumulative MEDCASE	1	ative Contract		lative San	
FY-80 MEDCASE Cost:	nme		view Results:		
		(to be title	d in by DCI)		
Study Objective:			-		 -
1. To compare and phosphate. 2. To	develope safe bading of sick g was determing ied gas tension	antisickling action prophylaxis for the cells with Prophylaxis as a function	evity of pyrisickle trait P was follow of PO2 and	soldiers ed by HPL PLP load	С. by
1. To compare and phosphate. 2. To describe to the compare and phosphate. 2. To describe the compare and phosphate. 2. To describe the compare and phosphate. 2. Let the compare and the compa	cading of sich g was determined gas tension loading.	antisickling action prophylaxis for the cells with Prophylax as a function one and examination was defined for	ivity of pyrisickle trait P was follow of FO2 and on of fixed	soldiers ed by HPL PLP load sickle ce	С. by
1. To compare and phosphate. 2. To describe the phosphate. 2. To describe the phosphate. 2. To describe the phosphate. 1. Let a propose the phosphate to the phosphate to the phosphate to the phosphate to the phosphate to the phosphate to the phosphate to the phosphate	cading of sich g was determined gas tension loading.	antisickling action prophylaxis for the cells with Prophylaxis and examination and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations and examinations are made with oxygonic prophylaxis.	ivity of pyrisickle trait P was follow of FO ₂ and on of fixed varied PO ₂ b	soldiers ed by HPL PLP load sickle ce	С. by
1. To compare and phosphate. 2. To or phosphate. 2. To or phosphate. 2. To or phosphate. 2. To or phosphate. 2. Percent sickling tonometry under variety under variety with or without PLP Progress during FY-80: The antisickling act above assay, and continuous of subjects to be strength.	cading of sich cading of sich gwas determined gas tension loading. tivity of PLP crelations were added before considered sin subjects	antisickling action prophylaxis for all cells with Prophylaxis and examination and examination was defined for the made with oxygonnpletion of study; a participating in participating in property and complete the c	ivity of pyrisickle trait LP was follow of FO2 and on of fixed varied PO2 by an affinity.	ed by HPL PLP load sickle ce	C. by
1. To compare and phosphate. 2. To or the compare and phosphate. 2. To or the compare and phosphate. 2. To or the compare and	cading of sich cading of sich gwas determined gas tension loading. tivity of PLP crelations were adied before constitution involved.	antisickling action prophylaxis for all cells with Prophylaxis and examination and examination was defined for the made with oxygonnpletion of study; a participating in participating in property and complete the c	ivity of pyrisickle trait P was follow of PO2 and on of fixed varied PO2 be affinity.	ed by HPL PLP load sickle ce	C. by lls

Publications or Abstracts, FY-80:

1 abstract, 1 manuscript in preparation:next sheet

Protocol #9019

JOHN A. KARK, MCC, MC

Publications FY '80:

- 1. Abstract: Inhibition of erythrocyte sickling by pyridoxal phosphate. Kark, JA, Hicks, CU, and Bongiovanni, R. Clin Res 28: 315A, 1930.
- 2. Manuscript in preparation:

 Kark, Bongiovanni, and Hicks. Inhibition of erythrocyte sickling
 by pyridoxal phosphate.

Data collection for this paper is complete, and data analysis is 85% complete.

Funding:

Looding requirements:

Personnel: GS-09 20 bra

Supplies: \$6,000

Travel: 500

Other: 500

DISPOSIMON FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

SGRD-UWH-B

Report on Annual Progress Reports for FY80

79THRU: Ch, Dept of Hematology FROM Dept of Hematology

DATE 5 Jan 8

CMT 1

Dir, Div of Medicine

LTC Kark/jp/6-3040

TO:

Ch, Clinical Investigation Service

WRAMC

1. Work Unit #9019

- a. As you probably know, the first phase of this work is completed and is being written up. We have demonstrated that PLP inhibits sickling effectively in vitro, have defined the conditions required for loading of sickle cells and normal red cells with PLP, and have determined the mechanism of action of PLP in contrast to pyridoxal as antisickling agents in the intact red cell. This data is well summarized in the abstracts written prior to this report and the most recent abstract.
- b. However, it should be clear to you that the mext phase of this work will begin when the two papers are completed and submitted to J Lab Clin Med and J Clin Invest. Our scheduled deadline is to submit these papers by the end of January, 1981.
- c. The next phase of this work, which has been outlined in the protocol is to analyze the exact site of modification on the hemoglobin molecule and to correlate the site of modification with changes in oxygen affinity and antisickling effect. We have reason to believe there is an important, interesting correlation between these two parameters. Since this work is active and substantial, I don't understand why you feel this work unit is nearly completed. However, if you would prefer, I could write up the second phase of the work as a new protocol and terminate this work unit. At the present, I can't see any advantage to doing this: but only additional paperwork for the same end result.

2. Work Unit #9020

- a. The data collected, and referred to in the abstracts, includes data on changes in oxygen affinity. This data collection is largely complete. We have been working this month, nearly full time, on a complete definition of changes in oxygen affinity for red cells loaded with PLP. Definitive experiments for the first phase of the work will probably be completed by 15 January 1980, and will be written up and submitted for publication within the first quarter of 1981.
- b. However, as indicated for Protocol #9010, the next phase of this work will be to correlate changes in oxygen affinity with the exact site of modification on the hemoglobin molecule. This will involve preparation of borohydride-

DA ::::.. 2496

REPLACES DD FORM 96, WHICH IS OBSOLETE.

SGRD-UWH-B

SUBJECT: Report on Annual Progress Reports for FY80

5 Jan 81

reduced modified globin, separation of alpha from beta globin, digestion of globin chains to peptides, and analysis of modified peptides and amino acids. This is a substantial piece of work, which will be dealt with in a separate series of papers. It is covered by this protocol. However, if you prefer that we submit new protocols. we certainly could do this.

Summary. The first phase of work outlined on both protocols is nearly completed. and 75% of it is written in rough draft. We are preparing about five papers which will cover this data. The second phase of the work, to be done during fiscal year 81, is covered in these protocols. I don't see any advantage to submitting new protocols to cover this work. However, you understand the administration of funds and personnel better than I, and it may be preferable to submit new, updated applications. If so, please request this, and I will comply in February.

John a. Krist

JOHN A. KARK, M.D.

1TC, MC

Vent of Hematology

Date: 10 Oct 80	Protocol No: 9	020	Status: Interim X		
Title of Project: The effect oxygen af	ts of B ₆ aldehyde finity	es on red cel	Final 1		
Starting Date: Aug 1979	Estimated C	Completion Da	ite: Aug 1981		
Principal Investigator: Jo	hn A. Kark, LTC,	MC			
Associate Investigators:	Facili	Facility: 1. Biochem. Lab, WRAMC 2. Hematol. Lab, WRAIR Dept/Svc 1. C.I.S. 2. Hematol., WRAIR, WRAM			
R. Bongiovanni, CPT, MSC L.S. Lessin, M.D., Prof M GWUSM	ed. Dept/S				
Key Words: Vitamin B6, Red	Blood Cells, Oxy	gen Affinity	, Hemoglobin		
Accumulative MEDCASE Cost:	Accumulative Cost:	Į.	Accumulative Supply Cost: \$1,886.00		
FY-SO MEDCASE Cost:			view Results: l in by DCI)		
Study Objective:					

- 1. To compare and contrast the site of binding with hemoglobin and the effect on oxygen affinity for pyridoxal and pyridoxal phosphate.
- 2. To develope a procedure for correction of the red cell storage defect in oxygen affinity of hemoglobin.

Technical Approach:

- 1. 14-C-pyridoxal was prepared and cleaned up by HPLC.
- 2. 14-C-pyridoxal was used to validate a simple Bio-Rex HPLC assay for modified hemoglobin.
- 3. Rate of modification of intracellular hemoglobin and stability of the \cdot adduct in the red cell was tested using these methods.
- 4. An improved HPLC method for separation and analysis of vitamin B6 compounds Progress during FY-80: was devised.
- 1. An improved method for synthesis of 1\hat{1}-C-pyridoxal was devised. 2. The rate and extent of modification of hemoglobin with pyridoxal was measured, and stability Number of subjects to be studied before completion of study: waknown: now involves only

Serious/unexpected side effects in subjects participating in project: small venous blood donati None possible: protocol involves small venous blood donations.

- Conclusions: 1. Pyridoxal reacts with red cells with a t1/2 of 20 min. are stable in the cell for several days.
- 2. Improved techniques for analysis of B6 in blood and for identificatio of hemoglobin binding sites are operational. Publications or Abstracts, FY-80:

Protectl # 9020

John A. Kack, WC, MC

Publications and abstracts, FY'80.

Abstract: Kark, J.A.Hicks, C.U., and Bongiovanni, R. Modification of intracellular hemoglobin by vitamin B₆. Blood 54: (Suppl 1): 55a, November '79. Manuscripts in preparation:

- 1. Kark and Bongiovanni. Preparation of 14-C-myridoxal.
- 2. Bongiovanni and Kark. An improved HPLC assay for the B6 compounds.
- Modification of intracellular hemoglobin with pyridoxal.
 Kark and Bongiovenni.

Date collection is complete for these 5 papers.

Funding:

Funding utilized, FY-80; \$1,886.00

Funding requirements, FY-81:

Personnel: GS-09 20 hours

Supplies: \$6,000

Other: 500

Travel: 500

Work Unit No.: 9021

Title of Project: Human Marrow in Mouse Chimera

Investigator: COL William H. Crosby, M.D.

Starting Date: Use of human tissue has not yet begun. Preliminary animal

studies are in progress. Estimated start up for use of

human tissue is 1 January 1981.

Estimated Date of Completion: 1 July 1981

Objective: To establish proliferating human marrow tissue in mice after

ablative total bod; radiation.

Key Words: Marrow Transplantation

Heterologous Transplantation

Technical Approach: A core of donor marrow is placed in a pouch beneath the

abdominal stem of a mouse. Ten days is allowed for vascularization of the graft. The mouse is subjected to irradition: 900 r from a Cs source. Immediately thereafter a transfusion of 10^8 donor marrow is given intravenously intending to populate the grafted marrow

issue.

Progress and Results: We have succeeded in transplanting rat marrow into mice,

but the marrow tissue has not survived, apparently

because of local infection.

Conclusion: Rat-in-mouse chimera has been accomplished previously. Survival

of implanted marrow tissue has not been previously attempted. Until we accomplish this in the rat-mouse model, we shall not

attempt to work with human tissue.

Publications: None.

Work Unit No.: 9022

Title of Project: Iron Tolerance Test

Investigators:

Principal: COL William H. Crosby, M.D.

Associate: SSG Darrell D. Ford

Starting Date: 9 April 1980

Estimated Date of Completion: 1 July 1981

Objectives: To determine if a small dose of oral iron (20 mg) can cause a change in the plasma iron concentration; effect upon such change

of food and ascorbic acid.

New Mords: from absorption from nutrition

Plasma (serum) Iron

Technical Approach:

To a normal fasting subject, we give by mouth 100 mg of ferrous sulfate (20 mg of elemental iron). Plasma from concentration is measured at intervals for eight hours to see if absorption of the iron causes an increase of the concentration. Some subjects are fed at the same time; some are given ascorbic acid; some receive both. We plan to substitute ferrous funarate for ferrous

sulfate. Furmarate is less soluble.

Progress and Results: Eighty-three iron tolerance tests have been completed using II healthy male volunteers. Those who are mildly iron deficient (having served as blood donors) have a definitely increased plasma iron concentration after dosing. Ascorbic acid does not increase absorption of iron-replete subjects.

Conclusion: The ITT using a small (20 mg) dose of inorganic iron provokes a significant rise in plasma iron concentration. This phenomenon may permit the study of absorption of food iron without using radioisotopes.

Publications: None.

Date: October 1980	Protoco	l No:	9024	Status: Interim
Title of Project:				Final XXX
The Effect of Microwave	Exposure on	Immu	ne Regulatory	Function.
Starting Date: 17 Mar 80	Esti	mated	Completion D	ate:
Principal Investigator: Be	n II. Boedek	er, CI	PT DVM	
Associate Investigators: LT Cindy Ewel, Dep	ot of Clin	Facili	ity: Bldg 4	O, WRAIR
COL Robert Reid, GI Svo	Invest e, WRAIR	Dept/	Svc Depart	ment of Clinical Investigation
Key Words:	فلا يسترين والمسيد الشاخ المستريق ماي الميار	4		
Accumulative MEDCASE Cost: 0	Accur. Cost:_	nulative	Contract 0	Accumulative Supply Cost: 0
FY-80 MEDCASE Cost:	0	Princip alle alle alle alle alle alle alle all		eview Results:ed in by DCI)
	oject has be	comple	etion of study	
Conclusions:				
Conclusions;				
•				

Publications or Abstracts, FY-80:

PATE: 22 September 80 PROTOCOL # 9030 STATUS: Interim

TITLE: Circulation Serom thorazymes in Mesent all Infarction

STARTING DATE: 15 June 1979 COMPLETION DATE: December 1981

PRINCIPAL INVESTIGATOR: Geoffrey M. Graeber, MD, MAJ, MC

Associate Investigators: John W. Harmon, MD, LTC, MC, FACS

Patrick J. Cafferty, Sp4, USA

Michael J. Reardon, DVM, PhD, MAJ, VC

FACILITIES: Dept of Experimental Surgery, Division of Surgery, WRAIR

Dept of Clinical Pathology, Division of Pathology, WRAIR

HEY WORDS: MAT, CPK, LDH, ISOENZYMES

STUDY OBJECTIVE: 1. Evaluate the anticipated elevations of total scrum CPK and LDH and the anticipated isoenzyme pattern changes in patients suffering from abdominal catastrophes.

 Evaluate the auticipated formices of total seria OFM and LOW and the isoenzyme patheons is putients after cardiac surgery.

3. Determine the diagnostic value of these tests in distinguishing mesenteric infarction from other abdominal catastrophes and the value in evaluating patients having postoperative MIs.

THEMNICAL APPROACH:

Patients who are seen by the General Surgery Service for acute abdominal emergencies have been entered into the protocol as soon as their consent has been obtained. Blood samples have been drawn before surgery, in the recovery room, and for up to seven days after surgery. The samples are analyzed for total and respective isoenzyme concentrations of creatine phosphokinase (CPK) and lactic dehydrogenase (LDH). Two distinct groups of patients can be delineated: those who had mesenteric infarctions and those who suffered other acute conditions.

Patients that are seen by the Thoracic Surgery Service for cardiac surgery have been entered into the protocol as soon as their consent has been obtained. Specimens are drawn preop, q 8 hr for the first 2 PO days and daily until the 7th postop day. Samples are analyzed for their total and isoenzyme concentration.

Patients who are undergoing routine intraabdominal procedures have served as control groups. Their serum CPK and LDH values have been determined on a similar basis to provide a control group.

Patients admitted to the CCU have served as the control groups. Their serum CPK and LDH have been analyzed by the same methods.

PROGRESS AND RESULTS: As noted in the original protocol, the study will need to be run over 18 months to gain adequate numbers. A total of 431 patients have been entered into the study. No changes or modifications in the protocol have been made.

> Initial results show that patients who have suffered mesenteric infarctions will exhibit CPK-MB bands in their sera. We have also seem inimal rises in the serum of the CPK-BB isoenzyme which was, theoretically, the most promising indicator.

> The results from the study of the LDH isoenzyme system shows that any elevations after restine purgery are due to LDHs, the predominant Isoenzyme in liver and skeletal muscle. When patients have suffered a mesenteric infarction, the LDH isoenzyme patterns show definite increases in LDH₃ and LDH₄. These findings are different from the changes seen in myocardial infarction when LDH,, becomes the predominant serum isoenzyme.

Review of the patient values after cardiac surgery shows a small elevation of CPK-MB, though not as high as those seen with patients suffering a MI.

Review of the control group values shows that CPK-MB and CPK-BB do not elevate after routine surgery. LDH elevations are only those compatible with skeletal muscle injury.

CONCLUSIONS:

There have been no serious or unexpected side effects of complciations in subjects participating in the project.

The CPK and LDH isoenzymes systems appear to be valid markers for mesenteric necrosis.

The serum changes in the CPK and LDH isoenzyme systems seen after surgery are compatible with skeletal muscle injury.

The elevations seen in CPK-MB after cardiac surgery are smaller than those seen with MI after cardiac surgery. CPK and LDH isoenzymes appear to be valid markers of myocardial damage.

UNDS FY 80: Personnel

None

Equipment

none

Supplies

\$10,000

Reprints

None

Funds requested for FY 81

See inclosure #1

Work Unit #9030 Circulating Serum Isoenzymes in Mesenteric Infarction

To obtain and process each patient sample as noted in the approved protocol and addenda, the following are the anticipated costs to be incurred:

1. The following items are needed to draw a sample:

a.	syringe (10 cc)	\$. 62 8
ъ.	needle (20 g)	. 06
c.	serum separation tube (6 ml)	. 23
d.	sample vials (3)	. 33
е.	alcohol prep	. 006
f.	4 x 4 gauze	. 014
		\$1.268 = \$1.27

- 2. Analysis of the sample requires the following:
 - a. CPU determinations:

1.	antibody inhibition (total enzyme)	\$ 1.63
2.	antibody inhibition (CPK-MB isoenzyme)	3.93
3.	control coagents	.48
4.	centrifichem reagents	.24

- 5. electrophoresis
 - sample tips (2) x .085 ea = a.
 - data card (1) x .053 ea = .053 Ъ.
 - agarose film (1) x .568 ea ≔ .568
 - .612 x .612 ea =CK substrate (1)
 - . 14 MOPSO buffer (1) x . 14 ea ≔ 1.543 =

Total cost of CPK analysis = \$7.82 ea

- b. LDH determinations
 - 1. centrifichem reagents .13
 - 2. electrophoresis
 - sample tip (1) x .085 ea .085
 - data card (1) x .053 ea =
 - agarose film (1) x .583 ea =с.
 - .586 LDH substrate (1)x .586 ca = d.
 - .075 universal buffer (1) x .075 =

1.382 \$1.51 Total cost of LDH analysis

3. The total estimated cost to obtain process and analyze each specimen is:

1. 1.27

2a 7.82

2b 1.51

\$10.60 each specimen

4. The anticipated numbers of patients entered into the protocol per week are -

abdominal patients	4
coronary care unit	7
thoracic palients	5
emergency patients	2
Average patient load/week	18

The number of patients times the number of samples per week $18 \times 7 = 126$ or approximatley 504 patient samples per month. Hence, the total number of patient samples for FY 81 is $504 \times 12 = 6048$.

The total anticipated cost of obtaining processing and analyzing these samples is

6048 \$10.60 \$64,108.80

Request funding also be available for earlier to the following equipment:

rorrowtuk edarbaser.	
Gilford System 102 Spectrophotometer	835.00
Corning 702 and 722 Electrophoresis System	2100.00
•	\$2935.00

6. Total anticipated costs for MU #9030 for FY 31 is:

Sample analysis	\$64.108.80
Contractual Svcs	2,935.00
	\$67,043.80

Date: 27 October 1980	Protocol N	0: 9031		Status: I	cterion X	
Title of Project:]	Ynal	
Study of Control Mechanis	ms for Human (: Gastric P	arietal C	ells		
		1.	i	•		•
Starting Date: 1980	Estime	led Comp	letion Date	≃: 1983	************	
Principal Investigator:	obn Harmon	and the second s				
Associate Investigators: Schmel Batzri	F	acility:	WRAMC, D	Div Surgery a ept Surgery pt Surgery		rgery
Richard Hirata	D	ept/Svc				
Key Words:					•.	
Stomach, Pe				e de la companya del la companya de	والراز والمعاولات والمتعادة الما المتعادة الما	
Accumulative MEDCASE Cost:	Accumula Cost:		1	Accurate Cost:	itive Suppl	
FY-80 MEDCASE Cost:		Peri	odic Revie			
		(to	be filled i	n by DCI)	*************	
Study Objective:			Ang			
To identify control mechan	nisms for huma	 m parieta	al cells	•		
Technical Approach:	•	• ,				<u>:</u>
To apply the methods devel animals, to man.	oped for stud	lying disp	xersed par	rietal cells	developed	in
			•			•
Progress during FY-80: I methodology for studying phuman studies have been per WRAMC	parietal cells	in anima	ols has be	en cot un a	HOTILIO L.	
Number of subjects to be stu	died before co	rapialion (of sludy:	20		~~~
Scrious/unexpected side effe	cts in subjects	padicip:	ding in pr	oject:		
Conclusions:						

Date: 27 October 1980	Protoc	col No:	9032	512	itus: Interim	X.
Title of Project:				<u></u>	Final	
In Vitro Analysis of Hun	an Colon	Ion Trai	sport Hechn	als.:		
Starting Date:	Es	timated	Completion D	ate:		~~~
		-			Princes, amagicales (Prince Philippelings) and high security of	
Principal Investigator:	ohn W., Ila	rmon, Ro	y Mong		Mary and the state of the state	~
Associate Investigators: Yuan Hneg Tai PhD A.	Olyw o le	Facil				
Ed Boedeker Richard Hirata Laurence: Johnson	ory were	Dept/	Svc WRANC -	Surgery Surgery	, Medicine - Medicine	· ·
Key Words: Colon Surg	ery					•
Accumulative MEDCASE Cost:	Accu		Contract		cumulative Supp st:	•
FY-80 MEDCASE Cost:			Periodic Re (to be fille		ults:- CI)	
Technical Approach: ,		i Tananda	مخالف دیدن بیشت	ninos fra	nos de eso sunto	to to
Colonic mucosa from huma suite taken to WRAIR and				SKIEG KK	.s. in the mas	
Progress during FY-80:			. •		· · ·	£. 4.
_	12 surgic	al speci	mens has bec	n studied	•	sangkann "T opological "Topological" ss
Number of subjects to be stu Serious/unexpected side effe		jects par	ticipating in	project:		**************************************
Conclusions: The study is progressing between the pathology ser	vice and ap	orily, the invo	estigators t are properl	tial to a o assure y studie	maintain good (ical ic
Funding requirements, FY-	-81:		•		•	
Travel, Conferent Printing & Representation		200 \$600			•	

: 98

			Status: Interim x			
7 7 7	or a chorce-kear	ind Dietary H etion Time Ta				
Starting Date: Jun 77	Estimated	Completion D.	lie: Jun 81			
Principal Investigator: Capt	James P. Dixon,	USAF, BSC	· · · · · · · · · · · · · · · · · · ·			
Associate Investigators: Col R.R. McMeekin, USA, N	AC Facil	ity:				
	Dept/	Svc Aerosp	ace Pathology			
Key Words:			•			
Accumulative MEDCASE Cost:	Accumulative	Contract	Accumulative Supply Cost:			
FY-80 MEDCASE Cost:		Periodic Review Results: (to be filled in by DCI)				
Study Objective: To evaluate habits and other stresses or jog performance of service p	n performance and	to relate t	d, altitude, dietary hese decre ents to the			
Technical Approach: By mean of correct divided by total to the physiological paramet at various altitudes.	time) will guage	performance	. This will be related	t r		
of correct divided by total to the physiological paramet	time) will guage ers of arterial	performance oxygen satur	. This will be related ation, respiration and hear	t r		
of correct divided by total to the physiological paramet at various altitudes. Progress during FY-80: Eigcompletely analyzed. Number of subjects to be stud	time) will guage ers of arterial the subjects have ied before comple	performance oxygen satur been comple tion of study:	This will be related ation, respiration and hear ted. Data has not been	t r		
of correct divided by total to the physiological paramet at various altitudes. Progress during FY-80: Eigcompletely analyzed.	time) will guage ers of arterial the subjects have ied before comple	performance oxygen satur been comple tion of study:	This will be related ation, respiration and hear ted. Data has not been	t r		

)gie: Sept. 19, 1980	Protocol No:	2036	Status: Interim	
		0:37.37	Inal	
itte of troject. Urease & D	caminases in Che	mistry & Modic	une	
			•	
Starting Date: June 28, 1977	Estimaled	Completion Da	ite: Ongoing	
Principal Investigator: Will	iam N. Fishbein,	MD, PhD		
associate Investigators:	Faci	lity: AFIP		
	Dep!	/Svc Bioches	nistry Division	•
key Words: myo adenylate d	leaminase defici	ency; lactate/	annonia exercise rati	o ',
ccuraulative MEDCASE	Accumulativ	e Contract	Accumulative Su	
030		المستدارية سيارات	Cose Q	
Y-80 MEDCASE Cost:	د این در در در در در در در در در در در در در	Periodic Res	dev Rosults: Lin by DOD	
refer to response a residence of the contract	ودوامه والمسام فيستني والمعتبين والمعارض والمسامرة		والمراجع والمتعارض المنطاع المتعارض الم	
Study Objective: Developmen	it of a diagnost	ic clinical bl	ocal lest for mADD	:
Managara Managara				
Cochnical Approach: Measu	mement of tacta meezing with par	te and ammonia tial venous ob	in antecubital vein struction.	blood
drawn and after sponge-squ	•			
drawn and after sponge-squ			•	
drawn and after sponge-squ				
drawn and after sponge-squ				
drawn and after sponge-squ				
drawn and after sponge-squ Progress during FY-80: Se	ven patients and	l five control	s have now been teste	d with
drawn and after sponge-squ Progress during FY-80: Se side-eff ets. No drugs or	· WRAMC tunds hav	ve been used.	The seven patients s	how no
drawn and after sponge-squ Progress during FY-80: Se	WRAMC funds have rmal increase in	ve been used. n lactate, lik	The seven patients see the first three rep	how no

. :

Date: 17 Oct 80	Protocol	No: 90	035A	Status:	Interim X
Title of Project:					Smal
•	laadaal Nasi	la Cha	of Ed U	- C	. f . htt . 1 . 1
The Educational and Psychol Aged Males Post Uncomplicat				an bexuality (n. wragle.
Starting Date: 24 April 1979	Estic	ated C	ompletion D	ate: 1980,	Dec
Principal Investigator:	P.J. Baldwi	n, R.1	I., D.N.Sc.,	George Mason	University
Associate Investigators: Liasion Officer:	·	Facili	ty: Wramc, u	nit 41	
MAJ(") Janet R. Southby, At	1C	Dept/S		Research Serv	
Key Words:	de communicación estados en estados de la constanción del constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanción de la constanc				
Sexuality, Males, Myocardia	d Infarctio	n			
Acord Convertision Acc	Δοσιμαν	duli ve	Condition	Accumi	wive flyydy
Cost: 0	Cost:	0	and the second s	Cost:	
FY-80 MEDCASE Cost:		به مسيد مخيد ر	Periodic Re	view Results:	ameter anders orders granders, of passages
	and a second district of the second second	, aprilia i reserva		d in by DOI) 🧻	nertin recognise indica victoria.
middle aged males post unco	·	•		20.17	
.Technical Approach:				· . ·	
Unchanged since last Annual	Progress B	lagont			
			•	•	•
Progress during FY-80:					
Ten subjects were obtained	for the stu	idy thi	s year.		
Number of subjects to be stud					ired
Serious/unexpected side effections	ets in subjec	ts par	licipating in	project:	
Conclusions:					•
None to date. Data analysis	s is in prog	ress.			
Publications or Abstracts, F	'Y-80·			.	
- ユーモキキスチ にしっこしょくひょうこ マノチョ ボストノ・ブレル ケベンタルフター 本					

CLINICAL INVESTIGATION PROGRAM

hork Unit lio.: 9036A

Funds Utilized, FY-80: None

Funding Requirements, FY-61: \$50.00

Personnel: (name and grade) MAJ Janet B. Southby, AMC

Equipment: (describe in detail including cost)

<u>Supplies:</u> (consumable, animal purchase) \$50.00

Travel: (mission oriented, training and presentation)

Others (equipment remarks, converges for converge, polecy ency appropriate)

DISPOSITION FORM

For use of this form, see AR 340-15, the proponent agency is TAGCEN.

REFERENCE OR OFFICE SYMBOL

SUBJECT

AFIP-CPQ-C

Annual Progress Report, #9037, Localization of Lymphocyte Antigen Markers in Fixed, Paraffin-Embedded Tissues

To Timothy M. Boehm, LTC, MC Department of Clinical

FROM Major John M. Langloss Chief, Division of

DATE 14 October 1980 CAT 1

JML/rm/62816

Investigation Service

Immunopathology

Since submitting our request for surgical specimens from WRAMC, we have found an alternative substrate obtained from other sources for our investigation of intracytoplasmic lymphocyte markers. No material has been obtained from WRANC. Please consider our project terminated. Thank you for your cooperation in this matter.

AJOR JOHN M. LANGLOSS, USAF

Chief, Division of Irraunopathology

Data: 17 Oct. 80	7 Oct. 80 Protocol No: 90398				
Title of Project:	Final				
Nurse Controlled Factors T Patients	hat Influence the Development	t of Diarrhea in Tube-fed			
Starting Date: 20 July 1979	Estimated Completion D	ate: Dec 1980			
Principal Investigator: ITC	Reuben B. Bowie, ANC				
Associate Investigators:	Facility: WRANC				
	Dept/Syc Nursing	Dept/Syc Nursing Research Service			
Key Words: Diarrhea, Table Feeding					
Cost: 0	Accumulative Control Cost: 0	Acetembašiva Supply Cost: \$43.50			
The state of the s	0 Periodic Re	and the state of t			
Brandon (Au ana Baran		d in by DCI)			
Secondary - To describe gre	nbe-fed parients as compared oss changes of the nose and t quency of changing the nasogruency of changing the nasogruency of Report	throat mucosa in response			
Progress during FY-80: To completed the study.	o date, a total of four (4) p	ortients have			
	died before completion of study:				
-	cts in subjects participating in p	project:			
lone Conclusions:					
Availability of patients wi	ho meet the study criteria we	we a problem. Study			

.or: Unit 40.: 9039B

runds ttilized, F1-60: None

Funding Requirements, FY-61: See attached Funding Requirements Sheet

Personnel: (name and grade) LTC Reuben B. Bowie, ANC

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase) Consumable: \$50.00

Travel: (mission oriented, training and presentation)

Other: (equipment rentals, contracts for service, animal care and reprints) Printing and reproduction: \$150.00

Data: 12 October 1980	Protocol	No: 90	4(0)	Status:	Interim X
Title of Project: Reducing D Injections in the Dorsoglut	iscomfort f eal Site by	rom Intra Proper B	muscular ody Posit	icus.	Final
Starting Date: 1 June 1979	Estir	nated Cou	roletion Da	ute: 31 Nec	1980
Principal Investigator: Fanni	e M. Rettig	, MAJ-ANC			
Associate Investigators: N	ONE	Facility:	WRAMC, W	ards 57,67 ar	10 68
		Dept/Svc	Nursing R	esearch Servi	ice
Key Words: Intramuscular In	jections, Pr	oper Body	Position	5	
Accumulativo MEDCASE Continuity	Accumi Cost:	aletive Co	ntract	Cost: 10	lative Supply
FY-80 MEDCASE Cost: NON				view Results: I in by DCI)	and company of a regular or company of property and page and page and page and page and page and page and page
Study Objective: (1) To aso from dorsoglateal injection rotated Ithan when femurs an side-lying position with fer effective position for reduce	re externall nurs interna	issume a p ly rotate ally rota	i. (2) I led or ext	ition with fe To ascertain ternally rota	emurs internall, whether the ated in an
Technical Approach: The son the general surgical and the study, they must meet the a. Oriented to time, possible assume a process during FY-80: Comparess during FY-80:	gynecology ne following place and pe one or side- red preopera (SEE THE	services g pre-oper erson lying por ative med ATTACHED	. For the rative crisition. ications c	e patients to iteria:	be a part of
	a analysis.			, , , , , , , , , , , , , , , , , , , ,	
Number of subjects to be stud Serious/unexpected side effect					
Conclusions: Will be submit	tted by 31 I	December	1980.		

Publications or Abstracts, FY-80: NONE

Continuation of Technical Approach: d. Could safely receive injections in the dorsogluteal site. Patients will have to be excluded from the study if only one injection is given or if there was a change in the type of medications after being randomly assigned to the study groups.

Each patient will receive two injections of Meperidine, promethazine and glycopyrrolate. All injections are given with a 22-gauge needle. The length of the needle will vary from 1-1 1/2 inches depending upon the size and weight of the patient. The number of patients comprising each group will remain even by assigning patients to one of the four conditions in a fixed order. Table 1 shows the four conditions which are the possible combinations of the three factors of concern.

The patient will be located by reviewing the operating room schedule the day prior to surgery. The patient will be randomly assigned to one of the four conditions (see table 1). Afterward the investigator will contact the patient and obtain the patient's written consent to participate in the study. At the time the preoperative medications will be ordered, the research nurse will give the appropriate medications at the bodside. The patient will be placed in the pre-defined position (hips either internally or externally rotated). The injection will be administered using the following technique. The nurse will conside the upper outer quadrant of the gladeus maximum muscle and palpate for underlying abnormally sensitive tissue. She will prepare the skin by swabbing with an alcohol gange and then administer the designated addication taking no less than rave accords to complete the injection to reduce possible pain induced by rapid injection of medication. The area will be massaged using an alcohol spenge for approximately five seconds. The patient will be asked to rate his discomfort from the injection on a discomfort scale. The patient will be positioned in the second designated position and the second injection vill be given in the opposite dorsagluteal site. The subject will then rate the discomfort from that injection.

TABLE 1
Assignment of Patients to Conditions .

Condition	Position	First Injection	Second Injection
Α	Prone	Internal rotation	External rotation
		Meperidine Promethazine Glycopyrrolate	Meperidine Promethazine Glycopyrrolate
ā	Prone	External rotation	Internal rotation
		Meperidine Promethazine Glycopyrrolate	Meperidine Promethazine Glycopyrrolate
С	Side-lying	Internal rotation	External rotation
		Meporidiae · Promothazine Glycopyrcolate	Neperidine Promethazine Clycopyrholate
О	Side tylen	External rotation	Internal rotation
		Meperidine Promethazine Glycopyrrolate	Meperidine Promethazine Glycopyrrolate

CLINICAL INVESTIGATION PROGRAM

work Unit Ho.: 9040B

Funds Utilized, FY-80: None

Funding Requirements, FY-61:

Personnel: (name and grade)

MAJ Fangie M. Rattig

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase) \$100.00

Conference Travel

Travel: (mission oriented, training and presentation) \$570.00

Other: (equipment rentals, contracts for service, snimal care not reprints) Printing & Reproduction, \$150.00

Data Analysis \$200.00

	Protoco	No: 90418	Status: Interim X	
Title of Project: Attitudes Accurrence	s of Health C ce of Violenc	are Workers toward e in close Relatio	d the Final puships.	
Starting Date: 1 June 1979) Estir	mated Completion D	ate: 1 Dec 80	
Principal Investigator: Sus	san B. Shiple	y, MAJ/ANC		
Associate Investigators: Donna C. Sylvester, MAJ/ANC		Facility: Walter Reed Army Medical Center		
		Dept/Svc Nursing Research Service		
Key Words: Violence, Abus	se, Marriage,	Family		
Accumulative MEDCASE	(dative Contract	Accumulative Supply Cost: <u>\$250,00</u>	
FY-80 MEDCASE Cost:	0		view Results: d in by DCI)	
Study Objective: The purp attituder of various grou rence of violence in close th care workers with victi	relationship ms of purpose coming entry	care yours the Ds; b. determine Eful injury who co Doints to the bad	and the victims and users the except of experience whe is contact with the	
of purposeful injury in or violence in further studi Technical Approach: Survey questionnaire of No Changes.	es,	access to and char	acterize the victim and	
or purposetul injury in or violence in further studi Technical Approach: Survey questionnaire of	der to gain a es. Ta random sam	nccess to and char	acterize the victim and	

The second secon

CLINICAL INVESTIGATION PROGRES.

Nork Unit Ho.: 9041 8

Funds Utilized, FY-SO: \$250.00

Funding Requirements, FY-61:

Personnel: (name and grade) MAJ(P) Susan B. Shipley

MAJ Donna C. Sylvester

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase)

Travel: (mission oriented, training and presentation) conference (personn)

\$1.000.00

Other: (equipment centals, contracts for service, animal care and

roprints)

inting and reproduction: \$150.00

Datenctober 15, 1980	Phrotoco	l No:work unit #908	30 Status: Interim X	
Title of Project:			Final	
•	Disease &	Coronary-Prode delication	avior	
Starting Date: September 26,	1978 Esti	rated Completion Da	te: October 1, 1981	
Principal Investigator: David			Department Med.	
Associate Investigators:		Facility: USUHS, WRAMC		
James E. Davia, M. D. Chief, Cardiology, WRAMC		Dept/Svc Cardiology, WRAMC, USUHS		
Key Words: Coronary Arter	y Disease,	Psychophysiology,	Psychological Correlates	
Accumulative MEDCASE Cost: none	Accum Cost:	ulative Contract	Accumulative Supply Cost: none	
FY-SO MEDCASE Cost:	none		dew Results:	
Study Objective:	and the first of the second second second second second second second second second second second second second			
SEE CONTINUATION	SHEET			
•.				
Technical Approach:				
			•	
Progress during FY-80:	.			
SEE CONTINUAT	ON SHEET	S		
Number of subjects to be stud			200	
Serious/unexpected side effec	ns in subjec	ets participating in p	roject: none	
Conclusions:	EE CONTINU	ATION SHEET		
Publications or Abstracts, F	Y-8**	, See Continue 1988	AHAE T	

Objectives, Methods, and Progress:

- area of this research project concerns associations between aspects of behavior and presence of coronary artery disease. Approximately 115 consecutive patients of WRAMC who were awaiting cardiac catheterization completed the Jenkins Activity Survey and were given the Roseiman diagnostic interview to measure Type A behavior. We have been investigating the possible relationship to various components of Type A (e.g., hostility, competitiveness, time urgency, speech patterns, etc.) to presence of coronary artery disease. It remains unclear from previous research whether the intensity of various components of Type A behavior is associated with greater risk of disease. Walle, strictly speaking, this question can only be answered by prospective saudy, tage recorded interviews of cardyos, cathodecized partents are being brothed down and analyzed item-by-item. We will examine the relationship of Type A components to angiographic results of cardiac catheterization and other standard risk factors obtained from MRAMC medical records. Angiographic data have been obtained for each patient. This analysis is mearing completion and should be concluded within six to sight months.
- 2. The second line of research being isometigated in this project concerns possible physiologic mechanisms linking behavior processes with rorenary artery disease. Research by Dembroski, Manuck and others has demonstrated that Type A subjects display elevated cardiovascular reactivity when presented with challenging tasks and situations. Dembroski and McDougall have recently presented some suggestive evidence that patients with a history of ischemic hearr disease show a trend toward similar enhanced cardiovascular responsiveness. Since January 1979, we have been measuring cardiovascular reactivity (bleed pressure and heart rate) in coases.

ested in determining how heart rate and blood pressure responsiveness vary in these patients as a function of a) magnitude of coronary artery disease and b) magnitude of Type A behavior. An association between cardiovascular responsiveness and coronary artery disease would lend credence to the notion that this responsiveness (or other physiologic correlates of this responsiveness) play a role in the pathogenesis of coronary disease. It is also not known how various processes which have been shown to be related to elevated pressor response (e.g., Type A; family history of disease) are themselves related to each other. Englity-three patients have been costed as far in this actuary, and data have been analyzed and written up for presentation at scientific meeting (see enclosed paper).

Research Goals for the Upcoming Year

We plan to complete data analysis for Study I at the collect data for reaction-time study outlined in original proposal.

Conclusions: Coronary artery disease, angiographically measured does not seem to be related systematically to cardiovascular response. We plan to repeat this study using a psychomotor reaction-time task which may reduce variability between conditions. There have been no side effects/complications associated with this rescribed project.

Funds Utilized: The study is funded by grants from NIH and USUHS. No additional funding is required from WRAMC.

Publications:

- 1. Krantz, D. S., Sanmarco, M. E., Selvester, R. & Matthews, K. A. Psychological correlates of progression of atherosclerosis in men. <u>Psychosomatic Medicine</u>, 1979, 41, 467-475.
- 2. Krantz, D. S. Cognitive processes and recovery from heart attack: A review and theoretical analysis. Journal of Human htress, 1980, 6 (0), 27-08.

- 3. Krantz, D. S., Glass, D. C., Schaeffer, M. & Davia, J. E. Behavior patterns and coronary disease: A critical evaluation. In J. T. Cacioppo & R. E. Petty (Eds.) Focus on cardiovascular psychophysiology. New York: Guilford, in press.
- 4. Krantz, D. S., Schaeffer, M., Davia, J. E., Dembroski, T. M., MacDougall, J. M. & Shaffer, R. T. Investigation of extent of coronary atherosclerosis, Type A behavior and cardiovascular response to social interaction. Paper presented at Society for Psychophysio-logical Research, Vancouver, B. C., October, 1980.

Type of Report: Interim: Approval for continuation of project requested for FY-81.

Work Unit No.: 9082

Title of Project: Treatment and Rehabilitation of Knce Injuries at the United

States Military Academy, West Point, NY 10996

Investigators:

Principal: LTC Walton W. Curl

Associate: LTC Keith L. Markey

Objectives: To develop predictive parameters and programs to lower the knee

injury rate of cadets at the United States Military Academy. It is also the objective to analyze and develop better treatment

modalities for those injuries which do occur.

Technical Approach:

Cadets who are participating in the intramural and inter-collegiate football, wrestling, and lacrosse programs are being screened as part of the pre-season physical examination for multiple parameters which might effect knee injury rate. These parameters include: joint laxity, height, weight, body type, etc. They data and following the individuals through the sport scason, determine what types of injuries they incur and it is hoped that a statistical correlation can be performed to relate these various parameters to knee injuries.

The treatment phase deals with the diagnosis and treatment of essentially isolated tears of the anterior cruciate ligament. Those who have a proven torn anterior cruciate ligament then undergo an acute repair and reconstruction of the torn anterior cruciate ligament utilizing the medial third of the patellar tendon. They are then casted with a long-leg cast with the bent knee at 60° for six weeks and then a cast-brace of 30-60° for six weeks. They are then started on a knee a habilitation program. These perfectly are then followed at a 3 and 6 months, 1 year, 2 year, and 5 year, and 10 year intervals for long term sequelae.

Progress and Results:

Preventive phase: The 200 intramural football players which were examined and evaluated utilizing Cybex, physical exam, and questionaire at the start of the intramural season are currently being analysed. No results have been concluded from this aspect of the study as yet. We are currently trying to correlate ligament laxity with injuries in a second on-going study and will try to incorporate these results with this aspect of the study.

Treatment phase: 132 anterior cruciate ligament injuries have been identified utilizing arthroscopy. Of these 43 have been treated using the medial one-third of the patella tendon to augment the repair of the anterior cruciate ligament and are undergoing treatment at the present time. There have been anterior cruciate ligaments that have not been operated on, however, none of these have been casted for a twelve week period, as the operated cruciate ligaments have been, since the cadets did not desire the twelve week casting. We have been in contact with the United States Naval Academy to discuss the combined study with their facility. The USNA is currently following their anterior cruciate ligament injuries non-operatively on a prospective basis and their data will, hopefully, be correlated with our results in the end.

Conclusions:

The study continues to be on-going. There have been no unexpected side effects or complications in the individuals participating in this project. Again no conclusions can be made as to the efficacy of the treatment phase nor can conclusions to drawn at to specific properties which may lead to knee (njuries. We feel that this as a reasonable alternative to not operating on the anterior reaction ligament and also seems to be doing better than repairing the cruciate ligament alone. The answers to these questions will not be able to be answered however, until the end of a five year course has past.

Funds Utilized, FY-80: The research secretary is funded for a part-time basis for FY-80. No other funds were utilized out of the clinical research investigation project.

Funding Requirements, FY-81:

Through CS3 + 1/ Time onts to. "C-8.

Equipment: benow Hill Braces for bracing anterior cruciate ligaments - \$285.00 ea, estimated number required - 60.

Travel: \$1,000.00 for TDY for the purpose of presenting results as well as visiting other medical centers to discuss the role of the anterior cruciate ligament.

Supplies: None

Other: None

Fublications & Abstracts /Y80: None as of yet.

Date: 12 October	Protocol	No: 9025	Status: Interim	~
Title of Project: The Physica Employed in		f Military Women re Occupations	Final y	_
Starting Date: None	Estim	ated Completion D	ate: None .	-
Principal Investigator:LTC E	ileen L. Fox,	, LTC Caroline G.	Brodkey and MAJ Fannie	M. Rettig
Associate Investigators:		Facility: WRAMC, Ft. Meade, MD and Ft. Belvoir, \		
		Dept/Svc Nursing	Research Service, WRAMC	 :
Key Words: Physical Fitnes	 35			•
Accumulative MEDCASE	Accumu	lative Contract	Accumulative Supply	 ,
Cost: \$1,500 (Not Expended)	Cost:	None	Cost: None	
FY-80 MEDCASE Cost: NO	DNE		eview Results:ed in by DCI)	
Study Objective: To evaluate care occupations. To determine the care occupations is comment three-month physical condition of physical crucis in a 31 for changes and/or correlative is used. The canical approach: It was planned to selected who foil the physical trained demographic data questions the beginning and ending of fitness test, the experiment months. Follow-up evaluate Progress foring FY 80: The three Ohio haloscale respinsenior investigator retired Number of subjects to be study.	mine if physicarate with a coup of militations between a pressure, and ing test and the study part group would have a cotocol was concern. We had the other died before a died before a cotocol was a	sical fitness of military expectate and with the goal tary women health a variables such vital respiratory (SEE THE AT and experiment grand experiment grands and experiment and have followed we been planned. The cancelled are two officers in completion of study ompletion of study	allitary women in health ions. To implement a of effecting an improve care providers. To obsus weight, anthrometric capacity, anthing, slee FACHED) oup from female voluntees a would have receive a and cardiorespiratory ch group completed a phy an exercise program for use of insistant fundinchase of this equipment, have been reassigned.	ment ervo P ers test at sical three
Conclusions: A film was mad WRAMC, PO & T Section decid A Program about Physical F:	de of the stated to adopt	aff and specialis this P.T. Test f	t physical test for wome or their program for FY	80.
as approved program for cor Publications or Abstracts, I	tinuied educ	cation.	, , , , , , , , , , , , , , , , , , , ,	•

Continuation of Study Objective: patterns, work parterns, relf imple, nutritional patterns, and improved physical firels.

N/A

CLINICAL INVESTIGATION PROGRAM

work Unit do.: 9086

Funds Utilized, FY-80: NONE

Funding Requirements, FY-81: NONE

Personnel: (name and grade) LTC Eileen h. Fox, LTC Caroline G. Brodkey,
MAJ FANNIE M. RETTIG
Equipment: (describe in detail including cost) NONE

Supplies: (consumable, animal purchase)

Travel: (mission oriented, training and presentation) NONE

Other: (aquipment rentals, contracts for service, animal care and

reprints)

Date:	6 October 1980	Protoco	1 No: 9038	Status: Interim X
Title of Therap	Project: A compary and Hypnosis in a	ison of the Group Sett	Use of Cognitive ing for Treating O	Final besity.
Starting	Daie: 29 April 1981) Esti	muted Completion D	ate: 30 June 1980
	al Tarrocki askora.	mund G. How	e, M.D.	
Associate Investigators: Charles B. Slater, CDR, MC, USN Angela LePage, Ens, USNR (3rd year medical student)		Facility: WRAMC, USUHS, NUMC		
		Dept/Svc Psychiatry, USUHS		
Key Wo	rds: Obesity, cog	nitive ther	⊸i apy, hypnosis, gro	up
	lative MEDCASE	Accumulative Contract Cost:		Accumulative Supply Cost:
FY-80 MEDCASE Cost:			ed in by DCI)	
_be_eff	ective as a means o	f persons w	er the proposed tr ith obesity losing	ed in by DCT) Cathent for obesity weight and maintaining theres for further

Technical Approach: Original study is being extended and modified to include a third group which combines hypnosis and cognitive therapy, to take place once a week over 10 weeks instead of twice a week over 5 weeks, and to be carried on be only the principal investigator.

Progress during FY-80: Of 22 persons beginning in hypnosis groups, 16 finished program and 11 lost weight at 3 month follow-up. Of 26 persons beginning cognitive therapy groups, 19 finished program, 18 lost weight at 3 month follow-up.

Number of subjects to be studied before completion of study: approximately 70
Serious/unexpected side effects in subjects participating in project: none

Conclusions: Though initial results are encouraging, they are not of significance unless weight losses are maintained at 6 month and 1 year follow-ups. Thus, conclusions cannot be made at this time.

Publications or Abstracts, FY-90:

Date: 30 September 1989	Protoco	l No:	9100		Status: Interim XXX			
-	of Compute action Moni		ted Drug		XMXXX			
Starting Date: 1 September 1	980 Esti	mated C	ompletion I	ate:	30 September 1981			
Principal Investigator: Ca	rl C. Peck,	LTC M	C					
Associate Investigators: Lawrence Flockenstein, Pharm D. Brian G. Schuster, MAJ MC James Wilson, Pharm D.		Facilit	Facility: WRAMC/USUHS					
		Dept/S	***		rmacology of Clinical Investigation			
Key Words: Daug Internatio	ns, Physici	an Educ	ation, Phari	nadole	০ন্ত্যু			
Accumulative NEDCASE Cost:	Accum Cost:_	ulalive	Contract		Accumulative Supply Cost:			
FY-80 MEDCAGE Cost:	The second secon		Periodic Re (to be fills					
program MEDIPHOR for its the frequency of adverse drumultiple drug regimens. Technical Approach: School WRAMC will be screened for zed drug monitoring program provided primary physicians potential problems of multiple Progress during FY-80: St screened to date had potential	clinical utilig conclions, high visk paracratical during clavel apod to austat the drug region	ity in de, and its disable (rug inter at Stanfiem in timens.	tecting drug impact on a receiving ractions utili- ord Universi heir patient	inter Pusic Pusic Single Sy I	ractions and reducing spans prescribing of significantly (the ABADIPHOR computed information obtained will)			
Number of subjects to be stu					50			
Serious/unexpected side effe	cts in subjec	cts part	copating in	proje	ct: None			
Conclusions: Would predict of as physician accurances of the	computer as vy interacti	sisted s	earch will i	harado;	on patient care as well			
Publication.	• • .							

CHARLES INVESTIGATION & BORRE

.ora Unit no.: 9100

Funds Utilized, FY-80: None

Funding Requirements, FY-61: \$3,000

Personnel: (name and grade)

Equipment: (describe in detail including cost)

Supplies: (consumable, animal purchase)

Travel: (mission oriented, training and presentation) 0500

Other: (equipment rentals, contracts for service, animal care and reprints) \$2,500 - Stanford Unividue access to REDIPHOR

DEPARTMENT OF THE ARMY BEADQUARTERS WALTER REED ARMY MEDICAL CANCOR Washington, D.C. 20012

WRAMC Regulation 70-1

. 8 January 1979

Clinical Investigation Program

WRAMC RESEARCH ACTIVITIES

																	20	radrap
Purpose .																		-Î.
Criteria		,		•		•			•	,	٠.	, .	•	~		,		2
Definition	ns	•	•	•		•	•	•			•		٠.	•	>	٠,		3
Committee	: 8	•	•	•	•		•				•		s.	-				<u>L</u> į
Clinical	Inv	est	iga	tia	a C	ozu	altt	ee	•			,	٠.			-		5
Human Use	: Co	mi.	tte	e .	-	•	•	u	•	•	٠.	•	~	*	u	•	- '	6
Chief, Cl																		
Records a	1.00	देशक	ort	s ·	•	• •	•		*		-	•	~	•	<u>. </u>	•		\mathcal{D}_{k}
Reports t																		
Request f	(1)	Pun	d,s		٠.		•		.•	->	•	٠.	*		4.			10
Informed																		
Research																		
Low Risk																		13
Research																		14
Research	. [6]	:22	lly	Lţţ	ir	med		•	•	•	•	4		•	-	-		15

- 1. PURPOSE. This regulation prescribes the policies and procedures applicable to the Clinical Investigation Program within the patient care facility of Valter Read Army Medical Conter.
- 2. CRITERIA. Clinical investigation activities will meet the following criteria:
- a. The objectives have scientific merin and also mesonably attainable.
- b. The investigators are competent to parform the investigators proposed.
- c. Resources required for the proposed studies are either available, or can be obtained, and are proportionate to the merit of the proposal.
- d. The studies will not have a deleterious effect upon the care of the sick and wounded.

^{*}This Regulation supersedes Williams outs of for-

8 January 1979

wa 70-1

- e. The studies are performed in a considered, coordinated, and professional manner.
- f. Whenever feasible, studies should be initially performed in animal models.
- g. The rights, well-being, and dignity of human subjects are maintained in accordance with the principles of the Declaration of Helsinki of the World Medical Association, and that wellten consent is obtained when indicated.
- h. Any research involving animals will conform with AR 70-18 and the Laboratory Animal Welfare Act (Public Law 89-544; 7 USC 2131 et seq).
- i. Assure compliance with existent military regulations to include AR 40-7, Use of Investigational Drugs in Humans; AR 40-37, Radio-isotope License Program (Human Use); AR 70-25, Use of Volunteers as Subjects of Research; and WRAMC Reg 40-10, Health Physics Regulation; AR 40-38, Malical Services Clinical Investigation Program.
- j. The voluntary consent of each adult human areject is essential. Each individual who initiates or directs the clinical investigation has a personal duty and responsibility for ascertaining the quality of the subject's consent. Before the acceptance of the subject, he must be given adequate explanation. He must be informed of the nature, duration and purpose of the study; the methods and means by which it is to be conducted; all inconveniences and means by which it is to be conducted; all inconveniences and hazards reasonably to be expected; and the effects upon his health or person which may possibly come from his participation in the study. He should be informed of ac benefits he may acquire from participation in the study, and if there should be no benefits, the participane should be so informed. The process of obtaining voluntary consent must be witnessed by an observer who is not a coinvestigator on the research protocol. Written consent will be obtained in accordance with the format outlined in the appendix and will be in nonmedical language that is easily understood by the subject. The investigator will be required to maintain copies of the written voluntary consent for five years following completion of the study. Copies of the consent forms for all protocols must be forwarded to Chief, Clinical Investigation Service, within one month of entry of the patient onto study. The consent form must include the patient's printed or typed name, address, and social security number.
- k) Children older than age seven, unless incapacitated, must assent (See definition seption for definition of assent.) to participantion in studies. Additionally, the printer coasen of the parent of

8 January 1979 WR 70-1

guardian must be secured and properly witnessed. An effort should be made to secure the written consent of the child utilizing a consent form written at his age level. In addition, "instructions to guardian" may need to be prepared that is written at an adult level. Both the processes of assent and securing written consent should be directed toward providing the patient and parent (guardian) the information given to adult volunteers, i.e., the nature, duration and purpose of the study, the methods and means by which it is to be conducted, etc.

3. DEFINITIONS.

- a. Clinical investigation under this program consists of the organized scientific inquicy, both in humans and ap directly related laboratory work, into clinical problems of significant concern in the necessary health care of members of the military community, including active duty personnel, dependents, and retiress. Chinical investigation at WRAMC shall include projects involving WRAMC patients, in each tigators, or facilities.
- b. Subjects are any persons who may be at risk because of participation as an object of clinical investigation by members of the AMEDD or their appointed representatives. These may include inpatients, outpatients, organ donors, informants, or normal individuals who participate in studies of medical, physiological, sociological, or psychological orientation. Selection of subjects must be equitable.
- c. At risk: A person is "at risk" if he/she may be exposed the possibility of herm (physical, paychological, an excisionical, as a consequence of activity which extends beyond use of established and accepted methods necessary to meet his/her needs. Determination of nature and extent of "at risk" is a natter of common sense and professional judgment. In most cases, utilization of someone's time (inconvenience) will constitute "risk" since the activity is not an accepted method to meet the person's needs. Responsibility for this determination resides at all levels of institutional and departmental review.
- d. Children: Persons who have not attained the legal age of consent to general medical care as determined under the law of the jurisdiction in which the reservoir is to be conducted (DC age 13)
- e. Research: A formal investigation designed to develop or contribute to generalizable knowledge. This may involve dietary pulations, alteration of dilly couldness at environment, per pionalizable record review.

- f. Minimal Risk in Children: The probability and magnitude of physical or psychological harm that is normally encountered in the daily lives, or in the routine medical or psychological examination of healthy children. Examples include immunization, modest changes in diet or schedule, obtaining blood and urine specimens, and most behavioral research.
- g. Assent: A child's affirmative agreement to participate in research which can only be given following an explanation appropriate to the level of understanding of the child. It is necognized that "assent" may have no legal status and may be difficult to obtain in young children; nevertheless, some sort of opportunity should be offered the child to agree to participate. (Ref Federal Register 43:2034-2114, Jan 13, 1978, and 43:31786-31794, Jul 21, 1978.)
- 4. COMMITTEES: The following committees will be appointed. At the option of the Chairman, the Clinical Investigation Committee and the Human Use Committee will meet either separately or simultaneously.
- a. Clinical Investigation Committee: To review all clinical investigation proposals for scientific adequacy and to establish priorities for apport. For the purpose of recommending new drugs which have not been released by the Food and Drug Administration, the Committee will serve also as the Therapeutic Agents Board (para 126, AR 40-2). This committee will be composed of a representative from each of the following:

Director, Medical Education (Chairman) Chief, Chinical Tovestigation Service (Secretary) Chief, Department of Medicine Rotating Service Chief from Department of Medicine Chief, Department of Surgery Rotating Jarvice Chief from Department of Jurgues Chief, Dusartment of Pathology Chief, Department of Radiology Chief, Department of Pediatrics Chief, Department of Psychiatry Chief, Department of Obstetrics and Gynecology Commander, USA Dental Activities (DENTAC) Director, WRAIR Chief, Nuclear Medicine Service Chief, Health Physics Chief, Pharmacy Service Director, Patient Administration Directorate Chief, Nursing Research Service Assistant Chief, Clinical Investigation Service A rotating senior clinical investigator (list to be established by Chinf, Clinical Investigation Service) Representative (USUHS)

The attendance of each member will be recorded in the minutes.

b. Human Use Committee: To review for medical safety and suitability all clinical investigation protocols involving the use of human subjects. This committee will be composed of a representative from each of the following:

Director, Medical Education (Chairman) Chief, Clinical Investigation Service (Secretary) Chief, Department of Clinical Pastoral Service A Legal Counsel Chief, Department of Nursing Chief, Department of Psychiatry Chief, Department of Obstetrics and Cynecology Chief, Nuclear Medicine Service Command Sergeant Major Director, Auman Resources Directorate CDR, WNA Dental Activities (DENTAC) Clinical Pharmacist, Mematology-Oncology Service Assistant Chief, Clinical Investigation Jervice Patients' rights vepresentative Repressidative (GREES) Director, Patient Administration Directorate A rotating senior clinical investigator (list to be established by Chief, Clinical Investigation Service)

The Attendance of each member will be recorded in the minutes.

c. Radioactive Drug lesearch Committee (RDRC): To review all research protocols using radioactive drugs in human subjects, and to insure that such protocols are in compliance with the Code of Coderal Regulation: Title 11, Cup 1. Duet 351. Ath protocol atilizing radioactive dougs will include radiologic assessment data, as an appendix to the protocol, including name of the radioaudlide, presence of any contaminants, maximum dose to be administered, radiation absorbed doses to whole body and other organs accumulating the isotope, dosage from any X-ray procedures that are part of the research study, and any limitation regarding patient population due to sex and age. A report will be made by the RDRC to the Clinical Investigation Committee regarding each radioactive drug protocol in humans. In addition, the Committee will be responsible for preparing the annual report on research use of a radioactive drug to the FDA. This Committee will be composed of at least five individuals, including Chief, Nuclear Yedicine Service; Chief, Health Physics; Chief, Clinical Investigation Service; Nuclear Medicine Service Pharmacist; and Chief. Radiation Therapy Service,

The RDRC will select a chairman, who will sign all applications, minutes, and reports of the Committee as well as a secretary. The RDRC will meet at least quarterly. A quorum consisting of a majority of the membership must be present, with attendance of at least individuals who are specialists in nuclear medicine, radioactive drug formulation, and radiation safety and dosimetry. Minutes will be kept, including numerical results on voting. No member shall vote on a protocol in which he is an investigator. The RDRC will submit an annual report to the FDA prior to 31 January of each year.

The investigator must submit a report (Appendix C) and a copy of the signed consent form to the RDRG within 15 days from the date of administration of the isotope.

- d. Functions of the Committees: Either the Chialcal Investigation Committee or Human Use Committee can terminate any investigation or place restrictions on a study at any time the Committees become concerned about the scientific merit of the study or adequacy of protection of human subjects. The Chief, Clinical Investigation Service can order a cessation of activity in any study tending an evaluation of the circumstances.
- 5. CLINICAL JUYESTIGATION COMMITTEE: The Clinical Investigation Committee will meet once monthly, usually on the fourth "wesday at 1400 hours. Special meetings can be called at any time, either upon request of the Commander, Chief, Clinical Investigation Service, or by written request of three Committee members. The Committee will review all new research phoposofis, either involving WRAMC patients, investicators, or facilities. Their review of proposals will address in particular scientific design, merit and funding. Departmental chairman will not vote on protocols from their own department, nor will any member vote on any protocol in which he is a colovestimeter. Remindie cally, the Committee will review approve band ouguing contacts. Each project will be reviewed at least once yearly, at the termination of the research and whenever there is a change either in the goals or the procedures or drugs used in human subjects, or deviation from the approved protocol. Adverse reactions to investigational drugs or procedures will be promptly reported to the Committee. The Committee will make recommendations to the Commander. Two-thirds of the rembership in attendance will constitute a majority. A majority is recessary for protocol approval. A majority of the Committee will constitute a quorum and will include at least three physicians and three nonohysicians. There will be no proxy voting. Investigators will be informed within one week of the meeting in unifing of the coroval/disapproval of the project and reasons for no doing. A isapproved protocol must be resubmitted for approval. The Committee

January 1979 48 70-1

may elect to approve a study with the addition of certain minor restraints/modifications. The Commander will have the right to disapprove any protocol on the grounds of being unsuitable for implementation at WRANG but cannot overrule the disapproval of the Committee. Appendix D outlines the administrative methods by which primary and secondary review of protocols and review of annual progress reports will be achieved.

- 6. HUMAN USE COMMITTEE: The Human Use Committee will meet once monthly, usually on the fourth Tuesday either concurrently or with the Clinical Investigation Committee following the Clinical Investigation Committee meeting. Special meetings can be called at any time, either upon request of the Commander, Chief, Clinical Investigation Service, or by written request of three Committee members. The Committee will review all new research proposals in which human subjects are used. Their review of proposals will address in particular, the protection of human research subjects. Periodically, at least once yearly, the Committee will review approved and ongoing investigational studies inwhich humans are used. Each project will be reviewed at legat once yearly and whenever there is a change in the goals or the procedures or drugs used in human subjects. The Committee will make recommendate tions to the Commander. Two thirds of the membership in attendance Ill constitute a majority. A majority is necessary for protocol approval. A majority of the Committee will constitute a quorum and will include at least three physicians and three nonphysicians. The Commander will have the right to disapprove any protocol on the grounds of being unsuitable for Applementation of MRAME but cannot overrule the disapproval of the Consitted. These will be no proxy voting.
- 7. CHIEF, CLINICAL INVESTIGATION SERVICE.
- a. Shall invertible as pecreousy/seconder of meetings. The will summarize the discussion on issues. Records of casting isnal review scard's activities will be retained indefinitely.
- b. Can terminate any project at any time panding Clinical Tavesization Committee and Human Use Committee review.
- c. Will be the contact with the Commander to assess available ity of resources to support projects and will manage those resources ith guidance from Committees and Commander.
- d. Will keep the Commander and Committees informed of the comminuing change: In FRACIES cequicaments.
- e. Will supervise under the guidance of the Glial of Enventingion Committee and Maman War Committee, the secretarial of ministrative appart staff a comment official and a simple formation of its properties.

f. Will advise the Clinical Investigation Committee regarding alternatives if priorities for support need to be established.

8. RECORDS AND REPORTS.

- a. Initial Protocol. Requests for initiating research projects will be submitted in one copy to the Commander, Walter Reed Army Medical Center, ATTN: Chief, Clinical Investigation Service. This will be submitted by the principal investigator through the chief of the respective service and department, and prepared as described in Appendix A. Protocols which do not conform to Appendix A will not be accepted by the Chief, Clinical Investigation Service. Frequent deficiencies in protocols include omission of an impact statement, failure to state the time required to complete the project, failure to include budget information, and failure to include signatures of the respective chief of service and department. When radiological, laboratory, or nursing support is required, the principal investigator should have obtained the concurrence of the appropriate chief of service prior to submission to the Clivical Investigation Committee. The chief of the department proposing the study will provide an indorsement that the proposal conforms to the criteria described in paragraph 2 above. To be placed on the agaids for the monthly committee meeting, the research protocol sust be received by the 25th of the month preceding the meeting. Pactocols will be distributed to the Counittes members? at least one week prior to the meeting, with appropriate agenda. Under no circumstances will a project require greater than three years to complete. If more than three years are needed, submission of a new protocol will be required.
- b. Addenda to Initial Protocols. Whenever there is a change either in the goals or the procedures or drugs used in human subjects, the investigator will submit an addendum to the Commander thru the chief of the respective service and department, and Chief, Clinical Investigation Service. If necessary, the Committee to 11 review chila addendum as a new research proposal.
- c. Annual Progress Reports: Annual progress reports will be prepared for each approved project as prescribed by AR 40-38, Clinical Investigation Program and wilt be submitted to Clinical Investigation Service prior to 15 August of each year until the investigation is completed. See Appendix B. Accurate preparation of budgetary data and/or documentation of abstracts or publications is essential. Failure to submit an annual progress report will result in termination of the project and withdrawal of the principal investigator's privilege to function as a principal investigator in any project.
- d. Interia Reports. Interia reports must be submitted at any time when important development, adversities or other circumstances occur which should be brought to the attention of higher headquarters. In particular, sometime reports must be submitted when unexpected deaths or livery the self-standard deaths or livery the self-standard deaths. In arms, assessed as a required within three self-size rays or the

development. They will be considered by the Chief, Clinical Investigation Service, who may elect to suspend work on the investigation until the Committee has an opportunity to meet.

- e. Final Reports. Final reports are required upon completion on termination of a specific research effort. The report will include a summary of all work performed, results obtained, together with copies of all publications, whether printed, in press or submitted for publication. Inclusion of references to previous progress in this is one tional. If the project is terminated prior to completion, the reason, for termination should be reported. Report is due within 30 days following completion or termination of affort.
- f. Special Therapeutic or Diagnostic Procedures. Any special therapeutic or diagnostic procedures or any new, hazardous, or otherwise noteworthy therapeutic or diagnostic measures will be recorded in Space 24 of the Form 8-274, Clinical Record Cover Short for Empatients.
- g. All reports will be loguarded to the Clinical Investigation Service following review by the appropriate this or service and department. The Clinical Investigation Service will stipped a procedutations to the appropriate hospital review committees. Tallowing review by the Commander of committee reports the Clinical Investigation Service will insure that reports are forwarded to the Surgeon General as required by AR 40-38.
- h. Radioactive Drug Protocols Involving Administ filon of Radioactive Drugs to Humans. The inventigator must stait a report (Appendix C) and a copy of the signed consent form to a Radioactive Drug Research Committee (RDRC) within 15 days from administration of the isotope.
- i. Volunteer Agreements. Ropion of volunteer a lements for all protocols must be focuseded to Chief, Olinical Envent stion fermice, within one month of entry of the patient onto study. The consent form must include the patient's printed or Typed name, address, and social security number (see Appendix A).
- 8. REPORTS TO PHARMACEUTICAL COMPANIES. For procurement of investigational drugs which have not yet been released by the Food and Drug Administration, detailed reports to the drug company are required by FDA (Form FD 1573). The reports are the responsibility of the principal investigator, and are a matter of direct communication between him of the free contag.

- 9. REQUEST FOR FUNDS. Requests for funds to support the clinical investigation program are presented to the Center Command annually during the month of March.
- a. Projects requiring refunding in the amount of \$1,000 or more are submitted each year prior to 1 March in the format of Appendix A for consideration. Projects requiring substantial increases (> 20% increase) in funding must undergo review by the Committee before funding will be approved.
- b. New proposals which require funds may be submitted at any time. Approval of funding is dependent upon availability of local, Health Services Command or Surgeon General resources. Format Appendix A.

10. INFORMED CONSENT.

- a. Patient Consent. The utilization of drugs or precedences where here yet been accepted or established by common use require the patient's consent. The patient must be informed, i.e., his/her consent must be based upon his/her having knowledge of the experimental nature, purpose, and possible hazards. The consent should be in writing, except as provided in paragraph 7b, AR 40-1, or if the patient is a child (see 11). The consent form must be witnessed by someone other than an investigator on the project. Copies of the written voluntary consent will be maintained by the principal investigator for five years after termination of the study and will be forwarded to the Chief, Clinical Investigation Service, within 30 days of entry of the patient onto study.
- b. Human Volunteer. Investigative studies in which drogs are employed are subject to, and must come to with 12 40-7, Use of Investigational Drugs and/or AR 70-25, Use of Voluntains as Subjects of Research in Addition to AR 40-38.

11. RESEARCH INVOLVING CHILDREN.

a. In general, research in children will not be undertaken unless appropriate studies have first been undertaken in animals, adults, or older children. If the project is minimal risk, it may be undertaken if the Clinical Investigation Committee and Human Use. Committee have approved the protocol, the assent of the child capable of understanding is obtained (possibly in writing), and written permission of the engage or grandian is secured.

- b. If the project is more than minimal risk, research that has potential direct benefit to the child, may be undertaken if the Clinical Investigation Committee, Human Use Committee, and the Office of the Surgeon General have approved the protocol, considering that the risk is justified by the anticipated benefit, that the risk benefit ratio is at least as favorable as that presented by alternative approaches, the assent of the child capable of understanding is obtained (possibly in writing), and written permission of the parent or guardian is secured.
- c. If the project is more than minimal risk and of no direct benefit for subjects, the research may be undertaken if the Clinical Investigation Committee, Ruman Use Committee, and the Office of the Surgeon General have approved the protocol, that the procedure presents experiences commensurate with those inherent in their actual medical situation and is likely to yield generalizable knowledge about the subject's condition, the knowledge is of vital importance, the assent of the child capable of understanding (possibly in writing) for obtained, and written packlession of the parameter guestian it secured.
- d. Appendix A includes the appropriate volunteer agreement for protocous involving research in calldren. On the opposite side must be "instructions to guardian" and if the project is directed at children capable of understanding written instructions, there must be "instructions to patient" written at a level comprehensible by the average aged participant in the project.
- e. The Human Use Committee will periodically no ritor the procuse of assent and permission in research involving children:
- 12. IOW RISK PROTOCOLS In ADULTS. A protocol in which there is a minimum possibility on it. May to be serjected to the study mights as mesulthof the study. The tudy may not involve an investigational drug or device and may involve only human subjects who is given fully informed consent. That is, the study may not involve subjects who are minors, prisoners, institutionalized mental flux med or mentally disabled. The study also may not include subjects temporamily mentally disturbed by reasons of unconsciousness or come. Low misk protocols may be undertaken after local approval by the Clinical Investigation Committee and Human Use Committee. These protocols will continue to be forwarded to the Human Use Review Office, who will notify the Chief, Clinical Investigation Service, immediately if there is any difficulty with either the protocol or the assessment of level of risk. The fell wing two mole meadle was seen accomplish of low risk studies.

8 January 1979

WR 70-1

a) Collection and analysis of additional small amounts of cerebrospinal fluid, amniotic fluid and venous or arterial blood when taken in conjunction with specimens of these fluids which are to be drawn for accepted clinical indications and do not require another puncture to obtain the additional amounts of these fluids for investigational purposes.

- b) Analysis of hair and nail clippings collected in a mondisfinguring manner and the analysis of deciduous teeth.
- c) Collection for analysis of excreta and external secretions including feces, urine, sweat, saliva, derumen and tears or swab culture specimens of body orifices, placenta expelled at delivery, umbilical cord blood after the cord is clamped at delivery, and amniotic fluid at the time of artificial rupture of the membranes prior to or during delivery.
- d) Recording of data by physical sensors applied either superficially or at a 11-handr and which do not involve significant input of energy into the subject. Such procedures include, but are not necessarily limited to weighing, electrocardiogram, electromyor graphy and detection of naturally occurring radioactivity, electroencephalogram, thermography, diagnostic echography and electroretinography, caliper measure of anticopomorphic characteris los and detection of naturally occurring radioactivity.
- e) Bloom drawing or quantities of blood less than 20 cm/6 weeks from adult subjects in whom their underlying medical condition is not known to be associated with anemia. These patients need not have a hematocrit done before obtaining the blood specimens.
- f) Bloom denoting of quantities of blood loss that 450 period gelea or 12% of the estimated blood volume, 7% of the body weight, whichever is lesser, from subjects who are not anomic. (Anomia is defined as a hematocrit < 40 for males, < 35-for female and are to be obtained, the protocol must state that a hematocrit and reticulocyte count be obtained in patients prior to entry onto study and be not anomic.
- g) Studies involving generally accepted, medically indicated diagnostic or therapeutic procedures or comparisons of two or more renerally accepted alternative procedures.
- h) Monroction on difficult sealouis of machinist to laggy specimens removed no the oil consequence of a widely supercise surgical indication.

- i) Collection of both supram and subgingival plaque, provided the procedure is no more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques.
- j) Voice recordings made for research purposes such as investigations or speech deficits.
 - k) Moderate exercise by healthy volunteers.
- 1) The use of survey research instruments (in views or questionsaires) and psychological tests, interviews and a seddures that are part of the standard battery of assessments used by psychologists in diagnostic studies and in the evaluation of judgmental, perceptual, learning and psychomotor processes, provided that the subjects are normal volunteers and that the data will be gathered anonymently or that confidentiality will be protected by procedures appropriate to the sensitivity of the data.
- m) to regress evaluation projects that make no course requirements on ... the subjects participating in the program and that with not benefit; the subjects in the program.
- n) Noninvasive pulmonary function testing such as (but not limited to) spicometry and plethsysmography.
- o) Collection and analysis of small amounts of internal socretions such as gastric contents and pulmodary aspirites when our oftion of these secretions does not involve the placement of cither a proofest tric tube or endotracheal suction tube solety for obtaining specimens for research purposes.
- p) diary respectings of distancy lates, by accompanies of line of invitation and the like, whether the distint remains among the contract.
- 13. Research in Pregnant Women Fetuses -- shall conform to the requirements of CVR 46.205 46.208.
 - A. Ceneral limitations.
- 1. No activity to which this subpart is applicable may be undertaken unless:
- a) Appropriate studies on animals and nonpregnant individuals have been morphished;
- b) Except where the purpose of the outlivies is to meet have health meads of the mother we the mention land to the military feet fetus is a single and, in all copy of the least of outlier outlier achieve.

8 January 1979

WR 70-1

- c) Individuals engaged in the activity will have no part in:
 (i) Any decisions as to the timing, method, and procedures used to terminate the pregnancy, and (ii) determining the viability of the fetus at the termination of the pregnancy; and
- d) No procedural changes which may cause greater than minimal risk to the fetus or the pregnant woman will be introduced into the procedure for terminating the pregnancy solely in the interest of the activity.
- 2. No inducements, monatary or otherwise, may be offered to terminate pregnancy for purposes of the activity.
 - B. Activities directed toward pregnant women as subjects.
- a) No pregnant women may be involved as a subject in an antivity covered by this subpart unless: (1) The purpose of the activity is to meet the health needs of the mother and the fetus will be placed at risk only to the minimum extent necessary to meet such needs, or (2) the risk to the fetus is minimal.
- b) An activity permitted under paragraph (a) of this section may be conducted only if the mother and father are legally competent and have given their informed consent after having been fully informed regarding possible impact on the fetus, except that the father's informed consent need not be secured if:
- 1) The purpose of the activity is to meet he health meeds of the mother;
- 2) His identity or whereabouts cannot reasonably be ascertained;
 - I have in mor remodestly a middle;
 - 4) the prognancy resulted from tipe.
 - C. Activities directed toward facuses in utaro as subjects.
- 1. No facus in utero may be involved as a subject in any activity covered by this subpart unless:
- a) The purpose of the activity is to meet the health needs of the particular fetus and the fetus will be placed at risk only to the minimum extant accessary to meet such needs, on

WR 70-1

8 January 1979

- b) The risk to the fetus imposed by the research is minimal and the purpose of the activity is the development of important biomedical knowledge which cannot be obtained by other means.
- 2. An activity permitted under paragraph (1) of this section may be conducted only if the mother and father are legally competent and have given their informed consent, except that the father's consent need not be secured if:
- a) His identity or whoreabouts cannot reasonably be ascertained.
 - b) He is not reasonably available, or
 - c) The pregnancy resulted from sape.
- D. Activities directed toward fecuses as learn, including nonviable for mass, a subjects.
- 1. Until it has been ascertained whether or not a februa or entropy is viable, a fetus or other may not be involved as a subject in an activity covered by this subpart unless:
- a) There will be no added risk to the fetus resulting from the activity, and the purpose of the activity is the development of important blomedical bookledge which manner be obtained by other means, or
- b) The purpose of the activity is to enhance the possibility of survival of the particular fetus to the point of viability.
- (c) No nonventile fetus may be envolved as a subject in ac activity covered by this subpact unless:
- (1) Vital functions of the fetus will not be applificially maintained,
- (2) Experimental activities which of themselves would terminate the heartbeat or respiration of the fetus will not be employed, and
- (3) The purpose of the activity is the development of important blooded hal knowledge which a most in the large attention means.

a) In the event the fetus ex utero is found to be viable, it may be included as a subject in the activity only to the extent permitted by and in accordance with the requirements of other subparts of this part.

- b) An activity permitted under paragraph (1) or (2) of this section may be conducted only if the mother and father are legally competent and have given their informed consent, except that the father's informed consent need not be ascured if: (1) his identity on whereabouts cannot reasonably be ascertained, (2) he is not reasonably available, or (3) the pregnancy resulted from rape.
- 14. RESEARCH, MENTALLY INFIRMED. An appropriate addendum to these regulations will be published when the federal regulations regarding research in the mentally infirmed are promulgated.

HEWE-QCR

FOR THE COMMENTAL

MAN, HSC. ADJUTANT

DISTRIBUTION .

I plus 100 copies to Clinical Inva algorities for

APPENDIX A

APPLICATION FOR CLINICAL INVESTIGATION PROJECT (New protocols must conform to this format and be complete.)

- 1. PRINCIPAL INVESTIGATOR:
- 2. PROJECT TITLE: (Enter short project title.)
- 3. OBJECTIVE: (Brief but specific statement of the objective of the project.)
- 4. HEDICAL APPLICATION: (Explain briefly the medical importance and possible usefulness of the project.)
- 5. STATUS: (What has been accomplished or published in the proposed area of study and in what manner will the project relate to an differ from that which has been accomplished. If references or personal communication with other Army medical facilities are involved, or indicate.
- 6. PLAN: (Charline exactly what is proposed to be accomplished in sufficient detail to indicate a clear course of action. Technological validity of procedures and chrosological steps should be shown.) (NOTE: The Surgeon General and the local Commander must have a very clear picture of how the investigation will proceed to meet the objective of one project. This paragraph frequently furnishes the basis for approval or disapproval of the project.)
- 7. BIBLIOGRAPHY: (List source of information.) (Include pertinent references and attach.)
- 8. FACILITIES TO BE USED: (Such as 'aboratory, wast or clinic.)
- 9. TIME REQUIRED TO COMPLETE: (Give month and year of expected start and anticipated completion. Under no circumstances will projects be funded for longer than three years without submission of a new protocol).
- 10. PERSONNEL TO CONDUCT PROJECT: (List names and positions of persons to be directly involved in project work. Attach short biographical sketch, including resume of education, research craining, and list of publications, for each person named.)

II. FUNDING IMPLICATIONS: (List total budget for the protocol, as well as the budget for the FY in which the protocol is approved.)

æ.	Total FY-78 for the Protocol Personnel: (itemize and explain need) \$ \$
ъ.	Equipment: (itemize and explain need)
c.	Consumable Supplies: (itemize)
, ժ.	Travel: (icemize and explain need)
e.	Modification of Facilities: (explain)
f,	Other (explain)
	TOTAL
•	
12.	DATE PREPARED: (give day, monen and year of preseration)
(Sign	nature of Principal Investigator)
	,
(S:	ignature of Department Chief)

Enter title and mailing address of Principal Investigator)

APPENDIX A

IMPACT STATEMENT

(Must be attached to each protocol enumerating impact considered to be beyond good patient care.)

	•			
Bed Occupano	9:			
Laboratory:				•
Radiology:	•			
Pharmacy:				÷
Mursing Serv	Ede:			-
Registrati				
Other:	<i>:</i>	•	•	
Approvals	Chief of Service	Ghief	of Dept	For Losp Comm
Date:	·			
Signature:	•		•	·
Name:				•
Grade:				
Position:				

33

VOLUNTEER AGREEMENT

- E
7.7

I,	, having attained by eighteenth
(18th) birthday, and others	ise having full capacity to consent, do
hereby volunteer to pacticipa	ate in an investigational study entitled:
· una	der the direction of
•	of the Department/Service/Institute of
	, Walter Reed Army Medical Center,
L'achimates D.C	•

The implications of my voluntary participation; the nature, duration and purpose of the study; the methods and means by which the study is to be conducted; and the known inconveniences and hazards have been thoroughly explained to me by the principal investigator or by one of the coinvestigators and such inconveniences and hazards are set forth in detail on the attached page of this Agreement, along with my initials or signature. I have been given an exportunity to ask questions concerning this investigational study and my participation in the study, and any such questions have been answered to my full and complete satisfaction.

During the oriese of my beastment as a patient of Wolfer Reed Army Medical Center, I have brea provided with a copy of a Privacy Ach statement (DD Form 2005), which has made me aware of the sofequards I have been given evailable to me because of the Privacy Act of 1974. the opportunity to review the DD Form 2005, ask questions and to retain a percoant copy. I have been made aware that the information gained about me, because of my participation in this investigational study, may be publicized in medical literature, discussed as an educational model, and used generally in the furtherance of medical science. I herely consent to provide such personal information as is requested of me for this investigational study and freely consent to the disclosure of pertinent personal information derived from my participation in this investigational study for teamns of publication in medica: disconsion as an education - those additional reacons which specifically relate to the forthorance of medical ocience.

I understand that in the event of physical injury esulcing from the research procedures, medical treatment for injuries or illness is available and that concensation may be available through judicial avenues. Information regarding judicial avenues of compensation is available from the Center Judge Advocate General.

I am aware that at any time during the course of this investigational study I may revoke my consent and withdraw from this study, without prejudice; however, I may be requested for medical reasons to undergo further examinations if in the opinion of my attending physician such examinations are necessary for my health or well being.

If there is any portion of this explanation that you don't understand, ask your doctor before signing.

Signature Date

Printed Name Social Security Number

Address (permanent)

I was present during the explanation referred to above, as well an during the Volunteer's opportunity to ask question. I haveby witness, the Volunteer's signature.

Signature Date

Principal Investigator's Signature

D. .

this page of the Volunteer Agreement, the principal investigator should set or full details concerning the investigational study, insofar as such would feet or influence the tentative subject in any way. This explanation should worded so that it can be clearly understood by the subject. The subject could place his initials at the end of the last line of explanation.

proper explanation should, at a minimum, provide the answers to the sllowing questions in lay language:

- 1. What will be administered or done to the subject?
- 2. How long will the subject's participation last?
- 3. To what costs or examinations will the subjects be required to submit?
- 4. Why is the investigation being conducted?
- 5. Has this particular study been done previously, and, if so, with what results?
- 6. What indomestables of discomforts is the subject likely to experience?
- 7. What risks or hazards can be reasonably anticipated?
- 8. What steps will be taken to prevent or minimize these ricks or haz-dards?
- 9. If blood is being drawn in the study, the total amount of blood should be accurately quantitated in both cols as insures.
- 10. The volunteer should be offered the opportunity to ask questions.
- 11. Alternatives to participation in the study should be identified. It Should be emphasized that participation in the study is entirely optional
- 12. An instruction that the subject is free to decline participation or terminate participation at any time without prejudice.
- 13. Can the patient expect to accrue any benefit from participation in the study; if none, so state.
- 14. A statement informing the volunteer of available opportunities for compensation for any injury incurred during the study.
- Exculpitor: 'anguage about a not le usada
- 16. For Occur by contends, where conditioned a time map that "where is no grant made that "where is under sed of remaining process." I shake the content of the content

VOLUNTEER AGREEMENT

(Children Under Legal Age of Consent)

I/We, havin	g full capacity to consent, do
hereby consent for my/our	·
(rel	ationship) (name of perticipant)
to participate in an investigation	nal study entitled:
under the direction of	of the Department/Service/ Walter Reed Army Medical
Institute of	Walter Reed Army Medical.
Center, Washington, D.C.	· .

The implications of his/her participation; the nature, duration, and purpose of the investigational study; the methods and means by walch it is to be conducted; and the inconveniences and hazards which may reasonably be expected have been explained to me/us by and are set forth on the attached page(s) of this Agreement which I/we have initialed or signed. I/We have been given an opportunity to ask questions concerning this investigational study, and any such questions have been answered to my/our full and complete satisfaction.

I/We certify that my/our child has remained an exclanation of this investigue conal study in terms that he/she can understand, that he/she has hed an opportunity to ack and has had answered any questions concerning this heady, and that he/she assents to participating in this study.

I/We have been provided with a copy of the Privacy Act statement (DD Form 2005) which has made me/us aware of the safeguards available to me/us as a result of the Privacy Act of 197%. I/We have been given a chance to review the DD Form 2005, to ask questioned and to retain a personal copy. I/We have been made aware that the information gained about my/our child, because of his/her particlepation in this investigational study, may be published in medical literature, discussed as an elucational medical and used parable in the furtherance of medical attended. My/our child along with myself/ourselves consent to provide such personal information as is requested of us for this investigational study and freely consent to the disclosure of personal information derived from his/her participation in this study for reasons of publication in medical literature, discussion as an educational model, and for those added tional reasons which specifically relate to the furtherance of medical science.

I/We understand that I/we may at any time curing the course of the investigational study revoke my/our consent and withdraw my/our child from this shuly mithout prejudice; however, he/she may be requested to this go further a thirdians, it, in the crimion of the attenting physician, much cominations and necessary for his her well being.

I/we understand that in the event of physical injury resulting, from the research procedures, medical treatment for the injuries, or ill one is available and that compensation may be evailable through judicial avenues.

signature	relationship	•	date
signature	relationship		date

I was present during the explanation referred to above, as well as during the parents'/guardians' and the child's opportunity for questions and hereby witness their signatures.

witness's signature		date
	in the section	. •
physician's signatur	70	date

ASSEMT STATEMET (Children Under Legal Acc of Consent)

I certify that I have received an explanation of this investigational study in terms that I can understant, that I have had an opportunity to tak and have received answers to any questions I had concerning this study, and that I agree to participate in this study.

*	patient's	ระธุมล่วประ		deile			
			••				

APPERUIN P

Annual Progress Report FY

Work Unit No :

Title of Project:

Investigators:

Principal: (senior investigator responsible for project)

Associate: (coinvestigators)

Objectives: (goal of research)

Technical Approach: (method of attaining objectives)

Progress and Resultur (occanized description of the research affort

in relation to this work unit which was performed during the period of this expert. If investigational drugs were used the information required by AR 40-7 must be included. The number of patients studied must be precisely

delineated.)

Conclusions: (complete statement of goals achieved to corrent stadies)

Wive there been serious or unexpected slaw affects, complica-

tions occurring in subjects participating?

Funding Requirements: (present and next FY)

Personnel: (Jame 151 zeade)

Equipment: Supplies: Travel: Other:

Publications: (list only those published during present FY or

abstracts from your service which are related to the research described in this report. Failure to enumerate publications or abstracts have compromised fund

dias of the protocol.)

Type of toport in a second, terminated interior

(Separat smooth in Grand on S. e. 10, 1720) which have visit a consequent of \$25 persions. The notice were pares. Double story interest scribes of the report, transfers are typical utining open a option. To not our a classe to \$50 person property.)

DISPOSITION Francisco de la constitución de la constitución de la constitución de la constitución de la constitución de la					-
ASSESSMENT SOME SOME SOME	TualeC1	and the second s			
HSWP-QCR	Radioactive	e Drug Resc	arch Repo	ort	
TO Secretary, RDRC Room 3E05, CIS WRAMC	FROM		.	DATE	CHT
l. Work Unit #:				• :	•
?. Work Unit Title:					
· · · · · · · · · · · · · · · · · · ·	-				
. Patient Information:					
a. Identification Code;	and the residence of the control of			st allow fo	r referencias (t)
b. ige:			•	•	
c. Sex:		,	. •	•	•
d. Weight:	end V y		•		,
. Pharmacological Bose Infor	rmation:		••		
a. Active Ingradients:		ند بالمعادد معادد الميدو بريستور مياد	,		
b. Maximum Amount Adminis	stered per Sub	oject:	~		
Rumio nucli d - Ladopmation:				. •	
a. Radionuplide Used (Inc	clude any sign	nifi ca nt co	ontaminan	ts) :	
b. Activity of Radionact	ida Useda				
c. Date Radionuclide Admi	inistered:				
Were X-ray procedures utilities this research protocol?	lized in conju	unction vit	th YES	NO	
Has any subject used in the in other radioactive drag	ris study part research stud	ticipated Hes?	Notes:	03	
			•		
		- 77 / 115-	175.		The Art of the second

Administrative Checklist for Evaluation of Providenta (available for distribution to principal investigators)

•				
	37	S	110	-
1. Administrative inadequacies:				
Is the format inappropriate?				
Has the protocol been signed off by the Chief of Service and Chief of Department?				
Is there an impact statement?				
Is the impact statement signed off by the lavelyed Services?		-		-
Is the budgetary information sufficiently sublicit? The exact type of supplies should be enumerated.	the other spile hades he			
Is there a justification for major equipment pur- chases?				
2. Adequacies of consent forms:			,	شنن ل سمية
A. Does the consent form contain:				
1) An explanation of the purpose of the rouds	A 2. A. (MIT)			
2) The duration of the study				-
3) A full explanation of what is going to happen to the marien				
4) A description of all discomfacts any pisks as lated to the research.	-			
5) A disclosure of an alternative to perticipable in the study. It should be emphasized that per ticipation in the study is entirely optional.	3			
 A description of any benefits to be expected from participation in the study 				
7) An offer to answer any questions concerning the study	10			
8 An instruction that we subject to a section of terminate participation of terminate participation of any time without projection.	.oa			

3-1-1

9) A statement informing the volunteer of available opportunities for compensation for any injury incurred during the study.

10) For Oncology protocols, a statement that "there is no guarantee that the proposed chemotherapy program is better than a standard program"


3. Is the language used in the consent form comprehensible by lay patients?

C. Is there exculpatory language in the protocol?

Signatura			
	1.2	•	

. From the telesty and Secondary Vertica of Profession

					
Reviewer:	r et mage en state Managengalden i	er an me energetildelikasjonelar lätteraturgeten flagereten.	, manda ang karamanan di ang kangana man Mas		 . ,
Recommendations	eńi cz	Committee:			
approval	<u> 77</u>	disapproval		provisional	
Narrative justif	ication	for recommend	dations:		•
					-
	٠				
		•.		•	
			•••		
					-
					•
Prioritization (sstanding, 3.0 ave				5 45 5 1.0) being out-
Scientific merit			(Assign	a number)	
Priority for fund	, .				



. Form for tringry and Secondary Vericus of Protocole Protocol Title: Reviewer: Recommendations to the Committee: 77 disapproval // provisional approval [7] approval with stipulation Narrative justification for recommendations: Prioritization (Assign a number between I and 5 with 1.0 being outstanding, 3.0 average, and 5.0 disapproval.)

(Assign a number)

Is the budget realistic and adequately justified?

Priority for funding ____

Scientific merit

3 62

Dear Professional Committee Member of Clinical Investigation Committee:

Enclosed is the FY-1978 Annual Progress Report (APR) for Work Unit &

It is requested that you represent the Clinical Investigation Committee by reviewing the APR for the enclosed protocol. Upon request, we will provide you with the original protocol, or you may come to the Clinical Investigation Service office during duty hours. The following questions are offered to you as guidelines to assist you in your review.

- 1) Is progress being made on the protocol?
- 2) Does the progress report indicate substantial deviation from the original protocol?
- 3) Is there any evidence of either unexpected sits effects or an increased incidence of expected untoward side effects?
- 4) Is the request for funding appropriate? (One should nonsider here the merit of the project, pravious budget, previous progress as locumented by abstracts or publications, and justified than for furthing in the APR.)

Commants:

Recommendations: (please check in box)

- [7] 1) That the APR and request for funding be approved by the Committee.
- 2) That the following additional information/classification be furnished by the principal Investigator.
- 7 3) That the entire Committee closely satisfies this APR and scaling the following specific aspects of the APR.

- I. Implementation of the System of Protocol Review (including the System of Primary and Sacondary Reviewers).
- A. Protocols must be received by the 25th of the preceding month (or next working day if the 25th is a weekend day or holiday) in order to be considered at the next meeting, usually the fourth Tuesday of each month. Protocols not approved by the Department and Service Chief would not be accepted. The investigator would be expected to provide Clinical Investigation Service with several key references from the bibliography of the protocol.
- B. Upon receipt of the protocol by Clinical Investigation Service, an administrative review and evaluation of the consent form would be undertaken. (See Incl #1 explanation and review sheet.) Any protocol with deficiencies would not proceed further in the review process until the deficiencies were resolved. Almon deficiencies in the content form would be corrected by the editorial staff in the Clinical Investigation Service office. The investigation would receive a revised consent form and in explanation for revisions.
- C. Protocols would then be read and revised by Chief and Ance Chief, Clinical Investigation Service, who would evaluate them primarily for adequacy of experimental design. The Chief and Asst Chief might elect to have an outside consultant review some protocols.
- D. These protocols judged to be of reasonably sound design would be forwarded on about the first of the month to two (2) primary reviewers and two (2) secondary reviewers. The primary and secondary reviewers would be members of the Committee. Any of the primary and secondary reviewers could utilize additional consultation. An attempt would to hade to select primary marievers from the C4 withee on the basis of knowledge/expertise allied with the area under investigation in the project. An exception would be Oncology protocols, which would be distributed to the Committee on a rotational basis. Primary reviewers would autompt to assess anientific merit, experimental design, and give some priority for funding. They would be provided the key references submitted by the principal investigator. Each primary noviewer would submit a written report to Clinical Investigation Service of his assessment of the protocol by the 15th of the month (see Incl. #2). At his discretion, he could consult with the investigator, and/ or another consultant reviewer and suggest modifications or simply submit a unitten report to Clinical Investigation Service.

The secondary reviewers would also be selected from the Committee, except that they would not have expertise or knowledge allied with the area under investigation. They would be selected on a rotational basis, would submit the same written reports as first reviewers, and would be especially expected to provide some degree of more remote perspective regarding the merit of a project.

- E. The entire Committee would be provided copies of the protocol, primary review and secondary review. Attendance of the investigator at the meeting would be optional but he would be provided with a copy of the minutes which would contain the reasons for approval/disapproval. The written protocol would be expected to be sufficiently explanatory that only adjunctive information would be the only input requested of the investigator at the meeting. The entire Committee would consider the protocol and reviewer's comments and vote for approval/disapproval. The numerical estimation of scientific merit and priority for funding from the reviewers would be recorded in the minutes. The entire Committee would have an opportunity to revise the numerical estimate of scientific merit; and priority for funding.
- F. A list of volunteer consultants and their areas of expertise would be compiled Lyon USUNC, AFRE, WRAIR and MRMC.

IT. Annual Review of Protocols

- A. Henceforth, the Service will issue investigators lab note—books, which will be vailable for inspection upon 24 hour notice and will be returned to Clinical Investigation Service upon completion of the project or the investigator's departure from VRAMC, at the discretion of the Chief, Clinical Investigation Service. For certain types of projects, a study record could suffice in lieu of a lab notebook.
- B. Funded protocols while have least approved more than three years before much so included to and Committee has approved. Cooperative group protocols not vertiining funding will be exempted from the three year limit. After three years, they are automatically considered terminated. Notice will be given to the principal investigator of those protocols where months prior to technation.
- C. On a random basis, periodic inspections will be made of the data books, consent forms, and general status of individual work units. Written recommendations will be made to the Committee based on the basis of these inspections. At least one week notice will be afforded investigators. The Committee may elect to terminate a project or give the investigator time to correct deficiencies prior to a reinspection.

- b. This year's Annual Progress Report will be divided into equal packages for each member of the Committee (see Incl #3) who can:
- 1) Cortify that the Annual Progress Report is adequate and the project merits continuation.
 - 2) Request additional data from the principal investigator.
- 3) Recommend the entire Committee closely scrutinize the project and decide whether or not continuation is warranted.

HOW TO WRITE A PROTOCOL

- A. The research process, a stepwise development
 - 1. Prior knowledge or opinion
 - 2. Inductive reasoning
 - 3. Formulation of hypotheses
 - 4. Deductive reasoning leading to experimental design, to test hypothesis
 - 5. Experimentation
 - 6. Evaluation and interpretation of data
 - 7. Conclusion

Protocol writing is a specific exercise in the scientific method. It's central feature is the statement of a hypothesis which is verifiable by experimentation. In addition, the protocol specifies planned procedures by which evidence may be obtained either to verify or to reject the hypothesis. Thus the protocol is a brief, orderly statement of the information and directions pertinent to carrying out the research process in a specific instance. The discipline it imposes is that of exact thinking and expression.

A suggested forms

- 1. Title
- 2. Background: Prior knowledge or opinion; inductive and deductive reasoning leading to the statement of the hypothesis
- 3. Hypothesis: Statement to be verified to rejected
- 4. Objective: Association to be gained

- 5. Materials and methods:
 - a. Experimental subjects; materials
 - . b. Technical methods (quantitative determinations)
 - c. Experimental design and procedures (the formal plan and directions for experimentation)
 - d. Analysis and interpretation of data, to include:
 - (1) Data tables in outline
 - (2) Outline of proposed calculations and statistical procedures as determined by the experimental design. These calculations should include prescriptions for
 - (a) The reduction of data
 - . Ili . determination of Their charactericity, Theodiptive values
 - (c) Estimates regarding the population parameters as indicated by the sample statistics, with an accessment of the uncertainty of such estimates
 - (d) Comparison between groups and the measure of uncertainty of such comparisons
 - (c) Provision for the discovery of interdependency of variables and the effect of such interdependency on interpretation of the results:
- 6. Tibliography

TIPS FOR WRITING AND PROCESSING PROTOCOLS

- 1. Make certain that approval of department chiefs is obtained before submission to Clinical Investigation Service.
- 2. Curriculum Vitae's are required of each investigator.
- 3. An appropriately signed off impact statement must be included;
- 4. Experimental design must be clearly specified.
- 5. Too frequently, the planned method of data analysis is inadequately outlined. This can lead to local disapproval, inordinate delay, or questions from the Office of the Surgeon General.
- 6. The exact population of patients to be studied is often inadequately identified. The age groups and excluding conditions from study must be precisely identified.
- 7. If the patients are at risk, there need be a description of how the risk will be minimized, i.e.; constant attended to a physician.
- 8. Any requests for funding should be substantiated in detail.
 You should be prepared for your requests to be critically analysed at the Clinical Investigation Committee meeting.
- 9. The major problem with protocols that are not approved is clarity in the writing of the protocols. All parts of the protocol should be comprehensible by tay personnel, as well as physicians and other professionals not in the particular area of investigation.

E = 3

0. Leave one inch margins on all four sides of the page.

IMPACT STATEMENT

Parients:	
Bed Occupancy:	
·Laboratory:	
Radiology:	
Pharmacy:	
Nursing Service.	
Registray:	
Other:	
Approvided	Chief of Service Ciffer of Lept Power
Date: Sig:	
Name:	
Grade:	
Position:	

Author Index

```
Adler RA:
            39
Alford JP: 68
Anderson JH: 493
Annable CR: 368
Armbrustmacher V: 146
Baker J: 415
Baldwin PJ: 591
Bank RL: 552, 560
Barnes S: 168, 174
Bass JW: 509
                7, 139, 140, 204, 205, 208, 209, 211, 212, 215, 216, 217,
Berenberg JL:
                219, 221, 223, 226, 227, 228, 229, 230, 231, 232, 236,
                237, 238, 239, 240, 241, 245, 246, 247, 248, 249, 250, 251, 252, 253, 255, 257, 258, 259, 262, 264, 267, 270, 272, 274, 275, 276, 496, 570
              22, 28, 30
Bergman SM:
Bergquist RJ: 336
Berne BH: 10, 401, 418, 430
Berry WR: 6, 200, 324
Blom J: 206, 214, 224, 233, 235, 254, 260, 261, 273
Bloomfield CJ: 233
Boedeker BH: 188, 203, 581, 588
Boehm TM: 7, 8, 10, 37, 40, 58, 62, 97, 156, 400
Bond-Liebertz MD: 360
Bongiovanni B: 396
Bongiovanni R: 8, 11, 135, 136, 318, 395, 515, 571, 572, 573, 574, 578
Boslego JW: 6, 296, 297, 308
Boswell B: 438
Bowie RB: 480, 594
Braham SL: 498, 501
Brewer TG:
Bridenbaugh RH: 554, 556, 558, 560, 562
Brinton CC: 6, 296, 297, 308
Brodkey CG: 609, 611
Bruton J: 5, 40, 41, 77, 125, 130, 155, 158, 167
Bryan J: 6, 297
Burgess DP: 11, 81, 502, 506, 507, 508, 510, 513, 516, 517, 518, 519
Burkhalter EL: 191, 193
Burman KD: 5, 6, 8, 36, 37, 38, 39, 40, 41, 43, 45, 48, 49, 50, 52,
             54, 58, 59, 60, 62, 63, 68, 74, 82, 104, 106, 108, 109,
             111, 112, 113, 114, 115, 117, 118, 123, 124, 133, 134,
             135, 137, 138, 140, 144, 154, 159, 163, 164, 167, 168,
             169, 170, 171, 173, 175, 176, 177, 178
Burton CL:
             333
Butkus DE:
             22
Butler P:
            500
Butler VM:
             78, 92, 122, 132, 168
Butler WM:
             570
```

Cabellon S: 328 Cafferty PJ: 582 Callahan M: 380 Canfield CJ: 312 Cannmann D: 50 Cassimatis EG: 554 Castell D: 0, 8, 180, 188, 196, 199 Cavalli F: 235 Chadwick SG: 353 Chapman R: 139, 140, 288 Charya RV: 415 Cheatham WW: 91 Chernow B: 8, 196 Chi G: 360 Chulay JD: 312, 314 Chun PKC: 35 Chow JA: 380 Ciak J: 6, 296, 297, 308 Clagett GP: 326, 328, 330 Collins GJ: 326, 328, 329 Copley B: 33 Corcoran R: 49 Corley J: 485 Corrigan DF: 40 Crosby WH: 579, 580 Cross AL: 320, 321 Crowley JM: 357 Cultner J: 208 Cupples HP: 334 Curl WW: 907 Curtis DJ: 187, 408, 501 Dahms WI: 67 Davia JE: 11, 35, 603, 606 Davis C: 377 Davis P: 10, 385 Davis RW: 10, 383 Dawson E: 78, 120 Dembroski TM: 606 DeMeester TR: 196 DeShazo RD: 10, 382, 383, 400 Detrick-Hooks B: 530, 540, 543, 551 Deutsch AJ: 396, 398, 435 Dickson E: 6, 317 Dimond RC: 7, 8, 39, 40, 41, 119, 121, 154, 157 Dixon JP: 589 Djuh Y-Y: 40, 118, 137, 138, 160 Dobek A: 6, 316, 317, 320, 321 Dubois A: 180

Duff P: 466, 467, 477, 478

24 Dugar M: 200 Dunn MA: Dunne MJ: 353 Durakovic A: 490

Dvorak HM: 10, 382, 383

Earll JM: 39, 40, 41, 95 Eddleman WL: 328

Edwards MS: 387 Eil E: 5, 125

Evans R III: 10, 37, 384, 387, 389, 390, 391, 392, 395, 415, 435, 436, 437

Ewel CH: 396, 398, 581

Fair C: 360

Fischer GW: 11, 502, 506, 507, 509

Fishbein WN: 590

Fishburne, FJ: 564, 565, 566

Fitz JD: 22

Fleckenstein L: 612

Floyd M: 10 Ford DD: 580

Fowler JE: 371, 376, 378

Fox EL: 609, 610

Frank T: 442, 443, 458, 459, 460

Frantz AG: 39, 40 Friedman M: 207

Galloway JA: 10, 400

Gemayal N: 75

George E: 522, 528, 531, 545

Gilbreath M: 297 Ginsburg SJ: 233 Glaines LT: 436

Glass AR: 5, 6, 7, 8, 11, 65, 70, 72, 75, 83, 85, 87, 89, 98, 100,

102, 104, 148

Glass DC: 606 Glickman A: 217 Golden R: 499, 500 Goldner FH: 179 Gotliet AJ: 211, 233 Graeber GM: 360, 582 Green BJ: 63

Gurevich Uvena J: 360

Haddock JB: 441, 442, 443, 458, 510, 511

Hannah JS: 11, 572

Harmon JS: 6, 9, 200, 322, 323, 324, 325, 588, 589

Harper G: 563

Harrison SM: 293, 294

Harton J: 119 Hasbargen J: 31, 32, 33 Haut MJ: 568, 569 Hayes K: 11 Heller PB: 440, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 461, 462, 463, 464, 465, 468, 469, 470, 471, 472, 473, 474, 475, 483, 484 Henderson RL: 351, 355 Hendricks LD: 312 Henry A: 31, 32, 33 Herald WJ: 293, 294 Hicks CU: 11, 572, 574, 578 Hirata RM: 189, 190 Hodges W: 297 Howe EG: 611 Hubbard V: 10, 385 11, 502, 562 Hunter JG: Hunter KW: 11, 507 Hutchison GB: 496, 497 Jabbari B: 563 Jahrling PB: 493 Janowitz WR: 8, 196 Jewell JS: 353 Johnson C: 35 Johnson JP: 5, 18, 19 Johnson LF: 8, 13, 144, 180, 182, 187, 188, 189, 190, 191, 193, 194, 195, 196, 197, 199, 200, 203, 322, 588 Jones L: 74 Kaliner M: 10, 385 Kaminski RJ: 195, 493 Karcher D: 520, 530, 535, 536, 540, 541, 543 Kark JA: 11, 568, 569, 571, 572, 573, 574, 575, 576, 577, 578 Keegan MT: 13 320, 467 Keiser JF: Kern S: 377 Kesler P: 40 8, 168, 175 Kessler P: Kidd GS: 7 Kikendall WJ: 187, 203 Killian PJ: 432, 433 Kimball DB: 14, 16, 256, 265 Klapholz H: 441, 443 Klayman D: 6 Klein T: 148 Kopecko D: 320 Kramer KK: 9, 331, 332 Krantz DS: 11, 603, 605, 606

Kumar DD: 10, 400

LaDuke DL: 556 Landes D: 510, 511, 513 Langloss JM: Latham KR: 8, 54, 108, 109, 117, 118 Layland DH: 344 Lawless OJ: 10, 412, 414, 417, 418, 430 Leapley P: 97 LePage A: 611 11, 571, 572, 573, 577 Lessin LS: Levine M: 536, 549 Levinson HI: 10, 383, 392 493 Lewis GE: Light JA: 9, 363, 364, 366, 367, 369, 370, 371, 373, 495 Lillemoe K: 324 Lindsey SM: 430 Lockwood BR: 566 Lohsen BW: 360 Iolik A: 6, 297 Londono S: 396 Lowell G: 509 Lukes Y: 104, 108, 112, 114, 116, 174, 176, 177, 178 MacDougall JM: 11,606 McChesney D: 6, 296, 308 McLeod DG: 379, 544 McMeekin RR: 589 Mansfield LE: 10, 383 Markey KL: 607, 907 Matthews KA: 605 Mayer MH: 357 Mehlman T: 6, 7, 77, 146, 152, 165 7 Mellitt R: Merriken RA: 353 Messe AD: 11, 502, 507, 517 Metcalfe DD: 10, 385 Metzger JF: 493 440, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, Michel TJ: 454, 455, 456, 457, 461, 462, 463, 464, 468, 469, 470, 471, 472, 473, 474, 475, 483, 484 Montgomery AA: 342, 344, 345, 346, 351 Moore JJ: 18, 19, 30, 31, 32 554 Morgan DW: 5, 125 Mozingo D: Mutter MM: 28, 129 Nash DA: 20, 22, 24, 26, 31, 32, 33 Neglia W: 440, 444, 447, 457, 496, 520, 522, 536, 537, 538, 540,

543, 544, 545, 546, 547, 548

Nelson HS: 10, 383, 438

Newhouse P: 558

Nickson JJ: 497 Nisce L: 207 Noel G: 39, 40 Nosler HJ: 353 O'Brian JT: 74 Oetgen W: 129 Ortiz A: 435 Osburne R: 8, 40

Oster CN: 293, 294, 310, 312, 314, 318, 320, 321

Oyewole MA: 189, 190, 588

Pamplin C: 312

Pangaro L: 5, 50, 52, 81 Papineau MB: 556

440, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 461, 462, 463, 464, 465, 468, 469, 470, 471, 472, 473, 474, 475 Park RC:

Peck CC: 612 Perone P: 146 Peters CJ: 493 Peterson HD: 380

Peura DA: 189, 190, 191, 193, 201, 202 Porpatich RK: 320

Potter MW: 142

Presbylick A: 442, 443, 458, 459, 460

Pulaski ET: 500, 501 Punch JL: 9, 345 Purohit V: 5, 125

Rajagopal KR: 291

Ramirez DA: 10, 390, 391

Raum WJ: 7

Raveche E: 6, 161 Reardon MJ: 582

581 Reid R:

Reltig FM: 596, 600, 609, 610

Rice MK: 162 326 Rich NM: Rogers JE: Roggers JE: 493

11, 214, 502, 506, 507, 509, 514, 516, 518, 520, 522, 523 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, Ruymann FB:

536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547,

548, 549, 550, 551

Sadoff J: 6, 296, 297, 308 Salander JM: 326, 328

570 Salvado AJ: Sanmarco ME: 605

```
Schaaf M: 7, 8, 39, 40, 119, 121, 146
Schaeffer M: 11, 606
Schetz M: 438
Schechter GS: 568, 569
Schuster BG:
                612
Schwartz DM: 9, 337, 338, 339, 341, 342, 344, 346, 351, 355, 357
Scovill J: 6, 317
Schuster DL:
                392
Sedge RK: 348, 355
Selvester R: 605
Shaffer RT: 11
Shaw F: 35
Shay SS: 195
Sheldon GM: 92, 120
Shelhamer J: 10, 385
Shipley SB: 601
Silverwood P:
Simon CMB: 480, 482
Sjogren RW: 184
Skiba-Powell H: 440, 441, 443, 458, 459, 460
Slater CB: 611
Smallridge RC: 5, 6, 7, 8, 40, 45, 50, 54, 59, 63, 74, 81, 104, 119, 121, 123, 129, 131, 133, 144, 146, 154, 157
Smith B:
           28
Smith CE: 6, 7, 63, 153, 165
            10, 383
Smith JA:
Smith LJ:
            10, 384, 385
            467
Smith PN:
             430
Snyder KL:
              362
Sonies BC:
              556
Sopolis RJ:
             481, 591, 592
326, 328
Southby JR:
Spebar MJ:
Speilman DE: 348
Stanbaugh KF:
                 346
Stein MR: 195
Steinberg A: 6, 161
Stotler R: 485
Strong D: 433
Strong S: 467
Stutzman L: 207
Stutzman RE: 378, 379
Summers RJ: 384, 387, 388, 435, 438, 439
Surr RK: 9, 337, 338, 339, 341
Swerdloff RS: 6, 7
Tai YH: 588
Takafuji E: 312
Taylor H Grant: 278, 280
Taylor I: 322
```

Tesar JT: 10, 412, 414, 432, 433 Thomas PJ: 11, 502, 506, 507, 509, 511, 516, 517, 518, 520, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547 Thompson PF: 142, 144, 360 49 Thrall J: Tiwary CM: 504, 505, 510, 511, 513, 515 Tjio JH: 6, 161 Tramont EC: 6, 293, 294, 295, 296, 297, 298, 308, 309, 312, 314, 317, 318, 320 Tseng YL: Van Nostrand D: 48, 129, 180, 182, 485, 487, 489, 490, 491, 492, 495 Vigersky RA: 5, 6, 7, 8, 56, 66, 79, 93, 95, 100, 110, 125, 127, 139, 140, 150, 152, 161, 165, 167, 168 438 Virtue C: Waddell TW: 566 Wain AJ: 563 Walden BE: 9, 342, 344, 345, 346, 348, 351, 357 395 Walker PF: Wang MD: 348 Ward KE: 8 Wartofsky L: 5, 8, 38, 39, 40, 41, 42, 43, 47, 48, 49, 50, 52, 54, 58, 59, 60, 62, 63, 68, 74, 81, 104, 108, 117, 123, 133, 137, 138, 142, 144, 154 Washburn TB: 40 24 Watkins B: 558 Watson R: Weber R: 438 Weisbaum G: 440, 452, 453, 454, 455, 456, 457 Weltz MD: 189, 190, 268, 271, 277, 278, 289 Wergeland FL: 335, 432, 433 Wertz FD: 333 Wheeler L: 148 Whitmore P: 539, 546 Whitmore PV: 333, 334 Whorton NE: 8, 40, 154, 157 Wilkinson EV: 342, 353 Williams DL: 357 Williams H: 146 Wilson J: 612 375 Wong HYC: Wong RKH: 180, 182, 188, 194, 197, 199 Wray HL: 5, 6, 59, 68, 77, 91, 106, 119, 121, 167, 168, 177 Za jtchuk JT:

Zollinger W: 6, 296, 297, 308

DISTRIBUTION

Number of Copies	Agency
2	Commander US Army Medical Research Command ATTN: SGRD-AJ Fort Detrick, MD 21701
2	Commander US Army Medical Research Command ATTN: SGRD-HR Fort Detrick, MD 21701
1	Defense Documentation Center ATTN: DDC-TCA, Cameron Station Alexandria, VA 22314
2	Commander HQ, US Army Health Services Command ATTN: HSPA-CI Fort Sam Houston, TX 78234
1	Superintendent Academy of Health Sciences, US Army ATTN: AHS-COM Fort Sam Houston, TX 78234
1	Each US Army Medical Center

DEPARTMENT OF CHRIST DAY STEATEN WALTER TYPE STOY MEDICAL CRITER WASHINGTON, O. C. 20012

SUPPLEMENT TO ANNUAL PROGRESS REPORT

FY-80

DEPARTMENT OF CLINICAL INVESTIGATION

Table of Contents

These reports were not submitted on time, so consequently this supplement had to be undertaken for all of the late investigators

		PAGE
*1004	Stress Ulceration in a Medical ICU: Incidence and Possible Prevention with Cimetidine. (FY-77 F)	1
1388	The Development of a Radioimmunoassay for Thyronine and 3,5-T2. (FY-78 F)	2
1306-79	Thyroid Status in Ob/Ob Mice. (FY-79 F)	3
1516	CALCB #7291, Postop Radiotherapy and Combinations of VCR, Cytoxan, Adriamycin, Actinomycin D in Rhabdomyosarcome. (FY-73 F)	5
1528	CALCB #7391, Clinical Trial of Radiotherapy + Chemotherapy (Cytoman, VCR, Actinomician D) in Managing Mon-Metastatic Ewing's Sarcoma. (FT-73 F)	6
1542	CALCB #7583, Adjuvant Chemotherapy in Osteogenic Sarcoma: Adriamycin Vs SDq Adriamycin, HD MTX - Loukovoric Rescues Vs SEq Adriamycin - Cytoxan. (FY-76 F)	7
1548	CALCB #7681, Fifects of Adriamycin with and without Added MER in Soft Tissue Sarcomas (A Phase III Study) (FY-77 F)	8
1566	CALGB #7811, Remission Induction of Recurrent Childhood ALL. (FY-79 F)	9
1568	CALGB #7892, Multimodel Therapy for Management of Primary Non Metastic Ewing's Sarcoma of Pelvic and Sacral Bones. (FY-79 F)	10 :
1569	CALGB #7893, Multimodal Therapy for the Management of Primary, Non-Metastatic Ewing's Sarcoma of Bone, Pelvic/Sacral Areas Excluded. (FY-79 F)	11
1571	CALGB #7891, Intergroup Rhabdomyosarcoma Study III: Alveolar Rhabdomyosarcoma of the Extremity in Clinical Groups I and II Patients. (FY-79 F)	12

*This Annual Progress Report was not late, but terminated, so it is included in this Suppleme: t.

	ivacità Careknosa, Brusse Carek bud, Sylving ambia, and Repatoma. (FY-80-1)	i
1573	CALGB #7911, Treatment of Primary Untreated Acute Lymphocytic Leukemia. (FY-79 F)	14
1574	CALGB #7981, Comparison of FAM Vs MA in Locally Advanced or Metastatic Gastric Cancer. A Phase III Study. (FY-80 I)	15
1577	CALGB #7921, Comparative Study of Three Remission Induction Regimens and Two Maintenance Regimens in Acute Myelogenous Leukemia. (FY-80 I)	16
1579	CALGB 7983, Surgical Adjuvant Systemic Chemotherapy with 5-FU, Adriamycin, and Mitomycin-C Vs Observation only in Gastric Adenocarcinoma. (FY-80 I)	17
1604	WRAMC 7205, Chemotherapy with DTIC and Adriamycin in Soft Tissue and Bone Sarcomas. (FY-73 $\rm F)$	18
1626	WRAMC 7405, Treatment of Advanced Renal Cell Carcinoma with a Combination of CCNU and Bleomycin. (FY-77 P F)	19
1644	WRAMC 7501, Evaluation of Adriamycin and Cis-Platinum Combina- tion Chemotherapy in Treatment of Malignant Disease. (FY-75 F).	20
1649	WRAMC 7602, Chemoimmunotherapy of Prostatic Carcinoma. (FY-76 I).	21
1658	WRAMC 7702, Adjuvant Chamotherapy of Prostntic Carcinoma with Adriamycin and Cis-Diamminedichloroplatinum II. (FT-78 I)	22
1666	WRAMC 7801, Immunological Evaluation and Phase One Immunotherapy of Patients with Various Carcinomas. (FY-78 I)	25
1672	Tumor Tissue for Extract Preparation. (FY-79 I)	24
16 80	WRAMC 7908, Use of Stroptozotocin in the Transport of Methodic Islet Call Carcinoma of the Pancreas and Metastatic Carcinoid. (FY-80 1)	25
1683	WRAMC 7911, Use of L-Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults and Children. (FY-80 I)	26
2104	Evaluation of Efficacy of Suppressing Platelet Activity in Patients with Intermittent Claudication. (FY-77 F)	27
2105	Rapid Screening for Coagulation Abnormalities. (FY-78 F)	29
2810	Comparative Study of High Dose Versus Low Dose Pre-Operative Radiation to Radical Cystectomy for Control of Transitional Cell Carcinoma of the Bladder. (FY-78 I)	30
4501	Clinical Evaluation of Fluorescence Scanning of the Thyroid with an Americium Source. (FY-73 F)	31

Author Index

33

S - HECE: Minutes of the Clinical Investigation and Harm Wee Juristice, No Chap

5. New Eusiness:

a) The minutes of the last meeting were reviewed and approved with one modification. MAD Wilson's TRC protocol will be classified as a "10 day" group entology protocol and so reflected in the minutes. After review of the specifies of AR 40-23 regulations, this was indeed considered to be a cooperative group encology protocol, since the drug is a NCI sponsored Cr up C drug.

The Communication approve the request for amendment of the 30 top 80 minutes classifying MAT Read's Sweat Inhibition protocol as "mon-significant risk." The manufacturer will have to submit justification that the interfaces is device is a nonsignificant risk device.

- b) The rotating Committee rembers were introduced: Daniel B. Nath, LTC MC, Chief, Nephrology Svc. (Rotating Svc Chief, Dept. of Medicine), Engene D. George, COL MC, Chief, Neurosurgery Svc. (Rotating Svc Chief, Pept. of Surgery), and Robert A. Prosek, Ph.D., Staff Audiologist, Army Audiology and Speech Center, (Rotating Sevier Investigator, Department of Clinical Investigation).
- c) Dr. Boehm reviewed the new DHKS-FDA regulations, discussing expedited review, liability of Committee members, new ingredients for informed consent, no compensation clause for low risk research, categories of research exempt from institutional review, opportunity for subjects to review the consent form. Copies of the new regulations, as well as summary sheets, were distributed to the Committee.
- d) The following annual progress reports were reviewed by the Committee: a) Work Unit 1905, Dr. Harrison's request for continuation of the T. Pallidum in N.S. protocol was approved. b) Work Unit 3159R, Dr. Berne's annual progress report was accepted as a final progress report. Dr. Berne was encouraged to write a new protocol identifying current directions of the research and justifying the request for fending. c) Work Units 1308, 1311, 1359 and 1360, Dr. Burman's annual progress reports were accepted by the Committee. d) Work Unit 1677, in. Bereaberg explained that accositis is a known side effect of adriamycin but that the incidence seen was higher than they expected. The annual progress report was accepted. a) Work Units, 1334, 1346, 1347 and 1353, these annual progress reports of Pr. Burman's were accepted as final reports. New protocols will be sabalized. No funding is accionized for EY 61. f) Work Unit 7216, because he was a seet, Dr. Rewhouse's a small progress report was tabled. g) Work Units 2010, 2011, 2018 and 2019, Dr. 1611's annual progress reports were accepted. Used this 2010 was accepted as a final progress report, while 2015, 2018, 2019 vere accepted as annual progress reports.

4. The rellowing addends were presented to the templifier:

a) I such at the SWGs footh. The Legal Investment of the English R. Buyesans, the Dr. 181. Religious Lips Greekey. Sv., N. 181. The English explained that Describe prophetical war to such a symmetry of the Company of

The following Annual Progress Reports were reviewed by the Clinical Investigation Committee on 24 Feb 81, and the following action was taken: (A copy of the minutes of that date involving the APR's is attached.)

- 1308 Inderal Kinetics in Hyperthyroidism. (FY-74 F)
- 1311 Treatment of Thyroid Storm with Anion-Exchange Resin. (FY-74 1)
- The Regulation of Extrathyroidal Conversion of Thyroxine (T4) to Triiodothyronine (T3). (F7-75 F)
- 1346 Thyroid Function Tests in Cord Blood, Maternal Sera and Aminotic Fluid. (FY-76 F)
- Investigations into the Physiology of L-Reverse T-3 (rT3) and -3-Diiothyronine (3-3 T2). (FY-76 F)
- 1353 The Regulation of T4 Conversion. A Creat Proposal. (FY-77 F)
- The Effect of Reverse T3 and 3, 3 T2 on Thyroid Gland Secretion, T4 Degradation, and Todide Loak in Thyrotoxic Patients. (FY-77 F)
- 1360 Investigations Concerning T3 Production Rates. (FY-77 1)
- WRAMC #7905, Treatment of Acute Leukesia with Low Dose Adrianycin Infusion. (FY-79 I)
- 1903 Persistence of T Pallidum in Mourosyphillis. (FY-75 I)
- Antilymphocyte Globulin (ALG) and Kidney Transplantation. A Controlled Double blind Study (FY-73 F)
- 2615 Immunological Monitoring of the Transplant Recipient. (FY-78 F)
- 2618 Inteitional Donor Specific Pretransplant Transfusion. (FY-80 1)
- 2619 Histocompatibility Antigens and Interstitial Cystitis. (FY-50 I)
- 3159R In Vivo Removal of Circulating Antibodies and Immune Complexes by Immunoadsorption. (FY-79 F)
- 7218 Physotigmine Infusion and Lithium Responsitivity. (FY-79 F)

Date: 3 MANUE 81	[Protoco	1 No: 1004	Status: ledecory	
		in a Medical TCU: sible Prevention v		
Starting Date:	Estis	nated Completion I	Mile: Timminated I March !!	
Principal to astigator: 1/	WRENCE F.	JOHNSON		
Associaic Javesligators: Michael T. Leegan	e averas ark a nama ye are s ankana	Facility: WRAMC		
David A. Peura			OF MED/GI SVC	
Key Words:	is an interpretation for a stranger large of the first	ام		
Accumidative MEDCASS Cost:	Accum Cast:	dati /e Codract	Accumulative Supply Cost:	
FY-80 MERCOASE Cost			eview Results:	
Study Objective: See pro	otogol	و همونوسوسوسوسوس بوریده از پر در سیموسوسوس	encomment of the term in the second of a state of the second of the seco	
	•			
	•.	•		
Technical approach: So	e protocol		•	
Progress during MY-80; se	udy termin. w to failu	ated by Smith Plin re of efficacy	e & French I Same (F)	
والمستقدم والمستقدم والمستقد والمستقد والمستقد والمستقد والمستقد والمستقدم والمستقدم والمستقد والمستقد والمستقد	and a special particular and the second seco		enal na marana ambana mana ambana	
Number of subjects to be stu Serious/unexpected side offe	died before ets in subje	complation of alargest complete complet	v: : project:	
	red blueding	g from UGL tract -	cebo in preventing. Data analysis and	

 $\vec{k}^{\, i}$

Date:	Protocol No:	1083	Status: Informe		
	opment of a Radioim and 3,5-T2.	munoassay i	final K		
Starting Date: 5 Jan 1973	Estimated C	ompletion D	ets: 30 Sand 1950		
Principal Investigator: Keit	th R. Latham, Ph.D				
Associate Investigators:	Facilit	Facility: WRAMC Dept/Svc Endocrine, Ward 47			
Kenneth D. Burman, M.D. Leonard Wartofsky, M.D. Robert C.Smallridge, M.D.	Dept/S				
Key Words: Radioimmunoas.	ay, Diiodothyroni	ne	•		
Accumulative MEDCASE Cost:	Accumulative Contract Cost:		Accumulative Supply Cost:		
FY-SO MEDCASE Cost:		Periodie Re (to be fille	view Resului: d in by DCI)		
Study Objective: Objective: to Develop the assay to study the lev pathophysiologic condition Technical Approach:	els of these hormo		om' 3,5-32 and to utilize a variety of pormal and		
I. Antibody to Tn was	as radiolabelled a	nd utilized	d in defining a standard		
Progress during FY-80: A Wartofsky, L., Wright, F	ssay for 3,5 T2 co .J. and Latham, K.	ompleted: Pa R. (1980) .	nngaro, L., Burman, K.D., J.Clin.Endoc.Metab. 50:1075.		
Number of subjects to be stud					
Serious/unexpected side effections only blood was uti	cts in subjects parti lized. (Note : bla	cipating in pool was obta	project: ained on other protocols and		
Conclusions:	-		Sira		
An effective assay fo	r 3,5 T2 has been	established	l and utilized.		

Publications or Abstracts, FY-80:

Starting Date: 27 John 1979	Uslimated Completion D	nie: 30 S priember 19de
Principal Investigator: 60	ith R. Latham, Ph.D.	anne e na cantacana de la cantacana com a describación de la cantacana de la cantacana de la cantacana de la c
Associate Inventigators:	Factily:	
Allen R. Glass, MD Yush-Chu L. Tsong, Ph. D.	Dept/Sive Endverin	e, Ward 47
Key Words: Tryodd, Oless	, Nico, Peceptor	
Accumulative MEDCASS Cost:		Accumulative Supply Cost:
FY-80 MOCALI Cash:	Marchin w	våccy Transford
	(to be fille	d in by DOI)
Study Objective:	(to be Alle	d 1a by DO9
•	ine if the genetically obese	
Obje cti ve: To detern	ine if the genetically obese	
Objective: To determine of a thyroid hormone d Technical Approxes: L. Liver Ogroid hor	ine if the genetically obese	mouse (ob/ob) accusulate
Objective: To determine to answer a thyroid hormone d Technical Approvata: 1. Liver thyroid hor 2. Pathways of thyro	ine if the genetically obese efect mone receptors were measured id hormone metabolism were in	mouse (ob/ob) accusulate in the obese and lean convestigated.
Objective: To determine of a thyroid hormone of Technical Approach: 1. Liver thyroid hor 2. Pathways of thyro Progress during FY-80: Abstract (enclosed)	ine if the genetically obese afoct	in the obese and lean convestigated.

The obese condition in the ob/cb masse is not due to an obvious peripheral \mathfrak{z}_i agree before. However, thyroid bormone metabolism alternations were observed and reported. \mathfrak{z}_i

Abstruct Reproduction Form

Attractions of control of the contro

130%	country, sliding so and telephone manaber of
	in the dread receive correspondence to Box.
• - 1	Chaplete Boses L. Cland D.

A
None Keith R. Lather, Dr.D.

Addrew Department of Medicine
Uniformed Sprvices University of the Healan Sciences

Bothwala, MD 20016

MONA 995-796-1571

B (see Rule L.)

Pare 1 (8400)

Cross market in

Pare 1 (8400)

LISTING

(none of warry in

A sign of two abstract must see in 1 december 1 in 1 december 2

TYPE ABSTRACT HERE/BE SURE TO STAY BITTHIN BORDER

Contects on F

to the transformal infectings only)

Peter poster session presentation (Consider for poster session of not scheeted for oral presentation (X)

Leader consider for poster session under any circumstances (

D CHECK SINGLE SUBSPECIALTY CLASSIFICATION:

Cardiovascular * _ _ _ no (_____) Chastal Epidemiology Cholcal Pharmacology Dermatology....... Fairocranology (see Pub 5) X . st.oenterology Highth Care Restach : is anatology Inspectension Luminology & Rheumatology ... Intectious Disease Matabolism (see Rule 5) Polmonary Renal & Electrolyte

for abstracts submitted to Cardiovascular only, select single suncategory and enter code no. (1-6) in space above, (1) Chincal, (2) Basic Science, (3) Electo-physiology-Dysthythmias, (4) behocardiography; (5) Radios yy-Radioini, lides; (6) Other Subclassification in dissipned to aid in reviewing process for is and is independent of program appendix. NUCLEAR THYROID HORMONE RECEPTORS IN OR/OB MICE, K.R. Lathan Y.L. Tseng and A.R. Ghiss. Uniformed Services University of the Health Sciences, Bethesda, MD, and Walter Reed Army Medical Center, Washington DC.

Mice (Co78L/63) homozygous for the reportion ob gene (ob/ob) decade obedity, hypomerabolism, and hypothermia efter cold across, the Land two conditions being reversible with high dose thyroid hamme (TH) therefore T evaluate the possibility of hypothyroidism in co/ob, sorum T4 and T5 (21%, ng/ml) and levels of hepatic millear receptors for T4 and T3 were measured in 10 wk old female ob/ob and is thin littermates (ab/o, ob). Solubilized number receptors (NR) were obtained by sedimentation of nuclei through 2.14 sources, triton X-100 treatment, and extraction in high seit. Molinum bin To object, the WBC, fmol/mg DNA) and affinity (Kg, M x 1671) of NR for both 14 and 13 were determined by saturation analysis (Scatchard). (b = p < 0.05 vs. object +/+).

	ob/ob		ob/+		4/+	
	13	T4	1.3	T/-	T3	T
Serum 1	TH 1.00 + 0.05*	13 + 3.	0.74 + 0.07	71 - 4	0.31 ± 0.0	7.60 - 7
M3C	14 15	22 : 3	16 76	21 2	16 7.5	27 - 2
$^{\rm K}$ d	10 ± 2	$2 < \epsilon $	$\sim \pm 1$	13 1	6 + 2	21 g

MBC and K_d of NR for T4 and T3 were not significantly different among graps; therefore, potential hypothyroidism in ob/ob is probably not related to defects in TH receptors. Low serum Th and high serum T3 in ob/ob may represent "low T4 euthyroidism", perhaps a compensatory response to increased T1 to T3 conversion secondary to increased food intake.

PLEASE CHECK ABSTRACT CAREFULLY FOR APPLARANCE BEFORE MAILING

BOTH THIS FORM AND THE FORM LETTER
OF TRANSMITTAL MUST BE SIGNED
BY A MEMBER (RULE 2)

KEITHR. LATHAM, Ph.D.

MEMBER'S SIGNATURE: .

Revised May 1975

1

PVCE: [50 September 1950] [Protection: CALSE 7 0] [C. 2000: Incoming title of the following a Conference of the California of the Californ

STAR ONE ATE: 1000
PRINCIPLE ONES FRONTED Dr. Johnson S Front
ASSOCIATE INVESTIGATORS:
Pr. Frederick Repman, M.D., Lo. MC Fronter
SENTER: Heading 10-Oneology
Production of Medicine
Key Volum: Language According Value of Medicine
Key Volum: Language According Value of Medicine
Fey Volum: Language According Value of Medicine
Fey Volum: Language According Value of Medicine
Fey Volum: Language Production Value of Medicine
Fey Volum: Language Production Value of Medicine
Fey Volume Transfer According Value of Medicine
Fy-Sociation Const. NA President Const. No. 1000: No. 100

STUDY C. P. STEVE: I. To receive the some of participant live of the control and sorvived rate. 2. To examine the adjustme toda of clamather by in prolonging disease tree one lead. 3. To examine the adjustme toda of clamather by in therapy and possible curve of patients with alvanced disease.

TECHNICAL NUMBEROACH: Useen 1 pts (USB) = 1. USB 2 NO/O2 qVIX12 4 Uses 0.715 NO/OB 15 daily 5 of wk 12, 25, 26, 45 4 Gyt 25 NO/AB postnot 6 42, vs 2. Rf + 1. Group 2 (nicroscopic residual eas) = 1. Above vs 3 RF + Dact 0.913 pg/OB 1-5 at 9,13,27,55 viz + VGA (M g as a 60 of sp 2.4 gross cost to 1 86 - 4, VGA q et a 72 of ats) + ACT B 1-5 rot 15,13,47,57 data cytosa 1-70 at 15 x2 th m syrotra vR 21 - 25 th FF vs 5. VGR + ACT B + syrotra as 250vi + 2T + Adr. 50 10/M2 Final 5,13,27,38,5) = 5

PROGRESS THRESS FY-30° 14 pro cosm 9800 have been cutered. One can 100 on day 127, 5 have lad 20 to day 40 or death; 3 yms → death; day 117 or 4 070; hay 315 → death; <2 yrs → death. I was 6 yes but 6 toos 100 4 are 100 at 5 yrs, 4 yes, 3 yms end 3 yrs place. I grad to 6 continue to cover 2 colors 100 at 5 cmor 100.0.

EDITED OF ADDRESS OF ALL PROPERTY OF THE PROPERTY OF ALL PROPERTY.

SERIOR OF ADDRESS OF ALL PROPERTY OF A PROPERT

PRESIDENTE STANSTRONGS, 12 ST: Almoray published 1977 Ca 2015, 1977 DATE: 30 September 1960 [PROTOGOL NO: CABO) 7391
THREE OF PROJECT: CLINICAL THAT OF RADIOTHERIST #
CHETOTHERAPY (CYTOXAN, VCR. ACTIBOTYCHE D) TO HAMAGING
NON-METASTATIC EMING'S SARCOMA

STARTING GAVE: 1973 [ESTIMATED CONTINUED DAYS: 1980 - PER WILL TO PRINCIPAL INVESTIGATOR: Dr. Jona men Blom FACTLIFF: Walter Read Army Medical ASSOCIATE INVESTIGATORS: Center SERVICE: liewatology-Opcology Department of Medicine KEY WORDS: Ewing's Sardoma ACCUMULATIVE MEDGASE ACCUMULATIVE CONTRACT ACCUMULATIVE SUPPLY COST: NA COST: NA 95.E: NA PERCODEC REVIEW RESULTS: FY-80 MEDCASE COST:

STUDY OBJECTIVE: 1. To study interval & pattern of matastic and local recurrence of tumor treating with either 1. irradiation to 1° alone?. irrad of 1° + systemic chemotherapy or 3. irrad of 1° + chemotherapy + bilatoral pulmonary irradiation.

2. To study survival time.

TECHNICAL APPROACH: Regimen I - VCR 5 mg/N²/vk x 6 + cytoxum 500 mg/N² IV x 6 + RT to lesion. vs Regimen II - VCR 1.5 mg/N²/vk x 6 + cytoxum 500 mg/N² IV x 6 + RT to lesion + both lung fields then actin 0 15 mg/NG qd 1-5 at 3 mos then VCR + pred 3rd - 7th wk then repeat q 3 wks x 6.

PROGRESS CHING FY-80. While her entered 8 pth. 2 pth are provious than 3 yru therapy and have no evidence of disease. 1 pt was 5 yrs p Rr. 8 was LVU. 1 pt control off study early & was LFU. 1 pt relapsed on day 584 & LFU. 1 pt expired on day 336. 2 pts were greater than 2 yrs p therapy with NED but lost to follow up.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: Completed SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

CONCLUSIONS: This study has been discorrated by CALGB and should be closed here.
Remaining pts will be followed for long term toxicity.

PUBLICATIONS/ABSTRACTS, FY-80: ASCO ACA C-425 413, 1978.

	,	West Car # 1542
DATE: 30 September 1939 TITLE OF PROJECT: Adjuvant	[69] O.M. No: Coffee () Checotherapy in Osteogenia	
Saccoma: Adriamycin vs Sac SEq Adriamycin — Cytoxan	g Adriasycia, ND NYK - Lad	so orle Heraner vo
STARTING DATE: 1975 PRINCIPAL INVESTIGATOR:	ESTELL 10 600	erios didigitado ma
ASSOCIATE INVESTEGATORS:		ter Royd Army Modical
	$\mathbf{J}_{V_{i} + V_{i}}$	tology Carelogy (tology Carelogy (torat of Medicine
KEY MORDS: Osteogeble Sarco	DIMI	
ACCUMULATE E MENCASE COST:	AGCUSULATIVE CONTRACT	1
FY-80 MEDCASE COST:	PERIODIC REVIE	
STUDY (SJECTION: To determine or pulmonary method of establishments of Ostablishments - Cyt	genic and either L. Adri m	rycin 2. Adriamycin – hi do

TECHNICAL APPR ACH: 1. Idrimite in 20 mg/M² ql m 3 q 4 macks x 6 courses. 2. Adrimite in 30 mg/M² IV qd Days 1-3 & 28-30 and hi dose MEM 200 mg/KY x 6 hours with subsequent leukovovium 12 mg IN q 6 h x 12 doses Day 56 & 77. Repeat cycle Day 105 6 courses each day. 3. Adriamycin - Cytoxan - closed June 1977.

PROGRESS Desired to the property of the property of the control of

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY:
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

CONCLUSIONS: 98 patients were accrued to this study. This was sufficient for cleavre. This study was closed 4/80 - Patients will be followed.

PUBLICATIONS/ABSTRACTS, FY-80: Manuscript for this study is pending.

WORK UNIT # 1548 PART: 30 September 1980 | PROTOCOL NO: CALOB 7681 STATUS: Interin Tittly of Project: Effects of Adrianycin with & without Added GER in Soft Tissue Sarconas (A phase III Study) STARTING LAND: 1976 ESTIMATED COMPUTITION DATE: FRINCIPAL INVESTIGATOR: Pr. Channes Blom FACILITY: Walter Reed Army Medical ASSOCIATE INVESTIGATORS: Center ___ SERVICE: Hematology-Oncology Department of Medicine KEY WORDS: Sarcoma ACCUMULATIVE MEDCASE ACCUMULATIVE CONTRACT ACCUMULATIVE SUPPLY COST: NA COST: NA COST: NA PERIODIC REVIEW RESULTS: FY-80 MEDCASE COST: None STUDY OBJECTIVE: To compare Adriamycin alone & with MER in induction of remission

TECHNICAL APPROACH: 1. Adriamydin 75 MG/M2 IV q 4 weeks

daily doses.

vs 2. Adriamycin & MER 1 mg 1C on days 1 & 8 q4 weeks

vs 3. Adriamycin 25 mg/M² days 1,2 & 3 q4 weeks

in inoperable soft tissue sarcomas and to compare monthly single vs 3 consequentive

vs 4. Number 3 plus MER 1mg TC on days 1 & 8 q4 weeks

PROGRESS DURING TY-80: 5 WRAMC pts. have been entered. 3 died in 1978. 1 was LFU on day 16 in 1978 and one had progressive disease in Feb 79 (day 100) and lost to follow up. CALGB entered 75 patients. There was an overall 25% response rate which did not vary per arm.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY:
SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:
None

CONCLUSIONA: This study was closed to pt. accrual. There was no difference in the Adrianycin achedules. Only 25% response rate was seen. Study is terminated.

PUBLICATIONS/ABSTRACTS, FY-80: Manuscript in draft form.

TARTING DATE: 1978	and the second s	ESTAMATED COMPLE	UON DATE:	Cloud
RINCIPAL INVESTIGATOR:		a alleger to control of the control		The second secon
SSOCIATE INVESTEGATORS:	ا غ	FACILITY: Walte. Cente		Medical
		SERVICE: Hemato	logy-Oncole	
EY WORDS:	e des combinations	Departi	ment of Ned	icine
CCUMULATIVE MEDCASE OST: None	ACCURI COST:	None	ACCOMUN.	WILVE SUPELY None
Y-80 MEDCASE COST:		PERIODIC REVIEW	TESOUTS:	
None			- •] - • [- • • • • • • • • • • • • • • • •	and the second second second second second second second second second second second second second second seco
TUDY OBJECTIVE: Effective t	inerapy ic	or relapsed childho	00,01.6.	•
•		•		
		•		
	•	•		
		•		
ECHNICAL APPROACH: Companies	n of T ?	SOPP and T-COTT (S.)	: r: 1979 :com	on the
	•			
			•	•
•	•*			
	•	•		•
	col close tric grou	ed because of lack	of funding	of CALGE
ANSWER TO REVIEW Study c		MENTS: No patients his is a final repor		WRAMC or CALGB ire no possible
conclus		its is a limit. repor	, c. riidic c	re no possible
				•

			WORK UNIT # 1558
DATE: 30 September 1980 PETILE OF MOLECT: Multimodel Ti Primary Non Metastic Ewing's Sa Bones.	ierapy T	to Nanagement of	GTATUS: Interim Final X
STARTING HATE: 1978 PRINCIPAL INVESTIGATOR: Eruce ASSOCIATE INVESTIGATORS:	Booth	SERVICE: Hematol	Reed Army Medical
KEY WORDS: Ewing's Sarcona		Departu	eat of Medicine
ACCUMULATIVE MEDCASE COST: NA	ACCUMU	ILATIVE CONTRACT NA	ACCUMULATIVE SUPPLY COST: NA
FY-80 MEDCASE COST: NA		PERIODIC REVIEW F	RESULTS: NA
STUDY OBJECTIVE: Not applic	cable,		
TECHNICAL APPROACH: Not appli	icable.		
PROGRESS DURING FY-80: No pati pates in intergroup studies.	ients er	ntered this study a	and CALCE no longer partici

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: None SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None CONCLUSIONS: None. CALGB no longer participates in this study.

PUBLICATIONS/ABSTRACTS, F7-80:

WORK UNIT # 1569

MULTIMODAL THERAPY FOR THE MANAGEMEN SARCOMA OF BONE, PELVIC/SACRAL AREAS	
PRINCIPAL INVESTIGATOR: LTC JEFFREY ASSOCIATE INVESTIGATORS:	FACILITY: Walter Read Army Medical Cents r
THE TRADES.	Department of Sedicane GLATIVE for arises Classifier a sur street Court Periodic Sevies in trues:
FY-80 MEDCASE COST:	(Periodic based) in secret
	I of patients with localized Ewing's sarcomastases at diagnosis with an intensive multi-
adri Regimen II- Mode vinc	Intermittent Chemotherapy with vincristine, amycin, cyclophosphamide, and actinomycin-D rate Dose Continuous Chemotherapy with ristine, cyclophosphamide, adriamycin, and nomycin-D
PROGRESS DURING FY-80: No WRAMC pati date to closi	ents were entered on this study, from startin ng of study.
NUMBER OF SUBJECTS TO BE STUDIED BEFO SERIOUS/UNEXPECTED SIDE EFFECTS IN SU None CONCLUSIONS:	ORE COMPLETION OF SINDY: OBJECTS PARTICIPATING IN PROJECT:

This study has been closed to patient entry.

			WORK UNIT # 15/1	
DATE: 30 September 1980 PR TITLE OF PROJECT: Intergroup Rha Alvéolar Rhabdomyosarcoma of th	abdomyo:	sarcoma Study Ilf:	STATUS: Interia Final X oups I & 11 Patients	
STARTING DATE: 1979		ESTIMATED COMPLETIO	N DATE: 17/A	
PRINCIPAL INVESTIGATOR: Dr. Jol	iannes	BLom	and the same and t	
ASSOCIATE INVESTIGATORS:		FACILITI: Walter R Center SERVICE: Hematolog	y-Oncology	
Name of the state		Department Department	t of Medicine	
KEY WORDS: Rhabdomyosarcoma ACCUMULATIVE MEDCASE COST: NA	ACCUMULATIVE CONTRACT COST: NA		ACCUMULATIVE SUPPLY COST: NA	
FY-80 MEDCASE COST: NA		PERIODIC REVIEW RES	ULTS:	
STUDY OBJECTIVE: To determine of be dropped from study VAC Rx Adriamycin + VCR + Cytoxan res prognostic 5. what significan	2. is V ult in	AC pulse better than increased CR 4. wha	sarcoma Cau 1. cytoxan sequential 3. will t pathology is	

TECHNICAL APPROACH: Multiple areas - very complex therapeutic schedules. Our pt received Regimen 25 - VCR $2mg/M^2$ IV q wk x 12 doses + DACT 0015 mg/KG/d d1-5 + Cytokan 10 mg/KG/day IV d1-3 then 20 mg/M^2 IV d o & 4 + DACT d1-5 + cytokan d1-3 repeat this 4 4 wks x 2 yrs.

PROGRESS DURING FY-80: One patient with extensive intrathoracic disease has been entered on this study. She received VCR, Actinomycin D, and Cytoxan per treatment arm #25 and obtained a CR when last seen on Day 116.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: See conclusions.

SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

None

CONCLUSIONS: Too early. This study is now under the direction of SWOG and follow up should therefore be transferred to Dept. Pediatrics.

Treatment for Molanoua, Ovario Eypernephroma, and Populoma.	ly of M-ANSA	(MSC 249000)	
PREMATE ASSESSED ASSE	ffroy L. Ber FAV SD	renberg, MG THILL William Cont Wild: hereal	* * * * * * * * * * * * * * * * * * * *
ACCUMULATIVE MEDICASIA	c April Metal I	VC CONTROL	Carcinoma, Hyperhephnoma, Hopaton Accar (M.: W.: W. William (Cost:
COST: FY-30 MEDCASE COST:	PEI	RIOTIC REVIEWS	erions:
(Sec. 4.2) to treatment with M- patients responding to continue and laboratory data regarding t	d M-AMSA ad		
TECHNICAL APPROACH: The first heavily treated with chemothera hepatic dysfunction may start a increased by 20 mg/M ² over the losuppression is encountered. Other severe texicilies such as toxicity may also be indication	py (expecia t () mg/M ² . previous do Myelosuppre extreme na	lly nitrosoure. Every three ise until 160 k, ssion will requese and vomit	a) or radiotherapy or with sects the dose will be g/n^2 is resched, or until myeurice dose modification.
FROCKESS DURENC FV and: Six pa no responses. Three patients h			

MUMBER OF SUBJUICES TO BE STUDIED BELONE COMPLETION OF STUDY: 162

SERIOUS TUTERPECTED SIDE FRECTS IN SUBJECTS PARTICIPATING IN PROJECT:

none

CONCLUSIONS:

none

PUBLICATIONS/ABSTRACTS, FY-80:

	2						
					TO:SC THE	r 70. <u>15</u> 7	3
DATE: 30 September 1	900 [11	wrodót.	MG: CASS	<u> </u>		Interior	
TITLE OF PROBLECT:						Final .	Σ.
Treatment of Melmary	Untreated	Acute 1.	Aubpochti	c Lentendi	ì.		
		•			•		
STARTING DITE: 25 Sep	et 79		ESTIMATE	D COMPLETE	OR DATE: C	iose 4/12	/ 80
PRINCIPAL INVESTIGATO	ik: Dr. Jel	trey L.	Berenber	8			
ASSOCIATE INVESTICATIO	RS:	1	FACILITY	: Malter	Reed Army	Modical.	
				Center		·	
	•	. ;	SERVICE:		ogy-Oncolog		
		1		Departus	ent of Madi	cine	
KEY WORDS: Acute Lyn	phosytic l	Leukemia					
ACCUMULATIVE MEDGASE		ACCUM	LATIVE CO.		ACCUMULA	TIVE SUPP	·LY
COST: None		COST:	None		COST:	None	
FY-80 MEDCASE COST:		L	Chuptoni C	REVILM R	76.14.65.5		
FI-80 REDUNSE COSI:	None		PRATORIC	KEV CLAY K	າວ () , ໄວ້ :		
CENTLY OF TRANSPORTERS		······································		1 1		5	
STUDY OBJECTIVE: 1.						a yeap rody	LLC
leukemia by testing h	right dose, .	an Norin	oue bunen	1 ((() () () () () () () ()	macerca,		
		•	•				
	•					-	
•	•	-			•		
TECHNICAL APPROACH: 3	·				n 111	7	6 j.d
and vs prednisone 40 vincristiae 2 mg/N ² I	market para	i daxame . ≀	engaoge z	य मञ्जूष्ट	ил раслен	rs recerv	e .
vincristiae 2 mg/M- 1	v q week b	< 4.	•			;	•
	•						•
			•		•		
•	•			• •			
	•			•		•	
•				• •			•
PROGRESS DURING FY-80 Protocol closed becau							(used lst arm c
							regime:
	•			•			
					•		••

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: N/A SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

CONCLUSIONS: The only patient treated will be followed for long term toxicity and survival. No subsequent reports will be submitted.

PHBLICATIONS//BSTRACTS, FY-80:

WORK UNIT # 1574

DVet: No. . breeder 1989 | Terrapolitie: CALOB 7981 | TUYED OF PROTECT: PROMITE PROFILE X COMPARISON OF FAM VS MA IN LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER. A PHASE III STUDY. \$140.000 . Tel: 12 Dec 79 TESTEMBER GOME, LIST DATE: 1982 PRINCIPAL CARLINGATOR: LTC JEFFREY L. BERENBERG, MC FACILITY: Walter Food Army Medical ASSOCIATE THE STROATORS: Center SERVICE: Found Lagy Oncology Persont work of Medicine KEY WORL .: Castric cancer ACCUME FOR THE CASE ALCOHOLATIVE CONTRACT Tracciba aldeba kirken COST: + COST: _____ * * Transford Payers FT-80 to Jilling of the

- SHOW not the 1. To determine whether intensified induction than you in a two-drug combination, excluding 5-fluorouracil will prolong the time to disease progression when compared to therapy with FAM in the treatment of patients.
- 2. To determine partial and complete response frequency, and the duration of response and survival of putients with reasonable, locally advanced, or with retastatic gastric cancer when the putients are treated with MA versus FAM and both regimens are followed by a common maintenance therapy employing mitomycin-C and 5-fluorouracil.

THORN IN . APPROVOH: Regimen A - 5-fluorouracil, mitomycin-C and adriamycin Regimen B - Mitomycin-C and adriamycin

PROGRESS IN REING FY-80: No WRAMC patients have been entered on study. CALGB has cantered 50 patients, however it is to early for evaluation of this study.

ROMARIA ON TUBBECTIONA RESERVACED BALLO O COMPLETION OF MILITERS TO PROJECT:

CONCLUDIONS: Too early for evaluation.

NOTE: UTHER IN PAIR: 30 September 1980 | PROTOCOL NO: CARAS TAKE THYLE OF PROJECU: Comparative Study of Three Venission Judgets of Neglical and Two Maintenance Regimens in Acete Myelogenous Laskewis ESTIMATED COMPLETION DATE: 1982 STARTING DATE: 20 Jon 60 PRINCIPAL INVESTIGATOR: Dr. Jelfr L. Barenbarg ASSOCIATE INVESTIGATORS: FACULITY: Walter Roed Army Modical Center SERVICE: Hematelogy-Oncology Department of Medicine KEY WORDS: Acute Myelogenous Leukemia ACCUMULATIVE SUPPLY ACCUMULATIVE MEDICASE . ACCUMULATIVE CONTRACT COST: None COST: None COST: None FY-80 MEDCASE COST: None 1. To determine if increasing intensity of Andrewion therapy v(1) increase remission rate. 2. To determine it eletrimest note will decrease infection rate during remission induction. TECHNICAL APPROACH: Pandomized: Regimen A with CO-Tempoxazolo po 146 6 ding induction. Regimen B without CO-Trimoxazole. Randomize between Regimen I) Dausconjoin (DER) 45 mg/M2 tV days 1,2,3 + ARA-C 100 mg/M2 LV by continuous infusion degree Regischity DNR 45 mg/ei2 IV days 1, 2, 3 + ARA-C 100 mg/H2 IV by continuous infusion 6-Anoguaining 100 mg/M² po days 1-7. Regimen 3) DNR 45 mg/M² IV + ARA-C 100 mg/M² IV by continuous infusion days 1-10. ANSWER TO REVIEWER'S COMMENTS: Maintenance: All patients receive two cycles of four monthly courses of chemotherapy: (1) ARA C 100 mg/m2 Scq iz h x 10 + 6 100 mg/m² po q iz h x 10; (2) ARA-C (as above) + Piednisone 40 mg/m² po day 1:5 + Vincris-(continued on the paragraph) time (VCR) 2 mg/m² iv on day 1 (3) ARA-C (as above) + PROGRESS DURING FI-80: Two WRAMC patients catered, help achieved a complete reministration. Continued from Technical Approach: Daunomycin iv 45 mg/m2 on day 1 and 2. (4) Same as course 2. After these cycles, patient are randomized to discontinuing therapy or continued therapy until relapse. NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: 550 SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: None

PUBLICATIONS/ABSTRACTS, FY-80:

CONCLUSIONS: Too early to evaluate.

		VOM UNIT NO. 1579
DATE: 30 September 1990 Int TITLE OF FROMET: Surgical Adju with 5-FU, Advisoyoin, and Nico Adenocarcinosi.	vant Systemic Chemotherapy mycin-C VS Observation only	Figure 7 in Captric
STARTING DATE: 1979 PRINCIPAL INVESTIGATOR: LTC Je ASSOCIATE INVESTIGATORJ:	ESTIDATED CONTEST Contest by Barocherg, Fill Market Market	C DATE: 1932
	Center	
	SERVICE: Remoted to	my-Oncology at of Medicine
KEY WORDS: Gastric Adenocarcin	oma '	
ACCUMULATIVE NEDGASE COST:	ACCOMMENTATIVE CONTRACT COST:	COST:
FY-80 MEDCASE COST:	PERCODIC PLATER PE	WEES:
of fluorograph, adri yet; and adenocateleona of the chomach postandard surgical resection along technical APPROACH: S-Fluorograph 600 mg/M2 1.v. of i.v. day 3 of each cycle, Advis	coduces a longer desent frae, ne, Observation only, Regime Rays 1, 8, 29 and 36 of eac	on II: Adjuyant Chemotheraps, in cycle, Wisomycin-C 10 mo//F
PROGRESS DURING TY-80: Too can	rly ion account of patients.	· · · · · · · · · · · · · · · · · · ·
ANSWER TO REVIEWER'S COMMENT	rs: No patients have been o	entered to date.
EUMBER OF SUBJECTS TO BE STUDIES SERIOUS/UNEXPLOTED SIDE EFFECTS		
CONCLUSIONS: None	***************************************	The state of the s

WORK	UNIT	#_10	604
STATU:		nter	in,

EXTE: 39 September 1900 [PROFOCOL NO: MRADO 7205]
TITLE OF PROJUCT: Chamotherapy with DTIC & Adrimayon, in Soft Tissue & Bone Seconds

& Adrimage in _____ Final A

STARTING BYFT: 1972 PRINCIPAL INVESTIGATOR: TD	ESTIMATED COMPLY	CION DACE: Closed they 78	
ASSOCIATE INVESTIGATORS:	FACILITY: Watter Reed Army Madical Center		
	SERVICE: Hemato Depart	logy-Oncology ment of Medicine	
KEY WORDS: Sarcoma ACCUMULATIVE MEDICASE COST: NA	ACCUMULATIVE CONTRACT COST: NA	ACCUSE ATIVE SUPPLY COST: NA	
FY-80 MEDCASE COST: NA	PERIODIC REVIEW I		

STUDY OBJECTIVE:

To determine the efficacy of DTIC & Adriamycin with soft tissue and bone sarcomas.

TECHNICAL APPROACH: Good risk pts: Adriamycin 60 mg/M 2 day 1 and DTIC 250 mg/M 2 IV x 5 days. Poor risk - Adriamycin 45 mg/M 2 day 1 & DTIC 200 mg/M 2 IV x 5 days.

PROGRESS DURING FY-80: This study was closed in May 1978. In past year 5 patients were lost to follow up. Other conclusions are as per 1978-79 report.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY:

SERTOUS/UNEXPECTED SIDE DEFECTS IN SUBJECTS PARTICIPATING IN PROJECT:

None

CONCLUSIONS: DTIC & Adrianycin - low response rate

Study should be terminated

PUBLICATIONS/ABSTRACTS, F7-80:

		WORLL WIT # 1626		
HAVE: 30 September 1980 PI Fight OF PRODUCT: Treatment of Carelegga with a Combination o	Advanced Renal Cell E CCNU and Bleomycin.	LNingt_A		
STARTING DATE: 1974 PRINCIPAL INVESTIGATOR: Dr. Jo	ESTIMATED COMPLET	FION DATE: Cloded 24 Aug 79		
PRINCIPAL INVESTIGATOR: Dr. Jo	phagnes Blom	The state of the s		
ASSOCIATE INVESTIGATORS: Dr. Charles Miller	FACILITY: Walter	FACILITY: Walter Reed Army Medical Center		
	Departs	SERVICE: Hematology-Oncology Department of Medicine		
KEY WORDS: Renal Cell Carcinoma	1			
ACCUMULATIVE MEDCASE COST: None	ACCUMULATIVE CONTRACT COST: None	ACCUMULATIVE SUPPLY COST:		
FY-80 MEDCASE COST: None	PERIODIC REVIEW A	RESULTS:		
of advage 2. To determ	ne efficacy of CCNU and BI med renal cell carcinoma. nine if this regimen would ats with locally advanced	l extend disease free surviva		

TECHNICAL APPROACH: CCMU 130 mg/M² p.o., every 6 weeks Bleomycin 15 mg I.V. weekly

PROGRESS DURING FY-80: One patient relapsed, leaving 7 still disease free. This patient developed bleomycin pulmonary toxicity.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETION OF STUDY: None SERIOUS/UNEXPECTED SIDE EFFECTS IN SUBJECTS PARTICIPATING IN PROJECT: Bleomycin lung toxicity producing death in two patients and morbid ty in one. CONCLUSIONS: This is a potentially toxic regimen with uncertain benefit. The remaining seven patients will be followed for long term toxicity.

PUBLICATIONS/ABSTRACTS, FY-80: Miller, C.F. et al: Adjuvant Chemotherapy of Ronal Cell Carcinoma Using a Combination of Bleomycin and Lomussine, ASCO vol 28 page 362, March 1980.

		WORK UNIT #1644		
10001 Ci - 50000:	[Forest Mariner WRAMC 7501] AND CIS-PLATINEM COMBINATION BEASE	\mathcal{Y}_{1}		
STARGER 19 ELE 1975	LEST CHARLETERS	LETTON DATE: 1980		
PROJUCE A VESTECA (ELE J		The second secon		
ASSOCIAL INTERIOR DEST	(FACILITY: Walter test Army Yestical			
	Con			
	SERVICE: Hemat	tology-Oncology		
	•	ctment of Medicine		
NEV NOOS: ADRIAMYCIN, CIS	-PLATINUM, MALIGNANCY	**************************************		
ACCUMPLATION MEDUASE	ACCUMULATIVE CONTRACT	LACCE GLATIVE SUPPLY		
COST:	COST:	COST:		
FY-80 NOW MOT COST:	PERIODIC MUNIE	,		
STUDY OF STANKE. To ovalu	gate the efficacy of cis-ula	tinum and adriamycin in		

TECHNICAL APPROAcd: Adriamycin 60 mg/m 2 /day IV every 21 days Cis-platinum 60 mg/m 2 /day IV every 21 days

patients with maliguancies.

Face DEGLE PURCOUS FY-1: No patients entered during 1980. Thirty-nine patients were entered prior to 1980.

Three patients with prior radiation experienced severe leukopenia.

This combination has also been piloted by CALGB and appears to have possible activity in prostate carcinoma.

the prostate subset. Consideration will be given to publication of the prostate subset.

LYOUR	TINELT	∤ :	1640

DAID: 10 to more 1900 TITLE Ol., a Nove: Chemofame Careinoma.		$\left\{\begin{array}{cccc} \mathbf{x}^{-1}(\mathbf{x},\mathbf{t}) & \text{if } \mathbf{x} & \mathbf{x}^{-1}(\mathbf{x},\mathbf{t}) \\ \mathbf{x}^{-1}(\mathbf{x},\mathbf{t}) & \text{if } \mathbf{x}^{-1}(\mathbf{x},\mathbf{t}) \end{array}\right.$
STARTING Val.: 1976		1981
FRIGGERAL LANG FRENCOAL LTG ASSOCIALE INVESTIGATIONS:	C Jeffrey L. Berenberg, MC	to di Array et e e e e e
	10.7AV	e telefolis. Cartifolis
KEY WORDS:		
ACCUMULANTY MERCARA COST:	Add TARRY (C. C.)	
FY-80 MEDCISE COST:	Phytosophis a	
STUDY OBJECTIVE:		

To study the efficacy of the combination of cyclophosphamide and 5-fluorouracil with and without BCG immunotherapy in the treatment of advanced Stage D carcinoma of the prostate.

TECHNICAL APPROACH: Regimen A - Cyclophosphamide 1000 mg/m 2 I.V. on day 1 5-fluorouracil 600 mg/m 2 I.V. on days 1 and 3 ECG 6 \times 10 8 units on days 14 and 21. Regimen B - Cyclophosphamide 1000 rg/m 2 I.V. on day 1 5-fluorouracil 600 mg/m 2 I.V. on days 1 and 8. This cycle to be repeated every 28 days. Addendum #1 changed the BCG vaccine to the Pasteur strain, 2- \times 10 8 viable units.

PROGRESS IN The FG-60: Desired objective of TO patients accumulated for evaluation of the Protocol 7602 to be evaluated and findings published.

NUMBER OF TRAJECTS TO SE STUDIED BUTO E C MEDITATION C	
SERIOUS/DEDAPLOYED STEW EFFLORS IN DELAPORS PARTICLES IN THE	IN PROJECT:

CONCLUSIONS: Pending evaluation of median survival values.

WORK UNIT # 1653

MARIE Of September 1996 Chemotherapy of Prostatic Careinoma with Adrianyein and Cis-Diamainedichloroplatinum II.

STARTICS FALS: 1977

FRINCIPAL AND MICHAEL LTC Jeffrey L. Berenberg, U.D. MC
ASSOCIATED INTESTIGATION:

KEY WORD:

ACCUMULATIVE MERCASE

COST:

FY-80 MEDCASE COST:

FRINCIPAL AND MICHAEL MARKET ACCUMULATIONS

PERSONNEL MERCASE COST:

PERSONNEL MERCASE MEDICASE COST:

PERSONNEL MEDICASE COST:

STUDY OBJECTIVE: To compare the efficacy of radiation therapy alone versus the combination of radiation therapy plus chemotherapy in the treatment of patients with operatively staged and histologically proven stage DI prostatic carcinoma.

TECHNICAL APPROACH: Regimen A Whole pelvic irradiation to a total dose of 4600 rads with an additional 2000 rads to the prostate bed. Regimen B - Radiation therapy as above Adriamycin 60 mg/m² I.V. day 1 every 28 days, Cis-Platinum 60 mg/m² I.V. day 1 every 28 days. Addendum #1 increased type of patients el gible for this protocol. Addendum #2 modified administration of cis-platinum to decrease toxic side effects.

PROCRESS DURALS FY-80: Two patients have been entered on study. No additional patients entered in FY 1980.

NUMBER OF SUBJECTS TO BE STUDIED BEFORE COMPLETED TO BE CARRY!
SERIOUS/UNEXPLOYED SIDE EFFECTS IN SUBJECTS PARCE OF A TRUE PROJECT:

CONCLUSTORIS: Too early for evaluation. The fall-off in accrual is due in part to competition with National Prostate Cancer Project protocol #600 which also evaluates adjuvant therapy in patients with DI disease. The desired number of patients can probably be entered by 1984. As the NPCP protocols do not look at adjuvant therapy with PUBLICATIONS/ASSTRACTS, FY-30: cis-platinum, this study should remain open.

WORK UNIT #1666 Ed. 1: 89 8 Stember 1980 [F. A.O.O. NO: WRANG 780]] by the state of χ THE E GA PROJECT: PROTOCOL FOR INMUNOLOGICAL EVALUATION AND PHASE ONE IMMUNOTHERAPY OF PAPIENTS WITH VARIOUS CARCINOMAS STALLING DAFF: 1978 | INSTERNITE COMPLETED BOOK Accru
THENCEPAL CAVESTIGATOR: JOHANNES BLOM, MD and MAJ LOUIS F. DIEUL, MC [ESTIMATED COMPLETION DEAD: Accrual completed ASSOCIATE INVESTIGATORS: FACILITY: Walter Food Army No.27 at SERVICE: Newar Alogo Charlogy DR. HERBERMAN - NIH Lep thest a Medicine Ker Mords: Immunotherapy, CARCINOMA ACCEMULATIVE CONTRACT | ACCEMULATIVE SUPPLY COST: | COST: | PERIODIC REVIEW RESULTS: ACCUMULATIVE MEDGASE COST: FY-SO MEDCASE COST: STUDY OBJECTIVE: To perform detailed immune evaluation in patients with tumor present and tumor entirely resected, following immunization with C. Parvum in an attempt to ascertain changes in cytotoxicity induced by immune agents and to determine if immune depression in cancer patients can be reversed. TECHNICAL APPROAGH: As per outlined submitted for FY 80 and detailed in original protocol. PRO MARS DURING FY-80: Three patients were added to the study LE CREW OF SUBJECTS TO SE STUDIED REFORE COMPLETION OF STUDY: Completed STREET JUNEAU STOR REPORTS IN SUBJECTS PARTICIPATING IN PROJECT: CONC' ISLOWS: Too early - will require follow-up. Data is now being processed at NIH. The results of this data will be compared to the patients' clinical course.

None

PUBLICATIONS/ABSTRACTS, FY-80:

		, ,,,,	WORK UNIT NO. 1672
DATE: September 1950 (C. Title G. E. DECT: Tumor Tissue			
STARTIS DOCE 1978 PRINCIPAL ENVISTICATORS: LTC Jet ASSOCIATE INVESTIGATORS:		City City and	le contrar la contrar de la co
RIY MCW >: Tumor tissue; extrac ACCEMULAR AS MEDGASA COST: FY-80 MED AR COST:	t prepa Adding COST:	ration; colon cand	er; antigen ACCOMULATIA AUGALY COST:
FY-80 MEDICAL COST;		PERCONC REVIEW	MoUMB:
C TOTAL COLORS COLORS COLORS		L	oma of the colon using
an antigen prepared from human			
TECHNICAL AND ACH: Obtain tume has obtained the necessary sample deposited in formalin, should be trimmed. Tumor tissue should be trimmed.	oles for se kept	r diagnostic purpos sterile, and rinse	ses. Tissue should not be ed with normal saline.
PROGRUSS DEATER TY-50: No tiss	sue obta	nined to date.	i
NUMBER OF COLLEGES TO BE STUDY SERIOUS/CONTROLED (106 ELFIOT	D BEFOR S 12 Sui	er eo marres en su Birero das comos	UDY:
CONCUEST AS: No data for evaluable obtained within next 6 months.	intion.	Study will be clo	osed If no tissue is

			wax una ro.tsca
PATE: 30 Seprember 1980 P TITLE OF PROJECT: Use of Strep of Metastatic Islet Cell Carci Carcinoid	tozotoc i	in in the Treatment	STOUSE Gradic X
STATING DAY E: Oct 79		Estravero comenta	10% Ball:
PRIJETPAL INVESTIGATOR: ASSOCIATE INVESTIGATORS:		C h	Reed Army Endles L
		SERVICE: Hematol Departs	ogy-Oncology cont of Molicine
KEY WORDS: ACCUMULATIVE MEDCASE COST:	ACCUMO COST:	DLATIVE CONTRACT	ACCUMULATIVE SUPPLY COST:
FY-80 MEDCASE COST:	L	PERIODIC REVIEW :	1
Clinical responses have been a Streptozotocin yields an overa objective response does not octumors (insulinoma and carcino drug have not yet Been performance to the streptozotoche streptozotoche sold a five-day intensive coursemployed using this drug, with bolus daily x 5 every 4-6 week x 4 weeks.	tl responder, erectively may ad in other contractions are regimed currents.	onse rate of approxedimention of sympt occur. Adequate other tumor types. available for intreen and a weekly residence given to a	imately 700. Even if an one Iron because producing linical trials with this arraous administration only, gimen have been widely schedule of 500 mg/m² TV
PROGRESS DURING FY-80: These diagnosis of carcinoid tumors. At post mortem, one patient was noid. This is part of a coope of class "C" drugs.	There, s found	were no responses to have metastatic	and all polients have explaid. Thelanoma instead of corei-
ANSWER TO REVIEWER'S COMMENTS: Patient data is reported	This is	s a crass C NCI Stu ormation only. It	dy for use of Streptozotocin. will remain open.
NUMBER OF SUBJECTS TO BE STUDY SERIOUS/UNEXPECTED SIDE EFFECT	ED BEFOR	PE COMPLETION OF SI	dor: G U. PROJECT:

None.

FUBLICATIONS/ADSTRACTS, FY-80:

CONCLUSIONS:

				WORK UNIT NO. 16	83
-DATE: 30 September 1980 IP:	STOCOL.	NO. WRANG 7911		STATUS: Inter	tra X
TITEE OF PROJECT: Use of 1-Asp.	aragina	se in the	*** *	Final	
Treatment of Acute Lymphoblast	ic Leuk	emia i n Adults .	and C	hildren.	** Your
omagetye) were finding 3070		Transfer to 700		Ost District	***
STARTING BAFE: October 1972 PRINCIPAL INVESTIGATOR:	· · · - · · · · - · -	1 E3 1 1/4 7 10 N 6 15H		<u> </u>	
ASSOCIATE INVESTIGATORS:		I FACILITY: Wall	lter	Reed Army Medica	1
10500,1770 1171 0120101		1			
		SERVICE: Form	itolo	gy-Oacology	-
		L. Dep.	ulne	at of Medicine	Marie to marie against
KEY WORDS:			• • • • • • • • • • • • • • • • • • • •		W acceptons
ACCUMULATIVE MEDCASE	}	LATAVE CONTRACT	l`	ACCUMULATIVE S	
COST:	COST:			COST:	
FY-80 MEDGASE COST:	h	PERIODIC PEVIL	A RE	sults:	
STUDY OBJECTIVE: Erwina Cartove	ora esp	araginase is an	anti	genically noncre	iss-remetive
asparaginase. It has activity	compant	able to that of	the	E. Coli preparat	ion in both
animal tumor of stems and in hu					
is qualitatively and quantitat.					
alternative to E. Coli asparag					
asparaginase therapy are requi-					
of the E. Coli preparation.					
magnita At Annino Acit.				_	
TECHNICAL APPROACH: Intravenous	s1y 1,00	00 IU/Kg 30,000	TU/m	2 per day x 10–2	0 days.
Intramuscularly 6,000 IU/m2 L.:	i.w. x	3 vaeks (9 dose:	s).		_
PROGRESS DURING FY-10:	. • .				
Po pul	Elents (entered.			ā-
NOTE ADDED FOR APPROVAL OF ANNU		***** **		s is a class "C"	
for use in patients allerg			It wi	11 rewain open.	Perhaps
one or two patients per ye	ar will	be entered.			
		44 A. A. C.		and the same of the same same same same same same same sam	
NUMBER OF SUBTLIES TO BE SHUDE					
SERICOS/UNAMPOUTED SIDE EFFECTS		JECIS PARCICIEZ	ATING	IN TROJECT:	·
	None				torre an annual se
THE TO USE WAS A					

None

26

Date: 8 March 1931	Protocol No: 2104	Status: Intonim		
Title of Project:	Suppressing Platelet Activity	linol X in Patients with		
Starting Date: May 1978	Estimated Completion I	Ode: Complete!		
Principal Investigator: Geo	orge J. Collins, Jr., COL, MC			
Associate Investigators: Salvatore Scialla, MAJ, MC Norman M. Rich, COL, MC		Facility: WRAMC, WRATR		
Earl Ferguson, MAJ, MC G. Patrick Clagett, LTC, M Mr. Charles Barr	Wept/Svc Periphe	Wept/Svc Peripheral Vascular Surgery		
Key Words: Platelets, Intermittent c	Inudication			
Accumulative MEDCASE Cost:	Accumulative Contract Cost:	Accumulative Supply Cost:		
FY-80 MEDCASE Cost:	and the second s	eview Rosulia:		

- Study Objective:
 1. To determine the relative effect of several platelet active drugs in suppressing in vivo and in vitro platelet function.
- 2. To determine whether or not these drugs cause a lowering of coagulation factors.
- 3. To determine if suppression of platelet function in patients with intermittent claudication results in objective improvement in exercise tolerance.

Tachaical Approach: Patients ranging in age from 40 to 70 years of either sex with intermittent claudication documented by lowering of ankle pressure after exercise were randonized into four treatment groups. One treatment group received placebo, one received 600 mg per day of aspirin, one received 600 mg per day of aspirin and 100 mg per day of persantine and one received 200 mg of sulfinpyrazone four times daily. Patients had a full coagulation screening battery including prothrombin time, activated partial thromboplastin time, fibrinogen, factors II, V, VII-X, (Cont'd)

Progress during PY-80: A total of 93 patients completed the entire test period, i.e., six months on drugs and all specified laboratory tests.

Number of subjects to be studied before completion of study: Completed.

Serious/unexpected side effects in subjects participating in project:

Only one patient withdraw due to a rash from aspirin.

Conclusions:

Data analysis has not been completed. It should be completed within six months.

Publications or Abstracts, FY-80: None

Appendix C - Detail Summary Short -

Technical Approach: (Cont'd) Vill antigen, IX, X, XI, XII, antithrophia TII, fibria split products, and protatine sulfate paracoagulation. The tests were done before taking medicines, after being on medications for two weeks, after being on medications for two months, and after being on medications for six months. In addition to this, patients had arm and ankle pressures before and after treadmill exercise at the same time i tervals.

Date: 8 March 1981	Protocol No:	2105	man parties to the first property and the contract of the cont	
Title of Project: Rapid Scr	eening for Coagu	lation Abnora	Final X	
	v de de		·	
Starting Date: May 1979	Estimated	Campletion I	Date: Complete Library 1980	
Principal Investigator: Geo	rge J. Collins, .	Jr., COL, MC		
Associate Investigators: Mr. Donald Christopher		Facility: CTS, WRAMC Hemotology, WRAIR		
Daniel Kinball, COL, MC Norman M. Pich, COL, MC Salvatore Scialla, MAJ, MC Mr. Charles Barr	外处化		eral Vascular Surgery	
Key Words:	mana ya wa wa wa wa wa wa wa ga wa 18 a			
Coagulation, Thromboolasto Accumulative MEDCASE Cost:	Accumulative Cost:		Accumulative Supply Cost:	
FY-80 MEDCASE Cost:		Periodic Re	eview Results: ed in by DCI)	
Study Objective: To devel screened for hypercoagulab screen as many as twenty p.	ility. The objec	ereby sizable tive of the	numbers of patients can be study is to be able to	
•				
batteries and thromboelaste	icion of hypercoa ography performed determinations we	gulability h . In additi	ular Surgery and Hematology/ ad coagulation screening on, twenty healthy volunteers results of thromboelastograph	
*Progress during FY-80: The been tabulated. Statistical	ne study was comp il analysis shoul	leted per ob d be complete	jective and the results have ed in six months.	
There were no side effects	or complications	A		
Number of subjects to be stu Serious/unexpected side offe			AND THE RESERVE THE PARTY OF TH	
Conclusions:	de dies von von der verdragen aussig verd verdrachten der			
Publications or Abstracts, 1	FY~80: None			

Date: 15 October 1930	Protocol No:	2810		
Radiation		ctomy for Con	Low Dose Pre-operative ntrol of Transitional	
Starting Date:	Estinuted	Completion F	Date:	
Principal Investigator:	DAVID G. McL	EOD, MD, COL	, MC, USA	
Associate Investigators:		Facility:		
RONALD DORN, MD, MAJOR, MC, USA		Dept/Svc Urology & Radiation Therapy		
Key Words: Cancer of	Bladder, irradiat	ion	•	
Accumulative MEDCASE Cost: 0	Accumulative Cost: 0		Accumulative Supply Cost: 0	
FY-80 NEDCASE Cost:	0		eview Rosultu: ed in by DCI)	
Study Objective:			generalisen in de la manda militari specificant de la manda de la manda de la manda de la manda de la manda de	
To compare short courses in the treatment of invas Technical Approach: No effects or increased inci	ive cancer of the deviation from pr	bladder.	erative radiation therapy re are no increased side de effects.	
Progress during 1920:	ired and no funds	needed.	makan apa turum atau sama atau na masa na masa na masa na masa na masa na masa na masa na masa na masa na masa	
Number of subjects to be st Serious/unexpected side eff have been no serious/unex	ects in subjects pa	rticipating in	project: To date there	
Conclusions: No con	clusions yet.			

Date: 31 OCT 80	Probablical No: 4501	Status: Interim		
	Evaluation of Fluorescence of the Thyroid with an Ame.			
Starting Date:	Estimated Completion	Date:		
Principal Investigator: Rob	ert J. Kaminski, 170, MC			
Associate Investigators:	Facility: Walte	Facility: Walter Reed Army Medical Cente.		
	Dept/Svc Dept o	Dept/Svc Dept of Radiology/Nuclear Med Soc		
Key Words:				
Accumulative MEDCASE Cost: \$19,500	Accumulative Contract Cost: \$19,59	Accumulative Supply Cost:		
FY-S0 MEDCASE Cost:		Review Republis: Readle by Dout)		
4501 we the pri	I evaluation of formescent recommended by the resident a pull fuscible of the furrest profession of the profession of th	struction are the day of		
Technical Approach:				
Progress during FY-80:				
	udied before completion of studects in subjects participating i			
_	5. 35 M. Budgeons Paretechning)	(1.0,000.		
Conclusions: Final ren	ort			

Publications or Abstracts, FY-80: $_{\rm None}$

AUTHOR INDEX

Barr, C.- 27,29
Berenberg, J.L.- 11,13,14,15,16,17,21,22,24
Blom, J. -6,12,18,19,20,23
Booth, B. -10
Burman, K.D.- 2

Christopher, D.- 29 Clagett, G.P.- 27 Collins, G.J.- 27,29

Dorn, R.- 30

Ferguson, E.- 27

Glass, A.R.- 3,4

Herberman, Dr.- 23

Johnson, L.F.- 1

Kaminski, R.J.- 31 Keegan, M.T.- 1 Kimball, D.B. -29

Latham, K.R.- 2,3,4

McLeod, D.G.- 30

Peura, D.A.- 1

Rich, N.M.-27,29 Ruyman, F.B.-5

Scialla, S.- 27,29 Smallridge, R.C.- 2

Tseng, Y.C.L.- 3,4

Wartofsky, L.- 2

